<SEC-DOCUMENT>0001628280-21-005630.txt : 20210325
<SEC-HEADER>0001628280-21-005630.hdr.sgml : 20210325
<ACCEPTANCE-DATETIME>20210325162403
ACCESSION NUMBER:		0001628280-21-005630
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		87
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210325
DATE AS OF CHANGE:		20210325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Neoleukin Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001404644
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36327
		FILM NUMBER:		21772667

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 360 - 1616 EASTLAKE AVE EAST
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98102
		BUSINESS PHONE:		206-732-2133

	MAIL ADDRESS:	
		STREET 1:		SUITE 360 - 1616 EASTLAKE AVE EAST
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98102

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AQUINOX PHARMACEUTICALS, INC
		DATE OF NAME CHANGE:	20140128

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AQUINOX PHARMACEUTICALS (USA) INC
		DATE OF NAME CHANGE:	20070626
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>nltx-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:6019b606-66e1-49bc-8c33-d6cc15ba3335,g:b750dab7-5d48-4ebb-bb7b-41a017d885d1,d:b53014c4f13844039ebc5a68643f31a2--><html xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nltx="http://www.aqxpharma.com/20201231" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nltx-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl80L2ZyYWc6OTcwY2NkMzllZmM3NDU5Njk3YzNlNTQ3MjU5YjI3ZDYvdGFibGU6OGQ0NjM4ZGZhNDg3NDk3MzlkMjQwMTY1ZTU5ZDI5OWQvdGFibGVyYW5nZTo4ZDQ2MzhkZmE0ODc0OTczOWQyNDAxNjVlNTlkMjk5ZF81LTEtMS0xLTA_ff210ed3-2065-4d13-bde0-eb6d2f64bcd8">false</ix:nonNumeric><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl80L2ZyYWc6OTcwY2NkMzllZmM3NDU5Njk3YzNlNTQ3MjU5YjI3ZDYvdGFibGU6OGQ0NjM4ZGZhNDg3NDk3MzlkMjQwMTY1ZTU5ZDI5OWQvdGFibGVyYW5nZTo4ZDQ2MzhkZmE0ODc0OTczOWQyNDAxNjVlNTlkMjk5ZF83LTEtMS0xLTA_07fccfa7-0691-4217-8171-75551638c780">2020</ix:nonNumeric><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl80L2ZyYWc6OTcwY2NkMzllZmM3NDU5Njk3YzNlNTQ3MjU5YjI3ZDYvdGFibGU6OGQ0NjM4ZGZhNDg3NDk3MzlkMjQwMTY1ZTU5ZDI5OWQvdGFibGVyYW5nZTo4ZDQ2MzhkZmE0ODc0OTczOWQyNDAxNjVlNTlkMjk5ZF84LTEtMS0xLTA_51017142-e3df-4890-8a5d-69e995c83fea">FY</ix:nonNumeric><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl80L2ZyYWc6OTcwY2NkMzllZmM3NDU5Njk3YzNlNTQ3MjU5YjI3ZDYvdGFibGU6OGQ0NjM4ZGZhNDg3NDk3MzlkMjQwMTY1ZTU5ZDI5OWQvdGFibGVyYW5nZTo4ZDQ2MzhkZmE0ODc0OTczOWQyNDAxNjVlNTlkMjk5ZF8xMS0xLTEtMS0w_cd8ce717-e05d-43cf-ac37-d11c10d5dd2a">0001404644</ix:nonNumeric><ix:nonNumeric contextRef="if6af04cfacce4158ab34277a1960ae3a_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzE2NDkyNjc0OTYxNDk_956254c7-b20d-4861-9cc1-c72b39fa063a">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="if6af04cfacce4158ab34277a1960ae3a_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTM5ODM_38a5a479-ddde-4ba0-9188-8ce886f75bc3">P1Y</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-5" name="us-gaap:RestructuringCharges" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xODE5L2ZyYWc6Njk3M2M5ZGFkMDU5NGQ5MDhmNTlhMmE1YmY4Mjg4MDQvdGV4dHJlZ2lvbjo2OTczYzlkYWQwNTk0ZDkwOGY1OWEyYTViZjgyODgwNF8xNjQ5MjY3NDQxOTY2_fa932cf2-6672-4c35-bc8a-4bfcc47229be">0</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nltx-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ic2b26b0a70bd4921be8f5b71cba81d62_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="idd7a0891c771440993dddc18188b0907_I20210322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e2fcca578804ccebdb1444503987c24_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9532edde7a4d48b5887af8007e83465c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i049d641cdc3c4012850e2abee7d5fe17_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i732d643094fe48eabda3a3bdcda606d7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cf36246e64844f0999cee0b4685f134_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc7d097a895f4d19ad4225c8b7a363e3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5203423d3b74826a3d7fe380aabf55b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f9b47e6f171422bb275e6ef86e39725_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b5b9988d4e248bc863b2725dbedccc0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nltx:NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie40aff3f920a4fa49c187c3ad3974bfb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nltx:NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d6e4cb98c3641c0b1a872248ed13060_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9394470fa9e045eaaa71a62dee88a970_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85f0f44c55744942ad3e1471a8246db3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cc2885987c54d929541504d3cf066e4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2b7aa4965884327b321e9713f816fca_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i815e5dda4d8349a9beb806cdf5433517_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54fb527f851045fcb24b611005c9b2a2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c771818b1a2410cbe3be150df63decf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64550577bf6444d791bf8bd32d649edd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i277fa222473b45ceb75d3af3ec082271_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d1ecd6573694fdfb6e3cad48ebf1c3c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6af04cfacce4158ab34277a1960ae3a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae8ed78b63224fe9a7fae1f526fde05d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>nltx:segment</xbrli:measure></xbrli:unit><xbrli:context id="ie23ad3f47f044a12afefd67475b342f7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe8d18d31bb743bea079e6b2de6ec19a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40320493bb114b7b9790c7199d64f1a0_D20190808-20190808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nltx:AcquisitionOfAssetsAxis">nltx:AquinoxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-08</xbrli:startDate><xbrli:endDate>2019-08-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1005fcc8fe5417da0ed149702b76a6f_D20190808-20190808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nltx:AcquisitionOfAssetsAxis">nltx:AquinoxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nltx:NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-08</xbrli:startDate><xbrli:endDate>2019-08-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i562c09437d76488daa016091ce08fa2a_D20190808-20190808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-08</xbrli:startDate><xbrli:endDate>2019-08-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bb0f20de0234580abbe24e6025eeb91_D20190808-20190808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="nltx:AcquisitionOfAssetsAxis">nltx:AquinoxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-08</xbrli:startDate><xbrli:endDate>2019-08-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc0c497a9b7e42ff89e71ed4e700c005_D20190808-20190808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-08</xbrli:startDate><xbrli:endDate>2019-08-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99076ffdc9d3414f812225c38a835667_I20190808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="nltx:AcquisitionOfAssetsAxis">nltx:AquinoxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia47d5cee66404f7cbae1aeec9577fc50_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nltx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7459e4cc288446f840ea60d80fbb934_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nltx:FurnitureFixturesAndITEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a680cc9adc946558b7938da05a43e34_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15d940e5d2f149acbb5357be4a7e366f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nltx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2208e67d526547b5819db3624bbe011a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nltx:FurnitureFixturesAndITEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i4705a5c4b4bc44d6bb8ba59262f94449_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nltx:OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6e7ca6980e0434682af1d48cf353254_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="option"><xbrli:measure>nltx:option</xbrli:measure></xbrli:unit><xbrli:context id="idf105168c8db4aaca79efa56d6480d67_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nltx:OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ed3c72fdd5244ab8974717f9b77a301_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nltx:OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc93ba96caae41caaf0f462dced9d9f5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nltx:OfficeSpaceFormerPrincipalExecutiveOfficesAndLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i551bbb0f39284233bd2bc07a764f6743_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nltx:OfficeSpaceFormerPrincipalExecutiveOfficesAndLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33f7bbfc02b54beb8163ea39433e3cad_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23ddd03e1fc94695ab704c560ff13b1a_D20200630-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-30</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i2bfb640b4f9448db81cd2eda573a733f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacf40562c9644cc9828d02f05554823f_D20200707-20200707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nltx:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-07</xbrli:startDate><xbrli:endDate>2020-07-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia289d260d3db4da2aacbed8339f37590_I20200707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nltx:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3397ebe8ae644e4aabdacd910f7b5d9e_I20200707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nltx:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcd7f5cd1b2a4a29a2a3ab167bb32bce_D20200707-20200707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-07</xbrli:startDate><xbrli:endDate>2020-07-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4106335c2a9e4f65a3bf48b670d2780f_D20191220-20191220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nltx:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-20</xbrli:startDate><xbrli:endDate>2019-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i244aa6bc78a741be9d0e8aafa2725d77_I20191220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nltx:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib79c600c3cf14f96b3f11cb86e2c6fe1_D20191220-20191220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-20</xbrli:startDate><xbrli:endDate>2019-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff8af19eb46e4d98bfc328b1fb63531e_D20191112-20191112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nltx:NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-12</xbrli:startDate><xbrli:endDate>2019-11-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6d4eed2171d4fda82da0d88564149d9_I20191112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4a634a968e049b7b556b6104f5c0ae5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nltx:NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1913c226c2e2462ba6fe703cb86f64c8_D20191217-20191217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-17</xbrli:startDate><xbrli:endDate>2019-12-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5612b1ceb0074b538a341f49adc28d80_I20191217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nltx:PreFundedCommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb2fe74f8fec43409b383c349c9d583a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nltx:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5126c731497844cf82463ebd9ba0ec2c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nltx:EquityIncentivePlanTwoThousandSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iceb04586e32a40cc920160798f9ddce9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nltx:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40473cfe46a34de087cfebd3e2af1629_D20191112-20191112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nltx:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-12</xbrli:startDate><xbrli:endDate>2019-11-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56d428d107ab495dbcb789afcb67f7ac_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nltx:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd60841f3d0c4c839e994b21197a5e5a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf570f55902f4cc28e0254cce74d57f7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i519925c39cf4455091866ca196cf1161_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98de22e11051465b8dcdb754ab88181e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ded9a42fb4c43d59acd21cbb286e7ab_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib836d4e8cc0846f3aae456d3e9c5c4a1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bf297e89d3a4439826cf1221fa7077e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic094ebf448aa42ca8ddd6b528bd22183_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nltx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ce8a1775eab43619ee74ee567323a06_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nltx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="offering"><xbrli:measure>nltx:offering</xbrli:measure></xbrli:unit><xbrli:context id="i9458a61fcd5441b4a06f3867c7b43644_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71f76aa20b85452986373dda65e0d335_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nltx:RestructuringPlan1July2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5d6fef6a34b42589a5f9af4fd295376_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nltx:RestructuringPlan1July2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b0667298aca423a94e3af1049753d11_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nltx:RestructuringPlan1July2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie44b93451c7140eaadb4a1b1ad21f5a2_I20181106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nltx:RestructuringPlan1November62018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i683ab08d4e50424b957c9a94c07b61de_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nltx:RestructuringPlan1November62018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i114d11c2e9f14956aaff2d2291a3bb3c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0287eaf6edad4bca9a12a64c9fd6bfd3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0fb710a1248468f89148e8f321466cd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i716d60022b294375af6a54233d5dafb2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ided3ec02dff84702acaa7ae1e47b2e5f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96ba60c113044d799a3a4c62cb49aed1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74a1d2bd4a394b7b96915526dbf4b948_D20200731-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nltx:AcqinoxCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-31</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99c20b1ea8274dc9b108a3b0bd76f6b1_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nltx:AcqinoxCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i342b1069b9d04ed099561a06485fbac8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i263816d2f8ea45e08a1dadaf18225ac9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40d4ac81f67244daa74169c591a76a81_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">nltx:UniversityOfWashingtonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e261bc82ccb41c588ae441128cc8612_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">nltx:UniversityOfWashingtonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6db8900a02d94ac0b3d9b45c02322b98_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">nltx:UniversityOfWashingtonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nltx:NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d0273c0483c4e869c87c35dd362ea8b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">nltx:UniversityOfWashingtonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b9bb655d75545a397e6154c4fb4f637_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">nltx:UniversityOfWashingtonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73035a213d0243978324cca10be3c694_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">nltx:UniversityOfWashingtonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib53014c4f13844039ebc5a68643f31a2_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1NTAw_80d8d92c-afa6-46a9-b544-1697f7ad02b5">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.533%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGFibGU6YTJiYjVkZGVhOGE5NDA1Mzk5ODE2OGRhMDU5MmU4NjQvdGFibGVyYW5nZTphMmJiNWRkZWE4YTk0MDUzOTk4MTY4ZGEwNTkyZTg2NF8wLTAtMS0xLTU5OA_9804787c-4767-4378-9674-3973c9180a1d">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8yMTk5MDIzMjU5NTIy_1734cedc-b410-4fab-8722-1c42b3d42e33"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8yMTk5MDIzMjU5NTIy_b7418163-a443-4aa1-88dd-4a4ee8d15f9d">December&#160;31</ix:nonNumeric>, 2020</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.533%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGFibGU6NjU5NjYxZmFkYzUxNDhjNGJmY2QxOTMxNTFlZGI2ZTAvdGFibGVyYW5nZTo2NTk2NjFmYWRjNTE0OGM0YmZjZDE5MzE1MWVkYjZlMF8wLTAtMS0xLTYwMA_77889dd8-557b-4e2d-85b1-ef7f7d1b5650">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1NTAx_8e46ba7b-cdf1-4423-97cd-9797e638c918">001-36327</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1NTA0_5f76358b-6e90-4915-bbbb-2f2d442ca9b3">Neoleukin Therapeutics, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGFibGU6MTQ2ZWFhNjlkNGU1NGVmM2E5ZjIxYTlhOGYwMTMzMTgvdGFibGVyYW5nZToxNDZlYWE2OWQ0ZTU0ZWYzYTlmMjFhOWE4ZjAxMzMxOF8wLTAtMS0xLTc3Nw_0f294580-1cb5-40bd-8b9b-30c101989ebe">Delaware</ix:nonNumeric><br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGFibGU6MTQ2ZWFhNjlkNGU1NGVmM2E5ZjIxYTlhOGYwMTMzMTgvdGFibGVyYW5nZToxNDZlYWE2OWQ0ZTU0ZWYzYTlmMjFhOWE4ZjAxMzMxOF8wLTEtMS0xLTU0Mjg_186bee8e-3cd9-4327-947b-30041e2c11fc">98-0542593</ix:nonNumeric><br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1NTA2_04c74e32-6751-4f18-abae-d594af0a6ace">188 East Blaine Street, Suite 450</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1NTA3_8f75b94a-c2db-4230-ae19-2dc750412493">Seattle</ix:nonNumeric>, <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1NTA4_c04ce68a-f969-4b56-807c-aa6b0eebf305">Washington</ix:nonNumeric>, <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1NTM5_7c731bc2-d9b0-4888-b18e-19ab56a96fa9">98102</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1ODYz_d61a9920-5cee-44bf-bf25-3bb477beb9d1">866</ix:nonNumeric>) <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1ODY3_e27df6da-0eeb-4e69-969d-7183b0c0d4c1">245-0312</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGFibGU6ZWRiNWUzYjA0ZjI4NDBiMWE3YzJmMGFkODE1MmE0OTQvdGFibGVyYW5nZTplZGI1ZTNiMDRmMjg0MGIxYTdjMmYwYWQ4MTUyYTQ5NF8xLTAtMS0xLTY3Nw_eec5e90c-e62d-48df-b07d-8dff9b35fc92">Common Stock, par value $0.000001</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGFibGU6ZWRiNWUzYjA0ZjI4NDBiMWE3YzJmMGFkODE1MmE0OTQvdGFibGVyYW5nZTplZGI1ZTNiMDRmMjg0MGIxYTdjMmYwYWQ4MTUyYTQ5NF8xLTItMS0xLTY3OQ_ea9e2d14-0d06-4657-bac2-f4edc7cd986c">NLTX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGFibGU6ZWRiNWUzYjA0ZjI4NDBiMWE3YzJmMGFkODE1MmE0OTQvdGFibGVyYW5nZTplZGI1ZTNiMDRmMjg0MGIxYTdjMmYwYWQ4MTUyYTQ5NF8xLTQtMS0xLTY4MQ_89a13257-a401-440e-b1af-1b9aec3f9554">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1NTUz_fc49f268-ea8f-40bf-a706-706cb5e92751">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1NTU0_6b8b7465-e006-4bbb-9bbf-618013e7b033">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1NTU1_506acf96-1b64-404f-a922-267e54518107">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1NTU2_4c662f6e-a5da-4ef7-9464-96ea26d108d8">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:17.640%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.608%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.593%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.731%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGFibGU6NzgxZDhhZmM1NzQ0NDIzY2IwNTVlNGE5MDYwMzlkMTIvdGFibGVyYW5nZTo3ODFkOGFmYzU3NDQ0MjNjYjA1NWU0YTkwNjAzOWQxMl8yLTAtMS0xLTEwNDc_16eabc4a-30f0-4dc0-b7ac-9ff261a04fdb">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGFibGU6NzgxZDhhZmM1NzQ0NDIzY2IwNTVlNGE5MDYwMzlkMTIvdGFibGVyYW5nZTo3ODFkOGFmYzU3NDQ0MjNjYjA1NWU0YTkwNjAzOWQxMl8yLTQtMS0xLTcxMw_acab4d48-cfa0-4cbe-9912-400d8e1c5efd">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging&#160;growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGFibGU6NzgxZDhhZmM1NzQ0NDIzY2IwNTVlNGE5MDYwMzlkMTIvdGFibGVyYW5nZTo3ODFkOGFmYzU3NDQ0MjNjYjA1NWU0YTkwNjAzOWQxMl80LTQtMS0xLTcxNQ_75cc73d5-04a3-4d94-b2c0-d68ad524a18b">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.&gt; 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ3NzAy_e8fb0f21-590d-48d2-b197-b3c67abb922f">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;YES&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xMTU0NDg3MjA5NzEyNQ_8cbad84f-e580-4188-9392-3291d88540fd">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;NO&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ic2b26b0a70bd4921be8f5b71cba81d62_I20200630" decimals="-5" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1NTYx_eb601cff-7955-40d5-8631-7be023ca01ca">546.0</ix:nonFraction>&#160;million as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter, based upon the closing sale price on The Nasdaq Global Market reported for such date. This excludes an aggregate of 5,596,426 shar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">es of the registrant&#8217;s common stock held as of such date by officers, directors and stockholders that the registrant has concluded are or were affiliates of the registrant. Exclusion of such shares should not be construed to indicate that the holder of any such shares possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant or that such person is controlled by or under common control with the registrant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="idd7a0891c771440993dddc18188b0907_I20210322" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8zMjk4NTM0ODg3NDIw_ae95f874-bd96-4bf7-b4f8-6fe8fdacb11f">42,326,033</ix:nonFraction> shares </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the registrant&#8217;s Common Stock issued and outstanding as of March&#160;22, 2021.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1NTg5_6b3c61ca-dd6e-4743-8439-de36bb7d66c3" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part III incorporates information by reference from the registrant&#8217;s definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, in connection with the registrant&#8217;s 2021 Annual Meeting of Stockholders (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Proxy Statement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</span></ix:nonNumeric></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib53014c4f13844039ebc5a68643f31a2_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOLEUKIN THERAPEUTICS, Inc.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT ON FORM 10-K</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEAR ENDED DECEMBER&#160;31, 2020</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.025%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_10">PART I</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_16">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_16">18</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_19">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_19">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_22">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_22">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_25">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_25">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_28">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_28">53</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_31">PART II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_34">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_34">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_37">Selected Financial Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_37">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_40">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_40">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_76">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_76">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_79">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_79">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_172">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_172">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_175">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_175">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_178">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_178">81</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_181">PART III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_184">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_184">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_187">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_187">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_190">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_190">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_193">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_193">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_196">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_196">82</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_199">PART IV</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_202">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_202">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_205">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_205">86</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_208">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_208">86</a></span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise indicated herein or as the context otherwise requires, references in this report to, &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar references refer to Neoleukin Therapeutics, Inc. (formerly Aquinox Pharmaceuticals, Inc.), a Delaware corporation. The name &#8220;Neoleukin&#8221; is a registered trademark of the Company in the United States. This report also contains references to registered marks, trademarks and trade names of other companies that are property of their respective holders. All other trademarks, registered marks and trade names appearing in this report are the property of their respective holders.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ib53014c4f13844039ebc5a68643f31a2_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. All statements other than statements of historical facts are &#8220;forward-looking statements&#8221; for purposes of these provisions, including those relating to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;intend&#8221; or &#8220;continue,&#8221; the negative of terms like these or other comparable terminology, and other words or terms of similar meaning in connection with any discussion of future operating or financial performance. These statements are only predictions. All forward-looking statements included in this Annual Report on Form 10-K are based on information available to us on the date hereof, and we assume no obligation to update any such forward-looking statements. Any or all of our forward-looking statements in this document may turn out to be wrong. Actual events or results may differ materially. Our forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown risks, uncertainties and other factors. We discuss many of these risks, uncertainties and other factors in this Annual Report on Form 10-K in greater detail under the heading &#8220;Item 1A&#8212;Risk Factors.&#8221; We caution investors that our business and financial performance are subject to substantial risks and uncertainties.</span></div><div id="ib53014c4f13844039ebc5a68643f31a2_13"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation, and autoimmunity using </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> protein design technology. We use sophisticated computational methods to design&#160;proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.&#160;Existing protein engineering treatments generally involve the modification of native proteins. With our proprietary platform we design completely new protein structures from the ground up, capable of demonstrating specific biological properties. Through this method we are able to produce proteins that, while resembling native proteins, may have novel molecular interfaces, differential activation of specific cell types, increased stability, or improved biodistribution compared to native proteins in order to deliver greater therapeutic benefit. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">De novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;proteins have the capacity to be cytokine receptor agonists, antagonists, or result in conditional activation of specific cytokine receptors such that they may regulate inflammation or the immune response to cancer. We are initially focused on key cytokine mimetics, which we refer to as Neoleukin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cytokine mimetics. Neoleukin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de&#160;novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cytokine mimetics can be modified to adjust affinity, thermodynamic stability, resistance to biochemical modification, pharmacokinetic characteristics, and targeting to tumor or inflamed tissues.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product&#160;candidate,&#160;NL-201,&#160;is&#160;a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;protein designed to mimic the therapeutic activity of the cytokines&#160;interleukin-2, or&#160;IL-2, and interleukin-15,&#160;or&#160;IL-15,&#160;for&#160;the potential treatment of various types of cancer, including renal cell carcinoma, or RCC, and melanoma, while limiting the toxicity caused by the preferential binding of&#160;native&#160;IL-2&#160;and&#160;IL-15&#160;to&#160;non-target&#160;cells.&#160;In preclinical studies, a closely-related precursor&#160;to&#160;NL-201&#160;demonstrated&#160;higher levels of activity and lower toxicity in multiple murine solid tumor syngeneic models as compared to recombinant,&#160;native&#160;IL-2.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Neoleukin/Aquinox Merger</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 8, 2019, Neoleukin Therapeutics, Inc., or Former Neoleukin, completed its merger with Aquinox Pharmaceuticals, Inc., or Aquinox, in accordance with the terms of the Agreement and Plan of Merger dated August 5, 2019, or the Merger Agreement by and among Aquinox, Former Neoleukin and Apollo Sub, Inc., a wholly-owned subsidiary of Aquinox. Pursuant to the Merger Agreement, Apollo Sub, Inc. merged with and into Former Neoleukin, with Former Neoleukin surviving the Merger as a wholly-owned subsidiary of Aquinox, referred to herein as the Merger. Upon completion of the Merger, Aquinox was renamed Neoleukin Therapeutics, Inc. and Former Neoleukin was renamed Neoleukin Corporation</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">De Novo&#160;Protein Design Technology</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary technology, which we refer to as our Neoleukin platform, uses a set of advanced computational algorithms and methods to design functional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proteins. A protein is generally defined as one or more chains of covalently-linked amino acids &#8211; totaling at least 50 amino acids &#8211; that assemble into a 3-dimensional structure. Human cells contain tens of thousands of different proteins; however, this is still only a small subset of all possible amino acid sequences that can be assembled to form a protein. While protein engineering to date has largely been conducted through the modification of native proteins, with our platform we are able to explore the full sequence space, guided by the physical principles that underlie protein folding, and design functional proteins from the ground up. Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proteins fit the above definition of a protein, but, unlike native proteins, are designed using our proprietary computational algorithms and methods. Successful </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de&#160;novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> protein design is a cutting-edge process that requires both the advanced computational tools of our proprietary platform and deep insight into how a sequence of amino acids will fold into a stable 3-dimensional protein.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To design a Neoleukin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;cytokine mimetic using the Neoleukin platform, we begin with an accurate model of the biological target. This is typically a high-resolution crystal structure but may instead be a computationally-modeled structure. Then, critical points of contact between molecular interfaces are identified so that essential interactions can be maintained or strengthened, and undesirable interactions can be avoided. Next, we use a computational algorithm to build&#160;idealized&#160;3-dimensional&#160;topologies.&#160;Finally, we use a separate computational algorithm to select amino acids for each position within the&#160;idealized&#160;3-dimensional&#160;topologies&#160;that maximizes interactions at the desired interface and the thermodynamic stability of the resulting protein. The resulting amino acid sequences are then expressed in bacteria, tested in the laboratory, and further modified to optimize the final sequence. The resulting protein is unlike anything that exists in nature and can be fine-tuned to improve on the desired biological activity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we are currently focused on the design of Neoleukin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;cytokine mimetics, we believe this approach could be used broadly to widen the therapeutic window and improve drug-like characteristics of therapeutic proteins, including chemical stability, pharmacokinetic properties, or novel routes of administration. Furthermore, we believe that the Neoleukin platform can also be used to generate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;proteins that inhibit activation of specific receptors, a property that could be valuable for treatment of inflammatory or autoimmune conditions. Computational design of therapeutic proteins is in a very early stage. The potential is vast, and we are focused on continuing to improve the technology and realizing the tremendous potential of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;protein design to improve human health.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business model is focused on three primary goals:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Develop proprietary</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;protein immunotherapies for the treatment of cancer and inflammatory conditions;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Become the leader in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;protein design for therapeutic applications by strengthening our intellectual property&#160;and know-how; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Collaborate with leading biotechnology, pharmaceutical, and academic partners to expand the scope of our platform.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key elements of our strategy are:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Rapidly advance&#160;NL-201&#160;to clinical&#160;proof-of-concept</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;NL-201&#160;is&#160;our lead product candidate and we believe it will be the first entirely</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;therapeutic protein to be evaluated in a clinical&#160;setting.&#160;We submitted a Clinical Trial Notification in Australia and an Investigational New Drug (or IND) Application to the FDA in the fourth quarter of 2020. On January 7, 2021, we received a clinical hold letter from the FDA related to the IND. We are currently working to address the FDA's comments related to development of a new assay that more precisely measures the amount of protein being administered and demonstration with this assay that dose and administration procedures will accurately deliver the intended dose, as well as addressing the FDA's other requests not related to the clinical hold.</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Generate preclinical data for additional product candidates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Our research activities are currently focused on the development of novel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;interleukin receptor agonists and antagonists to expand our pipeline. We are currently optimizing and evaluating several early research projects as potential clinical candidates. We initially intend to develop </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de&#160;novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> protein therapeutics to address significant unmet medical needs in oncology, inflammation, and autoimmune indications.</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Expand the capabilities of the Neoleukin platform.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;De novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;protein design is in the early stages of development and has the potential to generate therapeutics to treat a wide range of human diseases. We believe that there will be a rapid evolution in the enabling technology, such that it will be feasible to design more complex and dynamic proteins in the future. We intend to devote a significant amount of resources to building our computational talent and infrastructure in order to position Neoleukin as a leader in the design and development of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;protein therapeutics.</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Build partnerships to leverage the Neoleukin platform.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;There is substantial interest in the field of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;protein design for therapeutic applications. We intend to seek potential partners that can provide additional resources and expertise to further advance our pipeline and broaden our potential targets. We may also strategically pursue one or more collaborations to design, out-license,&#160;or&#160;co-develop</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;proteins.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NL-201</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead&#160;product candidate,&#160;NL-201,&#160;is&#160;an&#160;IL-2/IL-15&#160;immunotherapy&#160;designed to eliminate binding to the alpha subunit of&#160;the&#160;IL-2&#160;receptor (also known as CD25) while maintaining high-affinity binding to the beta and gamma subunits. In multiple preclinical animal models, a precursor to NL-201 demonstrated substantial anti-tumor activity without detectable binding to CD25, as compared to native IL-2. Following these preclinical studies, we further refined our precursor to extend its half-life, resulting in our NL-201 product candidate. We have since completed multi-dose, non-GLP and GLP toxicology studies of NL-201 in rats and non-human primates. This included completion of GLP in-life dosing with no unexpected toxicities observed. NL-201 is intended to be used as either a single-agent or in combination with complementary therapeutic modalities, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including checkpoint inhibitors. In addition, we believe NL-201 holds promise in combination with allogenic cell therapy to expand and maintain populations of transplanted CAR-T and natural killer, or NK, cells.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IL-2 is one of the few immuno-oncology drugs proven to work as a single agent. IL-2 has a demonstrated mechanism of action for treating tumors; however, it has encountered issues as a therapeutic due to the biased activation of cells that contain CD25. CD25 induces conformational changes in IL-2 that enable high-affinity binding to the beta and gamma subunits of the IL-2 receptor. Preferential binding to endothelial cells expressing CD25 is believed to exacerbate vascular leak syndrome, while preferential activation of CD25-expressing regulatory T cells can inhibit anti-cancer immune responses. Due to IL-2&#8217;s potential for high toxicity, with vascular leak syndrome and cytokine storm being frequent side effects, and reduced efficacy over time, its use as a therapeutic has been limited. Further, low-dose treatments have generally been insufficient to demonstrate activity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the problem posed by IL-2 is well understood, it has been difficult to modify native&#160;IL-2 to retain potent activation of IL-2 receptor signaling while eliminating binding to CD25. Instead of modifying native IL-2, computational methods were used to design a new sequence with the proper intermolecular interactions to efficiently bind the beta and gamma subunits while eliminating CD25 binding in preclinical models. As opposed to traditional recombinant human, or humanized, protein therapeutics, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proteins are entirely novel sequences with limited homology to native proteins. While there is a potential that patients may mount an anti-drug immune response against NL-201, we believe that this risk is mitigated by several factors, including the stability of the protein and its resistance to proteolytic degradation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Immunotherapy Market Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past several decades, the potential of the immune system to control and/or eliminate cancer has been better understood and appreciated. Immunotherapies, including allogenic stem cell transplantation, checkpoint inhibitors, and cellular therapies have led to impressive improvements in patient outcomes. Immunotherapy is one of the fastest growing segments of the oncology market. Immune checkpoint inhibitors are one of the most widely used classes of cancer immunotherapy. Checkpoint inhibitors promote an anti-cancer immune response by blocking inhibitory signals between cancer cells and the immune microenvironment. Patients with metastatic cancers, who previously had uniformly poor prognoses, now have the opportunity to achieve durable responses with checkpoint inhibitors. The initial drug in this class, ipilimumab, was approved in 2011. Since that time, many additional checkpoint inhibitors have been approved. In addition to checkpoint inhibitors, other notable cancer immunotherapies expected to improve cancer outcomes over the next decade&#160;include&#160;bi-specific&#160;T-cell&#160;engagers, immune agonists, and cellular therapies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limitations of Current Treatments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite achieving success in a subset of patients, checkpoint inhibitors often fail to control tumor growth. In addition, some patients do not tolerate checkpoint inhibitors. While checkpoint inhibitors work to block the mechanisms by which malignant cells evade immunological surveillance by anti-cancer T cells, they are less effective in patients who lack a favorable tumor microenvironment, expression of the inhibitory ligand, or sufficient tumor-specific antigens. For these patients, novel approaches to immunotherapy are needed that complement and/or enhance checkpoint inhibition. What is needed is a new class of agents that activate immune cells in the tumor microenvironment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that stimulation of&#160;the&#160;IL-2&#160;and&#160;IL-15&#160;pathways&#160;is an attractive approach to generate an anti-cancer immune response because it promotes the proliferation and activation of both CD8+ effector T cells and NK cells. Recombinant&#160;human&#160;IL-2,&#160;or&#160;aldesleukin, is a proven therapy and is approved for the treatment of adults with metastatic RCC or metastatic melanoma. However, significant toxicity has resulted in multiple boxed warnings in the labeling, including a requirement that administration occur in the hospital under supervision of an experienced physician. As a result of these toxicities, aldesleukin is not frequently used in the clinic. In addition, aldesleukin has a relatively modest rate of durable remissions, potentially because it preferentially stimulates the proliferation of regulatory T cells, which can inhibit the antitumor response. We believe there is a clear clinical need for an agent that stimulates an immunological response to cancer with greater selectivity and less toxicity than aldesleukin.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Initial Clinical Development Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We submitted our IND in December 2020.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2021, we received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to our Investigational New Drug (IND) Application to begin a Phase 1 clinical program for NL-201.  The FDA has informed us that we need to develop a new assay that more precisely measures the amount of protein being administered and demonstrate with this assay that dose and administration procedures will accurately deliver the intended dose of NL-201. The FDA also had additional requests not related to the clinical hold to be addressed by amendment of the IND. We are working diligently to address the FDA&#8217;s requests, and currently expect to resolve the clinical hold as well as to begin enrollment of patients in the first half of 2021; however, we do not have a definitive timeline as to when we will have clearance to proceed with clinical trials.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UW License Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;8, 2019, Former Neoleukin entered into an Exclusive License Agreement with the University of Washington, or UW, under which UW (on behalf of itself and Stanford University) granted us an exclusive worldwide license under certain patent rights, to make, have made, use, offer to sell, sell, offer to lease or lease, import, export or otherwise offer to dispose of licensed products in all fields of use, and a nonexclusive worldwide license to use certain&#160;know-how.&#160;The foregoing licenses are able to sublicense by us without UW&#8217;s consent, subject to certain limited conditions. We assumed the benefits and obligations of the Exclusive License Agreement in connection with the completion of the Merger. The Exclusive License Agreement was amended effective as of July 24, 2020 to, among other things, (i) add a jointly owned patent application directed to de novo cytokine antagonists to the agreement, (ii) specify royalties, milestone payments and sublicense consideration payments payable by Neoleukin for licensed products under certain patent rights related to the jointly owned patent application, (iii) specify the term for achievement of performance milestones for licensed products under certain patents rights related to the jointly owned patent application, and (iv) terminate UW&#8217;s right to participate in equity financings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the licensed rights, Former Neoleukin issued shares of common stock to UW, representing five percent of its fully-diluted capitalization on the date on which the Exclusive License Agreement was executed. Additionally, we are required to pay UW: (i)&#160;an annual maintenance fee starting in January 2022 (but excluding any year in which minimum annual royalties are paid); (ii) up to $875,000 in combined development and regulatory milestone payments with respect to each distinct class of licensed product; (iii)&#160;up to $10.0&#160;million in combined commercial milestone payments based on cumulative net sales of licensed products within each distinct class of licensed product; (iv)&#160;a low single digit royalty on net sales of licensed products sold by us and our sublicensees, which may be subject to reductions, and subject to minimum annual royalty payments following the first commercial sale of a licensed product; (v)&#160;a certain percentage of any sublicense consideration (other than royalties) we receive from sublicensees, ranging from 50% to low single digit percentages based on the stage of development at the time the sublicense is executed; and (vi)&#160;a certain percentage of consideration we receive from an acquisition of us or our assets, ranging from 50% to zero based on the stage of development at the relevant time. We are obligated to pay royalties on a&#160;country-by-country&#160;basis until the expiration of the last valid claim within the licensed patent rights in such country.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the expiration of the last valid claim within the licensed patent rights. We may terminate the agreement upon prior written notice to UW. UW may terminate the agreement by giving a specified number of days&#8217; notice if we permanently cease operations, become insolvent or similar, or if we challenge the validity of the licensed patent rights. In addition, UW may terminate the agreement for material breach that is not cured within a specified number of days, which cure period is to be at least doubled if we are proceeding diligently to cure the default.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Programs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond our initial focus&#160;on&#160;NL-201,&#160;our&#160;research team is working on further applying</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;protein design principles to develop therapeutics to address significant unmet medical needs in immuno-oncology, inflammation, and autoimmunity. Our research is powered by the Neoleukin platform, our computational framework for developing highly selective, hyper-stable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;immunomodulatory proteins.&#160;Beyond&#160;NL-201,&#160;we&#160;are developing targeted and conditionally&#160;active&#160;IL-2/IL-15&#160;mimetics,&#160;as well as cytokine mimetic programs for other oncology targets. Our research team is also actively applying the Neoleukin platform to generate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;receptor agonist and antagonist candidates against multiple targets of interest for inflammatory and autoimmune indications. As we validate additional candidates, they will enter our preclinical pipeline.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Due to the COVID-19 public health emergency, we have been investigating the application of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">de novo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> protein technology to prevent or treat SARS-CoV2 infection.  In November 2020, we announced the publication of our scientific work in the journal Science detailing the creation of CTC-445.2d, or NL-CVX1, a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">de novo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> protein decoy that is specifically designed to block infection of SARS-CoV-2, the virus causing the ongoing COVID-19 pandemic. Our findings demonstrated that NL-CVX1 blocks infection of human cells </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">in vitro</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, even when a high viral burden is used. Furthermore, intranasal administration of NL-CVX1 protected Syrian hamsters from a lethal dose of SARS-CoV-2.  We are currently planning a first-in-human trial of NL-CVX1, and will continue to evaluate the program as the SARS-CoV-2 landscape evolves.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intellectual property strategy is centered around robust protection of our pipeline molecules and enabling technologies. We have licensed rights to patents and patent applications stemming from provisional patent applications that our scientific co-founders authored while they were employees at the University of Washington, or UW. We have also licensed rights to a provisional patent application that we jointly own with UW. These patents and patent applications, as applicable, include disclosure and claims encompassing our NL-201 product candidate, the composition of matter of key molecule families, as well as methods of using the computational algorithms that form the basis of the Neoleukin platform. We have secured an exclusive license from UW to develop and commercialize products covered by these patents and patent applications. For NL-201 and related technology, two U.S. patents have issued and will expire in 2039, absent any patent term adjustments or extensions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional patent applications are pending in the United States and world-wide.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any patents that may issue from these patent applications in-licensed from UW are expected to expire in 2039, absent any patent term adjustments or extensions. As our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidate advances through research and development, we expect to seek to identify and protect new inventions, and have filed applications on new inventions such as methods of administration and combination therapies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, through our research efforts, we anticipate generating intellectual property covering novel compounds and significant improvements on existing molecules. We expect that patents that result from this new research will remain Neoleukin&#8217;s exclusive property, except to the extent jointly developed with third parties. In addition, our research team is extending and enhancing our computational technology and capabilities. We intend to protect improvements to the Neoleukin platform through a combination of new patent filings as well as the maintenance of trade secrets. We file U.S. non-provisional applications and PCT applications that claim the benefit of the priority date of earlier filed provisional applications, when appropriate. The PCT system allows a single application to be filed within 12 months of the original priority date of the patent application, and to designate all of the 153 PCT member states in which national patent applications can later be pursued based on the international patent application filed under the PCT. The PCT searching authority performs a patentability search and issues a non-binding patentability opinion which can be used to evaluate the chances of success for the national applications in foreign countries prior to having to incur the filing fees. Although a PCT application does not issue as a patent, it allows the applicant to seek protection in any of the member states through national-phase applications. At the end of the period of 2 1/2 years from the first priority date of the patent application, separate patent applications can be pursued in any of the PCT member states either by direct national filing or, in some cases by filing through a regional patent organization, such as the European Patent Organization. The PCT system delays expenses, allows a limited evaluation of the chances of success for national/regional patent applications and enables substantial savings where applications are abandoned within the first 2 1/2 years of filing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to pursue patent issuance and protection in key commercial markets where we expect significant product sales may occur.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by rapid evolution of technologies, fierce competition, and strong defense of intellectual property. While we believe that our Neoleukin platform and our knowledge, experience, and scientific resources provide us with competitive advantages going forward, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions, among others.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of next-generation&#160;IL-2&#160;or&#160;IL-15&#160;agonists for cancer immunotherapy is an area of intense interest within the biotechnology industry. We are aware of several&#160;IL-2&#160;or&#160;IL-15&#160;agonists in various stages of clinical development, including engineered variants of&#160;IL-2&#160;that attempt to improve on aldesleukin&#8217;s narrow therapeutic window by inhibiting&#160;IL-2&#8217;s&#160;natural high-affinity interaction with CD25 using traditional protein engineering approaches including steric inhibition and mutagenesis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors, either alone or with strategic partners, have substantially greater financial, technical, and human resources than we do. Accordingly, our competitors may be more successful than us in obtaining approval for treatments and achieving widespread market acceptance, rendering our treatments obsolete or non-competitive. Accelerated merger and acquisition activity in the biotechnology and biopharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. These companies also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, and patient registration for clinical trials and acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Our commercial opportunity could be substantially limited in the event that our competitors develop and commercialize products that are more effective, safer, less toxic, more convenient, or less expensive than our comparable products. In geographies that are critical to our commercial success, competitors may also obtain regulatory approvals before us, resulting in our competitors building a strong market position in advance of the entry of our products. We believe the factors determining the success of our programs will be the efficacy, safety, and convenience of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct manufacturing activities for the clinical development of our product candidates under individual purchase orders with third-party contract manufacturing organizations as we do not have a manufacturing facility and currently do not intend to develop one.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other health authorities worldwide regulate and inspect equipment, facilities and processes used in manufacturing pharmaceutical products prior to approval. If we or our partners fail to comply with applicable requirements and conditions of product approval, the FDA and/or other global health authorities may seek sanctions, including fines, civil penalties, injunctions, suspension of manufacturing operations, operating restrictions, withdrawal of FDA and/or other global health authorities&#8217; approval, seizure or recall of products and criminal prosecution.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have an organization for the sales, marketing and distribution of pharmaceutical products. We may rely on licensing and co-promotion agreements with strategic partners for the commercialization of our products in the United States and other territories. If we choose to build a commercial infrastructure to support marketing in the United States, such commercial infrastructure could be expected to include a targeted sales force supported by sales management, internal sales support, an internal marketing group and distribution support. To develop the appropriate commercial infrastructure internally, we would have to invest financial and management resources, some of which would have to be deployed prior to any confirmation that NL-201 will be approved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biopharmaceutical company that operates and anticipates seeking approval for pharmaceutical product candidates in the United States, we are subject to extensive regulation by the U.S. Food and Drug Administration, or FDA, and other federal, state, and local regulatory agencies. The Federal Food, Drug, and Cosmetic Act, or the FDC Act, and its implementing regulations set forth, among other things, requirements for the research, testing, development, manufacture, quality control, safety, effectiveness, approval, labeling, storage, record keeping, reporting, distribution, import, export, advertising and promotion of our products. Our pharmaceutical product candidates must be approved by the FDA before we can commence clinical trials or market those products in the United States.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the discussion below focuses on regulation in the United States, we conduct research activities and anticipate seeking approval for, and marketing of, our products in other countries and regions, such as Europe. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. Additionally, some significant aspects of regulation in Europe are addressed in a centralized way through the EMA, but country-specific regulation remains essential in many respects. The process of obtaining regulatory marketing approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Approval Process</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is the main regulatory body that controls pharmaceuticals in the United States, and its regulatory authority is based in the FDC Act. Pharmaceutical products are also subject to other federal and state statutes and regulations. Biological products used for the prevention, treatment, or cure of a disease or condition of a human being are subject to regulation under the FDC Act, except the section of the FDC Act which governs the approval of New Drug Applications, or NDAs. Biological products are approved for marketing under provisions of the Public Health Service Act, or PHSA, via a Biologics License Application, or BLA. However, the application process and requirements for approval of BLAs are very similar to those for NDAs. A failure to comply with any requirements during the product development, approval, or post-approval periods, may lead to administrative or judicial sanctions. These sanctions could include the imposition by the FDA or an institutional review board, or IRB, of a hold on clinical trials, refusal to approve pending marketing applications or supplements, withdrawal of approval, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal prosecution.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The steps required before a new biological product may be marketed in the United States generally include:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s Good Laboratory Practices regulations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">approval by an IRB at each clinical site before each trial may be initiated;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">performance of adequate and well-controlled clinical trials in accordance with federal regulations and with current good clinical practices, or GCPs, to establish the safety and efficacy of the investigational drug product for each targeted indication;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">submission of BLA to the FDA;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">satisfactory completion of an FDA inspection of the manufacturing facilities at which the investigational product is produced to assess compliance with cGMP, and to assure that the facilities, methods and controls are adequate; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">FDA review and approval of the BLA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the enactment of the Biologics Price Competition and Innovation Act of 2009, or BPCIA, an abbreviated pathway for the approval of biosimilar and interchangeable biological products was created. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interchangeable based on its similarity to an existing reference product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after licensure date of the reference product licensed under a BLA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical tests include laboratory evaluation of product chemistry, formulation, and toxicity, as well as animal trials to access the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements, including Good Laboratory Practices. The results of preclinical testing are submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long-term preclinical tests, such as tests of reproductive toxicity and carcinogenicity in animals, may continue after the IND is submitted. A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has neither commented on nor questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin. Clinical trials involve the administration of the investigational drug to patients under the supervision of qualified investigators following GCPs, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors. Clinical trials must be conducted: (i)&#160;in compliance with federal regulations; (ii)&#160;in compliance with GCPs, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators, and monitors; as well as (iii)&#160;under protocols that detail the parameters to be used in monitoring safety, and the efficacy criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may order the temporary or permanent discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA regulations or presents an unacceptable risk to the clinical trial patients. The trial protocol and informed consent information for patients in clinical trials must also be submitted to an IRB for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements, or may impose other conditions if it believes that the patients are subject to unacceptable risk. In some cases, clinical trials are overseen by an independent group of qualified experts organized by the trial sponsor, for example, the data safety monitoring board, or DSMB. The suspension or termination of development can occur during any phase of clinical trials if it is determined that the participants or patients are being exposed to an unacceptable health risk.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical investigation of an investigational drug is generally divided into three phases. Although the phases are usually conducted sequentially, they may overlap or be combined. The three phases of an investigation are generally described as follows:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:19pt">Phase 1 &#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Phase 1 includes the initial introduction of an investigational drug into humans. Phase 1 clinical trials may be conducted in patients with the target disease or condition or healthy volunteers. These trials are designed to evaluate the safety, metabolism, pharmacokinetics and pharmacologic actions of the investigational drug in humans, the side effects associated with increasing doses, and if possible, to gain early evidence on effectiveness. During Phase&#160;1 clinical trials, sufficient information about the investigational product&#8217;s pharmacokinetics and pharmacological effects may be obtained to permit the design of Phase&#160;2 clinical trials.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:19pt">Phase&#160;2 &#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Phase 2 includes controlled clinical trials conducted to evaluate the effectiveness of the investigational product for a particular indication(s) in patients with the disease or condition under study, to determine dosage tolerance and optimal dosage, and to identify possible adverse side effects and safety risks associated with the drug. Phase&#160;2 clinical trials are typically well-controlled, closely monitored, and conducted in a limited patient population.</span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:19pt">Phase&#160;3 &#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Phase 3 clinical trials are controlled clinical trials conducted in an expanded patient population at geographically dispersed clinical trial sites. They are performed after preliminary evidence suggesting effectiveness of the investigational product has been obtained, and are intended to further evaluate dosage, clinical effectiveness and safety, to establish the overall benefit-risk relationship of the product, and to provide an adequate basis for product approval. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the drug. A single Phase 3 trial may be sufficient in rare instances including (1) where the study is a large multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible or (2) when in conjunction with other confirmatory evidence.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality, purity and potency of the final product. Additionally, appropriate packaging must be selected and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, a BLA is submitted to the FDA to request market approval for the product in specified indications. The BLA must include the results of all preclinical, clinical, and other testing and a compilation of data relating to the product&#8217;s pharmacology, chemistry, manufacturing, and controls. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and effectiveness of the investigational drug product to the satisfaction of the FDA. The cost of preparing and submitting a BLA is substantial. The submission of most BLAs is additionally subject to a substantial user fee; there may be some instances in which the user fee is waived.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA will initially review the BLA for completeness before it accepts the BLA for filing. The FDA has 60&#160;days from its receipt of a BLA to determine whether the application will be accepted for filing based on the Agency&#8217;s threshold determination that it is sufficiently complete to permit substantive review. After the BLA submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of BLAs. For a new molecular entity, or NME, that is classified as a standard review product, FDA&#8217;s goal is to review the BLA within ten months of the date the FDA files the BLA; an application for an NME that is classified as a priority review product has a goal for review of six months from the date the FDA files the BLA. A BLA can be classified for priority review when the FDA determines the biologic product has the potential to treat a serious or life-threatening condition and, if approved, would be a significant improvement in safety or effectiveness compared to available therapies. The FDA can extend the review process by three or more additional months to consider certain late-submitted information or information intended to clarify information already provided in the submission.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA does not always achieve its performance goal and its review of BLAs can take significantly longer. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP. The FDA may refer applications for novel biological products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and are adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect the sponsor and one or more clinical sites to assure compliance with GCPs. After the FDA evaluates the BLA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing, time or information in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. The approval process is lengthy and difficult and notwithstanding the submission of any requested additional information, the FDA ultimately may refuse to approve an BLA if applicable regulatory criteria are not satisfied or if the FDA believes additional clinical data or other data and information are required. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than a company interprets the same data.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. FDA&#8217;s approval of a product may be significantly limited to specific disease and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings, or precautions be included in the product labeling. In addition, as a condition of BLA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the drug outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, restricted distribution, special monitoring, and the use of patient registries. The requirement for REMS can materially affect the potential market and profitability of the drug. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the drug&#8217;s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to some of the conditions established in an approved application, including changes in indications, labeling, manufacturing processes or facilities, or modification to a REMS, require submission and FDA approval of a new BLA or BLA supplement before the change can be implemented. A BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing BLA supplements as it does in reviewing BLAs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising and Promotion</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other federal regulatory agencies closely regulate the marketing and promotion of drugs through, among other things, standards and regulations for direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and promotional activities involving the Internet. A product cannot be commercially promoted before it is approved. After approval, product promotion can include only those claims relating to safety and effectiveness that are consistent with the labeling approved by the FDA. Healthcare providers are permitted to prescribe drugs for &#8220;off-label&#8221; uses&#8212;that is, uses not approved by the FDA and therefore not described in the drug&#8217;s labeling&#8212;because the FDA does not regulate the practice of medicine. However, FDA regulations impose stringent restrictions on manufacturers&#8217; communications regarding off-label uses. Broadly speaking, a manufacturer may not promote a drug for off-label use, but may engage in non-promotional, balanced communication regarding off-label use under specified conditions. Failure to comply with applicable FDA requirements and restrictions in this area may subject a company to adverse publicity and enforcement action by the FDA, the U.S. Department of Justice (DOJ), or the Office of the Inspector General of HHS, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosure of Clinical Trial Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sponsors of clinical trials of FDA-regulated products, including biological products, are required to register and disclose certain clinical trial information on the website www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of a clinical trial are then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of the results of clinical trials can be delayed in certain circumstances for up to two years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of clinical development programs as well as clinical trial design.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pediatric Research Equity Act, or PREA, NDAs or BLAs or supplements to NDAs or BLAs must contain data to assess the safety and effectiveness of the biological product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the biological product is safe and effective. The FDA may grant full or partial waivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA does not apply to any biological product with orphan product designation except a product with a new active ingredient that is a molecularly targeted cancer product intended for the treatment of an adult cancer and directed at a molecular target determined by FDA to be substantially relevant to the growth or progression of a pediatric cancer that is subject to an NDA or BLA submitted on or after August&#160;18, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Controls for Biologics</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend biologics licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases within the United States.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a BLA is approved, the product may also be subject to official lot release as a condition of approval. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the lot manufacturing history and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products, such as viral vaccines, before allowing the manufacturer to release the lots for distribution. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products. As with drugs, after approval of a BLA, biologics manufacturers must address any safety issues that arise, are subject to recalls or a halt in manufacturing, and are subject to periodic inspection after approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Regulations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After regulatory approval of a drug is obtained, a company is required to comply with a number of post-approval requirements. For example, as a condition of approval of a BLA, the FDA may require post-marketing testing, including Phase&#160;4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization. In addition, as a holder of an approved BLA, a company would be required to report adverse reactions and production problems to the FDA, to provide updated safety and efficacy information, and to comply with requirements concerning advertising and promotional labeling for any of its products. Also, quality control and manufacturing procedures must continue to conform to cGMP after </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval to assure and preserve the long-term stability of the drug or biological product. The cGMP requirements apply to all stages of the manufacturing process, including the production, processing, sterilization, packaging, labeling, storage and shipment of the drug product. The FDA periodically inspects manufacturing facilities to assess compliance with cGMP, which imposes extensive procedural and substantive record keeping requirements. In addition, changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon a company and any third-party manufacturers that a company may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our product candidates. Future FDA and state inspections may identify compliance issues at our facilities or at the facilities of our contract manufacturers that may disrupt production or distribution, or require substantial resources to correct.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may withdraw a product approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product or the failure to comply with applicable requirements may result in restrictions on a product, manufacturer or holder of an approved BLA, including withdrawal or recall of the product from the market or other voluntary, FDA-initiated or judicial action that could delay or prohibit further marketing. Further, the failure to maintain compliance with regulatory requirements may result in administrative or judicial actions, such as fines, warning or untitled letters, holds on clinical trials, product recalls or seizures, product detention or refusal to permit the import or export of products, refusal to approve pending applications or supplements, restrictions on marketing or manufacturing, injunctions or civil or criminal penalties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Newly discovered or developed safety or effectiveness data may require changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, and may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products under development.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enforcement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During all phases of development (pre- and post-marketing), failure to comply with applicable regulatory requirements may result in administrative or judicial sanctions. These sanctions could include the FDA&#8217;s imposition of a clinical hold on trials, refusal to approve pending applications, withdrawal of an approval, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, product detention or refusal to permit the import or export of products, injunctions, fines, civil penalties or criminal prosecution. Any agency or judicial enforcement action could have a material adverse effect on us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparable European and Other International Government Regulation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to FDA regulations in the United States, we will be subject to a variety of comparable regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some countries outside of the United States have a similar process that requires the submission of a clinical trial application, or CTA, much like the IND prior to the commencement of human clinical trials. In Europe, for example, a CTA must be submitted to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is approved in accordance with a country&#8217;s requirements, clinical trial development may proceed. To obtain regulatory approval to commercialize a new drug under European Union regulatory systems, we must submit a marketing authorization application, or MAA. The MAA is similar to the NDA, with the exception of, among other things, country-specific document requirements and environmental impact assessments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For other countries outside of the European Union, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted in accordance with GCPs and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Australia</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting clinical trials for therapeutic drug candidates in Australia is subject to regulation by Australian governmental entities.  Approval for inclusion in the Australian Register of Therapeutic Goods, or the ARTG, is required before a pharmaceutical drug product may be marketed in Australia.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, the process of obtaining approval of a new therapeutic drug product for inclusion in the ARTG requires compilation of clinical trial data.  Clinical trials conducted using &#8220;unapproved therapeutic goods&#8221; in Australia, being those which have not </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">yet been evaluated by the Therapeutic Goods Administration, or TGA, for quality, safety and efficacy must occur pursuant to either the Clinical Trial Notification, or CTN, or Clinical Trial Exemption, or CTX, process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CTN process broadly involves:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.3pt">completion of pre-clinical laboratory and animal testing;</span></div><div style="padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.3pt">submission to a Human Research Ethics Committee, or the HREC, of all material relating to the proposed clinical trial, including the trial protocol.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TGA does not review any data relating to the clinical trial;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.3pt">the institution or organisation at which the trial will be conducted, referred to as the &#8220;Approving Authority&#8221; gives the final approval for the conduct of the trial at the site, having due regard to the advice from the HREC; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.3pt">CTN trials cannot commence until the trial has been notified to the TGA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the CTX process:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.3pt">a sponsor submits an application to conduct a clinical trial to the TGA for evaluation and comment; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.3pt">a sponsor cannot commence a CTX trial until written advice has been received from the TGA regarding the application and approval for the conduct of the trial has been obtained from an ethics committee and the institution at which the trial will be conducted.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each case, it is required that:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.3pt">adequate and well-controlled clinical trials demonstrate the quality, safety and efficacy of the therapeutic product;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.3pt">evidence is compiled which demonstrates that the manufacture of the therapeutic drug product complies with the principles of cGMP;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.3pt">manufacturing and clinical data is derived to submit to the Australian Committee on Prescription Medicines, which makes recommendations to the TGA as to whether or not to grant approval to include the therapeutic drug product in the ARTG; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.3pt">an ultimate decision is made by the TGA whether to include the therapeutic drug product in the ARTG.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-clinical studies include laboratory evaluation of the therapeutic drug product as well as animal studies to assess the potential safety and efficacy of the drug.  The results of the pre-clinical studies form part of the materials submitted to the investigators HREC in the case of a CTN trial and part of the application to the TGA in the case of a CTX trial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve administering the investigational product to healthy volunteers or patients under the supervision of a qualified principal investigator.  The TGA has developed guidelines for a CTN.  Under the CTN process, all material relating to the proposed trial is submitted directly to the HREC of each institution at which the trial is to be conducted.  An HREC is an independent review committee set up under guidelines of the Australian National Health and Medical Research Council.  The role of an HREC is to ensure the protection of rights, safety and wellbeing of human subjects involved in a clinical trial by, among other things, reviewing, approving and providing continuing review of trial protocols and amendments, and of the methods and material to be used in obtaining and documenting informed consent of the trial subjects.  The TGA is formally notified by submission of a CTN application but does not review the safety of the drug or any aspect of the proposed trial.  The approving authority of each institution gives the final approval for the conduct of the clinical trial, having due regard to advice from the HREC.  Following approval, responsibility for all aspects of the trial conducted under a CTN application remains with the HREC of each investigator&#8217;s institution.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standards for clinical research in Australia are set by the TGA and the National Health and Medical Research Council, and compliance with GCPs is mandatory.  Guidelines, such as those promulgated by the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, or ICH, are required across all fields, including those related to pharmaceutical quality, nonclinical and clinical data requirements and study designs.  The basic requirements for preclinical data to support a first-in- human study under ICH guidelines are applicable in Australia.  Requirements related to adverse event reporting in Australia are similar to those required in other major jurisdictions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Healthcare Laws and Compliance Requirements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, our activities are potentially subject to additional regulation and oversight under other healthcare laws by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, other divisions of the United States Department of Health and Human Services (e.g., the Office of Inspector General), the DOJ, and individual U.S. Attorney offices within the DOJ, and state and local governments. These laws include the federal </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-Kickback Statute, which prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for either the referral of an individual, or purchasing, leasing, ordering or arranging for the purchase, lease or order of any good, facility, item or service reimbursable, in whole or part, under Medicare, Medicaid or another federal healthcare program. The term remuneration has been interpreted broadly to include anything of value. The federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor from federal Anti-Kickback Statute liability. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor, however, does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. In addition, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Affordable Care Act, further strengthened these laws by amending the intent standard under the federal Anti-Kickback Statute and the criminal health care fraud statutes (discussed below), such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the Affordable Care Act codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act (discussed below).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal civil and criminal false claims laws, including the False Claims Act, and civil monetary penalties laws prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the federal government, including the Medicare and Medicaid programs, or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, including the Medicare and Medicaid programs. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. Recently, several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of the product for off-label, and thus, non-covered, uses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, imposes requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes certain HIPAA standards directly applicable to business associates&#8212;independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the federal Physician Payments Sunshine Act within the Affordable Care Act, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) report annually to CMS information related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals, and applicable manufacturers and group purchasing organizations to report annually certain ownership and investment interests held by physicians and their immediate family members and payments or other &#8220;transfers of value&#8221; to such physician owners and their immediate family members.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of pharmaceutical products in a state, including, in some states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several local, state and foreign governments have enacted legislation requiring pharmaceutical companies to, among other things, establish compliance programs, file periodic reports with the state or foreign government, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/ or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing specified physician prescribing data to pharmaceutical companies for use in sales and marketing, and to prohibit other specified sales and marketing practices. In addition, our future commercial activities may also be subject to federal and state consumer protection and unfair competition laws.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including without limitation, civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government programs, such as Medicaid and Medicare, integrity obligations, injunctions, as well as reputational harm, administrative burdens, diminished profits and future earnings and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage, Reimbursement and Pricing</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any drug products for which we obtain regulatory approval. In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent that third-party payors provide coverage, and establish adequate reimbursement levels for such drug products. In the United States, third-party payors include federal healthcare programs, state healthcare programs, managed care providers, private health insurers and other organizations. The process for determining whether a third-party payor will provide coverage for a drug product may be separate from the process for setting the price of a drug product or for establishing the reimbursement rate that such a payor will pay for the drug product. Third-party payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of drug products and medical services, in addition to questioning their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA approvals. NL-201 or our future product candidates may not be considered medically necessary or cost-effective. A payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. If a drug product is reimbursed under a governmental healthcare program, such as Medicare, Medicaid or TRICARE, additional laws and program requirements will apply.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Different pricing and reimbursement schemes exist in other countries. In the European Union, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed upon. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for drugs, but monitor and control company profits. The downward pressure on healthcare costs in general, particularly prescription drugs, has become more intense. As a result, increasingly high barriers are being erected to the entry of new products. The European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. We may face competition for our product candidates from lower-priced products in foreign countries that have placed price controls on pharmaceutical products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, an increasing emphasis on managed </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">care in the United States has increased and will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, President Obama signed the Affordable Care Act, which substantially changed healthcare financing and the delivery by both governmental and private insurers, and significantly impacted the pharmaceutical industry. The Affordable Care Act impacts existing government healthcare programs and requires the development of new programs. For example, the Affordable Care Act provides for Medicare payment for performance initiatives and improvements to the physician quality reporting system and feedback program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among the Affordable Care Act&#8217;s provisions of importance to the pharmaceutical industry are the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biological products apportioned among these entities according to their market share in some government healthcare programs, that began in 2011;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, retroactive to January&#160;1, 2010, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs at 100% of AMP;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts, now 7% off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers&#8217; outpatient drugs to be covered under Medicare Part D;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the Federal Poverty Level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">a requirement to report annually specified financial arrangements with physicians and teaching hospitals, as defined in the Affordable Care Act and its implementing regulations, including reporting information related to &#8220;payments or other transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians (as defined above) and their immediate family members and payments or other &#8220;transfers of value&#8221; to such physician owners and their immediate family members;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">a requirement to annually report drug samples that manufacturers and distributors provide to licensed practitioners, pharmacies of hospitals and other healthcare entities; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. On August&#160;2, 2011, the President signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend proposals in spending reductions to Congress. The Joint Select Committee did not achieve its targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation&#8217;s automatic reductions to several government programs. These reductions include aggregate reductions to Medicare payments to providers of up to 2%&#160;per fiscal year, which went into effect on April&#160;1, 2013 and, due to subsequent legislative amendments, will stay in effect through 2029 unless additional Congressional action is taken. On January&#160;2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Furthermore, there has been heightened governmental scrutiny recently over the manner in which manufacturers set prices for their marketed products. For example, there have been several recent Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturer patient programs, and reform government program reimbursement methodologies for drug products. These new laws and initiatives may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our future customers and accordingly, our financial operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since its enactment, there have been judicial and Congressional challenges to certain aspects of Affordable Care Act, as well as efforts by the Trump administration to repeal or replace certain aspects of the Affordable Care Act, or ACA. Since January 2017, President Trump signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the Affordable Care Act. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed repeal legislation, the Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January&#160;1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. In November 2020, the United States Supreme Court held oral arguments on the Fifth Circuit U.S. Court of Appeals decision that held that the individual mandate is unconstitutional. It is uncertain how the United States Supreme Court will rule on this case or how healthcare measures of the Biden administration will impact the ACA and our business. Congress may consider other legislation to repeal or replace elements of the ACA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict what healthcare reform initiatives may be adopted in the future. However, we anticipate that Congress, state legislatures, and third-party payors may continue to review and assess alternative healthcare delivery and payment systems and may in the future propose and adopt legislation or policy changes or implementations effecting additional fundamental changes in the healthcare delivery system. We also expect ongoing initiatives to increase pressure on drug pricing. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Anti-Corruption Legislation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corruption of Foreign Public Officials Act, or CFPOA, prohibits Canadian businesses and individuals from giving or offering to give a benefit of any kind to a foreign public official, or any other person for the benefit of the foreign public official, where the ultimate purpose is to obtain or retain a business advantage. Under the CFPOA, companies may be liable for the actions of their employees or third-party agents, even if such persons operate outside of Canada.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employees</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had 70 employees, of whom 23 hold Ph.D. degrees or M.D. degrees and all of which are full time employees. We have no collective bargaining agreements with our employees and have not experienced any work stoppages. We believe that relations with our employees are good.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversity &amp; Inclusion </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to creating and maintaining a workplace free from discrimination or harassment on the basis of color, race, sex, national origin, ethnicity, religion, age, disability, sexual orientation, gender identification or expression or any other status protected by applicable law. Our management team and employees are expected to exhibit and promote honest, ethical and respectful conduct in the workplace. All of our employees must adhere to a code of conduct that sets standards for appropriate behavior and are required annual training to preventing, identify, report and stop any type of discrimination and harassment.</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruitment, hiring, development, training, compensation and advancement at the Company is based on qualifications, performance, skills and experience without regard to gender, race and ethnicity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competitive Pay &amp; Benefits </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to provide pay, comprehensive benefits, and services that help meet the varying needs of our employees. Our total rewards package includes competitive pay; comprehensive healthcare benefits package for employees, with family member healthcare benefits; paid leave and paid holidays; family medical leave and flexible work schedules.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we offer every full-time employee the benefit of equity ownership in the company through stock option grants and our employee stock purchase plan. We also sponsor a 401(k) plan that allows full-time employees to contribute a portion of their salary, subject to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statutory limits.  We make matching cash contributions up to a pre-defined annual maximum contribution per employee per year.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Development &amp; Training </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We focus on attracting, retaining, and cultivating talented individuals. We emphasize employee development and training by providing access to in house development and training sessions.</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees are encouraged to attend scientific, clinical, and technological meetings and conferences and have access to broad resources they need to be successful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Safety </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The safety, health and wellness of our employees is a top priority. In response to COVID-19, we have implemented safety protocols including shift work scheduling to reduce number of people in the facility, requirements for the wearing of masks and for social distancing, increased cleaning procedures and readily available hand sanitizer.</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These protocols comply with health and safety standards as required by federal, state and local government agencies, taking into consideration guidelines of the Centers for Disease Control and Prevention and other public health authorities. In addition, the Company has provided work-at-home arrangements for employees who are able to do so.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 8, 2019, Neoleukin Therapeutics, Inc., or Former Neoleukin, completed its merger with Aquinox Pharmaceuticals, Inc., or Aquinox, in accordance with the terms of the Agreement and Plan of Merger dated August 5, 2019, or the Merger Agreement by and among Aquinox, Former Neoleukin and Apollo Sub, Inc., a wholly-owned subsidiary of Aquinox. Pursuant to the Merger Agreement, Apollo Sub, Inc. merged with and into Former Neoleukin, with Former Neoleukin surviving the Merger as a wholly-owned subsidiary of Aquinox, referred to herein as the Merger. Upon completion of the Merger, Aquinox was renamed Neoleukin Therapeutics, Inc. and Former Neoleukin was renamed Neoleukin Corporation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2020, we sold all issued and outstanding capital stock of our Canadian subsidiary, Aquinox Pharmaceuticals (Canada) Inc., to an unrelated third party. On December 31, 2020, Neoleukin Corporation was merged into Neoleukin Therapeutics, Inc. As a result of these transactions, as of December 31, 2020, we have no subsidiaries.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available free of charge on our website our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports as soon as reasonably practicable after we electronically file or furnish such materials to the Securities and Exchange Commission, or SEC. The reports are also available at www.sec.gov. Our website address is www.neoleukin.com. The information contained on, or that can be accessed through, our website is not part of, and is not incorporated by reference into, this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neoleukin and our other registered or common law trademarks, service marks, or trade names appearing in this Annual Report on Form 10-K are the property of Neoleukin Therapeutics, Inc. Other trademarks, service marks, or trade names appearing in this Annual Report on Form 10-K are the property of their respective owners.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="ib53014c4f13844039ebc5a68643f31a2_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An investment in our common stock involves various risks, and prospective investors are urged to carefully consider the matters discussed in the section titled &#8220;Risk Factors&#8221; prior to making an investment in our common stock. These risks include, but are not limited to, the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We will require substantial additional capital to finance our operations which may not be available to us on acceptable terms, or at all. If we fail to obtain necessary financing, we may be unable to complete the development and potential commercialization of our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We have incurred significant losses in every quarter since our inception and anticipate that we will continue to incur significant losses in the future.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We have a limited operating history, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We currently have no source of product revenue and may never become profitable.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our product candidates are in early stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. If we are unable to complete development of, or commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our business is heavily dependent on the success of our Neoleukin platform and of our most advanced product candidate, NL-201. Existing and future preclinical studies and clinical trials of these product candidates may not be successful, and if we are unable to commercialize these product candidates or experience significant delays in doing so, our business will be materially harmed. NL-201 is currently the subject of a clinical hold from the FDA, which prevents us from initiating clinical trials of this candidate in the U.S. We are working to respond to the FDA's requests, but do not have a definitive timeline as to when or if we will be able to obtain clearance to proceed.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our future clinical trials or those of any future collaborators may reveal significant adverse events not seen in our preclinical studies and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of our products may be delayed and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our approach to the discovery and development of our therapeutic treatments is based on de novo protein design technology which is unproven and may not result in marketable products.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We expect to rely on third parties to conduct certain of our preclinical studies or clinical trials. If those third parties do not perform as contractually required, fail to satisfy legal or regulatory requirements, miss expected deadlines or terminate the relationship, our development program could be delayed with potentially material and adverse effects on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We rely on third-party manufacturers and suppliers to supply components of our product candidates. The loss of our third-party manufacturers or suppliers, or our or their failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The outbreak of the novel strain of coronavirus, SARS-CoV-2, which causes COVID-19, could adversely impact our business, including our preclinical development activities and planned clinical trials.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we are not able to obtain, maintain, and enforce patent protection for our product candidates, our Neoleukin platform technology, or other proprietary technologies we may develop, development and commercialization of our product candidates may be adversely affected.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider the following risk factors, in addition to the other information contained in this Annual Report on Form 10-K and the information incorporated by reference herein. If any of the events described in the following risk factors occurs, our business, operating results and financial condition could be seriously harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this Annual Report on Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Capital Needs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional capital to finance our operations which may not be available to us on acceptable terms, or at all. If we fail to obtain necessary financing, we may be unable to complete the development and potential commercialization of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of biopharmaceutical product candidates is capital-intensive. If our product candidates enter and advance through preclinical studies and clinical trials, we will need substantial additional funds to expand or create our development, regulatory, manufacturing, marketing, and sales capabilities. We have used substantial funds to develop our technology and product candidates and will require significant funds to conduct further research and development and preclinical testing and clinical trials of our product candidates, to seek regulatory approvals for our product candidates and to manufacture and market products, if any, which are approved for commercial sale. In addition, we expect to continue incurring costs associated with operating as a public company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical studies and clinical trials for our product candidates will require substantial funds to complete. As of December 31, 2020, we had approximately $192.6 million in cash and cash equivalents. We expect to incur substantial expenditures in the foreseeable future as we seek to advance NL-201 and any future product candidates through preclinical and clinical development, the regulatory approval process and, if approved, commercial launch activities. Based on our current operating plan, we believe that our available cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements into 2023. However, our future capital requirements and the period for which we expect our existing resources to support our operations, fund expansion, develop new or enhanced products, or otherwise respond to competitive pressures, may vary significantly from what we expect and we may need to seek additional funds sooner than planned. Our monthly spending levels vary based on new and ongoing research and development and other corporate activities. Because the length of time and activities associated with successful research and development of our product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any marketing and commercialization activities for approved products. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the timing, cost and progress of preclinical and clinical development activities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the number and scope of preclinical and clinical programs we decide to pursue;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the progress of the development efforts of parties with whom we have entered or may in the future enter into collaborations and/or research and development agreements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the timing and amount of milestone and other payments we may receive or make under our collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to maintain our current licenses and to establish new collaboration arrangements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the costs involved in prosecuting and enforcing patent and other intellectual property claims;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the costs of manufacturing our product candidates by third parties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the cost of regulatory submissions and timing of regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the potential delays in our preclinical studies, our development programs and our planned clinical trials due to the effects of the COVID-19 pandemic;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the cost of commercialization activities if our product candidates or any future product candidates are approved for sale, including marketing, sales and distribution costs; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our efforts to enhance operational systems and hire additional personnel, including personnel to support development of our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain funding on a timely basis or on acceptable terms, we may have to delay, reduce or terminate our research and development programs and preclinical studies or clinical trials, limit strategic opportunities or undergo reductions in our workforce or other corporate restructuring activities. We do not expect to realize revenue from sales of commercial products or royalties from licensed products in the foreseeable future, if at all, and, in no event, before our product candidates are clinically tested, approved for commercialization and successfully marketed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be required to seek additional funding in the future and currently intend to do so through additional collaborations and/or licensing agreements, public or private equity offerings or debt financings, credit or loan facilities, or a combination of one or more of these funding sources. If we raise additional funds by issuing equity securities, our stockholders will suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Our future debt financings, if available, are likely to involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of our equity securities received any distribution of our corporate assets. If we raise additional funds through licensing or collaboration arrangements with third parties, we may have to relinquish valuable rights to our product candidates or grant licenses on terms that are not favorable to us. We also could be required to seek collaborators for product candidates at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates or technologies that we otherwise would seek to develop or commercialize ourselves. Failure to obtain capital when needed on acceptable terms may force us to delay, limit or terminate our product development and commercialization of our current or future product candidates, which could have a material and adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses in every quarter since our inception and anticipate that we will continue to incur significant losses in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company with a limited operating history. Investment in biotechnology is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval or become commercially viable. We do not have any products approved by regulatory authorities for marketing or commercial sale, we have not generated any revenue from product sales to date, and all of our product candidates are in preclinical development. We continue to incur significant expenses related to our ongoing operations. As a result, we are not profitable and have incurred losses in every reporting period since our inception in 2003. For the years ended December 31, 2020 and 2019, we reported a net loss of $33.3 million and $69.4 million, respectively. As of December 31, 2020, we had an accumulated deficit since inception of $332.8 million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and operating losses for the foreseeable future as we seek to identify, acquire and conduct research and development of future product candidates, and potentially begin to commercialize any future products that may achieve regulatory approval. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our financial condition. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. Our prior losses and expected future losses have had, and will continue to have, an adverse effect on our financial condition. If any of our future product candidates fail in clinical trials or do not gain regulatory approval, or if approved, fails to achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a limited operating history, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations to date have been primarily limited to organizing and staffing our company, acquiring product and technology rights, discovering and developing novel de novo proteins, undertaking preclinical studies, and, prior to the merger, developing small molecule drug candidates and conducting clinical trials of rosiptor. We have not yet obtained regulatory approval for any product candidate. Consequently, evaluating our performance, viability or possibility of future success will be more difficult than if we had a longer operating history or approved products on the market. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no source of product revenue and may never become profitable. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenues from commercial product sales, or otherwise. Our ability to generate revenue from product sales and achieve profitability will depend upon our ability, alone or with any future collaborators, to successfully commercialize any products that we may develop, in-license, or acquire in the future. Even if we can successfully achieve regulatory approval for any future product candidates, we do not know when any of these products will generate revenue from product sales for us, if at all. Our ability to generate revenue from any of our future product candidates also depends on several additional factors, including our or any future collaborators&#8217; ability to: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">complete development activities, including the necessary clinical trials; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">complete and submit Biologics License Applications, or BLAs, to the U.S. Food and Drug Administration, or FDA, and obtain regulatory approval for indications for which there is a commercial market; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">complete and submit applications to, and obtain regulatory approval from, foreign regulatory authorities; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">set a commercially viable price for our products; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">establish and maintain supply and manufacturing relationships with third parties, and ensure adequate and legally compliant manufacturing of bulk drug substances and drug products to maintain that supply; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">develop a commercial organization capable of sales, marketing and distribution for any products for which we obtain marketing approval and intend to sell ourselves in the markets in which we choose to commercialize on our own; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">find suitable distribution partners to help us market, sell, and distribute our approved products in other markets; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">obtain coverage and adequate reimbursement from third-party payors, including government and private payors; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">achieve market acceptance for our products, if any; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">establish, maintain and protect our intellectual property rights; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">attract, hire, and retain qualified personnel. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because of the numerous risks and uncertainties associated with biological product development, any future product candidates may not advance through development or achieve the endpoints of applicable clinical trials. Therefore, we are unable to predict the timing or amount of increased expenses, or when or if we will be able to achieve or maintain profitability. In addition, our expenses could increase beyond expectations if we decide, or are required by the FDA or foreign regulatory authorities, to perform studies or trials in addition to those that we currently anticipate. Even if we can complete the development and regulatory process for any future product candidates, we anticipate incurring significant costs associated with commercializing these products. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we can generate revenues from the sale of any future product candidates that may be approved, we may not become profitable and may need to obtain additional funding to continue operations. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require additional capital to finance our operations which may not be available to us on acceptable terms, or at all. If we fail to obtain necessary financing, we may be unable to complete the development and potential commercialization of future product candidates. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. Our operations have consumed substantial amounts of cash since inception. If we identify and advance any current or future product candidates into clinical trials and launch and commercialize any product candidates for which we receive regulatory approval, we expect research and clinical development expenses, and our selling, general and administrative expenses to increase substantially. In connection with our ongoing activities, we believe that our existing cash and cash equivalents will be sufficient to fund our operating requirements for at least the next 12 months. However, circumstances may cause us to consume capital more rapidly than we anticipate. We will likely require additional capital for the further development and potential commercialization of future product candidates and may also need to raise additional funds sooner to pursue a more accelerated development of future product candidates. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we need to secure additional financing, fundraising efforts may divert our management from our day-to-day activities, which may adversely affect our ability to develop and commercialize future product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we do not raise additional capital when required or on acceptable terms, we may need to: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">significantly delay, scale back or discontinue clinical trials related to the development or commercialization of any of our future product candidates or cease operations altogether; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">seek strategic alliances for research and development programs at an earlier stage than we would otherwise desire or on terms less favorable than might otherwise be available; or </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">relinquish, or license on unfavorable terms, our rights to any future product candidates that we otherwise would seek to develop or commercialize ourselves. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we need to conduct additional fundraising activities and we do not raise additional capital in sufficient amounts or on terms acceptable to us, we may be prevented from pursuing development and commercialization efforts, which will have a material adverse effect on our business, operating results and prospects. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed elsewhere in this &#8220;Risk Factors&#8221; section. We have based this estimate on assumptions that may prove to be wrong, and we could spend our available capital resources sooner than we currently expect. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to identify additional product candidates for development;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">if we in-license or acquire product candidates from third parties, the cost of in-licensing or acquisition;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the initiation, progress, timing, costs and results of clinical trials for any future product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the clinical development plans we establish for any future product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the achievement of milestones and our obligation to make milestone payments under our present or any future in-licensing agreements; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the number and characteristics of product candidates that we discover, or in-license and develop; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the outcome, timing and cost of regulatory review by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies than those that we currently expect; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the cost to establish, maintain, expand, and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending, and enforcing any patent claims and maintaining and enforcing other intellectual property rights; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the effects of COVID-19 on our business and financial results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the effect of competing technological and market developments; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the costs and timing of the implementation of commercial-scale outsourced manufacturing activities; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the costs and timing of establishing sales, marketing, distribution, and pharmacovigilance capabilities for any product candidates for which we may receive regulatory approval in territories where we choose to commercialize products on our own. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to expand our operations or otherwise capitalize on our business opportunities due to a lack of capital, our business, results of operations, financial condition and cash flows, and future prospects could be materially adversely affected. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Discovery, Development and Commercialization</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates are in early stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. If we are unable to complete development of, or commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in the early stages of our development efforts. We have no products on the market and all of our product candidates, including NL-201, are still in the preclinical or drug discovery stages, and we may not ever obtain regulatory approval for any of our product candidates. We have limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA. Before obtaining regulatory approval for the commercial distribution of our product candidates, we or an existing or future collaborator must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of our product candidates. We submitted an Investigational New Drug application, or IND, with respect to NL-201 in December 2020. On January 7, 2021, we received a clinical hold letter from the FDA related to our IND.  In the letter, the FDA informed us that we need to develop a new assay that more precisely measures the amount of protein being administered and demonstrate with this assay that dose and administration procedures will accurately deliver the intended dose of NL-201. The FDA also had additional requests not related to the clinical hold to be addressed by amendment of the IND.  While we believe that we will be able to develop the requested assay and respond to the FDA's requests,  we do not have a definitive timeline as to when or if we will be able to obtain clearance to proceed. In </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition, it is possible that the FDA may deny our re-submission or  require additional testing before allowing clinical testing in humans. Additionally, we have a portfolio of targets and programs that are in earlier stages of discovery and preclinical development and may never advance to clinical-stage development. If we do not receive regulatory approvals for clinical testing and commercialization of our product candidates, we may not be able to continue our operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have the financial resources to continue development of, or to enter into collaborations for, a product candidate if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, product candidates, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">preclinical study results may show the product candidate to be less effective than desired or to have harmful or problematic side effects, which could cause us to delay or even abandon clinical testing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">negative or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">product-related side effects experienced by patients in our clinical trials or by individuals using drugs or therapeutic biologicals similar to our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our third-party manufacturers&#8217; inability to successfully manufacture our products or to meet regulatory specifications;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">inability of any third-party contract manufacturer to scale up manufacturing of our product candidates and those of our collaborators to supply the needs of clinical trials or commercial sales;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays in submitting INDs or comparable foreign applications or delays or failures in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">conditions imposed by the FDA, the European Medicines Agency, or EMA, or other applicable regulatory authorities regarding the scope or design of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays in enrolling patients in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">high drop-out rates of our clinical trial patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">inadequate supply or quality of product candidate components or materials or other supplies necessary for the conduct of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">inability to obtain alternative sources of supply for which we have a single source for product candidate components or materials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">greater than anticipated costs of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">manufacturing costs, formulation issues, pricing or reimbursement issues or other factors that no longer make a product candidate economically feasible;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">harmful side effects or inability of our product candidates to meet efficacy endpoints during clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">failure to demonstrate a benefit-risk profile acceptable to the FDA, EMA or other applicable regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">unfavorable inspection and review by the FDA, EMA or other applicable regulatory authorities of one or more clinical trial sites or manufacturing facilities used in the testing and manufacture of any of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays and changes in regulatory requirements, policy, and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">varying interpretations of our data by the FDA, EMA or other applicable regulatory authorities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our future partners&#8217; inability to complete development of, or commercialize our product candidates, or significant delays in doing so due to one or more of these factors, could have a material and adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, cancer therapies are sometimes characterized as first-line, second-line, or third-line, and the FDA often approves new therapies initially only for advanced cancers, i.e. third-line or beyond. When cancer is detected early enough, first-line therapy, usually chemotherapy, surgery, radiation therapy, immunotherapy, hormone therapy, or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second- and third-line therapies are administered to patients when prior therapy is not effective. We expect our clinical trials for NL-201 will be with patients who have received one or more prior treatments. Subsequently, for those of our products that prove to be sufficiently beneficial, if any, we would expect to seek approval in earlier lines of therapy. Any product candidates we develop, even if approved, may not be successfully approved for earlier lines of therapy, and, prior to any such approvals, we will likely have to conduct additional clinical trials, which are often very lengthy, expensive, and have a significant risk of failure.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is heavily dependent on the success of our Neoleukin platform and of our most advanced product candidate, NL-201. Existing and future preclinical studies and clinical trials of these product candidates may not be successful, and if we are unable to commercialize these product candidates or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is heavily dependent on our ability to obtain regulatory approval of and then successfully launch and commercialize our product candidates. We have invested a significant portion of our efforts and financial resources in the development of our proprietary system of advanced computational algorithms and methods for the design of functional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proteins, which we refer to as our Neoleukin platform, with an initial focus on key cytokine mimetics, which we refer to as Neoleukin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cytokine mimetics. Our lead product candidate, NL-201, is a Neoleukin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> protein derived from our Neoleukin platform. However, NL-201 and our other product candidates are still in the preclinical or earlier stage. Our ability to generate commercial product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our lead product candidates. Our product candidates may not be successful in clinical trials or receive regulatory approval. Even if they are successful in clinical trials, regulatory authorities may not complete their review in a timely manner, or additional delays may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory authority policy during the period of product development, clinical trials, and the review process. Regulatory authorities may approve a product candidate for targets, disease indications or patient populations that are not as broad as we intended or desired, approve more limited indications than requested, or require distribution restrictions or strong safety language, such as contraindications or boxed warnings. Regulatory authorities may also require Risk Evaluation and Mitigation Strategies, or REMS, or the performance of costly post-marketing clinical trials. Even if we successfully obtain regulatory approvals to market our product candidates, our revenues will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets for patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, if approved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to seek regulatory approval to commercialize our product candidates both in the United States and in selected foreign countries. In order to market and sell our product candidates in the European Union and many other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. The approval procedure varies among countries and can involve additional testing. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We may be required to expend significant resources to obtain regulatory approval, which may not be on a timely basis or successful at all, and to comply with ongoing regulations in these jurisdictions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our Neoleukin platform, NL-201, and our other product candidates will depend on many factors, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">successful completion of necessary preclinical studies to enable the initiation of clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">successful enrollment of patients in, and the completion of, our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">obtaining adequate financing to perform the expensive clinical development programs anticipated for approval;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">receiving required regulatory authorizations for the development and approvals for the commercialization of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">establishing and maintaining arrangements with third-party manufacturers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">obtaining and maintaining patent and trade secret protection and non-patent exclusivity for our product candidates and their components;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">enforcing and defending our intellectual property rights and claims;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">achieving desirable therapeutic properties for our product candidates&#8217; intended indications;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with third parties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">acceptance of our product candidates, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">effectively competing with other therapies, including those that are currently in development; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">maintaining an acceptable safety profile of our product candidates through clinical trials and following regulatory approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not achieve any one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future clinical trials or those of any future collaborators may reveal significant adverse events not seen in our preclinical studies and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If significant adverse events or other side effects are observed in any of our clinical trials, we may have difficulty recruiting patients to our clinical trials, patients may drop out of our trials, we may be required to pause, delay, or abandon the trials or our development efforts of one or more product candidates altogether, we may be required to have more restrictive labeling, or we may experience the delay or denial of regulatory approval by the FDA, EMA or other applicable regulatory authorities. We, the FDA, EMA or other applicable regulatory authorities, or an IRB may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects or patients in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. We designed NL-201 to mimic the therapeutic activity of the cytokine interleukin-2, or IL-2, and interleukin-15, or IL-15, while limiting the toxicity caused by the preferential binding of native IL-2 and native IL-15 to cells that co-express the alpha subunit, known as CD25. However, it is possible NL-201 will demonstrate significant adverse events similar to, or in addition to, those associated with IL-2 and IL-15, such as vascular leak syndrome, hypotension, impaired kidney and liver function, and mental status changes. Therapies involving cytokines have been known to cause side effects such as neurotoxicity and cytokine release syndrome.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, de novo proteins are a new class of therapeutics that have not been previously tested in humans. De novo proteins can be substantially different from all known proteins and as a result, it is unknown to what extent, if any, these de novo proteins will produce immunologic reactions in patients. Immunologic reactions could substantially limit the effectiveness of the treatment, the duration of treatment, or represent safety risks.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if any of our product candidates receives marketing approval, the FDA could require us to adopt a REMS to ensure that the benefits of the product outweigh its risks, which may include, among other things, a Medication Guide outlining the risks of the product for distribution to patients and a communication plan to health care practitioners. Furthermore, if we or others later identify undesirable side effects caused by any of our products, several potentially significant negative consequences could result, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulatory authorities may suspend or withdraw approvals of such product;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulatory authorities may require additional warnings on the label of such product;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may be required to change the way such a product is administered or conduct additional clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we could be sued and held liable for harm caused to patients; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our reputation may suffer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these developments could materially harm our business, financial condition and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of our products may be delayed and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials and the submission of regulatory filings. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, or at all, the commercialization of our products may be delayed or never achieved and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:94%">Our approach to the discovery and development of our therapeutic treatments is based on novel de novo protein design technology that are unproven and may not result in marketable products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The success of our business depends primarily upon our ability to discover, develop, and commercialize a pipeline of product candidates using our Neoleukin platform. Unlike traditional protein-based therapeutics that modify native proteins, our Neoleukin platform designs new proteins from the ground up. Our platform uses advanced computational algorithms and methods to design functional de novo proteins that are hyper-stable, modifiable, and are designed to optimize desired intermolecular interactions and eliminate undesirable interactions. While we believe this approach will enable us to develop product candidates that may offer unique therapeutic benefits, the scientific basis of our efforts to develop product candidates using our Neoleukin platform is ongoing and may not result in viable product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have had favorable preclinical study results related to precursors to NL-201, we are still in the early stages of product development of NL-201.  Our approach may be unsuccessful in moving NL-201 from preclinical studies into clinical development, discovering additional product candidates, and NL-201 or any product candidates that we are currently developing may be shown to have harmful side effects or may have other characteristics that may necessitate additional clinical testing or make the product candidates unmarketable or unlikely to receive marketing approval. If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not tested any of our product candidates in any clinical trials. We may ultimately discover that our Neoleukin platform and any product candidates resulting therefrom do not possess certain properties required for therapeutic effectiveness. Our product candidates may also be unable to remain stable in the human body for the period of time required for the drug to reach the target tissue, or they may trigger immune responses that inhibit the activity of the product candidate or that cause adverse side effects in humans. We may spend substantial funds attempting to mitigate these properties and may never succeed in doing so. In addition, product candidates based on our Neoleukin platform may demonstrate different chemical and pharmacological properties in patients than they do in laboratory studies. Our Neoleukin platform and any product candidates resulting therefrom may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective, or harmful ways.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or extensively studied product candidates. Because the FDA has no prior experience with de novo proteins as therapeutics, we anticipate that this may increase the complexity, uncertainty and length of the regulatory approval process for our product candidates. We or any future partners may be required to perform additional or unanticipated clinical trials to obtain approval or be subject to post-marketing testing requirements to maintain regulatory approval. If the products resulting from our Neoleukin platform and research programs prove to be ineffective, unsafe, or commercially unviable, our Neoleukin Platform and pipeline would have little, if any, value, which would have a material and adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and clinical development involve a lengthy and expensive process, with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our current product candidates or any future product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates are in preclinical or earlier development and their risk of failure is high. It is impossible to predict when or if any of our product candidates will receive regulatory approval. To obtain the requisite regulatory approvals to commercialize any product candidates, we must demonstrate through extensive preclinical studies and lengthy, complex, and expensive clinical trials that our product candidates are safe and effective in humans. Clinical testing can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the success of later-stage clinical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials. The design of a clinical trial can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful, and a clinical trial can fail at any stage of testing, and we have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. Differences in trial design between early-stage clinical trials and later-stage clinical trials make it difficult to extrapolate the results of earlier clinical trials to later clinical trials. Moreover, clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in clinical trials have nonetheless failed to obtain marketing approval of their products. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or to unfavorable safety profiles, notwithstanding promising results in earlier trials, and we could face similar setbacks. There is typically a high rate of failure of product candidates proceeding through clinical trials. Most product candidates that commence clinical trials are never approved as products and there can be no assurance that any of our future clinical trials will ultimately be successful or support clinical development of our current or any of our future product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencement of our future clinical trials is subject to finalizing the trial design and receiving approval from the FDA to proceed with clinical testing or similar approval from the FDA, EMA, or comparable foreign regulatory authorities. Even after we submit our IND or comparable submissions in other jurisdictions, the FDA, EMA, or comparable foreign regulatory authorities could disagree that we have satisfied their requirements to commence our clinical trials or disagree with our study design, which may require us to complete additional preclinical studies or amend our protocols or impose stricter conditions on the commencement of clinical trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter substantial delays in the commencement or completion, or termination or suspension, of our clinical trials, which could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or any collaborators may experience delays in initiating or completing clinical trials or may experience numerous unforeseen events during, or as a result of, any future clinical trials that we could conduct that could delay or prevent our ability to receive marketing approval or commercialize NL-201 or any future product candidates, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may be unable to generate sufficient preclinical, toxicology, or other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> data to obtain regulatory authorizations to commence a clinical trial;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may experience issues in reaching a consensus with regulatory authorities on trial design;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulators or institutional review boards, or IRBs, ethics committees, FDA, EMA or other applicable regulatory authorities, may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective contract research organizations, or CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">clinical trial sites may deviate from trial protocol or drop out of a trial;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">clinical trials of any product candidates may fail to show safety or efficacy, produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials or we may decide to abandon product development programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the number of subjects required for clinical trials of any product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or subjects may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may elect to, or regulators, IRBs, or ethics committees may require that we or our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants in our trials are being exposed to unacceptable health risks;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the cost of clinical trials of any of our product candidates may be greater than we anticipate;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate to initiate or complete a given clinical trial;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may be unable to obtain or manufacture sufficient quantities of our product candidates for use in clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">reports from clinical testing of other therapies may raise safety or efficacy concerns about our product candidates; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may fail to establish an appropriate safety profile for a product candidate based on clinical or preclinical data for such product candidate as well as data emerging from other molecules in the same class as our product candidate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs of the institutions in which such trials are being conducted, or the FDA, EMA or other regulatory authorities, or if a clinical trial is recommended for suspension or termination by the Data Safety Monitoring Board, or the DSMB, for such trial. A suspension or termination may be imposed due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA, or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product or treatment, failure to establish or achieve clinically meaningful trial endpoints, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Clinical studies may also be delayed or terminated as a result of ambiguous or negative interim results. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Further, the FDA, EMA, or other regulatory authorities may disagree with our clinical trial design and our interpretation of data from clinical trials, or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development costs will increase if we experience delays in clinical testing or obtaining marketing approvals. We do not know whether any of our clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates and may allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations. Any delays in our clinical development programs may harm our business, financial condition, and results of operations significantly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment of patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the number and location of clinical sites we enroll, the proximity of patients to clinical sites, the eligibility and exclusion criteria for the trial, the design of the clinical trial, the inability to obtain and maintain patient consents, the risk that enrolled participants will drop out before completion, competing clinical trials, and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs or therapeutic biologics that may be approved for the indications being investigated by us. Furthermore, we expect to rely on our collaborators, CROs, and clinical trial sites to ensure the proper and timely conduct of our future clinical trials, including the patient enrollment process, and we have limited influence over their performance. Additionally, we could encounter delays if treating physicians encounter unresolved ethical issues associated with enrolling patients in future clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or might require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, slow down or halt our product candidate development and approval process and jeopardize our ability to seek and obtain the marketing approval required to commence product sales and generate revenue, which would cause the value of our company to decline and limit our ability to obtain additional financing if needed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim and preliminary or topline data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publish interim topline or preliminary data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary or topline data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse differences between interim or preliminary or topline data and final data could significantly harm our reputation and business prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain regulatory approval in international jurisdictions would prevent any future product candidates from being marketed outside the United States.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market and sell our products in the European Union and other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. A failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory approval process in others. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market. If we are unable to obtain approval of any of our future product candidates by regulatory authorities in the European Union or another jurisdiction, the commercial prospects of that product candidate may be significantly diminished and our business prospects could decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently enacted and future legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain marketing approval of, and commercialization of, our future product candidates and affect the prices we may obtain.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations that govern, among other things, marketing approvals, coverage, pricing and reimbursement for new drug products vary from country to country. In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our future product candidates, restrict or regulate post-approval activities and affect our ability to successfully sell any product candidates for which we obtain marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States in recent years, Congress has considered reductions in Medicare reimbursement for drugs administered by physicians. The Centers for Medicare and Medicaid Services, or CMS, the agency that administers the Medicare program, also has the authority to revise reimbursement rates and to implement coverage restrictions for drugs. Cost reduction initiatives and changes in coverage implemented through legislation or regulation could decrease utilization of, and reimbursement for, any approved products, which in turn could affect the price we can receive for those products. While Medicare regulations apply only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in establishing their own coverage polices and reimbursement rates. Therefore, any reduction in reimbursement that results from federal legislation or regulation may result in a similar reduction in payments from private payors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, President Obama signed into law the Affordable Care Act in an effort to, among other things, broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on pharmaceutical and medical device manufacturers and impose additional health policy reforms. The Affordable Care Act, among other things, also expanded manufacturers&#8217; rebate liability to include covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations, increased the minimum rebate due for innovator drugs from 15.1% of average manufacturer price, or AMP, to 23.1% of AMP and capped the total rebate amount for innovator drugs at 100% of AMP. The Affordable Care Act and subsequent legislation and regulation also revised the definition of AMP for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices. Furthermore, the Affordable Care Act imposes a significant annual, nondeductible fee on companies that manufacture or import certain branded prescription drug products. Substantial provisions affecting compliance were enacted, which may affect our business practices with healthcare practitioners, and a significant number of provisions are not yet, or have only recently become, effective. Certain provisions of the Affordable Care Act have been subject to judicial and Congressional challenges, as well as efforts by the Trump administration to repeal or replace certain aspects of the Affordable Care Act. Since January 2017, President Trump has signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the Affordable Care Act. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the Affordable Care Act. While Congress has not passed repeal legislation, the Tax Cuts and Jobs Act includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. The Affordable Care Act has also been subject to judicial challenge. In December 2018, a federal district court judge, in a challenge brought by a number of state attorneys general, found the Affordable Care Act unconstitutional in its entirety. Pending appeals, which could take some time, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Affordable Care Act is still operational in all respects. Congress may consider other legislation to repeal or replace elements of the Affordable Care Act. Because of the continued uncertainty about the implementation of Affordable Care Act, including the potential for further legal challenges or repeal of Affordable Care Act, we cannot quantify or predict with any certainty the likely impact of the Affordable Care Act or its repeal on our business, prospects, financial condition or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. On August 2, 2011, the President signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2% per fiscal year that went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2029 unless additional Congressional action is taken. On January 2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our customers and accordingly, our financial operations. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. Furthermore, there has been heightened governmental scrutiny recently over the manner in which manufacturers set prices for their marketed products. For example, there have been several recent Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer&#8217;s patient programs, and reform government program reimbursement methodologies for drug products. We cannot be sure whether additional legislative changes will be enacted, or whether existing regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our future product candidates, if any, may be.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the European Union and other potentially significant markets for our future product candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which has resulted in lower average selling prices. Furthermore, the increased emphasis on managed healthcare in the United States and on country and regional coverage, pricing and reimbursement controls in the European Union will put additional pressure on product coverage, pricing, reimbursement and utilization, which may adversely affect our business, results of operations, financial condition and cash flows and future prospects. These pressures can arise from various sources, including but not limited to, rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product candidate in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, which could negatively impact the revenues we are able to generate from the sale of the product in that particular country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates even if our product candidates obtain marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Laws and regulations governing international operations may preclude us from developing, manufacturing and selling certain product candidates outside of the United States and require us to develop and implement costly compliance programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we expand our operations outside of the United States, we must comply with numerous laws and regulations in each jurisdiction in which we plan to operate. We must also comply with U.S. laws applicable to the foreign operations of U.S. businesses and individuals, such as the Foreign Corrupt Practices Act, or FCPA. The creation and implementation of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FCPA prohibits any U.S. individual or business from paying, offering, authorizing payment or offering anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the DOJ. The SEC is involved with enforcement of the books and records provisions of the FCPA.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various laws, regulations and executive orders also restrict the use and dissemination outside the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. Our expanding presence outside the United States will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside the United States, which could limit our growth potential and increase our development costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure to comply with laws governing international business practices may result in substantial penalties, including suspension or debarment from government contracting. Violation of the FCPA can result in significant civil and criminal penalties. Indictment alone under the FCPA can lead to suspension of the right to do business with the U.S. government until the pending claims are resolved. Conviction of a violation of the FCPA can result in long-term disqualification as a government contractor. The termination of a government contract or relationship as a result of our failure to satisfy any of our obligations under laws governing international business practices would have a negative impact on our operations and harm our reputation and ability to procure government contracts. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we are able to commercialize our future product candidates, the products may not receive coverage and adequate reimbursement from third-party payors, which could harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize any products successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government authorities, private health insurers, health maintenance organizations and third-party payors. Patients who are prescribed medications for the treatment of their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Coverage and adequate reimbursement from government healthcare programs, such as Medicare and Medicaid, and private health insurers are critical to new product acceptance. Patients are unlikely to use our future product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. As a result, government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Third-party payors may also seek additional clinical evidence, beyond the data required to obtain marketing approval, demonstrating clinical benefits and value in specific patient populations before covering our products for those patients. We cannot be sure that coverage and adequate reimbursement will be available for any product that we commercialize and, if reimbursement is available, what that level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or are available only at limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, obtaining coverage does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sales and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may only be temporary. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used. Reimbursement rates may also be based in part on existing reimbursement amounts for lower cost drugs or may be bundled into the payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage and reimbursement determination process is often a time-consuming and costly process with no assurance that coverage and adequate reimbursement will be obtained or applied consistently. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never marketed a drug before. If we are able to identify and acquire a product candidate that is ultimately approved for sale but are unable to establish an effective sales force and marketing infrastructure or enter into acceptable third-party sales and marketing or licensing arrangements, we may be unable to generate any revenue.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have an infrastructure for the sales, marketing and distribution of pharmaceutical drug products and the cost of establishing and maintaining such an infrastructure may exceed the cost-effectiveness of doing so. While we do not currently have any product candidates in clinical development, if we were able to identify and establish product candidates and advance them through clinical development, in order to market any products that may ultimately be approved by the FDA and comparable foreign regulatory authorities, we must build our sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. If we are unable to establish adequate sales, marketing, and distribution capabilities, whether independently or with third parties, we may not be able to generate product revenue and may not become profitable. We will be competing with many companies that have extensive and well-funded sales and marketing operations. Without an internal commercial organization or the support of a third party to perform sales and marketing functions, we may be unable to compete successfully against these more established companies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to use our Neoleukin platform to expand our pipeline of product candidates and develop marketable products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business depends in part upon our ability to discover, develop, and commercialize products based on our Neoleukin platform, which may fail to identify other potential product candidates for clinical development for a number of reasons. Our research methodology may be unsuccessful in identifying potential product candidates or our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval. If any of these events occur, we may be forced to abandon our development efforts for a program or for multiple programs, which would materially harm our business and could potentially cause us to cease operations. Research programs to identify new product candidates require substantial technical, financial, and human resources.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus our research and development efforts on our lead product candidate, NL-201, with initial indications including renal cell carcinoma and melanoma. As a result, we may forgo or delay pursuit of opportunities with other product candidates that later prove to have greater commercial potential. Due to the ongoing COVID-19 public health emergency, we are also utilizing a portion of our research and computational bandwidth to investigate the potential application of our de novo protein technology toward COVID-19. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, including companies developing novel treatments and technology platforms in oncology. If these companies develop technologies or product candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize product candidates may be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of drugs is highly competitive. Our product candidates, if approved, will face significant competition and our failure to effectively compete may prevent us from achieving significant market penetration. Most of our competitors have significantly greater resources than we do and we may not be able to successfully compete. We compete with a variety of multinational biopharmaceutical companies, specialized biotechnology companies, and emerging biotechnology companies, as well as with technologies and product candidates being developed at academic institutions, governmental agencies, and other public and private research institutions. Our competitors have developed, are developing, or will develop product candidates and processes competitive with our product candidates and processes. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments, including those based on novel technology platforms that enter the market. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we are trying, or may try, to develop product candidates. There is intense and rapidly evolving competition in the biotechnology, biopharmaceutical, and interleukin and immunoregulatory therapeutics fields. Competition from many sources exists or may arise in the future. Our competitors include larger and better funded biopharmaceutical, biotechnological, and therapeutics companies, including companies focused on oncology therapeutics, as well as numerous small companies. Moreover, we also compete with current and future therapeutics developed at universities and other research institutions. Some </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of these companies are well-capitalized and, in contrast to us, have significant clinical experience, and may include our future partners. In addition, these companies compete with us in recruiting scientific and managerial talent.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend partially on our ability to develop and commercialize therapeutics that are safer and more effective than competing products. Our commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective, or less expensive than the therapeutics we develop.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, NL-201, is under development for the treatment of advanced solid tumors, including melanoma and renal cell carcinoma. If approved, it would face competition from approved advanced melanoma and renal cell carcinoma treatments, including multiple checkpoint inhibitors, tyrosine kinase inhibitors, VEGF inhibitors, recombinant human IL-2, and several chemotherapy drugs or combinations. Further, we are aware of several IL-2 or IL-15 agonists in various stages of clinical and preclinical development.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales, and supply resources or experience than we have. If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage, and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, less expensive, or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biologics Price Competition and Innovation Act of 2009, or the BPCIA, was enacted as part of the Affordable Care Act to establish an abbreviated pathway for the approval of biosimilar biological products (both highly similar and interchangeable biosimilar biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an approved biologic. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the first licensure date of the reference product licensed under a BLA. The law is complex and some provisions are still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A biological product submitted for licensure under a BLA is eligible for a period of exclusivity that commences on the date of its licensure, unless its date of licensure is not considered a date of first licensure because it falls within an exclusion under the PBCIA. There is a risk that this exclusivity could be shortened due to congressional action or otherwise, potentially creating the opportunity for generic competition sooner than anticipated. Most states have enacted substitution laws that permit substitution of only interchangeable biosimilars.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The extent to which a highly similar biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to rely on third parties to conduct certain of our preclinical studies or clinical trials. If those third parties do not perform as contractually required, fail to satisfy legal or regulatory requirements, miss expected deadlines or terminate the relationship, our development program could be delayed with potentially material and adverse effects on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to rely in the future on third-party clinical investigators, CROs, clinical data management organizations, and consultants to assist or provide the design, conduct, supervision, and monitoring of preclinical studies and clinical trials of our product candidates. Because we intend to rely on these third parties and will not have the ability to conduct all preclinical studies or clinical trials independently, we will have less control over the timing, quality, and other aspects of preclinical studies and clinical trials than we would have had we conducted them on our own. These investigators, CROs, and consultants will not be our employees, and we will have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties with which we may contract might not be diligent, careful, or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we will be responsible for ensuring that each of our preclinical studies and clinical trials are conducted in accordance with the general investigational plan and protocols for the trial as well as applicable legal and regulatory requirements. The FDA generally requires preclinical studies to be conducted in accordance with Good Laboratory Practices and clinical trials to be conducted in accordance with Good Clinical Practices, including for designing, conducting, recording, and reporting the results of preclinical studies and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity, and confidentiality of clinical trial participants are protected. Our reliance on third parties that we do not control will not relieve us of these responsibilities and requirements. Any adverse development or delay in our preclinical studies or clinical trials as a result of our reliance on third parties could have a material and adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with these third-party CROs or others terminate, we may not be able to enter into arrangements with alternative CROs or other third parties or to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO begins work. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third-party manufacturers and suppliers to supply components of our product candidates. The loss of our third-party manufacturers or suppliers, or our or their failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate facilities for drug manufacturing, storage, distribution, or quality testing. We currently rely, and expect to continue to rely, on third-party contract manufacturers to manufacture bulk drug substances, drug products, raw materials, samples, components, or other materials and reports, and conduct fill-finish services. Reliance on third-party manufacturers may expose us to different risks than if we were to manufacture product candidates ourselves. There can be no assurance that our preclinical and clinical development product supplies will not be limited, available at acceptable prices. In particular, any replacement of our manufacturer could require significant effort and expertise because there may be a limited number of qualified replacements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing process for a product candidate is subject to review by the FDA, EMA, or other applicable regulatory authorities. We, and our suppliers and manufacturers, must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as current Good Manufacturing Practices, or cGMPs. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the FDA and foreign regulatory authorities. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, EMA or other applicable regulatory authorities, we may not be able to rely on their manufacturing facilities for the manufacture of elements of our product candidates and approval may be delayed. Moreover, although we do not control the manufacturing process at our contract manufacturers and are completely dependent on them for compliance with current regulatory requirements, we are responsible for ensuring that our products comply with regulatory requirements. If any of our manufacturers fails to comply with such requirements or to perform its obligations in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such to another third party. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to enable us, or to have another third party, manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines; and we may be required to repeat some of the development program. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to rely on third-party manufacturers if we receive regulatory approval for any product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. Any manufacturing facilities used to produce our products will be subject to periodic review and inspection by the FDA, EMA, or other applicable regulatory authorities, including for continued compliance with cGMP requirements, quality control, quality assurance, and corresponding maintenance of records and documents. If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Our or a third party&#8217;s failure to execute on our manufacturing requirements, comply with cGMPs, or maintain a compliance status acceptable to the FDA, EMA, or other applicable regulatory authorities could adversely affect our business in a number of ways, including:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">an inability to initiate or continue clinical trials of product candidates under development;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">loss of the cooperation of future collaborators;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">subjecting third-party manufacturing facilities to additional inspections by regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">requirements to cease distribution or to recall batches of our product candidates; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our contract manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments. For example, in December 2019 the outbreak of COVID-19 originated in Wuhan, China, has since spread across the globe. To date, this pandemic has resulted in extended shutdowns of businesses in the United States, Canada and many other countries and has had ripple effects to businesses around the world. Global health concerns, such as COVID-19, could also result in adverse effects to our manufacturing operations. If our contract manufacturers were to encounter any of these difficulties, our ability to provide our product candidates to patients in preclinical and clinical trials, or to provide product for treatment of patients once approved, would be jeopardized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our third-party manufacturers may encounter difficulties in production. If we or any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials, our ability to obtain marketing approval, or our ability to provide supply of our products for patients, if approved, could be delayed or stopped.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are biopharmaceuticals, and the process of manufacturing biopharmaceuticals is complex, time-consuming, highly regulated, and subject to multiple risks. Our contract manufacturers must comply with legal requirements, cGMPs, and guidelines for the bulk manufacturing, fill-finish services, packaging, and storage of biopharmaceuticals used in clinical trials and, if approved, marketed products. Our contract manufacturers may have limited experience in the manufacturing of cGMP batches.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing biopharmaceuticals is highly susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics, and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. If microbial, viral, or other contaminations are discovered at our third-party manufacturers&#8217; facilities, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. Moreover, if the FDA determines that our third-party manufacturers&#8217; facilities are not in compliance with FDA laws and regulations, including those governing cGMPs, the FDA may deny approval of our application until the deficiencies are corrected or we replace the manufacturer in our application with a manufacturer that is in compliance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process scale-up, process reproducibility, stability issues, compliance with cGMPs, lot consistency and timely availability of raw materials. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that manufacturers will be able to manufacture the approved product, or provide fill-finish services, to specifications acceptable to the FDA, EMA, or other applicable regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product or to meet potential future demand. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization, commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scaling up a biopharmaceutical manufacturing process is a difficult and uncertain task, and our third-party manufacturers may not have the necessary capabilities to complete the implementation, manufacturing, and development process. If we are unable to adequately validate or scale-up the manufacturing process at our current manufacturers&#8217; facilities, we will need to transfer to another manufacturer and complete the manufacturing validation process, which can be lengthy. If we are able to adequately validate and scale-up the manufacturing process for our product candidates with a contract manufacturer, we will still need to negotiate with such contract manufacturer an agreement for commercial supply and it is not certain we will be able to come to agreement on terms acceptable to us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that any stability or other issues relating to the manufacture of any of our product candidates or products will not occur in the future. Our de novo protein product candidates may not demonstrate sufficient long-term stability to support a BLA filing or obtain approval, or the product shelf life may be limited by stability results. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or stability of our product candidates that may not be detectable in final product testing. If our third-party manufacturers were to encounter any of these difficulties, our ability to provide any product candidates to patients in planned clinical trials and products to patients, once approved, would be jeopardized. Any delay, interruption or other issues that arise in the manufacture, fill- finish, packaging, or storage of clinical trial supplies could delay the completion of planned clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely. Any adverse development affecting clinical or commercial manufacturing of our product candidates or products may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our product candidates or products. We may also have to take inventory write-offs and incur other charges and expenses for product candidates or products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Accordingly, failures or difficulties faced at any level of our supply chain could adversely affect our business and delay or impede the development and commercialization of any of our product candidates or products, if approved, and could have an adverse effect on our business, prospects, financial condition, and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our process development efforts, we also may make changes to the manufacturing processes at various points during development, for various reasons, such as controlling costs, achieving scale, decreasing processing time, increasing manufacturing success rate or other reasons. Such changes carry the risk that they will not achieve their intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of our ongoing clinical trials or future clinical trials. In some circumstances, changes in the manufacturing process may require us to perform </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials. For instance, changes in our process during the course of clinical development may require us to show the comparability of the product used in earlier clinical phases or at earlier portions of a trial to the product used in later clinical phases or later portions of the trial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may, in the future, seek to enter into collaborations with other third parties for the discovery, development and commercialization of our product candidates. If our collaborators cease development efforts under our collaboration agreements, or if any of those agreements are terminated, these collaborations may fail to lead to commercial products, and we may never receive milestone payments or future royalties under these agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect a significant portion of our future revenue and cash resources to be derived from collaboration agreements or other similar agreements into which we may enter in the future for research, development, and commercialization of other therapeutic technologies or product candidates. Biopharmaceutical companies are our likely future collaborators for any marketing, distribution, development, licensing, or broader collaboration arrangements. If we fail to enter into future collaborations on commercially reasonable terms, or at all, or such collaborations are not successful, we may not be able to execute our strategy to develop certain targets, product candidates, or disease areas that we believe could benefit from the resources of either larger biopharmaceutical companies or those specialized in a particular area of relevance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from research and development collaborations depends upon continuation of the collaborations, payments for research and development services, and resulting options to acquire any licenses of successful product candidates, and the achievement of milestones, contingent payments, and royalties, if any, derived from future products developed from our research. If we are unable to successfully advance the development of our product candidates or achieve milestones, revenue and cash resources from milestone payments under our collaboration agreements will be substantially less than expected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to future collaboration agreements, we expect to have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Moreover, our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations involving our product candidates may pose the following risks to us:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on preclinical studies or clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial, or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the foregoing, our current and any future collaboration agreements may not lead to development or commercialization of our product candidates in the most efficient manner or at all. If a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated. Any failure to successfully develop or commercialize our product candidates pursuant to our current or any future collaboration agreements could have a material and adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, to the extent that any of our future collaborators were to terminate a collaboration agreement, we may be forced to independently develop these product candidates, including funding preclinical studies or clinical trials, assuming marketing and distribution costs and defending intellectual property rights, or, in certain instances, abandon product candidates altogether, any of which could result in a change to our business plan and have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may have conflicts with our collaborators that could delay or prevent the development or commercialization of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may have conflicts with our collaborators, such as conflicts concerning the interpretation of preclinical or clinical data, the achievement of milestones, the interpretation of contractual obligations, payments for services, development obligations or the ownership of intellectual property developed during our collaboration. If any conflicts arise with any of our collaborators, such collaborator may act in a manner that is adverse to our best interests. Any such disagreement could result in one or more of the following, each of which could delay or prevent the development or commercialization of our product candidates, and in turn prevent us from generating revenues: unwillingness on the part of a collaborator to pay us milestone payments or royalties we believe are due to us under a collaboration, which could require us to raise additional capital; uncertainty regarding ownership of intellectual property rights arising from our collaborative activities, which could prevent us from entering into additional collaborations; unwillingness by the collaborator to cooperate in the development or manufacture of the product, including providing us with product data or materials; unwillingness on the part of a collaborator to keep us informed regarding the progress of its development and commercialization activities or to permit public disclosure of the results of those activities; initiating of litigation or alternative dispute resolution options by either party to resolve the dispute; or attempts by either party to terminate the agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not successfully engage in strategic transactions, including any additional collaborations we seek, which could adversely affect our ability to develop and commercialize product candidates, impact our cash position, increase our expenses, and present significant distractions to our management.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may consider strategic transactions, such as additional collaborations, acquisitions of companies, asset purchases, and out- or in-licensing of product candidates or technologies that we believe will complement or augment our existing business. In particular, we will evaluate and, if strategically attractive, seek to enter into additional collaborations, including with major biotechnology or biopharmaceutical companies. The competition for collaborators is intense, and the negotiation process is time-consuming and complex. Any new collaboration may be on terms that are not optimal for us, and we may not be able to maintain any new collaboration if, for example, development or approval of a product candidate is delayed, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales of an approved product candidate do not meet expectations or the collaborator terminates the collaboration. In addition, a significant number of recent business combinations among large pharmaceutical companies has resulted in a reduced number of potential future strategic partners. Our collaborators may consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the strategic partner&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed strategic partner&#8217;s evaluation of a number of factors. These factors may include the design or results of clinical trials, the likelihood of approval by the FDA, EMA, or other applicable regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. Moreover, if we acquire assets with promising markets or technologies, we may not be able to realize the benefit of acquiring such assets if we are not able to successfully integrate them with our existing technologies. We may encounter numerous difficulties in developing, testing, manufacturing, and marketing any new products resulting from a strategic acquisition that delay or prevent us from realizing their expected benefits or enhancing our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that following any such collaboration, or other strategic transaction, we will achieve the expected synergies to justify the transaction. For example, such transactions may require us to incur non-recurring or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. These transactions would entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty, and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership, and the inability to retain key employees of any acquired business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and would have a material and adverse effect on our business, financial condition, results of operations, and prospects. Conversely, any failure to enter any additional collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our product candidates and have a negative impact on the competitiveness of any product candidate that reaches market.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The outbreak of the novel strain of coronavirus, SARS-CoV-2, which causes COVID-19, could adversely impact our business, including our preclinical development activities and planned clinical trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public health crises such as pandemics or similar outbreaks could adversely impact our business. The outbreak of a novel strain of coronavirus, which causes the disease called COVID-19, has evolved into a global pandemic.  As a result of the COVID-19 pandemic, or similar pandemics, we may experience disruptions that could severely impact our business, manufacturing, preclinical development activities, preclinical studies and planned clinical trials, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays or disruptions in preclinical development activities, including non-clinical experiments and investigational new drug application-enabling good laboratory practice standard toxicology studies due to unforeseen circumstances in supply chain;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">interruption or delays in the operations of the FDA and comparable foreign regulatory agencies, which may impact timelines for regulatory submission, trial initiation and regulatory approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">interruption or delays in our CROs and collaborators meeting expected deadlines or complying with regulatory requirements related to preclinical development activities, preclinical studies and planned clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">interruptions of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, productions slowdowns, limited availability of raw materials, or stoppages and disruptions in delivery systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays or difficulties in any planned clinical site initiation, including difficulties in obtaining IRB approvals, recruiting clinical site investigators and clinical site staff;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">delays or difficulties in enrolling patients in clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">increased rates of patients withdrawing from any planned clinical trials following enrollment as a result of contracting COVID-19 or being forced to quarantine;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">diversion of healthcare resources away from the conduct of our preclinical development activities, preclinical studies and planned clinical trials, including the diversion of hospitals serving as any potential clinical trial sites and hospital staff supporting the conduct of our planned clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">interruption of planned key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures (particularly any procedures that may be deemed non-essential), which may impact the integrity of subject data and planned clinical study endpoints;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">limitations on employee or collaborator resources that would otherwise be focused on the conduct of our preclinical development activities, preclinical studies and planned clinical trials, including because of sickness of employees or their families, the desire of employees to avoid contact with large groups of people, an increased reliance on working from home or mass transit disruptions; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">reduced ability to engage with the medical and investor communities due to the cancellation of conferences scheduled throughout the year.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other factors arising from the COVID-19 pandemic could worsen in countries afflicted with COVID-19, or could return to countries where the pandemic has been partially contained, each of which could further adversely impact our ability to conduct preclinical development activities, preclinical studies and planned clinical trials and our business generally, and could have a material adverse impact on our operations and financial condition and results.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the trading prices for our common stock and other biopharmaceutical companies, as well as the broader equity and debt markets, have been highly volatile as a result of the COVID-19 pandemic and the resulting impact on economic activity. As a result, we may face difficulties raising capital when needed, and any such sales may be on unfavorable terms to us. Further, to the extent we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of existing stockholders will be diluted. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic may impact our business, manufacturing, preclinical development activities, preclinical studies and planned clinical trials and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of COVID-19, the duration of the pandemic, the potential for a second pandemic after it is contained, travel restrictions and actions to address the pandemic or treat its impact, such as social distancing and quarantines or lock-downs in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to grow our organization, and we may experience difficulties in managing our growth and expanding our operations, which could adversely affect our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had approximately 70 full-time employees. As our development and commercialization plans and strategies develop, we expect to expand our employee base for managerial, operational, financial and other resources. In addition, we have limited experience in product development. As our product candidates enter and advance through preclinical studies and clinical trials, we will need to expand our development and regulatory capabilities and contract with other organizations to provide manufacturing and other capabilities for us. In the future, we expect to have to manage additional relationships with collaborators or partners, suppliers, and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial, and management controls, reporting systems, and procedures. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls. Our inability to successfully manage our growth and expand our operations could have a material and adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success largely depends on the continued service of key management, advisors and other specialized personnel. We currently do not maintain key person insurance on any of these individuals. The loss of one or more members of our management team or other key employees or advisors could delay our research and development programs and have a material </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and adverse effect on our business, financial condition, results of operations, and prospects. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are dependent on the continued service of our technical personnel because of the highly technical nature of our product candidates and technologies related to our Neoleukin Platform, and the specialized nature of the regulatory approval process. Because our management team and key employees are not obligated to provide us with continued service, they could terminate their employment with us at any time without penalty.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. We also face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations. Our future success will depend in large part on our continued ability to attract and retain other highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental regulation, and commercialization. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover and develop product candidates will be limited which could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with healthcare professionals, principal investigators, consultants, customers (actual and potential) and third-party payors are and will be subject, directly and indirectly, to applicable anti-kickback, fraud and abuse, privacy, transparency and other healthcare laws and regulations, which could expose us to penalties, including without limitation, civil, criminal and administrative sanctions, civil penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, integrity obligations, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings and the curtailment or restructuring of our operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biopharmaceutical company, even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are and will be applicable to our future arrangements with third-party payors and customers who are in a position to purchase, recommend and/or prescribe our product candidates for which we obtain marketing approval. These broadly applicable fraud and abuse and other healthcare laws and regulations may constrain our future business or financial arrangements and relationships with healthcare professionals, principal investigators, consultants, customers, and third-party payors and other entities, including our marketing practices, educational programs and pricing policies. Restrictions under applicable federal and state healthcare laws and regulations that may affect our ability to operate include, but are not limited to, the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the federal Anti-Kickback Statute, which, among other things, prohibits persons from knowingly and willfully soliciting, offering, receiving or providing paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">federal civil and criminal false claims laws, including the federal civil False Claims Act, and civil monetary penalty laws impose criminal and civil penalties, including through civil whistleblower or qui tam actions, among other things, prohibits individuals or entities from knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment or approval that are false or fraudulent or from knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">HIPAA, which, among other things, imposes criminal liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or to obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g. public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services relating to healthcare matters;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">HIPAA, as amended by HITECH, and its implementing regulations, which also imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without the appropriate authorization by entities subject to the law, such as health plans, healthcare clearinghouses and healthcare providers;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the federal Physician Payments Sunshine Act and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to CMS, information related to &#8220;payments or other transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians (as defined above) and their immediate family members and payments or other &#8220;transfers of value&#8221; to such physician owners and their immediate family members; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">analogous local, state and foreign laws and regulations, including: state anti-kickback and false claims laws which may apply to our business practices, including, but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by state governmental and non-governmental third-party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government; local, state and foreign laws that require drug manufacturers to track gifts and other remuneration and items of value provided to healthcare professionals and entities and file reports relating to pricing and marketing information and/or register their pharmaceutical sales representatives; and local, state and foreign laws that govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our internal operations and any business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Recent healthcare reform legislation has also strengthened these laws. For example, the Affordable Care Act, among other things, amends the intent requirement of the federal Anti-Kickback Statute, such that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the Affordable Care Act codified case law that a claim that includes items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, agency guidance, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to us, we may be subject to penalties, including without limitation, significant civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, integrity obligations, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings, and the curtailment or restructuring of our operations. If any physicians or other healthcare providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Moreover, we expect there will continue to be federal, state, local and foreign laws and regulations, proposed and implemented, that could impact our operations and business. The extent to which future legislation or regulations, if any, relating to healthcare fraud abuse laws or enforcement, may be enacted or what effect such legislation or regulation would have on our business remains uncertain.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may form strategic alliances in the future, and we may not realize the benefits of such alliances.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may form strategic alliances, create joint ventures or collaborations or enter into licensing arrangements with third parties that we believe will complement or augment our existing business. These relationships or those like them may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for any future drug candidates and programs because our research and development pipeline may be insufficient, our drug candidates and programs may be deemed to be at too early a stage of development for collaborative effort and third parties may not view our drug candidates and programs as having the requisite potential to demonstrate safety and efficacy. If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. We cannot be certain that, following a strategic transaction or license, we will achieve the revenues or specific net income that justifies such transaction. Any delays in entering into new strategic partnership agreements related to our drug candidates could also delay the development and commercialization of our drug candidates and reduce their competitiveness even if they reach the market.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, CROs, consultants, vendors and collaboration partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, principal investigators, CROs, consultants, vendors and collaboration partners, including intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards we have established, comply with federal and state data privacy and security, fraud and abuse and other healthcare laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use or misrepresentation of information obtained in the course of clinical trials or creating fraudulent data in our pre-clinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct for our directors, officers and employees, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, results of operations, financial condition and cash flows from future prospects, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:92%">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will face an inherent risk of product liability exposure related to the testing of our product candidates in clinical trials and will face an even greater risk if we commercialize any of our product candidates. If we cannot successfully defend ourselves against claims that our product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">decreased demand for any product candidates that we may develop;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">injury to our reputation and significant negative media attention;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">significant time and costs to defend the related litigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">loss of revenue; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the inability to commercialize any product candidates that we may develop.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently maintain product liability insurance coverage for our trials, but the amount may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage for each new clinical trial we begin and if we successfully commercialize any product candidate. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may engage in future acquisitions that could disrupt our business, cause dilution to our stockholders and harm our business, results of operations, financial condition and cash flows and future prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may, in the future, make acquisitions of, or investments in, companies that we believe have products or capabilities that are a strategic or commercial fit with our future product candidates and business or otherwise offer opportunities for our company. In connection with these acquisitions or investments, we may:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">issue stock that would dilute our stockholders&#8217; percentage of ownership;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">incur debt and assume liabilities; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">incur amortization expenses related to intangible assets or incur large and immediate write-offs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to complete acquisitions on favorable terms, if at all. If we do complete an acquisition, we cannot assure you that it will ultimately strengthen our competitive position or that it will be viewed positively by customers, financial markets or investors. Furthermore, future acquisitions could pose numerous additional risks to our operations, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">problems integrating the purchased business, products or technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">increases to our expenses;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the failure to discover undisclosed liabilities of the acquired asset or company;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">diversion of management&#8217;s attention from their day-to-day responsibilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">harm to our operating results or financial condition;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">entrance into markets in which we have limited or no prior experience; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">potential loss of key employees, particularly those of the acquired entity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to complete any acquisitions or effectively integrate the operations, products or personnel gained through any such acquisition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our U.S. net operating losses to offset future taxable income will be subject to Section 382 limitations and may be limited by other factors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had U.S. net operating losses, or NOLs, of $58.1 million, for Federal tax purposes, for which we have recorded a full valuation allowance and R&amp;D credit carryovers of $1.0 million, which may be offset by future taxable income. These NOLs and tax credit carryforwards will expire in various years beginning in 2028, if not utilized. Unused losses incurred in taxable years beginning on or prior to December 31, 2017 will carry forward to offset future taxable income, if any, until such unused losses expire. Under the Tax Cuts and Jobs Act, as modified by the CARES Act, unused U.S. federal NOLs generated in tax years beginning after December 31, 2017, will not expire and may be carried forward indefinitely but the deductibility of such federal NOLs (particularly those generated in taxable years beginning after December 31, 2020) in taxable years beginning after December 31, 2020, is limited to 80% of current year taxable income. It is uncertain if and to what extent various states will conform to the Tax Cuts and Jobs Act or the CARES Act. Utilization of the NOLs will be subject to an annual limitation due to historical or future ownership changes rules pursuant to Sections 382 and 383 of the Internal Revenue Code, or the Code.  In addition, if we have experienced an ownership change in the past or will experience an ownership change as a result of future changes in our stock ownership, some of which changes are outside of our control, the tax benefits related to the NOLs may be limited or lost. Any such disallowances may result in greater tax liabilities than we would incur in the absence of such a limitation and any increased liabilities could adversely affect our business, results of operations, financial condition, cash flow and future prospects. As a result, even if we attain profitability, we may be unable to use all or a material portion of our NOLs and other tax attributes, which could adversely affect our future cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to obtain, maintain, and enforce patent protection for our product candidates, our Neoleukin platform technology, or other proprietary technologies we may develop, development and commercialization of our product candidates may be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our ability to obtain and maintain patents and other forms of intellectual property rights, including in-licenses of intellectual property rights of others, for our product candidates, as well as our ability to preserve our trade secrets, to prevent third parties from infringing upon our proprietary rights and to operate without infringing upon the proprietary rights of others. Under our License Agreement with the University of Washington, dated July 8, 2019, as amended on October 29, 2020, effective July 24, 2020, we have an exclusive license to develop and commercialize products covered by patent applications with claims covering the composition of matter of key molecule families as well as methods of using the computational algorithms that form the basis of the Neoleukin platform. However, we may not be able to apply for patents on certain aspects of our product candidates in a timely fashion or at all. Further, we may not be able to prosecute all necessary or desirable patent applications, or maintain, enforce, and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing, and prosecution of all patent applications that we license from third parties, or to maintain the rights to patents licensed to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. Future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing products and technology. There is no guarantee that any of our pending patent applications will result in issued or granted patents, that any of our future issued or granted patents will not later be found to be invalid or unenforceable or that any future issued or granted patents will include claims that are sufficiently broad to cover our product </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates or to provide meaningful protection from our competitors. Moreover, the patent position of biotechnology and biopharmaceutical companies can be highly uncertain because it involves complex legal and factual questions. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our current and future proprietary technology and product candidates are covered by valid and enforceable patents or are effectively maintained as trade secrets. If third parties disclose or misappropriate our proprietary rights, it may materially and adversely affect our position in the market.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. Assuming the other requirements for patentability are met, currently, the first to file a patent application is generally entitled to the patent. However, prior to March 16, 2013, in the United States, the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our pending patent applications, or that we were the first to file for patent protection of such inventions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Patent and Trademark Office, or USPTO, and various foreign governmental patent agencies require compliance with a large number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. The standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology and biopharmaceutical patents. As such, we do not know the degree of future protection that we will have on our proprietary products and technology. The process of obtaining patents is time consuming, expensive and sometimes unpredictable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once granted, for a given period after allowance or grant patents may remain open to opposition, interference, re-examination, post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, nullification, or derivation action in court or before patent offices or similar proceedings, during which time third parties can raise objections against such initial grant. Such proceedings may continue for a protracted period of time and an adverse determination in any such proceedings could reduce the scope of the allowed or granted claims thus attacked, or could result in our patents being invalidated in whole or in part, or being held unenforceable, which could allow third parties to commercialize our product candidates and compete directly with us without payment to us. In addition, there can be no assurance that:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">others will not or may not be able to make, use or sell compounds that are the same as or similar to our product candidates but that are not covered by the claims of the patents that we own or license;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we or our licensors, or our future collaborators are the first to make the inventions covered by each of our issued patents and pending patent applications that we own or license;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we or our licensors, or our future collaborators are the first to file patent applications covering certain aspects of our inventions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">others will not independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a third party may not challenge our patents and, if challenged, a court would hold that our patents are valid, enforceable and infringed;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">any issued patents that we own or have licensed or that we may license in the future will provide us with any competitive advantages, or will not be challenged by third parties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may develop additional proprietary technologies that are patentable;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the patents of others will not have a material or adverse effect on our business, financial condition, results of operations, and prospects; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our competitors do not conduct research and development activities in countries where we do not have enforceable patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our licensors or collaborators fail to maintain patent applications and later-issued patents covering our product candidates, our competitors might be able to enter the market, which could have a material and adverse effect on our business, financial condition, results of operations, and prospects. In addition, if the breadth or strength of protection provided by our patent applications and later-issued patents is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could be required to incur significant expenses to strengthen our intellectual property rights, and our intellectual property rights may be inadequate to protect our competitive position.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process is expensive and time-consuming, and we or our future potential licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our future potential licensors will fail to identify patentable aspects of inventions made in the course of our development and commercialization activities before it is too late to obtain patent protection on them. Further, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are prosecuting patents. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the expiration of the patent. However, the applicable authorities, including the FDA in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States, and these foreign laws may also be subject to change. For example, methods of treatment and manufacturing processes may not be patentable in certain jurisdictions. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or in some cases not at all. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our patent applications and the enforcement or defense of our issued patents may be impacted by the application of or changes in U.S. and foreign standards.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standards that the USPTO and foreign patent offices use to grant patents are not always applied predictably or uniformly and can change. Consequently, our pending patent applications may not be allowed and, if allowed, may not contain the type and extent of patent claims that will be adequate to conduct our business as planned. Additionally, any issued patents we currently own or obtain in the future may have a shorter patent term than expected or may not contain claims that will permit us to stop competitors from using our technology or similar technology or from copying our product candidates. Similarly, the standards that courts use to interpret patents are not always applied predictably or uniformly and may evolve, particularly as new technologies develop. In addition, changes to patent laws in the United States or other countries may be applied retroactively to affect the validation enforceability, or term of our patent. For example, the U.S. Supreme Court has recently modified some legal standards applied by the USPTO in examination of U.S. patent applications, which may decrease the likelihood that we will be able to obtain patents and may increase the likelihood of challenges to patents we obtain or license. In addition, changes to the U.S. patent system have come into force under the Leahy-Smith America Invents Act, or the Leahy-Smith Act, which was signed into law in September 2011. The Leahy-Smith Act included a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#8220;first to file&#8221; system in which the first inventor to file a patent application will be entitled to the patent. Third parties are allowed to submit prior art before the issuance of a patent by the USPTO, and may become involved in opposition, derivation, reexamination, inter-partes review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, which could adversely affect our competitive position.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we cannot predict with certainty the impact the Leahy-Smith Act or any potential future changes to the U.S. or foreign patent systems will have on the operation of our business, the Leahy-Smith Act and such future changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, results of operations, financial condition and cash flows and future prospects.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining any patent protection we may receive will depend on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our future potential licensors fail to maintain the patents and patent applications covering our future product candidates, our competitive position would be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims by third parties claiming ownership of what we regard as our own intellectual property.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees, including our senior management, were previously employed at universities or at other biotechnology or biopharmaceutical companies, including our competitors or potential competitors. Some of these employees, including members of our senior management, executed proprietary rights, non-disclosure and non-competition agreements, in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we, or these employees, have used or disclosed confidential information or intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. We are not aware of any threatened or pending claims related to these matters or concerning the agreements with our senior management, but in the future litigation may be necessary to defend against such claims. In addition, third parties may from time to time make claims over what we regard as our intellectual property, or we may get into disputes with licensors or licensees of our intellectual property rights over the interpretation of the license terms. Our licensors may have the right to terminate their license agreements with us or pursue damages or other legal remedies. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for some of our technology and products, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturing organizations, consultants, advisors and other third parties. We also generally enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts both within and outside the United States may be less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we expect all of our employees to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, others may independently discover our trade secrets and proprietary information. For example, the FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not currently clear how the FDA&#8217;s disclosure policies may change in the future, if at all.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on our product candidates throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we and our licensors or future collaborators may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may export otherwise infringing products to territories where we have patent protection, but where enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirements for patentability may differ in certain countries, particularly developing countries. For example, unlike other countries, China has a heightened requirement for patentability, and specifically requires a detailed description of medical uses of a claimed drug. In India, unlike the United States, there is no link between regulatory approval of a drug and its patent status. Furthermore, generic or biosimilar drug manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors&#8217; or collaborators&#8217; patents, requiring us or our licensors or collaborators to engage in complex, lengthy and costly litigation or other proceedings. Generic or biosimilar drug manufacturers may develop, seek approval for, and launch biosimilar versions of our products. In addition to India, certain countries in Europe and developing countries, including China, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we and our licensors or collaborators may have limited remedies if patents are infringed or if we or our licensors or collaborators are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our and our licensors&#8217; or collaborators&#8217; efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to any competitive advantage we may have.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Others may be able to make compounds that are the same as or similar to our future product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We or any of our licensors or strategic partners might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We or any of our licensors or strategic partners might not have been the first to file patent applications covering certain of our inventions.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">It is possible that our pending patent applications will not lead to issued patents.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Issued patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges by our competitors.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We may not develop additional proprietary technologies that are patentable.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The patents of others may have an adverse effect on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price has been and will likely continue to be volatile and may decline regardless of our operating performance, resulting in substantial losses for investors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock has been, and is likely to continue to be, volatile for the foreseeable future. The trading price of our common stock could be subject to wide fluctuations in response to various factors, some of which are beyond our control. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this report, these factors include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the success of competitive products or technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulatory actions with respect to our products or our competitors&#8217; products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">actual or anticipated changes in our growth rate relative to our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">results of clinical trials, including both safety and efficacy, of any of our future product candidates or those of our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">regulatory or legal developments in the United States and other countries;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the recruitment or departure of key personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the level of expenses related to any of our future product candidates or clinical development programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the results of our efforts to in-license or acquire additional product candidates or products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">announcement or expectation of additional financing efforts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">sales of our common stock by us, our insiders or our other stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">market conditions in the pharmaceutical and biotechnology sectors; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">general economic, industry and market conditions, including market volatility and economic uncertainty related to the COVID-19 pandemic.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of these risks or any of a broad range of other risks, including those described in this &#8220;Risk Factors&#8221; section and elsewhere in this report, could have a dramatic and material adverse impact on the market price of our common stock.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our amended and restated certificate of incorporation, or certificate of incorporation, and amended and restated bylaws, or bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders, or remove our current management. These include provisions that:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">permit our board of directors to issue up to 5,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">provide that all vacancies on our board of directors, including as a result of newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#8217;s notice;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">not provide for cumulative voting rights, thereby allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">provide that special meetings of our stockholders may be called only by the board of directors or by such person or persons requested by a majority of the board of directors to call such meetings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, who are responsible for appointing the members of our management. Because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which may discourage, delay or prevent someone from acquiring us or merging with us whether or not it is desired by or beneficial to our stockholders. Under Delaware law, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other things, the board of directors has approved the transaction. Any provision of our certificate of incorporation or bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The exclusive forum provisions in our restated certificate of incorporation and amended and restated bylaws may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restated certificate of incorporation, to the fullest extent permitted by law, will provide that the Court of Chancery of the State of Delaware will be the exclusive forum for: any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, or the DGCL, our restated certificate of incorporation, or our restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. This exclusive forum provision does not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended, or the Exchange Act. It could apply, however, to a suit that falls within one or more of the categories enumerated in the exclusive forum provision and asserts claims under the Securities Act, inasmuch as Section 22 of the Securities Act, creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rule and regulations thereunder. There is uncertainty as to whether a court would enforce such provision with respect to claims under the Securities Act, and our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we amended and restated our restated bylaws to provide that the federal district courts of the United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or a Federal Forum Provision. Our decision to adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware holding that such provisions are facially valid under </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delaware law. While there can be no assurance that federal or state courts will follow the holding of the Delaware Supreme Court or determine that the Federal Forum Provision should be enforced in a particular case, application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state court.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These choice of forum provisions may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find the choice of forum provisions contained in our restated certificate of incorporation or amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are no longer an &#8220;emerging growth company,&#8221; however, we are still a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we ceased to be an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act, on December 31, 2019, we are a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates is less than $700.0 million and our annual revenue is less than $100.0 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250.0 million or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0 million. As a smaller reporting company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become a "large accelerated filer" and have to comply with more rigorous disclosure and reporting requirements and regulations </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cease to be a &#8220;smaller reporting company&#8221; or a &#8220;non-accelerated filer&#8221; in the future, we may be subject to certain disclosure requirements that are applicable to other public companies that had not been applicable to us previously. These requirements include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">compliance with the auditor attestation requirements in the assessment of our internal control over financial reporting once we are an accelerated filer or large accelerated filer;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">compliance with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">full disclosure and analysis obligations regarding executive compensation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will be able to comply with the applicable regulations in a timely manner, if at all. Inability to comply with these regulations could impact our ability to raise additional capital.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to securities litigation, which is expensive and could divert management attention.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock has been and will continue to be volatile. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders, directors and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates together beneficially own a majority of our outstanding voting stock. These stockholders are able to determine the outcome of all matters requiring stockholder approval. For example, these stockholders are able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain an effective system of internal control over financial reporting in the future, we may not be able to accurately report our business, results of operations, financial condition and cash flows and future prospects, which may adversely affect investor confidence in us and, as a result, the value of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures and that we furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. This assessment needs to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting that results in more than a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis. Section 404 of the Sarbanes-Oxley Act also generally requires an attestation from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. However, for as long as we are not an accelerated filer or large accelerated filer, we intend to take advantage of the exemption permitting us not to comply with the independent registered public accounting firm attestation requirement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compliance with Section 404 will require that we incur substantial accounting expense and expend significant management efforts. We currently do not have an internal audit group, and we will need to hire additional accounting and financial staff with appropriate public company experience and technical accounting knowledge and compile the system and process documentation necessary to perform the evaluation needed to comply with Section 404. We may not be able to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and testing process, if we fail to identify and to remediate any significant deficiencies or material weaknesses that may be identified, or encounter problems or delays in the implementation of internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by the Nasdaq Stock Market, or NASDAQ, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the periodic reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations would suffer in the event of computer system failures or security breaches.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we collect, store and transmit confidential information, including intellectual property, proprietary business information and personal information. Despite the implementation of security measures, our internal computer systems, and those of our CROs and other third parties on which we rely, are vulnerable to damage from computer viruses, unauthorized access, cyberattacks, natural disasters, fire, terrorism, war and telecommunication and electrical failures. Cyberattacks are increasing in their frequency, sophistication and intensity. Cyberattacks could include the deployment of harmful malware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. Significant disruptions of our information technology systems or security breaches could adversely affect our business operations and/or result in the loss, misappropriation, and/or unauthorized access, use or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information and personal information), and could result in financial, legal, business and reputational harm to us. If such disruptions were to occur and cause interruptions in our operations, it could result in a material </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disruption of our product development programs. For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our future product candidates could be delayed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business disruptions could seriously harm our future revenues and financial condition and increase our costs and expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics such as the COVID-19 pandemic and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. We do not carry insurance for all categories of risk that our business may encounter. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce our product candidates. Our ability to obtain clinical supplies of product candidates could be disrupted, if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption. The ultimate impact on us, our significant suppliers and our general infrastructure of being consolidated in certain geographical areas is unknown, but our operations and financial condition could suffer in the event of a major earthquake, fire or other natural disaster. Further, any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our business, results of operations, financial condition and cash flows from future prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred and will incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we have incurred and will incur significant legal, accounting and other expenses that we did not incur as a private company, and these expenses will likely increase even more given we are no longer an &#8220;emerging growth company.&#8221; We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Protection Act, as well as rules adopted, and to be adopted, by the SEC and NASDAQ. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have substantially increased our legal and financial compliance costs and made some activities more time-consuming and costly. The increased costs will increase our consolidated net loss. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in the past and may in the future grant rights to some of our stockholders that require us to register the resale of our common stock or other securities on behalf of these stockholders and/or facilitate public offerings of our securities held by these stockholders, including in connection with potential future acquisition or capital-raising transactions. For example, in connection with our public offering of common stock on September 19, 2016, we entered into a registration rights agreement with the Baker Entities that together, based on information available to us, collectively beneficially owned approximately 45.1% of our common stock as of September 19, 2016. Under the registration rights agreement, we agree that, if at any time and from time to time after December 19, 2016, the Baker Entities demand that we register their shares of our common stock for resale under the Securities Act, we would be obligated to effect such registration. On January 6, 2017, pursuant to the registration rights agreement, we registered for resale, from time to time, up to 10,536,092 shares of our common stock held by the Baker Entities. Our registration obligations under this registration rights agreement cover all shares now held or hereafter acquired by the Baker Entities, would be in effect for up to ten years, and would include our obligation to facilitate certain underwritten public offerings of our common stock by the Baker Entities in the future. If the Baker Entities or any other holders of registration rights with respect to our common stock, by exercising their registration and/or underwriting rights or otherwise, sell a large number of our shares, or the market perceives that the Baker Entities or such holders intend to sell a large number of our shares, this could adversely affect the market price of our common stock. We have registered all currently reserved shares of common stock that we may issue under our equity compensation plans and intend to register in the future any additional reserved or issued shares of common stock. These registered shares can be freely sold in the public market upon issuance, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to volume limitations applicable to affiliates. We have also filed registration statements covering the sale of up to $400.0 million of any combination of our common stock, preferred stock, debt securities or warrants and may conduct one or more sales of securities pursuant to such registration statement, from time to time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that significant additional capital will be needed in the future to continue our planned operations. To raise capital, we may sell substantial amounts of common stock or securities convertible into or exchangeable for common stock. These future issuances of common stock or common stock-related securities, including the exercise of outstanding options and any additional shares issued in connection with acquisitions, if any, may result in material dilution to our stockholders. New investors could also gain rights, preferences and privileges senior to those of holders of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to our 2014 Equity Incentive Plan, our compensation committee is authorized to grant equity-based incentive awards to our directors, executive officers and other employees and service providers, including officers, employees and service providers of our subsidiaries and affiliates. Future option grants and issuances of common stock under our 2014 Equity Incentive Plan may have an adverse effect on the market price of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us, or our business. If one or more of the securities or industry analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></div><div id="ib53014c4f13844039ebc5a68643f31a2_19"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1B. Unresolved Staff Comments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ib53014c4f13844039ebc5a68643f31a2_22"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Properties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located at 188 East Blaine Street, Suite 450, Seattle, Washington 98102 where we lease 33,300 square feet of office space that we use for laboratory, discovery, research and development and general and administrative purposes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also lease approximately 6,272 square feet of office space at 360-1616 Eastlake Avenue East, Seattle, Washington 98102. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing facilities are adequate for our near-term needs. We believe that suitable additional or alternative space would be available if required in the future on commercially reasonable terms.</span></div><div id="ib53014c4f13844039ebc5a68643f31a2_25"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Legal Proceedings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently subject to any material legal proceedings.</span></div><div id="ib53014c4f13844039ebc5a68643f31a2_28"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Mine Safety Disclosures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="ib53014c4f13844039ebc5a68643f31a2_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="ib53014c4f13844039ebc5a68643f31a2_34"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Price Range of Our Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on The Nasdaq Global Market under the symbol &#8220;NLTX.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholders</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;22, 2021, there were 42,326,033 shares of our common stock outstanding, which were held by 10 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">holders of record of our common stock, including The Depository Trust Company, which holds shares of our common stock on behalf of an indeterminate number of beneficial owners.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not paid any cash dividends on our common stock since our inception. We do not intend to pay any cash dividends in the foreseeable future, but intend to retain all earnings, if any, for use in our business operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be included in an amendment to this Annual Report on Form 10-K or incorporated by reference from our definitive proxy statement to be filed pursuant to Regulation 14A.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Performance Graph</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a &#8220;smaller reporting company,&#8221; as defined by Rule 12b-2 of the Exchange Act, and pursuant to Instruction 6 to Item 201(e) of Regulation S-K we are not required to provide the stock performance graph.</span></div><div style="margin-top:18pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="ib53014c4f13844039ebc5a68643f31a2_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Selected Financial Data.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a &#8220;smaller reporting company,&#8221; as defined by Rule 12b-2 of the Exchange Act, and pursuant to Item 301(c) of Regulation S-K we are not required to provide selected financial data.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="ib53014c4f13844039ebc5a68643f31a2_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div id="ib53014c4f13844039ebc5a68643f31a2_43"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that reflect our plans, estimates and beliefs, and involve risks and uncertainties. Actual events or results may differ materially. Our forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown risks, uncertainties and other factors. We discuss many of these risks, uncertainties and other factors in this Annual Report on Form 10-K in greater detail under the heading &#8220;Item 1A&#8212;Risk Factors.&#8221; We caution investors that our business and financial performance are subject to substantial risks and uncertainties.</span></div><div id="ib53014c4f13844039ebc5a68643f31a2_46"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation, and autoimmunity using </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> protein design technology. We use sophisticated computational methods to design&#160;proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.&#160;Our lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.</span></div><div id="ib53014c4f13844039ebc5a68643f31a2_49"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Loss</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our operating expenses for the years ended December&#160;31, 2020 and 2019 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,927&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,716)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,616)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of Aquinox Canada</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,826)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,826)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,728&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,959&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,231)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consists primarily of costs incurred under arrangements with third parties, such as CROs, manufacturing organizations, and consultants, personnel related costs (including stock-based compensation and travel expenses), facility-related costs and lab supplies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the year ended December&#160;31, 2020 were $24.3 million compared to $4.4&#160;million for the year ended December&#160;31, 2019. The increase in research and development expenses during the year ended December&#160;31, 2020 was due to increased expenses incurred from IND-enabling activities related to our lead product candidate, NL-201, and in connection with the advancement of other Neoleukin technologies.  Lower research and development costs during the year ended December&#160;31, 2019 reflect the fact that prior to the merger between Aquinox and Former Neoleukin in August 2019, all research and development activities with rosiptor had been suspended since June 2018.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquired in-process Research and Development</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquired in-process research and development expense arose from the merger between Aquinox and Former Neoleukin in August 2019 and was expensed immediately as management determined that the asset has no alternative future use.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of personnel related costs (including severance, stock-based compensation and travel expenses), facility-related costs, insurance, and professional fees for consulting, legal and accounting services.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, general and administrative expenses were $17.2&#160;million compared to $18.8&#160;million for the year ended December&#160;31, 2019. The higher general and administrative expenses the year ended December 31, 2019 as compared to the year ended December 31, 2020 were primarily due to severance costs and the recognition of stock-based compensation expense for certain options that vested as a result of the merger between Aquinox and Former Neoleukin in August 2019. The general and administrative expenses for the year ended December 31, 2020 reflect an increase in personnel related costs, facility-related costs, and professional service fees.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on sale of Aquinox Canada</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain relates to the sale of Aquinox Canada in July 2020. The gain of $7.8 million recognized is the total consideration of $8.2 million, less transaction costs of $0.4 million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income, net (in thousands) </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:43.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,052)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,066)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income during the year ended December&#160;31, 2020 decreased compared to the year ended December&#160;31, 2019 due to a decrease in interest rates, partially offset by higher cash and money market fund balances for the year ended December&#160;31, 2020.</span></div><div style="margin-top:12pt"><span><br/></span></div><div id="ib53014c4f13844039ebc5a68643f31a2_52"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred net losses and negative cash flows from our operations and relied upon sales of common and preferred stock to fund our operations. Our operating activities used $24.6 million and $15.4&#160;million of cash flows during the years ended December&#160;31, 2020 and 2019, respectively. As of December&#160;31, 2020, we had an accumulated deficit of $332.8&#160;million, working capital of $186.6&#160;million, and cash and cash equivalents of $192.6&#160;million. We believe that our existing capital resources will be sufficient to fund our operations into 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the years ended December&#160;31, 2020 and 2019 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:60.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.661%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,575)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,219)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(688)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,341&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,155&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,341&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,165&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in operating activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $24.6 million for the year ended December&#160;31, 2020 compared to $15.4 for the year ended December 31, 2019. Net cash used in operating activities for the year ended December 31, 2020 increased compared to the year ended December 31, 2019 due to an increase in operating expenses resulting primarily from expenses incurred in developing our lead product candidate, NL-201, and partially offset by cash received from the sale of Aquinox Canada, as compared to a reduction in costs in the year ended December 31, 2019 due to the restructuring in the second half of 2018 and the halting of all development activities relating to rosiptor.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in investing activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $2.2 million for the year ended December&#160;31, 2020 and consisted primarily of purchases laboratory and IT equipment. Net cash used in investing activities of $0.7 in the year ended December 31, 2019 consisted of purchases of property and equipment, offset partially by cash received in the merger between Aquinox and Former Neoleukin.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by financing activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $77.1 for the year ended December&#160;31, 2020 compared to $82.2 in the year ended December 31, 2019. For the year ended December 31, 2020, net cash provided by financing activities consisted primarily of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceeds received in our offering of common stock and pre-funded warrants in July 2020 of $71.3 million, net of underwriting discounts, commissions, and offering costs, as well as proceeds from the exercise of stock options of $5.7 million. For the year December 31, 2019, cash provided by financing activities was the result of  proceeds received in our offering of common stock and pre-funded warrants in December 31, 2019 of $80.7 million, net of underwriting discounts and commissions and offering costs.</span></div><div id="ib53014c4f13844039ebc5a68643f31a2_55"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating and Capital Expenditure Requirements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated product revenue or achieved profitability since our inception and we expect to continue to incur net losses for the foreseeable future. As of December&#160;31, 2020, we had approximately $192.6&#160;million in cash and cash equivalents. Based on our current operating plan, we believe that our available cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements into 2023. However, our future capital requirements and the period for which we expect our existing resources to support our operations, fund expansion, develop new or enhanced products, or otherwise respond to competitive pressures, may vary significantly from our expectation and we may need to seek additional funds sooner than planned. Unless and until we generate sufficient revenue to be profitable, we will seek to fund our operations through public or private equity or debt financings or other sources. If we raise additional funds through the issuance of convertible debt securities, these securities could have rights senior to those of our common stock and could contain covenants that restrict our operations. There can be no assurance that we will be able to obtain additional equity or debt financing on terms acceptable to us, if at all. Our failure to obtain sufficient funds on acceptable terms when needed could have a negative impact on our business, results of operations, financial condition, cash flows and future prospects. Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and characteristics of any future product candidates we develop or may acquire;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of researching and developing our product candidates or any future product candidates, and conducting preclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of, and the costs involved in, obtaining regulatory approvals for any future product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing our future product candidates and any products that may achieve regulatory approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of commercialization activities if any future product candidates are approved for sale, including marketing, sales and distribution costs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and amount of sales of, or royalties on, future approved products, if any;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any product liability or other lawsuits related to our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expenses needed to attract and retain skilled personnel; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see Item 1A of this Annual Report titled &#8220;Risk Factors&#8221; for additional risks associated with our substantial capital requirements.</span></div><div id="ib53014c4f13844039ebc5a68643f31a2_58"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our long-term contractual cash obligations as of December&#160;31, 2020 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,341&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,904&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,509&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,013&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,401&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,394&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,904&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Operating lease obligations reflect remaining minimum commitments for our office and laboratory spaces in Seattle, Washington. Please see Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Notes to Consolidated Financial Statements included in Part II Item 8 of this Annual Report on Form 10-K for additional information pertaining to operating lease commitments. </span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">In December 2020, the Company entered into a non-cancelable contract to purchase laboratory equipment for $0.8 million. The equipment is expected to be delivered in the first half of 2021 and will be paid for out of existing cash reserves. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into contracts in the normal course of business with CROs for clinical and preclinical research studies, external manufacturers for product for use in our clinical trials, and other research supplies and other services as part of our operations. These contracts generally provide for termination on notice, and therefore are cancelable contracts and not included in the table of contractual obligations and commitments.</span></div><div id="ib53014c4f13844039ebc5a68643f31a2_61"></div><div style="margin-top:6pt"><span><br/></span></div><div id="ib53014c4f13844039ebc5a68643f31a2_64"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milestone, Royalty-Based and Other Commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an exclusive license agreement with the University of Washington, or UW, under which UW (on behalf of itself and Stanford University) granted us an exclusive worldwide license under certain patent rights, to make, have made, use, offer to sell, sell, offer to lease or lease, import, export or otherwise offer to dispose of licensed products in all fields of use, and a nonexclusive worldwide license to use certain know-how. The foregoing licenses are sublicensable without UW&#8217;s consent, subject to certain limited conditions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the licensed rights, we issued shares of common stock to UW, which upon the Merger were exchanged for 188,974 shares of our common stock and 4,197 shares of our non-voting convertible preferred stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we are required to pay; (i)&#160;an annual maintenance fee starting in January 2022 (but excluding any year in which minimum annual royalties are paid); (ii) up to $0.9&#160;million in combined development and regulatory milestone payments with respect to each distinct class of licensed product; (iii)&#160;up to $10.0&#160;million in combined commercial milestone payments based on cumulative net sales of licensed products within each distinct class of licensed products, beginning when cumulative net sales of the class of licensed products equals or exceeds $100.0&#160;million, with the majority payable when cumulative net sales of the class of licensed products equals or exceeds $1.0&#160;billion; (iv)&#160;a low single-digit royalty on net sales of licensed products sold by us and our sublicensees, which may be subject to reductions, and subject to minimum annual royalty payments following the first commercial sale of a licensed product; (v)&#160;a certain percentage of any sublicense consideration (other than royalties) we receive from sublicensees, based on the stage of development at the time the sublicense is executed; and (vi)&#160;a certain percentage of consideration we receive from an acquisition of us or our assets based on the stage of development at the relevant time. We are obligated to pay royalties on a country-by-country basis until the expiration of the last valid claim within the licensed patent rights in such country.</span></div><div id="ib53014c4f13844039ebc5a68643f31a2_67"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these consolidated financial statements in accordance with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities. We evaluate those estimates and judgments on an ongoing basis. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in the notes to our consolidated financial statements appearing elsewhere in this Annual Report, we believe the following accounting policies to be most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred and include, but are not limited to, employee-related expenses, including salaries, benefits and stock based compensation, expenses incurred under agreements with CROs that conduct clinical trials and preclinical studies, the cost of acquiring, developing and manufacturing clinical trial materials, costs incurred in relation to purchase of technology licenses and patent rights, facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, and other supplies and costs associated with clinical trials, preclinical activities, and regulatory operations. Restructuring costs associated with the termination of research and development programs and related employees are included in research and development costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development costs are expensed in the period incurred unless we believe a development project meets generally accepted accounting criteria for deferral and amortization. No product development expenditures have been deferred to date. We record costs for certain development activities based on our evaluation of the progress to completion of specific tasks or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued liabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The cost of such award will be recognized over the period during which services are provided in exchange for the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">award, generally the vesting period. We account for forfeitures as they occur. All share-based payments to employees are recognized in the consolidated financial statements based upon their respective grant-date fair values.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of options granted using the Black-Scholes option pricing model. This approximation uses assumptions regarding a number of inputs that required us to make significant estimates and judgments, including the expected term of the options. We also make decisions regarding the method of calculating the expected stock price volatility and the risk-free interest rate used in the model. The expected volatility assumption is based on industry peer information and we expect to continue to do so until it has adequate and relevant historical volatility of its common stock. Additionally, because we have no significant history to calculate the expected term, the simplified method calculation is used.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is inherent uncertainty in our forecasts and projections and, if we had made different assumptions and estimates than those described previously, the amount of our stock-based compensation expense, net loss and net loss per common stock amounts could have been materially different.</span></div><div style="margin-top:18pt"><span><br/></span></div><div id="ib53014c4f13844039ebc5a68643f31a2_70"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2(p), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently issued and recently adopted accounting standards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Notes to Consolidated Financial Statements included in Part II Item 8 of this Annual Report on Form&#160;10-K.</span></div><div id="ib53014c4f13844039ebc5a68643f31a2_73"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements as of December&#160;31, 2020.</span></div><div id="ib53014c4f13844039ebc5a68643f31a2_76"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a &#8220;smaller reporting company,&#8221; as defined by Rule 12b-2 of the Exchange Act, and pursuant to Item 305 of Regulation S-K we are not required to provide quantitative and qualitative disclosures about market risk.</span></div><div id="ib53014c4f13844039ebc5a68643f31a2_79"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8. Financial Statements and Supplementary Data.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:92.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PAGE</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neoleukin Therapeutics, Inc.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_82">Report</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_82">s</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_82"> of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_82">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_85">Consolidated balance sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_85">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_91">Consolidated statements of operations and comprehensive loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_91">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_94">Consolidated statements of cash flow</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_94">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_97">Consolidated statements of stockholders&#8217; equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_97">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_103">Notes to the consolidated financial statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ib53014c4f13844039ebc5a68643f31a2_103">67</a></span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:24pt;text-align:center"><span><br/></span></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Report of Independent Registered Public Accounting Firm </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Neoleukin Therapeutics, Inc. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheet of Neoleukin Therapeutics, Inc. (the "Company") as of December 31, 2020, the related consolidated statements of operations, stockholders' equity, and cash flows, for the year ended December 31, 2020, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020, and the results of its operations and its cash flows for the period ended December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Opinion</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical audit matters are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ Deloitte &amp; Touche LLP</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Seattle, Washington  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 25, 2021 </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have served as the Company's auditor since 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="ib53014c4f13844039ebc5a68643f31a2_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:24pt;text-align:center"><span><br/></span></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and Board of Directors of</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neoleukin Therapeutics, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheet of Neoleukin Therapeutics, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2019, the related consolidated statements of operations, cash flows, and stockholders&#8217; equity, for the period ended December 31, 2019, and the related notes (collectively referred to as the &#8220;2019 financial statements&#8221;). In our opinion, the 2019 financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2019, and the results of its operations and its cash flows for the period ended December 31, 2019, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our&#160;responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Deloitte LLP</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chartered Professional Accountants</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vancouver, Canada</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 12, 2020</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began serving as the Company&#8217;s auditor in 2007. In 2020, we became the predecessor auditor.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="ib53014c4f13844039ebc5a68643f31a2_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOLEUKIN THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMy0xLTEtMS0w_1eb37097-c7b3-4171-8942-3c7f2d6db01d">192,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMy0zLTEtMS0w_4e6fc524-329b-4514-a547-c84471464826">143,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfNC0xLTEtMS0w_46a467b5-e0d5-41c0-a1fa-e59bc33d33bf">1,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfNC0zLTEtMS0w_b1ebb3e6-87df-4815-a43d-4970f20754f1">503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfNS0xLTEtMS0w_38e0728f-fb95-4308-be02-333829de2806">194,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfNS0zLTEtMS0w_c2025281-97d4-42cd-a953-2a849706bbc8">143,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfNi0xLTEtMS0w_16b5d318-1772-4b6b-a789-effcbcb146bc">3,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfNi0zLTEtMS0w_9d539945-cf1a-47c4-acae-7dd64c1ede26">2,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use asset </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfNy0xLTEtMS0w_bcd9d49a-c45e-4dcc-92c4-a70d815ac8a9">10,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfNy0zLTEtMS0w_c8ecb5a2-0727-47f1-b8a4-4feefbfe6368">770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible asset, net </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfOC0xLTEtMS0w_8c2e71ea-2e74-4c9e-81f1-0d6ac2b49427">347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfOC0zLTEtMS0w_7ae6e8ee-961c-490a-81ec-d526be9f06f9">567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfOS0xLTEtMS0w_c23128fe-2328-4f0a-9a8a-fc76504eece8">1,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfOS0zLTEtMS0w_de4f39e1-3be4-4746-95bc-dad3150e3604">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTAtMS0xLTEtMA_00d374d0-b3c4-4442-afb5-dfe706c668a2">210,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTAtMy0xLTEtMA_861549b3-4096-41a2-9bbc-15d203b25a5f">147,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and other liabilities </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTMtMS0xLTEtMA_09d76391-88f4-4e1f-9e18-a09749a625b2">7,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTMtMy0xLTEtMA_e78d7825-7c02-4b20-8a47-feee48cd69eb">4,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liability </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTQtMS0xLTEtMA_8b4b0848-c4a2-406a-aaec-65fbf0d09927">659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTQtMy0xLTEtMA_e33c0997-09e1-406a-b3a3-5210fe0f126d">556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease liability </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTUtMS0xLTEtMA_97fd0e40-293e-4ffb-bfa9-9be6505f504e">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTUtMy0xLTEtMA_c4041c71-61fc-4106-903a-0307ab620c8e">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTYtMS0xLTEtMA_cdc9b334-3ffb-404a-9f44-931eb3492ef0">7,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTYtMy0xLTEtMA_85a8b246-6800-4058-964f-399f214c6ab6">4,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current operating lease liability </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTctMS0xLTEtMA_2e968ffa-cfd3-4132-a31c-1d409a4549d5">11,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTctMy0xLTEtMA_661098f9-e172-4cb4-83bc-eae90de1dd4a">447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current finance lease liability </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTgtMS0xLTEtMA_b82fe168-c82c-41bf-bbf6-3ef4d662b5d8">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTgtMy0xLTEtMA_a9eb4465-00ba-406a-9f10-ee851c3df4bd">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjAtMS0xLTEtMA_b9708867-d788-4532-8280-086535cc4941">19,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjAtMy0xLTEtMA_55bad94e-dd2f-4d5a-a270-806bdf8759f9">5,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="6" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjQtMC0xLTEtNDkxL3RleHRyZWdpb246MTZmMjUwMzI5NTNkNDg5N2I2YjM3NWU5ODY3NTMwY2RfMjE5OTAyMzI1NTc2NA_028e48b7-1749-4196-a8da-8a94ebd15432"><ix:nonFraction unitRef="usdPerShare" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="6" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjQtMC0xLTEtNDkxL3RleHRyZWdpb246MTZmMjUwMzI5NTNkNDg5N2I2YjM3NWU5ODY3NTMwY2RfMjE5OTAyMzI1NTc2NA_f906b5fd-c6a4-45d4-a1ef-fb1c70e67cc9">0.000001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjQtMC0xLTEtNDkxL3RleHRyZWdpb246MTZmMjUwMzI5NTNkNDg5N2I2YjM3NWU5ODY3NTMwY2RfMjE5OTAyMzI1NTc4MA_c3c00584-7be7-4811-885b-2fdf551ddf7f"><ix:nonFraction unitRef="shares" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjQtMC0xLTEtNDkxL3RleHRyZWdpb246MTZmMjUwMzI5NTNkNDg5N2I2YjM3NWU5ODY3NTMwY2RfMjE5OTAyMzI1NTc4MA_e41f3c56-ea49-41d1-99a5-d6bfeeecbb33">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December 31, 2020 and 2019; <ix:nonFraction unitRef="shares" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjQtMC0xLTEtNDkxL3RleHRyZWdpb246MTZmMjUwMzI5NTNkNDg5N2I2YjM3NWU5ODY3NTMwY2RfMjE5OTAyMzI1NTc5Mw_34274fda-2f6e-4165-9a37-c5f5a6189524"><ix:nonFraction unitRef="shares" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjQtMC0xLTEtNDkxL3RleHRyZWdpb246MTZmMjUwMzI5NTNkNDg5N2I2YjM3NWU5ODY3NTMwY2RfMjE5OTAyMzI1NTc5Mw_85803062-0bf2-408b-a359-0c4e3ebfb649">42,196,296</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjQtMC0xLTEtNDkxL3RleHRyZWdpb246MTZmMjUwMzI5NTNkNDg5N2I2YjM3NWU5ODY3NTMwY2RfMjE5OTAyMzI1NTgwNg_91754555-285a-49b3-8a4b-f0220d737ee3"><ix:nonFraction unitRef="shares" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjQtMC0xLTEtNDkxL3RleHRyZWdpb246MTZmMjUwMzI5NTNkNDg5N2I2YjM3NWU5ODY3NTMwY2RfMjE5OTAyMzI1NTgwNg_d03035ae-1c67-4171-9965-475feb0ca4fc">37,996,849</ix:nonFraction></ix:nonFraction> issued and outstanding at December 31, 2020 and 2019, respectively </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjQtMS0xLTEtMA_ccaf4725-2433-4274-a403-f7dd389c092b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjQtMy0xLTEtMA_655c9b22-56c4-4495-be59-7c784c366631">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjUtMC0xLTEtNDkxL3RleHRyZWdpb246ZDYwMWZjMDNhOTQ1NDdjZDlmNWI2NDQwNWJmYjJhNTRfMjE5OTAyMzI1NTcyMw_65436cc9-6be5-4208-aac4-53ce7e6ee591"><ix:nonFraction unitRef="usdPerShare" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjUtMC0xLTEtNDkxL3RleHRyZWdpb246ZDYwMWZjMDNhOTQ1NDdjZDlmNWI2NDQwNWJmYjJhNTRfMjE5OTAyMzI1NTcyMw_a8c39275-f1b9-4303-8469-b621fd84ad52">0.000001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjUtMC0xLTEtNDkxL3RleHRyZWdpb246ZDYwMWZjMDNhOTQ1NDdjZDlmNWI2NDQwNWJmYjJhNTRfMjE5OTAyMzI1NTczNw_2cd676a0-2a33-4e24-8cd5-c606378f7154"><ix:nonFraction unitRef="shares" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjUtMC0xLTEtNDkxL3RleHRyZWdpb246ZDYwMWZjMDNhOTQ1NDdjZDlmNWI2NDQwNWJmYjJhNTRfMjE5OTAyMzI1NTczNw_7599d89c-cd61-4be9-a0ef-88b32eafe41c">5,000,000</ix:nonFraction></ix:nonFraction> authorized at December&#160;31, 2020 and 2019; <ix:nonFraction unitRef="shares" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjUtMC0xLTEtNDkxL3RleHRyZWdpb246ZDYwMWZjMDNhOTQ1NDdjZDlmNWI2NDQwNWJmYjJhNTRfMjE5OTAyMzI1NTc0NA_1afa781f-f218-436d-8093-e9a142ff4e78"><ix:nonFraction unitRef="shares" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjUtMC0xLTEtNDkxL3RleHRyZWdpb246ZDYwMWZjMDNhOTQ1NDdjZDlmNWI2NDQwNWJmYjJhNTRfMjE5OTAyMzI1NTc0NA_4a680058-2ace-4aaa-aa06-fbe892125b2b"><ix:nonFraction unitRef="shares" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjUtMC0xLTEtNDkxL3RleHRyZWdpb246ZDYwMWZjMDNhOTQ1NDdjZDlmNWI2NDQwNWJmYjJhNTRfMjE5OTAyMzI1NTc0NA_9fab9556-aedf-495d-9b3b-4bd341e123b8"><ix:nonFraction unitRef="shares" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjUtMC0xLTEtNDkxL3RleHRyZWdpb246ZDYwMWZjMDNhOTQ1NDdjZDlmNWI2NDQwNWJmYjJhNTRfMjE5OTAyMzI1NTc0NA_af749fa3-edb3-4ad0-8232-70dc9c19e3ea">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding at December&#160;31, 2020 and 2019 </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjUtMS0xLTEtMA_e9417bdf-6f72-4a49-86f0-dbccb3b4ac26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjUtMy0xLTEtMA_e9c833a3-ddea-4071-83eb-52c0aa7e330b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjYtMS0xLTEtMA_18221191-f085-489e-a030-10d6fd4926a0">524,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjYtMy0xLTEtMA_43376d90-d29c-41f5-b54d-4984c0ad785e">441,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjctMS0xLTEtMA_d7a812a7-5307-4683-81a9-e0d8cee812c3">332,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjctMy0xLTEtMA_3f117a4a-91d3-42fe-a37a-cff2ac279059">299,529</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjgtMS0xLTEtMA_a978a4fd-2b25-41af-ad14-b1c42f363b2c">191,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjgtMy0xLTEtMA_015ce860-2b3c-4a8e-8e9c-723f8259abfb">141,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjktMS0xLTEtMA_1f50cb4a-e50e-46b7-a2d0-8540ab9efa42">210,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjktMy0xLTEtMA_8408006d-f181-4aad-a217-ced04fd9fa6a">147,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes form an integral part of these consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="ib53014c4f13844039ebc5a68643f31a2_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOLEUKIN THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:72.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating loss</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfNC0xLTEtMS0w_d1b47021-dec6-4495-aa79-67dd40aa1102">24,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfNC0zLTEtMS0w_6c51e519-2541-4b67-9965-393a3abe92a3">4,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired in-process research and development </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfNS0xLTEtMS0w_9ff7e493-dea9-4085-9738-64b818573515">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfNS0zLTEtMS0w_4b0f97ba-bfed-4e4e-b387-373ab13255ff">47,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfNi0xLTEtMS0w_a2525821-968f-46fc-a48b-8511f6745fd4">17,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfNi0zLTEtMS0w_fbefd4c9-821b-4496-b775-937f07fdba39">18,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of Aquinox Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainOrLossOnSaleOfStockInSubsidiary" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfNi0xLTEtMS0xNTg5_cbb5ca22-94e6-4840-9d60-78c35ef55cd5">7,826</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainOrLossOnSaleOfStockInSubsidiary" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfNi0zLTEtMS0xNTkx_d85d9d2a-fcd0-46f3-be91-3136976a83f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfNy0xLTEtMS0w_241ebce6-04c2-4253-958d-a3b876c26521">33,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfNy0zLTEtMS0w_99393d35-bb1a-4394-9ccc-922974c7364d">70,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfMTItMS0xLTEtMA_ec2d13be-3b15-4bcd-9a2f-22548585870d">451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfMTItMy0xLTEtMA_e19910af-4827-43f7-82a3-8b6d3e068ae0">1,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfMTMtMS0xLTEtMA_57c34d90-ca3e-4acf-a287-a2bfdbc665db">33,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfMTMtMy0xLTEtMA_f85333c4-a0ce-4c0e-a9a8-ee53b469b1d3">69,442</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per common stock - basic and diluted </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfMTQtMS0xLTEtMA_b024699e-89e8-4213-ade4-cba0ed704d2d">0.64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfMTQtMy0xLTEtMA_72eabc4d-5b0f-4b10-a08c-4386d7550a8b">2.57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted weighted average number of common stock outstanding </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfMTUtMS0xLTEtMA_51655bdb-a367-4fff-b886-8795a716da9d">51,825,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfMTUtMy0xLTEtMA_cf1e63c0-b6b1-4b30-b45e-2c83a25fd016">27,030,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes form an integral part of these consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="ib53014c4f13844039ebc5a68643f31a2_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOLEUKIN THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:72.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended  December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMy0xLTEtMS0w_c49e78dc-0107-4249-be6b-b95eb4b4bfcf">33,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMy0zLTEtMS0w_e0a6f0e5-e93b-4b06-a308-8475e81127c0">69,442</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfNS0xLTEtMS0w_3a06ff08-0723-4763-95fe-92041a474bb7">5,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfNS0zLTEtMS0w_3c877a36-d62c-4825-916e-d27a043bb608">7,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired in-process research&#160;&amp; development </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfNi0xLTEtMS0w_c1420d31-b13c-4fc5-ad4e-6741e253c7d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfNi0zLTEtMS0w_b9b6d720-b669-4f63-88da-9fa2895d9811">47,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfNy0xLTEtMS0w_68f17cd8-9e7f-4e19-ac42-68a322dc718c">785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfNy0zLTEtMS0w_e858e887-039a-4c67-9e92-2351efe067a5">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on disposal of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfOC0xLTEtMS00NTQ3_bbd75940-2e3d-488a-9e6f-4432ffc9d989">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfOC0zLTEtMS00NTYx_ea66c710-56ea-4251-aba3-b8ead1114cc7">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfOS0xLTEtMS00NTQ3_4aa0a599-f1bb-4b09-bb31-531c38670ddd">1,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfOS0zLTEtMS00NTYx_95ffc336-0ecd-4797-a5ba-8a6baaf09627">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Write-off of right-of-use asset upon lease termination</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" name="nltx:WriteOffOfRightOfUseAssetUponLeaseTermination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTAtMS0xLTEtNDU0Nw_25057abf-20d0-481b-a83f-3546eec34d80">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="nltx:WriteOffOfRightOfUseAssetUponLeaseTermination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTAtMy0xLTEtNDU2MQ_06c66f48-15be-4ac4-86fe-03733d4db164">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized foreign exchange loss and others</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTEtMS0xLTEtNTQyMA_121ee386-f926-4b8f-b9cb-3eb34892f4ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTEtMy0xLTEtNTQyMA_a0475924-9bdf-43c2-a81f-3771d9bbbcc5">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets and non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTAtMS0xLTEtMA_340edc96-f1e1-4576-9e26-281143f0b50d">2,481</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTAtMy0xLTEtMA_251b4722-bb81-4dbf-88c0-768aa9ab4f8f">290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTEtMS0xLTEtMA_c89c6e2e-cb20-404c-b688-9e467ae411e7">3,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTEtMy0xLTEtMA_5a7fd794-3221-4fc9-b149-6b29f4905fce">2,007</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" name="nltx:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTQtMS0xLTEtNDU1Nw_76daa806-9fb9-4842-aa00-471835248bda">169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="nltx:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTQtMy0xLTEtNDU1Nw_95087ddb-3995-4ef6-8ecd-39ac7a909a32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" name="nltx:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTUtMS0xLTEtNDU1Nw_bf0a6010-a91d-4260-9278-435b4ead8e97">598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" sign="-" name="nltx:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTUtMy0xLTEtNDU1Nw_1feaaca0-f7b4-43a2-aeca-b3ddec85faac">237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTItMS0xLTEtMA_bfa54c11-0934-40ba-aa8b-d578d3f02dc7">24,575</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTItMy0xLTEtMA_10e76793-2702-4337-a987-e94158d4228a">15,394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition of Neoleukin Therapeutics, Inc., net of cash acquired </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="nltx:AcquisitionOfAssetsNetCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTQtMS0xLTEtMA_14a12441-6edd-4ff1-9fb7-b40bc499d63d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" name="nltx:AcquisitionOfAssetsNetCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTQtMy0xLTEtMA_f42c2c7c-643e-40bf-9cc5-59ed62140c31">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTctMS0xLTEtMA_984419c9-0e07-47ea-b463-1c8052ba7bcb">2,219</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTctMy0xLTEtMA_d4ab8ea3-abd6-4025-a206-f6b70bf76f85">879</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTgtMS0xLTEtMA_4d731e0a-46fe-4be4-904d-295c5b430116">2,219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTgtMy0xLTEtMA_d62b0348-e26d-4549-8a02-3e846d1ac9cd">688</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from public offering of common stock and pre-funded warrants, net of commissions of $<ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="nltx:CommissionsOnPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjAtMC0xLTEtNDg0L3RleHRyZWdpb246MzBlYWVhMjYxZTQwNDZiYTkxMDdhMDI1MjFjYzJiNmJfMjE5OTAyMzI1NTcwNA_4897014c-1ff0-4e59-8e44-c0aa50297f7d">4,575</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="nltx:CommissionsOnPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjAtMC0xLTEtNDg0L3RleHRyZWdpb246MzBlYWVhMjYxZTQwNDZiYTkxMDdhMDI1MjFjYzJiNmJfMjE5OTAyMzI1NTcxNA_576c545e-774e-4705-9d6a-38ede703e78e">5,173</ix:nonFraction> in 2020 and 2019, respectively.</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjAtMS0xLTEtMA_6b2231aa-ca53-43cf-bd2b-4136a1a143b7">71,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjAtMy0xLTEtMA_53bd2c63-a4c3-411e-85d9-20bb89103256">81,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjEtMS0xLTEtMA_1b0731fd-5d1f-4016-9821-3aefbd1c28b0">355</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjEtMy0xLTEtMA_67da3976-392a-4109-a1aa-5f6175b3e85a">352</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjItMS0xLTEtMA_e2512171-8117-4599-bf8c-485657b2c4c0">5,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjItMy0xLTEtMA_d598e290-5e73-4447-b767-b1220f1e2e57">1,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from issuance of common stock under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjYtMS0xLTEtNTQ4Ng_fe57a009-f44f-47d7-8be2-0bd7d80e3dc9">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjYtMy0xLTEtNTQ4Ng_7856ba3d-62b0-47b9-8c49-de86533b912a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment on finance lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjMtMS0xLTEtMA_06c6a63a-8ccb-4141-9fdd-e3d906930561">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjMtMy0xLTEtMA_b4f9aa36-7efd-4c1d-ad3a-7e810ef73a30">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjQtMS0xLTEtMA_a86b8352-2e60-41f6-9f4f-9bc11aeb9160">77,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjQtMy0xLTEtMA_afe3250a-daff-421e-9bd7-20692ff7a3d2">82,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjUtMS0xLTEtMA_27cd6ed7-f6d1-4484-b991-5e011232f333">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjUtMy0xLTEtMA_3963e615-9cb5-4603-8d7c-4bb042c947d1">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net change in cash, cash equivalents, and restricted cash during the year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjYtMS0xLTEtMA_78c043d1-8635-4bdd-98e9-6d26c24fd740">50,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjYtMy0xLTEtMA_65367329-117b-4f3a-86e3-962598c428a5">66,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash at beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjctMS0xLTEtMA_b241fea7-b27c-4c37-81ae-466898f8fd42">143,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i049d641cdc3c4012850e2abee7d5fe17_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjctMy0xLTEtMA_46582ef1-70e6-4c4f-b669-f40b4ed26410">76,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash at end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjgtMS0xLTEtMA_1c685bb2-7e06-45d9-a123-dd885a6ef670">193,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjgtMy0xLTEtMA_6ca783b7-55bd-4228-81b3-d3f245d0ce90">143,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets acquired through the issuance of common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="nltx:OtherCurrentAssetsAcquiredThroughTheIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMzMtMS0xLTEtMA_b85a593f-8841-4590-924d-341f601cfd77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" name="nltx:OtherCurrentAssetsAcquiredThroughTheIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMzMtMy0xLTEtMA_0e7f9051-a3cc-4ee7-a11f-5dfa7da98c23">560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and intangibles acquired through the issuance of common stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="nltx:PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMzQtMS0xLTEtMA_9600d164-4fea-4d9f-9aba-2604f8c870ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="nltx:PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMzQtMy0xLTEtMA_3ddae8bc-42c4-46dc-9cd6-c7dbe480951d">1,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable, finance lease and other liabilities assumed through the issuance of common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMzUtMS0xLTEtMA_8f356fc8-198b-4f18-8f9a-6759dbb9db92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMzUtMy0xLTEtMA_03d186dd-6f5f-4703-8935-246670b448ad">1,673</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities arising from obtaining right-of-use asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMzYtMS0xLTEtMA_82c7c30e-214e-4c18-8770-01b3e6dab9f3">10,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMzYtMy0xLTEtMA_b571c4e4-4150-4fb8-b791-18243dd0d3c5">1,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of property and equipment unpaid at period end</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMzMtMS0xLTEtNDQzMw_87402e12-5914-4737-b5f1-71cb84864cbb">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMzMtMy0xLTEtNDQzMw_4ec46b06-cc0c-4cd4-ad76-7685199ce953">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes form an integral part of these consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="ib53014c4f13844039ebc5a68643f31a2_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOLEUKIN THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders' Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.315%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.912%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.730%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Non-Voting<br/>Convertible<br/>Preferred&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balances, December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i732d643094fe48eabda3a3bdcda606d7_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfOS0xLTEtMS0w_60c7667d-6b27-4941-99e7-41d35ae3e47c">23,537,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5cf36246e64844f0999cee0b4685f134_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfOS05LTEtMS0w_39f15b98-80e5-4ea9-96a1-2865d33ed722">302,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ibc7d097a895f4d19ad4225c8b7a363e3_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfOS0xMS0xLTEtMA_39b570dd-85ad-4a9b-8015-89a4f3543544">230,087</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i049d641cdc3c4012850e2abee7d5fe17_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMi0xNS0xLTEtMjgwMw_dbdeb4f2-bc2c-4a79-a9c9-52ab4f29577f">72,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock for Former Neoleukin common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia5203423d3b74826a3d7fe380aabf55b_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTAtMS0xLTEtMA_98cbf324-3251-497e-af42-dc0c2c3fc8ce">4,589,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4f9b47e6f171422bb275e6ef86e39725_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTAtOS0xLTEtMA_dd17aa7e-dbf2-4435-a8c9-0d1ac688e157">15,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMy0xNS0xLTEtMjgwMw_903629f0-d577-4066-aef4-af35d96b648e">15,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of convertible preferred stock for Former Neoleukin common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9b5b9988d4e248bc863b2725dbedccc0_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTEtNS0xLTEtMA_a885b0ef-275d-4ae3-9316-52b4d182cf7c">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ie40aff3f920a4fa49c187c3ad3974bfb_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTEtOS0xLTEtMA_511dea10-e841-400c-b55e-a36539021e1c">33,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b5b9988d4e248bc863b2725dbedccc0_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfNC0xNS0xLTEtMjgwMw_4ec74324-29d2-4c82-828f-9a1a5d80093a">33,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Conversion of convertible preferred stock into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia5203423d3b74826a3d7fe380aabf55b_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfNS0xLTEtMS0yNzYy_471a4ec7-9638-4550-a397-4af09dc41164">10,192,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i9b5b9988d4e248bc863b2725dbedccc0_D20190101-20191231" decimals="INF" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfNS01LTEtMS0yNzkx_724ed378-905b-45a4-9e7a-3bfda5234d77">102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock, net of discounts, commissions and offering expenses of $<ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfNi0wLTEtMS0yNzU0L3RleHRyZWdpb246ZTAxZjYwOTEwM2I0NDUyYzg2MDkxNTRkNGZiOWY0ZWNfMjE5OTAyMzI1NTY4NQ_b3f1633c-d58c-4abc-944f-3cb15ba4e73f">5,525</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia5203423d3b74826a3d7fe380aabf55b_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfNi0xLTEtMS0yNzYy_49bd2e87-8808-4769-805f-880ac31b225b">10,263,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4f9b47e6f171422bb275e6ef86e39725_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfNi05LTEtMS0yNzkx_a1362e06-5a9d-4c5c-876a-d76a2ac3d657">80,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfNi0xNS0xLTEtMjgwMw_7c3ebd7a-3110-44ca-8626-9ba80e528e78">80,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock to University of Washington</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia5203423d3b74826a3d7fe380aabf55b_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfNy0xLTEtMS0yNzYy_8a71c310-5457-4672-af02-efaa5edc8320">12,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4f9b47e6f171422bb275e6ef86e39725_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfNy05LTEtMS0yNzkx_2d4e93ec-2d7a-45b1-8b5e-a617fb1b1a03">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfNy0xNS0xLTEtMjgwMw_55a87377-9a40-4556-9dde-57619b6d0618">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Conversion of common stock to pre-funded warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="ia5203423d3b74826a3d7fe380aabf55b_D20190101-20191231" decimals="INF" sign="-" format="ixt:numdotdecimal" name="nltx:StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfOC0xLTEtMS0yNzYy_5683ffda-3614-427c-b26b-4b00d0a9aecb">10,925,481</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ia5203423d3b74826a3d7fe380aabf55b_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfOS0xLTEtMS0yNzYy_1a3330dc-5028-490c-bea5-678256e3034f">326,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4f9b47e6f171422bb275e6ef86e39725_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfOS05LTEtMS0yNzkx_a5d0c58b-fec6-4539-9858-14aeb3e8840e">1,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfOS0xNS0xLTEtMjgwMw_ee1bf612-ee1a-4566-bb2e-b6170a562359">1,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i4f9b47e6f171422bb275e6ef86e39725_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTItOS0xLTEtMA_33fc7bc4-d7f3-4420-a95b-685295d4e024">7,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTAtMTUtMS0xLTI4MDM_044c8fad-1aac-43f3-be0c-09e323dfe00f">7,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i0d6e4cb98c3641c0b1a872248ed13060_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTMtMTEtMS0xLTA_22ade35a-1332-414a-b908-88649511d19e">69,442</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTEtMTUtMS0xLTI4MDM_9f947dd2-5338-460d-839c-c21b037e69ff">69,442</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balances, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9394470fa9e045eaaa71a62dee88a970_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTQtMS0xLTEtMA_4ccd3809-aa70-42b2-bb6b-4c77ea6d2a25">37,996,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i85f0f44c55744942ad3e1471a8246db3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTQtOS0xLTEtMA_adc4c33e-8834-4019-9a7f-e925ad26edd4">441,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9cc2885987c54d929541504d3cf066e4_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTQtMTEtMS0xLTA_b7320ea0-bd3b-42bb-be7a-14b0876e1803">299,529</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTItMTUtMS0xLTI4MDM_36c47b8f-d18b-420b-b323-39e87ab63f69">141,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock and pre-funded warrants, net of discounts, commissions and offering expenses of $<ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfOC0wLTEtMS0xNjM1L3RleHRyZWdpb246YmQzMzk4MjkyZmYyNGNhMWIwZTQ5MjMwNWQ1YzI0ZDdfMjE5OTAyMzI1NTY4Mg_12197f47-d898-4e5e-af0b-f485b705bc55">4,930</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2b7aa4965884327b321e9713f816fca_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfOC0xLTEtMS0xNjAx_7bc58a16-9987-4798-8c38-cf903b3101d8">3,262,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i815e5dda4d8349a9beb806cdf5433517_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfOC05LTEtMS0xNjAz_122dfc0b-75ea-4b01-996a-12c58d6efd4f">71,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTMtMTUtMS0xLTI4MDM_91b42a54-b1cc-4fba-96f9-d326288aac54">71,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2b7aa4965884327b321e9713f816fca_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfOS0xLTEtMS0xNjE1_0ad3e24c-b4e6-420e-bb44-ee289c8be259">882,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i815e5dda4d8349a9beb806cdf5433517_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfOS05LTEtMS0xNjE5_b27e2af3-9bdb-4043-97e0-4512aeb25eed">5,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTQtMTUtMS0xLTI4MDM_095f740e-b734-49a8-b2c8-8fda4e75c879">5,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock units vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2b7aa4965884327b321e9713f816fca_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMjEtMS0xLTEtMA_4c29ad36-8132-49c2-98d1-b0cd688bd04c">36,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2b7aa4965884327b321e9713f816fca_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTYtMS0xLTEtNDQwOA_84684cec-e41e-48ff-8b56-89cf81afd9cb">18,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i815e5dda4d8349a9beb806cdf5433517_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTYtOS0xLTEtNDQwOA_a8a516d3-f6a4-419e-a0f2-bf17efb20a06">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTYtMTUtMS0xLTQ0MDg_a9001011-59c8-4eae-8dd2-f800e4a7589e">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i815e5dda4d8349a9beb806cdf5433517_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMjItOS0xLTEtMA_1d204a36-a27d-4c8a-9068-9c7c27f3ed1e"><ix:nonFraction unitRef="usd" contextRef="i815e5dda4d8349a9beb806cdf5433517_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMjItOS0xLTEtMA_31455b16-498c-411e-b2de-b85c1d8d83b7">5,622</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTYtMTUtMS0xLTI4MDM_20f7b2e1-c644-4744-89bb-be9d1b86d402"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTYtMTUtMS0xLTI4MDM_8ef4d7c4-2af4-482a-9224-ac23b06dc3f5">5,622</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54fb527f851045fcb24b611005c9b2a2_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMjMtMTEtMS0xLTA_1d0b8816-bcf0-46d7-bc0b-9249d192d16e"><ix:nonFraction unitRef="usd" contextRef="i54fb527f851045fcb24b611005c9b2a2_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMjMtMTEtMS0xLTA_ddc33729-142d-4220-9c9b-9ea5fa96ef5d">33,277</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTctMTUtMS0xLTI4MDM_2f4b8e2a-5461-449c-80e4-0dc9fe9ac554"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTctMTUtMS0xLTI4MDM_b024471e-6be8-4bda-bee4-5ca765a34696">33,277</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances, December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c771818b1a2410cbe3be150df63decf_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMjQtMS0xLTEtMA_3fc1559d-f5da-42e1-922b-e1b03257ced4"><ix:nonFraction unitRef="shares" contextRef="i8c771818b1a2410cbe3be150df63decf_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMjQtMS0xLTEtMA_d4019ef7-64de-44f6-8d81-81df59c53f9b">42,196,296</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64550577bf6444d791bf8bd32d649edd_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMjQtOS0xLTEtMA_6df19335-e354-4500-9a94-bb7e010c0eb2"><ix:nonFraction unitRef="usd" contextRef="i64550577bf6444d791bf8bd32d649edd_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMjQtOS0xLTEtMA_9efe793b-61aa-41d5-97e2-cf0465946199">524,022</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i277fa222473b45ceb75d3af3ec082271_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMjQtMTEtMS0xLTA_428c4ed6-9344-41e4-8d3d-df9f01a2046a"><ix:nonFraction unitRef="usd" contextRef="i277fa222473b45ceb75d3af3ec082271_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMjQtMTEtMS0xLTA_9d31cb3f-dbc9-433d-be9e-2a7c8d073467">332,806</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTgtMTUtMS0xLTI4MDM_2ad84739-67d9-4fe3-a8a7-bef05033b0fa"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTgtMTUtMS0xLTI4MDM_65f02429-c69d-424c-bc2d-562985bd861f">191,216</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes form an integral part of these consolidated financial statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="ib53014c4f13844039ebc5a68643f31a2_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOLEUKIN THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div id="ib53014c4f13844039ebc5a68643f31a2_106"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDYvZnJhZzoxYzFkYjVkNjlkZDc0OGYwYTYzMWIwODgyNDlmNWNmOC90ZXh0cmVnaW9uOjFjMWRiNWQ2OWRkNzQ4ZjBhNjMxYjA4ODI0OWY1Y2Y4XzEyMjQ_5388df32-f995-47c5-be14-efcb0a912a7d" continuedAt="ifcd17fe40d5e481687c2a259b6e145bc" escape="true">Nature of operations</ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="ifcd17fe40d5e481687c2a259b6e145bc"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neoleukin Therapeutics, Inc. (&#8220;Neoleukin&#8221; or &#8220;the Company&#8221;) is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> protein design technology. Neoleukin uses sophisticated computational methods to design&#160;proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.&#160;The Company&#8217;s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.</span></ix:continuation></div><div style="margin-top:6pt"><span><br/></span></div><div id="ib53014c4f13844039ebc5a68643f31a2_109"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMzAy_8c35e1a6-7574-4460-9077-a276445653cb" continuedAt="i7ab941c6c3ef4f30a446cb0bf201c638" escape="true">Basis of presentation and summary of significant accounting policies</ix:nonNumeric></span></div><ix:continuation id="i7ab941c6c3ef4f30a446cb0bf201c638" continuedAt="i79b638a92b1a414ca2c9e05122cee7af"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a) <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMjk2_5267e6c3-380a-4e0a-8a7a-66d809122fc5" continuedAt="i3ac1392cc6914be5844712c81a939972" escape="true">Basis of presentation</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3ac1392cc6914be5844712c81a939972" continuedAt="id0416ff3a91543dc895cdc51459e5cf8">The accompanying consolidated financial statements are presented in United States (&#8220;U.S.&#8221;) dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The financial results are presented on a consolidated basis. All intercompany transactions are eliminated on consolidation. </ix:continuation></span></div><div style="margin-top:6pt"><ix:continuation id="id0416ff3a91543dc895cdc51459e5cf8" continuedAt="ie0f60aebfc7040398623081cfd8e05bc"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company sold all of the issued and outstanding capital stock of Aquinox Pharmaceuticals (Canada) (&#8220;Aquinox Canada&#8221;) to an unrelated third party, as further described in Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale of Aquinox Canada</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie0f60aebfc7040398623081cfd8e05bc">. On December 31, 2020, Neoleukin Corporation, the Company's wholly owned subsidiary, was merged into the Company. As a result, the Company consists of a single operating company without any subsidiaries at December 31, 2020.</ix:continuation> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b) <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMjk4_f2ac624c-4ac9-466c-bfaf-1b913083916c" continuedAt="i67906bad4b2c4c9182dc4e9566a34662" escape="true">Use of estimates and assumptions</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i67906bad4b2c4c9182dc4e9566a34662">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant areas requiring estimates include valuation and recognition of stock-based compensation, the incremental borrowing rate utilized in the measurement of operating and finance lease liabilities, amortization and depreciation of property, plant and equipment and intangible assets, and pre-clinical, clinical, and other accruals. Actual results could differ from those estimates.</ix:continuation></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c) <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzE2NDkyNjc0OTYxMzA_402fb23d-e6a3-4502-b43a-a67de8da1101" continuedAt="i15173f446d7b4f8f996f839963383285" escape="true">Reclassification</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i15173f446d7b4f8f996f839963383285">The Company reclassified amounts related to prior year amortization of operating lease right-of-use assets, loss on disposal of property and equipment, changes in operating lease liabilities, and payment of offering costs in the consolidated statements of cash flows to conform to current year presentation. This reclassification had no effect on cash used in operating activities or cash provided by financing activities.</ix:continuation> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d) <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzE2NDkyNjc0OTYxMzI_1d4c154a-0570-42dc-8e36-a715f8a5f310" continuedAt="i91e55b98610d444bbf67bc12301a3e68" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i91e55b98610d444bbf67bc12301a3e68"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company determines if the contract is or contains a lease. Lease liabilities are recognized on the lease commencement date based on the estimated present value of lease payments over the lease term. To determine the present value of the lease payments, the Company utilizes its estimated incremental borrowing rate based on information available at the lease commencement date as the interest rate implicit in the lease is typically not readily determinable. The related right-of-use assets are recorded net of any lease incentives received. Variable lease cost primarily includes building operating expenses as charged to the Company by its landlords.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We include options to extend the lease in our lease liability and right-of-use asset when it is reasonably certain that we will exercise that option. None of our options to extend the rental term of any existing leases were considered reasonably certain as of December 31, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For leases of office space, the Company has elected to not separate the lease components from the non-lease components.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For leases of office space with a lease term of <ix:nonNumeric contextRef="i3d1ecd6573694fdfb6e3cad48ebf1c3c_I20201231" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzE2NDkyNjc0OTYxOTA_3deef86e-d0dc-4596-a42e-acbce0b95d44">12</ix:nonNumeric> months or less and which do not include an option to purchase the underlying asset, the Company has elected to recognize the lease payments in the statement of operations on a straight-line basis over the lease term.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(e) <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMjk5_e748e1ad-1829-4f75-8de1-98076eac4eb4" continuedAt="i9544bd77c03c41e5b73ead4d48ac6d34" escape="true">Cash, cash equivalents, and restricted cash</ix:nonNumeric></span></div><ix:continuation id="i9544bd77c03c41e5b73ead4d48ac6d34"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly liquid investments with maturities of three months or less at the date of acquisition are considered to be cash equivalents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash, included in Other non-current assets in the consolidated balance sheets, includes cash deposits the Company maintains with its bank as collateral for the irrevocable letters of credits related to its lease obligations.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="i79b638a92b1a414ca2c9e05122cee7af" continuedAt="i80580e2a41cb44ca9e67fe97982e5596"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzE2NDkyNjc1MjI2NzQ_c3c50190-8c2b-4792-b5cf-acfdeae21e40" escape="true"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzE2NDkyNjc1MjI2NzQ_f722fb9b-fcad-4ad8-b15a-55afc3a828c3" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90YWJsZTplZGFkMjdhNDE5MWQ0NWYzYjRiZTEzYWEzZTIwNTllOS90YWJsZXJhbmdlOmVkYWQyN2E0MTkxZDQ1ZjNiNGJlMTNhYTNlMjA1OWU5XzEtMS0xLTEtNTU0OA_73db0383-9df1-4ff4-b276-7b48ebc1a76c">192,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90YWJsZTplZGFkMjdhNDE5MWQ0NWYzYjRiZTEzYWEzZTIwNTllOS90YWJsZXJhbmdlOmVkYWQyN2E0MTkxZDQ1ZjNiNGJlMTNhYTNlMjA1OWU5XzEtMy0xLTEtNTU1MA_bdfabd21-1796-4633-9ec5-5d60d0529917">143,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90YWJsZTplZGFkMjdhNDE5MWQ0NWYzYjRiZTEzYWEzZTIwNTllOS90YWJsZXJhbmdlOmVkYWQyN2E0MTkxZDQ1ZjNiNGJlMTNhYTNlMjA1OWU5XzItMS0xLTEtNTU0OA_45160e56-974e-43c7-ae0b-ffda4df4ad6b">878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90YWJsZTplZGFkMjdhNDE5MWQ0NWYzYjRiZTEzYWEzZTIwNTllOS90YWJsZXJhbmdlOmVkYWQyN2E0MTkxZDQ1ZjNiNGJlMTNhYTNlMjA1OWU5XzItMy0xLTEtNTU1MA_b796134a-d580-4101-9f2c-3999a9f1b523">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90YWJsZTplZGFkMjdhNDE5MWQ0NWYzYjRiZTEzYWEzZTIwNTllOS90YWJsZXJhbmdlOmVkYWQyN2E0MTkxZDQ1ZjNiNGJlMTNhYTNlMjA1OWU5XzMtMS0xLTEtNTU0OA_54a9dc28-9049-47c8-9f71-7f4c8cede975">193,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90YWJsZTplZGFkMjdhNDE5MWQ0NWYzYjRiZTEzYWEzZTIwNTllOS90YWJsZXJhbmdlOmVkYWQyN2E0MTkxZDQ1ZjNiNGJlMTNhYTNlMjA1OWU5XzMtMy0xLTEtNTU1MA_c907007f-befb-40fa-8074-d796c35fda74">143,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(f) <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMzEx_a120f076-3793-44a3-93c7-382a4e07ee37" continuedAt="icf0f440f0cce42f69cc7d108fbf7433a" escape="true">Property and equipment</ix:nonNumeric></span></div><ix:continuation id="icf0f440f0cce42f69cc7d108fbf7433a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost and are amortized using the straight-line basis over a range of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzE2NDkyNjc0OTYxNDk_956254c7-b20d-4861-9cc1-c72b39fa063a">three</span> to <ix:nonNumeric contextRef="iae8ed78b63224fe9a7fae1f526fde05d_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzE2NDkyNjc0OTYxNjE_516bf8ec-1d6d-4c7b-81f2-42056e758e10">seven years</ix:nonNumeric>. Expenditures for improvements to the Company&#8217;s office spaces are capitalized and expenditures for maintenance and repairs are expensed as incurred. Leasehold improvements are amortized over the lesser of useful life and term of the lease.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the carrying value of property and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition, and other economic factors. Based on management&#8217;s assessment there were no indicators of impairment of property and equipment as at December&#160;31, 2020 and 2019.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(g) <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzE2NDkyNjc0OTYxNDc_d9cbd895-53af-4f6c-87c5-a9aaac69a8ef" continuedAt="i036f0b2112b442e1ae0063d72b2f6bbc" escape="true">Earnings (loss) per share</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i036f0b2112b442e1ae0063d72b2f6bbc">Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Common stock equivalents are included in the calculation of diluted earnings per share only in periods of net income. Such common stock equivalents are excluded in the calculation of diluted net loss per share in periods of net loss as inclusion of such amounts would be anti-dilutive. Outstanding pre-funded warrants as of December&#160;31, 2020 of <ix:nonFraction unitRef="shares" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzMyOTg1MzQ5NTk1Mzk_19ccbf22-60b4-4acf-b6c5-22c1926bc300">12,663,010</ix:nonFraction> are considered outstanding as of their issuance date and are included in the basic and diluted net loss per share calculation because they are fully vested and exercisable at any time for a nominal cash consideration.</ix:continuation></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(h) <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="nltx:AssetAcquisitionsintangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMzEy_8692fe03-a166-4c0a-94a6-b5eb2edc7ae7" continuedAt="i11d4f8031bc04af4b1563661fd572a5a" escape="true">Asset acquisitions/Intangible assets</ix:nonNumeric></span></div><ix:continuation id="i11d4f8031bc04af4b1563661fd572a5a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of acquisition, the Company determines if a transaction should be accounted for as a business combination or acquisition of assets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For an acquisition of assets, the cost of acquiring the asset group, including transaction costs, is allocated to the acquired assets and assumed liabilities based on their relative fair values without giving rise to goodwill. Acquired in-process research and development assets are expensed if management determines that the assets do not have an alternative future use. Other long-lived intangible assets are recorded at the acquired cost and amortized using the straight-line method over their estimated useful life. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset is tested for impairment when events or changes in circumstances indicate that the carrying value of the asset may not be recoverable.&#160;The Company recognizes an impairment loss when carrying amount is not recoverable and the estimated fair value of the intangible asset is less than its carrying value.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(i) <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMzEz_4729c5e1-ec8f-40f0-84ec-34ff391b5046" continuedAt="i4d536b23f14d463b9d0a3085846b0461" escape="true">Income taxes</ix:nonNumeric></span></div><ix:continuation id="i4d536b23f14d463b9d0a3085846b0461"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the differences between events that have been recognized in the Company&#8217;s consolidated financial statements and the tax bases of assets and liabilities recognized at enacted tax rates. In estimating future tax consequences, Accounting Standards Codification ("ASC") 740 generally considers all expected future events other than enactments of and changes in the tax law or rates. The measurement of deferred tax assets is reduced, if necessary, by the extent of the valuation allowance. We will establish a valuation allowance for deferred tax assets if it is more likely than not that these items will expire before we are able to realize their benefits or that future deductibility is uncertain. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment tax credits relating to scientific research and experimental development are accounted for as a reduction in operating expenses. They are recorded in the period when there is reasonable assurance the credits will be realized. If investment tax credit amounts subsequently received are less or more than originally recorded, the difference is treated as a change in estimate.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="i80580e2a41cb44ca9e67fe97982e5596" continuedAt="i13adeb019ede41ea876bb881ca95529a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(j) <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMzE0_1526cf6a-012b-4e8c-850d-328b323969c5" continuedAt="iebe2f0e2dbca445dbdde05e318ad7c5b" escape="true">Research and development costs</ix:nonNumeric></span></div><ix:continuation id="iebe2f0e2dbca445dbdde05e318ad7c5b"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred and include items such as: employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations that conduct clinical trials and preclinical studies, the cost of acquiring, developing and manufacturing clinical trial materials, facilities, and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, and other supplies and costs associated with clinical trials, preclinical activities, and regulatory operations. Restructuring costs associated with the termination of research and development programs and related employees are included in research and development costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development costs are expensed in the period incurred unless management believes a development project meets generally accepted accounting criteria for deferral and amortization. No product development expenditures have been deferred to date. The Company records costs for certain development activities based on management&#8217;s evaluation of the progress to completion of specific tasks or information provided to the Company by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued expense.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(k) <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMzE1_35240b48-b22a-4eb6-8ccd-e2346a9b1fb2" continuedAt="i45633b40595c4a81a6f89610c6af6dc5" escape="true">Accounting for stock-based compensation</ix:nonNumeric></span></div><ix:continuation id="i45633b40595c4a81a6f89610c6af6dc5"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued stock options and restricted stock units (&#8220;RSUs&#8221;). The Company measures the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The cost of such award is recognized on a straight-line basis over the requisite service period, which is generally the vesting period. The Company accounts for forfeitures as they occur. We utilize newly issued shares to satisfy option exercises.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of options using the Black-Scholes option pricing model on the grant date. This approximation uses assumptions regarding a number of inputs that requires management to make significant estimates and judgments. The expected term represents the period that the Company&#8217;s stock-based awards are expected to be outstanding. As the Company does not have sufficient historical experience for determining the expected term of the stock option awards granted, the Company has based its expected term for awards issued to employees on the simplified method, which represents the average period from vesting to the expiration of the stock option. In addition, the Company does not have sufficient trading history for the Company&#8217;s common stock, and therefore, the expected stock price volatility for the Company&#8217;s common stock was estimated by taking the average historical price volatility for industry peers. The Company has never declared or paid any cash dividends to common stockholders and does not presently plan to pay cash dividends in the foreseeable future. Consequently, the Company used an expected dividend yield of zero. The risk-free interest rate was based on the yields of treasury securities with maturities similar to the expected term of the options for each option group.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each RSU is measured using the closing price of the Company&#8217;s common stock on the date of grant.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(l) <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMzA3_9877ced6-1adb-484a-833a-6003aae52124" continuedAt="i5a6b6c21a88746a2b33e2d0995d61261" escape="true">Restructuring costs</ix:nonNumeric></span></div><ix:continuation id="i5a6b6c21a88746a2b33e2d0995d61261"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for restructuring costs in accordance with ASC 420,&#160;Exit or Disposal Cost Obligations. ASC 420 specifies that a liability for a cost associated with an exit or disposal activity be recognized when the liability is incurred, except for a liability where employees are required to render service until they are terminated in order to receive termination benefits and will be retained to render service beyond the minimum retention period. A liability for such one-time termination benefits shall be measured initially at the communication date based on the fair value of the liability as of the termination date and recognized ratably over the future service period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The charges that the Company expects to incur in connection with the restructuring are subject to a number of assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the restructuring plan.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(m) <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMjk0_fc181b10-4218-4b9e-9661-b14100231945" continuedAt="id9c297170c3b4e3db0ea133c2de1801f" escape="true">Segment reporting</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id9c297170c3b4e3db0ea133c2de1801f">The Company operates in <ix:nonFraction unitRef="segment" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzE2NDkyNjc1MjU4ODA_57cbdc7a-b466-4f2b-887f-079550689f6a">one</ix:nonFraction> segment, the research and development of&#160;de novo&#160;protein therapeutics using sophisticated computational algorithms and methods to address unmet medical needs. Our primary areas of focus are in oncology, inflammation, and autoimmunity. The Company&#8217;s operations and its assets are held in the United States.</ix:continuation></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(n) <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMzEw_3d153df4-9a0e-4de5-aff3-01551939af36" continuedAt="i3e65bf01bf72457384a67b259583bfdf" escape="true">Fair value of financial instruments</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3e65bf01bf72457384a67b259583bfdf">The carrying amounts of certain of the Company&#8217;s financial instruments, including cash, cash equivalents, receivables, accounts payable and other liabilities, approximate their fair values because of their nature and/or short maturities.</ix:continuation></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, and December&#160;31, 2019, the Company had $<ix:nonFraction unitRef="usd" contextRef="ie23ad3f47f044a12afefd67475b342f7_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzMyOTg1MzQ5MzUwODk_d5e601f3-f781-40bf-9f93-aefdd7929fdb">108.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibe8d18d31bb743bea079e6b2de6ec19a_I20191231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzMyOTg1MzQ5MzUwOTg_bceb6c0e-866a-46f5-aaf8-c58490f0ffb2">40.0</ix:nonFraction> million in money market funds, respectively. Money market funds are level one financial instruments as their pricing can be obtained from an actively traded exchange.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="i13adeb019ede41ea876bb881ca95529a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(o) <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMjk1_bfeeeeca-b5d5-4f0c-aee8-7e4dd8e10ffa" continuedAt="iaa1f6bc4ec0746279595021bb2a83cdc" escape="true">Concentration of credit risk</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaa1f6bc4ec0746279595021bb2a83cdc">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents. Cash and cash equivalents are invested in accordance with the Company&#8217;s investment policy. The primary objective for the Company&#8217;s investment portfolio is the preservation of capital and maintenance of liquidity and includes guidelines on the quality of financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk.</ix:continuation></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(p) <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMzA5_40d220ca-a5ca-491b-a3a6-64bbe9e2af7e" continuedAt="if809683b2c7048caab4d86b18fa59ccd" escape="true">Recently issued and recently adopted accounting standards</ix:nonNumeric></span></div><ix:continuation id="if809683b2c7048caab4d86b18fa59ccd"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12 &#8220;Simplifying the Accounting for Income Taxes.&#8221; The objective of the standard is to improve areas of GAAP by removing certain exceptions permitted by ASC Topic 740-- Income Taxes and clarifying existing guidance to facilitate consistent application. ASU 2019-12 is effective for fiscal years and interim periods beginning after December&#160;15, 2020. The Company has incurred net losses since its inception and maintains a full valuation allowance on the net deferred tax assets. As such, the Company does not expect the adoption of this standard to have a material impact on the financial condition, results of operations and cash flows, or financial statement disclosures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued &#8220;ASU 2018-15, Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.&#8221; The objective of the standard is to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The Company adopted this standard on January 1, 2020 on a prospective basis. The adoption of this ASU did not have a material impact on the Company&#8217;s financial condition, results of operations, cash flows, and financial statement disclosures.</span></div></ix:continuation></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="ib53014c4f13844039ebc5a68643f31a2_112"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="nltx:AcquisitionOfAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90ZXh0cmVnaW9uOmIxMTU2ODgxNDdhYTQ5N2NiOGE2ZWFjZTVjOTg1YTczXzEyNDU_9ef3d3f3-cbc4-42ad-8ba1-8306f9fb2fea" continuedAt="i80a9203c05514cfa967a79e8c61b9981" escape="true">Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc.</ix:nonNumeric></span></div><ix:continuation id="i80a9203c05514cfa967a79e8c61b9981" continuedAt="ife6a9d0f51ae449cbe9e7ec5d33e2f94"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;8, 2019, Neoleukin Therapeutics, Inc., or Former Neoleukin, and Aquinox Pharmaceuticals, Inc., or Aquinox, completed a transaction pursuant to the Agreement and Plan of Merger dated August&#160;5, 2019. Former Neoleukin became a wholly owned subsidiary of Aquinox and Aquinox subsequently changed its name to Neoleukin Therapeutics, Inc. All of the outstanding shares of common stock of the Former Neoleukin were exchanged for <ix:nonFraction unitRef="shares" contextRef="i40320493bb114b7b9790c7199d64f1a0_D20190808-20190808" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90ZXh0cmVnaW9uOmIxMTU2ODgxNDdhYTQ5N2NiOGE2ZWFjZTVjOTg1YTczXzMyOTg1MzQ4ODUzMzM_8e01ca8d-511b-4c42-adcb-06d7a1d705da">4,589,771</ix:nonFraction> shares of common stock of the Company and <ix:nonFraction unitRef="shares" contextRef="ib1005fcc8fe5417da0ed149702b76a6f_D20190808-20190808" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90ZXh0cmVnaW9uOmIxMTU2ODgxNDdhYTQ5N2NiOGE2ZWFjZTVjOTg1YTczXzMyOTg1MzQ4ODUzMzc_852e98a0-96ab-409e-b12e-b53ebf80478e">101,927</ix:nonFraction> shares of non-voting convertible preferred stock of the Company.</span></div><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="nltx:AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90ZXh0cmVnaW9uOmIxMTU2ODgxNDdhYTQ5N2NiOGE2ZWFjZTVjOTg1YTczXzEyNDY_2a66be7a-b3f9-4ac9-b291-81c59db97c69" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total consideration paid was $<ix:nonFraction unitRef="usd" contextRef="i562c09437d76488daa016091ce08fa2a_D20190808-20190808" decimals="-5" name="nltx:AcquisitionsOfAssetsConsiderationTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90ZXh0cmVnaW9uOmIxMTU2ODgxNDdhYTQ5N2NiOGE2ZWFjZTVjOTg1YTczXzMyOTg1MzQ4ODUzNDE_d9c7c7c2-12dc-47ff-9d51-3145b567fa1a">51.6</ix:nonFraction> million and consisted of (in thousands, except share amounts):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:83.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of <ix:nonFraction unitRef="shares" contextRef="i40320493bb114b7b9790c7199d64f1a0_D20190808-20190808" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozNTkxNGZlMjY2ODE0YTI1Yjk1NDY3NjI4NjY1ZGI0Yy90YWJsZXJhbmdlOjM1OTE0ZmUyNjY4MTRhMjViOTU0Njc2Mjg2NjVkYjRjXzEtMC0xLTEtNTcwL3RleHRyZWdpb246MjgxMTc5ZDg0NTU0NDY1M2IyOTQ0NTdhYWJjMjM1NjFfMjE5OTAyMzI1NTYwOQ_2725e9e3-b372-4ead-b9a1-fc383837dc4f">4,589,771</ix:nonFraction> Aquinox common stock</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i40320493bb114b7b9790c7199d64f1a0_D20190808-20190808" decimals="-3" format="ixt:numdotdecimal" name="nltx:AcquisitionsOfAssetsFairValueOfSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozNTkxNGZlMjY2ODE0YTI1Yjk1NDY3NjI4NjY1ZGI0Yy90YWJsZXJhbmdlOjM1OTE0ZmUyNjY4MTRhMjViOTU0Njc2Mjg2NjVkYjRjXzEtMS0xLTEtMA_577865ca-0b76-452c-b42d-f2eae76ede0c">15,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of <ix:nonFraction unitRef="shares" contextRef="ib1005fcc8fe5417da0ed149702b76a6f_D20190808-20190808" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozNTkxNGZlMjY2ODE0YTI1Yjk1NDY3NjI4NjY1ZGI0Yy90YWJsZXJhbmdlOjM1OTE0ZmUyNjY4MTRhMjViOTU0Njc2Mjg2NjVkYjRjXzItMC0xLTEtNTcwL3RleHRyZWdpb246MTE1ZTIwNDFjMWQzNDkwZWJlOGM5OTFmY2VmZjhhNjRfMjE5OTAyMzI1NTYyMA_476d9918-e7d8-4086-bb75-f0eda1119ad1">101,927</ix:nonFraction> Aquinox convertible preferred stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6bb0f20de0234580abbe24e6025eeb91_D20190808-20190808" decimals="-3" format="ixt:numdotdecimal" name="nltx:AcquisitionsOfAssetsFairValueOfSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozNTkxNGZlMjY2ODE0YTI1Yjk1NDY3NjI4NjY1ZGI0Yy90YWJsZXJhbmdlOjM1OTE0ZmUyNjY4MTRhMjViOTU0Njc2Mjg2NjVkYjRjXzItMS0xLTEtMA_3fe1c925-dfd2-4da1-916e-8be052d0a940">33,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash consideration for fractional shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i562c09437d76488daa016091ce08fa2a_D20190808-20190808" decimals="-3" name="nltx:AcquisitionsOfAssetsCashConsiderationForFractionalShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozNTkxNGZlMjY2ODE0YTI1Yjk1NDY3NjI4NjY1ZGI0Yy90YWJsZXJhbmdlOjM1OTE0ZmUyNjY4MTRhMjViOTU0Njc2Mjg2NjVkYjRjXzMtMS0xLTEtMA_3b5c4c94-31fb-40b7-bbe1-d24c04b53e9d">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i562c09437d76488daa016091ce08fa2a_D20190808-20190808" decimals="-3" sign="-" format="ixt:numdotdecimal" name="nltx:AcquisitionsOfAssetsTransactionCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozNTkxNGZlMjY2ODE0YTI1Yjk1NDY3NjI4NjY1ZGI0Yy90YWJsZXJhbmdlOjM1OTE0ZmUyNjY4MTRhMjViOTU0Njc2Mjg2NjVkYjRjXzQtMS0xLTEtMA_f955aa77-0524-4348-b446-cc43a9fc8e54">3,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i562c09437d76488daa016091ce08fa2a_D20190808-20190808" decimals="-3" format="ixt:numdotdecimal" name="nltx:AcquisitionsOfAssetsConsiderationTransferred" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozNTkxNGZlMjY2ODE0YTI1Yjk1NDY3NjI4NjY1ZGI0Yy90YWJsZXJhbmdlOjM1OTE0ZmUyNjY4MTRhMjViOTU0Njc2Mjg2NjVkYjRjXzUtMS0xLTEtMA_6aa5e9e1-259c-471b-963e-18b16ddd138e">51,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Aquinox securities issued to stockholders of Former Neoleukin was based on the closing stock price on August&#160;7, 2019, the last day of trading prior to the completion of the transaction.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction was accounted for as an asset acquisition as Former Neoleukin did not meet the definition of a business as substantially all of the value was in the In-Process Research&#160;&amp; Development (&#8220;IPR&amp;D&#8221;) asset. The estimated fair value of the IPR&amp;D asset of $<ix:nonFraction unitRef="usd" contextRef="icc0c497a9b7e42ff89e71ed4e700c005_D20190808-20190808" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90ZXh0cmVnaW9uOmIxMTU2ODgxNDdhYTQ5N2NiOGE2ZWFjZTVjOTg1YTczXzMyOTg1MzQ4ODUzNTM_4019c192-7bac-489f-8e41-9d6ebe257b36">47.7</ix:nonFraction> million was expensed as the Company determined that the asset has no alternative future use.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="ife6a9d0f51ae449cbe9e7ec5d33e2f94"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90ZXh0cmVnaW9uOmIxMTU2ODgxNDdhYTQ5N2NiOGE2ZWFjZTVjOTg1YTczXzEyNDc_f72d780a-65de-411d-bf1c-e23e23e3a025" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the assets acquired and liabilities assumed (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:83.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i99076ffdc9d3414f812225c38a835667_I20190808" decimals="-3" format="ixt:numdotdecimal" name="nltx:AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozMWZlYzExNzA3MDI0M2Y1YTJiN2RhNTA5OWRiOTJjYS90YWJsZXJhbmdlOjMxZmVjMTE3MDcwMjQzZjVhMmI3ZGE1MDk5ZGI5MmNhXzItMS0xLTEtMA_4e1c844e-a3d2-46bf-b1e7-c66082bc9df7">3,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, prepayments and deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i99076ffdc9d3414f812225c38a835667_I20190808" decimals="-3" name="nltx:AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozMWZlYzExNzA3MDI0M2Y1YTJiN2RhNTA5OWRiOTJjYS90YWJsZXJhbmdlOjMxZmVjMTE3MDcwMjQzZjVhMmI3ZGE1MDk5ZGI5MmNhXzMtMS0xLTEtMA_c04be4c3-5354-4542-bf54-d58c4754b681">560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i99076ffdc9d3414f812225c38a835667_I20190808" decimals="-3" format="ixt:numdotdecimal" name="nltx:AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozMWZlYzExNzA3MDI0M2Y1YTJiN2RhNTA5OWRiOTJjYS90YWJsZXJhbmdlOjMxZmVjMTE3MDcwMjQzZjVhMmI3ZGE1MDk5ZGI5MmNhXzQtMS0xLTEtMA_090fec62-df38-4434-adfb-18679493967d">1,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i99076ffdc9d3414f812225c38a835667_I20190808" decimals="-3" format="ixt:numdotdecimal" name="nltx:AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozMWZlYzExNzA3MDI0M2Y1YTJiN2RhNTA5OWRiOTJjYS90YWJsZXJhbmdlOjMxZmVjMTE3MDcwMjQzZjVhMmI3ZGE1MDk5ZGI5MmNhXzUtMS0xLTEtMA_a2b1a764-8005-419b-b829-7b74d86b9e8c">47,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i99076ffdc9d3414f812225c38a835667_I20190808" decimals="-3" name="nltx:AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozMWZlYzExNzA3MDI0M2Y1YTJiN2RhNTA5OWRiOTJjYS90YWJsZXJhbmdlOjMxZmVjMTE3MDcwMjQzZjVhMmI3ZGE1MDk5ZGI5MmNhXzYtMS0xLTEtMA_076e1a1d-4253-4fe6-93ad-03d4bbf9beb5">659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i99076ffdc9d3414f812225c38a835667_I20190808" decimals="-3" format="ixt:numdotdecimal" name="nltx:AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozMWZlYzExNzA3MDI0M2Y1YTJiN2RhNTA5OWRiOTJjYS90YWJsZXJhbmdlOjMxZmVjMTE3MDcwMjQzZjVhMmI3ZGE1MDk5ZGI5MmNhXzctMS0xLTEtMA_847c1ce0-a7cd-4468-99db-4157514cace3">53,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i99076ffdc9d3414f812225c38a835667_I20190808" decimals="-3" format="ixt:numdotdecimal" name="nltx:AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozMWZlYzExNzA3MDI0M2Y1YTJiN2RhNTA5OWRiOTJjYS90YWJsZXJhbmdlOjMxZmVjMTE3MDcwMjQzZjVhMmI3ZGE1MDk5ZGI5MmNhXzktMS0xLTEtMA_0865e4fa-4d45-40c3-b2c9-186645b8049d">1,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i99076ffdc9d3414f812225c38a835667_I20190808" decimals="-3" name="nltx:AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozMWZlYzExNzA3MDI0M2Y1YTJiN2RhNTA5OWRiOTJjYS90YWJsZXJhbmdlOjMxZmVjMTE3MDcwMjQzZjVhMmI3ZGE1MDk5ZGI5MmNhXzEwLTEtMS0xLTA_a14713d7-2d7c-4504-8627-8a188a88a003">201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i99076ffdc9d3414f812225c38a835667_I20190808" decimals="-3" format="ixt:numdotdecimal" name="nltx:AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozMWZlYzExNzA3MDI0M2Y1YTJiN2RhNTA5OWRiOTJjYS90YWJsZXJhbmdlOjMxZmVjMTE3MDcwMjQzZjVhMmI3ZGE1MDk5ZGI5MmNhXzExLTEtMS0xLTA_2abc6242-1116-46d2-822a-a1fec8d1d752">1,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i99076ffdc9d3414f812225c38a835667_I20190808" decimals="-3" format="ixt:numdotdecimal" name="nltx:AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozMWZlYzExNzA3MDI0M2Y1YTJiN2RhNTA5OWRiOTJjYS90YWJsZXJhbmdlOjMxZmVjMTE3MDcwMjQzZjVhMmI3ZGE1MDk5ZGI5MmNhXzEyLTEtMS0xLTA_bd85a82a-d275-4670-872c-119b28e7945f">51,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="ib53014c4f13844039ebc5a68643f31a2_118"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90ZXh0cmVnaW9uOjE1NGQ0YmFjYzI4ZTQzZTk5ZmJjMWJiOWIwZmQxYzlmXzE1Ng_bf399520-a5bf-43c9-8db7-c334f48747fc" continuedAt="i1978b4698b7e4470b1e1973bb0c703a1" escape="true">Property and equipment, net</ix:nonNumeric></span></div><ix:continuation id="i1978b4698b7e4470b1e1973bb0c703a1"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90ZXh0cmVnaW9uOjE1NGQ0YmFjYzI4ZTQzZTk5ZmJjMWJiOWIwZmQxYzlmXzE1Nw_09c36d70-83e7-462b-b7cb-bc64dea5b622" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.911%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Book Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia47d5cee66404f7cbae1aeec9577fc50_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZToyMDYzNWM4YzA1OGU0MTA3OTU3YzU0N2FjZDQyNGNiYy90YWJsZXJhbmdlOjIwNjM1YzhjMDU4ZTQxMDc5NTdjNTQ3YWNkNDI0Y2JjXzMtMS0xLTEtMA_ed690952-dbd2-40e2-b1a0-ddd892c5c429">3,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia47d5cee66404f7cbae1aeec9577fc50_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZToyMDYzNWM4YzA1OGU0MTA3OTU3YzU0N2FjZDQyNGNiYy90YWJsZXJhbmdlOjIwNjM1YzhjMDU4ZTQxMDc5NTdjNTQ3YWNkNDI0Y2JjXzMtMy0xLTEtMA_aca1a085-5829-4476-97c5-0ac81ccfac71">426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia47d5cee66404f7cbae1aeec9577fc50_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZToyMDYzNWM4YzA1OGU0MTA3OTU3YzU0N2FjZDQyNGNiYy90YWJsZXJhbmdlOjIwNjM1YzhjMDU4ZTQxMDc5NTdjNTQ3YWNkNDI0Y2JjXzMtNS0xLTEtMA_20e64744-45b7-4f21-b912-96fed248b944">2,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture, fixtures, and IT equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7459e4cc288446f840ea60d80fbb934_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZToyMDYzNWM4YzA1OGU0MTA3OTU3YzU0N2FjZDQyNGNiYy90YWJsZXJhbmdlOjIwNjM1YzhjMDU4ZTQxMDc5NTdjNTQ3YWNkNDI0Y2JjXzQtMS0xLTEtMA_07f412e6-0da9-431a-a9a9-73214570b23b">753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7459e4cc288446f840ea60d80fbb934_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZToyMDYzNWM4YzA1OGU0MTA3OTU3YzU0N2FjZDQyNGNiYy90YWJsZXJhbmdlOjIwNjM1YzhjMDU4ZTQxMDc5NTdjNTQ3YWNkNDI0Y2JjXzQtMy0xLTEtMA_5c534ebc-bf6f-4a30-ac16-8137a3258faa">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7459e4cc288446f840ea60d80fbb934_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZToyMDYzNWM4YzA1OGU0MTA3OTU3YzU0N2FjZDQyNGNiYy90YWJsZXJhbmdlOjIwNjM1YzhjMDU4ZTQxMDc5NTdjNTQ3YWNkNDI0Y2JjXzQtNS0xLTEtMA_10ede25d-4968-4a14-b2aa-20c2561521a4">594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZToyMDYzNWM4YzA1OGU0MTA3OTU3YzU0N2FjZDQyNGNiYy90YWJsZXJhbmdlOjIwNjM1YzhjMDU4ZTQxMDc5NTdjNTQ3YWNkNDI0Y2JjXzUtMS0xLTEtMA_7c30e9eb-e009-4169-970e-8cf2bc3fa2a1">4,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZToyMDYzNWM4YzA1OGU0MTA3OTU3YzU0N2FjZDQyNGNiYy90YWJsZXJhbmdlOjIwNjM1YzhjMDU4ZTQxMDc5NTdjNTQ3YWNkNDI0Y2JjXzUtMy0xLTEtMA_c925a16a-1d23-46af-86e2-b591e7563272">585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZToyMDYzNWM4YzA1OGU0MTA3OTU3YzU0N2FjZDQyNGNiYy90YWJsZXJhbmdlOjIwNjM1YzhjMDU4ZTQxMDc5NTdjNTQ3YWNkNDI0Y2JjXzUtNS0xLTEtMA_13df2528-c7dd-4952-90fa-24b585bd88b9">3,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.911%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Book Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1a680cc9adc946558b7938da05a43e34_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZTo1NzRjNDczMDgxMDY0NTU0OTMwNTJjNGE5MTZmYmM1MC90YWJsZXJhbmdlOjU3NGM0NzMwODEwNjQ1NTQ5MzA1MmM0YTkxNmZiYzUwXzItMS0xLTEtMA_4556ef02-976b-40b8-be71-aab30d5a62e6">490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1a680cc9adc946558b7938da05a43e34_I20191231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZTo1NzRjNDczMDgxMDY0NTU0OTMwNTJjNGE5MTZmYmM1MC90YWJsZXJhbmdlOjU3NGM0NzMwODEwNjQ1NTQ5MzA1MmM0YTkxNmZiYzUwXzItMy0xLTEtMA_57585b99-057e-4a47-8e5a-afd8afb5e347">333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1a680cc9adc946558b7938da05a43e34_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZTo1NzRjNDczMDgxMDY0NTU0OTMwNTJjNGE5MTZmYmM1MC90YWJsZXJhbmdlOjU3NGM0NzMwODEwNjQ1NTQ5MzA1MmM0YTkxNmZiYzUwXzItNS0xLTEtMA_fd2bdd56-eb53-43fe-8fdb-9c474d176d5a">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i15d940e5d2f149acbb5357be4a7e366f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZTo1NzRjNDczMDgxMDY0NTU0OTMwNTJjNGE5MTZmYmM1MC90YWJsZXJhbmdlOjU3NGM0NzMwODEwNjQ1NTQ5MzA1MmM0YTkxNmZiYzUwXzMtMS0xLTEtMjE4_62c354c2-f050-47f1-9b25-c30b64614a30">1,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i15d940e5d2f149acbb5357be4a7e366f_I20191231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZTo1NzRjNDczMDgxMDY0NTU0OTMwNTJjNGE5MTZmYmM1MC90YWJsZXJhbmdlOjU3NGM0NzMwODEwNjQ1NTQ5MzA1MmM0YTkxNmZiYzUwXzMtMy0xLTEtMjE4_0fbe8576-da00-4ffd-97a2-4af9a705c950">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i15d940e5d2f149acbb5357be4a7e366f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZTo1NzRjNDczMDgxMDY0NTU0OTMwNTJjNGE5MTZmYmM1MC90YWJsZXJhbmdlOjU3NGM0NzMwODEwNjQ1NTQ5MzA1MmM0YTkxNmZiYzUwXzMtNS0xLTEtMjE4_22a506ce-d593-4d92-a42b-3538b61a5828">1,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture, fixtures, and IT equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2208e67d526547b5819db3624bbe011a_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZTo1NzRjNDczMDgxMDY0NTU0OTMwNTJjNGE5MTZmYmM1MC90YWJsZXJhbmdlOjU3NGM0NzMwODEwNjQ1NTQ5MzA1MmM0YTkxNmZiYzUwXzMtMS0xLTEtMA_11325f68-1477-440d-a377-690e45f9a1db">743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2208e67d526547b5819db3624bbe011a_I20191231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZTo1NzRjNDczMDgxMDY0NTU0OTMwNTJjNGE5MTZmYmM1MC90YWJsZXJhbmdlOjU3NGM0NzMwODEwNjQ1NTQ5MzA1MmM0YTkxNmZiYzUwXzMtMy0xLTEtMA_31195fef-c4ae-4908-be3b-34385df72785">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2208e67d526547b5819db3624bbe011a_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZTo1NzRjNDczMDgxMDY0NTU0OTMwNTJjNGE5MTZmYmM1MC90YWJsZXJhbmdlOjU3NGM0NzMwODEwNjQ1NTQ5MzA1MmM0YTkxNmZiYzUwXzMtNS0xLTEtMA_61ba8cc6-3cda-40aa-bd66-cc2a8173e200">450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZTo1NzRjNDczMDgxMDY0NTU0OTMwNTJjNGE5MTZmYmM1MC90YWJsZXJhbmdlOjU3NGM0NzMwODEwNjQ1NTQ5MzA1MmM0YTkxNmZiYzUwXzQtMS0xLTEtMA_4155eea7-2ccc-4d7b-8312-1a25d23260ca">2,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZTo1NzRjNDczMDgxMDY0NTU0OTMwNTJjNGE5MTZmYmM1MC90YWJsZXJhbmdlOjU3NGM0NzMwODEwNjQ1NTQ5MzA1MmM0YTkxNmZiYzUwXzQtMy0xLTEtMA_3bdc7330-0878-4269-a8c5-4e3b293c12c2">688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZTo1NzRjNDczMDgxMDY0NTU0OTMwNTJjNGE5MTZmYmM1MC90YWJsZXJhbmdlOjU3NGM0NzMwODEwNjQ1NTQ5MzA1MmM0YTkxNmZiYzUwXzQtNS0xLTEtMA_cf46e4af-7623-462e-95e2-aca9daa8e88c">2,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense on property and equipment totaled $<ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90ZXh0cmVnaW9uOjE1NGQ0YmFjYzI4ZTQzZTk5ZmJjMWJiOWIwZmQxYzlmXzk1_61df6079-c545-478a-bf7d-5d2edfe0d20a">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90ZXh0cmVnaW9uOjE1NGQ0YmFjYzI4ZTQzZTk5ZmJjMWJiOWIwZmQxYzlmXzk5_8c2388a1-1fd2-491e-a405-398815f25f2e">0.2</ix:nonFraction> million for the years ended December&#160;31, 2020 and 2019, respectively.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="ib53014c4f13844039ebc5a68643f31a2_121"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjEvZnJhZzo5ZGMzNTA1OTVkNjc0MmY5YWU5ZWE5OTBmNDg4ZGU0OS90ZXh0cmVnaW9uOjlkYzM1MDU5NWQ2NzQyZjlhZTllYTk5MGY0ODhkZTQ5XzMx_2a134d28-935e-44a5-bb14-34e3452eac37" continuedAt="ib5a68daeac68460083a52074ba716c24" escape="true">Intangible asset, net</ix:nonNumeric></span></div><ix:continuation id="ib5a68daeac68460083a52074ba716c24"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjEvZnJhZzo5ZGMzNTA1OTVkNjc0MmY5YWU5ZWE5OTBmNDg4ZGU0OS90ZXh0cmVnaW9uOjlkYzM1MDU5NWQ2NzQyZjlhZTllYTk5MGY0ODhkZTQ5XzMy_4f3cca30-f3c2-44a9-badd-8dfc69f79e86" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes intangible asset (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjEvZnJhZzo5ZGMzNTA1OTVkNjc0MmY5YWU5ZWE5OTBmNDg4ZGU0OS90YWJsZTozZWRiMzIyMzQ2ODM0ZmUwOGJkODIxMWUwYjVhZjAzMS90YWJsZXJhbmdlOjNlZGIzMjIzNDY4MzRmZTA4YmQ4MjExZTBiNWFmMDMxXzEtMS0xLTEtMA_5f2c9898-90bf-427d-b8b6-a869a1705ce8">659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjEvZnJhZzo5ZGMzNTA1OTVkNjc0MmY5YWU5ZWE5OTBmNDg4ZGU0OS90YWJsZTozZWRiMzIyMzQ2ODM0ZmUwOGJkODIxMWUwYjVhZjAzMS90YWJsZXJhbmdlOjNlZGIzMjIzNDY4MzRmZTA4YmQ4MjExZTBiNWFmMDMxXzEtMy0xLTEtMA_0b13dcb5-f91f-4833-bdaf-14301abfa085">659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjEvZnJhZzo5ZGMzNTA1OTVkNjc0MmY5YWU5ZWE5OTBmNDg4ZGU0OS90YWJsZTozZWRiMzIyMzQ2ODM0ZmUwOGJkODIxMWUwYjVhZjAzMS90YWJsZXJhbmdlOjNlZGIzMjIzNDY4MzRmZTA4YmQ4MjExZTBiNWFmMDMxXzItMS0xLTEtMA_50a492d2-6d0c-4d87-8241-e63d3b561904">312</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjEvZnJhZzo5ZGMzNTA1OTVkNjc0MmY5YWU5ZWE5OTBmNDg4ZGU0OS90YWJsZTozZWRiMzIyMzQ2ODM0ZmUwOGJkODIxMWUwYjVhZjAzMS90YWJsZXJhbmdlOjNlZGIzMjIzNDY4MzRmZTA4YmQ4MjExZTBiNWFmMDMxXzItMy0xLTEtMA_acf7025f-6ebc-441c-a6e9-2a9afc32ccf0">92</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net intangible asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjEvZnJhZzo5ZGMzNTA1OTVkNjc0MmY5YWU5ZWE5OTBmNDg4ZGU0OS90YWJsZTozZWRiMzIyMzQ2ODM0ZmUwOGJkODIxMWUwYjVhZjAzMS90YWJsZXJhbmdlOjNlZGIzMjIzNDY4MzRmZTA4YmQ4MjExZTBiNWFmMDMxXzMtMS0xLTEtMA_61f898ec-22c4-4cc2-a405-5d5aa06c9f60">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjEvZnJhZzo5ZGMzNTA1OTVkNjc0MmY5YWU5ZWE5OTBmNDg4ZGU0OS90YWJsZTozZWRiMzIyMzQ2ODM0ZmUwOGJkODIxMWUwYjVhZjAzMS90YWJsZXJhbmdlOjNlZGIzMjIzNDY4MzRmZTA4YmQ4MjExZTBiNWFmMDMxXzMtMy0xLTEtMA_42a2f48f-6459-4cf5-ac13-4700413a6529">567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Merger as discussed in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an assembled workforce was acquired. In an asset acquisition, an assembled workforce meets the asset recognition criteria and is separately recognized as an intangible asset and amortized over its expected life. The amortization period has been established as <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjEvZnJhZzo5ZGMzNTA1OTVkNjc0MmY5YWU5ZWE5OTBmNDg4ZGU0OS90ZXh0cmVnaW9uOjlkYzM1MDU5NWQ2NzQyZjlhZTllYTk5MGY0ODhkZTQ5XzE2NDkyNjc0NDIwNTY_6b624b79-7e31-4262-a8ee-24e5bec50b1a">3</ix:nonNumeric> years based on management's judgement. The Company will recognize $<ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjEvZnJhZzo5ZGMzNTA1OTVkNjc0MmY5YWU5ZWE5OTBmNDg4ZGU0OS90ZXh0cmVnaW9uOjlkYzM1MDU5NWQ2NzQyZjlhZTllYTk5MGY0ODhkZTQ5XzIxOTkwMjMyNTY3ODA_9b00d72a-5925-491d-8692-849a218190cc">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjEvZnJhZzo5ZGMzNTA1OTVkNjc0MmY5YWU5ZWE5OTBmNDg4ZGU0OS90ZXh0cmVnaW9uOjlkYzM1MDU5NWQ2NzQyZjlhZTllYTk5MGY0ODhkZTQ5XzIxOTkwMjMyNTY3ODg_2ab8ce98-8e71-4074-9c81-8edfa53d43c8">0.1</ix:nonFraction> million of amortization expense in fiscal years 2021 and 2022, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span><br/></span></div><div id="ib53014c4f13844039ebc5a68643f31a2_124"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjQvZnJhZzo0NzQ2MmIzMjNlZTA0Mjk0OGUyZTVkYmNmMGYwMmZiMi90ZXh0cmVnaW9uOjQ3NDYyYjMyM2VlMDQyOTQ4ZTJlNWRiY2YwZjAyZmIyXzQ4_3a009772-be25-41b9-9184-4bf562a1c707" continuedAt="ifa630a3e2fc04c11a88c8b4db54ee7ed" escape="true">Accounts payable and other liabilities</ix:nonNumeric></span></div><ix:continuation id="ifa630a3e2fc04c11a88c8b4db54ee7ed"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjQvZnJhZzo0NzQ2MmIzMjNlZTA0Mjk0OGUyZTVkYmNmMGYwMmZiMi90ZXh0cmVnaW9uOjQ3NDYyYjMyM2VlMDQyOTQ4ZTJlNWRiY2YwZjAyZmIyXzQ5_c19cdc18-ad57-431d-b907-2a592e9e9976" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjQvZnJhZzo0NzQ2MmIzMjNlZTA0Mjk0OGUyZTVkYmNmMGYwMmZiMi90YWJsZTplZjg5MzY2NmE4MTA0MmM0ODVlMmEwNGQ4NWY2NDFmZC90YWJsZXJhbmdlOmVmODkzNjY2YTgxMDQyYzQ4NWUyYTA0ZDg1ZjY0MWZkXzEtMS0xLTEtMA_3d9c9347-07ab-40da-842b-8b7dc050ed58">1,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjQvZnJhZzo0NzQ2MmIzMjNlZTA0Mjk0OGUyZTVkYmNmMGYwMmZiMi90YWJsZTplZjg5MzY2NmE4MTA0MmM0ODVlMmEwNGQ4NWY2NDFmZC90YWJsZXJhbmdlOmVmODkzNjY2YTgxMDQyYzQ4NWUyYTA0ZDg1ZjY0MWZkXzEtMy0xLTEtMA_babb1c24-a522-4ac9-95ad-d7afd102d14b">1,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and preclinical expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nltx:AccruedClinicalExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjQvZnJhZzo0NzQ2MmIzMjNlZTA0Mjk0OGUyZTVkYmNmMGYwMmZiMi90YWJsZTplZjg5MzY2NmE4MTA0MmM0ODVlMmEwNGQ4NWY2NDFmZC90YWJsZXJhbmdlOmVmODkzNjY2YTgxMDQyYzQ4NWUyYTA0ZDg1ZjY0MWZkXzItMS0xLTEtMA_fafd72fd-1bb7-47ea-aa3e-a4bcb106612e">1,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" name="nltx:AccruedClinicalExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjQvZnJhZzo0NzQ2MmIzMjNlZTA0Mjk0OGUyZTVkYmNmMGYwMmZiMi90YWJsZTplZjg5MzY2NmE4MTA0MmM0ODVlMmEwNGQ4NWY2NDFmZC90YWJsZXJhbmdlOmVmODkzNjY2YTgxMDQyYzQ4NWUyYTA0ZDg1ZjY0MWZkXzItMy0xLTEtMA_dabf47c3-8f36-40d9-9c79-4028d08065a9">944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and vacation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjQvZnJhZzo0NzQ2MmIzMjNlZTA0Mjk0OGUyZTVkYmNmMGYwMmZiMi90YWJsZTplZjg5MzY2NmE4MTA0MmM0ODVlMmEwNGQ4NWY2NDFmZC90YWJsZXJhbmdlOmVmODkzNjY2YTgxMDQyYzQ4NWUyYTA0ZDg1ZjY0MWZkXzMtMS0xLTEtMA_3a04c649-9496-492c-8b17-c5acd221ba7f">3,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjQvZnJhZzo0NzQ2MmIzMjNlZTA0Mjk0OGUyZTVkYmNmMGYwMmZiMi90YWJsZTplZjg5MzY2NmE4MTA0MmM0ODVlMmEwNGQ4NWY2NDFmZC90YWJsZXJhbmdlOmVmODkzNjY2YTgxMDQyYzQ4NWUyYTA0ZDg1ZjY0MWZkXzMtMy0xLTEtMA_9d6b775c-dde4-4d64-90d2-f01256406c75">1,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjQvZnJhZzo0NzQ2MmIzMjNlZTA0Mjk0OGUyZTVkYmNmMGYwMmZiMi90YWJsZTplZjg5MzY2NmE4MTA0MmM0ODVlMmEwNGQ4NWY2NDFmZC90YWJsZXJhbmdlOmVmODkzNjY2YTgxMDQyYzQ4NWUyYTA0ZDg1ZjY0MWZkXzQtMS0xLTEtMA_bb9b17ad-6dd7-4d5a-b1c9-1b9cb19e65b0">927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjQvZnJhZzo0NzQ2MmIzMjNlZTA0Mjk0OGUyZTVkYmNmMGYwMmZiMi90YWJsZTplZjg5MzY2NmE4MTA0MmM0ODVlMmEwNGQ4NWY2NDFmZC90YWJsZXJhbmdlOmVmODkzNjY2YTgxMDQyYzQ4NWUyYTA0ZDg1ZjY0MWZkXzQtMy0xLTEtMA_ab14a8a8-b52e-4aa3-ad38-5109af448273">339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjQvZnJhZzo0NzQ2MmIzMjNlZTA0Mjk0OGUyZTVkYmNmMGYwMmZiMi90YWJsZTplZjg5MzY2NmE4MTA0MmM0ODVlMmEwNGQ4NWY2NDFmZC90YWJsZXJhbmdlOmVmODkzNjY2YTgxMDQyYzQ4NWUyYTA0ZDg1ZjY0MWZkXzUtMS0xLTEtMA_3e163eb9-d03e-424a-a44b-4a4c8ae9ba00">7,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjQvZnJhZzo0NzQ2MmIzMjNlZTA0Mjk0OGUyZTVkYmNmMGYwMmZiMi90YWJsZTplZjg5MzY2NmE4MTA0MmM0ODVlMmEwNGQ4NWY2NDFmZC90YWJsZXJhbmdlOmVmODkzNjY2YTgxMDQyYzQ4NWUyYTA0ZDg1ZjY0MWZkXzUtMy0xLTEtMA_b357eb69-73dc-44b2-9785-4b2155bc03b9">4,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="ib53014c4f13844039ebc5a68643f31a2_127"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzM1NDI_716cdb4e-6b42-4612-98e6-d79e891cb7d4" continuedAt="i16673e5d143e4bb3b5b9a4e7ef9a290c" escape="true"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzM1NDI_b4de3fe8-3f60-4ebd-9fb8-a05255fdea59" continuedAt="i605431e812274770ae8cd004d80d5719" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i16673e5d143e4bb3b5b9a4e7ef9a290c" continuedAt="i1a338012c31e4d6eb01444e8d6120841"><ix:continuation id="i605431e812274770ae8cd004d80d5719" continuedAt="i609e0c56068d40d4892b0855e6b51c6a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into lease arrangements for its facilities as well as certain equipment, classified either as operating or finance leases.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a lease agreement for approximately <ix:nonFraction unitRef="sqft" contextRef="i4705a5c4b4bc44d6bb8ba59262f94449_I20201231" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzE2NDkyNjc0NjgxNzE_ba89107b-37aa-4d23-8250-cbebd814e9b2">33,300</ix:nonFraction> square feet of office space in Seattle, Washington for the Company&#8217;s principal executive offices, a laboratory for research and development and related uses (the "Blaine lease"). In January 2020, the Company issued an irrevocable letter of credit in the amount of $<ix:nonFraction unitRef="usd" contextRef="id6e7ca6980e0434682af1d48cf353254_I20200131" decimals="-5" name="us-gaap:SecurityDeposit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzMyOTg1MzQ5MDg2Mzg_52303418-5606-4d7c-8458-9c5098e6438d">0.5</ix:nonFraction> million for the security deposit in accordance with the terms of the lease. The lease commenced on January 15, 2020 and rent obligations were scheduled to commence on December 1, 2020. The Company will also be responsible for the payment of additional rent to cover the Company&#8217;s share of the annual operating and tax expenses and utilities costs for the building. The lease was originally scheduled to expire on December 1, 2028, with the option to extend the lease for <ix:nonFraction unitRef="option" contextRef="idf105168c8db4aaca79efa56d6480d67_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="nltx:NumberOfOptionToExtendLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzE2NDkyNjc0NjgxNzg_e7e761ee-a6e2-4434-8d34-910b53dafcc2">two</ix:nonFraction> <ix:nonNumeric contextRef="idf105168c8db4aaca79efa56d6480d67_D20200101-20201231" format="ixt-sec:durwordsen" name="nltx:LeaseAgreementExtendedPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzE2NDkyNjc0NjkwMzU_cf7ce2bf-5ae6-4e94-9f64-ca66632cd28f">five-year</ix:nonNumeric> terms.  The lease provides for a tenant improvement allowance of $<ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-5" name="nltx:TenantImprovementAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzMyOTg1MzQ5MDg2NDU_fd842326-4504-45c0-884f-bdfe0564aa27">8.0</ix:nonFraction> million, which is included in the base rent, and an optional additional tenant improvement allowance with a maximum amount of $<ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-5" name="nltx:AdditionalTenantImprovements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzIxOTkwMjMyODExMjA_8da8b72a-f532-4886-a154-9f2a338725f0">1.5</ix:nonFraction> million, which will result, if elected, in additional rent expense recognized over the term of the lease. In September 2020, the Company elected to utilize this additional tenant improvement allowance. This resulted in a remeasurement of the lease liability due to an increase in lease payments over the term of the lease. The Company recorded an increase to the lease liability and related right-of-use asset of $<ix:nonFraction unitRef="usd" contextRef="i5ed3c72fdd5244ab8974717f9b77a301_I20200930" decimals="-5" name="nltx:OperatingLeaseRightOfUseAssetIncreaseDueToRemeasurement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzMyOTg1MzQ5MDg2NjE_d5223fc6-c357-4c59-8fa1-10207b3c9565"><ix:nonFraction unitRef="usd" contextRef="i5ed3c72fdd5244ab8974717f9b77a301_I20200930" decimals="-5" name="nltx:OperatingLeaseLiabilityIncreaseDueToRemeasurement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzMyOTg1MzQ5MDg2NjE_fed2c2b9-98dd-4c85-9bd1-18cf542bb3be">1.0</ix:nonFraction></ix:nonFraction> million.  In November 2020, the Company executed an amendment to this lease that extends the scheduled rent commencement date to February 1, 2021 and the base term expiration to February 1, 2029. This amendment was accounted for as a modification to the lease and resulted in an immaterial reduction of the lease liability and related right-of-use asset.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31,2020, there was a tenant improvement allowance receivable of $<ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-5" name="nltx:TenantImprovementAllowanceReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzIxOTkwMjMyODExMjU_79f98d52-d152-4fac-9c44-d49b1f270e2c">0.9</ix:nonFraction> million recorded in other current assets on the consolidated balance sheets related to reimbursable build-out costs incurred by the Company.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a lease agreement&#160;for approximately <ix:nonFraction unitRef="sqft" contextRef="icc93ba96caae41caaf0f462dced9d9f5_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzExMg_4c570e1c-004b-4725-8abd-4ff2dfb08aa9">6,272</ix:nonFraction> square feet of office space in Seattle, Washington, for the Company&#8217;s former principal executive offices, a laboratory for research and development and related uses. In June 2020, the Company executed an amendment to this lease pursuant to which the Company has the option to terminate the lease, without penalty, at any point subsequent to November 1, 2020 with <ix:nonNumeric contextRef="i551bbb0f39284233bd2bc07a764f6743_D20200601-20200630" format="ixt-sec:durday" name="nltx:NumberOfDaysAdvanceNoticeMustBeGivenToTerminateTheLease" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzE2NDkyNjc0NjkwMzk_67dc90c4-8b38-42f8-8187-efc4c51776ce">45</ix:nonNumeric> days advance written notice. At December 31, 2020, the Company determined that it is reasonably certain to not exercise this termination option. On March 24, 2021, the Company executed a second amendment to this lease, pursuant to which the term of the lease is extended through September 30, 2026. This will result in an increase in fixed rental payments over the updated term. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2020, the Company terminated its lease agreement for <ix:nonFraction unitRef="sqft" contextRef="i33f7bbfc02b54beb8163ea39433e3cad_I20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzYzNw_4a8805e3-a15f-4ec6-8761-85cadcb56dab">10,946</ix:nonFraction> square feet of office space in Vancouver, Canada. The lease termination resulted in an extinguishment of the lease liability and the write-off of the related right-of-use asset. After incurring additional expenses included in the termination fee of $<ix:nonFraction unitRef="usd" contextRef="i23ddd03e1fc94695ab704c560ff13b1a_D20200630-20200630" decimals="-5" name="nltx:TerminationFeesForLeaseTermination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzMyOTg1MzQ5MDg2ODk_f6c0e0f8-c447-4e10-b6ba-74eb62a9abd6">0.5</ix:nonFraction> million, the Company recognized a loss of $<ix:nonFraction unitRef="usd" contextRef="i23ddd03e1fc94695ab704c560ff13b1a_D20200630-20200630" decimals="-5" sign="-" name="us-gaap:GainLossOnTerminationOfLease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzMyOTg1MzQ5MDg2NzU_cfc62a6d-51ce-4d0a-9e74-dd8864d97376">0.3</ix:nonFraction> million on the termination of the lease, which was recorded in general and administrative expenses in June 2020. In addition, the Company wrote-off leasehold improvements and other property and equipment associated with the lease and incurred a loss on disposal of $<ix:nonFraction unitRef="usd" contextRef="i23ddd03e1fc94695ab704c560ff13b1a_D20200630-20200630" decimals="-5" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzMyOTg1MzQ5MDg2ODI_133cbde2-83c0-4257-986d-ad6b2dc01928">0.2</ix:nonFraction> million in June 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, and December&#160;31, 2019, the Company&#8217;s operating lease right-of-use assets were $<ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzE0OTU_47fd67c5-91e1-42a9-9ed5-a6891f7b57a2">10.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzMyOTg1MzQ5MDg3MTY_22c89cf1-bee8-4926-985d-d6dc6f9a1ba3">0.8</ix:nonFraction> million, respectively. As of December&#160;31, 2020, and December&#160;31, 2019, the Company's</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">finance lease right-of use-assets, included within property and equipment on the consolidated balance sheet, were $<ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzE1NDM_65945406-5de0-4323-9779-cd8f042a137c">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzE2NDkyNjc0NjgxOTk_dbe04eb0-368c-4114-a9d9-fb9a02acc8f4">0.3</ix:nonFraction>&#160;million, respectively. </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="i1a338012c31e4d6eb01444e8d6120841"><ix:continuation id="i609e0c56068d40d4892b0855e6b51c6a"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzM1NDM_19d41a45-ffa1-4946-b14b-fe6ab8b44553" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjYjdkOGQ5OWQ3OTg0YjRhOWJkZTY4YmQzY2NiMDg1My90YWJsZXJhbmdlOmNiN2Q4ZDk5ZDc5ODRiNGE5YmRlNjhiZDNjY2IwODUzXzItMS0xLTEtMA_b620c4db-c41f-48ac-b2d8-95d7016ce434">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjYjdkOGQ5OWQ3OTg0YjRhOWJkZTY4YmQzY2NiMDg1My90YWJsZXJhbmdlOmNiN2Q4ZDk5ZDc5ODRiNGE5YmRlNjhiZDNjY2IwODUzXzItMy0xLTEtNTg0OQ_3bbc698f-ade9-4118-bfb9-82fb900bc406">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjYjdkOGQ5OWQ3OTg0YjRhOWJkZTY4YmQzY2NiMDg1My90YWJsZXJhbmdlOmNiN2Q4ZDk5ZDc5ODRiNGE5YmRlNjhiZDNjY2IwODUzXzMtMS0xLTEtMA_822431e8-757e-4a57-9077-120526d06232">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjYjdkOGQ5OWQ3OTg0YjRhOWJkZTY4YmQzY2NiMDg1My90YWJsZXJhbmdlOmNiN2Q4ZDk5ZDc5ODRiNGE5YmRlNjhiZDNjY2IwODUzXzMtMy0xLTEtNTg0OQ_9351ec0d-5029-4f5a-be41-0d455720a1a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjYjdkOGQ5OWQ3OTg0YjRhOWJkZTY4YmQzY2NiMDg1My90YWJsZXJhbmdlOmNiN2Q4ZDk5ZDc5ODRiNGE5YmRlNjhiZDNjY2IwODUzXzQtMS0xLTEtMA_f8812169-2fe5-4f59-8fe3-dc6cc0311937">2,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjYjdkOGQ5OWQ3OTg0YjRhOWJkZTY4YmQzY2NiMDg1My90YWJsZXJhbmdlOmNiN2Q4ZDk5ZDc5ODRiNGE5YmRlNjhiZDNjY2IwODUzXzQtMy0xLTEtNTg0OQ_2776dd32-3c9c-4fd3-98f6-2ed11e1b296c">197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjYjdkOGQ5OWQ3OTg0YjRhOWJkZTY4YmQzY2NiMDg1My90YWJsZXJhbmdlOmNiN2Q4ZDk5ZDc5ODRiNGE5YmRlNjhiZDNjY2IwODUzXzUtMS0xLTEtMA_73e1a276-8a3c-4589-b50d-7590a33fe4fb">348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjYjdkOGQ5OWQ3OTg0YjRhOWJkZTY4YmQzY2NiMDg1My90YWJsZXJhbmdlOmNiN2Q4ZDk5ZDc5ODRiNGE5YmRlNjhiZDNjY2IwODUzXzUtMy0xLTEtNTg0OQ_28c2af51-67d5-4d81-b15e-f2522f27ef55">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjYjdkOGQ5OWQ3OTg0YjRhOWJkZTY4YmQzY2NiMDg1My90YWJsZXJhbmdlOmNiN2Q4ZDk5ZDc5ODRiNGE5YmRlNjhiZDNjY2IwODUzXzYtMS0xLTEtMA_114dec38-ccdb-4dc1-a7fd-87a91a0f02ea">321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjYjdkOGQ5OWQ3OTg0YjRhOWJkZTY4YmQzY2NiMDg1My90YWJsZXJhbmdlOmNiN2Q4ZDk5ZDc5ODRiNGE5YmRlNjhiZDNjY2IwODUzXzYtMy0xLTEtNTg0OQ_0553a004-2991-4d0d-85db-12ee2a29c827">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjYjdkOGQ5OWQ3OTg0YjRhOWJkZTY4YmQzY2NiMDg1My90YWJsZXJhbmdlOmNiN2Q4ZDk5ZDc5ODRiNGE5YmRlNjhiZDNjY2IwODUzXzctMS0xLTEtMA_e7b64449-1acf-470f-aa41-2dd2ad6d5cf5">3,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjYjdkOGQ5OWQ3OTg0YjRhOWJkZTY4YmQzY2NiMDg1My90YWJsZXJhbmdlOmNiN2Q4ZDk5ZDc5ODRiNGE5YmRlNjhiZDNjY2IwODUzXzctMy0xLTEtNTg0OQ_733ebd4c-2600-4eb8-baa1-c8f62a745711">502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="nltx:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzM1NDQ_d641632c-45cd-49e5-9461-313193da2b92" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term&#8212;finance leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpmN2JkZjc0YzE5YmE0ZWExYmE3M2NjZGY5YjAxZGI4YS90YWJsZXJhbmdlOmY3YmRmNzRjMTliYTRlYTFiYTczY2NkZjliMDFkYjhhXzEtMS0xLTEtMA_92906772-dfcf-4cde-b7ed-4ff7f28daec1">2.45</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpmN2JkZjc0YzE5YmE0ZWExYmE3M2NjZGY5YjAxZGI4YS90YWJsZXJhbmdlOmY3YmRmNzRjMTliYTRlYTFiYTczY2NkZjliMDFkYjhhXzEtMy0xLTEtNTg2Mg_e77c916c-e868-48fd-aeba-0aeb6a7fd2ed">3.33</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term&#8212;operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpmN2JkZjc0YzE5YmE0ZWExYmE3M2NjZGY5YjAxZGI4YS90YWJsZXJhbmdlOmY3YmRmNzRjMTliYTRlYTFiYTczY2NkZjliMDFkYjhhXzItMS0xLTEtMA_c69787e5-e43b-4edd-a0ce-9450dd4009e3">7.97</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpmN2JkZjc0YzE5YmE0ZWExYmE3M2NjZGY5YjAxZGI4YS90YWJsZXJhbmdlOmY3YmRmNzRjMTliYTRlYTFiYTczY2NkZjliMDFkYjhhXzItMy0xLTEtNTg2Mg_9d7da0c1-c990-4247-ab98-3c21a830fce2">1.83</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate&#8212;finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpmN2JkZjc0YzE5YmE0ZWExYmE3M2NjZGY5YjAxZGI4YS90YWJsZXJhbmdlOmY3YmRmNzRjMTliYTRlYTFiYTczY2NkZjliMDFkYjhhXzMtMS0xLTEtMA_669236c0-c46f-48bd-8ee0-6ca2e00ee2fb">7.11</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpmN2JkZjc0YzE5YmE0ZWExYmE3M2NjZGY5YjAxZGI4YS90YWJsZXJhbmdlOmY3YmRmNzRjMTliYTRlYTFiYTczY2NkZjliMDFkYjhhXzMtMy0xLTEtNTg2Mg_27559146-c085-46f2-a2d4-6e748f540ef1">7.11</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate&#8212;operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpmN2JkZjc0YzE5YmE0ZWExYmE3M2NjZGY5YjAxZGI4YS90YWJsZXJhbmdlOmY3YmRmNzRjMTliYTRlYTFiYTczY2NkZjliMDFkYjhhXzQtMS0xLTEtMA_57cd2d8a-b2d8-4a18-ad2c-1f99877069be">12.88</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpmN2JkZjc0YzE5YmE0ZWExYmE3M2NjZGY5YjAxZGI4YS90YWJsZXJhbmdlOmY3YmRmNzRjMTliYTRlYTFiYTczY2NkZjliMDFkYjhhXzQtMy0xLTEtNTg2Mg_4f681041-ff19-446f-b90e-3cd0e65f4bf7">5.37</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzM1NDU_e88c800a-5c34-412b-92b2-865ebadd1d24" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjMjNhMWMyYWY4MjA0NTg3YjgxZTkxYjY3ZmJkZGM3OC90YWJsZXJhbmdlOmMyM2ExYzJhZjgyMDQ1ODdiODFlOTFiNjdmYmRkYzc4XzEtMS0xLTEtMA_031194d1-fadf-4999-b4e7-8031c0848630">460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjMjNhMWMyYWY4MjA0NTg3YjgxZTkxYjY3ZmJkZGM3OC90YWJsZXJhbmdlOmMyM2ExYzJhZjgyMDQ1ODdiODFlOTFiNjdmYmRkYzc4XzEtMy0xLTEtNTg3Mg_7fa92ca2-aeae-4c5c-9b6e-42e294454cee">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" name="nltx:FinanceLeasePrincipalAndInterestPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjMjNhMWMyYWY4MjA0NTg3YjgxZTkxYjY3ZmJkZGM3OC90YWJsZXJhbmdlOmMyM2ExYzJhZjgyMDQ1ODdiODFlOTFiNjdmYmRkYzc4XzItMS0xLTEtMA_6dc8b98c-3d02-44c3-b843-c72f41bff0f8">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" name="nltx:FinanceLeasePrincipalAndInterestPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjMjNhMWMyYWY4MjA0NTg3YjgxZTkxYjY3ZmJkZGM3OC90YWJsZXJhbmdlOmMyM2ExYzJhZjgyMDQ1ODdiODFlOTFiNjdmYmRkYzc4XzItMy0xLTEtNTg3Mg_bbc1d5b0-cc03-4246-957a-099e1ef74e58">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of the present value of the operating lease payments for the Blaine lease did not include the option to extend the lease for <ix:nonFraction unitRef="option" contextRef="i2bfb640b4f9448db81cd2eda573a733f_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="nltx:NumberOfOptionToExtendLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzE2NDkyNjc0NjgyMTI_946fa64f-ed78-409e-ace3-d7c2d3efd809">two</ix:nonFraction> <ix:nonNumeric contextRef="i2bfb640b4f9448db81cd2eda573a733f_D20200101-20201231" format="ixt-sec:durwordsen" name="nltx:LeaseAgreementExtendedPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzE2NDkyNjc0NjkwMzg_03bd2101-ee55-45b1-96b9-0da5252d973e">five year</ix:nonNumeric> terms.</span></div><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzM1NDA_cf2e3e32-5ea7-4f0a-b34e-68e2fb0c4a32" escape="true"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzM1NDY_9f46fce0-4846-48af-8593-757f1ab72d4a" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the future payments under the Company&#8217;s operating and finance lease liabilities were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Lease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzEtMS0xLTEtMA_ad90361d-deae-4b2f-8166-b9ee806c714f">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzEtMy0xLTEtMA_faf2b1b0-45c6-4654-a96c-b49e182c48c5">2,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzItMS0xLTEtMA_656fe15e-afa7-4f2f-aabb-fb2203a8c50d">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzItMy0xLTEtMA_d74bd0b6-ea88-473a-b204-40492bc3c458">2,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzMtMS0xLTEtMA_d2b02234-c540-424e-af42-a5cbcf9491d2">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzMtMy0xLTEtMA_02a5689a-3ac0-428f-be76-6b7016fa37f4">2,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzQtMS0xLTEtMA_b3f70a0e-032e-4773-981c-787a4685d376">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzQtMy0xLTEtMA_648c4ae2-96a9-4483-aff8-0d0078947cac">2,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzUtMS0xLTEtMzUzMw_d6b128a2-66db-4f9f-a8b1-a2843768554a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzUtMy0xLTEtMzUzMw_8e28b605-9a06-4999-807f-758af2f43765">2,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzYtMS0xLTEtMzUzMw_a12ba635-3e67-4007-b466-59e4046654ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzYtMy0xLTEtMzUzMw_b913d427-07c3-47ad-bd69-24de45400322">7,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzUtMS0xLTEtMA_3a59d0d6-323d-4cb4-af39-82037c9a5062">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzUtMy0xLTEtMA_60e8114b-c1e4-4fb8-9898-1c196e0d32d4">19,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzYtMS0xLTEtMA_d1031294-fa3e-4fe2-a4de-ccab2d1d4d72">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzYtMy0xLTEtMA_9679fb61-8f99-4707-8e69-ab020cb213c6">7,572</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzctMS0xLTEtMA_6a1b1afe-ebd5-40fc-97a4-4905278c77b5">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzctMy0xLTEtMA_0aa7bff9-f615-40f0-a6b8-79cbf4de8602">11,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzgtMS0xLTEtMA_f7c7b9d4-3425-4023-afe3-12ea13d0acef">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzgtMy0xLTEtMA_75aa2db2-529d-437e-a427-eed3f3981f63">659</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current lease liabilities&#8212;December&#160;31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzktMS0xLTEtMA_4982a6ab-14b8-4cf1-abe3-db65a35a5d1e">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzktMy0xLTEtMA_fe41bf05-4f0e-4cc9-b821-92a208e77e90">11,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="ib53014c4f13844039ebc5a68643f31a2_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTQwNTg_7e2cd63f-e7eb-4717-bb62-032ccc33df8a" continuedAt="iba416712f23d4e70b4f3895856f44b5c" escape="true">Stockholders&#8217; equity</ix:nonNumeric></span></div><ix:continuation id="iba416712f23d4e70b4f3895856f44b5c" continuedAt="i10e393746bdf4726a6c4d5e1b3b536d6"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a) Common stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzgyNDYzMzcyNjY1Mzc_44466627-6451-4b3b-9386-099fa25796c9"><ix:nonFraction unitRef="shares" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzgyNDYzMzcyNjY1Mzc_de942fe3-b730-4692-a6bb-3fb9c9967470">100,000,000</ix:nonFraction></ix:nonFraction> shares of common stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="6" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzgyNDYzMzcyNjY1ODQ_8a960b14-2d2e-4604-bf51-7656992adf92"><ix:nonFraction unitRef="usdPerShare" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="6" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzgyNDYzMzcyNjY1ODQ_cc94f43b-3f60-4789-ab5a-6150474f4854">0.000001</ix:nonFraction></ix:nonFraction> per share as of December&#160;31, 2020. As of December&#160;31, 2020, and 2019, the total number of shares of common stock issued and outstanding was <ix:nonFraction unitRef="shares" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzgyNDYzMzcyNjY2OTk_5ba54886-df5e-46ef-95ed-fa243be936f2"><ix:nonFraction unitRef="shares" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzgyNDYzMzcyNjY2OTk_c815da13-5d1f-45b8-96b2-4b991d7a7cf8">42,196,296</ix:nonFraction></ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzgyNDYzMzcyNjY3MDg_8d85fa0f-776a-41ab-8309-a6dc92eacd79"><ix:nonFraction unitRef="shares" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzgyNDYzMzcyNjY3MDg_efe039d2-001f-4228-8c1c-9219ce8b600f">37,996,849</ix:nonFraction></ix:nonFraction>, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, the Company completed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="iacf40562c9644cc9828d02f05554823f_D20200707-20200707" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MDI0MTY_51191d58-4f1a-4e24-b7b4-2801764dcfbf">3,262,471</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia289d260d3db4da2aacbed8339f37590_I20200707" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MDI0NjE_039a2e63-3732-41a1-88d3-e195db08a3ce">15.25</ix:nonFraction> per share and pre-funded warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i3397ebe8ae644e4aabdacd910f7b5d9e_I20200707" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MDI1MTE_c84a4844-7da1-4605-b361-e48d65b0c2e2">1,737,529</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3397ebe8ae644e4aabdacd910f7b5d9e_I20200707" decimals="6" name="nltx:PreFundedWarrantIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MDI1NTY_26d951bf-6888-4f88-8914-1646d04b0ae2">15.249999</ix:nonFraction> per prefunded warrant.  The pre-funded warrants can be exercised at any time after issuance for an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3397ebe8ae644e4aabdacd910f7b5d9e_I20200707" decimals="6" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MDI2Nzg_caaf3478-e61e-492c-855d-c8c6899413b4">0.000001</ix:nonFraction> per share. The aggregate net proceeds received by the Company from the offering were $<ix:nonFraction unitRef="usd" contextRef="ibcd7f5cd1b2a4a29a2a3ab167bb32bce_D20200707-20200707" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTM5MjA_e05dec0d-02b6-4668-b4e2-3cf35d5c88a7">71.3</ix:nonFraction>&#160;million, net of underwriting discounts, commissions, and offering costs of approximately $<ix:nonFraction unitRef="usd" contextRef="ibcd7f5cd1b2a4a29a2a3ab167bb32bce_D20200707-20200707" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MDI4NjQ_682ad3e4-9b9f-4d43-990a-61e067237dea">4.9</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2019, the Company completed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i4106335c2a9e4f65a3bf48b670d2780f_D20191220-20191220" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTM5MzU_7b871b57-51b0-4c28-b48e-028799c6de7b">10,263,750</ix:nonFraction> shares of its common stock at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="i244aa6bc78a741be9d0e8aafa2725d77_I20191220" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTM5NDc_e14f65a8-ca88-4ee2-8ac9-f47343c5dd89">8.40</ix:nonFraction> per share. The aggregate net proceeds received by the Company from the offering, net of underwriting discounts, commissions, and offering costs of approximately $<ix:nonFraction unitRef="usd" contextRef="ib79c600c3cf14f96b3f11cb86e2c6fe1_D20191220-20191220" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTM5NTQ_3f7d13db-d24f-416d-a132-1e11cf0837dc">5.5</ix:nonFraction>&#160;million, were $<ix:nonFraction unitRef="usd" contextRef="ib79c600c3cf14f96b3f11cb86e2c6fe1_D20191220-20191220" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTM5Njg_656196b7-9072-4a6d-93e9-07d117b53270">80.7</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b) Preferred stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MDc2ODk_245d5181-84f7-4d60-a622-e07a9c641e75"><ix:nonFraction unitRef="shares" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MDc2ODk_c6fa0fd6-c3ee-4d15-9b60-70f95886be3f">5,000,000</ix:nonFraction></ix:nonFraction> shares of preferred stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MDc2OTQ_22a74ae7-629c-44e3-8d2d-7b1437dd6dbf"><ix:nonFraction unitRef="usdPerShare" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MDc2OTQ_e4047a3f-673d-45d2-a163-d2f816bc2860">0.000001</ix:nonFraction></ix:nonFraction> per share. As of December&#160;31, 2020 and December&#160;31, 2019, <ix:nonFraction unitRef="shares" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0NTUyNzg_1e63d879-865e-423b-bdbf-7b251eff12d0"><ix:nonFraction unitRef="shares" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0NTUyNzg_23ae5e15-e6a1-4c7b-b7c4-d698abeda481"><ix:nonFraction unitRef="shares" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0NTUyNzg_517e14f3-5c95-449f-b17f-5d9c58b94664"><ix:nonFraction unitRef="shares" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0NTUyNzg_f3006b77-4cfd-463e-852f-97161cf8c368">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares of preferred stock were issued or outstanding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c) Merger with Former Neoleukin</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;8, 2019, the Company issued <ix:nonFraction unitRef="shares" contextRef="i40320493bb114b7b9790c7199d64f1a0_D20190808-20190808" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzY0NQ_f77eb730-7ad0-43bc-8175-a412a5f20086">4,589,771</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="ib1005fcc8fe5417da0ed149702b76a6f_D20190808-20190808" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzY3NQ_be04afbc-3646-475b-a2c1-b27f891063ce">101,927</ix:nonFraction> shares of non-voting convertible preferred stock as consideration in the Merger among Aquinox, Former Neoleukin and Apollo Merger Inc. (see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Each share of non-voting convertible preferred stock was convertible into <ix:nonFraction unitRef="shares" contextRef="i562c09437d76488daa016091ce08fa2a_D20190808-20190808" decimals="INF" name="nltx:StockConversionRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzkwMQ_7bb3de92-0434-457e-b703-770bf72b4247">100</ix:nonFraction> shares of common stock and was entitled to receive dividends, on an as-is converted to common stock basis, when dividends are paid to common stockholders. The holders of preferred stock were only entitled to vote when it impacts the rights of the preferred stockholder.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;12, 2019, the Company&#8217;s stockholders approved the conversion of <ix:nonFraction unitRef="shares" contextRef="iff8af19eb46e4d98bfc328b1fb63531e_D20191112-20191112" decimals="INF" format="ixt:numdotdecimal" name="nltx:ConvertiblePreferredStockToBeConverted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzEyNTA_07eae89b-a7f3-49c3-8f05-21ccf3796611">101,927</ix:nonFraction> shares of non-voting convertible preferred stock into <ix:nonFraction unitRef="shares" contextRef="id6d4eed2171d4fda82da0d88564149d9_I20191112" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzEzMDc_4293a08e-fb7d-4a5b-9119-de91149c9933">10,192,700</ix:nonFraction> shares of the Company&#8217;s common stock. As of December&#160;31, 2020, the Company did <ix:nonFraction unitRef="shares" contextRef="ie4a634a968e049b7b556b6104f5c0ae5_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0NTUzODc_91e091aa-0b0b-41df-ac96-bde471aef18d">no</ix:nonFraction>t have any outstanding non-voting convertible preferred stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d) December 2019 pre-funded common stock warrants</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;17, 2019, Neoleukin entered into an exchange agreement (the &#8220;Exchange Agreement&#8221;) with certain stockholders, pursuant to which the Company exchanged an aggregate of <ix:nonFraction unitRef="shares" contextRef="i1913c226c2e2462ba6fe703cb86f64c8_D20191217-20191217" decimals="INF" format="ixt:numdotdecimal" name="nltx:StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NTM_daa1af63-f7ad-42b5-985f-465b85d26731">10,925,481</ix:nonFraction> shares of common stock held by the stockholders&#160;for&#160;pre-funded&#160;warrants&#160;(the &#8220;Exchange Warrants&#8221;) to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i5612b1ceb0074b538a341f49adc28d80_I20191217" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE3ODI_38fd2daf-37e7-4578-9027-6a4b1d065b63">10,925,481</ix:nonFraction> shares of common stock (subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting common stock), with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5612b1ceb0074b538a341f49adc28d80_I20191217" decimals="6" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE5NTU_193370b2-254d-4ac5-ad2f-00afdc5c2660">0.000001</ix:nonFraction> per share. The Exchange Warrants may be exercised at any time after the date of issuance, except that the Exchange Warrants cannot be exercised by the stockholders if, after giving effect thereto, the stockholders would beneficially own more than <ix:nonFraction unitRef="number" contextRef="i1913c226c2e2462ba6fe703cb86f64c8_D20191217-20191217" decimals="INF" name="nltx:PercentageOfOutstandingStockPerStockholderMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzIyMDU_0aad6df8-c17d-445b-8b5b-1a97006e622a">9.99</ix:nonFraction>% of the outstanding common stock, subject to certain exceptions. The holders of the Exchange Warrants will not have the right to vote on any matter except to the extent required by Delaware law.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Exchange Warrants meet the conditions for equity classification, the proceeds previously received for the shares of common stock will remain in additional paid-in capital. Upon the exercise of the warrants the proceeds received along with the exercise price will be recorded in common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(e) Stock option plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2014, the Company&#8217;s stockholders approved the 2014 Equity Incentive Plan (&#8220;2014 Plan&#8221;) which became effective in March 2014. The 2014 Plan is the successor to and continuation of the Joint Canadian Stock Option Plan (the &#8220;2006 Plan&#8221;). No further grants will be made under the 2006 Plan. The 2014 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards, and other forms of equity awards to employees, directors, and consultants.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the maximum number of shares of common stock that may be issued under the 2014 Plan was <ix:nonFraction unitRef="shares" contextRef="ifb2fe74f8fec43409b383c349c9d583a_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MTM4ODg_c7d440dc-db1b-4d64-942d-9a31c7694914">9,786,363</ix:nonFraction>. The number of shares of common stock reserved for issuance under the 2014 Plan will be increased by the number of shares subject to stock options granted under the 2006 Plan that would have otherwise returned to the 2006 Plan, such as upon the expiration or termination of a stock award prior to vesting. As of December&#160;31, 2020, there were  <ix:nonFraction unitRef="shares" contextRef="i5126c731497844cf82463ebd9ba0ec2c_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzIxOTkwMjMyODkzNDU_8f6c0817-734f-47d7-a6b7-a787310f076a">23,958</ix:nonFraction>  shares subject to stock options granted under the 2006 Plan. Additionally, the number of shares of common stock reserved for issuance under the 2014 Plan will automatically increase on January&#160;1 of each year for a period of up to <ix:nonNumeric contextRef="iceb04586e32a40cc920160798f9ddce9_D20200101-20201231" format="ixt-sec:duryear" name="nltx:PeriodSharesReservedForIssuanceWillIncrease" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MTM4MzI_bc5bfa60-5d47-4afd-b95d-6c6ea3b05e93">10</ix:nonNumeric> years, beginning on January&#160;1, 2015 and ending on and including January&#160;1, 2024, by <ix:nonFraction unitRef="number" contextRef="iceb04586e32a40cc920160798f9ddce9_D20200101-20201231" decimals="4" name="nltx:StockBasedCompensationIncreaseInCommonStockIssuancePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MTM4Mjg_e38d7607-6499-4c03-9df3-d153d5e8ad25">4.00</ix:nonFraction>% of the total number of shares of capital stock </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="i10e393746bdf4726a6c4d5e1b3b536d6" continuedAt="i95b1d4f55f2940bfa9725a0c7bc32dee"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outstanding on December&#160;31 of the preceding calendar year, or a lesser number of shares determined by the board of directors. On November&#160;12, 2019, the Company&#8217;s stockholders approved the increase in the number of shares reserved from issuance under the 2014 Plan by <ix:nonFraction unitRef="shares" contextRef="i40473cfe46a34de087cfebd3e2af1629_D20191112-20191112" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MTExNTY_b2539715-6355-4c65-b2a2-55bc2580decb">4,500,000</ix:nonFraction> shares. All awards granted pursuant to the 2014 Plan have a contractual term of <ix:nonNumeric contextRef="iceb04586e32a40cc920160798f9ddce9_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTQwMTA_677ada03-71d0-4082-9bfd-2b9fc8f9202b">ten years</ix:nonNumeric>. All awards granted to date are equity classified and subject to service based vesting, typically over a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTM5ODM_38a5a479-ddde-4ba0-9188-8ce886f75bc3">one</span> to <ix:nonNumeric contextRef="iae8ed78b63224fe9a7fae1f526fde05d_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTM5ODQ_a426f920-3fde-422d-8114-9a4fea25be42">four years</ix:nonNumeric>.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares available to be granted under the 2014 Plan was <ix:nonFraction unitRef="shares" contextRef="ifb2fe74f8fec43409b383c349c9d583a_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzIxOTkwMjMyODkzNDE_8371e81f-73c5-40a0-aac6-e9d94c8232a4">6,037,532</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i56d428d107ab495dbcb789afcb67f7ac_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MTM4NDU_1c050846-45e1-4049-bea7-7594ea25ac05">6,556,534</ix:nonFraction> as of December&#160;31, 2020 and 2019 respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stock options</span></div><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTQwMjU_8afb1f71-c9a2-4f02-83e5-e0b8386e6d35" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company's stock option activity and related information for the year ended December&#160;31, 2020 is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:34.039%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life<br/>(In Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value   <br/>(In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzEtMS0xLTEtMzkyNw_96596da2-addd-4c03-985a-e2d8d47d0b4d">5,840,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzEtMy0xLTEtMzkyNw_f1805625-95f4-4d8e-9dd9-2b026aae17a2">5.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzEtNS0xLTEtMzkyNw_f8ccf464-172c-42b1-ba44-c2245de4f52b">7.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzEtNy0xLTEtMzkyNw_6b941d05-4e69-4938-a969-c79eb8b47d45">45,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzItMS0xLTEtMzkyNw_e0ec3fae-f17b-4669-b52e-b5cb283c3f57">2,404,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzItMy0xLTEtMzkyNw_18baec90-c8da-46f3-946d-80107b6561b7">11.6</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzMtMS0xLTEtMzkyNw_af06e5d5-784a-4ae3-a97e-af1b0bef199d">882,624</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzMtMy0xLTEtMzkyNw_2c549bb9-a171-4c24-8e24-598220cbfce1">6.42</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzQtMS0xLTEtMzkyNw_c34a4768-6fe5-471d-aac9-00af1f6726f9">515,925</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzQtMy0xLTEtMzkyNw_e9624ba4-473d-4cdf-baca-655df3de8e1a">15.69</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzUtMS0xLTEtMzkyNw_0ed10cbd-df25-45d7-9bae-4909749110f0">6,846,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzUtMy0xLTEtMzkyNw_6712b20b-c6a4-47ed-8502-0b8234512acb">6.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzUtNS0xLTEtMzkyNw_7374b899-9cd9-48a7-98bf-b2bbd7056cea">8.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzUtNy0xLTEtMzkyNw_90d70661-a1e4-4858-b869-51a2b2c10398">53,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzYtMS0xLTEtNTgxNQ_f8955dbd-b1d9-4cc4-8efa-e4e4eb1c0b67">1,878,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzYtMy0xLTEtNTgxNQ_da2e9e67-2937-46e4-a16d-3c4e5bcedcfa">5.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzYtNS0xLTEtNTgxNQ_caa24c43-3bad-41d0-916d-1ab8fc254e90">7.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzYtNy0xLTEtNTgxNQ_3247c4d1-4ab2-45d5-8733-cd515a180e64">17,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, <ix:nonFraction unitRef="shares" contextRef="ib2b7aa4965884327b321e9713f816fca_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzcxNDY4MjU2MTIzNzE_eb1e322c-c1c5-4950-a5b5-c7368d8c23e7">882,624</ix:nonFraction> shares of common stock were issued upon exercise of options with an aggregate intrinsic value of $<ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MTQ2NjI_2cdef402-dbef-4b56-8f09-7b8471c0e135">6.0</ix:nonFraction> million. During the year ended December&#160;31, 2019, <ix:nonFraction unitRef="shares" contextRef="ia5203423d3b74826a3d7fe380aabf55b_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MTQ2Nzg_442ce288-60f1-4646-bae5-60629b731f87">326,094</ix:nonFraction> shares of common stock were issued upon exercise of options with an aggregate intrinsic value of $<ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MTQ2NzQ_7875da96-6154-473e-bdf0-78983aa39c36">1.3</ix:nonFraction> million. The weighted-average grant date fair value of options granted during the years ended December&#160;31, 2020 and December&#160;31, 2019 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzI3NDg3NzkxMTg3NDk_a9e785a5-6f89-4a0c-b817-27c821187dfe">8.70</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzI3NDg3NzkxMTg3NTc_e3516621-ad14-4e41-ab80-2531244f0ea1">2.17</ix:nonFraction> per share, respectively.</span></div><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc1MDEzNTM_d8449650-4dc9-4349-be1c-723357b28c21" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted is estimated using the Black-Scholes option pricing model with the following weighted average assumptions:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:65.311%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZToyMDhjYzYyYmRmNGY0ZWJiOThhNTI2ZWZhMjdmMmFlYi90YWJsZXJhbmdlOjIwOGNjNjJiZGY0ZjRlYmI5OGE1MjZlZmEyN2YyYWViXzItMS0xLTEtNzEwNw_f0f04864-2488-4b5d-9c7e-1c46f9f6f7bb">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZToyMDhjYzYyYmRmNGY0ZWJiOThhNTI2ZWZhMjdmMmFlYi90YWJsZXJhbmdlOjIwOGNjNjJiZGY0ZjRlYmI5OGE1MjZlZmEyN2YyYWViXzItMy0xLTEtNzEwNw_7cdad612-d78e-47bb-aa5b-a17416c8d8a5">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZToyMDhjYzYyYmRmNGY0ZWJiOThhNTI2ZWZhMjdmMmFlYi90YWJsZXJhbmdlOjIwOGNjNjJiZGY0ZjRlYmI5OGE1MjZlZmEyN2YyYWViXzMtMS0xLTEtNzEwNw_9f36f7f3-ff13-43e2-874b-e517d87ccdb4">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZToyMDhjYzYyYmRmNGY0ZWJiOThhNTI2ZWZhMjdmMmFlYi90YWJsZXJhbmdlOjIwOGNjNjJiZGY0ZjRlYmI5OGE1MjZlZmEyN2YyYWViXzMtMy0xLTEtNzEwNw_538f2076-5818-460b-89d2-a6f1a986fb32">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected terms (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZToyMDhjYzYyYmRmNGY0ZWJiOThhNTI2ZWZhMjdmMmFlYi90YWJsZXJhbmdlOjIwOGNjNjJiZGY0ZjRlYmI5OGE1MjZlZmEyN2YyYWViXzQtMS0xLTEtNzEwNw_9ba57496-c5fe-49fa-b54c-038523ef666f">6.02</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZToyMDhjYzYyYmRmNGY0ZWJiOThhNTI2ZWZhMjdmMmFlYi90YWJsZXJhbmdlOjIwOGNjNjJiZGY0ZjRlYmI5OGE1MjZlZmEyN2YyYWViXzQtMy0xLTEtNzEwNw_2402e15c-de3b-4ea1-9275-f35edfc119ed">6.07</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZToyMDhjYzYyYmRmNGY0ZWJiOThhNTI2ZWZhMjdmMmFlYi90YWJsZXJhbmdlOjIwOGNjNjJiZGY0ZjRlYmI5OGE1MjZlZmEyN2YyYWViXzUtMS0xLTEtNzEwNw_10168e3f-fad5-4047-b9e8-75cde30a01d6">0.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZToyMDhjYzYyYmRmNGY0ZWJiOThhNTI2ZWZhMjdmMmFlYi90YWJsZXJhbmdlOjIwOGNjNjJiZGY0ZjRlYmI5OGE1MjZlZmEyN2YyYWViXzUtMy0xLTEtNzEwNw_1092cadf-cf36-4d3d-a71c-f3f805e24b29">1.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Restricted stock units</span></div><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTQwMjc_b2724ed2-6e77-4198-8d9e-a2aa652c8772" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company's restricted stock unit activity and related information for the year ended December&#160;31, 2020 is as follows: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:57.320%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.168%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.169%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd60841f3d0c4c839e994b21197a5e5a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo5ZjUwYmZiZjc1NWI0NmU4YTFhMmQzNzcxNmM0YmM5Yi90YWJsZXJhbmdlOjlmNTBiZmJmNzU1YjQ2ZThhMWEyZDM3NzE2YzRiYzliXzEtMS0xLTEtNDgxOA_ee18b8cc-1769-432f-b9ad-710231a0b50c">72,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd60841f3d0c4c839e994b21197a5e5a_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo5ZjUwYmZiZjc1NWI0NmU4YTFhMmQzNzcxNmM0YmM5Yi90YWJsZXJhbmdlOjlmNTBiZmJmNzU1YjQ2ZThhMWEyZDM3NzE2YzRiYzliXzEtMy0xLTEtNDgxOA_7a3930bd-470b-4f5a-940d-244337b53d0a">3.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf570f55902f4cc28e0254cce74d57f7_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo5ZjUwYmZiZjc1NWI0NmU4YTFhMmQzNzcxNmM0YmM5Yi90YWJsZXJhbmdlOjlmNTBiZmJmNzU1YjQ2ZThhMWEyZDM3NzE2YzRiYzliXzItMS0xLTEtNDgxOA_d989839a-d54c-42a4-aaf9-7bada97c5d28">152,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icf570f55902f4cc28e0254cce74d57f7_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo5ZjUwYmZiZjc1NWI0NmU4YTFhMmQzNzcxNmM0YmM5Yi90YWJsZXJhbmdlOjlmNTBiZmJmNzU1YjQ2ZThhMWEyZDM3NzE2YzRiYzliXzItMy0xLTEtNDgxOA_2340c84e-1902-4286-898e-450f69ea7216">9.26</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icf570f55902f4cc28e0254cce74d57f7_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo5ZjUwYmZiZjc1NWI0NmU4YTFhMmQzNzcxNmM0YmM5Yi90YWJsZXJhbmdlOjlmNTBiZmJmNzU1YjQ2ZThhMWEyZDM3NzE2YzRiYzliXzMtMS0xLTEtNDgxOA_e551c4df-81c1-45c2-bfdd-198a5dae7832">36,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icf570f55902f4cc28e0254cce74d57f7_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo5ZjUwYmZiZjc1NWI0NmU4YTFhMmQzNzcxNmM0YmM5Yi90YWJsZXJhbmdlOjlmNTBiZmJmNzU1YjQ2ZThhMWEyZDM3NzE2YzRiYzliXzMtMy0xLTEtNDgxOA_da8ceb16-b807-4261-8aaa-d55467aa4e7e">3.47</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icf570f55902f4cc28e0254cce74d57f7_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo5ZjUwYmZiZjc1NWI0NmU4YTFhMmQzNzcxNmM0YmM5Yi90YWJsZXJhbmdlOjlmNTBiZmJmNzU1YjQ2ZThhMWEyZDM3NzE2YzRiYzliXzQtMS0xLTEtNDgxOA_b9376e12-a3b4-4014-812a-ffee0e25bf23">1,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icf570f55902f4cc28e0254cce74d57f7_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo5ZjUwYmZiZjc1NWI0NmU4YTFhMmQzNzcxNmM0YmM5Yi90YWJsZXJhbmdlOjlmNTBiZmJmNzU1YjQ2ZThhMWEyZDM3NzE2YzRiYzliXzQtMy0xLTEtNDgxOA_5fab42df-0f8c-4eec-ba7e-bdad4cc40b62">3.47</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i519925c39cf4455091866ca196cf1161_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo5ZjUwYmZiZjc1NWI0NmU4YTFhMmQzNzcxNmM0YmM5Yi90YWJsZXJhbmdlOjlmNTBiZmJmNzU1YjQ2ZThhMWEyZDM3NzE2YzRiYzliXzUtMS0xLTEtNDgxOA_0dbe508e-4679-4a32-9436-2f69c63ca0ae">186,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i519925c39cf4455091866ca196cf1161_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo5ZjUwYmZiZjc1NWI0NmU4YTFhMmQzNzcxNmM0YmM5Yi90YWJsZXJhbmdlOjlmNTBiZmJmNzU1YjQ2ZThhMWEyZDM3NzE2YzRiYzliXzUtMy0xLTEtNDgxOA_e3be6fa6-de1f-49d6-a85c-407c31252f84">8.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="i95b1d4f55f2940bfa9725a0c7bc32dee" continuedAt="i3e7942f21f094926bd8e1366945b74a7"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(f) Stock-based compensation</span></div><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTQwMjg_6a3d548e-6356-4177-adf4-8f9daa0da626" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is classified in the consolidated statements of operations as follows (in thousands):</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:56.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.761%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98de22e11051465b8dcdb754ab88181e_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo0MmQzZjQxYjE4OWY0ZmMxYmQ0YTAwOWJiYjkyNmM1My90YWJsZXJhbmdlOjQyZDNmNDFiMTg5ZjRmYzFiZDRhMDA5YmJiOTI2YzUzXzItMS0xLTEtMzcwNQ_ed08f034-24cc-43d0-ac6f-f067825c6fce">1,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ded9a42fb4c43d59acd21cbb286e7ab_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo0MmQzZjQxYjE4OWY0ZmMxYmQ0YTAwOWJiYjkyNmM1My90YWJsZXJhbmdlOjQyZDNmNDFiMTg5ZjRmYzFiZDRhMDA5YmJiOTI2YzUzXzItMy0xLTEtMzcwNQ_19771a77-ce42-459b-b98a-882f179dc9b5">486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib836d4e8cc0846f3aae456d3e9c5c4a1_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo0MmQzZjQxYjE4OWY0ZmMxYmQ0YTAwOWJiYjkyNmM1My90YWJsZXJhbmdlOjQyZDNmNDFiMTg5ZjRmYzFiZDRhMDA5YmJiOTI2YzUzXzMtMS0xLTEtMzcwNQ_eaa2e79e-1999-4bc3-b925-19f4bc7d6232">3,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bf297e89d3a4439826cf1221fa7077e_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo0MmQzZjQxYjE4OWY0ZmMxYmQ0YTAwOWJiYjkyNmM1My90YWJsZXJhbmdlOjQyZDNmNDFiMTg5ZjRmYzFiZDRhMDA5YmJiOTI2YzUzXzMtMy0xLTEtMzcwNQ_62212570-b3cf-4626-9660-0c513a497bf9">7,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo0MmQzZjQxYjE4OWY0ZmMxYmQ0YTAwOWJiYjkyNmM1My90YWJsZXJhbmdlOjQyZDNmNDFiMTg5ZjRmYzFiZDRhMDA5YmJiOTI2YzUzXzQtMS0xLTEtMzcwNQ_5d330255-9828-4672-81db-76fc73e87219">5,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo0MmQzZjQxYjE4OWY0ZmMxYmQ0YTAwOWJiYjkyNmM1My90YWJsZXJhbmdlOjQyZDNmNDFiMTg5ZjRmYzFiZDRhMDA5YmJiOTI2YzUzXzQtMy0xLTEtMzcwNQ_bc7b4a0d-b15b-4399-864b-86098e2e7378">7,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized compensation for all stock-based compensation was $<ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MDY5NzI_fab9c19a-983f-449b-a14a-4cfb433669f7">24.9</ix:nonFraction> million as of December&#160;31, 2020, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MDcwMzA_0ac18e79-ebc2-4ad0-ad79-b168ee5b8e76">3.15</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(g) Employee stock purchase plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2020 Employee Stock Purchase Plan (&#8220;2020 ESPP&#8221;) was adopted by the Company&#8217;s Board of Directors in March 2020 and approved by the Company&#8217;s stockholders in May 2020. A total of <ix:nonFraction unitRef="shares" contextRef="ic094ebf448aa42ca8ddd6b528bd22183_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzcxNDY4MjU2MTIzNjc_e31b7c62-d9b9-4544-8a56-36b82d20aa90">759,936</ix:nonFraction> shares of common stock have been reserved for issuance under the 2020 ESPP.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to share and dollar limits as described in the plan, the 2020 ESPP allows eligible employees to contribute, through payroll deductions, up to <ix:nonFraction unitRef="number" contextRef="ic094ebf448aa42ca8ddd6b528bd22183_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc1MDEzNTY_54d6c4f7-1680-485f-a883-9151f511e578"><ix:nonFraction unitRef="number" contextRef="ic094ebf448aa42ca8ddd6b528bd22183_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc1MDEzNTY_9b19ce78-ef4f-457a-b6d1-25abf744cb90">15</ix:nonFraction></ix:nonFraction>% of their earnings for the purchase of the Company&#8217;s shares of common stock at the lower of <ix:nonFraction unitRef="number" contextRef="i6ce8a1775eab43619ee74ee567323a06_D20200101-20201231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTQwNDg_ca48909a-b266-40dd-af7b-f6287f28a660">85</ix:nonFraction>% of the closing price of the Company&#8217;s common stock on the first trading day of the offering period or <ix:nonFraction unitRef="number" contextRef="i6ce8a1775eab43619ee74ee567323a06_D20200101-20201231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTQwNTM_2035434f-c011-43bd-ab9e-9e7b24e5b5c5">85</ix:nonFraction>% of the closing price of the Company&#8217;s common stock on the last trading day of the offering period. There are <ix:nonFraction unitRef="offering" contextRef="i6ce8a1775eab43619ee74ee567323a06_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="nltx:EmployeeStockPurchasePlanNumberOfOfferingPerYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTQwMzA_e45e1e14-dec5-4eff-b069-03d12ccdf15f">two</ix:nonFraction> <ix:nonNumeric contextRef="i6ce8a1775eab43619ee74ee567323a06_D20200101-20201231" format="ixt-sec:durwordsen" name="nltx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTQwNDU_b1afcb1c-8209-4999-b9f3-4b723b76fa80">six-month</ix:nonNumeric> offering periods during each fiscal year, ending on May 15 and November 15. </span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3e7942f21f094926bd8e1366945b74a7">During the year ended December&#160;31, 2020, the Company issued <ix:nonFraction unitRef="shares" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzgyNDYzMzcyNTY0ODY_47289b9d-e40c-41ca-96e9-0e31ee4d39e4">18,352</ix:nonFraction> shares of common stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9458a61fcd5441b4a06f3867c7b43644_I20201231" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzgyNDYzMzcyNTY0OTI_1bcf3adc-27f2-4478-bec9-3d4d41d9d9a8">10.84</ix:nonFraction> under the 2020 ESPP. Cash received from the purchases under the 2020 ESPP for the year ended December&#160;31, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzgyNDYzMzcyNTY0OTg_e4c599e6-615d-4109-a3fe-dcdc4ab24f72">0.2</ix:nonFraction> million.</ix:continuation> </span></div><div style="margin-top:6pt"><span><br/></span></div><div id="ib53014c4f13844039ebc5a68643f31a2_145"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNDUvZnJhZzo5YmYyYTkwODMzNWQ0NzZjOGFhZGMyZDM4ZWFlNjQ5OS90ZXh0cmVnaW9uOjliZjJhOTA4MzM1ZDQ3NmM4YWFkYzJkMzhlYWU2NDk5XzI1MTc_23292033-e02e-4370-b376-5dadbbff0fd1" continuedAt="i0f4f8c85bee54a7081c8bd3d2d0d3fae" escape="true">Restructuring</ix:nonNumeric></span></div><ix:continuation id="i0f4f8c85bee54a7081c8bd3d2d0d3fae"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the Company&#8217;s Board of Directors approved a restructuring plan to reduce operating costs and better align the Company&#8217;s workforce with the needs of its business following the June&#160;27, 2018 announcement that its Phase 3 Leadership 301 clinical trial evaluating once-daily, oral rosiptor for the treatment of IC/BPS failed to meet its primary endpoint. The Company has halted all further development activities with rosiptor. In 2018 and 2019, the Company incurred and paid aggregate restructuring charges of $<ix:nonFraction unitRef="usd" contextRef="i71f76aa20b85452986373dda65e0d335_I20191231" decimals="-5" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNDUvZnJhZzo5YmYyYTkwODMzNWQ0NzZjOGFhZGMyZDM4ZWFlNjQ5OS90ZXh0cmVnaW9uOjliZjJhOTA4MzM1ZDQ3NmM4YWFkYzJkMzhlYWU2NDk5XzMyOTg1MzQ4OTQzNzY_318de1a1-2008-4763-b6d4-cf0bb0cbf4b0">7.4</ix:nonFraction> million related to clinical trial closing costs, contract cancellations, closing of its office in San Bruno, California, severance payments and other employee-related costs. During the second quarter of 2019, the Company revised its original estimate of aggregate restructuring charges lower by $<ix:nonFraction unitRef="usd" contextRef="if5d6fef6a34b42589a5f9af4fd295376_D20190401-20190630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RestructuringReserveAccrualAdjustment1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNDUvZnJhZzo5YmYyYTkwODMzNWQ0NzZjOGFhZGMyZDM4ZWFlNjQ5OS90ZXh0cmVnaW9uOjliZjJhOTA4MzM1ZDQ3NmM4YWFkYzJkMzhlYWU2NDk5XzE2NDkyNjc0NTI5Mzc_0afe0b3b-c8c5-4415-8b0e-ce8e3650e27f">2.0</ix:nonFraction>&#160;million based upon updated information from its vendors related to a completed project. There were <ix:nonFraction unitRef="usd" contextRef="i71f76aa20b85452986373dda65e0d335_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RestructuringReserve" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNDUvZnJhZzo5YmYyYTkwODMzNWQ0NzZjOGFhZGMyZDM4ZWFlNjQ5OS90ZXh0cmVnaW9uOjliZjJhOTA4MzM1ZDQ3NmM4YWFkYzJkMzhlYWU2NDk5XzE2NDkyNjc0NTI5OTM_2c09c414-7848-4b97-8d6c-9fd0b0bec6bf"><ix:nonFraction unitRef="usd" contextRef="i8b0667298aca423a94e3af1049753d11_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RestructuringReserve" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNDUvZnJhZzo5YmYyYTkwODMzNWQ0NzZjOGFhZGMyZDM4ZWFlNjQ5OS90ZXh0cmVnaW9uOjliZjJhOTA4MzM1ZDQ3NmM4YWFkYzJkMzhlYWU2NDk5XzE2NDkyNjc0NTI5OTM_e021b6d4-f612-419b-9539-e3caef3b4e25">no</ix:nonFraction></ix:nonFraction> amounts accrued as of December&#160;31, 2020 or December&#160;31, 2019.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;6, 2018, the Company&#8217;s Board of Directors approved an additional restructuring plan to further reduce operating costs.  The Company incurred and paid aggregate restructuring charges of $<ix:nonFraction unitRef="usd" contextRef="ie44b93451c7140eaadb4a1b1ad21f5a2_I20181106" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNDUvZnJhZzo5YmYyYTkwODMzNWQ0NzZjOGFhZGMyZDM4ZWFlNjQ5OS90ZXh0cmVnaW9uOjliZjJhOTA4MzM1ZDQ3NmM4YWFkYzJkMzhlYWU2NDk5XzE2NDkyNjc0NTI5NTE_ae00a1d1-0304-4079-b613-d05f04436e45">1.6</ix:nonFraction>&#160;million related to severance payments and other employee-related costs.  There were <ix:nonFraction unitRef="usd" contextRef="i683ab08d4e50424b957c9a94c07b61de_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RestructuringReserve" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNDUvZnJhZzo5YmYyYTkwODMzNWQ0NzZjOGFhZGMyZDM4ZWFlNjQ5OS90ZXh0cmVnaW9uOjliZjJhOTA4MzM1ZDQ3NmM4YWFkYzJkMzhlYWU2NDk5XzE2NDkyNjc0NTI5NjQ_671686f5-86b1-4280-8e7d-93d3911270ec">no</ix:nonFraction> amounts accrued as of December&#160;31, 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, the Company incurred and paid an immaterial amount of restructuring charges. For the year ended December&#160;31, 2019, restructuring recoveries of $<ix:nonFraction unitRef="usd" contextRef="i4ded9a42fb4c43d59acd21cbb286e7ab_D20190101-20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNDUvZnJhZzo5YmYyYTkwODMzNWQ0NzZjOGFhZGMyZDM4ZWFlNjQ5OS90ZXh0cmVnaW9uOjliZjJhOTA4MzM1ZDQ3NmM4YWFkYzJkMzhlYWU2NDk5XzE2NDkyNjc0NTI5NjY_ba1198c4-56a6-408c-87c5-6a489638616a">1.9</ix:nonFraction>&#160;million were recorded in research and development expenses and restructuring costs of $<ix:nonFraction unitRef="usd" contextRef="i3bf297e89d3a4439826cf1221fa7077e_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNDUvZnJhZzo5YmYyYTkwODMzNWQ0NzZjOGFhZGMyZDM4ZWFlNjQ5OS90ZXh0cmVnaW9uOjliZjJhOTA4MzM1ZDQ3NmM4YWFkYzJkMzhlYWU2NDk5XzE2NDkyNjc0NTI5ODA_831dedce-dec8-4122-815d-efebf0ce44ba">0.7</ix:nonFraction>&#160;million were recorded in general and administrative expenses.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="ib53014c4f13844039ebc5a68643f31a2_151"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTEvZnJhZzo1OWNkZmE1NTEyOTY0MjYzOGNlMDhlNGVmODhiMTM1NC90ZXh0cmVnaW9uOjU5Y2RmYTU1MTI5NjQyNjM4Y2UwOGU0ZWY4OGIxMzU0XzI4_26e3dd8f-c5aa-4399-837b-ce312b79892c" continuedAt="ia0021bd6c6b74673b48714b243340b18" escape="true">Other income, net</ix:nonNumeric></span></div><ix:continuation id="ia0021bd6c6b74673b48714b243340b18"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTEvZnJhZzo1OWNkZmE1NTEyOTY0MjYzOGNlMDhlNGVmODhiMTM1NC90ZXh0cmVnaW9uOjU5Y2RmYTU1MTI5NjQyNjM4Y2UwOGU0ZWY4OGIxMzU0XzI5_5f533d96-4664-4b6d-8af6-ddd847016b25" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income is presented for all periods (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:71.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTEvZnJhZzo1OWNkZmE1NTEyOTY0MjYzOGNlMDhlNGVmODhiMTM1NC90YWJsZTo0NDBkMmY4ZjY1Y2U0ZmM4ODcxOTAxYzFkYWYzMGFhZC90YWJsZXJhbmdlOjQ0MGQyZjhmNjVjZTRmYzg4NzE5MDFjMWRhZjMwYWFkXzItMS0xLTEtMA_7093468a-0040-4eeb-a363-3fbe76c6a011">490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTEvZnJhZzo1OWNkZmE1NTEyOTY0MjYzOGNlMDhlNGVmODhiMTM1NC90YWJsZTo0NDBkMmY4ZjY1Y2U0ZmM4ODcxOTAxYzFkYWYzMGFhZC90YWJsZXJhbmdlOjQ0MGQyZjhmNjVjZTRmYzg4NzE5MDFjMWRhZjMwYWFkXzItMy0xLTEtMA_8923e99e-177e-483c-9c5a-10d88f22efcb">1,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange gains (losses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTEvZnJhZzo1OWNkZmE1NTEyOTY0MjYzOGNlMDhlNGVmODhiMTM1NC90YWJsZTo0NDBkMmY4ZjY1Y2U0ZmM4ODcxOTAxYzFkYWYzMGFhZC90YWJsZXJhbmdlOjQ0MGQyZjhmNjVjZTRmYzg4NzE5MDFjMWRhZjMwYWFkXzMtMS0xLTEtMA_2173bb16-34d4-4b37-b0fc-b3470261f3b9">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTEvZnJhZzo1OWNkZmE1NTEyOTY0MjYzOGNlMDhlNGVmODhiMTM1NC90YWJsZTo0NDBkMmY4ZjY1Y2U0ZmM4ODcxOTAxYzFkYWYzMGFhZC90YWJsZXJhbmdlOjQ0MGQyZjhmNjVjZTRmYzg4NzE5MDFjMWRhZjMwYWFkXzMtMy0xLTEtMA_7613dab0-9e5a-4575-a12e-10087087bac4">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTEvZnJhZzo1OWNkZmE1NTEyOTY0MjYzOGNlMDhlNGVmODhiMTM1NC90YWJsZTo0NDBkMmY4ZjY1Y2U0ZmM4ODcxOTAxYzFkYWYzMGFhZC90YWJsZXJhbmdlOjQ0MGQyZjhmNjVjZTRmYzg4NzE5MDFjMWRhZjMwYWFkXzQtMS0xLTEtMA_84ce4ad8-61ad-47d3-a11c-5e3177c1e3ea">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTEvZnJhZzo1OWNkZmE1NTEyOTY0MjYzOGNlMDhlNGVmODhiMTM1NC90YWJsZTo0NDBkMmY4ZjY1Y2U0ZmM4ODcxOTAxYzFkYWYzMGFhZC90YWJsZXJhbmdlOjQ0MGQyZjhmNjVjZTRmYzg4NzE5MDFjMWRhZjMwYWFkXzQtMy0xLTEtMA_66fae3dc-2ec6-43ac-9e29-a539487b2975">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTEvZnJhZzo1OWNkZmE1NTEyOTY0MjYzOGNlMDhlNGVmODhiMTM1NC90YWJsZTo0NDBkMmY4ZjY1Y2U0ZmM4ODcxOTAxYzFkYWYzMGFhZC90YWJsZXJhbmdlOjQ0MGQyZjhmNjVjZTRmYzg4NzE5MDFjMWRhZjMwYWFkXzUtMS0xLTEtMA_c6934b52-931a-4002-b70f-26f49fe0b1f2">451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTEvZnJhZzo1OWNkZmE1NTEyOTY0MjYzOGNlMDhlNGVmODhiMTM1NC90YWJsZTo0NDBkMmY4ZjY1Y2U0ZmM4ODcxOTAxYzFkYWYzMGFhZC90YWJsZXJhbmdlOjQ0MGQyZjhmNjVjZTRmYzg4NzE5MDFjMWRhZjMwYWFkXzUtMy0xLTEtMA_cc899a81-b9e9-4a96-a8e6-98b76ccb609e">1,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="ib53014c4f13844039ebc5a68643f31a2_154"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTQvZnJhZzo0YjFlOGQwYWY3YTY0OWFmYWEzYjAzMjAyYTNkZGUyMS90ZXh0cmVnaW9uOjRiMWU4ZDBhZjdhNjQ5YWZhYTNiMDMyMDJhM2RkZTIxXzQwMA_71c6bfa4-94a4-4a09-ba3c-a5145b5a54cf" continuedAt="ifab2757fc1794dd5ad189a2616d7cfe0" escape="true">Net loss per common stock</ix:nonNumeric></span></div><ix:continuation id="ifab2757fc1794dd5ad189a2616d7cfe0"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTQvZnJhZzo0YjFlOGQwYWY3YTY0OWFmYWEzYjAzMjAyYTNkZGUyMS90ZXh0cmVnaW9uOjRiMWU4ZDBhZjdhNjQ5YWZhYTNiMDMyMDJhM2RkZTIxXzM5OQ_28c0f5cc-1fa2-4032-afbb-6441b9c9b878" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company excluded the following potentially dilutive shares from diluted net loss per share as the effect would have been anti-dilutive for all periods presented:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEARS ENDED </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i114d11c2e9f14956aaff2d2291a3bb3c_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTQvZnJhZzo0YjFlOGQwYWY3YTY0OWFmYWEzYjAzMjAyYTNkZGUyMS90YWJsZTo0NTZlMDYxY2NjYWQ0NDA5Yjg5MDNmZjgxM2UxZDQxYS90YWJsZXJhbmdlOjQ1NmUwNjFjY2NhZDQ0MDliODkwM2ZmODEzZTFkNDFhXzItMS0xLTEtMA_427ec367-ab32-4180-b20b-164110887e7c">6,848,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0287eaf6edad4bca9a12a64c9fd6bfd3_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTQvZnJhZzo0YjFlOGQwYWY3YTY0OWFmYWEzYjAzMjAyYTNkZGUyMS90YWJsZTo0NTZlMDYxY2NjYWQ0NDA5Yjg5MDNmZjgxM2UxZDQxYS90YWJsZXJhbmdlOjQ1NmUwNjFjY2NhZDQ0MDliODkwM2ZmODEzZTFkNDFhXzItMy0xLTEtMA_8db27ed9-6a25-472d-a69d-64b5b44f61a9">5,840,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib0fb710a1248468f89148e8f321466cd_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTQvZnJhZzo0YjFlOGQwYWY3YTY0OWFmYWEzYjAzMjAyYTNkZGUyMS90YWJsZTo0NTZlMDYxY2NjYWQ0NDA5Yjg5MDNmZjgxM2UxZDQxYS90YWJsZXJhbmdlOjQ1NmUwNjFjY2NhZDQ0MDliODkwM2ZmODEzZTFkNDFhXzMtMS0xLTEtMA_360303f4-bef6-4727-97b5-493fe0c9b9f7">186,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i716d60022b294375af6a54233d5dafb2_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTQvZnJhZzo0YjFlOGQwYWY3YTY0OWFmYWEzYjAzMjAyYTNkZGUyMS90YWJsZTo0NTZlMDYxY2NjYWQ0NDA5Yjg5MDNmZjgxM2UxZDQxYS90YWJsZXJhbmdlOjQ1NmUwNjFjY2NhZDQ0MDliODkwM2ZmODEzZTFkNDFhXzMtMy0xLTEtMA_cdf6afec-167e-48e8-baba-4fe8dbe074c9">72,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable under 2020 ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ided3ec02dff84702acaa7ae1e47b2e5f_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTQvZnJhZzo0YjFlOGQwYWY3YTY0OWFmYWEzYjAzMjAyYTNkZGUyMS90YWJsZTo0NTZlMDYxY2NjYWQ0NDA5Yjg5MDNmZjgxM2UxZDQxYS90YWJsZXJhbmdlOjQ1NmUwNjFjY2NhZDQ0MDliODkwM2ZmODEzZTFkNDFhXzQtMS0xLTEtNDc1OA_cb9febcb-7eac-4684-a76c-8c858d912aa1">22,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96ba60c113044d799a3a4c62cb49aed1_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTQvZnJhZzo0YjFlOGQwYWY3YTY0OWFmYWEzYjAzMjAyYTNkZGUyMS90YWJsZTo0NTZlMDYxY2NjYWQ0NDA5Yjg5MDNmZjgxM2UxZDQxYS90YWJsZXJhbmdlOjQ1NmUwNjFjY2NhZDQ0MDliODkwM2ZmODEzZTFkNDFhXzQtMy0xLTEtNDc1OA_52c4ef8d-1a64-48d4-b9f8-2544ef31b425">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTQvZnJhZzo0YjFlOGQwYWY3YTY0OWFmYWEzYjAzMjAyYTNkZGUyMS90YWJsZTo0NTZlMDYxY2NjYWQ0NDA5Yjg5MDNmZjgxM2UxZDQxYS90YWJsZXJhbmdlOjQ1NmUwNjFjY2NhZDQ0MDliODkwM2ZmODEzZTFkNDFhXzQtMS0xLTEtMA_eb546186-73b7-4361-8b2b-dde817000f45">7,057,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTQvZnJhZzo0YjFlOGQwYWY3YTY0OWFmYWEzYjAzMjAyYTNkZGUyMS90YWJsZTo0NTZlMDYxY2NjYWQ0NDA5Yjg5MDNmZjgxM2UxZDQxYS90YWJsZXJhbmdlOjQ1NmUwNjFjY2NhZDQ0MDliODkwM2ZmODEzZTFkNDFhXzQtMy0xLTEtMA_cd5145ae-8213-497d-b602-5021d3f5d436">5,912,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="ib53014c4f13844039ebc5a68643f31a2_157"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzM3OTk_d3f4975d-7b70-4dc4-960e-62af4bf24f5c" continuedAt="i5330f079139243ecbf9f4a2f339f7fdf" escape="true">Income taxes</ix:nonNumeric></span></div><ix:continuation id="i5330f079139243ecbf9f4a2f339f7fdf" continuedAt="if8b405c6e32b4c1a9e44522b9c9cc01d"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzM4MDA_48c581ef-1192-43c3-ab7d-4424cab276fd" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax recovery varies from the amounts that would be computed by applying the expected U.S. federal income tax rate (21%) as shown in the following table:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statutory federal income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzItMS0xLTEtMA_4f28c16e-e164-47a8-9e95-9a7b0d38ba69">21.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzItMy0xLTEtMA_5bb8986a-4bb7-4d70-97f5-77dbdc909f08">21.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzMtMS0xLTEtMA_31dd0e4c-b718-46e0-837e-016179983142">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzMtMy0xLTEtMA_5c671a26-be99-4a49-baae-54b49ba87adf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzQtMS0xLTEtMA_90a309ed-81f0-494e-ae8c-547072316624">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzQtMy0xLTEtMA_1abc5a88-67b4-4c20-8436-667af39dbed1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzUtMS0xLTEtMA_775788bc-3482-4191-84f8-e37d0bb6d81c">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzUtMy0xLTEtMA_2f1a702b-2c11-4db9-9579-95c3fab35b72">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzYtMS0xLTEtMA_c0a6b8e9-1c17-402f-8473-c46d39dc4fbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzYtMy0xLTEtMA_7de8b897-56f1-48e2-b9db-ba53fa321225">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzctMS0xLTEtMA_ef1429cd-6747-4e1d-ad62-d3a3dfe16cc9">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzctMy0xLTEtMA_0e56075b-2cb0-4eaf-bd5d-c63cec7f3b50">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposal of Aquinox Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzgtMS0xLTEtNzM4Mg_267bb732-830b-407a-b80d-d8d8133a8743">5.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzgtMy0xLTEtNzM4NQ_56ab3832-7f2c-447f-a166-c2615f6bce4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzgtMS0xLTEtMA_fb5b1301-dc6f-42e2-8f48-2e8de8b3b4c6">26.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzgtMy0xLTEtMA_8ab91791-079c-4b8c-a975-43bfbfef0466">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expiration of NOLs (section 382)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="3" sign="-" name="nltx:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzktMS0xLTEtMA_4e3dcfa6-b316-4a27-b4bd-88ae5abb71ca">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="3" sign="-" name="nltx:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzktMy0xLTEtMA_7f188313-9293-4595-b271-dbc88f0f6bba">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax Credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzExLTEtMS0xLTczODk_9c7798ab-87bb-4e50-b821-56c55f06ba4a">2.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzExLTMtMS0xLTczOTI_f5e48f49-1229-4044-9f1b-7710df4af0f7">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzExLTEtMS0xLTA_a17680b1-b06b-4da1-8356-bcd8a3cdff15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzExLTMtMS0xLTA_45c441e9-65e4-4026-b23c-1f9edf2cd1bc">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax recovery</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="2" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzEyLTEtMS0xLTA_75dc547a-bc34-4515-80c0-e2fb472f0a90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="2" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzEyLTMtMS0xLTA_63ca0f5f-a807-4d25-be44-7c6ac02106af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:5pt"><ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzM4MDE_c556491a-315c-4e38-86f5-f3b89fdae554" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net loss before taxes (in thousands):</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZToxYjAzNDRiNjFjMDE0M2YxYjM3YTc0MDQ4ZDBhMzQxMi90YWJsZXJhbmdlOjFiMDM0NGI2MWMwMTQzZjFiMzdhNzQwNDhkMGEzNDEyXzItMS0xLTEtMA_ad6aedc5-5301-45b0-955b-ef2d7cc7fa06">522</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZToxYjAzNDRiNjFjMDE0M2YxYjM3YTc0MDQ4ZDBhMzQxMi90YWJsZXJhbmdlOjFiMDM0NGI2MWMwMTQzZjFiMzdhNzQwNDhkMGEzNDEyXzItMy0xLTEtMA_f878df52-1529-4581-916c-4eacfc49eb7f">2,129</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZToxYjAzNDRiNjFjMDE0M2YxYjM3YTc0MDQ4ZDBhMzQxMi90YWJsZXJhbmdlOjFiMDM0NGI2MWMwMTQzZjFiMzdhNzQwNDhkMGEzNDEyXzMtMS0xLTEtMA_28f7fd2f-b70f-45dc-b230-0b98d19ac7b6">32,755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZToxYjAzNDRiNjFjMDE0M2YxYjM3YTc0MDQ4ZDBhMzQxMi90YWJsZXJhbmdlOjFiMDM0NGI2MWMwMTQzZjFiMzdhNzQwNDhkMGEzNDEyXzMtMy0xLTEtMA_43a81f65-3946-464e-b1f6-ef2c32d71b44">67,313</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZToxYjAzNDRiNjFjMDE0M2YxYjM3YTc0MDQ4ZDBhMzQxMi90YWJsZXJhbmdlOjFiMDM0NGI2MWMwMTQzZjFiMzdhNzQwNDhkMGEzNDEyXzQtMS0xLTEtMA_9dc91805-8412-4688-afea-eb8ad4fd835d">33,277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZToxYjAzNDRiNjFjMDE0M2YxYjM3YTc0MDQ4ZDBhMzQxMi90YWJsZXJhbmdlOjFiMDM0NGI2MWMwMTQzZjFiMzdhNzQwNDhkMGEzNDEyXzQtMy0xLTEtMA_d2138324-a847-42c4-a3d3-705d0798d761">69,442</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><ix:continuation id="if8b405c6e32b4c1a9e44522b9c9cc01d" continuedAt="i1802241056e047fea2f79535f6ad433d"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income tax assets and liabilities result from the temporary differences between the amount of assets and liabilities recognized for financial statement and income tax purposes. <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzM3OTg_c95fe53d-a77e-455c-b2c6-031e8414ec65" continuedAt="if75fa21cc5f6476c86a6bcf3dcd04f94" escape="true">The significant components of the deferred income tax assets are as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="if75fa21cc5f6476c86a6bcf3dcd04f94"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzMtMS0xLTEtNzQzNQ_9f410e7d-f021-4fce-8f5c-8bafc78a0d79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzMtMy0xLTEtNzQ0MQ_6a108185-5d44-4dcf-878f-f3ecb792d5bb">39,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. net operating losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzQtMS0xLTEtNzQzNQ_ff5e9b68-c007-47d2-9dec-e6dcb9c6a990">12,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzQtMy0xLTEtNzQ0MQ_dc6e815d-2813-4f1a-9a4a-35adf6d212c0">5,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development deductions and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzUtMS0xLTEtNzQzNQ_a76e8fe3-8e18-4136-8fc6-987f17bf5b7e">1,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzUtMy0xLTEtNzQ0MQ_3b25f7a0-b84b-4f67-8299-8bb9f21cc3d1">11,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzYtMS0xLTEtNzQzNQ_6ff6b5ba-b2f0-4da4-93a4-ae3fffd505eb">422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzYtMy0xLTEtNzQ0MQ_a87bf78e-c5f7-4554-a8b8-556658fe2a4b">1,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease Liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nltx:DeferredTaxAssetsLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzctMS0xLTEtNzQzNQ_30684683-6c4d-4695-9504-b5496bd0aa1f">2,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" name="nltx:DeferredTaxAssetsLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzctMy0xLTEtNzQ0MQ_1d6fc871-0f3d-4f52-bc8e-75b9b641a91d">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzgtMS0xLTEtNzQzNQ_e85d8c4b-2d93-4464-8164-9600e0a888fb">717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzgtMy0xLTEtNzQ0MQ_1a896e75-5ef0-454e-91a2-0e946b60af99">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzktMS0xLTEtNzQzNQ_6bbbe1e4-3e25-450c-8061-1e1d40d8b8fb">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzktMy0xLTEtNzQ0MQ_541ca0ba-ecdb-4741-96c9-6dfcf3fa66c3">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets:</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzEwLTEtMS0xLTc0MzU_564e7512-f1a1-42e9-bf8e-e72fee775937">17,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzEwLTMtMS0xLTc0NDE_bc7261d5-3cda-4348-9417-79806e15f062">58,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU Assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzMtMS0xLTEtMA_2faa76e6-ea20-4f21-b55e-035016807dd7">2,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzMtMy0xLTEtMA_c12a073c-e474-4c91-af4b-b6070cb767f7">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzQtMS0xLTEtMA_2767ca02-a841-4d09-a4bf-b0a396636051">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzQtMy0xLTEtMA_19f32be5-4e7b-43f4-bc36-3fab58363f9c">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzUtMS0xLTEtMA_8dc59654-a02d-4f4c-a91f-7d5570d9786e">2,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzUtMy0xLTEtMA_60756f99-3fb7-431e-a7c2-448d84fc89e9">229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="nltx:DeferredTaxAssetsBeforeValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzYtMS0xLTEtMA_9ea263a7-9148-41dc-927d-aae9fdb7269f">14,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="nltx:DeferredTaxAssetsBeforeValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzYtMy0xLTEtMA_37c5618b-5495-44c7-923b-be9c58778cc0">57,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzE2LTEtMS0xLTc0MzU_309c386c-a77c-4631-8e34-2615ed6ec35f">14,893</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzE2LTMtMS0xLTc0NDE_8bb12743-25cb-481f-8398-e57a4c633bab">57,815</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzE3LTEtMS0xLTc0MzU_0407869c-5a7d-44fa-9caf-16b27a7d3356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzE3LTMtMS0xLTc0NDE_be1b6c91-f5d9-4e10-bf43-50e5adc1669b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2020, the Company sold all issued and outstanding capital stock of its Canadian subsidiary, Aquinox Canada, to an unrelated third party for cash consideration. As of the date of sale, Aquinox Canada&#8217;s remaining assets included intellectual property and other assets developed through past research and development activities, all of which had no book value. The transaction resulted in a net gain on sale of $<ix:nonFraction unitRef="usd" contextRef="i74a1d2bd4a394b7b96915526dbf4b948_D20200731-20200731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainOrLossOnSaleOfStockInSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzE2NDkyNjc0NTY1Njk_45c558f9-55d4-4da6-a9fd-a423d135009a">7.8</ix:nonFraction>&#160;million. The sale of Aquinox Canada triggered a significant capital loss carryforward for tax purposes. However, most of the capital loss carryforward is limited by the prior ownership change under Section 382.  The remaining unlimited portion of the capital loss carryforward will be subject to a full valuation allowance as the Company has determined that it is more likely than not that the benefit of the loss will not be realized. After the sale, Aquinox Canada's tax attributes of $<ix:nonFraction unitRef="usd" contextRef="i99c20b1ea8274dc9b108a3b0bd76f6b1_I20200731" decimals="-5" format="ixt:numdotdecimal" name="nltx:DeferredTaxAssetsTaxCreditCarryforwardsReducedDueToSaleOfForeignEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzE2NDkyNjc0NTY1ODM_d41a19fe-7153-45cf-85d8-a3767a172428">51.7</ix:nonFraction>&#160;million including the net operating losses, scientific research and experimental development expenditures and investment tax credits are no longer reflected in the deferred tax assets and valuation allowance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and December&#160;31, 2019, the Company had U.S. federal net operating losses ("NOL") carryforwards for tax purposes of approximately $<ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzE0ODA_e28da804-5337-47af-9570-452e6791d8d9">58.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzE1MDE_d34195cb-39f1-46d2-8b4a-995c5afa6571">25.5</ix:nonFraction> million, respectively, which were available to reduce taxable income. Of the $<ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzIxOTkwMjMyNjIyMjg_e28da804-5337-47af-9570-452e6791d8d9">58.1</ix:nonFraction> million of federal NOL carryforwards, $<ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-5" format="ixt:numdotdecimal" name="nltx:OperatingLossCarryforwardsSubjectToExpiration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzE2MzU_50fcee55-d2db-4dd7-b5b2-128a6c75d741">1.7</ix:nonFraction> million will expire between the years 2028 and 2037 and the remaining $<ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-5" format="ixt:numdotdecimal" name="nltx:OperatingLossCarryforwardsNotSubjectToExpiration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzE2OTY_a1e9224f-13b3-4251-8306-dd69c349f0c3">56.4</ix:nonFraction> million are indefinite. The Company also has U.S. federal research &amp; development tax credits of $<ix:nonFraction unitRef="usd" contextRef="i342b1069b9d04ed099561a06485fbac8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzIxOTkwMjMyNjM1MTY_2e5eb869-1b81-4a9c-8e91-b72cfc28926d">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i263816d2f8ea45e08a1dadaf18225ac9_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzIxOTkwMjMyNjM1MzU_1f8ace37-225e-49e3-90f1-afe90a2fc602">0.2</ix:nonFraction> million as of December&#160;31, 2020 and December&#160;31, 2019, respectively, that begin to expire in 2039. The Company completed a formal study under IRC Section 382 through 2019  to determine the U.S. tax attributes available for use.  The U.S. attributes disclosed reflect the conclusion of that study. However, subsequent ownership changes may further affect the limitation in future years. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company maintains a full valuation allowance on its net U.S. deferred tax assets. The assessment regarding whether a valuation allowance is required considers both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. In making this assessment, significant weight is given to evidence that can be objectively verified. In its evaluation, the Company considered its cumulative losses and its forecasted losses in the near-term as significant negative evidence. Therefore, the Company determined that the negative evidence outweighed the positive evidence and a full valuation allowance on its assets will be maintained. The Company will continue to assess the realizability of its assets going forward and will adjust the valuation allowance as needed. The valuation allowance decreased by $<ix:nonFraction unitRef="usd" contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzgyNDYzMzcyMjQ0MDA_916cdf4a-8d39-40d8-8084-6f1bfd828bd9">42.9</ix:nonFraction>&#160;million for the year ended December&#160;31, 2020. The decrease is primarily due to the sale of Aquinox Canada and the write-off of the related tax attributes, and partially offset by an increase in US net operating losses and research and development tax credits. The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzgyNDYzMzcyMjQ0MzA_17033ce6-d7e0-40a4-badd-29981ae49c14">0.6</ix:nonFraction>&#160;million for the year ended December&#160;31, 2019. The increase is primarily related to an increase in deferred tax assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies judgment in the determination of the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. As of December&#160;31, 2020, the Company had no uncertain tax positions.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1802241056e047fea2f79535f6ad433d">The Company currently files income tax returns in the United States, the jurisdictions in which the Company believes that it is subject to tax. Further, while the statute of limitations in each jurisdiction where an income tax return has been filed generally limits the examination period, as a result of loss carryforwards, the limitation period for examination generally does not expire until several years after the loss carryforwards are utilized. Other than routine audits by tax authorities for tax credits and tax refunds that the Company has claimed, the Company is not aware of any other material income tax examination currently in progress by any taxing jurisdiction.</ix:continuation></span></div><div style="margin-top:6pt"><span><br/></span></div><div id="ib53014c4f13844039ebc5a68643f31a2_163"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="nltx:LicenseAgreementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNjMvZnJhZzoyNjE1OTZjMTQ4MWY0YjAzOGVhNWU3YjNmMmIxM2FjYi90ZXh0cmVnaW9uOjI2MTU5NmMxNDgxZjRiMDM4ZWE1ZTdiM2YyYjEzYWNiXzYxMDE_942ab977-ddae-440c-a2f1-0751d6f0d996" continuedAt="i7eba42d946074f51a532638daa3ec163" escape="true">License and patent agreements</ix:nonNumeric></span></div><ix:continuation id="i7eba42d946074f51a532638daa3ec163"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an exclusive license agreement with the University of Washington, or UW, under which UW (on behalf of itself and Stanford University) granted the Company an exclusive worldwide license under certain patent rights, to make, have made, use, offer to sell, sell, offer to lease or lease, import, export or otherwise offer to dispose of licensed products in all fields of use, and a nonexclusive worldwide license to use certain know-how. The foregoing licenses are sublicensable by the Company without UW&#8217;s consent, subject to certain limited conditions. The Exclusive License Agreement was amended effective as of July 24, 2020 to, among other things, (i) add a jointly owned de novo cytokine antagonist to the agreement, (ii) specify royalties, milestone payments and sublicense consideration payments payable by Neoleukin for certain jointly licensed products, (iii) specify the term for achievement of performance milestones for certainly jointly licensed products, and (iv) terminate UW&#8217;s right to participate in equity financings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the licensed rights, the Company issued <ix:nonFraction unitRef="shares" contextRef="i40d4ac81f67244daa74169c591a76a81_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNjMvZnJhZzoyNjE1OTZjMTQ4MWY0YjAzOGVhNWU3YjNmMmIxM2FjYi90ZXh0cmVnaW9uOjI2MTU5NmMxNDgxZjRiMDM4ZWE1ZTdiM2YyYjEzYWNiXzY3Nw_734267a5-3b6a-49f8-b1d9-6166ba971529">536,813</ix:nonFraction> shares of common stock to UW. These shares were exchanged for <ix:nonFraction unitRef="shares" contextRef="i0e261bc82ccb41c588ae441128cc8612_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNjMvZnJhZzoyNjE1OTZjMTQ4MWY0YjAzOGVhNWU3YjNmMmIxM2FjYi90ZXh0cmVnaW9uOjI2MTU5NmMxNDgxZjRiMDM4ZWE1ZTdiM2YyYjEzYWNiXzc0Mg_aa2170e8-16c3-4ef1-a080-8764de51a2f0">188,974</ix:nonFraction> shares of common stock of the Company and <ix:nonFraction unitRef="shares" contextRef="i6db8900a02d94ac0b3d9b45c02322b98_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNjMvZnJhZzoyNjE1OTZjMTQ4MWY0YjAzOGVhNWU3YjNmMmIxM2FjYi90ZXh0cmVnaW9uOjI2MTU5NmMxNDgxZjRiMDM4ZWE1ZTdiM2YyYjEzYWNiXzc4Nw_6b136ac4-b471-409e-99c5-79d0b3f98f23">4,197</ix:nonFraction> shares of non-voting convertible preferred stock on the completion of the Merger. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the Company is required to pay; (i)&#160;an annual maintenance fee starting in January 2022 (but excluding any year in which minimum annual royalties are paid); (ii) up to $<ix:nonFraction unitRef="usd" contextRef="i2d0273c0483c4e869c87c35dd362ea8b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="nltx:LicenseArrangementsAmountsPayableOnDevelopmentalMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNjMvZnJhZzoyNjE1OTZjMTQ4MWY0YjAzOGVhNWU3YjNmMmIxM2FjYi90ZXh0cmVnaW9uOjI2MTU5NmMxNDgxZjRiMDM4ZWE1ZTdiM2YyYjEzYWNiXzEyMzI_6bf4a9d3-e2fc-4349-8c7a-86814e34b0fb">0.9</ix:nonFraction> million in combined development and regulatory milestone payments with respect to each distinct class of licensed product; (iii)&#160;up to $<ix:nonFraction unitRef="usd" contextRef="i2d0273c0483c4e869c87c35dd362ea8b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="nltx:LicenseArrangementsAmountsPayableBasedOnNetSales" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNjMvZnJhZzoyNjE1OTZjMTQ4MWY0YjAzOGVhNWU3YjNmMmIxM2FjYi90ZXh0cmVnaW9uOjI2MTU5NmMxNDgxZjRiMDM4ZWE1ZTdiM2YyYjEzYWNiXzEzNjI_6de808eb-45eb-4025-a016-c07e5517813f">10.0</ix:nonFraction> million in combined commercial milestone payments based on cumulative net sales of licensed products within each distinct class of licensed products, beginning when cumulative net sales of the class of licensed products equals or exceeds $<ix:nonFraction unitRef="usd" contextRef="i4b9bb655d75545a397e6154c4fb4f637_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNjMvZnJhZzoyNjE1OTZjMTQ4MWY0YjAzOGVhNWU3YjNmMmIxM2FjYi90ZXh0cmVnaW9uOjI2MTU5NmMxNDgxZjRiMDM4ZWE1ZTdiM2YyYjEzYWNiXzE1OTU_4597734c-1d96-460b-9c3d-40b42b436e6a">100.0</ix:nonFraction> million, with the majority payable when cumulative net sales of the class of licensed products equals or exceeds $<ix:nonFraction unitRef="usd" contextRef="i73035a213d0243978324cca10be3c694_D20200101-20201231" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNjMvZnJhZzoyNjE1OTZjMTQ4MWY0YjAzOGVhNWU3YjNmMmIxM2FjYi90ZXh0cmVnaW9uOjI2MTU5NmMxNDgxZjRiMDM4ZWE1ZTdiM2YyYjEzYWNiXzE3MDM_8c2a6b0f-31d1-4ce6-ac8e-46f9e930fc7f">1.0</ix:nonFraction> billion; (iv)&#160;a low single-digit royalty on net sales of licensed products sold by the Company and its sublicensees, which may be subject to reductions, and subject to minimum annual royalty payments following the first commercial sale of a licensed product; (v)&#160;a certain percentage of any sublicense consideration (other than royalties) the Company receives from sublicensees, based on the stage of development at the time the sublicense is executed; and (vi)&#160;a certain percentage of consideration the Company receives from an acquisition of the Company or its assets based on the stage of development at the relevant time. The Company is obligated to pay royalties on a country-by-country basis until the expiration of the last valid claim within the licensed patent rights in such country.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the expiration of the last valid claim within the licensed patent rights. The Company may terminate the agreement upon prior written notice to UW. UW may terminate the agreement by a specified number of days&#8217; notice if the Company permanently ceases operations, becomes insolvent or similar, or if the Company challenges the validity of the licensed patent rights. In addition, UW may terminate the agreement for material breach that is not cured within a specified number of days, which cure period is to be at least doubled if the Company is proceeding diligently to cure the default.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="ib53014c4f13844039ebc5a68643f31a2_169"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNjkvZnJhZzo0ZDNiYjQ5OGVlMTQ0MDI1YmIwMDAyOTljOWFmMGQ2MC90ZXh0cmVnaW9uOjRkM2JiNDk4ZWUxNDQwMjViYjAwMDI5OWM5YWYwZDYwXzYxNA_30402614-a126-4b92-81b1-39430f911612" continuedAt="i0d131ee9e1624937ac4a28fc7bdeed7f" escape="true">Commitments and contingencies</ix:nonNumeric></span></div><ix:continuation id="i0d131ee9e1624937ac4a28fc7bdeed7f"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company entered into a non-cancelable contract to purchase laboratory equipment for  $<ix:nonFraction unitRef="usd" contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNjkvZnJhZzo0ZDNiYjQ5OGVlMTQ0MDI1YmIwMDAyOTljOWFmMGQ2MC90ZXh0cmVnaW9uOjRkM2JiNDk4ZWUxNDQwMjViYjAwMDI5OWM5YWYwZDYwXzEzNQ_b116c23a-bca4-47c1-930c-1c2d278b1c98">0.8</ix:nonFraction> million. The equipment is expected to be delivered in the first half of 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may be subject from time to time to various proceedings, lawsuits, disputes, or claims. Although the Company cannot predict with assurance the outcome of any litigation, it does not believe there are currently any such actions that, if resolved unfavorable, would have a material impact on the Company&#8217;s financial condition, results of operations or cash flows.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="ib53014c4f13844039ebc5a68643f31a2_1797"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="us-gaap:DefinedContributionPlanTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNzk3L2ZyYWc6MzlkYWEwYTQzNDFkNDVjNmJiNzIzY2U4YTNmNTZlMzkvdGV4dHJlZ2lvbjozOWRhYTBhNDM0MWQ0NWM2YmI3MjNjZThhM2Y1NmUzOV8xNjQ5MjY3NDQzNDA5_a640bc8e-b41c-4b98-b222-8a8f8028cfc9" continuedAt="i563a4c0809084e6e8048506caf9ace19" escape="true">401(k) plan</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i563a4c0809084e6e8048506caf9ace19">In May 2020, the Company established a 401(k) plan that allows full-time employees to contribute a portion of their salary, subject to statutory limits.  The Company makes matching cash contributions up to a pre-defined annual maximum contribution per employee per year. During the year ended December 31, 2020, the Company&#8217;s total expense for the matching contributions was immaterial.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:6pt"><span><br/></span></div><div id="ib53014c4f13844039ebc5a68643f31a2_1779"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231" name="nltx:SubsidiarySaleOfStockTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNzc5L2ZyYWc6ZTRkMThmMmZmZDMxNGU1NTllODVkNzBiNjFhNTM1MWMvdGV4dHJlZ2lvbjplNGQxOGYyZmZkMzE0ZTU1OWU4NWQ3MGI2MWE1MzUxY18xNjQ5MjY3NDQ0MjYy_f140ad40-07e2-41c4-9941-ee96a8d91096" continuedAt="i2512bae87ef941bfa6bc63a461cdb694" escape="true">Sale of Aquinox Canada</ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="i2512bae87ef941bfa6bc63a461cdb694"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2020, the Company sold all issued and outstanding capital stock of its Canadian subsidiary, Aquinox Canada, to an unrelated third party for cash consideration of $<ix:nonFraction unitRef="usd" contextRef="i74a1d2bd4a394b7b96915526dbf4b948_D20200731-20200731" decimals="-5" format="ixt:numdotdecimal" name="nltx:ProceedsFromSaleOfStockOfSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNzc5L2ZyYWc6ZTRkMThmMmZmZDMxNGU1NTllODVkNzBiNjFhNTM1MWMvdGV4dHJlZ2lvbjplNGQxOGYyZmZkMzE0ZTU1OWU4NWQ3MGI2MWE1MzUxY184MjQ2MzM3MjEwMjEy_9552a668-99fe-43e4-961d-0ebdb852119b">8.2</ix:nonFraction>&#160;million. The Company concluded that the sale did not meet the criteria for discontinued operations reporting as it did not represent a strategic shift that had a major effect on the Company&#8217;s operations and financial results. As of the date of sale, Aquinox Canada&#8217;s remaining assets included intellectual property and other assets developed through past research and development activities, all of which had no book value. The transaction resulted in a net gain on sale of $<ix:nonFraction unitRef="usd" contextRef="i74a1d2bd4a394b7b96915526dbf4b948_D20200731-20200731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainOrLossOnSaleOfStockInSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNzc5L2ZyYWc6ZTRkMThmMmZmZDMxNGU1NTllODVkNzBiNjFhNTM1MWMvdGV4dHJlZ2lvbjplNGQxOGYyZmZkMzE0ZTU1OWU4NWQ3MGI2MWE1MzUxY184MjQ2MzM3MjEwODgw_46b70793-3d67-4763-9244-bfcddcb8af95">7.8</ix:nonFraction>&#160;million, after deducting $<ix:nonFraction unitRef="usd" contextRef="i74a1d2bd4a394b7b96915526dbf4b948_D20200731-20200731" decimals="-5" format="ixt:numdotdecimal" name="nltx:TransactionRelatedCostIncurredForSaleOfSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNzc5L2ZyYWc6ZTRkMThmMmZmZDMxNGU1NTllODVkNzBiNjFhNTM1MWMvdGV4dHJlZ2lvbjplNGQxOGYyZmZkMzE0ZTU1OWU4NWQ3MGI2MWE1MzUxY184MjQ2MzM3MjEwODk0_0aa2818d-27e3-4dc5-8181-51437a12c661">0.4</ix:nonFraction>&#160;million in transaction costs, which is recorded as a reduction of operating loss in the Company&#8217;s consolidated statement of operations. The sale of Aquinox Canada triggered a significant capital loss carryforward for tax purposes. However, the deferred tax asset related to the capital loss carryforward will be subject to a full valuation allowance as the Company has determined that it is more likely than not that the benefit of the loss will not be realized. Refer to Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information.</span></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="ib53014c4f13844039ebc5a68643f31a2_172"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ib53014c4f13844039ebc5a68643f31a2_175"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A. Controls and Procedures.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of disclosure controls and procedures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our Chief Executive Officer (our principal executive officer) and our Chief Financial Officer (our principal accounting officer) have evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) prior to the filing of this annual report. Based on that evaluation, they have concluded that, as of the end of the period covered by this annual report, our disclosure controls and procedures were, in design and operation, effective at a reasonable assurance level.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended. Our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the 2013 framework in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#8212;Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on its evaluation under the framework in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#8212;Integrated Framework,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> our management concluded that our internal control over financial reporting was effective as of December&#160;31, 2020.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in internal control over financial reporting.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160; There have not been any changes in our internal control over financial reporting during the quarter ended December&#160;31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inherent limitation on the effectiveness of internal control.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of any system of internal control over financial reporting, including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, any system of internal control over financial reporting, including ours, no matter how well designed and operated, can only provide reasonable, not absolute assurances. In addition, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. We intend to continue to monitor and upgrade our internal controls as necessary or appropriate for our business, but cannot assure you that such improvements will be sufficient to provide us with effective internal control over financial reporting</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report does not include an attestation report of the Company&#8217;s independent registered public accounting firm regarding internal control over financial reporting. Management&#8217;s report was not subject to attestation by the Company&#8217;s independent registered public accounting firm pursuant to rules of the Securities and Exchange Commission that permit the Company to provide only management&#8217;s report in this Annual Report.</span></div><div id="ib53014c4f13844039ebc5a68643f31a2_178"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9B. Other Information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="ib53014c4f13844039ebc5a68643f31a2_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Part III is omitted from this report because we will file a definitive proxy statement within 120 days after the end of our 2020 fiscal year pursuant to Regulation 14A for our 2021 Annual Meeting of Stockholders, or the 2021 Proxy Statement, and the information to be included in the 2021 Proxy Statement is incorporated herein by reference.</span></div><div id="ib53014c4f13844039ebc5a68643f31a2_184"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;10. Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The information required by this Item concerning our executive officers and our directors and nominees for director, including information with respect to our audit committee and audit committee financial expert, may be found under the section entitled &#8220;Proposal No.&#160;1 Election of Directors,&#8221; &#8220;Information Regarding the Board of Directors and Corporate Governance,&#8221; and &#8220;Information About Our Executive Officers&#8221; appearing in the 2021 Proxy Statement. Such information is incorporated herein by reference.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information required by this Item concerning our code of ethics may be found under the section entitled &#8220;Information Regarding the Board of Directors and Corporate Governance&#8221; appearing in the 2021 Proxy Statement. Such information is incorporated herein by reference.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) The information required by this Item concerning compliance with Section&#160;16(a) of the Securities Exchange Act of 1934 may be found in the section entitled &#8220;Delinquent Section&#160;16(a) Reports&#8221; appearing in the 2021 Proxy Statement. Such information is incorporated herein by reference.</span></div><div id="ib53014c4f13844039ebc5a68643f31a2_187"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;11. Executive Compensation.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item may be found under the sections entitled &#8220;Director Compensation,&#8221; &#8220;Executive Compensation&#8221; and &#8220;Equity Compensation Plan Information&#8221; appearing in the 2021 Proxy Statement. Such information is incorporated herein by reference.</span></div><div id="ib53014c4f13844039ebc5a68643f31a2_190"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The information required by this Item with respect to security ownership of certain beneficial owners and management may be found under the section entitled &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; appearing in the 2021 Proxy Statement. Such information is incorporated herein by reference.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information required by this Item with respect to securities authorized for issuance under our equity compensation plans may be found under the sections entitled &#8220;Equity Compensation Plan Information&#8221; appearing in the 2021 Proxy Statement. Such information is incorporated herein by reference.</span></div><div id="ib53014c4f13844039ebc5a68643f31a2_193"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The information required by this Item concerning related party transactions may be found under the section entitled &#8220;Transactions with Related Persons&#8221; appearing in the 2021 Proxy Statement. Such information is incorporated herein by reference.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information required by this Item concerning director independence may be found under the sections entitled &#8220;Information Regarding the Board of Directors and Corporate Governance&#8212;Independence of the Board of Directors&#8221; and &#8220;Information Regarding the Board of Directors and Corporate Governance&#8212;Information Regarding Committees of the Board of Directors&#8221; appearing in the 2021 Proxy Statement. Such information is incorporated herein by reference.</span></div><div id="ib53014c4f13844039ebc5a68643f31a2_196"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;14. Principal Accounting Fees and Services.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item may be found under the section entitled &#8220;Proposal No.&#160;2 Ratification of Appointment of Independent Registered Public Accounting Firm&#8221; appearing in the 2021 Proxy Statement. Such information is incorporated herein by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">Table of Contents</a></span></div><div><span><br/></span></div></div></div><div id="ib53014c4f13844039ebc5a68643f31a2_199"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="ib53014c4f13844039ebc5a68643f31a2_202"></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15. Exhibits, Financial Statement Schedules.</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.84pt">The following documents are filed as part of this report:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">Financial Statements and Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">Financial Statement Schedules</span></div><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Statement Schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">Exhibits are incorporated herein by reference or are filed with this report as indicated below (numbered in accordance with Item 601 of Regulation S-K).</span></div><div style="margin-top:18pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.28pt">Exhibits</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits listed below on the Exhibit Index are filed herewith or are incorporated by reference to exhibits previously filed with the SEC.</span></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312519213526/d771862dex21.htm">Agreement and Plan of Merger by and between Aquinox Pharmaceuticals, Inc., Apollo Sub, Inc., and Neoleukin Therapeutics, Inc., dated August&#160;5, 2019&#8212;Incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on August&#160;6, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312514095845/d688616dex31.htm">Amended and Restated Certificate of Incorporation of Neoleukin Therapeutics, Inc.&#8212;Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on March&#160;12, 2014</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312514074419/d619679dex36.htm">Amended and Restated Bylaws of Neoleukin Therapeutics, Inc.&#8212;Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K, filed with the Securities and Exchange Commission on April 13, 2020</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312519218513/d674165dex31.htm">Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Stock, filed August&#160; 8, 2019&#8212;Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission August&#160;12, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312519290610/d821827dex34.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation of Neoleukin Therapeutics, Inc., filed August&#160; 9, 2019&#8212;Incorporated by reference to Exhibit 3.4 to our Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2019 filed with the Securities and Exchange Commission on November&#160; 13, 2019.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312519290610/d821827dex35.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation of Neoleukin Therapeutics, Inc., filed November&#160; 13, 2019&#8212;Incorporated by reference to Exhibit 3.5 to our Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2019 filed with the Securities and Exchange Commission on November&#160; 13, 2019.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312514195836/d704250dex41.htm">Specimen Common Stock Certificate of the Registrant&#8212;Incorporated by reference to Exhibit 4.1 to our Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2014 filed with the Securities and Exchange Commission on May&#160;13, 2014</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">T</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">able of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7"> C</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">onten</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">ts</a></span></div><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312516714936/d259461dex101.htm">Registration Rights Agreement, dated September&#160; 19, 2016, by and between Aquinox Pharmaceuticals, Inc. and the persons listed on Schedule A attached thereto&#8212;Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on September&#160;20, 2016</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312520071545/d882730dex43.htm">Description of Securities Registered Under Section&#160;12 of the Securities Exchange Act of 1934, as amended</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312519317938/d651170dex41.htm">Form of Pre-Funded Warrant&#8212;Incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on December&#160;19, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312520186835/d920444dex41.htm">Form of Pre-Funded Warrant&#8212; Incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on July 2, 2020.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312519218513/d674165dex101.htm">Exclusive&#160;Start-Up&#160;License Agreement, dated July&#160; 8, 2019, by and between the University of Washington and Neoleukin Therapeutics, Inc.&#8212;Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission August&#160;12, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312519218513/d674165dex102.htm">Facility Use Agreement, dated December&#160; 4, 2018, by and between Institute for Systems Biology and Neoleukin Therapeutics, Inc.&#8212;Incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed with the Securities and Exchange Commission August&#160;12, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312519218513/d674165dex103.htm">Amendment No.&#160;1 to the Facility Use Agreement, dated April&#160; 17, 2019, by and between Institute for Systems Biology and Neoleukin Therapeutics, Inc.&#8212;Incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K filed with the Securities and Exchange Commission August&#160;12, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.4+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312519213526/d771862dex101.htm">Separation Agreement and Release, dated August&#160; 5, 2019, by and between Aquinox Pharmaceuticals, Inc., and David J. Main&#8212;Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on August&#160;6, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.5+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312519213526/d771862dex103.htm">Transition Retention Agreement, dated August&#160; 5, 2019, by and between Aquinox Pharmaceuticals, Inc., and Kamran Alam&#8212;Incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on August&#160;6, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312519290610/d821827dex107.htm">Lease Agreement, dated September&#160; 23, 2019, by and between Neoleukin Therapeutics, Inc. and ARE-Eastlake&#160;Avenue No.&#160;3,&#160; LLC. Incorporated by reference to Exhibit 10.7 to our Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2019 filed with the Securities and Exchange Commission on November&#160;13, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312520071545/d882730dex108.htm">Lease Agreement, dated December&#160;23, 2019, by and between Neoleukin Therapeutics, Inc. and ARE-Eastlake&#160;Avenue No.&#160;3,&#160;LLC</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.8+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312514024524/d619679dex101.htm">Joint Canadian Stock Option Plan&#8212;Incorporated by reference to Exhibit 10.1 to our Registration Statement on Form S-1 (File No.&#160;333-193615) filed with the Securities and Exchange Commission on January&#160;28, 2014</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.9+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312514024524/d619679dex102.htm">Forms of Option Agreement for Registrant&#8217;s Joint Canadian Stock Option Plan&#8212;Incorporated by reference to Exhibit 10.2 to our Registration Statement on Form S-1 (File No.&#160;333-193615) filed with the Securities and Exchange Commission on January&#160;28, 2014</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.10+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312519292399/d841489dex101.htm">Neoleukin Therapeutics, Inc. 2014 Equity Incentive Plan, as amended November&#160; 12, 2019&#8212;Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on November&#160;14, 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.11+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312514024524/d619679dex104.htm">Forms of Option Agreement and Option Grant Notice for Registrant&#8217;s 2014 Equity Incentive Plan&#8212;Incorporated by reference to Exhibit&#160;10.4 to our Registration Statement on Form S-1 (File No.&#160;333-193615) filed with the Securities and Exchange Commission on January&#160;28, 2014</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.12+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000156459020021546/nltx-ex101_6.htm">Neoleukin Therapeutics, Inc. 2020 Employee Stock Purchase Plan&#8212;Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on May 6, 2020. </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.13</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312514024524/d619679dex105.htm">Form of Indemnity Agreement entered into between the Registrant and each of its directors and its executive officers&#8212;Incorporated by reference to Exhibit&#160;10.5 to our Registration Statement on Form S-1 (File No.&#160;333-193615) filed with the Securities and Exchange Commission on January&#160;28, 2014</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.14*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312519317938/d651170dex101.htm">Exchange Agreement, dated December&#160; 17, 2019, by and among Neoleukin Therapeutics, Inc., 667, L.P. and Baker Brothers Life Sciences, L.P.&#8212;Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on December&#160;19, 2019</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">T</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">able of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7"> C</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">onten</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">ts</a></span></div><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312516457597/d131054dex101.htm">Lease Agreement, dated February&#160; 5, 2016, by and between Aquinox Pharmaceuticals (Canada) Inc. and 560677 B.C. Ltd. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on February&#160;10, 2016</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000156459020021920/nltx-ex101_86.htm">Executive Employment Agreement, dated March 16, 2020, Neoleukin Therapeutics, Inc. and Robert Ho&#8212;Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 filed with the Securities and Exchange Commission on May 6, 2020.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312520109503/d857228dex101.htm">Amended and Restated Executive Employment Agreement, dated April 15, 2020, by and between Neoleukin Therapeutics, Inc., and Jonathan G. Drachman&#8212;Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on April 17, 2020</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000119312520186835/d920444dex11.htm">Underwriting Agreement, dated July 1, 2020, by and among Neoleukin Therapeutics, Inc., and BofA Securities, Inc. and Piper Sandler &amp; Co. as Representatives of the several Underwriters named in Schedule A thereto&#8212; Incorporated by reference to Exhibit 1.1 to our Current Report on Form 8-K filed with the Securities and Exchange Commission on July 2, 2020.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000156459020039671/nltx-ex101_130.htm">First Amendment to Lease, dated June 18, 2020, by and between Neoleukin Therapeutics, Inc. and ARE-Eastlake Avenue No. 3, LLC&#8212;Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 filed with the Securities and Exchange Commission on August 12, 2020.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1404644/000156459020039671/nltx-ex102_301.htm">Form of Restricted Stock Unit Grant Notice for Registrant&#8217;s 2014 Equity Incentive Plan&#8212; Incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 filed with the Securities and Exchange Commission on August 12, 2020</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1021-uwagreementamendment.htm">Amendment No. 1 to Exclusive Start-Up License Agreemen</a></span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1021-uwagreementamendment.htm">t, </a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1021-uwagreementamendment.htm">dated July 24, 2020</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1021-uwagreementamendment.htm">, by a</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1021-uwagreementamendment.htm">nd between the University of Washington and Neoleukin Therapeutics, Inc.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1022-hollyvanceemploymen.htm">Executive Employment Agreement, dated September 29, 2020, by and between Neoleukin Therapeutics, Inc., and Holly Vance</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1023rigakupoupdated1.htm">Purchase Order, dated November 25, 2020, by and between Neoleukin Therapeutics, Inc. and Rigaku Americas Corporation</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1024neoleukinleaseamendm.htm">First Amendment to Lease, dated November 5, 2020, by and between Neoleukin Therapeutics, Inc. and ARE-Seattle No. 28, LLC</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex211-listofsubsidiaries.htm">List of subsidiaries of the Registrant</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex231-consentofindependent.htm">Consent of Deloitte &amp; Touche LLP, Independent Registered Public Accounting Firm.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex232-consentofindependent.htm">Consent of Deloitte LLP, Independent Registered Public Accounting Firm.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nltx-20201231xex311.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nltx-20201231xex312.htm">Certification of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="nltx-20201231xex312.htm">Chief Financial Officer pursuant to Rule 13a-14(a).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="nltx-20201231xex321.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section&#160;1350.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.2#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="nltx-20201231xex322.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section&#160;1350.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Instance Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Labels Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Indicates a management contract or compensatory plan.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;This certification is deemed not filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (Exchange Act), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.</span></div><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="ib53014c4f13844039ebc5a68643f31a2_205"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">T</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">able of</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7"> C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">onten</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib53014c4f13844039ebc5a68643f31a2_7">ts</a></span></div><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;16. Form 10-K Summary.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N/A</span></div><div id="ib53014c4f13844039ebc5a68643f31a2_208"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:61.216%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neoleukin Therapeutics, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: March 25, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Jonathan G. Drachman</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jonathan G. Drachman</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">President&#160;&amp;&#160;Chief&#160;Executive&#160;Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:32.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.726%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.591%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Jonathan G. Drachman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director, President&#160;&amp; Chief Executive Officer<br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 25, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jonathan G. Drachman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Robert Ho</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer<br/>(Principal Financial and Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 25, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Robert Ho</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Martin Babler</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 25, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Martin Babler</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ M. Cantey Boyd</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 25, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">M. Cantey Boyd</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Erin Lavelle</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 25, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Erin Lavelle</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Sarah Noonberg</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 25, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sarah Noonberg</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Todd Simpson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 25, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Todd Simpson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Lewis T. Williams</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 25, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lewis T. Williams</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>2
<FILENAME>ex1021-uwagreementamendment.htm
<DESCRIPTION>EX-10.21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id846ac24ce36461d9c33315f95535c60_1"></div><div style="min-height:72pt;width:100%"><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.21</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">AMENDMENT NO. 1</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">TO EXCLUSIVE START-UP LICENSE AGREEMENT</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Amendment No. 1 to the Exclusive Start-Up License Agreement (this &#8220;Amendment No. 1&#8221;) effective as of July 24, 2020 (the &#8220;Amendment No. 1 Effective Date&#8221;), is entered into between the University of Washington (&#8220;University&#8221;), and Neoleukin Corporation, formerly known as Neoleukin Therapeutics, Inc. (&#8220;Company&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Parties previously entered into that certain Exclusive Start-Up License Agreement dated as of July 8, 2019 (the &#8220;Agreement&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Parties wish to amend the Agreement in certain respects on the terms and conditions set forth herein.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW THEREFORE, capitalized terms not defined in this Amendment No. 1 shall have the meaning ascribed in the Agreement, and the Parties hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Background</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  &#91;***&#93;.  The Parties desire to add the Jointly Owned Licensed Patents (as defined herein below) within the scope of the licenses granted to Company under the Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Section 1 of the Agreement is hereby amended to add the following new definitions&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Jointly Owned Application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set forth in Amendment No. 1 to this Agreement.</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Jointly Owned Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means (a) the Jointly Owned Application, (b) all patent cooperation treaty (PCT) applications, non-provisional applications, divisions, continuations, and claims in continuationsinpart that are entitled to claim priority to, or that share a common priority claim with, and are directed to subject matter specifically described in the Jointly Owned Application&#59; (c)&#160;any patents that issue from patent applications in clauses (a) and (b), (d)&#160;extensions, renewals, substitutes, re-examinations and re-issues of any of the items in (a) or (b) or (c)&#59; and (e)foreign counterparts of any of the items in (a), (b), (c) or (d) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">wherever and whenever filed.  For the avoidance of doubt, Jointly Owned Licensed Patents is&#47;are a Licensed Patents for all purposes in the Agreement, except where Jointly Owned Licensed Patents are specifically called out in the Agreement.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Jointly Owned Licensed Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any method, process, composition, product, service, or component part thereof that (a) would, but for the granting of the rights set forth in this Agreement, infringe a Valid Claim contained in the Jointly Owned Licensed Patents. For the avoidance of doubt, Jointly Owned Licensed Product is a Licensed Product for all purposes in the Agreement, except where Jointly Owned Licensed Product is specifically called out in the Agreement.</font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Section 2.3 of the Agreement is hereby amended by adding the following new sentences to the end of Section 2.3.  &#8220;Notwithstanding the foregoing, if a Sublicense is only for the Jointly Owned Licensed Patents (and not any other Licensed Patents), then the foregoing requirement to include obligations, terms and conditions in favor of HHMI shall not apply. During the term of this Agreement and for so long as Company has an exclusive license to University&#8217;s rights in the Jointly Owned Licensed Patents pursuant to this Agreement, Company shall not license its own rights in Jointly Owned Licensed Patents separate from University&#8217;s rights in Jointly Owned Licensed Patents.&#8221;</font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Section 2.5 of the Agreement is hereby amended by adding the following new sentence to the end of Section&#160;2.5&#58;  &#8220;The foregoing rights of the federal government of the United States of America do not apply to the Jointly Owned Licensed Patents as no federal funding was used in the generation of the inventions claimed in the Jointly Owned Application.&#8221;</font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Section 2.6 of the Agreement is hereby amended and restated in its entirety as follows&#58;  </font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Rights to Subsidiaries of Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Company may extend rights granted to Company under this Agreement to any entities that control Company (which, as of the Amendment No. 1 Effective date includes Neoleukin Therapeutics, Inc.) or are under common control with Company including wholly owned subsidiaries (collectively </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Subsidiaries&#8221;) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of Company, provided that (a) Company is responsible for all acts of such Subsidiaries as if they were acts of Company, (b) such Subsidiary is bound to perform all obligations to University and HHMI of this Agreement, other than making payments pursuant to Article 6 &#8220;Payments, Reimbursements, Reports, and Records&#8221;, as if such Subsidiary were Company, and (c) Company reports to University pursuant to Section 13.10 &#8220;Notices&#8221; that such Subsidiary will be exercising rights under this Agreement prior to such Subsidiary exercising any such rights under this Agreement, provided that no notice is necessary if the Subsidiary is Neoleukin Therapeutics, Inc. For avoidance of doubt, Company may perform any obligation of Subsidiary on Subsidiary&#8217;s behalf. For </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">purposes of this Section 2.6 only, &#8220;control&#8221; of another person, organization or entity shall mean the ability, directly or indirectly, to direct the activities of the relevant entity, and shall include, without limitation (i) ownership or direct control of fifty percent (50%) or more of the outstanding voting stock or other ownership interest of the other organization or entity, or (ii) possession of, or the power to elect or appoint fifty percent (50%) or more of the members of the governing body of the organization or other entity.</font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Section 2.7 of the Agreement is hereby amended by adding the following new sentence to the end of Section&#160;2.7&#58;  &#8220;The Parties acknowledge that the Jointly Owned Licensed Patents were not developed (in whole or in part) by employees of HHMI and therefore the license granted to Company to the Jointly Owned Licensed Patents, by inclusion under section 2.1 of this Agreement, is not subject to the HHMI License.&#8221;</font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.01pt">Section 4.1 of the Agreement is hereby amended and restated in its entirety as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Pre-Agreement Patent Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  With respect to the Licensed Patents, other than the Jointly Owned Application, Company has reviewed such Licensed Patents and as of the Effective Date is not aware of any basis to challenge or dispute the inventorship, validity, or enforceability of any of the claims made in such Licensed Patents.  With respect to the Jointly Owned Application, each Party has reviewed the Jointly Owned Application and as of the Amendment No. 1 Effective Date is not aware of any basis to challenge or dispute the inventorship, validity, or enforceability of any of the claims made in the Jointly Owned Application.</font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Section 4 of the Agreement is hereby amended by adding the following new Section 4.4 immediately following the end of Section 4.3&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Patent Prosecution for Jointly Owned Application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The rights and obligations set forth in Sections 4.2 and 4.3 above shall apply to Licensed Patents other than the Jointly Owned Licensed Patents.  University and Company will consult on the preparation, filing and prosecution of the Jointly Owned Licensed Patents, provided that Company will have the first right to file, prosecute, and maintain, as applicable, at Company&#8217;s sole expense, the Jointly Owned Licensed Patents.  Company may thereafter abandon or allow to lapse any or all patents or patent applications resulting from the Jointly Owned Licensed Patents, provided that Company will notify University of any abandoned or lapsed patents at least &#91;***&#93; days prior to such abandonment or lapse and University will have the right, at University&#8217;s sole expense, to control the prosecution and maintenance of such patents. </font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Section 5.2 of the Agreement is hereby amended by adding the following new sentence to the end of Section 5.2.  &#8220;The Parties acknowledge that the performance category for the Jointly Owned Licensed Products that were added as Section A2.4 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">pursuant to Amendment No. 1 to this Agreement shall be treated as a separate performance category for the above referenced renegotiation and termination procedures&#59; provided that the payment for the Performance Milestone Extension with respect to such performance category shall be &#91;***&#93;.&#8221; </font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.67pt">Section 9.6 of the Agreement is hereby amended by adding the following new sentence to the end of Section 9.6.  &#8220;Notwithstanding the foregoing, but Subject to Section 9.8, upon termination of this Agreement, any Sublicense to the extent granting rights to the Jointly Owned Licensed Patents will not automatically terminate in total, as rights granted by Company to Company&#8217;s rights in the Jointly Owned Licensed Patents would remain, but rights granted by Company to University&#8217;s rights in the Jointly Owned License Patents would automatically terminate unless converted into a direct license with University pursuant to Section 9.8.&#8221;</font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">j.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.67pt">Section 9.8 of the Agreement is hereby amended by adding the following new sentence to the end of Section 9.8.  &#8220;With respect to the Jointly Owned Licensed Patents, the procedures and obligations set forth in this Section 9.8 shall only apply to the University&#8217;s ownership interest in the Jointly Owned Licensed Patents.&#8221;</font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">k.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Section 13.2 of the Agreement is hereby amended and restated in its entirety as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The rights and licenses granted by University in this Agreement are personal to Company and Company will not assign its interest or delegate its duties under this Agreement without the written consent of University, which consent will not to be unreasonably withheld or delayed&#59; any such assignment or delegation made without written consent of University will not release Company from its obligations under this Agreement. Notwithstanding the foregoing, Company, without the prior approval of University, may assign all, but no less than all, of its rights and delegate all, but no less than all, of its duties under this Agreement to a Third Party provided that&#58; (a)&#160;the assignment is made to such Third Party as a part of and in connection with an Acquisition, (b)&#160;Company obtains from such Third Party written agreement to honor all obligations under this Agreement accrued by Company before Acquisition and all obligations under this Agreement to accrue by such Third Party assignee after Acquisition, and (c)&#160;Company provides written notice to University of the Acquisition, together with a substitution of parties document or copy of the assignment confirming compliance with (b)&#160;above, no later than &#91;***&#93;&#160;days after the close of the Acquisition. Additionally, notwithstanding the foregoing, Company may assign all of its interest and delegate its duties under this Agreement, as amended by Amendment No. 1, to Neoleukin Therapeutics, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Parent Co.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), whether by written agreement or by operation of law, in connection with a merger of Company with and into Parent Co. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Merger</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). For the avoidance of doubt, following the consummation of the Merger, Parent Co. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">will enjoy the same rights and will remain subject to the same obligations that Company enjoyed and was subject to pursuant to the Agreement, as amended by Amendment No. 1. Any assignment made in violation of this Section&#160;13.2 &#8220;Assignment&#8221; is void and will constitute an act of breach that requires remedy under Section&#160;9.2 &#8220;Termination by University&#8221;. This Agreement will inure to the benefit of Company and University and their respective permitted assignees and trustees.</font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">l.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.67pt">Exhibit A1.1 is hereby amended to add the following patent application to the end of the list of Licensed Patents&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.236%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.497%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UW Ref No.</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Patent No.</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Filing Date</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Type</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Status</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">m.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:5.67pt">Exhibit A2 is hereby amended to add the following performance milestones for the Jointly Owned Licensed Products&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A2.4</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Milestones for Jointly Owned Licensed Products</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A2.4.1 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Performance Milestone 1</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A2.4.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Performance Milestone 2</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A2.4.3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Performance Milestone 3</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A2.4.4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Performance Milestone 4</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A2.4.5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Performance Milestone 5</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A2.4.6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Performance Milestone 6</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A2.4.7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Performance Milestone 7</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">n.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Exhibit A3.2 of the Agreement is hereby amended and restated in its entirety as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Running Royalty Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Company will pay to University within &#91;***&#93; days after the last day of each calendar quarter during the term of this Agreement an amount equal to (a) with respect to Licensed Products other than the Jointly Owned Licensed Product &#91;***&#93; of Net Sales of such Licensed Products during such quarter as a running royalty payment, and (b) with respect to the Jointly Owned Licensed Product &#91;***&#93; of Net Sales of the Jointly Owned Licensed Products during such quarter as a running royalty payment.  On a country-by-</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">country basis, and a Licensed Product-by-Licensed Product basis, if in a country there is no Valid Claim that covers the Licensed Product, then the foregoing royalty rate shall be reduced by &#91;***&#93; with respect to Net Sales of such Licensed Product in such country.</font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">o.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Exhibit A3.2 of the Agreement is hereby amended and restated in its entirety as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A3.2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Third Party Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If Company or its Sublicensees are required to pay royalties to a Third Party based on Company&#8217;s or such Sublicensee&#8217;s manufacture, use, offer for sale, sale or import of Licensed Product subject to one or more patents of such Third Party that create a total royalty burden for the Licensed Product of greater than (a) with respect to Licensed Products other than the Jointly Owned Licensed Product &#91;***&#93; (such figure including the above running royalty to University) or (b) with respect to the Jointly Owned Licensed Products &#91;***&#93; (such figure including the above running royalty to University), then in each case the royalty Company pays to University may be reduced by the lesser of (i) &#91;***&#93; of the royalty otherwise due to the University absent of a Third Party royalty reduction, (ii) &#91;***&#93; of the royalty actually paid to the Third Party, or (iii) the percent Company may reduce such Third Party royalty by based on a royalty stacking provision for the same product. To qualify for this reduction the Third Party patent must be required for the manufacture, use, offer for sale, sale or import of the Licensed Product.</font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">p.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Exhibit A3.4 of the Agreement is hereby amended by adding the following at the end of Exhibit A3.4&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The foregoing milestones shall not apply to the Jointly Owned Licensed Product, and Company will pay to University the following non-cumulative, non-creditable, and non-refundable milestone achievement payments within &#91;***&#93; days of achieving the corresponding milestone, whether achieved by Company or a Sublicensee, for the first Jointly Owned Licensed Product&#58;</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.555%"><tr><td style="width:1.0%"></td><td style="width:18.727%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.073%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#a6a6a6;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#a6a6a6;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Milestone</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Performance Milestone 4 in A.2.4.4</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Performance Milestone 5 in A.2.4.5</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Performance Milestone 6 in in A.2.4.6</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$&#91;***&#93;</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cumulative Net Sales of $&#91;***&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$&#91;***&#93;</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Cumulative Net Sales of $&#91;***&#93;</font></div></td></tr></table></div><div style="margin-bottom:12pt;padding-left:54pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">q.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Exhibit A3.5 of the Agreement is hereby amended by striking the last sentence of Section A3.5.1 and adding the following at the end of Exhibit A3.5&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A3.5.2  The Parties agree, that as of the Amendment No. 1 Effective Date, Company has met all of its obligations with respect to Section A3.5.1 and all obligations of Company and rights of University and&#47;or its Assignee as set forth in Section A3.5.1 are hereby terminated and shall have no further force or effect.</font></div><div style="margin-bottom:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">r.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.01pt">Exhibit A3.6 of the Agreement is hereby amended by adding the following at the end of Exhibit A3.6&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The foregoing sublicense consideration percentages shall not apply to a Sublicense solely for the Jointly Owned Licensed Patents (i.e., does not include rights granted to any other Licensed Patents), and the following sublicense consideration percentages will apply to a Sublicense solely for the Jointly Owned Licensed Patents (i.e., does not include rights granted to any other Licensed Patents)&#58;</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.881%"><tr><td style="width:1.0%"></td><td style="width:14.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.752%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#a6a6a6;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#a6a6a6;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Milestone Has Been Achieved at the Date of Execution of the Sublicense</font></td><td colspan="3" style="background-color:#a6a6a6;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sublicense Consideration Percentage</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.881%"><tr><td style="width:1.0%"></td><td style="width:14.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.752%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A3.6.8</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No Milestone achieved</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;%</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A3.6.9</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Performance Milestone 1 in A2.4.1</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;% </font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A3.6.10</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Production Methods of GLP material established for Jointly Owned Licensed Product</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;%</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A 3.6.11</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Performance Milestone 2 in A2.4.2</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;%</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A 3.6.12</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Performance Milestone 3 in A2.4.3</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;%</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A3.6.13</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Performance Milestone 4 in A2.4.4</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;%</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A3.6.14</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Performance Milestone 5 in A2.4.5</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;% </font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A3.6.15</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Performance Milestone 6 in A2.4.6 or initiation of a registrational Phase 2 study</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;%</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A3.6.16</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Performance Milestone 7 in A2.4.7</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;***&#93;%</font></div></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Amendment No. 1 shall be effective for all purposes as of the Amendment No. 1 Effective Date.  Except as expressly modified herein, the Agreement shall continue to remain in full force and effect in accordance with its terms.  This Amendment No. 1 may be executed in counterparts, each of which shall be deemed to be an original and together shall be deemed to be one and the same document.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Parties have caused this Amendment No. 1 to be executed by their respective duly authorized representatives effective as of the Amendment No. 1 Effective Date.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">University of Washington&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">  &#47;s&#47; Dennis Hanson</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">  Dennis Hanson</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">  Associate Director, Innovation Development&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Neoleukin Corporation&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">  &#47;s&#47; Jonathan Drachman</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">  Jonathan Drachman</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">  Chief Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>3
<FILENAME>ex1022-hollyvanceemploymen.htm
<DESCRIPTION>EX-10.22
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i935436218bc5444fbec503ce00679960_1"></div><div style="min-height:51pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3pt;padding-left:126.9pt;padding-right:126.9pt;text-align:center"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">  Exhibit 10.22</font></div><div style="padding-left:63.97pt;padding-right:63.97pt;text-align:center"><font><br></font></div><div style="padding-left:64.36pt;padding-right:64.36pt;text-align:center;text-indent:-0.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXECUTIVE EMPLOYMENT AGREEMENT</font></div><div><font><br></font></div><div style="margin-top:10.85pt;padding-left:5pt;padding-right:14.15pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Executive Employment Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), made between Neoleukin Therapeutics, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Holly Vance </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and, collectively with the Company, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), is entered into as of September 29, 2020, to be effective as of the Effective Date (as defined below).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company desires for Executive to provide services to the Company and wishes to provide Executive with certain compensation and benefits in return for such employment services&#59; and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Whereas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, Executive wishes to be employed by the Company and to provide personal services to the Company in return for certain compensation and benefits.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:9.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Now, Therefore</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in consideration of the mutual promises and covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree as follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:77.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;Employment by the Company.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:8.45pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.1&#160;&#160;&#160;&#160;Employment. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement shall govern the terms of Executive&#8217;s employment with the Company, effective as of the commencement of Executive&#8217;s employment with the Company, which shall occur on October 19, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:14.6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.2&#160;&#160;&#160;&#160;Position. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Executive shall serve as the Company&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">General Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. During the term of Executive&#8217;s employment with the Company, Executive will devote Executive&#8217;s best efforts and substantially all of Executive&#8217;s business time and attention to the business of the Company.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:34.1pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.3&#160;&#160;&#160;&#160;Duties and Location. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Executive shall perform such duties as are typically performed by a General Counsel. Executive will report to the Company&#8217;s Chief Executive Officer. Executive&#8217;s primary office location shall be the Company&#8217;s office located in Seattle, Washington.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:11.8pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.4&#160;&#160;&#160;&#160;Policies and Procedures. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The employment relationship between the Parties shall be governed by the general employment policies and practices of the Company, except that when the terms of this Agreement differ from or are in conflict with the Company&#8217;s general employment policies or practices, this Agreement shall control.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;Compensation.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:24.6pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.1&#160;&#160;&#160;&#160;Salary. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For services to be rendered hereunder, Executive shall receive a base salary at the rate of Three Hundred and Fifty Thousand U.S. Dollars ($350,000) per year (such base salary, as may be increased (but not decreased) from time to time, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Base Salary&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), subject to standard payroll deductions and withholdings and payable in accordance with the Company&#8217;s regular payroll schedule.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.15pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.2&#160;&#160;&#160;&#160;Bonus. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Executive will be eligible for an annual discretionary bonus of up to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">40% </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of Executive&#8217;s Base Salary (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Annual Bonus&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">). Whether Executive receives an Annual Bonus for </font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any given year, and the amount of any such Annual Bonus, will be determined by the Company&#8217;s Board of Directors (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Board&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) or the compensation committee thereof in its sole discretion based upon the Company&#8217;s and Executive&#8217;s achievement of objectives and milestones to be determined on an annual basis by the Board or the compensation committee thereof. Annual Bonuses are typically paid no later</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.65pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FW&#47;11604751.4</font></div><div style="margin-top:4.25pt;padding-left:5pt;padding-right:11.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">than March 15th of the year following the applicable bonus year. Executive will not be eligible for, and will not earn, any Annual Bonus (including a prorated bonus) if Executive&#8217;s employment terminates for any reason before any Annual Bonus is paid, except as otherwise expressly provided in Section 6.3 below.</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;Standard Company Benefits. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Executive shall be entitled to participate in all employee benefit programs for which Executive is eligible under the terms and conditions of the benefit plans that may be in effect from time to time and provided by the Company to its employees.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;Expenses. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company will reimburse Executive for reasonable travel, entertainment or other expenses incurred by Executive in furtherance or in connection with the performance of Executive&#8217;s duties hereunder, in accordance with the Company&#8217;s expense reimbursement policy as in effect from time to time.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.95pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">5.&#160;&#160;&#160;&#160;Equity. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">On the Effective Date, as an inducement to enter into this Agreement, the Company will grant Executive an option (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8221;) to purchase Two Hundred Twenty Thousand (220,000) shares of the Company&#8217;s common stock with a per-share exercise price equal to the fair market value of a share of the Company&#8217;s common stock on the date of grant, as determined by the Board or the compensation committee thereof. 1&#47;4th of the shares underlying the Stock Option will vest and become exercisable on the one-year anniversary of the grant date, and 1&#47;48th of the shares underlying the Stock Option will vest and become exercisable on a monthly basis thereafter, such that 100% of the shares underlying the Stock Option shall be vested and exercisable as of the four-year anniversary of the grant date, in each case so long as Executive remains employed by the Company through each applicable vesting date. The Stock Option will be subject to terms and conditions consistent with those provided in the Company&#8217;s 2014 Equity Incentive Plan, and will be governed in all respects by the terms of the stock option agreement to be entered into between Executive and the Company, except as specifically provided herein. Further details regarding the Stock Option will be provided to Executive upon approval of such grant by the Board.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:77.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;Termination of Employment&#59; Severance.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:9.05pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.1&#160;&#160;&#160;&#160;At-Will Employment. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Executive&#8217;s employment relationship is at-will. Either Executive or the Company may terminate the employment relationship at any time, with or without Cause or advance notice. In the event Executive&#8217;s employment relationship is terminated for any reason, Executive shall be entitled to receive Executive&#8217;s earned but unpaid Base Salary, unreimbursed business expenses properly incurred by Executive pursuant to Section 4 and any other compensation or benefit earned by or owed to (but not yet paid to) Executive through and including the date of termination, payable in a lump sum on the next regularly scheduled payroll date following the date on which Executive&#8217;s employment terminated, or at such other date as shall be specified under the terms of the employee benefit plan pursuant to which such compensation or benefit is payable.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:9.5pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.2&#160;&#160;&#160;&#160;Severance Benefits for Termination Without Cause or Resignation with Good Reason Unrelated to a Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event Executive&#8217;s employment with the Company is terminated by the Company without Cause or Executive resigns for Good Reason prior to a </font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:5pt;padding-right:9.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Change of Control (as defined below) or more than twelve (12) months following a Change of Control, provided that Executive remains in compliance with the terms of this Agreement and the Confidentiality Agreement (as defined below) and subject to Section 7 below, the Company or its successor, as the case may be, shall provide Executive with the following severance benefits&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:149.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;The Company shall pay Executive, as severance, the equivalent of nine (9)</font></div><div style="margin-top:3.1pt;padding-left:5pt;padding-right:9.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">months of Executive&#8217;s Base Salary in effect as of the date of Executive&#8217;s employment termination. This severance will be paid in the form of salary continuation, payable on the Company&#8217;s regular payroll dates, subject to standard payroll deductions and withholdings, starting on the 60th day after Executive&#8217;s termination date, with the first payment to include those payments that would have occurred earlier but for the 60-day delay.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:9.2pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Provided that Executive is then eligible for and timely elects continued coverage under COBRA, the Company shall pay Executive&#8217;s COBRA premiums to continue Executive&#8217;s coverage (including coverage for eligible dependents, if applicable) through the period starting on Executive&#8217;s termination date and ending on the earliest to occur of&#58; (a) nine (9) months following Executive&#8217;s termination date&#59; (b) the date Executive becomes eligible for comparable group health insurance coverage through a new employer&#59; or (c) the date Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination. In the event Executive becomes covered under another employer&#8217;s comparable group health plan or otherwise ceases to be eligible for COBRA during this time period, Executive must immediately notify the Company of such event. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it cannot pay the COBRA premiums without a substantial risk of violating applicable law, the Company instead shall pay to Executive, on the first day of each calendar month, a fully taxable cash payment equal to the applicable COBRA premiums for that month, subject to applicable tax withholdings, for the remainder of the COBRA premium period. Executive may, but is not obligated to, use such payments toward the cost of COBRA premiums.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:13.45pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.3&#160;&#160;&#160;&#160;Severance Benefits for Termination Without Cause or Resignation with Good Reason Related to a Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event Executive&#8217;s employment with the Company is terminated by the Company without Cause or Executive resigns for Good Reason during the twelve (12) month period immediately following a Change of Control, and provided that Executive remains in compliance with the terms of this Agreement and the Confidentiality Agreement and subject to Section 7 below, the Company, or its successor, as the case may be, shall provide Executive with the following severance benefits&#58;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:149.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;The Company shall pay Executive, as severance, the equivalent of twelve</font></div><div style="margin-top:0.1pt;padding-left:5pt;padding-right:6.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(12) months of Executive&#8217;s base salary in effect as of the date of Executive&#8217;s employment termination. This severance will be paid in the form of salary continuation, payable on the Company&#8217;s regular payroll dates, subject to standard payroll deductions and withholdings, starting on the 60th day after Executive&#8217;s termination date, with the first payment to include those payments that would have occurred earlier but for the 60-day delay.</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:8.5pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Provided that Executive is then eligible for and timely elects continued coverage under COBRA, the Company shall pay Executive&#8217;s COBRA premiums to continue Executive&#8217;s coverage (including coverage for eligible dependents, if applicable) through the period starting on Executive&#8217;s termination date and ending on the earliest to occur of&#58; (a) twelve (12) months following Executive&#8217;s termination date&#59; (b) the date Executive becomes eligible for comparable group health insurance coverage through a new employer&#59; or (c) the date Executive ceases to be eligible for COBRA continuation coverage for any reason, including plan termination. In the event Executive </font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:4.5pt;padding-left:5pt;padding-right:8.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">becomes covered under another employer&#8217;s comparable group health plan or otherwise ceases to be eligible for COBRA during this time period, Executive must immediately notify the Company of such event. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it cannot pay the COBRA premiums without a substantial risk of violating applicable law, the Company instead shall pay to Executive, on the first day of each calendar month, a fully taxable cash payment equal to the applicable COBRA premiums for that month, subject to applicable tax withholdings, for the remainder</font></div><div style="margin-top:3pt;padding-left:5pt;padding-right:14.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of the COBRA premium period. Executive may, but is not obligated to, use such payments toward the cost of COBRA premiums.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:14.3pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;The Company shall pay Executive an amount equal to 100% of Executive&#8217;s target annual bonus, payable in a lump sum, less deductions and withholdings, at the same time as the first severance payment described in Section 6.3(i) above. For the avoidance of doubt, the amount payable pursuant to this Section 6.3(iii) shall not be subject to proration based on the portion of the year elapsed as of the date of termination.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:14.35pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;The vesting of all unvested equity-based incentive compensation awards then held by Executive shall be accelerated such that 100% of the shares underlying such awards shall be deemed immediately vested and exercisable&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in the case of any unvested equity-based incentive compensation awards that are subject to performance-based vesting terms as of the date of such termination, the treatment of such performance-based vesting conditions shall be governed by the applicable equity plan and award agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:113.05pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.4&#160;&#160;&#160;&#160;Termination for Cause&#59; Resignation Without Good Reason&#59; Death or</font></div><div style="margin-top:0.05pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disability.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:149.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;If Executive resigns without Good Reason or the Company terminates</font></div><div style="padding-left:5pt;padding-right:13.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Executive&#8217;s employment for Cause, Executive shall not be entitled to receive any payments or benefits under this Agreement, other than as set forth in Section 6.1. In addition, Executive shall resign from all positions and terminate any relationships as an employee, advisor, officer or director with the Company and any of its affiliates, each effective on the date of termination.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:16pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Executive&#8217;s employment shall terminate automatically upon the death or Total Disability of Executive. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Total Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean Executive&#8217;s inability, with reasonable accommodation, to perform the duties of her position for a period or periods aggregating ninety (90) calendar days in any period of one hundred eighty days (180) consecutive days as a result of any medically recognized physical or mental illness, loss of legal capacity or any other cause beyond Executive&#8217;s control. Executive and the Company hereby acknowledge that Executive&#8217;s ability to perform the duties specified in Section 1 is the essence of this Agreement. Termination hereunder shall be deemed to be effective (a) at the end of the calendar month in which Executive&#8217;s death occurs or (b) immediately upon a reasonable determination by the Board or the compensation committee thereof of Executive&#8217;s Total Disability. In the case of termination of employment under this Section 6.4(ii), Executive shall not be entitled to receive any payments or benefits under this Agreement, other than as set forth in Section 6.1.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:8.3pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;Conditions to Receipt of Severance Benefits. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The receipt of the severance benefits set forth in Section 6.2 and Section 6.3 above shall be subject to Executive signing and not revoking a separation agreement and release of claims in a form reasonably satisfactory to the Company and Executive (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Separation Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) no later than 60 days following the date of termination. No severance benefits will be paid or provided unless and until the Separation Agreement becomes effective and non-revocable. Executive shall also resign from all positions and terminate any </font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:5pt;padding-right:8.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">relationships as an employee, advisor, officer or director with the Company and any of its affiliates, each effective on the date of termination.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:8.3pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;Section 409A. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">It is intended that all of the severance benefits and other payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)</font></div><div style="margin-top:3pt;padding-left:5pt;padding-right:7.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provided under Treasury Regulations 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9), and this Agreement will be construed to the greatest extent possible as consistent with those provisions, and to the extent not so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section 409A. All payments and benefits that are payable upon a termination of employment hereunder shall be paid or provided only upon Executive&#8217;s &#8220;separation from service&#8221; from the Company (within the meaning of Section 409A). For purposes of Section 409A (including, without limitation, for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii)), Executive&#8217;s right to receive any installment payments under this Agreement (whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment.</font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:11.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed by the Company at the time of Executive&#8217;s termination to be a &#8220;specified employee&#8221; for purposes of Section 409A(a)(2)(B)(i), and if any of the payments upon termination set forth herein and&#47;or under any other agreement with the Company are deemed to be &#8220;deferred compensation&#8221;, then to the extent delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) and the related adverse taxation under Section 409A, such payments shall not be provided to Executive prior to the earliest of (i) the expiration of the six-month period measured from the date of Executive&#8217;s termination with the Company, (ii) the date of Executive&#8217;s death or (iii) such earlier date as permitted under Section 409A without the imposition of adverse taxation.</font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:10.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Upon the first business day following the expiration of such applicable Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Paragraph shall be paid in a lump sum to Executive, and any remaining payments due shall be paid as otherwise provided herein or in the applicable agreement. No interest shall be due on any amounts so deferred.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.55pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;Section 280G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event that the severance and other benefits provided for in this Agreement or otherwise payable to Executive (i) constitute &#8220;parachute payments&#8221; within the meaning of Section 280G of the Code and (ii) but for this Section 9, would be subject to the excise tax imposed by Section 4999 of the Code, then, Executive&#8217;s severance and other benefits under this Agreement shall be payable either (i) in full, or (ii) as to such lesser amount which would result in no portion of such severance and other benefits being subject to the excise tax under Section 4999 of the Code, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the excise tax imposed by Section 4999 of the Code, results in the receipt by Employee on an after-tax basis of the greatest amount of severance benefits under this Agreement, notwithstanding that all or some portion of such severance benefits may be taxable under Section 4999 of the Code. Any reduction shall be made in the following manner&#58; first a pro rata reduction of (i) cash payments subject to Section 409A as deferred compensation and (ii) cash payments not subject to Section 409A, and second a pro rata cancellation of (i) equity-based compensation subject to Section 409A as deferred compensation and (ii) equity-based compensation not subject to Section 409A. Reduction in either cash payments or equity compensation benefits shall be made prorata between and among benefits which are subject to Section 409A and benefits which are exempt from Section 409A. Unless the Company and Employee otherwise agree in writing, any determination required under this Section 9 shall be made in writing by the</font></div><div style="margin-top:0.1pt;padding-left:5pt;padding-right:13.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Company&#8217;s independent public accountants (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accountants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), whose determination shall be conclusive and binding upon Employee and the Company for all purposes. For purposes of making the </font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:0.1pt;padding-left:5pt;padding-right:13.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">calculations required by this Section 9, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Company and Employee shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this Section 9. The Company shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section 9.</font></div><div style="margin-top:3pt;padding-left:77.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;Definitions.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.6pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.1&#160;&#160;&#160;&#160;Cause. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of this Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Cause&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">for termination will mean&#58; (a) a material breach of any of Executive&#8217;s obligations or duties pursuant to this Agreement or the Confidentiality Agreement, which remains uncured seven days after Executive becomes aware of the breach by formal written notification by the Company&#59; (b) gross negligence or willful misconduct in the course of employment&#59; (c) any action or activity that is contrary to applicable insider trading rules or any other applicable securities rules or legislation&#59; or (d) a material act or omission involving substantial dishonesty or fraud that harms or would reasonably be expected to harm the Company.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:17.15pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.2&#160;&#160;&#160;&#160;Good Reason. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of this Agreement, Executive shall have &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; for resignation from employment with the Company if any of the following actions are taken by the Company without Executive&#8217;s prior written consent&#58; (a) any material and adverse change to Executive&#8217;s position, authority, responsibilities, or job location in effect under this Agreement&#59; (b) any material reduction in base salary or bonus opportunity as provided under this Agreement&#59; (c) an assignment to Executive of any duties materially inconsistent with Executive&#8217;s status as General Counsel&#59; or (d) any failure to secure the agreement of any successor entity to fully assume the Company&#8217;s obligations under this Agreement. In order to resign for Good Reason, Executive must provide written notice to the Board within 60 days after the first occurrence of the event giving rise to Good Reason setting forth the basis for Executive&#8217;s resignation, allow the Company at least 30 days from receipt of such written notice to cure such event, and if such event is not reasonably cured within such period, Executive must resign from all positions Executive then holds with the Company not later than 90 days after the expiration of the cure period.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:7.95pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.3&#160;&#160;&#160;&#160;Change of Control. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of this Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Change of Control&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the occurrence of one or more of the following&#58; (a) a merger, a consolidation, a reorganization or an arrangement that results in a transfer of more than fifty percent (50%) of the total voting power of the Company&#8217;s outstanding securities to a person or a group of persons different from a person or a group of persons holding those securities immediately prior to such transaction (other than the Company or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company)&#59; (b) a direct or indirect sale or other transfer of beneficial ownership of securities of the Company possessing more than fifty percent (50%) of the total combined voting power of the Company&#8217;s outstanding securities to a person or a group of persons different from a person or a group of persons holding those securities immediately prior to such transaction (other than the Company or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company)&#59; (c) a direct or indirect sale or other transfer of the right to appoint more than fifty percent (50%) of the directors of the Board or otherwise directly or indirectly control the management, affairs and business of the Company to a person or a group of persons different from a person or a group of persons holding this right immediately prior to such transaction (other than the Company or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company)&#59; (d) a direct or indirect sale or other transfer of all or substantially all of the assets of the Company to a person or a group of persons different from a person or a group of persons holding those assets immediately prior to such transaction (other than the Company or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company)&#59; or (e) a complete liquidation, </font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-left:5pt;padding-right:7.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">dissolution or winding-up of the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that a Change in Control will not be deemed to have occurred if such Change in Control results solely from the issuance, in connection with a bona fide financing or series of financings by the Company, of voting securities of the Company or any rights to acquire voting securities of the Company which are convertible into voting securities.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:77.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;Proprietary Information Obligations. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As a condition of employment, Executive shall</font></div><div style="margin-top:3pt;padding-left:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">execute and abide by the Company&#8217;s standard form of Employee Invention Assignment, Confidentiality and Non-Competition Agreement (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Confidentiality Agreement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:77.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;Outside Activities During Employment.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:9.7pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.1&#160;&#160;&#160;&#160;Non-Company Business. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except with the prior written consent of the Board, Executive will not during the term of Executive&#8217;s employment with the Company undertake or engage in any other employment, occupation or business enterprise, other than ones in which Executive is a passive investor. Executive may engage in civic and not-for-profit activities so long as such activities do not materially interfere with the performance of Executive&#8217;s duties hereunder.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:15.6pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.2&#160;&#160;&#160;&#160;No Adverse Interests. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Executive agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known to be adverse or antagonistic to the Company, its business or prospects, financial or otherwise.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:7.15pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;Dispute Resolution. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To ensure the timely and economical resolution of disputes that may arise in connection with Executive&#8217;s employment with the Company, Executive and the Company agree that any and all disputes, claims, or causes of action arising from or relating to the enforcement, breach, performance, negotiation, execution, or interpretation of this Agreement, Executive&#8217;s employment, or the termination of Executive&#8217;s employment, including but not limited to statutory claims, shall be resolved to the fullest extent permitted by law by final, binding and confidential arbitration, by a single arbitrator, in Seattle, Washington conducted by JAMS, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JAMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) under the then applicable JAMS rules or by another arbitration provider if mutually agreed upon by Executive and Board. By agreeing to this arbitration procedure, both Executive and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. The Company acknowledges that Executive will have the right to be represented by legal counsel at any arbitration proceeding. The arbitrator shall&#58; (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law&#59; and (b) issue a written arbitration decision, to include the arbitrator&#8217;s essential findings and conclusions and a statement of the award. The arbitrator shall be authorized to award any or all remedies that Executive or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS&#8217; arbitration fees in excess of the amount of court fees that would be required of Executive if the dispute were decided in a court of law. Nothing in this Agreement is intended to prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:77.05pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;General Provisions.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:18.65pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.1&#160;&#160;&#160;&#160;Notices. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any notices provided must be in writing and will be deemed effective upon the earlier of personal delivery (including personal delivery by email or fax) or the next day after sending by overnight carrier, to the Company at its primary office location and to Executive at the address as listed on the Company payroll.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:12.7pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.2&#160;&#160;&#160;&#160;Severability. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction to the extent possible in keeping with the intent of the parties.</font></div><div style="margin-top:3pt;padding-left:5pt;padding-right:17.55pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.3&#160;&#160;&#160;&#160;Waiver. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any waiver of any breach of any provisions of this Agreement must be in writing to be effective, and it shall not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:9.95pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.4&#160;&#160;&#160;&#160;Complete Agreement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement, together with the Confidentiality Agreement, constitutes the entire agreement between Executive and the Company with regard to this subject matter and is the complete, final, and exclusive embodiment of the Parties&#8217; agreement with regard to this subject matter. This Agreement is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations. It is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified or amended except in a writing signed by a duly authorized officer of the Company.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:26.15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.5&#160;&#160;&#160;&#160;Counterparts. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together will constitute one and the same Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:26.15pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.6&#160;&#160;&#160;&#160;Headings. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The headings of the paragraphs hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:20.6pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.7&#160;&#160;&#160;&#160;Successors and Assigns. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement is intended to bind and inure to the benefit of and be enforceable by Executive and the Company, and their respective successors, assigns, heirs, executors and administrators, except that Executive may not assign any of his duties hereunder and he may not assign any of his rights hereunder without the written consent of the Company, which shall not be withheld unreasonably.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5pt;padding-right:9.35pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.8&#160;&#160;&#160;&#160;Tax Withholding and Indemnification. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All payments and awards contemplated or made pursuant to this Agreement will be subject to withholdings of applicable taxes in compliance with all relevant laws and regulations of all appropriate government authorities. Executive acknowledges and agrees that the Company has neither made any assurances nor any guarantees concerning the tax treatment of any payments or awards contemplated by or made pursuant to this Agreement. Executive has had the opportunity to retain a tax and financial advisor and fully understands the tax and economic consequences of all payments and awards made pursuant to the Agreement.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;padding-right:59.9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.9&#160;&#160;&#160;&#160;Choice of Law. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All questions concerning the construction, validity and interpretation of this Agreement will be governed by the laws of the State of Washington.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:127.1pt;padding-right:127.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Remainder of Page Intentionally Left Blank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;</font></div><div style="margin-top:3pt;padding-left:5pt;padding-right:14.15pt;text-indent:72pt"><font><br></font></div><div style="padding-right:14.15pt"><font><br></font></div><div style="padding-right:14.15pt"><font><br></font></div><div style="padding-right:14.15pt"><font><br></font></div><div style="padding-right:14.15pt"><font><br></font></div><div style="padding-right:14.15pt"><font><br></font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:51pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="padding-right:14.15pt"><font><br></font></div><div style="padding-right:14.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Parties have executed this Agreement on the day and year first written above.</font></div><div><font><br></font></div><div style="margin-top:10.85pt;padding-left:296.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NEOLEUKIN THERAPEUTICS, INC.</font></div><div><font><br></font></div><div style="padding-left:296.5pt;padding-right:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:131%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:131%;text-decoration:underline">&#47;s&#47; Jonathan G. Drachman, M.D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:131%"> Name&#58; Jonathan Drachman</font></div><div style="padding-left:292.5pt;padding-right:5.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Title&#58; Chief Executive Officer</font></div><div><font><br></font></div><div style="margin-top:11.4pt;padding-left:296.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">HOLLY VANCE</font></div><div><font><br></font></div><div style="padding-left:297pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Holly Vance</font></div><div style="padding-left:297pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:127.1pt;padding-right:127.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Signature Page to H. Vance Employment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;</font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>4
<FILENAME>ex1023rigakupoupdated1.htm
<DESCRIPTION>EX-10.23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ie24719176d344d44b553a10ccc1bb632_1"></div><div style="min-height:19pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.768%"><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:0.01pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neoleukin Therapeutics, Inc.</font></div><div style="padding-right:42.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:129%">1616 Eastlake Ave E Suite 360</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%">Seattle, WA 98102</font></div><div style="margin-top:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EIN&#58; 83-2585260</font></div><div style="margin-top:12.8pt;padding-right:24.35pt;text-align:right"><font><br></font></div><div style="margin-top:2.2pt;padding-right:24.3pt;text-align:right"><font><br></font></div></div><div style="display:inline-block;max-width:6.463%;min-width:5.463%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.769%"><div style="padding-right:24.3pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.23</font></div><div style="padding-right:24.3pt;text-align:right"><font><br></font></div><div style="padding-right:24.3pt;text-align:right"><font style="color:#595959;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">PURCHASE ORDER</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:43.55pt;padding-right:23.95pt;text-indent:-8.35pt"><font><br></font></div><div style="padding-right:23.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">P.O. # 20201118-001 RIGAKU </font></div><div style="padding-right:23.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DATE&#58;  18  NOVEMBER 2020</font></div></div></div><div style="margin-top:0.55pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.061%"><tr><td style="width:1.0%"></td><td style="width:34.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">VENDOR&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">RIGAKU AMERICAS CORPORATION</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">9009 New Trails Drive</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">The Woodlands, TX 77381-5209 (281)362-2300</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SHIP TO&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Neoleukin Therapeutics, Inc. 188 E BLAINE ST SUITE 450</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SEATTLE, WA 98102</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(206)604-0724</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">BILL TO&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Neoleukin Therapeutics, Inc. 1616 Eastlake Avenue East Suite 360</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Seattle, WA 98102 </font></div></td></tr></table></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMMENTS OR SPECIAL INSTRUCTIONS&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:0.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.734%"><tr><td style="width:1.0%"></td><td style="width:23.786%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REQUISITIONER</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ACCOUNT NUMBER</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUOTATION NUMBER</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PX28752rev1</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TAX STATUS</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taxable</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PAYMENT TERMS</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net 30 days</font></td></tr></table></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.138%"><tr><td style="width:1.0%"></td><td style="width:16.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.367%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #a6a6a6;border-top:1pt solid #a6a6a6;padding:2px 1pt 2px 23.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CATALOG NUMBER</font></td><td colspan="3" style="border-left:1pt solid #a6a6a6;border-top:1pt solid #a6a6a6;padding:2px 1pt 2px 63.6pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION</font></td><td colspan="3" style="border-left:1pt solid #a6a6a6;border-top:1pt solid #a6a6a6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:8.55pt;padding-left:10.67pt;padding-right:10.67pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNIT PRICE</font></div></td><td colspan="3" style="border-left:1pt solid #a6a6a6;border-top:1pt solid #a6a6a6;padding:2px 8.25pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUANTITY</font></td><td colspan="3" style="border-left:1pt solid #a6a6a6;border-right:1pt solid #a6a6a6;border-top:1pt solid #a6a6a6;padding:2px 1pt 2px 19.9pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXT. PRICE</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #a6a6a6;border-top:1pt solid #a6a6a6;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #a6a6a6;border-top:1pt solid #a6a6a6;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3.55pt;padding-left:10.75pt;padding-right:17.3pt;text-indent:-0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XtaLAB Synergy-R diffractometer system</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:10.75pt;padding-right:17.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:118%">See quotation PX28752rev1 below for details</font></div></td><td colspan="3" style="border-left:1pt solid #a6a6a6;border-top:1pt solid #a6a6a6;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:10.15pt;padding-right:10.15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$792,069.00</font></div></td><td colspan="3" style="border-left:1pt solid #a6a6a6;border-top:1pt solid #a6a6a6;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-right:10.15pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></td><td colspan="3" style="border-left:1pt solid #a6a6a6;border-right:1pt solid #a6a6a6;border-top:1pt solid #a6a6a6;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-right:10.15pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$792,069.00</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #a6a6a6;padding:0 10pt 0 1pt;text-indent:31.5pt"></td><td colspan="3" style="border-top:1pt solid #a6a6a6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #a6a6a6;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #a6a6a6;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUBTOTAL</font></td><td colspan="3" style="border-left:1pt solid #a6a6a6;border-right:1pt solid #a6a6a6;border-top:1pt solid #a6a6a6;padding:2px 11.15pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$792,069.00</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES TAX</font></td><td colspan="3" style="border-left:1pt solid #a6a6a6;border-right:1pt solid #a6a6a6;border-top:1pt solid #a6a6a6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TOTAL DUE</font></td><td colspan="3" style="border-bottom:1pt solid #a6a6a6;border-left:1pt solid #a6a6a6;border-right:1pt solid #a6a6a6;border-top:1pt solid #a6a6a6;padding:0 1pt"></td></tr></table></div><div style="margin-top:0.2pt"><font><br></font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ie24719176d344d44b553a10ccc1bb632_4"></div><hr style="page-break-after:always"><div style="min-height:69pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.768%"><div style="margin-top:4.7pt;padding-left:89.3pt;padding-right:1.9pt;text-indent:-27.2pt"><font><br></font></div></div><div style="display:inline-block;max-width:6.463%;min-width:5.463%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.769%"></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">            </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.793%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TO&#58;     Neoleukin Therapeutics, Inc.<br>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1616 Eastlake Ave E<br>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Seattle, WA 98102</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">DATE&#58;              November 19, 2020</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">VALIDITY&#58;     60 days</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">DELIVERY&#58;    5 &#8211; 6 months ARO</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SHIPMENT&#58;    FOB Destination to</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Customer&#8217;s loading dock                                </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk of loss passes to Buyer at FOB point.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">TITLE&#58;           Title transfers to Buyer at FOB point.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PHONE&#58;<br>FAX&#58;<br>EMAIL&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INSTALLATION&#58;         Included<br>WARRANTY&#58;               One Year<br>PAYMENT TERMS&#58;    50% on Dec. 15, 2020, 30% on shipment, 20% on installation, Net 30</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;padding-right:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">XtaLAB Synergy-R (Cu) HyPix-Arc 150&#176; Curved HPC Detector</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The XtaLAB Synergy-R diffractometer combines leading edge components and user-inspired software. The foundation of the system is the PhotonJet-R source which integrates the second generation true microfocus MicroMax 007HF rotating anode generator with a specialized confocal MaxFlux optic to provide a uniquely small focal spot. The intense, monochromatic beam from the PhotonJet-R optimizes signal-to-noise for the small crystals used in today&#8217;s crystallography laboratories. The XtaLAB Synergy- R system also includes a new kappa goniometer that features a unique telescopic two-theta arm to provide total flexibility for your diffraction experiment. The XtaLAB Synergy-R is compatible with a wide range of CCD and hybrid photon counting (HPC) detectors to allow you to design the best diffractometer for your</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">samples.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes for Purchasing Manager&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:0.42pt;padding-right:41.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taxes (for&#58; Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Indiana, Maryland, Massachusetts, Michigan, New Jersey, New York, North Carolina, Pennsylvania, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, Wisconsin) will be added to invoice if applicable. If Buyer claims tax exempt status, Buyer agrees to provide Rigaku (Seller) with a tax exemption certificate acceptable to local taxing authorities in the jurisdiction concerned.</font></div><div><font><br></font></div><div style="padding-right:41.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seller offers to sell to Buyer, and Buyer agrees to purchase from Seller, the goods and services described below, subject to the terms and conditions stated on the face of this Quotation and Seller&#8217;s standard terms and conditions, attached. Seller hereby objects to any additional or different terms stated in Buyer&#8217;s request for quotation, purchase order, or any other document of Buyer. Any modification of these terms of sale must be specifically agreed to in writing by Seller. This contract is binding upon Seller&#8217;s receipt of Buyer&#8217;s Purchase Order for same. Please address Purchase Order to Rigaku Americas Corporation to the address at the bottom of this page, or email to </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">purchaseorder&#64;rigaku.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="margin-top:4.7pt;padding-right:0.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Payment terms beyond Net 30 days are subject to a 7.5% interest charge and&#47;or loss of applicable discounts. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred method of payment is check or ACH payments. Credit card purchases are limited to $20,000. This contract is binding upon Seller&#8217;s receipt of Buyer&#8217;s Purchase Order for same.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prices are listed in USD.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prices are based on quoted payment terms.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prices and specifications subject to change without notice.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:7%">Page </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:7%">1 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:7%">of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:7%">6</font></div><div><font><br></font></div></div></div><div id="ie24719176d344d44b553a10ccc1bb632_7"></div><hr style="page-break-after:always"><div style="min-height:69pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:4.7pt;padding-right:41.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quotation validity subject to compliance with US Government export regulations for Analytical X-ray instrumentation.</font></div><div><font><br></font></div><div style="padding-right:41.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total system price includes delivery, assembly, installation, 12 months on-site labor and parts warranty (excluding consumables), and on-site basic operation&#47;maintenance training.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-right:41.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inside delivery is not included. If inside delivery is required, an additional charge will apply. When accepting delivery, please note on transport documents any shortage or damage, and advise Rigaku immediately at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">installcoordinator&#64;rigaku.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:47.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rigaku</font></div><div style="margin-top:0.45pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#47;s&#47; Eric Reinheimer</font></div><div style="padding-left:47.9pt;padding-right:336.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eric Reinheimer, Ph.D., MRSC Western Regional Account Manager Rigaku Oxford Diffraction SBU</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:4.7pt;padding-left:52pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accepted by&#58;</font></div><div style="margin-top:0.2pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#47;s&#47; Robert Ho</font></div><div style="padding-left:52pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Robert Ho, CFO&#160;&#160;&#160;&#160;</font></div><div style="margin-top:0.5pt;padding-left:52pt;padding-right:377.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">Neoleukin Therapeutics, Inc. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:7%">Page </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:7%">2 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:7%">of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:7%">6</font></div><div><font><br></font></div></div></div><div id="ie24719176d344d44b553a10ccc1bb632_10"></div><hr style="page-break-after:always"><div style="min-height:69pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.177%"><tr><td style="width:1.0%"></td><td style="width:8.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.051%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0079c2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM</font></td><td colspan="3" style="background-color:#0079c2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.95pt;padding-left:4.77pt;padding-right:4.77pt;text-align:center"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QTY</font></div></td><td colspan="3" style="background-color:#0079c2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.95pt;padding-left:133.77pt;padding-right:133.77pt;text-align:center"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION</font></div></td><td colspan="3" style="background-color:#0079c2;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 20.35pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TOTAL</font></td></tr><tr style="height:240pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.82pt;padding-right:2.82pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1</font></div></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.4pt;padding-right:152.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">XtaLAB Synergy-R diffraction System Includes&#58;</font></div><div style="padding-left:22.5pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:122%;padding-left:14.55pt">4-circle kappa goniometer with unique telescopic two-theta arm</font></div><div style="padding-left:22.5pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:122%;padding-left:14.55pt">Large radiation protection cabinet interlocked for safety</font></div><div style="padding-left:22.5pt;padding-right:10.9pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Bright cabinet and sample lighting with electronically controlled intensity</font></div><div style="padding-left:22.5pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:121%;padding-left:14.55pt">Control computer &#8211; Windows &#8211; 24&#8221; monitor</font></div><div style="padding-left:22.5pt;padding-right:21pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">CrysAlis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Pro </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Multi-user&#47;multi-site software license </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that is easy to use and can be fully automated from data collection through data reduction and processing</font></div><div style="padding-left:22.5pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:122%;padding-left:14.55pt">Cryo Mount</font></div><div style="padding-left:5.4pt;padding-right:12.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PhotonJet-R (Cu) includes the world&#8217;s most popular rotating anode generator with a specialized Confocal MaxFlux optic featuring&#59;</font></div><div style="padding-left:27pt;text-indent:-22.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%;padding-left:19.05pt">Loading&#58; 1200 W</font></div><div style="padding-left:27pt;text-indent:-22.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%;padding-left:19.05pt">Copper anode&#58; direct drive, one supplied (4364F501)</font></div><div style="padding-left:27pt;text-indent:-22.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%;padding-left:19.05pt">Effective focal size&#58; approximately 70 microns</font></div><div style="padding-left:27pt;text-indent:-22.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%;padding-left:19.05pt">Filament&#58; 1 box of 3 filaments is provided</font></div><div style="padding-left:27pt;padding-right:36.8pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">CMF optic, housing and all necessary parts for coupling to the MM007-HF anode</font></div><div style="padding-left:27pt;text-indent:-22.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%;padding-left:19.05pt">Optimal performance with samples of 300 microns or smaller</font></div><div style="margin-top:0.65pt;padding-left:27pt;padding-right:14.1pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:19pt">Remote control slits for divergence adjustment from 9 mR to 1 mR.</font></div></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:8.5pt;padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.82pt;padding-right:2.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:113%">2</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:113%">1</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Refrigerated heat exchanger </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(water cooled)</font></div><div style="padding-left:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:106%">Close temperature control to &#177; .1&#176;C</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.82pt;padding-right:2.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">3</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">1</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">Filaments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#58; (3 per box) 0.1 x 1 mm</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.82pt;padding-right:2.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">4</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">1</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PhotonJet-R (Cu) direct drive rotating anode assembly, Cu target</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.82pt;padding-right:2.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.4pt;padding-right:30.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HyPix-Arc 150&#176; Curved Hybrid Photon Counting (HPC) Detector Features&#58;</font></div><div style="padding-left:23.4pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:14.55pt">Minimal reflection profile distortion</font></div><div style="padding-left:23.4pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%;padding-left:14.55pt">All reflections measured under the same conditions</font></div><div style="padding-left:23.4pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%;padding-left:14.55pt">Capture more photons per image with 150&#176; of 2&#952; coverage</font></div><div style="padding-left:23.4pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%;padding-left:14.55pt">70 Hz readout for fast data collection</font></div><div style="padding-left:23.4pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%;padding-left:14.55pt">Scintillator free design</font></div><div style="padding-left:23.4pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;padding-left:14.55pt">100 mu pixels</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.82pt;padding-right:2.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">XtaLAB Synergy Flow Robot</font></div><div style="margin-top:9.15pt;padding-left:5.4pt;padding-right:4.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The XtaLAB Synergy Flow robotic system allows you to now take full advantage of the high performance of your system by incorporating a 6- axis Universal Robot which provides unattended data acquisition, enhanced productivity, and standardized workflow to your crystallographic research environment. A XtaLAB Synergy Flow system can be used as part of a lab workflow and sample submission protocol that minimizes human contact.</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:7%">Page </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:7%">3 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:7%">of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:7%">6</font></div><div><font><br></font></div></div></div><div id="ie24719176d344d44b553a10ccc1bb632_13"></div><hr style="page-break-after:always"><div style="min-height:69pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.177%"><tr><td style="width:1.0%"></td><td style="width:8.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.051%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0079c2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM</font></td><td colspan="3" style="background-color:#0079c2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.95pt;padding-left:4.77pt;padding-right:4.77pt;text-align:center"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QTY</font></div></td><td colspan="3" style="background-color:#0079c2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.95pt;padding-left:133.77pt;padding-right:133.77pt;text-align:center"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION</font></div></td><td colspan="3" style="background-color:#0079c2;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 20.35pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TOTAL</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.2pt;padding-right:0.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6</font></div><div style="padding-left:4.75pt;padding-right:4.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">cont</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Features&#58;</font></div><div style="padding-left:23.4pt;padding-right:7.6pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unattended data collection of up to 48 samples is carried out without users present in the laboratory. This allows higher productivity where the system is always collecting data with a user is not present, such as overnight or over the weekend.</font></div><div style="padding-left:23.4pt;padding-right:22pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A unique X-ray safe dewar drawer system with a side loading port allows pucks to be loaded without opening the enclosure door and without interrupting data collection.</font></div><div style="padding-left:23.4pt;padding-right:12.05pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Intelligent Goniometer Head (iGH), a motorized marvel provides automated sample centering as fast as 6 seconds on a dual camera system, the standard for our robotic instruments. Manual and point and click control are also available for fine-tuning centering or targeting a specific feature or part of the sample.</font></div><div style="padding-left:23.4pt;padding-right:18.05pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Force free end effector envelopes the sample in liquid nitrogen and transports it without applying force to the pin for high reliability.</font></div><div style="padding-left:23.4pt;padding-right:5.95pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Samples are stored in an LN2 dewar with a capacity of 48 samples stored in 3 Uni-pucks. Dewar accessories include a bar code reader, a defrost system, rotatable lid, level sensor and automatic LN2 dosing system. Accepted pins include the ALS standard from ALS and the SPINE standard from EMBL.</font></div><div style="margin-top:6.55pt;padding-left:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Includes&#58;</font></div><div style="padding-left:23.4pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%;padding-left:14.55pt">Built in UR3 6-axis Universal Robot</font></div><div style="padding-left:23.4pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%;padding-left:14.55pt">Side loading dewar with (3) Uni-pucks</font></div><div style="padding-left:23.4pt;padding-right:44.8pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intelligent Goniometer Head with dual camera optical sample alignment</font></div><div style="margin-top:0.75pt;padding-left:23.4pt;padding-right:17.05pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">CrysAlisPro software interface for robot operation, sample queuing, sample sorting, and crystal judgements.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.82pt;padding-right:2.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">7</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Deluxe Starter Kit for XtaLAB Synergy Flow Robot</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes&#58;</font></div><div style="padding-left:23.4pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%;padding-left:14.55pt">(7) UniPucks, UniPuck Took Kit, UniPuck Rack Kit</font></div><div style="padding-left:23.4pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%;padding-left:14.55pt">Spines and CryoLoops</font></div><div style="padding-left:23.4pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%;padding-left:14.55pt">Pin set and tong</font></div><div style="padding-left:23.4pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%;padding-left:14.55pt">Dry Shipper</font></div><div style="padding-left:23.4pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;padding-left:14.55pt">Vessel Dewar and Dewar Flask</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.82pt;padding-right:2.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">8</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">1</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">CSCOBRA&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The non-liquid Cryostream designed for use in labs where</font></div></td><td colspan="3" rowspan="6" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">access to liquid nitrogen is logistically difficult to achieve or prohibitively</font></td></tr><tr style="height:13pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expensive.</font></td></tr><tr style="height:13pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:23.4pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:109%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:109%;padding-left:14.55pt">Temperature range of 80&#8211;400K</font></div></td></tr><tr style="height:13pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">House N2 kit</font></td></tr><tr style="height:13pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:102%">1</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt 2px 6.4pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cobra Table Stand for XtaLAB Synergy-R</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.82pt;padding-right:2.82pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">9</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Applications Training at the Customer&#8217;s Site</font></div><div style="margin-top:0.05pt;padding-left:22.65pt;padding-right:25.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Applications training at customer&#8217;s site (up to 3 days) by a Rigaku Applications Scientist.</font></div><div style="margin-top:0.05pt;padding-left:22.65pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%;padding-left:14.55pt">Travel and expenses are included.</font></div><div style="margin-top:0.8pt;padding-left:23.4pt;padding-right:55.9pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Training must be completed within three months of system installation.</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 5.75pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total for Items 1 &#8211; 9</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 5.7pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$989,781</font></td></tr><tr><td colspan="9" style="border-left:1pt solid #000000;padding:2px 5.7pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Less Package Discount</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 5.7pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">-$197,712</font></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt 2px 254.85pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discounted Total for Items 1 &#8211; 9</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 5.7pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$792,069</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:7%">Page </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:7%">4 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:7%">of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:7%">6</font></div><div><font><br></font></div></div></div><div id="ie24719176d344d44b553a10ccc1bb632_16"></div><hr style="page-break-after:always"><div style="min-height:69pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.7pt;padding-left:33.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTES&#58;</font></div><div style="padding-left:56pt;padding-right:41.8pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Due to some state and&#47;or country regulations, a radiation leakage survey (by use of a Radiation Meter and Paddle) must be performed upon completion of x-ray source equipment. The customer is responsible for providing a Radiation Meter and Paddle if such survey for registration of x-ray source equipment is required for operation. To avoid any delays in registration of operation, please check with your institution&#8217;s Radiation Safety Officer (RSO), if available, or state and&#47;or country web sites for specific Radiation Safety Regulations prior to installation. If your institution does not currently possess  a Radiation Meter and Paddle and one is required, then one may be purchased from Rigaku.</font></div><div style="padding-left:56pt;padding-right:41.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">User agrees to provide internet access to control computers with ports available for TeamViewer. Failure to comply may result in charges for support.</font></div><div style="padding-left:56pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15pt">Transformers and&#47;or UPS system are not included with this quotation.</font></div><div style="margin-top:0.05pt;padding-left:56pt;padding-right:41.9pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:15pt">PhotonJet-R (Cu) anode must be returned to Rigaku for re-balancing. Shipping, insurance and duties (if applicable) to and from RAC are the responsibility of Buyer.</font></div><div><font><br></font></div><div style="padding-left:33.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ACCEPTANCE CRITERIA&#58;</font></div><div style="padding-left:33.5pt;padding-right:50.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The equipment shall be deemed acceptable after complete installation of the x-ray system and when the following performance specifications have been met.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:56pt;padding-right:41.8pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Continual operation of the XtaLAB Synergy-R generator for seven (7) days. (Rigaku will not be on-site for the entire testing process.)</font></div><div style="padding-left:56pt;padding-right:41.95pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The successful data collection on a cytidine or ylid crystal to 0.83 &#197; to an R-merge of 3.5% or less and a crystallographic refinement to R1 &#61; 3.5% or less.</font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.312%"><tr><td style="width:1.0%"></td><td style="width:8.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0079c2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.95pt;padding-left:4.77pt;padding-right:4.77pt;text-align:center"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM</font></div></td><td colspan="3" style="background-color:#0079c2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.95pt;padding-left:4.77pt;padding-right:4.77pt;text-align:center"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QTY</font></div></td><td colspan="3" style="background-color:#0079c2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.95pt;padding-left:133.3pt;padding-right:133.3pt;text-align:center"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION</font></div></td><td colspan="3" style="background-color:#0079c2;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 20.35pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TOTAL</font></td></tr><tr><td colspan="12" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OPTIONS&#58;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.05pt;padding-right:2.05pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">A</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.22pt;padding-right:0.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5.4pt;padding-right:10.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">XtalCheck-S In-Situ Well Plate Scanner Attachment (XTC-S) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XtalCheck-S In-situ Well Plate Scanner Attachment to measure crystals or powders in well plates. This device is mountable on the omega axis of the goniometer and provides motorized X and Y to access all wells on a standard SBS format well plate, either full height or low profile plate types. Motion control is provided along the beam direction for centering and image focusing. An additional video microscope is provided over the collimator for video imaging the plate contents and crystal alignment for X-ray diffraction in-situ. The XtalCheck-S is fully integrated into CrysAlisPro software. It is easily added or removed by the user on demand.</font></div><div style="padding-left:5.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Specifications&#58;</font></div><div style="padding-left:23.4pt;padding-right:22.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">XtalCheck-S includes simple attachment to the Synergy Universal Kappa Goniometer</font></div><div style="padding-left:23.4pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:121%;padding-left:14.55pt">Full accessibility to all sample wells, horizontally and vertically</font></div><div style="padding-left:23.4pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%;padding-left:14.55pt">Includes XtalCheck-S software that provides for</font></div><div style="padding-left:54.95pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:119%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:119%;padding-left:14.51pt">Automated imaging of crystallization drops</font></div><div style="margin-top:0.1pt;padding-left:54.95pt;padding-right:25.65pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;padding-left:14.46pt">X-ray data collection of single X-ray images or partial data sets</font></div><div style="margin-top:0.1pt;padding-left:23.4pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:113%;padding-left:14.55pt">In-Situ Video System</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$45,325</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:7%">Page </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:7%">5 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:7%">of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:7%">6</font></div><div><font><br></font></div></div></div><div id="ie24719176d344d44b553a10ccc1bb632_19"></div><hr style="page-break-after:always"><div style="min-height:38pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Standard Terms and Conditions of Sale</font></div><div><font><br></font></div></div><div style="margin-top:0.35pt"><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.768%"><div style="margin-top:4.8pt;padding-left:17.25pt;padding-right:0.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">This entire agreement supersedes any other oral and&#47;or written communication on this subject. This document and any other documents specifically referred to as being a part hereof constitute the entire agreement on the subject matter and shall not be modified except in writing signed by both parties.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:26.25pt;text-indent:-9.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;text-decoration:underline">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;padding-left:4.55pt;text-decoration:underline">PRICE</font></div><div style="margin-top:0.05pt;padding-left:17.25pt;padding-right:0.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Purchase price for each item of equipment is guaranteed until midnight Central Time on the date shown in the &#8220;Valid Until&#8221; block on page one. Prices designated as &#8220;List Prices&#8221; are subject to change without notice. Prices are stated in currency listed and do not include taxes of any kind.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:26.3pt;text-indent:-9.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;text-decoration:underline">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;padding-left:4.6pt;text-decoration:underline">TAXES &#38; DUTIES</font></div><div style="margin-top:0.05pt;padding-left:17.25pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">If Seller is required by law to collect taxes on any amount subject to this contract, Seller will include such taxes on each applicable invoice and those amounts shall be due on Buyer&#8217;s receipt of the invoice. If Buyer claims tax-exempt status, Buyer shall provide Seller a tax exemption certificate or other documentation acceptable to the appropriate taxing authority.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:17.25pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Unless otherwise stated, Buyer is solely responsible for all other taxes which Seller is not required by law to collect, and any other charges imposed on shipment of the purchased goods. Seller shall not be liable for any delay, loss, or indirect, special, liquidated, incidental, or consequential damages resulting from Buyer&#8217;s failure to timely pay amounts for which it is responsible.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.25pt;padding-right:0.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Buyer is responsible for all duties including customs clearance charges, as applicable, outside of the United States and&#47;or European Community, unless otherwise stated.</font></div><div><font><br></font></div><div style="padding-left:26.3pt;text-indent:-9.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;text-decoration:underline">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;padding-left:4.6pt;text-decoration:underline">PAYMENT TERMS</font></div><div style="padding-left:17.25pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Payment shall be made in accordance with the terms stated on page one of this contract. In the event that delivery is delayed at Buyer&#8217;s request, Buyer shall pay Seller 90% of the total contract amount on the original delivery date.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:26.25pt;text-indent:-9.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;text-decoration:underline">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;padding-left:4.55pt;text-decoration:underline">SOFTWARE LICENSE</font></div><div style="margin-top:0.05pt;padding-left:17.25pt;padding-right:0.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Any software which is used in conjunction with the goods sold by this contract is transferred pursuant to a separate license agreement. Unless otherwise stated, the software is not  sold to Buyer and title to the software shall not pass to Buyer.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:26.25pt;text-indent:-9.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;text-decoration:underline">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;padding-left:4.55pt;text-decoration:underline">SHIPMENT</font></div><div style="margin-top:0.1pt;padding-left:17.25pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Shipment shall be made in accordance with the terms stated on page one. If inside  delivery is required and not expressly made a part of this contract, an additional charge will apply.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:26.25pt;text-indent:-9.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;text-decoration:underline">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;padding-left:4.55pt;text-decoration:underline">DELIVERY</font></div><div style="margin-top:0.1pt;padding-left:17.25pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Delivery shall be made in accordance with the terms stated on page one. In the event that delivery is delayed at Buyer&#8217;s request&#58; (1) the equipment warranty period will commence on the original delivery date, and (2) Seller may store the goods at Seller&#8217;s facility or at such other location as Seller may choose at Seller&#8217;s sole discretion, and Buyer shall be responsible for all storage and incidental charges, regardless of the location at which the goods are stored.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:26.25pt;text-indent:-9.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;text-decoration:underline">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;padding-left:4.55pt;text-decoration:underline">TITLE</font></div><div style="margin-top:0.1pt;padding-left:17.25pt;padding-right:0.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Buyer grants, and Seller retains, a security interest in all goods to secure payment therefore until all amounts due are paid, and Buyer agrees that it shall execute all documents necessary to secure such interest to Seller. Buyer shall not grant to any third party a security or other interest in the goods purchased pursuant to this contract which is in conflict with this paragraph.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:26.25pt;text-indent:-9.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;text-decoration:underline">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;padding-left:4.55pt;text-decoration:underline">EQUIPMENT WARRANTY</font></div><div style="margin-top:0.05pt;padding-left:17.25pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">New goods, except expendables and supplies, are warranted against defects in materials and workmanship that materially affect the functionality of the goods until the earlier of twelve months from installation or fourteen months from delivery. Seller&#8217;s sole obligation under this warranty shall be to repair or replace defective components, including the cost of shipping parts and providing labor for installation, if applicable.</font></div><div><font><br></font></div><div style="padding-left:17.25pt;padding-right:0.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">This warranty does not extend to other vendors&#8217; products that are supplied to Buyer in conjunction with this contract. Those products are warranted by their respective manufacturer&#8217;s or vendor&#8217;s warranties in effect on the date of shipment to Buyer. Seller assigns to Buyer all rights it may have in such warranties. All warranties are contingent upon proper use of the goods and operation of the same within manufacturer&#8217;s specifications.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:17.25pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">THIS WARRANTY IS EXPRESSLY IN LIEU OF ALL OTHER WARRANTIES, INCLUDING BUT NOT LIMITED TO IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, AND CONSTITUTES THE ONLY WARRANTY OF SELLER WITH RESPECT TO THE GOODS.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:26.3pt;text-align:justify;text-indent:-9.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;text-decoration:underline">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;padding-left:4.6pt;text-decoration:underline">LIMITATION OF LIABILITY</font></div><div style="margin-top:0.05pt;padding-left:17.25pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Seller shall not be liable for any incidental, consequential or special damages, including, but not limited to any loss of business, income or profits, Buyer&#8217;s expenses for downtime, or for making up downtime, and any labor costs of Buyer related to the functioning of components covered by this Agreement. Seller&#8217;s liability on any claim of any kind of loss, injury, or allocated damages shall not exceed the fraction of the purchase price allocable to the component giving rise to such claim. The foregoing states the exclusive remedy of the Buyer and the exclusive liability of Seller. Seller agrees to indemnify and hold harmless Buyer and Buyer&#8217;s employees, officers, directors, affiliates, partially or wholly owned subsidiaries, agents, successors and assigns from all claims arising from or connected with the Seller&#8217;s performance of this contract, except for claims arising from the negligence, recklessness, or willful misconduct of Buyer or Buyer&#8217;s employees, officers, directors, affiliates, partially or wholly owned subsidiaries, agents, successors, and assigns. In the</font></div></div><div style="display:inline-block;max-width:6.463%;min-width:5.463%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.769%"><div style="margin-top:4.85pt;padding-left:7pt;padding-right:4.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">event such a claim is asserted, Buyer will notify Seller immediately, and Seller&#8217;s counsel will represent Buyer. If Buyer elects to be represented through its own counsel in addition to Seller&#8217;s counsel, Buyer is responsible for its attorney&#8217;s fees and associated expenses.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:19.6pt;text-indent:-12.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;text-decoration:underline">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;padding-left:5.1pt;text-decoration:underline">DELAYS</font></div><div style="margin-top:0.05pt;padding-left:7pt;padding-right:5.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">If Seller suffers delay in performance due to any cause beyond its reasonable control including, but not limited to, acts of God, act or failure to act of government, act or omission of Buyer, war, fire, flood, strike or labor trouble, sabotage, or delay in obtaining from others suitable services, materials, components, equipment, or transportation, the time for Seller&#8217;s performance shall be extended a period of time equal to the period of the delay and its consequences. Seller will give the Buyer written notice within a reasonable time after  Seller becomes aware of any such delay.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:19.6pt;text-indent:-12.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;text-decoration:underline">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;padding-left:5.1pt;text-decoration:underline">SITE PREPARATION</font></div><div style="margin-top:0.05pt;padding-left:7pt;padding-right:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Buyer shall prepare the installation site at Buyer&#8217;s expense&#59; provide utilities in accordance with Seller&#8217;s pre-installation instructions and specifications&#59; furnish uncrating, rigging, electrical (including step-up or step-down transformer if needed), plumbing, or other assistance, as required, and furnish materials and labor for connecting specified utilities to the purchased goods.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:7pt;padding-right:5.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">It is the Buyer&#8217;s sole responsibility to comply with X-ray registration, and satisfy all federal, state, and local X-ray radiation safety regulations with appropriate regulatory authorities.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:19.6pt;text-indent:-12.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;text-decoration:underline">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;padding-left:5.1pt;text-decoration:underline">INSTALLATION</font></div><div style="margin-top:0.1pt;padding-left:7pt;padding-right:5.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">On-site installation and instrumentation start up are provided by Seller at no additional charge unless otherwise stated in the quotation. Software applications training is offered per specifications and options in the body of the quotation.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:19.6pt;text-indent:-12.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;text-decoration:underline">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;padding-left:5.15pt;text-decoration:underline">CANCELLATION &#38; DAMAGES</font></div><div style="padding-left:7pt;padding-right:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Buyer may not cancel or terminate this contract for convenience, nor may it direct suspension of Seller&#8217;s manufacture of the purchased goods or delivery of the same, except with Seller&#8217;s written consent and then only with tender of payment to Seller sufficient to compensate Seller for all direct and consequential costs incurred as a result of Buyer&#8217;s agreement to this contract and subsequent cancellation, plus a reasonable amount for profit. Buyer understands and agrees that the goods sold pursuant to this contract may be customized and not re-sellable to other customers, and that Seller&#8217;s loss due to Buyer&#8217;s cancellation may be the entire contract price and, in such cases, agrees that Seller may reasonably require the payment of 100% of the contract price notwithstanding Buyer&#8217;s desire to cancel.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:19.6pt;text-indent:-12.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;text-decoration:underline">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;padding-left:5.15pt;text-decoration:underline">OBJECTIONS TO CHANGES</font></div><div style="margin-top:0.1pt;padding-left:7pt;padding-right:5.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Seller objects to any changes to these terms and conditions, which Buyer seeks to impose by means of terms stated in Buyer&#8217;s request for quotation, purchase order, or any other document of Buyer. Issuance of a purchase order hereto by Buyer constitutes Buyer&#8217;s assent to Seller&#8217;s terms and conditions. Acceptance of the quotation is expressly limited to the terms and conditions set forth herein. Any modification of these terms of sale must be specifically agreed to in writing by Rigaku.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:19.7pt;text-indent:-12.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;text-decoration:underline">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;padding-left:5.25pt;text-decoration:underline">AMENDMENT IN WRITING</font></div><div style="margin-top:0.05pt;padding-left:7pt;padding-right:5.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">These standard terms and conditions may not be amended except by a separate written agreement signed by both the Buyer and Seller. Alteration of the text of this document shall not constitute modification of the terms and conditions of this contract.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:19.6pt;text-indent:-12.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;text-decoration:underline">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;padding-left:5.15pt;text-decoration:underline">GOVERNING LAW</font></div><div style="margin-top:0.1pt;padding-left:7pt;padding-right:5.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">This contract shall be enforced pursuant to the law of the jurisdiction for the Seller&#8217;s office which issued this quotation, i.e. Texas, Massachusetts, Canada or the UK.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:19.7pt;text-indent:-12.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;text-decoration:underline">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;padding-left:5.25pt;text-decoration:underline">ASSIGNMENT</font></div><div style="margin-top:0.05pt;padding-left:7pt;padding-right:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Buyer&#8217;s obligations pursuant to this contract may not be assigned without the express, written agreement of Seller.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:19.6pt;text-indent:-12.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;text-decoration:underline">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;padding-left:5.15pt;text-decoration:underline">SEVERABILITY</font></div><div style="padding-left:7pt;padding-right:5.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">In the event that a court of competent jurisdiction shall hold any portion of this contract to be void or unenforceable, that portion of this contract shall be severed and the remainder shall remain in full force and effect.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:17.8pt;text-indent:-10.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;text-decoration:underline">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;padding-left:3.35pt;text-decoration:underline">TRADE COMPLIANCE TERMS&#47;OBLIGATIONS</font></div><div style="margin-top:0.05pt;padding-left:7pt;padding-right:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">U.S. export controls regulate the shipment of U.S.-origin Rigaku products that are exported or reexported to foreign countries. If Buyer exports or reexports products or technology of</font></div><div style="padding-left:7pt;padding-right:5.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">U.S. origin, or containing U.S. origin, it is the Buyer&#8217;s responsibility to ascertain its compliance obligations under the U.S. export laws and regulations, as well as any foreign export laws and regulations that may apply. The U.S. maintains economic sanctions against certain countries, including but not limited to, Cuba, Iran, North Korea, Sudan, and Syria. The export, reexport, sale, supply, or service, directly or indirectly, from the U.S. or by a U.S. person, wherever located, to any sanctioned countries is strictly prohibited without prior authorization by the U.S. Government. Buyer shall not sell, transfer, export or reexport Rigaku products to prohibited countries, or individuals listed on U.S. Government denied party lists, or for prohibited end-uses.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:17.8pt;text-indent:-10.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;text-decoration:underline">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%;padding-left:3.35pt;text-decoration:underline">COMPLIANCE WITH THE FOREIGN CORRUPT PRACTICES ACT</font></div><div style="margin-top:0.05pt;padding-left:7pt;padding-right:5.15pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Buyer acknowledges and agrees to comply with the U.S. Foreign Corrupt Practices Act, which prohibits the corrupt offer, payment, promise to pay or authorization of payment of anything of value, directly or indirectly, to a foreign official, political party or official thereof, or candidate for political office for the purpose of influencing any official act or inducing the official to use his influence to obtain or retain business.</font></div></div></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:6.3pt"><font><br></font></div><div style="height:32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:7%">Page </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:7%">6 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:7%">of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:7%">6</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>5
<FILENAME>ex1024neoleukinleaseamendm.htm
<DESCRIPTION>EX-10.24
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i2696b8e45b6b4867b27d247f87c1ddfa_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 10.24</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FIRST AMENDMENT TO LEASE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THIS FIRST AMENDMENT TO LEASE (this &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Amendment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is made as of November&#160;5th, 2020, by and between </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARE-SEATTLE NO. 28, LLC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Landlord</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOLEUKIN THERAPEUTICS, INC.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tenant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Landlord and Tenant are now parties to that certain lease dated as of December 23, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  Pursuant to the Lease, Tenant leases certain premises consisting of approximately 33,300 rentable square feet (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Premises</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) located in that certain building located at 188 East Blaine Street, Seattle, Washington.  The Premises are more particularly described in the Lease.  Capitalized terms used herein without definition shall have the meanings defined for such terms in the Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Landlord and Tenant desire, subject to the terms and conditions set forth below, to amend the work letter attached to the Lease as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit C</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Work Letter</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), as provided in this First Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in consideration of the foregoing Recitals, which are incorporated herein by this reference, the mutual promises and conditions contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt;text-decoration:underline">Rent Commencement Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  As of the date of this First Amendment, Landlord and Tenant acknowledge agree that the defined term &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rent Commencement Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; set forth in the second paragraph of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Lease is hereby deleted and that the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rent Commencement Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; under the Lease shall be February 1, 2021.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt;text-decoration:underline">Implementation of Changes</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  As of the date of this First Amendment, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Work Letter is hereby deleted in its entirety and replaced with the following&#58;      </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;If Landlord approves such Change, Tenant may cause the approved Change to be instituted.  If any TI Permit modification or change is required as a result of such Change, Tenant shall promptly provide Landlord with a copy of such TI Permit modification or change.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt;text-decoration:underline">Budget For Tenant Improvements.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this First Amendment, the final sentence of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Work Letter is hereby deleted in its entirety.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt;text-decoration:underline">Excess TI Costs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  As of the date of this First Amendment, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Work Letter is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;(e) Excess TI Costs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Landlord shall have no obligation to bear any portion of the cost of any of the Tenant Improvements except to the extent of the TI Allowance.  Tenant shall be responsible for any and all TI Costs in excess of the TI Allowance (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Excess TI Costs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  The TI Allowance and Excess TI Costs are herein referred to as the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TI Fund</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;  Notwithstanding anything to the contrary set forth in this </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Tenant shall be fully and solely liable for TI Costs and the cost of Minor Variations in excess of the TI Allowance.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Payment of TI Costs</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary contained in the Work Letter, Landlord&#8217;s reimbursement of TI Costs under </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shall be subject to the terms of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5(e</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Tenant Server Room</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In connection with Tenant&#8217;s use and occupancy of the Premises, Tenant shall have the right, at Tenant&#8217;s sole cost and expense, to construct, pursuant to plans and specifications reasonably approved by Landlord, an enclosure of approximately 400 square feet in a location in the Building garage designated by Landlord, for the storage and operation of Tenant&#8217;s server equipment serving the Premises (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Server Room</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).  Notwithstanding anything to the contrary contained in the Lease, the construction of the Server Room shall constitute an Alteration under the Lease and shall be subject to the terms and conditions of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Lease.  Tenant shall have all of the obligations under the Lease with respect to the Server Room as though the Server Room were part of the Premises, excluding the obligation to pay Base Rent.  Tenant shall be responsible for any additional Utilities and&#47;or Operating Expenses relating to the Server Room.  Tenant shall maintain appropriate records, obtain and maintain appropriate permits, insurance, implement reporting procedures, and take or cause to be taken all other actions necessary or required under applicable Legal Requirements in connection with the use of the Server Room.  Landlord shall have no obligation to make any repairs or other improvements to the Server Room and Tenant shall maintain the same, at Tenant&#8217;s sole cost and expense, in the same condition following the construction of the Server Room as though the same were part of the Premises.  Tenant shall, at Tenant&#8217;s sole cost and expense, surrender the Server Room at the expiration or earlier termination of the term of the Lease free of any debris and trash and free of any Hazardous Materials in accordance with the requirements of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 28</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Lease.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Brokers</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Landlord and Tenant each represents and warrants that it has not dealt with any broker, agent or other person (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Broker</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) in connection with the transaction reflected in this First Amendment and that no Broker brought about this transaction.  Landlord and Tenant each hereby agrees to indemnify and hold the other harmless from and against any claims by any Broker claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable, with regard to this First Amendment.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt;text-decoration:underline">OFAC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Tenant and all beneficial owners of Tenant are currently (a) in compliance with and shall at all times during the Term of this Lease remain in compliance with the regulations of the Office of Foreign Assets Control (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFAC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of the U.S. Department of Treasury and any statute, executive order, or regulation relating thereto (collectively, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFAC Rules</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), (b) not listed on, and shall not during the term of this Lease be listed on, the Specially Designated Nationals and Blocked Persons List, Foreign Sanctions Evaders List, or the Sectoral Sanctions Identification List, which are all maintained by OFAC and&#47;or on any other similar list maintained by OFAC or other governmental authority pursuant to any authorizing statute, executive order, or regulation, and (c) not a person or entity with whom a U.S. person is prohibited from conducting business under the OFAC Rules.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.67pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-5.54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">i.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This First Amendment is the entire agreement between the parties with respect to the subject matter contained in this First Amendment and supersedes all prior and contemporaneous oral and written agreements and discussions.  This First Amendment may be amended only by an agreement in writing, signed by the parties hereto.  Except as amended and&#47;or modified by this First Amendment, the Lease is hereby ratified and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered and unchanged by this First Amendment.  In the event of any conflict between the provisions of this First Amendment and the provisions of the Lease, the provisions of this First Amendment shall prevail.  Whether or not specifically amended by this First Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to the purpose and intent of this First Amendment.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-8.31pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This First Amendment is binding upon and shall inure to the benefit of the parties hereto, and their respective successors and assigns.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-11.08pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">iii.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This First Amendment may be executed in 2 or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature process complying with the U.S. federal ESIGN Act of 2000) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.  Electronic signatures shall be deemed original signatures for purposes of this First Amendment and all matters related thereto, with such electronic signatures having the same legal effect as original signatures. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-11.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">iv.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Landlord and Tenant intend to be bound by this First Amendment and to deliver notarized signatures to this First Amendment, but are unable to deliver notarized signatures due to the Stay Home-Stay Healthy Proclamation by the Governor of the State of Washington, Proclamation 20 - 25.  Landlord and Tenant are delivering signatures without notary, with the intent to be fully bound by this First Amendment and will, as soon as reasonably possible, deliver notarized signatures for this First Amendment. Landlord and Tenant each acknowledge that the other party intends to rely on the statements in this First Amendment.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#91;Signatures are on the next page.&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the parties hereto have executed this First Amendment as of the dates set forth below.</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TENANT&#58;</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOLEUKIN THERAPEUTICS, INC.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a Delaware corporation</font></div><div style="padding-left:216pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jonathan G. Drachman        </font></div><div style="margin-bottom:6pt;padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Its&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CEO</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LANDLORD&#58;</font></div><div style="padding-left:216pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARE-SEATTLE NO. 28, LLC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a Delaware limited liability company</font></div><div style="margin-bottom:12pt;padding-left:243.35pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;     ALEXANDRIA REAL ESTATE EQUITIES, L.P., a Delaware limited partnership, managing member</font></div><div style="margin-bottom:24pt;padding-left:270.7pt;text-indent:-27.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;     ARE-QRS CORP., a Maryland corporation, general partner&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                       By&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Gregory Kay</font></div><div style="margin-bottom:6pt;padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">            &#160;&#160;&#160;&#160;          Its&#58; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Vice President RE Legal Affairs</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">LANDLORD&#8217;S ACKNOWLEDGMENT</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.160%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">STATE OF CALIFORNIA&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; )</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; ) &#167;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">County of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; ) </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On ______________, 2020, before me, ________________________________, a Notary Public, personally appeared ___________________________________ who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is&#47;are subscribed to the within instrument and acknowledged to me that he&#47;she&#47;they executed the same in his&#47;her&#47;their authorized capacity(ies), and that by his&#47;her&#47;their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WITNESS my hand and official seal.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Signature of Notary</font></div><div style="padding-left:288pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Affix seal here)</font></div><div style="padding-left:288pt;text-indent:36pt"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">TENANT&#8217;S ACKNOWLEDGMENT</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.858%"><tr><td style="width:1.0%"></td><td style="width:40.043%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">STATE OF WASHINGTON</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COUNTY OF KING</font></div></td><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ss.</font></div><div><font><br></font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On this ____ day of ___________, 2020, before me personally appeared ___________________, to me known to be the Authorized Signatory of Amazon.com Services LLC, a Delaware limited liability company, that executed the within and foregoing instrument, and acknowledged the said instrument to be the free and voluntary act and deed of said corporation for the uses and purposes therein mentioned, and on oath stated that they were authorized to execute said instrument.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, I have hereunto set my hand and affixed my official seal the day and year first above written.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 217pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(Signature of Notary)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 217pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(Legibly Print or Stamp Name of Notary)</font></td></tr></table></div><div style="margin-top:3pt;padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notary public in and for the State of Washington,</font></div><div style="margin-top:3pt;padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">residing at </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-top:6pt;padding-left:216pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">My appointment expires </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="margin-bottom:24pt;padding-left:270.7pt;text-indent:-27.35pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>6
<FILENAME>ex211-listofsubsidiaries.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib0da4bfb808a45ff89f8cfda3583638f_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LIST OF SUBSIDIARIES OF NEOLEUKIN THERAPEUTICS, INC.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:33.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.648%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subsidiaries</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incorporation</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>ex231-consentofindependent.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i45f7cf4de1154f998463d5f6841c42e5_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">We consent to the incorporation by reference in Registration Statement Nos. 333-194490, 333-203179, 333-210172, 333-216572, 333-223589, 333-234734, 333-237124 and 333-238021 on Form S-8 and No. 333-251294 on Form S-3 of our report dated March 25, 2021, relating to the financial statements of Neoleukin Therapeutics, Inc. appearing in this Annual Report on Form 10-K of Neoleukin Therapeutics, Inc. for the year ended December 31, 2020.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#47;s&#47; Deloitte &#38; Touche LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Seattle, Washington</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">March 25, 2021</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>8
<FILENAME>ex232-consentofindependent.htm
<DESCRIPTION>EX-23.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ide3377e7ed144c029609cb8a1f3185fc_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 23.2</font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">We consent to the incorporation by reference in Registration Statement Nos.333-194490, 333-203179, 333-210172, 333-216572, 333-223589, 333-234734, 333-237124 and 333-238021 on Form S-8 and No. 333-251294 on Form S-3 of our report dated March 12, 2020, relating to the financial statements of Neoleukin Therapeutics, Inc. appearing in this Annual Report on Form 10-K of Neoleukin Therapeutics, Inc. for the year ended December 31, 2020.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#47;s&#47; Deloitte LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Chartered Professional Accountants</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Vancouver, Canada</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">March 25, 2021</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>nltx-20201231xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i217689873dbe4836b3dbd0df02ce10d8_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jonathan G. Drachman, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Annual Report on Form 10-K of Neoleukin Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and&#160;15d-15(e))&#160;and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and&#160;15d-15(f))&#160;for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.24pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.67pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.965%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March 25, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Jonathan G. Drachman</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jonathan G. Drachman</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chief Executive Officer</font></div></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>nltx-20201231xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i5620d2d7c4f8494d8a4a632c83b44c82_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Robert Ho, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Annual Report on Form 10-K of Neoleukin Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and&#160;15d-15(e))&#160;and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and&#160;15d-15(f))&#160;for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.24pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.67pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.965%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March 25, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Robert Ho</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Robert Ho</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chief Financial Officer</font></div></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>nltx-20201231xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i3eb83b282f914690a4ff082ef0d303ef_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOLEUKIN THERAPEUTICS, INC.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Neoleukin Therapeutics, Inc. (the &#8220;Company&#8221;) on Form&#160;10-K&#160;for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Jonathan G. Drachman, Chief Executive Officer of the Company, certify, pursuant to Rule&#160;13a-14(b)&#160;under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Exchange Act&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:39.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:57.905%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47;&#160;&#160;&#160;&#160;Jonathan G. Drachman</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jonathan G. Drachman</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chief Executive Officer</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;25, 2021 </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form&#160;10-K&#160;to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Neoleukin Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form&#160;10-K),&#160;irrespective of any general incorporation language contained in such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>12
<FILENAME>nltx-20201231xex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i09b581fcc6e245d8b5aef106fa6a4af3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEOLEUKIN THERAPEUTICS, INC.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Neoleukin Therapeutics, Inc. (the &#8220;Company&#8221;) on Form&#160;10-K&#160;for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Kamran Alam, Interim Chief Financial Officer of the Company, certify, pursuant to Rule&#160;13a-14(b)&#160;under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Exchange Act&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47;&#160;&#160;&#160;&#160;Robert Ho</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Robert Ho</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chief Financial Officer</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;25, 2021 </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form&#160;10-K&#160;to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Neoleukin Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form&#160;10-K),&#160;irrespective of any general incorporation language contained in such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>nltx-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:6019b606-66e1-49bc-8c33-d6cc15ba3335,g:b750dab7-5d48-4ebb-bb7b-41a017d885d1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nltx="http://www.aqxpharma.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.aqxpharma.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nltx-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nltx-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nltx-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nltx-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.aqxpharma.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.aqxpharma.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.aqxpharma.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.aqxpharma.com/role/ConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1004005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsParenthetical" roleURI="http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlowsParenthetical">
        <link:definition>1405401 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1006006 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>1407402 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Natureofoperations" roleURI="http://www.aqxpharma.com/role/Natureofoperations">
        <link:definition>2101101 - Disclosure - Nature of operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Basisofpresentationandsummaryofsignificantaccountingpolicies" roleURI="http://www.aqxpharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies">
        <link:definition>2102102 - Disclosure - Basis of presentation and summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpresentationandsummaryofsignificantaccountingpoliciesTables" roleURI="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesTables">
        <link:definition>2303301 - Disclosure - Basis of presentation and summary of significant accounting policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies" roleURI="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies">
        <link:definition>2204201 - Disclosure - Basis of presentation and summary of significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails" roleURI="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails">
        <link:definition>2405403 - Disclosure - Basis of presentation and summary of significant accounting policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpresentationandsummaryofsignificantaccountingpoliciesCashandcashequivalentsandrestrictedcashDetails" roleURI="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesCashandcashequivalentsandrestrictedcashDetails">
        <link:definition>2406404 - Disclosure - Basis of presentation and summary of significant accounting policies - Cash and cash equivalents and restricted cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsInc" roleURI="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsInc">
        <link:definition>2107103 - Disclosure - Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncTables" roleURI="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncTables">
        <link:definition>2308302 - Disclosure - Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails" roleURI="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails">
        <link:definition>2409405 - Disclosure - Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails" roleURI="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails">
        <link:definition>2410406 - Disclosure - Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. - Schedule of Total Consideration Paid (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>2411407 - Disclosure - Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. - Summary of the Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Propertyandequipmentnet" roleURI="http://www.aqxpharma.com/role/Propertyandequipmentnet">
        <link:definition>2112104 - Disclosure - Property and equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandequipmentnetTables" roleURI="http://www.aqxpharma.com/role/PropertyandequipmentnetTables">
        <link:definition>2313303 - Disclosure - Property and equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandequipmentnetScheduleofPropertyandEquipmentDetails" roleURI="http://www.aqxpharma.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails">
        <link:definition>2414408 - Disclosure - Property and equipment, net - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandequipmentnetAdditionalInformationDetails" roleURI="http://www.aqxpharma.com/role/PropertyandequipmentnetAdditionalInformationDetails">
        <link:definition>2415409 - Disclosure - Property and equipment, net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Intangibleassetnet" roleURI="http://www.aqxpharma.com/role/Intangibleassetnet">
        <link:definition>2116105 - Disclosure - Intangible asset, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetnetTables" roleURI="http://www.aqxpharma.com/role/IntangibleassetnetTables">
        <link:definition>2317304 - Disclosure - Intangible asset, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetnetSummaryofIntangibleAssetDetails" roleURI="http://www.aqxpharma.com/role/IntangibleassetnetSummaryofIntangibleAssetDetails">
        <link:definition>2418410 - Disclosure - Intangible asset, net - Summary of Intangible Asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Accountspayableandotherliabilities" roleURI="http://www.aqxpharma.com/role/Accountspayableandotherliabilities">
        <link:definition>2119106 - Disclosure - Accounts payable and other liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountspayableandotherliabilitiesTables" roleURI="http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesTables">
        <link:definition>2320305 - Disclosure - Accounts payable and other liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountspayableandotherliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails" roleURI="http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails">
        <link:definition>2421411 - Disclosure - Accounts payable and other liabilities - Schedule of Accounts Payable and Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.aqxpharma.com/role/Leases">
        <link:definition>2122107 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.aqxpharma.com/role/LeasesTables">
        <link:definition>2323306 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails">
        <link:definition>2424412 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofComponentsofLeaseExpenseDetails" roleURI="http://www.aqxpharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails">
        <link:definition>2425413 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashflowInformationRelatedtoLeasesDetails" roleURI="http://www.aqxpharma.com/role/LeasesSupplementalCashflowInformationRelatedtoLeasesDetails">
        <link:definition>2426414 - Disclosure - Leases - Supplemental Cash flow Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails" roleURI="http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails">
        <link:definition>2427415 - Disclosure - Leases - Schedule of Company's Operating and Finance Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails_1" roleURI="http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails_1">
        <link:definition>2427415 - Disclosure - Leases - Schedule of Company's Operating and Finance Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Stockholdersequity" roleURI="http://www.aqxpharma.com/role/Stockholdersequity">
        <link:definition>2128108 - Disclosure - Stockholders' equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityTables" roleURI="http://www.aqxpharma.com/role/StockholdersequityTables">
        <link:definition>2329307 - Disclosure - Stockholders' equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityAdditionalInformationDetails" roleURI="http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails">
        <link:definition>2430416 - Disclosure - Stockholders' equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityScheduleofStockOptionActivityDetails" roleURI="http://www.aqxpharma.com/role/StockholdersequityScheduleofStockOptionActivityDetails">
        <link:definition>2431417 - Disclosure - Stockholders' equity - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityScheduleofWeightedAverageAssumptionsDetails" roleURI="http://www.aqxpharma.com/role/StockholdersequityScheduleofWeightedAverageAssumptionsDetails">
        <link:definition>2432418 - Disclosure - Stockholders' equity - Schedule of Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequityScheduleofRSUActivityDetails" roleURI="http://www.aqxpharma.com/role/StockholdersequityScheduleofRSUActivityDetails">
        <link:definition>2433419 - Disclosure - Stockholders' equity - Schedule of RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersequitySummaryofStockbasedCompensationExpenseDetails" roleURI="http://www.aqxpharma.com/role/StockholdersequitySummaryofStockbasedCompensationExpenseDetails">
        <link:definition>2434420 - Disclosure - Stockholders' equity - Summary of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://www.aqxpharma.com/role/Restructuring">
        <link:definition>2135109 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringAdditionalInformationDetails" roleURI="http://www.aqxpharma.com/role/RestructuringAdditionalInformationDetails">
        <link:definition>2436421 - Disclosure - Restructuring - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Otherincomenet" roleURI="http://www.aqxpharma.com/role/Otherincomenet">
        <link:definition>2137110 - Disclosure - Other income, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherincomenetTables" roleURI="http://www.aqxpharma.com/role/OtherincomenetTables">
        <link:definition>2338308 - Disclosure - Other income, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherincomenetScheduleofOtherIncomeNetDetails" roleURI="http://www.aqxpharma.com/role/OtherincomenetScheduleofOtherIncomeNetDetails">
        <link:definition>2439422 - Disclosure - Other income, net - Schedule of Other Income Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Netlosspercommonstock" roleURI="http://www.aqxpharma.com/role/Netlosspercommonstock">
        <link:definition>2140111 - Disclosure - Net loss per common stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetlosspercommonstockTables" roleURI="http://www.aqxpharma.com/role/NetlosspercommonstockTables">
        <link:definition>2341309 - Disclosure - Net loss per common stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetlosspercommonstockScheduleofSecuritiesExcludedFromComputationofEarningsPerShareDetails" roleURI="http://www.aqxpharma.com/role/NetlosspercommonstockScheduleofSecuritiesExcludedFromComputationofEarningsPerShareDetails">
        <link:definition>2442423 - Disclosure - Net loss per common stock - Schedule of Securities Excluded From Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Incometaxes" roleURI="http://www.aqxpharma.com/role/Incometaxes">
        <link:definition>2143112 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesTables" roleURI="http://www.aqxpharma.com/role/IncometaxesTables">
        <link:definition>2344310 - Disclosure - Income taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncometaxRecoveryDetails" roleURI="http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails">
        <link:definition>2445424 - Disclosure - Income Taxes - Schedule of Income tax Recovery (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofNetLossIncomeBeforeTaxesDetails" roleURI="http://www.aqxpharma.com/role/IncomeTaxesScheduleofNetLossIncomeBeforeTaxesDetails">
        <link:definition>2446425 - Disclosure - Income Taxes - Schedule of Net (Loss) Income Before Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails" roleURI="http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails">
        <link:definition>2447426 - Disclosure - Income Taxes - Components of Deferred Income Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.aqxpharma.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>2448427 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Licenseandpatentagreements" roleURI="http://www.aqxpharma.com/role/Licenseandpatentagreements">
        <link:definition>2149113 - Disclosure - License and patent agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseandpatentagreementsAdditionalInformationDetails" roleURI="http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails">
        <link:definition>2450428 - Disclosure - License and patent agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Commitmentsandcontingencies" roleURI="http://www.aqxpharma.com/role/Commitmentsandcontingencies">
        <link:definition>2151114 - Disclosure - Commitments and contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.aqxpharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>2452429 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kplan" roleURI="http://www.aqxpharma.com/role/A401kplan">
        <link:definition>2153115 - Disclosure - 401(k) plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofAquinoxCanada" roleURI="http://www.aqxpharma.com/role/SaleofAquinoxCanada">
        <link:definition>2154116 - Disclosure - Sale of Aquinox Canada</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofAquinoxCanadaDetails" roleURI="http://www.aqxpharma.com/role/SaleofAquinoxCanadaDetails">
        <link:definition>2455430 - Disclosure - Sale of Aquinox Canada (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="nltx_AcquisitionsOfAssetsConsiderationTransferred" abstract="false" name="AcquisitionsOfAssetsConsiderationTransferred" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_StockBasedCompensationIncreaseInCommonStockIssuancePercentage" abstract="false" name="StockBasedCompensationIncreaseInCommonStockIssuancePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants" abstract="false" name="StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nltx_FurnitureFixturesAndITEquipmentMember" abstract="true" name="FurnitureFixturesAndITEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet" abstract="false" name="AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_AcquisitionsOfAssetsTransactionCosts" abstract="false" name="AcquisitionsOfAssetsTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets" abstract="false" name="AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_PreFundedCommonStockWarrantsMember" abstract="true" name="PreFundedCommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nltx_LicenseArrangementsAmountsPayableOnDevelopmentalMilestones" abstract="false" name="LicenseArrangementsAmountsPayableOnDevelopmentalMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_AcquisitionsOfAssetsCashConsiderationForFractionalShares" abstract="false" name="AcquisitionsOfAssetsCashConsiderationForFractionalShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_AccruedClinicalExpensesCurrent" abstract="false" name="AccruedClinicalExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_PublicStockOfferingMember" abstract="true" name="PublicStockOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nltx_OtherCurrentAssetsAcquiredThroughTheIssuanceOfCommonStock" abstract="false" name="OtherCurrentAssetsAcquiredThroughTheIssuanceOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_AcquisitionOfAssetsAxis" abstract="true" name="AcquisitionOfAssetsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability" abstract="false" name="AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_IncomeTaxesDisclosureLineItems" abstract="true" name="IncomeTaxesDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nltx_IncomeTaxesDisclosureTable" abstract="true" name="IncomeTaxesDisclosureTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nltx_PreFundedWarrantIssuedPricePerShare" abstract="false" name="PreFundedWarrantIssuedPricePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="nltx_UniversityOfWashingtonMember" abstract="true" name="UniversityOfWashingtonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nltx_DeferredTaxAssetsBeforeValuationAllowance" abstract="false" name="DeferredTaxAssetsBeforeValuationAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_LicenseAndPatentAgreementsTable" abstract="true" name="LicenseAndPatentAgreementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nltx_OperatingLeaseLiabilityIncreaseDueToRemeasurement" abstract="false" name="OperatingLeaseLiabilityIncreaseDueToRemeasurement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_LicenseAgreementAbstract" abstract="true" name="LicenseAgreementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nltx_PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock" abstract="false" name="PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_RestructuringPlan1July2018Member" abstract="true" name="RestructuringPlan1July2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nltx_StockConversionRatio" abstract="false" name="StockConversionRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear" abstract="false" name="EmployeeStockPurchasePlanNumberOfOfferingPerYear" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset" abstract="false" name="AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_PercentageOfOutstandingStockPerStockholderMaximum" abstract="false" name="PercentageOfOutstandingStockPerStockholderMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nltx_SubsidiarySaleOfStockAbstract" abstract="true" name="SubsidiarySaleOfStockAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nltx_ProceedsFromSaleOfStockOfSubsidiary" abstract="false" name="ProceedsFromSaleOfStockOfSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_NonVotingConvertiblePreferredStockMember" abstract="true" name="NonVotingConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nltx_AcquisitionOfAssetsDisclosureTextBlock" abstract="false" name="AcquisitionOfAssetsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nltx_RestructuringPlan1November62018Member" abstract="true" name="RestructuringPlan1November62018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract" abstract="true" name="AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nltx_SubsidiarySaleOfStockTextBlock" abstract="false" name="SubsidiarySaleOfStockTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nltx_LicenseAgreementDisclosureTextBlock" abstract="false" name="LicenseAgreementDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" abstract="false" name="AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_AdditionalTenantImprovements" abstract="false" name="AdditionalTenantImprovements" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_AcquisitionOfAssetsTable" abstract="true" name="AcquisitionOfAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nltx_StockIncentivePlanTwoThousandFourteenMember" abstract="true" name="StockIncentivePlanTwoThousandFourteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nltx_TransactionRelatedCostIncurredForSaleOfSubsidiary" abstract="false" name="TransactionRelatedCostIncurredForSaleOfSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents" abstract="false" name="AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_NumberOfDaysAdvanceNoticeMustBeGivenToTerminateTheLease" abstract="false" name="NumberOfDaysAdvanceNoticeMustBeGivenToTerminateTheLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember" abstract="true" name="OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nltx_OperatingLossCarryforwardsNotSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsNotSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_EquityIncentivePlanTwoThousandSixMember" abstract="true" name="EquityIncentivePlanTwoThousandSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nltx_AssetAcquisitionsintangibleAssetsPolicyTextBlock" abstract="false" name="AssetAcquisitionsintangibleAssetsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nltx_AcquisitionOfAssetsAbstract" abstract="true" name="AcquisitionOfAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities" abstract="false" name="AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_LicenseArrangementsAmountsPayableBasedOnNetSales" abstract="false" name="LicenseArrangementsAmountsPayableBasedOnNetSales" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_A2020EmployeeStockPurchasePlanMember" abstract="true" name="A2020EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nltx_OperatingLossCarryforwardsSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract" abstract="true" name="AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nltx_AcqinoxCanadaMember" abstract="true" name="AcqinoxCanadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nltx_LicenseAndPatentAgreementsLineItems" abstract="true" name="LicenseAndPatentAgreementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nltx_ConvertiblePreferredStockToBeConverted" abstract="false" name="ConvertiblePreferredStockToBeConverted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nltx_WriteOffOfRightOfUseAssetUponLeaseTermination" abstract="false" name="WriteOffOfRightOfUseAssetUponLeaseTermination" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_SignificantAccountingPoliciesLineItems" abstract="true" name="SignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment" abstract="false" name="AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_FinanceLeasePrincipalAndInterestPayments" abstract="false" name="FinanceLeasePrincipalAndInterestPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_DeferredTaxAssetsLeaseLiability" abstract="false" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_CommissionsOnPublicOffering" abstract="false" name="CommissionsOnPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nltx_OperatingLeaseRightOfUseAssetIncreaseDueToRemeasurement" abstract="false" name="OperatingLeaseRightOfUseAssetIncreaseDueToRemeasurement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_TenantImprovementAllowance" abstract="false" name="TenantImprovementAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_TenantImprovementAllowanceReceivable" abstract="false" name="TenantImprovementAllowanceReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_AcquisitionsOfAssetsFairValueOfSharesIssued" abstract="false" name="AcquisitionsOfAssetsFairValueOfSharesIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_NumberOfOptionToExtendLease" abstract="false" name="NumberOfOptionToExtendLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_LeaseAgreementExtendedPeriod" abstract="false" name="LeaseAgreementExtendedPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nltx_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nltx_OfficeSpaceFormerPrincipalExecutiveOfficesAndLaboratoryMember" abstract="true" name="OfficeSpaceFormerPrincipalExecutiveOfficesAndLaboratoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nltx_TerminationFeesForLeaseTermination" abstract="false" name="TerminationFeesForLeaseTermination" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_AcquisitionOfAssetsDomain" abstract="true" name="AcquisitionOfAssetsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits" abstract="false" name="AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" abstract="false" name="ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nltx_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nltx_AquinoxMember" abstract="true" name="AquinoxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nltx_PeriodSharesReservedForIssuanceWillIncrease" abstract="false" name="PeriodSharesReservedForIssuanceWillIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nltx_SignificantAccountingPoliciesTable" abstract="true" name="SignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed" abstract="false" name="AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_DeferredTaxAssetsTaxCreditCarryforwardsReducedDueToSaleOfForeignEntity" abstract="false" name="DeferredTaxAssetsTaxCreditCarryforwardsReducedDueToSaleOfForeignEntity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nltx_AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock" abstract="false" name="AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nltx_AcquisitionOfAssetsNetCashAcquired" abstract="false" name="AcquisitionOfAssetsNetCashAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>nltx-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:6019b606-66e1-49bc-8c33-d6cc15ba3335,g:b750dab7-5d48-4ebb-bb7b-41a017d885d1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CoverPage" xlink:type="simple" xlink:href="nltx-20201231.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nltx-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b0e9e641-a2db-4990-a685-311d99eb5379" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_41337c0f-4ab2-44be-a785-f711eac7cbf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b0e9e641-a2db-4990-a685-311d99eb5379" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_41337c0f-4ab2-44be-a785-f711eac7cbf7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_90d9cd2f-ac8c-4287-a93f-45ab69cc4430" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b0e9e641-a2db-4990-a685-311d99eb5379" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_90d9cd2f-ac8c-4287-a93f-45ab69cc4430" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_a71c5160-1224-43ee-9c92-982f053787f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b0e9e641-a2db-4990-a685-311d99eb5379" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_a71c5160-1224-43ee-9c92-982f053787f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_22767beb-9a52-4e0c-ae82-77657c485e99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fd4ab1c5-dcf1-494b-9c28-2820b2eb3fa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_22767beb-9a52-4e0c-ae82-77657c485e99" xlink:to="loc_us-gaap_StockholdersEquity_fd4ab1c5-dcf1-494b-9c28-2820b2eb3fa8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_66e45fca-5d50-4919-8f26-b2e098df3ea3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_22767beb-9a52-4e0c-ae82-77657c485e99" xlink:to="loc_us-gaap_Liabilities_66e45fca-5d50-4919-8f26-b2e098df3ea3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dae84818-cdbd-45d4-abf5-aac1b4fed167" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_34f947fc-0b89-4d82-82a9-90861d16d699" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dae84818-cdbd-45d4-abf5-aac1b4fed167" xlink:to="loc_us-gaap_CommonStockValue_34f947fc-0b89-4d82-82a9-90861d16d699" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_b753ff9c-e549-4ccd-b5b4-27ea62ae122a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dae84818-cdbd-45d4-abf5-aac1b4fed167" xlink:to="loc_us-gaap_AdditionalPaidInCapital_b753ff9c-e549-4ccd-b5b4-27ea62ae122a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_806b1a76-2ee6-4be8-b9ab-0b5f34ac92d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dae84818-cdbd-45d4-abf5-aac1b4fed167" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_806b1a76-2ee6-4be8-b9ab-0b5f34ac92d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_915becb7-9b0b-464c-ae8d-d57dcc5a7d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dae84818-cdbd-45d4-abf5-aac1b4fed167" xlink:to="loc_us-gaap_PreferredStockValue_915becb7-9b0b-464c-ae8d-d57dcc5a7d4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d7eddd3e-1c2d-4649-8a3b-e491f784dfbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_80786c3e-2c73-4f1b-a2e9-077c739d09e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d7eddd3e-1c2d-4649-8a3b-e491f784dfbd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_80786c3e-2c73-4f1b-a2e9-077c739d09e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_1ccb107d-5462-455e-b066-c3b4a805ed94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d7eddd3e-1c2d-4649-8a3b-e491f784dfbd" xlink:to="loc_us-gaap_OtherAssetsCurrent_1ccb107d-5462-455e-b066-c3b4a805ed94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e39fd6b1-81db-4bf0-aa71-9da5b569324f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e8719835-4509-413e-a9d8-f8bc3e114a53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e39fd6b1-81db-4bf0-aa71-9da5b569324f" xlink:to="loc_us-gaap_AssetsCurrent_e8719835-4509-413e-a9d8-f8bc3e114a53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2c041082-7ec0-44d3-b77a-9aba60c4daaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e39fd6b1-81db-4bf0-aa71-9da5b569324f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2c041082-7ec0-44d3-b77a-9aba60c4daaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_826f167f-3711-48df-ac74-ac1f73692e8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e39fd6b1-81db-4bf0-aa71-9da5b569324f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_826f167f-3711-48df-ac74-ac1f73692e8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_078686ef-3511-453d-9c2e-8bdb1905f053" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e39fd6b1-81db-4bf0-aa71-9da5b569324f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_078686ef-3511-453d-9c2e-8bdb1905f053" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5f70477c-6d3e-458f-bd67-60fcfeb78865" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e39fd6b1-81db-4bf0-aa71-9da5b569324f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5f70477c-6d3e-458f-bd67-60fcfeb78865" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_47d2d8a5-98ca-45d1-916b-bed42f7eefeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ef0ae83e-c751-4567-b2f6-58299fa68a85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_47d2d8a5-98ca-45d1-916b-bed42f7eefeb" xlink:to="loc_us-gaap_LiabilitiesCurrent_ef0ae83e-c751-4567-b2f6-58299fa68a85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c0f55948-330c-4aef-9cce-ae3d67b9865c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_47d2d8a5-98ca-45d1-916b-bed42f7eefeb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c0f55948-330c-4aef-9cce-ae3d67b9865c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_00621069-f097-4665-9f23-6ed5d827a168" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_47d2d8a5-98ca-45d1-916b-bed42f7eefeb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_00621069-f097-4665-9f23-6ed5d827a168" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nltx-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nltx-20201231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_84b6f75d-d5ca-4d76-8005-11b7880ebce7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bd4e1a5b-d4d1-4f58-bcb4-58d8c19c719b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_84b6f75d-d5ca-4d76-8005-11b7880ebce7" xlink:to="loc_us-gaap_OperatingIncomeLoss_bd4e1a5b-d4d1-4f58-bcb4-58d8c19c719b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_58dec5ad-d5a7-4e4b-835f-3f48a7ee23ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_84b6f75d-d5ca-4d76-8005-11b7880ebce7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_58dec5ad-d5a7-4e4b-835f-3f48a7ee23ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e446298e-f00d-4369-a641-a5675e36c8d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary_cb6c1cfb-ea12-4cbd-bae5-64198519961d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e446298e-f00d-4369-a641-a5675e36c8d0" xlink:to="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary_cb6c1cfb-ea12-4cbd-bae5-64198519961d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0c236990-fcb5-405c-b79d-92ea86dfee17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e446298e-f00d-4369-a641-a5675e36c8d0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0c236990-fcb5-405c-b79d-92ea86dfee17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_f2e172e6-5211-4954-8f14-d3ce42feb04c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e446298e-f00d-4369-a641-a5675e36c8d0" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_f2e172e6-5211-4954-8f14-d3ce42feb04c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_772d2170-ad3a-4d40-92e6-463120f8b9fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e446298e-f00d-4369-a641-a5675e36c8d0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_772d2170-ad3a-4d40-92e6-463120f8b9fd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nltx-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_708b2ca8-b8fd-4fac-a117-5115e63a2bcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_cf1f0c27-928b-4c05-91b7-2bf7eae90016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_708b2ca8-b8fd-4fac-a117-5115e63a2bcf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_cf1f0c27-928b-4c05-91b7-2bf7eae90016" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_c05cdd3d-b260-4713-963e-81c9cf2f6cb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_708b2ca8-b8fd-4fac-a117-5115e63a2bcf" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_c05cdd3d-b260-4713-963e-81c9cf2f6cb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7f4466ce-b528-4a74-a311-41f0269fa48d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_708b2ca8-b8fd-4fac-a117-5115e63a2bcf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7f4466ce-b528-4a74-a311-41f0269fa48d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_3555ffdb-5aa3-49a0-bb91-bf478980f740" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_708b2ca8-b8fd-4fac-a117-5115e63a2bcf" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_3555ffdb-5aa3-49a0-bb91-bf478980f740" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_48a8867c-477c-461d-ae29-02e7f2d83ff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_708b2ca8-b8fd-4fac-a117-5115e63a2bcf" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_48a8867c-477c-461d-ae29-02e7f2d83ff8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_850d3e6a-31f9-4d95-9f0c-5f52c4a2df2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8fe4ade0-6fb2-4121-adf4-73b797ee535b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_850d3e6a-31f9-4d95-9f0c-5f52c4a2df2c" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8fe4ade0-6fb2-4121-adf4-73b797ee535b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_770cc347-240d-445d-ade1-1022d36f5fc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_850d3e6a-31f9-4d95-9f0c-5f52c4a2df2c" xlink:to="loc_us-gaap_ShareBasedCompensation_770cc347-240d-445d-ade1-1022d36f5fc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_08903a21-f7dd-4bbe-b2d3-650f5c487ce6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_850d3e6a-31f9-4d95-9f0c-5f52c4a2df2c" xlink:to="loc_us-gaap_NetIncomeLoss_08903a21-f7dd-4bbe-b2d3-650f5c487ce6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_7f95c2b4-b653-4c83-9b9b-e006e385106d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_850d3e6a-31f9-4d95-9f0c-5f52c4a2df2c" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_7f95c2b4-b653-4c83-9b9b-e006e385106d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_WriteOffOfRightOfUseAssetUponLeaseTermination_a47a22b2-92af-465d-8c07-4a0d9705b0d9" xlink:href="nltx-20201231.xsd#nltx_WriteOffOfRightOfUseAssetUponLeaseTermination"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_850d3e6a-31f9-4d95-9f0c-5f52c4a2df2c" xlink:to="loc_nltx_WriteOffOfRightOfUseAssetUponLeaseTermination_a47a22b2-92af-465d-8c07-4a0d9705b0d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_741f1e43-c299-4509-9068-cbe6e47389bf" xlink:href="nltx-20201231.xsd#nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_850d3e6a-31f9-4d95-9f0c-5f52c4a2df2c" xlink:to="loc_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_741f1e43-c299-4509-9068-cbe6e47389bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a608f4c2-0ee9-4c08-b61d-e928fd439cd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_850d3e6a-31f9-4d95-9f0c-5f52c4a2df2c" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a608f4c2-0ee9-4c08-b61d-e928fd439cd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c30464e5-36fe-4502-a998-693aa0d13b77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_850d3e6a-31f9-4d95-9f0c-5f52c4a2df2c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c30464e5-36fe-4502-a998-693aa0d13b77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_1234a7f9-fbea-4e56-8e48-1123e5eb71d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_850d3e6a-31f9-4d95-9f0c-5f52c4a2df2c" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_1234a7f9-fbea-4e56-8e48-1123e5eb71d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_IncreaseDecreaseInOperatingLeaseLiabilities_e3074000-487f-4b3c-9bce-c382d5158241" xlink:href="nltx-20201231.xsd#nltx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_850d3e6a-31f9-4d95-9f0c-5f52c4a2df2c" xlink:to="loc_nltx_IncreaseDecreaseInOperatingLeaseLiabilities_e3074000-487f-4b3c-9bce-c382d5158241" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_8146eca2-cf66-489f-9e45-768f7f46f333" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_850d3e6a-31f9-4d95-9f0c-5f52c4a2df2c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_8146eca2-cf66-489f-9e45-768f7f46f333" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_dbfaf1fa-3028-4b3a-bde2-cb660d28d588" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_850d3e6a-31f9-4d95-9f0c-5f52c4a2df2c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_dbfaf1fa-3028-4b3a-bde2-cb660d28d588" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bfcf2af8-af0c-43fc-ae72-ed85370f6421" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_82456b7a-4583-405b-8463-d251248ec528" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bfcf2af8-af0c-43fc-ae72-ed85370f6421" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_82456b7a-4583-405b-8463-d251248ec528" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsNetCashAcquired_3b10785f-ab44-4eb0-a913-9c2b29ca0837" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsNetCashAcquired"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bfcf2af8-af0c-43fc-ae72-ed85370f6421" xlink:to="loc_nltx_AcquisitionOfAssetsNetCashAcquired_3b10785f-ab44-4eb0-a913-9c2b29ca0837" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2e3782cd-c605-4eb9-b783-e6ed57ef3d0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c2c60b46-2bad-426c-ba9a-10099c392269" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2e3782cd-c605-4eb9-b783-e6ed57ef3d0c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c2c60b46-2bad-426c-ba9a-10099c392269" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b2d41f4d-770f-4a54-972f-fb297a7b91de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2e3782cd-c605-4eb9-b783-e6ed57ef3d0c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b2d41f4d-770f-4a54-972f-fb297a7b91de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8b812ae2-fb12-4c9b-8035-2ebb2bceafb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2e3782cd-c605-4eb9-b783-e6ed57ef3d0c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8b812ae2-fb12-4c9b-8035-2ebb2bceafb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4758e1d5-2c7d-4eaa-87c0-6fdc52a7c011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2e3782cd-c605-4eb9-b783-e6ed57ef3d0c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4758e1d5-2c7d-4eaa-87c0-6fdc52a7c011" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="nltx-20201231.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nltx-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="nltx-20201231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Natureofoperations" xlink:type="simple" xlink:href="nltx-20201231.xsd#Natureofoperations"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/Natureofoperations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies" xlink:type="simple" xlink:href="nltx-20201231.xsd#Basisofpresentationandsummaryofsignificantaccountingpolicies"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#BasisofpresentationandsummaryofsignificantaccountingpoliciesTables"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="nltx-20201231.xsd#BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesCashandcashequivalentsandrestrictedcashDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#BasisofpresentationandsummaryofsignificantaccountingpoliciesCashandcashequivalentsandrestrictedcashDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesCashandcashequivalentsandrestrictedcashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a88ad051-5fab-4598-bf6e-d42726992226" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_473c51eb-ec59-448f-a095-7773e41f681f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a88ad051-5fab-4598-bf6e-d42726992226" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_473c51eb-ec59-448f-a095-7773e41f681f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_468a13c0-8b66-4b01-bea9-ae8dc8758208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a88ad051-5fab-4598-bf6e-d42726992226" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_468a13c0-8b66-4b01-bea9-ae8dc8758208" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsInc" xlink:type="simple" xlink:href="nltx-20201231.xsd#MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsInc"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsInc" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncTables"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionsOfAssetsConsiderationTransferred_e6071891-9af8-4715-be19-0161a44baa0d" xlink:href="nltx-20201231.xsd#nltx_AcquisitionsOfAssetsConsiderationTransferred"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionsOfAssetsCashConsiderationForFractionalShares_6e8bb38a-fb90-45cc-b2e0-53c9e2b452d0" xlink:href="nltx-20201231.xsd#nltx_AcquisitionsOfAssetsCashConsiderationForFractionalShares"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nltx_AcquisitionsOfAssetsConsiderationTransferred_e6071891-9af8-4715-be19-0161a44baa0d" xlink:to="loc_nltx_AcquisitionsOfAssetsCashConsiderationForFractionalShares_6e8bb38a-fb90-45cc-b2e0-53c9e2b452d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionsOfAssetsFairValueOfSharesIssued_eab3b161-3697-419a-8bb3-a2b06bfd2b69" xlink:href="nltx-20201231.xsd#nltx_AcquisitionsOfAssetsFairValueOfSharesIssued"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nltx_AcquisitionsOfAssetsConsiderationTransferred_e6071891-9af8-4715-be19-0161a44baa0d" xlink:to="loc_nltx_AcquisitionsOfAssetsFairValueOfSharesIssued_eab3b161-3697-419a-8bb3-a2b06bfd2b69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionsOfAssetsTransactionCosts_3f26dec8-5298-494d-97be-3da74df43d9e" xlink:href="nltx-20201231.xsd#nltx_AcquisitionsOfAssetsTransactionCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nltx_AcquisitionsOfAssetsConsiderationTransferred_e6071891-9af8-4715-be19-0161a44baa0d" xlink:to="loc_nltx_AcquisitionsOfAssetsTransactionCosts_3f26dec8-5298-494d-97be-3da74df43d9e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed_846086d1-6b97-4d53-952e-a9a4de91ee3f" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities_a82b4786-7425-4ca0-8b4e-7b2dba942de6" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed_846086d1-6b97-4d53-952e-a9a4de91ee3f" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities_a82b4786-7425-4ca0-8b4e-7b2dba942de6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability_2f09de90-6e1d-4098-95aa-e2bd0e8be829" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed_846086d1-6b97-4d53-952e-a9a4de91ee3f" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability_2f09de90-6e1d-4098-95aa-e2bd0e8be829" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7183e1a4-30a3-47ea-aefa-857ff10881a5" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed_3e942b33-89df-4f48-8f23-e1b7efb83d04" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7183e1a4-30a3-47ea-aefa-857ff10881a5" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed_3e942b33-89df-4f48-8f23-e1b7efb83d04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet_9754ad42-473e-4a78-94e9-7192beec1cfd" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7183e1a4-30a3-47ea-aefa-857ff10881a5" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet_9754ad42-473e-4a78-94e9-7192beec1cfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet_31ec9a9e-9c24-4571-8aa7-f1392451c143" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents_288019d9-aa24-42b8-a8b4-717d7a9844bf" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet_31ec9a9e-9c24-4571-8aa7-f1392451c143" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents_288019d9-aa24-42b8-a8b4-717d7a9844bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits_6f444716-3741-43e0-94af-9c03f8f1c069" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet_31ec9a9e-9c24-4571-8aa7-f1392451c143" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits_6f444716-3741-43e0-94af-9c03f8f1c069" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment_b54fad59-a941-4448-94c0-2681678ba91c" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet_31ec9a9e-9c24-4571-8aa7-f1392451c143" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment_b54fad59-a941-4448-94c0-2681678ba91c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets_3da3bb6a-3833-4b10-ac09-79206309b8d8" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet_31ec9a9e-9c24-4571-8aa7-f1392451c143" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets_3da3bb6a-3833-4b10-ac09-79206309b8d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset_1283a98c-8753-4397-9ec3-b9d685439f95" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet_31ec9a9e-9c24-4571-8aa7-f1392451c143" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset_1283a98c-8753-4397-9ec3-b9d685439f95" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Propertyandequipmentnet" xlink:type="simple" xlink:href="nltx-20201231.xsd#Propertyandequipmentnet"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/Propertyandequipmentnet" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/PropertyandequipmentnetTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#PropertyandequipmentnetTables"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/PropertyandequipmentnetTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#PropertyandequipmentnetScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_517029ec-c84b-45b9-b952-544b0f769500" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5321f383-5015-4617-8e78-ee2b05cb8f70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_517029ec-c84b-45b9-b952-544b0f769500" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5321f383-5015-4617-8e78-ee2b05cb8f70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_83208882-6cbb-428a-829b-c38c1494b831" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_517029ec-c84b-45b9-b952-544b0f769500" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_83208882-6cbb-428a-829b-c38c1494b831" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/PropertyandequipmentnetAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#PropertyandequipmentnetAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/PropertyandequipmentnetAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Intangibleassetnet" xlink:type="simple" xlink:href="nltx-20201231.xsd#Intangibleassetnet"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/Intangibleassetnet" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/IntangibleassetnetTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#IntangibleassetnetTables"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/IntangibleassetnetTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/IntangibleassetnetSummaryofIntangibleAssetDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#IntangibleassetnetSummaryofIntangibleAssetDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/IntangibleassetnetSummaryofIntangibleAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c4b11439-e812-4d71-b54e-a41d7d3140f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7a55481d-1847-468b-b107-4cee883abde2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c4b11439-e812-4d71-b54e-a41d7d3140f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7a55481d-1847-468b-b107-4cee883abde2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3c114228-ccf4-4160-9d84-5ab659091b19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c4b11439-e812-4d71-b54e-a41d7d3140f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3c114228-ccf4-4160-9d84-5ab659091b19" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Accountspayableandotherliabilities" xlink:type="simple" xlink:href="nltx-20201231.xsd#Accountspayableandotherliabilities"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/Accountspayableandotherliabilities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#AccountspayableandotherliabilitiesTables"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#AccountspayableandotherliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_b7132454-32c3-4601-b6b1-11e516149f27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_6979778d-1700-4a2b-96ce-d5479696fd96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_b7132454-32c3-4601-b6b1-11e516149f27" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_6979778d-1700-4a2b-96ce-d5479696fd96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AccruedClinicalExpensesCurrent_be17c688-eeb0-411e-a222-9cb89a65a337" xlink:href="nltx-20201231.xsd#nltx_AccruedClinicalExpensesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_b7132454-32c3-4601-b6b1-11e516149f27" xlink:to="loc_nltx_AccruedClinicalExpensesCurrent_be17c688-eeb0-411e-a222-9cb89a65a337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_af30fad3-bcaf-4e86-a566-d52f5e9b05ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_b7132454-32c3-4601-b6b1-11e516149f27" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_af30fad3-bcaf-4e86-a566-d52f5e9b05ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_9198469a-9b91-4f5a-8480-1990320a0f1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_b7132454-32c3-4601-b6b1-11e516149f27" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_9198469a-9b91-4f5a-8480-1990320a0f1c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Leases" xlink:type="simple" xlink:href="nltx-20201231.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#LeasesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#LeasesScheduleofComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_b949a660-3638-48bd-98d5-1c5babea8cb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_2a99ccf7-a07b-44f2-9552-975e5bff4892" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_b949a660-3638-48bd-98d5-1c5babea8cb8" xlink:to="loc_us-gaap_OperatingLeaseCost_2a99ccf7-a07b-44f2-9552-975e5bff4892" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_0dcd547c-782e-4167-a930-dbd9bbf9d67a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_b949a660-3638-48bd-98d5-1c5babea8cb8" xlink:to="loc_us-gaap_ShortTermLeaseCost_0dcd547c-782e-4167-a930-dbd9bbf9d67a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e2f0f338-15da-45c5-a6cc-525525499583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_b949a660-3638-48bd-98d5-1c5babea8cb8" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e2f0f338-15da-45c5-a6cc-525525499583" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_0e1c4d27-8bb9-484d-b85e-2e20f068bbf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_b949a660-3638-48bd-98d5-1c5babea8cb8" xlink:to="loc_us-gaap_VariableLeaseCost_0e1c4d27-8bb9-484d-b85e-2e20f068bbf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_21b3ce05-11e1-402d-be2b-bcd80e4720cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_b949a660-3638-48bd-98d5-1c5babea8cb8" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_21b3ce05-11e1-402d-be2b-bcd80e4720cc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/LeasesSupplementalCashflowInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#LeasesSupplementalCashflowInformationRelatedtoLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/LeasesSupplementalCashflowInformationRelatedtoLeasesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_f826b200-9de0-4e66-8675-08ab283b3b7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_9f6dc943-8d82-49bc-85fd-fdccc511d8a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_f826b200-9de0-4e66-8675-08ab283b3b7b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_9f6dc943-8d82-49bc-85fd-fdccc511d8a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_5f9dbe42-78ee-4218-a154-05993c4a0956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_f826b200-9de0-4e66-8675-08ab283b3b7b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_5f9dbe42-78ee-4218-a154-05993c4a0956" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3618a6ba-4583-48a5-b4c3-c64172256ea2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_72e3d537-d3a9-436d-80f7-e70f59312c8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3618a6ba-4583-48a5-b4c3-c64172256ea2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_72e3d537-d3a9-436d-80f7-e70f59312c8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_34ced9d4-b70d-43ae-8306-a55c2eff8574" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3618a6ba-4583-48a5-b4c3-c64172256ea2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_34ced9d4-b70d-43ae-8306-a55c2eff8574" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_963b184b-3074-4caa-b345-222582ee5066" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3618a6ba-4583-48a5-b4c3-c64172256ea2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_963b184b-3074-4caa-b345-222582ee5066" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_a6fe734e-5998-43ef-a444-acc95199c462" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3618a6ba-4583-48a5-b4c3-c64172256ea2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_a6fe734e-5998-43ef-a444-acc95199c462" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_2b7a24cd-aaf9-437c-ab2e-3d1eaaf2aa5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3618a6ba-4583-48a5-b4c3-c64172256ea2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_2b7a24cd-aaf9-437c-ab2e-3d1eaaf2aa5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_e63c3e0e-ad9a-4076-a66f-195c71d66275" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3618a6ba-4583-48a5-b4c3-c64172256ea2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_e63c3e0e-ad9a-4076-a66f-195c71d66275" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f85d3821-5a95-4a52-b1cc-d71f1dc769ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5864a448-e34d-499e-9e14-39c3c38b745a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f85d3821-5a95-4a52-b1cc-d71f1dc769ab" xlink:to="loc_us-gaap_OperatingLeaseLiability_5864a448-e34d-499e-9e14-39c3c38b745a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f0a3aa4e-f091-401c-ab5d-7141fb1f701d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f85d3821-5a95-4a52-b1cc-d71f1dc769ab" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f0a3aa4e-f091-401c-ab5d-7141fb1f701d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f9939cfb-5554-4e8a-92c0-3884f4eefa47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d56b4463-59c9-42bb-b867-32a10590687d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_f9939cfb-5554-4e8a-92c0-3884f4eefa47" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d56b4463-59c9-42bb-b867-32a10590687d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c51adaec-0ed8-4c8e-9ee1-219f20cc0de3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_f9939cfb-5554-4e8a-92c0-3884f4eefa47" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c51adaec-0ed8-4c8e-9ee1-219f20cc0de3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="nltx-20201231.xsd#LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_93cebcd6-798a-4500-b3ca-d61660d3bea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b6c54044-43fe-42e4-8dbc-753a795e8811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_93cebcd6-798a-4500-b3ca-d61660d3bea5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b6c54044-43fe-42e4-8dbc-753a795e8811" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_67d74d70-a03b-4f82-802c-ec6128ad930c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_93cebcd6-798a-4500-b3ca-d61660d3bea5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_67d74d70-a03b-4f82-802c-ec6128ad930c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_26eef06e-5113-477a-8ccc-398d66f09abf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_93cebcd6-798a-4500-b3ca-d61660d3bea5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_26eef06e-5113-477a-8ccc-398d66f09abf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_95710535-0b05-4136-90f0-14a7fe621402" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_93cebcd6-798a-4500-b3ca-d61660d3bea5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_95710535-0b05-4136-90f0-14a7fe621402" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_48505921-54f7-4e9d-be47-7af7a6cff400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_93cebcd6-798a-4500-b3ca-d61660d3bea5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_48505921-54f7-4e9d-be47-7af7a6cff400" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_17dad7ba-3aec-42b4-9681-06f104b6075c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_93cebcd6-798a-4500-b3ca-d61660d3bea5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_17dad7ba-3aec-42b4-9681-06f104b6075c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3051221b-a64c-408b-84fe-f2e17ecdaa34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3e2506f2-562d-4b73-a6aa-7b60e100099d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3051221b-a64c-408b-84fe-f2e17ecdaa34" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3e2506f2-562d-4b73-a6aa-7b60e100099d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_f964618c-a5fc-4fe5-ae5a-c713b82dc327" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3051221b-a64c-408b-84fe-f2e17ecdaa34" xlink:to="loc_us-gaap_FinanceLeaseLiability_f964618c-a5fc-4fe5-ae5a-c713b82dc327" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Stockholdersequity" xlink:type="simple" xlink:href="nltx-20201231.xsd#Stockholdersequity"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/Stockholdersequity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/StockholdersequityTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#StockholdersequityTables"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/StockholdersequityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#StockholdersequityAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/StockholdersequityScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#StockholdersequityScheduleofStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/StockholdersequityScheduleofStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/StockholdersequityScheduleofWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#StockholdersequityScheduleofWeightedAverageAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/StockholdersequityScheduleofWeightedAverageAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/StockholdersequityScheduleofRSUActivityDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#StockholdersequityScheduleofRSUActivityDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/StockholdersequityScheduleofRSUActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/StockholdersequitySummaryofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#StockholdersequitySummaryofStockbasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/StockholdersequitySummaryofStockbasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Restructuring" xlink:type="simple" xlink:href="nltx-20201231.xsd#Restructuring"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/Restructuring" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/RestructuringAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#RestructuringAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/RestructuringAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Otherincomenet" xlink:type="simple" xlink:href="nltx-20201231.xsd#Otherincomenet"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/Otherincomenet" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/OtherincomenetTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#OtherincomenetTables"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/OtherincomenetTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/OtherincomenetScheduleofOtherIncomeNetDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#OtherincomenetScheduleofOtherIncomeNetDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/OtherincomenetScheduleofOtherIncomeNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8539a795-ff2d-4afd-8ed6-8a48005877d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_14513682-b46e-47f9-b895-22df8578443c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_8539a795-ff2d-4afd-8ed6-8a48005877d9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_14513682-b46e-47f9-b895-22df8578443c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ae9f1e51-4f35-486f-aded-7b78016923cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_8539a795-ff2d-4afd-8ed6-8a48005877d9" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ae9f1e51-4f35-486f-aded-7b78016923cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_e39083ca-9067-4bff-99fc-1651a0d02740" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_8539a795-ff2d-4afd-8ed6-8a48005877d9" xlink:to="loc_us-gaap_InvestmentIncomeNet_e39083ca-9067-4bff-99fc-1651a0d02740" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Netlosspercommonstock" xlink:type="simple" xlink:href="nltx-20201231.xsd#Netlosspercommonstock"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/Netlosspercommonstock" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/NetlosspercommonstockTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#NetlosspercommonstockTables"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/NetlosspercommonstockTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/NetlosspercommonstockScheduleofSecuritiesExcludedFromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#NetlosspercommonstockScheduleofSecuritiesExcludedFromComputationofEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/NetlosspercommonstockScheduleofSecuritiesExcludedFromComputationofEarningsPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Incometaxes" xlink:type="simple" xlink:href="nltx-20201231.xsd#Incometaxes"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/Incometaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/IncometaxesTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#IncometaxesTables"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/IncometaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#IncomeTaxesScheduleofIncometaxRecoveryDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_46cc0446-5dc0-4888-813f-ac86f0817e8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ce044b9e-b8d0-45ca-820f-d4103b4fc7c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_46cc0446-5dc0-4888-813f-ac86f0817e8f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ce044b9e-b8d0-45ca-820f-d4103b4fc7c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_d84d61f9-3bad-4d0d-a1e5-1695cb86454c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_46cc0446-5dc0-4888-813f-ac86f0817e8f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_d84d61f9-3bad-4d0d-a1e5-1695cb86454c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent_dfaa7aa7-6eb4-4de7-91a0-508fb0dcf084" xlink:href="nltx-20201231.xsd#nltx_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_46cc0446-5dc0-4888-813f-ac86f0817e8f" xlink:to="loc_nltx_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent_dfaa7aa7-6eb4-4de7-91a0-508fb0dcf084" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_9601d44a-c636-4184-9fbf-c7bf598a9396" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_46cc0446-5dc0-4888-813f-ac86f0817e8f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_9601d44a-c636-4184-9fbf-c7bf598a9396" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_26199c5c-c535-4a70-ba34-6a777e60581c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_46cc0446-5dc0-4888-813f-ac86f0817e8f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_26199c5c-c535-4a70-ba34-6a777e60581c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_61131017-b005-4358-b1e4-aba43d43a928" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_46cc0446-5dc0-4888-813f-ac86f0817e8f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_61131017-b005-4358-b1e4-aba43d43a928" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_2a2b82be-5c76-40d3-b2f5-4d018c314c58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_46cc0446-5dc0-4888-813f-ac86f0817e8f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_2a2b82be-5c76-40d3-b2f5-4d018c314c58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_819b015e-9f8e-4e06-8d43-64ec6a545a93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_46cc0446-5dc0-4888-813f-ac86f0817e8f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_819b015e-9f8e-4e06-8d43-64ec6a545a93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_48023253-1721-407f-bbf5-c99d39a32a94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_46cc0446-5dc0-4888-813f-ac86f0817e8f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_48023253-1721-407f-bbf5-c99d39a32a94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2f9a3f97-86ca-42bb-b518-8e9f73e9330a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_46cc0446-5dc0-4888-813f-ac86f0817e8f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2f9a3f97-86ca-42bb-b518-8e9f73e9330a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_4dede58a-8460-403c-86eb-a570688cdc5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_46cc0446-5dc0-4888-813f-ac86f0817e8f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_4dede58a-8460-403c-86eb-a570688cdc5a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/IncomeTaxesScheduleofNetLossIncomeBeforeTaxesDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#IncomeTaxesScheduleofNetLossIncomeBeforeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/IncomeTaxesScheduleofNetLossIncomeBeforeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb369da-db19-46c2-b6c0-60ed25a3e75b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_525975b3-d345-4ee0-8377-3f29ce09bdf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb369da-db19-46c2-b6c0-60ed25a3e75b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_525975b3-d345-4ee0-8377-3f29ce09bdf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_7bf1e385-8b43-4d76-8f90-640821e150df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0eb369da-db19-46c2-b6c0-60ed25a3e75b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_7bf1e385-8b43-4d76-8f90-640821e150df" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nltx_DeferredTaxAssetsBeforeValuationAllowance_d85bc0a3-1315-4a0c-9bd7-0e6da0097838" xlink:href="nltx-20201231.xsd#nltx_DeferredTaxAssetsBeforeValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1b2fa5f3-2e3f-4b8b-bbe9-fd4158b1f721" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nltx_DeferredTaxAssetsBeforeValuationAllowance_d85bc0a3-1315-4a0c-9bd7-0e6da0097838" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1b2fa5f3-2e3f-4b8b-bbe9-fd4158b1f721" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_b9dfe257-ea81-4e7f-b290-062c7dddfb6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_nltx_DeferredTaxAssetsBeforeValuationAllowance_d85bc0a3-1315-4a0c-9bd7-0e6da0097838" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_b9dfe257-ea81-4e7f-b290-062c7dddfb6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_89045ba1-fa8e-4320-af76-a8d4dcbab698" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_8e104ea4-368f-42d3-9360-0295a35529a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_89045ba1-fa8e-4320-af76-a8d4dcbab698" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_8e104ea4-368f-42d3-9360-0295a35529a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_956c34bb-4d3c-4b36-a938-78fdf5796b85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_89045ba1-fa8e-4320-af76-a8d4dcbab698" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_956c34bb-4d3c-4b36-a938-78fdf5796b85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_DeferredTaxAssetsLeaseLiability_d6188030-2590-490e-b58c-be7691219df6" xlink:href="nltx-20201231.xsd#nltx_DeferredTaxAssetsLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_89045ba1-fa8e-4320-af76-a8d4dcbab698" xlink:to="loc_nltx_DeferredTaxAssetsLeaseLiability_d6188030-2590-490e-b58c-be7691219df6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_326d6213-18f3-40f0-83ae-11bdb09e47be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_89045ba1-fa8e-4320-af76-a8d4dcbab698" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_326d6213-18f3-40f0-83ae-11bdb09e47be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_c43032f4-08b0-48f7-8794-455e0c2566cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_89045ba1-fa8e-4320-af76-a8d4dcbab698" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_c43032f4-08b0-48f7-8794-455e0c2566cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_1d29b048-4eb8-4ef0-811e-80329eed4833" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_89045ba1-fa8e-4320-af76-a8d4dcbab698" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_1d29b048-4eb8-4ef0-811e-80329eed4833" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_ef143e61-e035-4582-8536-44f0ae636633" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_89045ba1-fa8e-4320-af76-a8d4dcbab698" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_ef143e61-e035-4582-8536-44f0ae636633" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_c40fc325-9794-41cb-96a5-9442f39e81ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7e57ee17-bd1e-4410-916c-30a87cf0e44a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c40fc325-9794-41cb-96a5-9442f39e81ae" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7e57ee17-bd1e-4410-916c-30a87cf0e44a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_DeferredTaxAssetsBeforeValuationAllowance_88f79410-2be1-4fde-8e6f-70a7fe82a476" xlink:href="nltx-20201231.xsd#nltx_DeferredTaxAssetsBeforeValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_c40fc325-9794-41cb-96a5-9442f39e81ae" xlink:to="loc_nltx_DeferredTaxAssetsBeforeValuationAllowance_88f79410-2be1-4fde-8e6f-70a7fe82a476" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_585a93be-1bac-4252-bda4-0622ec38a5da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_fdcfb124-795e-4334-b007-7db1cb826587" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_585a93be-1bac-4252-bda4-0622ec38a5da" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_fdcfb124-795e-4334-b007-7db1cb826587" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_afc88159-0c59-4a81-a69f-aef36e03da22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_585a93be-1bac-4252-bda4-0622ec38a5da" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_afc88159-0c59-4a81-a69f-aef36e03da22" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Licenseandpatentagreements" xlink:type="simple" xlink:href="nltx-20201231.xsd#Licenseandpatentagreements"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/Licenseandpatentagreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#LicenseandpatentagreementsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Commitmentsandcontingencies" xlink:type="simple" xlink:href="nltx-20201231.xsd#Commitmentsandcontingencies"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/Commitmentsandcontingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/A401kplan" xlink:type="simple" xlink:href="nltx-20201231.xsd#A401kplan"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/A401kplan" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/SaleofAquinoxCanada" xlink:type="simple" xlink:href="nltx-20201231.xsd#SaleofAquinoxCanada"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/SaleofAquinoxCanada" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/SaleofAquinoxCanadaDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#SaleofAquinoxCanadaDetails"/>
  <link:calculationLink xlink:role="http://www.aqxpharma.com/role/SaleofAquinoxCanadaDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>nltx-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:6019b606-66e1-49bc-8c33-d6cc15ba3335,g:b750dab7-5d48-4ebb-bb7b-41a017d885d1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CoverPage" xlink:type="simple" xlink:href="nltx-20201231.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/CoverPage" xlink:type="extended" id="i67a6457c665d4b6da6b2e5e6202bb9e0_CoverPage"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nltx-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="i901a5ca71ded41f398d42da30a5c34a0_ConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nltx-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i3b9512eeb44b48d7b225d47bebe1d6fb_ConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nltx-20201231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="ie047428b107042d992b37a43ff979728_ConsolidatedStatementsofOperations"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nltx-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i52589d5fb7a04775bfbdc1a42d8f098c_ConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="nltx-20201231.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended" id="i252664355cb243e7a0efe24fab021455_ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nltx-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i99070faf69e4451caa819005d0bc4933_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_74539f33-5c71-4d05-86b5-4f9eb4f73ba8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_74539f33-5c71-4d05-86b5-4f9eb4f73ba8" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_9136f30c-5cb0-4374-8c03-99cb308bbaf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_SharesOutstanding_9136f30c-5cb0-4374-8c03-99cb308bbaf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_34cf7246-c08a-45e1-8226-dc41a7dc663d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockholdersEquity_34cf7246-c08a-45e1-8226-dc41a7dc663d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_bc4c3552-7406-4917-98f5-f1976062876f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_bc4c3552-7406-4917-98f5-f1976062876f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_3ca74839-c49d-49ea-b532-77eb2811af62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_3ca74839-c49d-49ea-b532-77eb2811af62" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_427fbe85-1ac4-49a5-8e95-a8640ca3a62f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_427fbe85-1ac4-49a5-8e95-a8640ca3a62f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a544dd48-eda0-45e5-a1a1-ea00ef9334e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a544dd48-eda0-45e5-a1a1-ea00ef9334e7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_474e31cc-8b54-4ce6-ac6c-5c94742e8bcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_474e31cc-8b54-4ce6-ac6c-5c94742e8bcd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_e69e6935-e1af-407c-87af-494143c6e25c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_e69e6935-e1af-407c-87af-494143c6e25c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_24cdaa10-48ad-4c0d-93e5-833e6ee034ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_24cdaa10-48ad-4c0d-93e5-833e6ee034ee" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants_c2f384e1-ee6d-405c-8fa9-e7d8f7aaad96" xlink:href="nltx-20201231.xsd#nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants_c2f384e1-ee6d-405c-8fa9-e7d8f7aaad96" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a1514162-f04f-4891-8ded-d9dae22b4936" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a1514162-f04f-4891-8ded-d9dae22b4936" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ca3596d5-1c49-4b7d-98ec-43689209b90b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ca3596d5-1c49-4b7d-98ec-43689209b90b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f54944ea-5754-4f58-8322-a9b07d964065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f54944ea-5754-4f58-8322-a9b07d964065" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_818b9cbd-5a5f-4fac-a3c8-2ff42f952da0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_818b9cbd-5a5f-4fac-a3c8-2ff42f952da0" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_16363db3-09e9-4a39-b3b7-b3f11d7e97ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_16363db3-09e9-4a39-b3b7-b3f11d7e97ca" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a92301c8-a66f-471d-b0f1-2b150d0e0b5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a92301c8-a66f-471d-b0f1-2b150d0e0b5b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a143f083-0685-4b0f-a1d7-b02ce6c2e55f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_NetIncomeLoss_a143f083-0685-4b0f-a1d7-b02ce6c2e55f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_d76f20e6-5add-4797-b313-9ebbdb0a7ff6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a1758e32-2b20-4bf0-ae6d-f83046178a64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_86ff619e-c21d-4c85-a6bd-cd58fbb1b93c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_74539f33-5c71-4d05-86b5-4f9eb4f73ba8" xlink:to="loc_us-gaap_StatementTable_86ff619e-c21d-4c85-a6bd-cd58fbb1b93c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_04aa4728-5c00-4b51-992f-24ca2b623a4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_86ff619e-c21d-4c85-a6bd-cd58fbb1b93c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_04aa4728-5c00-4b51-992f-24ca2b623a4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_04aa4728-5c00-4b51-992f-24ca2b623a4a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_04aa4728-5c00-4b51-992f-24ca2b623a4a" xlink:to="loc_us-gaap_EquityComponentDomain_04aa4728-5c00-4b51-992f-24ca2b623a4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_578ee1b0-3238-47e7-a61c-ab6cac3b968d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_04aa4728-5c00-4b51-992f-24ca2b623a4a" xlink:to="loc_us-gaap_EquityComponentDomain_578ee1b0-3238-47e7-a61c-ab6cac3b968d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_037d2744-b130-4f77-afac-22e2055ea1e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_578ee1b0-3238-47e7-a61c-ab6cac3b968d" xlink:to="loc_us-gaap_CommonStockMember_037d2744-b130-4f77-afac-22e2055ea1e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4c9b6ede-01f2-4daf-868f-641de0eabba5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_578ee1b0-3238-47e7-a61c-ab6cac3b968d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4c9b6ede-01f2-4daf-868f-641de0eabba5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d415526b-1900-44bf-9566-0307a7d25358" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_578ee1b0-3238-47e7-a61c-ab6cac3b968d" xlink:to="loc_us-gaap_RetainedEarningsMember_d415526b-1900-44bf-9566-0307a7d25358" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_baaa87a1-b871-48fb-b4d1-cfd3a4e1b8af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_86ff619e-c21d-4c85-a6bd-cd58fbb1b93c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_baaa87a1-b871-48fb-b4d1-cfd3a4e1b8af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_baaa87a1-b871-48fb-b4d1-cfd3a4e1b8af_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_baaa87a1-b871-48fb-b4d1-cfd3a4e1b8af" xlink:to="loc_us-gaap_ClassOfStockDomain_baaa87a1-b871-48fb-b4d1-cfd3a4e1b8af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d9e9cbc8-422d-4bb5-bcef-1aea435fc64a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_baaa87a1-b871-48fb-b4d1-cfd3a4e1b8af" xlink:to="loc_us-gaap_ClassOfStockDomain_d9e9cbc8-422d-4bb5-bcef-1aea435fc64a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_NonVotingConvertiblePreferredStockMember_c745d9ce-43bf-4dfc-8921-0d5d8fea5d14" xlink:href="nltx-20201231.xsd#nltx_NonVotingConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d9e9cbc8-422d-4bb5-bcef-1aea435fc64a" xlink:to="loc_nltx_NonVotingConvertiblePreferredStockMember_c745d9ce-43bf-4dfc-8921-0d5d8fea5d14" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="nltx-20201231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended" id="ib795f08264ce4cb5881970a3f63c063c_ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Natureofoperations" xlink:type="simple" xlink:href="nltx-20201231.xsd#Natureofoperations"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/Natureofoperations" xlink:type="extended" id="ibf6c7117ecbb4fe89d7310522cf24738_Natureofoperations"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies" xlink:type="simple" xlink:href="nltx-20201231.xsd#Basisofpresentationandsummaryofsignificantaccountingpolicies"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies" xlink:type="extended" id="i9c39d3abc2424026a91d268be0a057b5_Basisofpresentationandsummaryofsignificantaccountingpolicies"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#BasisofpresentationandsummaryofsignificantaccountingpoliciesTables"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesTables" xlink:type="extended" id="i05df73a018a749f1b7a6c91a0d96ca92_BasisofpresentationandsummaryofsignificantaccountingpoliciesTables"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="nltx-20201231.xsd#BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies" xlink:type="extended" id="ibbe87f06dc2144318048ad9496cd506a_BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails" xlink:type="extended" id="i5aed77ab5d7c42ed90b3391a3227d392_BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nltx_SignificantAccountingPoliciesLineItems_022857e3-f6a7-468c-ad39-0beba973ec2c" xlink:href="nltx-20201231.xsd#nltx_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6bcaf886-00e7-4222-abab-7f85c15515c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_SignificantAccountingPoliciesLineItems_022857e3-f6a7-468c-ad39-0beba973ec2c" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6bcaf886-00e7-4222-abab-7f85c15515c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3eb78200-3b94-42f0-ac52-0112589865d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_SignificantAccountingPoliciesLineItems_022857e3-f6a7-468c-ad39-0beba973ec2c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3eb78200-3b94-42f0-ac52-0112589865d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_3f540be3-cbbf-4302-842a-4fdff873b4b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_SignificantAccountingPoliciesLineItems_022857e3-f6a7-468c-ad39-0beba973ec2c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_3f540be3-cbbf-4302-842a-4fdff873b4b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_59d5432b-002b-446e-b46a-8b9d32e54596" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_SignificantAccountingPoliciesLineItems_022857e3-f6a7-468c-ad39-0beba973ec2c" xlink:to="loc_us-gaap_NumberOfOperatingSegments_59d5432b-002b-446e-b46a-8b9d32e54596" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a3e52c60-4b62-4cce-b12c-b0064b7fd852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_SignificantAccountingPoliciesLineItems_022857e3-f6a7-468c-ad39-0beba973ec2c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a3e52c60-4b62-4cce-b12c-b0064b7fd852" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_SignificantAccountingPoliciesTable_10a12aa1-1bb2-4c33-af35-343110c81724" xlink:href="nltx-20201231.xsd#nltx_SignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nltx_SignificantAccountingPoliciesLineItems_022857e3-f6a7-468c-ad39-0beba973ec2c" xlink:to="loc_nltx_SignificantAccountingPoliciesTable_10a12aa1-1bb2-4c33-af35-343110c81724" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c449831d-fb53-4238-a658-6ba26a2ea208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nltx_SignificantAccountingPoliciesTable_10a12aa1-1bb2-4c33-af35-343110c81724" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c449831d-fb53-4238-a658-6ba26a2ea208" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c449831d-fb53-4238-a658-6ba26a2ea208_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c449831d-fb53-4238-a658-6ba26a2ea208" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c449831d-fb53-4238-a658-6ba26a2ea208_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_242f8116-5f8d-4b57-b961-dda5ddf80f39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c449831d-fb53-4238-a658-6ba26a2ea208" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_242f8116-5f8d-4b57-b961-dda5ddf80f39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember_13b02f0c-7806-41fd-b953-2e810e26ddcc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OfficeBuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_242f8116-5f8d-4b57-b961-dda5ddf80f39" xlink:to="loc_srt_OfficeBuildingMember_13b02f0c-7806-41fd-b953-2e810e26ddcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ba5a7a95-c23d-4a26-8d69-321fd68304c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nltx_SignificantAccountingPoliciesTable_10a12aa1-1bb2-4c33-af35-343110c81724" xlink:to="loc_srt_RangeAxis_ba5a7a95-c23d-4a26-8d69-321fd68304c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ba5a7a95-c23d-4a26-8d69-321fd68304c0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ba5a7a95-c23d-4a26-8d69-321fd68304c0" xlink:to="loc_srt_RangeMember_ba5a7a95-c23d-4a26-8d69-321fd68304c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_566a76bf-fec1-4d19-9ac6-be4ce8abdb9b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ba5a7a95-c23d-4a26-8d69-321fd68304c0" xlink:to="loc_srt_RangeMember_566a76bf-fec1-4d19-9ac6-be4ce8abdb9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3b0d6f29-49c4-4a21-ac2f-d79ef92b7424" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_566a76bf-fec1-4d19-9ac6-be4ce8abdb9b" xlink:to="loc_srt_MinimumMember_3b0d6f29-49c4-4a21-ac2f-d79ef92b7424" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fa4fa825-90c9-4ade-9a19-a93fc68ab291" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_566a76bf-fec1-4d19-9ac6-be4ce8abdb9b" xlink:to="loc_srt_MaximumMember_fa4fa825-90c9-4ade-9a19-a93fc68ab291" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_36c0e914-9528-48de-9248-cb0b1547459e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nltx_SignificantAccountingPoliciesTable_10a12aa1-1bb2-4c33-af35-343110c81724" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_36c0e914-9528-48de-9248-cb0b1547459e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_36c0e914-9528-48de-9248-cb0b1547459e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_36c0e914-9528-48de-9248-cb0b1547459e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_36c0e914-9528-48de-9248-cb0b1547459e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_448fdc76-cf2e-4e51-aeef-75dfb5931780" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_36c0e914-9528-48de-9248-cb0b1547459e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_448fdc76-cf2e-4e51-aeef-75dfb5931780" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_73204ffa-0dc4-4e86-83c6-2f27c6c0ceb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_448fdc76-cf2e-4e51-aeef-75dfb5931780" xlink:to="loc_us-gaap_MoneyMarketFundsMember_73204ffa-0dc4-4e86-83c6-2f27c6c0ceb1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesCashandcashequivalentsandrestrictedcashDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#BasisofpresentationandsummaryofsignificantaccountingpoliciesCashandcashequivalentsandrestrictedcashDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesCashandcashequivalentsandrestrictedcashDetails" xlink:type="extended" id="i7fefc931aa054abd8021eb22e007fe22_BasisofpresentationandsummaryofsignificantaccountingpoliciesCashandcashequivalentsandrestrictedcashDetails"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsInc" xlink:type="simple" xlink:href="nltx-20201231.xsd#MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsInc"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsInc" xlink:type="extended" id="i77199164ecd341469db53141f659b69e_MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsInc"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncTables"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncTables" xlink:type="extended" id="i999d2ee3d20843259cc6ae1ee60bdc09_MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncTables"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails" xlink:type="extended" id="i7f738465552049c48573a4e2bbccf1e4_MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1e0c20ba-9545-4728-bbfa-c83ab16202dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_d73da2f9-3bbc-4327-807e-ad92c3117530" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e0c20ba-9545-4728-bbfa-c83ab16202dd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_d73da2f9-3bbc-4327-807e-ad92c3117530" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_5d17cb3b-baaf-4f09-acf0-812638042a53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e0c20ba-9545-4728-bbfa-c83ab16202dd" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_5d17cb3b-baaf-4f09-acf0-812638042a53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsTable_f364584b-a152-499d-9413-8eb7cf52368c" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e0c20ba-9545-4728-bbfa-c83ab16202dd" xlink:to="loc_nltx_AcquisitionOfAssetsTable_f364584b-a152-499d-9413-8eb7cf52368c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsAxis_02603bb6-baf4-4c96-bbcd-7db8b637bf33" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nltx_AcquisitionOfAssetsTable_f364584b-a152-499d-9413-8eb7cf52368c" xlink:to="loc_nltx_AcquisitionOfAssetsAxis_02603bb6-baf4-4c96-bbcd-7db8b637bf33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsDomain_02603bb6-baf4-4c96-bbcd-7db8b637bf33_default" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nltx_AcquisitionOfAssetsAxis_02603bb6-baf4-4c96-bbcd-7db8b637bf33" xlink:to="loc_nltx_AcquisitionOfAssetsDomain_02603bb6-baf4-4c96-bbcd-7db8b637bf33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsDomain_14c11126-a975-4bb3-8950-9c14892142d9" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nltx_AcquisitionOfAssetsAxis_02603bb6-baf4-4c96-bbcd-7db8b637bf33" xlink:to="loc_nltx_AcquisitionOfAssetsDomain_14c11126-a975-4bb3-8950-9c14892142d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AquinoxMember_0aef0364-7e42-4594-8578-a507b94add92" xlink:href="nltx-20201231.xsd#nltx_AquinoxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_AcquisitionOfAssetsDomain_14c11126-a975-4bb3-8950-9c14892142d9" xlink:to="loc_nltx_AquinoxMember_0aef0364-7e42-4594-8578-a507b94add92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e7150dfb-bc53-4720-acd8-d90fb43fc004" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nltx_AcquisitionOfAssetsTable_f364584b-a152-499d-9413-8eb7cf52368c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e7150dfb-bc53-4720-acd8-d90fb43fc004" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e7150dfb-bc53-4720-acd8-d90fb43fc004_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e7150dfb-bc53-4720-acd8-d90fb43fc004" xlink:to="loc_us-gaap_ClassOfStockDomain_e7150dfb-bc53-4720-acd8-d90fb43fc004_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ac94f9c4-ee47-42bb-a1df-229541aa2266" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e7150dfb-bc53-4720-acd8-d90fb43fc004" xlink:to="loc_us-gaap_ClassOfStockDomain_ac94f9c4-ee47-42bb-a1df-229541aa2266" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_NonVotingConvertiblePreferredStockMember_dde08889-2a91-4365-bc5a-f85c7dea446a" xlink:href="nltx-20201231.xsd#nltx_NonVotingConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ac94f9c4-ee47-42bb-a1df-229541aa2266" xlink:to="loc_nltx_NonVotingConvertiblePreferredStockMember_dde08889-2a91-4365-bc5a-f85c7dea446a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b26e1e0c-2ada-479c-9dfd-4b496a422961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nltx_AcquisitionOfAssetsTable_f364584b-a152-499d-9413-8eb7cf52368c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b26e1e0c-2ada-479c-9dfd-4b496a422961" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b26e1e0c-2ada-479c-9dfd-4b496a422961_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b26e1e0c-2ada-479c-9dfd-4b496a422961" xlink:to="loc_us-gaap_EquityComponentDomain_b26e1e0c-2ada-479c-9dfd-4b496a422961_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_73413e38-2e31-49ab-ae51-9921ab21a278" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b26e1e0c-2ada-479c-9dfd-4b496a422961" xlink:to="loc_us-gaap_EquityComponentDomain_73413e38-2e31-49ab-ae51-9921ab21a278" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ffb81b2f-9f68-466a-8675-65c8232ad3c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_73413e38-2e31-49ab-ae51-9921ab21a278" xlink:to="loc_us-gaap_CommonStockMember_ffb81b2f-9f68-466a-8675-65c8232ad3c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5eb23d1b-0acd-4dad-b5e4-3c08cc2e8dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nltx_AcquisitionOfAssetsTable_f364584b-a152-499d-9413-8eb7cf52368c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5eb23d1b-0acd-4dad-b5e4-3c08cc2e8dd4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5eb23d1b-0acd-4dad-b5e4-3c08cc2e8dd4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5eb23d1b-0acd-4dad-b5e4-3c08cc2e8dd4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5eb23d1b-0acd-4dad-b5e4-3c08cc2e8dd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b3c67d55-02bc-4dbd-aa3c-e276bd16e155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5eb23d1b-0acd-4dad-b5e4-3c08cc2e8dd4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b3c67d55-02bc-4dbd-aa3c-e276bd16e155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_8a9d972b-2038-4798-afa2-8bc754b87833" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b3c67d55-02bc-4dbd-aa3c-e276bd16e155" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_8a9d972b-2038-4798-afa2-8bc754b87833" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails" xlink:type="extended" id="i3b0abd822353451997f7045b0ece809b_MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b226ad37-73ca-4a34-b43d-dee7b1c8e35e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionsOfAssetsFairValueOfSharesIssued_79d93186-a790-40fa-9601-f7ec9b972117" xlink:href="nltx-20201231.xsd#nltx_AcquisitionsOfAssetsFairValueOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b226ad37-73ca-4a34-b43d-dee7b1c8e35e" xlink:to="loc_nltx_AcquisitionsOfAssetsFairValueOfSharesIssued_79d93186-a790-40fa-9601-f7ec9b972117" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionsOfAssetsCashConsiderationForFractionalShares_99c1f78f-99b8-42ac-b0c2-10442be90367" xlink:href="nltx-20201231.xsd#nltx_AcquisitionsOfAssetsCashConsiderationForFractionalShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b226ad37-73ca-4a34-b43d-dee7b1c8e35e" xlink:to="loc_nltx_AcquisitionsOfAssetsCashConsiderationForFractionalShares_99c1f78f-99b8-42ac-b0c2-10442be90367" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionsOfAssetsTransactionCosts_ccdd99bb-cf1b-4409-85a2-9d058e0cbc1e" xlink:href="nltx-20201231.xsd#nltx_AcquisitionsOfAssetsTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b226ad37-73ca-4a34-b43d-dee7b1c8e35e" xlink:to="loc_nltx_AcquisitionsOfAssetsTransactionCosts_ccdd99bb-cf1b-4409-85a2-9d058e0cbc1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionsOfAssetsConsiderationTransferred_4bf9327e-7abf-4073-8b9a-2db7dab2a0ba" xlink:href="nltx-20201231.xsd#nltx_AcquisitionsOfAssetsConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b226ad37-73ca-4a34-b43d-dee7b1c8e35e" xlink:to="loc_nltx_AcquisitionsOfAssetsConsiderationTransferred_4bf9327e-7abf-4073-8b9a-2db7dab2a0ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_60ab0255-246c-4391-a8a0-1541902a91a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b226ad37-73ca-4a34-b43d-dee7b1c8e35e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_60ab0255-246c-4391-a8a0-1541902a91a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsTable_2e5de5e3-c655-45fd-a837-f3dba5adf2a9" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b226ad37-73ca-4a34-b43d-dee7b1c8e35e" xlink:to="loc_nltx_AcquisitionOfAssetsTable_2e5de5e3-c655-45fd-a837-f3dba5adf2a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_260656ab-50f1-438e-bba8-252066454b48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nltx_AcquisitionOfAssetsTable_2e5de5e3-c655-45fd-a837-f3dba5adf2a9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_260656ab-50f1-438e-bba8-252066454b48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_260656ab-50f1-438e-bba8-252066454b48_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_260656ab-50f1-438e-bba8-252066454b48" xlink:to="loc_us-gaap_EquityComponentDomain_260656ab-50f1-438e-bba8-252066454b48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6bcd58aa-6151-46c3-b2a9-8c9fd52b143b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_260656ab-50f1-438e-bba8-252066454b48" xlink:to="loc_us-gaap_EquityComponentDomain_6bcd58aa-6151-46c3-b2a9-8c9fd52b143b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5e101f8f-0321-45b9-9081-347d6bc08166" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6bcd58aa-6151-46c3-b2a9-8c9fd52b143b" xlink:to="loc_us-gaap_CommonStockMember_5e101f8f-0321-45b9-9081-347d6bc08166" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_65d6e8a7-8989-4b62-9b93-149cb1ef07c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nltx_AcquisitionOfAssetsTable_2e5de5e3-c655-45fd-a837-f3dba5adf2a9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_65d6e8a7-8989-4b62-9b93-149cb1ef07c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_65d6e8a7-8989-4b62-9b93-149cb1ef07c5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_65d6e8a7-8989-4b62-9b93-149cb1ef07c5" xlink:to="loc_us-gaap_ClassOfStockDomain_65d6e8a7-8989-4b62-9b93-149cb1ef07c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5fb31a9b-55ac-492c-88f0-7552d7eb9f4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_65d6e8a7-8989-4b62-9b93-149cb1ef07c5" xlink:to="loc_us-gaap_ClassOfStockDomain_5fb31a9b-55ac-492c-88f0-7552d7eb9f4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_df0693a9-9416-4669-8024-1a32eb6cedd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5fb31a9b-55ac-492c-88f0-7552d7eb9f4f" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_df0693a9-9416-4669-8024-1a32eb6cedd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_NonVotingConvertiblePreferredStockMember_a259c58e-1a76-427d-8142-e52983edac4e" xlink:href="nltx-20201231.xsd#nltx_NonVotingConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5fb31a9b-55ac-492c-88f0-7552d7eb9f4f" xlink:to="loc_nltx_NonVotingConvertiblePreferredStockMember_a259c58e-1a76-427d-8142-e52983edac4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsAxis_d8af1656-b5bb-4643-beae-77b9fea31a21" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nltx_AcquisitionOfAssetsTable_2e5de5e3-c655-45fd-a837-f3dba5adf2a9" xlink:to="loc_nltx_AcquisitionOfAssetsAxis_d8af1656-b5bb-4643-beae-77b9fea31a21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsDomain_d8af1656-b5bb-4643-beae-77b9fea31a21_default" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nltx_AcquisitionOfAssetsAxis_d8af1656-b5bb-4643-beae-77b9fea31a21" xlink:to="loc_nltx_AcquisitionOfAssetsDomain_d8af1656-b5bb-4643-beae-77b9fea31a21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsDomain_b0f59593-27cf-49e0-9b4b-2215f9a627ee" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nltx_AcquisitionOfAssetsAxis_d8af1656-b5bb-4643-beae-77b9fea31a21" xlink:to="loc_nltx_AcquisitionOfAssetsDomain_b0f59593-27cf-49e0-9b4b-2215f9a627ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AquinoxMember_822d5f41-a354-443f-8a8e-6bc45be538dd" xlink:href="nltx-20201231.xsd#nltx_AquinoxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_AcquisitionOfAssetsDomain_b0f59593-27cf-49e0-9b4b-2215f9a627ee" xlink:to="loc_nltx_AquinoxMember_822d5f41-a354-443f-8a8e-6bc45be538dd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="i32c5d9215ae94fb383bc82f0d12aa3e5_MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_def8d204-cf61-4689-994a-76a2e7273046" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract_1daa4abd-86d1-4f37-a346-8a1e0650eaa7" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_def8d204-cf61-4689-994a-76a2e7273046" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract_1daa4abd-86d1-4f37-a346-8a1e0650eaa7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents_31430b50-e0d6-4e69-a834-dae1efda8bda" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract_1daa4abd-86d1-4f37-a346-8a1e0650eaa7" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents_31430b50-e0d6-4e69-a834-dae1efda8bda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits_103f626e-b0ad-471b-bd75-5ffbc18feb04" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract_1daa4abd-86d1-4f37-a346-8a1e0650eaa7" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits_103f626e-b0ad-471b-bd75-5ffbc18feb04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment_5d47f4eb-ea88-4b7c-9b29-1998cfa9ae68" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract_1daa4abd-86d1-4f37-a346-8a1e0650eaa7" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment_5d47f4eb-ea88-4b7c-9b29-1998cfa9ae68" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets_df6cadab-521c-491f-9c46-9b96be01dd9f" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract_1daa4abd-86d1-4f37-a346-8a1e0650eaa7" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets_df6cadab-521c-491f-9c46-9b96be01dd9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset_6982a497-be72-40a3-959d-8d666622a4f8" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract_1daa4abd-86d1-4f37-a346-8a1e0650eaa7" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset_6982a497-be72-40a3-959d-8d666622a4f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet_1651cae6-f186-491c-bdc6-7aa04ae6e079" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract_1daa4abd-86d1-4f37-a346-8a1e0650eaa7" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet_1651cae6-f186-491c-bdc6-7aa04ae6e079" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract_859e989c-21b6-4a77-9285-d26231ca782d" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_def8d204-cf61-4689-994a-76a2e7273046" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract_859e989c-21b6-4a77-9285-d26231ca782d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities_24fe6f52-575c-4bbd-8f0b-716fa2111594" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract_859e989c-21b6-4a77-9285-d26231ca782d" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities_24fe6f52-575c-4bbd-8f0b-716fa2111594" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability_0f11b068-f0a5-4a99-9a8d-eca1ca3196ff" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract_859e989c-21b6-4a77-9285-d26231ca782d" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability_0f11b068-f0a5-4a99-9a8d-eca1ca3196ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed_27ec48cc-0f75-4699-9b27-063a4a7bfc17" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract_859e989c-21b6-4a77-9285-d26231ca782d" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed_27ec48cc-0f75-4699-9b27-063a4a7bfc17" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_809d83c3-c05d-4860-becf-bc7d6a6ae4b3" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_def8d204-cf61-4689-994a-76a2e7273046" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_809d83c3-c05d-4860-becf-bc7d6a6ae4b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsTable_e34bc850-eaea-4b6a-8152-d1bb43cf6c81" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_def8d204-cf61-4689-994a-76a2e7273046" xlink:to="loc_nltx_AcquisitionOfAssetsTable_e34bc850-eaea-4b6a-8152-d1bb43cf6c81" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsAxis_f26d5c30-636e-4f5a-9467-7fb1e621f69b" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nltx_AcquisitionOfAssetsTable_e34bc850-eaea-4b6a-8152-d1bb43cf6c81" xlink:to="loc_nltx_AcquisitionOfAssetsAxis_f26d5c30-636e-4f5a-9467-7fb1e621f69b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsDomain_f26d5c30-636e-4f5a-9467-7fb1e621f69b_default" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nltx_AcquisitionOfAssetsAxis_f26d5c30-636e-4f5a-9467-7fb1e621f69b" xlink:to="loc_nltx_AcquisitionOfAssetsDomain_f26d5c30-636e-4f5a-9467-7fb1e621f69b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsDomain_623c7787-e017-4cee-b199-64c13742a5e0" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nltx_AcquisitionOfAssetsAxis_f26d5c30-636e-4f5a-9467-7fb1e621f69b" xlink:to="loc_nltx_AcquisitionOfAssetsDomain_623c7787-e017-4cee-b199-64c13742a5e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AquinoxMember_591e53ce-c607-49ae-a8c3-dad39589b21d" xlink:href="nltx-20201231.xsd#nltx_AquinoxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_AcquisitionOfAssetsDomain_623c7787-e017-4cee-b199-64c13742a5e0" xlink:to="loc_nltx_AquinoxMember_591e53ce-c607-49ae-a8c3-dad39589b21d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Propertyandequipmentnet" xlink:type="simple" xlink:href="nltx-20201231.xsd#Propertyandequipmentnet"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/Propertyandequipmentnet" xlink:type="extended" id="i84891adb7cb24213a2d6f664fd081a56_Propertyandequipmentnet"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/PropertyandequipmentnetTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#PropertyandequipmentnetTables"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/PropertyandequipmentnetTables" xlink:type="extended" id="i27c7e973178245b0b3dcfc0dcb7a3287_PropertyandequipmentnetTables"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#PropertyandequipmentnetScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails" xlink:type="extended" id="id0832dff91814e448e306f729c7c5d7a_PropertyandequipmentnetScheduleofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_630e8867-2774-4613-af54-e7d4962a9f5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_56ee91c8-a765-412b-987f-e2632cfe9333" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_630e8867-2774-4613-af54-e7d4962a9f5e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_56ee91c8-a765-412b-987f-e2632cfe9333" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_cf744b6c-611c-4a5b-8ba1-2c21c3f945a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_630e8867-2774-4613-af54-e7d4962a9f5e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_cf744b6c-611c-4a5b-8ba1-2c21c3f945a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_506feee2-19ba-43c4-beb6-f2a63046e740" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_630e8867-2774-4613-af54-e7d4962a9f5e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_506feee2-19ba-43c4-beb6-f2a63046e740" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d4b476f4-543c-4d31-8488-f64a819072de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_630e8867-2774-4613-af54-e7d4962a9f5e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d4b476f4-543c-4d31-8488-f64a819072de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7d75d37f-9a27-4bae-9737-df5612f660f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d4b476f4-543c-4d31-8488-f64a819072de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7d75d37f-9a27-4bae-9737-df5612f660f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d75d37f-9a27-4bae-9737-df5612f660f4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7d75d37f-9a27-4bae-9737-df5612f660f4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d75d37f-9a27-4bae-9737-df5612f660f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_83aa278f-6bdb-41de-9e5f-8467b07a7de0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7d75d37f-9a27-4bae-9737-df5612f660f4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_83aa278f-6bdb-41de-9e5f-8467b07a7de0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_7874713d-4752-4ff7-b94d-827851dfcbea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_83aa278f-6bdb-41de-9e5f-8467b07a7de0" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_7874713d-4752-4ff7-b94d-827851dfcbea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_LaboratoryEquipmentMember_b6a19afb-5620-41e6-8299-7940bd4ab25f" xlink:href="nltx-20201231.xsd#nltx_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_83aa278f-6bdb-41de-9e5f-8467b07a7de0" xlink:to="loc_nltx_LaboratoryEquipmentMember_b6a19afb-5620-41e6-8299-7940bd4ab25f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_FurnitureFixturesAndITEquipmentMember_62672387-73da-439b-b264-c54245ecca2d" xlink:href="nltx-20201231.xsd#nltx_FurnitureFixturesAndITEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_83aa278f-6bdb-41de-9e5f-8467b07a7de0" xlink:to="loc_nltx_FurnitureFixturesAndITEquipmentMember_62672387-73da-439b-b264-c54245ecca2d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/PropertyandequipmentnetAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#PropertyandequipmentnetAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/PropertyandequipmentnetAdditionalInformationDetails" xlink:type="extended" id="i4d2a43933ee0496db7804dfb49e037ec_PropertyandequipmentnetAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Intangibleassetnet" xlink:type="simple" xlink:href="nltx-20201231.xsd#Intangibleassetnet"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/Intangibleassetnet" xlink:type="extended" id="id1550e0976e0417e8d30732c57af5140_Intangibleassetnet"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/IntangibleassetnetTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#IntangibleassetnetTables"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/IntangibleassetnetTables" xlink:type="extended" id="i1aed2de63556474cab5e3383bfd0dffb_IntangibleassetnetTables"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/IntangibleassetnetSummaryofIntangibleAssetDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#IntangibleassetnetSummaryofIntangibleAssetDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/IntangibleassetnetSummaryofIntangibleAssetDetails" xlink:type="extended" id="i4dbff832d82747e2ac3927d6e413ea83_IntangibleassetnetSummaryofIntangibleAssetDetails"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Accountspayableandotherliabilities" xlink:type="simple" xlink:href="nltx-20201231.xsd#Accountspayableandotherliabilities"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/Accountspayableandotherliabilities" xlink:type="extended" id="i6517be3f50fd42d097ac7e9c2cb2d07d_Accountspayableandotherliabilities"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#AccountspayableandotherliabilitiesTables"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesTables" xlink:type="extended" id="i8cef95d740b94d3ebf05558ad77ba883_AccountspayableandotherliabilitiesTables"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#AccountspayableandotherliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails" xlink:type="extended" id="if432b537db084a3d9d55660e69a65921_AccountspayableandotherliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Leases" xlink:type="simple" xlink:href="nltx-20201231.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/Leases" xlink:type="extended" id="ib3a1666a895b4b8fb428549f40a9fd19_Leases"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/LeasesTables" xlink:type="extended" id="ib9ec04f8f325466098aa42e7bd0503fa_LeasesTables"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#LeasesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails" xlink:type="extended" id="i9ac2ec958a96425f9c5ed0f44b2f9441_LeasesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_c9f1f3a0-a735-43f7-8280-f4bfa59a4713" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_c9f1f3a0-a735-43f7-8280-f4bfa59a4713" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_e50a5b7d-907c-45ea-9d3e-42fc7d9aeb95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_us-gaap_SecurityDeposit_e50a5b7d-907c-45ea-9d3e-42fc7d9aeb95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_NumberOfOptionToExtendLease_93774220-c364-40c7-94c4-659a1a08773a" xlink:href="nltx-20201231.xsd#nltx_NumberOfOptionToExtendLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_nltx_NumberOfOptionToExtendLease_93774220-c364-40c7-94c4-659a1a08773a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_LeaseAgreementExtendedPeriod_7f6087b2-a04b-47bb-85ac-f7bf9a573f63" xlink:href="nltx-20201231.xsd#nltx_LeaseAgreementExtendedPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_nltx_LeaseAgreementExtendedPeriod_7f6087b2-a04b-47bb-85ac-f7bf9a573f63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_TenantImprovementAllowance_daff0918-6553-4a0b-96f5-bc06aee8df29" xlink:href="nltx-20201231.xsd#nltx_TenantImprovementAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_nltx_TenantImprovementAllowance_daff0918-6553-4a0b-96f5-bc06aee8df29" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AdditionalTenantImprovements_ca0de8b7-b822-4115-8d44-64ddd37d279a" xlink:href="nltx-20201231.xsd#nltx_AdditionalTenantImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_nltx_AdditionalTenantImprovements_ca0de8b7-b822-4115-8d44-64ddd37d279a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_OperatingLeaseRightOfUseAssetIncreaseDueToRemeasurement_bc612983-cf30-48b3-be79-751f87b45f88" xlink:href="nltx-20201231.xsd#nltx_OperatingLeaseRightOfUseAssetIncreaseDueToRemeasurement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_nltx_OperatingLeaseRightOfUseAssetIncreaseDueToRemeasurement_bc612983-cf30-48b3-be79-751f87b45f88" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_OperatingLeaseLiabilityIncreaseDueToRemeasurement_cd070e32-a705-459e-bdb6-97e206f4210e" xlink:href="nltx-20201231.xsd#nltx_OperatingLeaseLiabilityIncreaseDueToRemeasurement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_nltx_OperatingLeaseLiabilityIncreaseDueToRemeasurement_cd070e32-a705-459e-bdb6-97e206f4210e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_TenantImprovementAllowanceReceivable_d12a0431-a96d-4f61-bf13-797b93b7f490" xlink:href="nltx-20201231.xsd#nltx_TenantImprovementAllowanceReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_nltx_TenantImprovementAllowanceReceivable_d12a0431-a96d-4f61-bf13-797b93b7f490" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_NumberOfDaysAdvanceNoticeMustBeGivenToTerminateTheLease_53e9d3d8-c8b9-4486-9154-838391e99bb5" xlink:href="nltx-20201231.xsd#nltx_NumberOfDaysAdvanceNoticeMustBeGivenToTerminateTheLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_nltx_NumberOfDaysAdvanceNoticeMustBeGivenToTerminateTheLease_53e9d3d8-c8b9-4486-9154-838391e99bb5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_TerminationFeesForLeaseTermination_9fe1df5f-773e-46b5-8dc0-b16ae0624e50" xlink:href="nltx-20201231.xsd#nltx_TerminationFeesForLeaseTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_nltx_TerminationFeesForLeaseTermination_9fe1df5f-773e-46b5-8dc0-b16ae0624e50" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_1a863cab-7460-481e-8c78-de1a6ec9f523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_1a863cab-7460-481e-8c78-de1a6ec9f523" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4faa977c-ab92-4988-8c0f-d4189d5f2efa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4faa977c-ab92-4988-8c0f-d4189d5f2efa" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1dfe744d-92fd-487d-97a1-604f83c2a23d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1dfe744d-92fd-487d-97a1-604f83c2a23d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_4742a072-8fe2-46bd-b903-15eb7948c60f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_4742a072-8fe2-46bd-b903-15eb7948c60f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_eee9fffe-0a59-48eb-9c5e-90941040468b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_eee9fffe-0a59-48eb-9c5e-90941040468b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_32731f6c-9d32-4497-b2f3-e254fdfd8a70" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_eee9fffe-0a59-48eb-9c5e-90941040468b" xlink:to="loc_srt_StatementGeographicalAxis_32731f6c-9d32-4497-b2f3-e254fdfd8a70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_32731f6c-9d32-4497-b2f3-e254fdfd8a70_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_32731f6c-9d32-4497-b2f3-e254fdfd8a70" xlink:to="loc_srt_SegmentGeographicalDomain_32731f6c-9d32-4497-b2f3-e254fdfd8a70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d20b270d-1dd1-4e73-bcb3-5234650136dc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_32731f6c-9d32-4497-b2f3-e254fdfd8a70" xlink:to="loc_srt_SegmentGeographicalDomain_d20b270d-1dd1-4e73-bcb3-5234650136dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA_40aef1bc-716d-4a8d-8772-6565f5cc8dc1" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_WA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d20b270d-1dd1-4e73-bcb3-5234650136dc" xlink:to="loc_stpr_WA_40aef1bc-716d-4a8d-8772-6565f5cc8dc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_50a53e23-acaf-4eb3-9d8a-9009a3cd81d0" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d20b270d-1dd1-4e73-bcb3-5234650136dc" xlink:to="loc_country_CA_50a53e23-acaf-4eb3-9d8a-9009a3cd81d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4140ca1e-d894-45b0-b520-fc5a5aa38522" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_eee9fffe-0a59-48eb-9c5e-90941040468b" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4140ca1e-d894-45b0-b520-fc5a5aa38522" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_4140ca1e-d894-45b0-b520-fc5a5aa38522_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4140ca1e-d894-45b0-b520-fc5a5aa38522" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_4140ca1e-d894-45b0-b520-fc5a5aa38522_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f6d04937-0db7-4fc2-8ac8-ae5cbba38c35" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4140ca1e-d894-45b0-b520-fc5a5aa38522" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f6d04937-0db7-4fc2-8ac8-ae5cbba38c35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember_c8d5d5ad-4e93-4193-9c49-ab3dc3b8b749" xlink:href="nltx-20201231.xsd#nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f6d04937-0db7-4fc2-8ac8-ae5cbba38c35" xlink:to="loc_nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember_c8d5d5ad-4e93-4193-9c49-ab3dc3b8b749" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_OfficeSpaceFormerPrincipalExecutiveOfficesAndLaboratoryMember_cd1e3d5c-7ff0-4eec-9d1f-af66c0e9c49f" xlink:href="nltx-20201231.xsd#nltx_OfficeSpaceFormerPrincipalExecutiveOfficesAndLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f6d04937-0db7-4fc2-8ac8-ae5cbba38c35" xlink:to="loc_nltx_OfficeSpaceFormerPrincipalExecutiveOfficesAndLaboratoryMember_cd1e3d5c-7ff0-4eec-9d1f-af66c0e9c49f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_62fc71f7-2ebd-48da-b25f-f3147fcd6380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_eee9fffe-0a59-48eb-9c5e-90941040468b" xlink:to="loc_us-gaap_CreditFacilityAxis_62fc71f7-2ebd-48da-b25f-f3147fcd6380" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_62fc71f7-2ebd-48da-b25f-f3147fcd6380_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_62fc71f7-2ebd-48da-b25f-f3147fcd6380" xlink:to="loc_us-gaap_CreditFacilityDomain_62fc71f7-2ebd-48da-b25f-f3147fcd6380_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d67d3c49-cccb-4146-827f-bafac951602a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_62fc71f7-2ebd-48da-b25f-f3147fcd6380" xlink:to="loc_us-gaap_CreditFacilityDomain_d67d3c49-cccb-4146-827f-bafac951602a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_1b2b81a2-0320-4e56-8dc6-f0b9573e8752" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_d67d3c49-cccb-4146-827f-bafac951602a" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_1b2b81a2-0320-4e56-8dc6-f0b9573e8752" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#LeasesScheduleofComponentsofLeaseExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails" xlink:type="extended" id="i049fc7156ee84343acc0363c5fc42180_LeasesScheduleofComponentsofLeaseExpenseDetails"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/LeasesSupplementalCashflowInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#LeasesSupplementalCashflowInformationRelatedtoLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/LeasesSupplementalCashflowInformationRelatedtoLeasesDetails" xlink:type="extended" id="i5dd2dfcb9c1c4cf69b765c1454226169_LeasesSupplementalCashflowInformationRelatedtoLeasesDetails"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="extended" id="ia9b7aa4b7461448f8e21813daba22add_LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Stockholdersequity" xlink:type="simple" xlink:href="nltx-20201231.xsd#Stockholdersequity"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/Stockholdersequity" xlink:type="extended" id="ibcd76dc0b197420a9541d64914dbbf5b_Stockholdersequity"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/StockholdersequityTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#StockholdersequityTables"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/StockholdersequityTables" xlink:type="extended" id="id9fc9e558af94c82b6f424214376c318_StockholdersequityTables"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#StockholdersequityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails" xlink:type="extended" id="ic241dcd2aef34095859d710cb035d23f_StockholdersequityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2f73bc91-e444-4962-b6d1-01a13da948d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2f73bc91-e444-4962-b6d1-01a13da948d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c4f46429-cc45-4b69-8752-f339985d2cba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c4f46429-cc45-4b69-8752-f339985d2cba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_69b4c5b7-25d6-41a3-bb01-6ccea805d4da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_CommonStockSharesIssued_69b4c5b7-25d6-41a3-bb01-6ccea805d4da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_19f0a786-476d-4a0e-acb0-b67951432015" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_19f0a786-476d-4a0e-acb0-b67951432015" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8a7924f3-12bc-49d2-b141-92d1d3c9daca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8a7924f3-12bc-49d2-b141-92d1d3c9daca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_144944d2-c862-4ecc-84bb-9d0523ef5693" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_144944d2-c862-4ecc-84bb-9d0523ef5693" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5a1d898f-2014-4dd4-a8d4-cf5497459ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5a1d898f-2014-4dd4-a8d4-cf5497459ebd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PreFundedWarrantIssuedPricePerShare_56c91886-16d9-4d0f-8b2c-cbf78d114c26" xlink:href="nltx-20201231.xsd#nltx_PreFundedWarrantIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_nltx_PreFundedWarrantIssuedPricePerShare_56c91886-16d9-4d0f-8b2c-cbf78d114c26" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d9134b12-9cdc-4b92-a92a-1125f8494c00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d9134b12-9cdc-4b92-a92a-1125f8494c00" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2e75745d-6d88-4b21-bca4-0c20f1f38de7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2e75745d-6d88-4b21-bca4-0c20f1f38de7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_2c48a1bc-994d-407a-a20a-f9bc2315ff08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_2c48a1bc-994d-407a-a20a-f9bc2315ff08" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_85b78195-160c-4244-b6e5-2609e07000b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_85b78195-160c-4244-b6e5-2609e07000b3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8400fdd8-fd56-466f-9921-4b0916912ad3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8400fdd8-fd56-466f-9921-4b0916912ad3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_74c01bc9-5365-41d6-bbf9-72b8f0c39459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_74c01bc9-5365-41d6-bbf9-72b8f0c39459" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_8f88ef43-c4fd-4e61-b63f-b428267273f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_8f88ef43-c4fd-4e61-b63f-b428267273f6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_e98a8781-ce6a-47e0-9b0f-9336bf5c31f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_e98a8781-ce6a-47e0-9b0f-9336bf5c31f1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_StockConversionRatio_ace464e5-22be-4cbd-9932-babb2431cf8a" xlink:href="nltx-20201231.xsd#nltx_StockConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_nltx_StockConversionRatio_ace464e5-22be-4cbd-9932-babb2431cf8a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_ConvertiblePreferredStockToBeConverted_1192ea42-7f0b-457f-81eb-2ae534209f9f" xlink:href="nltx-20201231.xsd#nltx_ConvertiblePreferredStockToBeConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_nltx_ConvertiblePreferredStockToBeConverted_1192ea42-7f0b-457f-81eb-2ae534209f9f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2319fec8-9b8f-44be-a675-f66bf92b2f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2319fec8-9b8f-44be-a675-f66bf92b2f5d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants_7a1ac86c-3492-41c8-b91f-6b0e1bd177ee" xlink:href="nltx-20201231.xsd#nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants_7a1ac86c-3492-41c8-b91f-6b0e1bd177ee" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PercentageOfOutstandingStockPerStockholderMaximum_29c7c25d-aba8-4257-9b49-f82dc7b0dfd6" xlink:href="nltx-20201231.xsd#nltx_PercentageOfOutstandingStockPerStockholderMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_nltx_PercentageOfOutstandingStockPerStockholderMaximum_29c7c25d-aba8-4257-9b49-f82dc7b0dfd6" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_70e576f0-4d09-4b53-bef3-ef038858776c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_70e576f0-4d09-4b53-bef3-ef038858776c" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fe3e5dff-9232-4dbc-b4d1-432ca4018781" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fe3e5dff-9232-4dbc-b4d1-432ca4018781" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PeriodSharesReservedForIssuanceWillIncrease_c060f226-43be-4c70-a0f6-f117c5fe454d" xlink:href="nltx-20201231.xsd#nltx_PeriodSharesReservedForIssuanceWillIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_nltx_PeriodSharesReservedForIssuanceWillIncrease_c060f226-43be-4c70-a0f6-f117c5fe454d" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_StockBasedCompensationIncreaseInCommonStockIssuancePercentage_fb087a87-2aff-4c63-9012-92eee74713cb" xlink:href="nltx-20201231.xsd#nltx_StockBasedCompensationIncreaseInCommonStockIssuancePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_nltx_StockBasedCompensationIncreaseInCommonStockIssuancePercentage_fb087a87-2aff-4c63-9012-92eee74713cb" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b536783e-9d91-40b6-a4cf-50e5dc119992" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b536783e-9d91-40b6-a4cf-50e5dc119992" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_71e3e3a8-adc3-479f-a44d-1738be072946" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_71e3e3a8-adc3-479f-a44d-1738be072946" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2b086514-436a-4595-aadc-1441a33c8085" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2b086514-436a-4595-aadc-1441a33c8085" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_86387f88-8a41-4797-819d-48aab6eef0ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_86387f88-8a41-4797-819d-48aab6eef0ad" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ffb60704-eb4c-4d6f-b10f-1b786e47279e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ffb60704-eb4c-4d6f-b10f-1b786e47279e" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_bdacb67a-a6fa-4ba2-b2d3-8134728ff91b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_bdacb67a-a6fa-4ba2-b2d3-8134728ff91b" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_99801b40-dbc9-4ecf-8e6a-a10cc852a552" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_99801b40-dbc9-4ecf-8e6a-a10cc852a552" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_88d246ba-4c10-444c-a859-c62e6d1f0516" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_88d246ba-4c10-444c-a859-c62e6d1f0516" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a10d2109-abf1-4f03-a04e-8f3fe351f19a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a10d2109-abf1-4f03-a04e-8f3fe351f19a" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7980ac42-ecdb-4fcd-9702-542e8bb9630b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7980ac42-ecdb-4fcd-9702-542e8bb9630b" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_3b136227-59c9-4765-86d0-de965ab93409" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_3b136227-59c9-4765-86d0-de965ab93409" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_b2c386ef-e359-41a5-8944-a9262f762dfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_b2c386ef-e359-41a5-8944-a9262f762dfa" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear_7241e565-bf52-47b7-8de0-6750de33c637" xlink:href="nltx-20201231.xsd#nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear_7241e565-bf52-47b7-8de0-6750de33c637" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_903027df-323c-42e4-9a5d-ff8a4ba8bc81" xlink:href="nltx-20201231.xsd#nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_903027df-323c-42e4-9a5d-ff8a4ba8bc81" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6f98a447-f19e-4700-b54b-8e0974d9d177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6f98a447-f19e-4700-b54b-8e0974d9d177" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3780dd2a-a3ce-4a9e-b58f-966af4b51804" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3780dd2a-a3ce-4a9e-b58f-966af4b51804" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2621c5a-c6a1-4b2b-b2f8-c85d4e30718c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2621c5a-c6a1-4b2b-b2f8-c85d4e30718c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_bd16f878-e0c0-431c-88e5-ac52c49c8247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2621c5a-c6a1-4b2b-b2f8-c85d4e30718c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_bd16f878-e0c0-431c-88e5-ac52c49c8247" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bd16f878-e0c0-431c-88e5-ac52c49c8247_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bd16f878-e0c0-431c-88e5-ac52c49c8247" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bd16f878-e0c0-431c-88e5-ac52c49c8247_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2bbb006-54eb-4807-ad3c-19eba93c52d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bd16f878-e0c0-431c-88e5-ac52c49c8247" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2bbb006-54eb-4807-ad3c-19eba93c52d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PublicStockOfferingMember_0b54056a-d192-44be-8da4-e409d27fc55a" xlink:href="nltx-20201231.xsd#nltx_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2bbb006-54eb-4807-ad3c-19eba93c52d4" xlink:to="loc_nltx_PublicStockOfferingMember_0b54056a-d192-44be-8da4-e409d27fc55a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_114488b2-3155-4219-adbb-d29a8f8fe5b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2621c5a-c6a1-4b2b-b2f8-c85d4e30718c" xlink:to="loc_us-gaap_AwardTypeAxis_114488b2-3155-4219-adbb-d29a8f8fe5b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_114488b2-3155-4219-adbb-d29a8f8fe5b1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_114488b2-3155-4219-adbb-d29a8f8fe5b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_114488b2-3155-4219-adbb-d29a8f8fe5b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8231e91-a4a6-42a7-a6d8-6657bdcf01d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_114488b2-3155-4219-adbb-d29a8f8fe5b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8231e91-a4a6-42a7-a6d8-6657bdcf01d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PreFundedWarrantsMember_064a7499-7bfc-4217-a3cf-c5e0eb2a55ea" xlink:href="nltx-20201231.xsd#nltx_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8231e91-a4a6-42a7-a6d8-6657bdcf01d3" xlink:to="loc_nltx_PreFundedWarrantsMember_064a7499-7bfc-4217-a3cf-c5e0eb2a55ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_0bd53865-6b53-4c07-91dd-0a460acc0d30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8231e91-a4a6-42a7-a6d8-6657bdcf01d3" xlink:to="loc_us-gaap_EmployeeStockMember_0bd53865-6b53-4c07-91dd-0a460acc0d30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsAxis_77c48069-b23d-4752-a87e-bf18eea8b9f8" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2621c5a-c6a1-4b2b-b2f8-c85d4e30718c" xlink:to="loc_nltx_AcquisitionOfAssetsAxis_77c48069-b23d-4752-a87e-bf18eea8b9f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsDomain_77c48069-b23d-4752-a87e-bf18eea8b9f8_default" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_nltx_AcquisitionOfAssetsAxis_77c48069-b23d-4752-a87e-bf18eea8b9f8" xlink:to="loc_nltx_AcquisitionOfAssetsDomain_77c48069-b23d-4752-a87e-bf18eea8b9f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsDomain_8ed3d052-d5cf-4d39-9612-31ada8a15584" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_nltx_AcquisitionOfAssetsAxis_77c48069-b23d-4752-a87e-bf18eea8b9f8" xlink:to="loc_nltx_AcquisitionOfAssetsDomain_8ed3d052-d5cf-4d39-9612-31ada8a15584" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AquinoxMember_f59d7e8e-0f74-4897-9128-77db59cbe1d3" xlink:href="nltx-20201231.xsd#nltx_AquinoxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_AcquisitionOfAssetsDomain_8ed3d052-d5cf-4d39-9612-31ada8a15584" xlink:to="loc_nltx_AquinoxMember_f59d7e8e-0f74-4897-9128-77db59cbe1d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e88355ab-c34b-43d6-8c3c-c5668c097572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2621c5a-c6a1-4b2b-b2f8-c85d4e30718c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e88355ab-c34b-43d6-8c3c-c5668c097572" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e88355ab-c34b-43d6-8c3c-c5668c097572_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e88355ab-c34b-43d6-8c3c-c5668c097572" xlink:to="loc_us-gaap_EquityComponentDomain_e88355ab-c34b-43d6-8c3c-c5668c097572_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_224cf3c1-e4d1-45f1-a4ed-bc896c06669d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e88355ab-c34b-43d6-8c3c-c5668c097572" xlink:to="loc_us-gaap_EquityComponentDomain_224cf3c1-e4d1-45f1-a4ed-bc896c06669d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c70aa67c-2539-45f3-b85a-7e2cd28e8d22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_224cf3c1-e4d1-45f1-a4ed-bc896c06669d" xlink:to="loc_us-gaap_CommonStockMember_c70aa67c-2539-45f3-b85a-7e2cd28e8d22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_be6368f5-be05-46b6-bc95-6b3aea800dfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2621c5a-c6a1-4b2b-b2f8-c85d4e30718c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_be6368f5-be05-46b6-bc95-6b3aea800dfc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_be6368f5-be05-46b6-bc95-6b3aea800dfc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_be6368f5-be05-46b6-bc95-6b3aea800dfc" xlink:to="loc_us-gaap_ClassOfStockDomain_be6368f5-be05-46b6-bc95-6b3aea800dfc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d87f3ab5-85e2-4c44-99ee-40b106f6d1a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_be6368f5-be05-46b6-bc95-6b3aea800dfc" xlink:to="loc_us-gaap_ClassOfStockDomain_d87f3ab5-85e2-4c44-99ee-40b106f6d1a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_NonVotingConvertiblePreferredStockMember_a113bb7d-ec84-4b7b-8349-fc1ed10dd9f9" xlink:href="nltx-20201231.xsd#nltx_NonVotingConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d87f3ab5-85e2-4c44-99ee-40b106f6d1a5" xlink:to="loc_nltx_NonVotingConvertiblePreferredStockMember_a113bb7d-ec84-4b7b-8349-fc1ed10dd9f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PreFundedCommonStockWarrantsMember_1dcfd567-ee0c-4409-9a78-b173e8b279ee" xlink:href="nltx-20201231.xsd#nltx_PreFundedCommonStockWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d87f3ab5-85e2-4c44-99ee-40b106f6d1a5" xlink:to="loc_nltx_PreFundedCommonStockWarrantsMember_1dcfd567-ee0c-4409-9a78-b173e8b279ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4db84f37-1f0c-4217-9fc2-7947a3d72df5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2621c5a-c6a1-4b2b-b2f8-c85d4e30718c" xlink:to="loc_us-gaap_PlanNameAxis_4db84f37-1f0c-4217-9fc2-7947a3d72df5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4db84f37-1f0c-4217-9fc2-7947a3d72df5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_4db84f37-1f0c-4217-9fc2-7947a3d72df5" xlink:to="loc_us-gaap_PlanNameDomain_4db84f37-1f0c-4217-9fc2-7947a3d72df5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c94c97d4-9653-4d31-bbb6-7165fcf17d99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_4db84f37-1f0c-4217-9fc2-7947a3d72df5" xlink:to="loc_us-gaap_PlanNameDomain_c94c97d4-9653-4d31-bbb6-7165fcf17d99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_StockIncentivePlanTwoThousandFourteenMember_f9c685f9-afea-42b4-a3b0-fd5168d140ea" xlink:href="nltx-20201231.xsd#nltx_StockIncentivePlanTwoThousandFourteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c94c97d4-9653-4d31-bbb6-7165fcf17d99" xlink:to="loc_nltx_StockIncentivePlanTwoThousandFourteenMember_f9c685f9-afea-42b4-a3b0-fd5168d140ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_EquityIncentivePlanTwoThousandSixMember_2f86158c-f702-47a1-93c0-7012ed793a6a" xlink:href="nltx-20201231.xsd#nltx_EquityIncentivePlanTwoThousandSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c94c97d4-9653-4d31-bbb6-7165fcf17d99" xlink:to="loc_nltx_EquityIncentivePlanTwoThousandSixMember_2f86158c-f702-47a1-93c0-7012ed793a6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_A2020EmployeeStockPurchasePlanMember_e89daf55-672b-404f-9a7b-827c2cd6a1f2" xlink:href="nltx-20201231.xsd#nltx_A2020EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c94c97d4-9653-4d31-bbb6-7165fcf17d99" xlink:to="loc_nltx_A2020EmployeeStockPurchasePlanMember_e89daf55-672b-404f-9a7b-827c2cd6a1f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e85f9319-8ab5-4857-92df-9ebd065431f4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2621c5a-c6a1-4b2b-b2f8-c85d4e30718c" xlink:to="loc_srt_RangeAxis_e85f9319-8ab5-4857-92df-9ebd065431f4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e85f9319-8ab5-4857-92df-9ebd065431f4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e85f9319-8ab5-4857-92df-9ebd065431f4" xlink:to="loc_srt_RangeMember_e85f9319-8ab5-4857-92df-9ebd065431f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_93c2474c-a6df-4211-8094-43cedf51cc7d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e85f9319-8ab5-4857-92df-9ebd065431f4" xlink:to="loc_srt_RangeMember_93c2474c-a6df-4211-8094-43cedf51cc7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7d2e8643-2702-4c29-804d-c801f258ce46" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_93c2474c-a6df-4211-8094-43cedf51cc7d" xlink:to="loc_srt_MinimumMember_7d2e8643-2702-4c29-804d-c801f258ce46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_13b2f6ff-aa4c-4c5d-b0df-a547884b81d6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_93c2474c-a6df-4211-8094-43cedf51cc7d" xlink:to="loc_srt_MaximumMember_13b2f6ff-aa4c-4c5d-b0df-a547884b81d6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/StockholdersequityScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#StockholdersequityScheduleofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/StockholdersequityScheduleofStockOptionActivityDetails" xlink:type="extended" id="i8c57f021c1874bffb28a99f1133dc064_StockholdersequityScheduleofStockOptionActivityDetails"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/StockholdersequityScheduleofWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#StockholdersequityScheduleofWeightedAverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/StockholdersequityScheduleofWeightedAverageAssumptionsDetails" xlink:type="extended" id="if368992eafea47a5ae298dafc1abd60d_StockholdersequityScheduleofWeightedAverageAssumptionsDetails"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/StockholdersequityScheduleofRSUActivityDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#StockholdersequityScheduleofRSUActivityDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/StockholdersequityScheduleofRSUActivityDetails" xlink:type="extended" id="if50a90f405e141e286ead7ec237b347a_StockholdersequityScheduleofRSUActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fdb39b71-da26-486c-bc36-f80e12349fc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0cbdde5-a5a8-49a1-bb76-3d9502e27218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fdb39b71-da26-486c-bc36-f80e12349fc5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0cbdde5-a5a8-49a1-bb76-3d9502e27218" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_59fecea0-2c4f-4c75-96ea-0c9913b2c2c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0cbdde5-a5a8-49a1-bb76-3d9502e27218" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_59fecea0-2c4f-4c75-96ea-0c9913b2c2c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_eb5f71ab-dbcb-406f-b2f3-ba429ab90c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0cbdde5-a5a8-49a1-bb76-3d9502e27218" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_eb5f71ab-dbcb-406f-b2f3-ba429ab90c6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6ae267cb-e5bd-4ccf-88c2-416f174138bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0cbdde5-a5a8-49a1-bb76-3d9502e27218" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6ae267cb-e5bd-4ccf-88c2-416f174138bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_072f9e81-aa31-47ff-b2a0-f6a590047423" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0cbdde5-a5a8-49a1-bb76-3d9502e27218" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_072f9e81-aa31-47ff-b2a0-f6a590047423" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1cc3d7d3-b767-480c-aa83-0b4202795fb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b5eac660-fd50-4804-a3a4-a41f324cdd0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fdb39b71-da26-486c-bc36-f80e12349fc5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b5eac660-fd50-4804-a3a4-a41f324cdd0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cfb69c38-4a4e-4a94-86ea-cbd791b2d87c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b5eac660-fd50-4804-a3a4-a41f324cdd0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cfb69c38-4a4e-4a94-86ea-cbd791b2d87c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9f643b9a-0b9d-4eef-b17d-626946556367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b5eac660-fd50-4804-a3a4-a41f324cdd0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9f643b9a-0b9d-4eef-b17d-626946556367" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3d535ff5-0bd3-4a88-9fbd-8b73532a6f9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b5eac660-fd50-4804-a3a4-a41f324cdd0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3d535ff5-0bd3-4a88-9fbd-8b73532a6f9a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f2b49b6e-5ca9-4cfc-8eec-8a8a8b3c4b72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b5eac660-fd50-4804-a3a4-a41f324cdd0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f2b49b6e-5ca9-4cfc-8eec-8a8a8b3c4b72" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a9de4481-08bd-4d1f-b4a0-fcb8d94dc4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9f822180-b41c-48e6-a4a6-afb25ad8444a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fdb39b71-da26-486c-bc36-f80e12349fc5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9f822180-b41c-48e6-a4a6-afb25ad8444a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6055318b-9ed2-4a2e-91ea-ea2cd22b8a94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9f822180-b41c-48e6-a4a6-afb25ad8444a" xlink:to="loc_us-gaap_AwardTypeAxis_6055318b-9ed2-4a2e-91ea-ea2cd22b8a94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6055318b-9ed2-4a2e-91ea-ea2cd22b8a94_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6055318b-9ed2-4a2e-91ea-ea2cd22b8a94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6055318b-9ed2-4a2e-91ea-ea2cd22b8a94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c6ee62e-d939-4910-b3bd-81b7b5316495" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6055318b-9ed2-4a2e-91ea-ea2cd22b8a94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c6ee62e-d939-4910-b3bd-81b7b5316495" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_041b5af7-1884-4837-9c0e-3308b212cf9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c6ee62e-d939-4910-b3bd-81b7b5316495" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_041b5af7-1884-4837-9c0e-3308b212cf9d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/StockholdersequitySummaryofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#StockholdersequitySummaryofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/StockholdersequitySummaryofStockbasedCompensationExpenseDetails" xlink:type="extended" id="id042eddba2a84beca8e4a3163e1cdd45_StockholdersequitySummaryofStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e359938-5a3f-4cdc-9a0d-25af9acf9648" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b45bfcaa-3427-4ef6-abc7-256c40452d19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e359938-5a3f-4cdc-9a0d-25af9acf9648" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b45bfcaa-3427-4ef6-abc7-256c40452d19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e94f28c2-21e0-4c05-917d-0617123c5fed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e359938-5a3f-4cdc-9a0d-25af9acf9648" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e94f28c2-21e0-4c05-917d-0617123c5fed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_24d2e19c-257e-4164-869f-a8c5adc14e86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e94f28c2-21e0-4c05-917d-0617123c5fed" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_24d2e19c-257e-4164-869f-a8c5adc14e86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_24d2e19c-257e-4164-869f-a8c5adc14e86_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_24d2e19c-257e-4164-869f-a8c5adc14e86" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_24d2e19c-257e-4164-869f-a8c5adc14e86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2d35cfa8-9ba0-43de-8c5e-da17e2bfd4a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_24d2e19c-257e-4164-869f-a8c5adc14e86" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2d35cfa8-9ba0-43de-8c5e-da17e2bfd4a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_35acfedd-46f9-4a3a-b7aa-084727ddc7b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2d35cfa8-9ba0-43de-8c5e-da17e2bfd4a1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_35acfedd-46f9-4a3a-b7aa-084727ddc7b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1f9ecfa1-dd0b-47cf-819f-19f8f94a864e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2d35cfa8-9ba0-43de-8c5e-da17e2bfd4a1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1f9ecfa1-dd0b-47cf-819f-19f8f94a864e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Restructuring" xlink:type="simple" xlink:href="nltx-20201231.xsd#Restructuring"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/Restructuring" xlink:type="extended" id="i104c96f0cc5046ecaa47318b8b6e27f0_Restructuring"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/RestructuringAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#RestructuringAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/RestructuringAdditionalInformationDetails" xlink:type="extended" id="ia5387910e981494a8150717a1e8578a1_RestructuringAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_50ee28c3-fc88-4d86-80e6-2b862629793a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_b3dcecde-93d4-415d-8f10-0214ca3a674b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50ee28c3-fc88-4d86-80e6-2b862629793a" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_b3dcecde-93d4-415d-8f10-0214ca3a674b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_3b55271f-4c11-4fe4-a57a-56d5a6fd1269" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50ee28c3-fc88-4d86-80e6-2b862629793a" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_3b55271f-4c11-4fe4-a57a-56d5a6fd1269" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_0bb2adc7-470e-4d1e-b62f-5b06980cea9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50ee28c3-fc88-4d86-80e6-2b862629793a" xlink:to="loc_us-gaap_RestructuringReserve_0bb2adc7-470e-4d1e-b62f-5b06980cea9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_fa36d119-ae1c-49f8-9df9-81e980786a03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50ee28c3-fc88-4d86-80e6-2b862629793a" xlink:to="loc_us-gaap_RestructuringCharges_fa36d119-ae1c-49f8-9df9-81e980786a03" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5c9a0262-e865-42f0-9c54-eb836003f7af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50ee28c3-fc88-4d86-80e6-2b862629793a" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5c9a0262-e865-42f0-9c54-eb836003f7af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_42680315-72b9-4583-b0d4-d0609e07ecf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5c9a0262-e865-42f0-9c54-eb836003f7af" xlink:to="loc_us-gaap_RestructuringPlanAxis_42680315-72b9-4583-b0d4-d0609e07ecf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_42680315-72b9-4583-b0d4-d0609e07ecf9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_42680315-72b9-4583-b0d4-d0609e07ecf9" xlink:to="loc_us-gaap_RestructuringPlanDomain_42680315-72b9-4583-b0d4-d0609e07ecf9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_b1eeeb9e-c32f-4a7b-9314-45b445a10bb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_42680315-72b9-4583-b0d4-d0609e07ecf9" xlink:to="loc_us-gaap_RestructuringPlanDomain_b1eeeb9e-c32f-4a7b-9314-45b445a10bb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_RestructuringPlan1July2018Member_011e2a49-1bb3-4cb1-bff4-cf2a40d3051b" xlink:href="nltx-20201231.xsd#nltx_RestructuringPlan1July2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_b1eeeb9e-c32f-4a7b-9314-45b445a10bb8" xlink:to="loc_nltx_RestructuringPlan1July2018Member_011e2a49-1bb3-4cb1-bff4-cf2a40d3051b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_RestructuringPlan1November62018Member_4602221f-bc96-4fd9-a910-7f3bdbfabe1a" xlink:href="nltx-20201231.xsd#nltx_RestructuringPlan1November62018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_b1eeeb9e-c32f-4a7b-9314-45b445a10bb8" xlink:to="loc_nltx_RestructuringPlan1November62018Member_4602221f-bc96-4fd9-a910-7f3bdbfabe1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ddae4b0f-d042-49b7-bf3e-c014266896af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5c9a0262-e865-42f0-9c54-eb836003f7af" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ddae4b0f-d042-49b7-bf3e-c014266896af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ddae4b0f-d042-49b7-bf3e-c014266896af_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ddae4b0f-d042-49b7-bf3e-c014266896af" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ddae4b0f-d042-49b7-bf3e-c014266896af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_37bac6ce-52ed-4c9a-a08e-94b02e973097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ddae4b0f-d042-49b7-bf3e-c014266896af" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_37bac6ce-52ed-4c9a-a08e-94b02e973097" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ccac093f-238e-403e-8f90-c21e4959378a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_37bac6ce-52ed-4c9a-a08e-94b02e973097" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ccac093f-238e-403e-8f90-c21e4959378a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8c7da214-9a40-40f5-8361-a44d5fc8e6b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_37bac6ce-52ed-4c9a-a08e-94b02e973097" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8c7da214-9a40-40f5-8361-a44d5fc8e6b7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Otherincomenet" xlink:type="simple" xlink:href="nltx-20201231.xsd#Otherincomenet"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/Otherincomenet" xlink:type="extended" id="i7a8aaf6ea27444e9b9fb4872f46dd810_Otherincomenet"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/OtherincomenetTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#OtherincomenetTables"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/OtherincomenetTables" xlink:type="extended" id="i7896a66b2dbf4f75b697122ac65ad64e_OtherincomenetTables"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/OtherincomenetScheduleofOtherIncomeNetDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#OtherincomenetScheduleofOtherIncomeNetDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/OtherincomenetScheduleofOtherIncomeNetDetails" xlink:type="extended" id="i8b055eb5417642d3ab25d516ffc51fe1_OtherincomenetScheduleofOtherIncomeNetDetails"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Netlosspercommonstock" xlink:type="simple" xlink:href="nltx-20201231.xsd#Netlosspercommonstock"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/Netlosspercommonstock" xlink:type="extended" id="iaef294bc55284bb7b858a5d085e41c8c_Netlosspercommonstock"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/NetlosspercommonstockTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#NetlosspercommonstockTables"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/NetlosspercommonstockTables" xlink:type="extended" id="i52b83219ff5b4a3494aa70127e2fd01a_NetlosspercommonstockTables"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/NetlosspercommonstockScheduleofSecuritiesExcludedFromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#NetlosspercommonstockScheduleofSecuritiesExcludedFromComputationofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/NetlosspercommonstockScheduleofSecuritiesExcludedFromComputationofEarningsPerShareDetails" xlink:type="extended" id="ib0895a49e2cc452cb1a8f1fa8d0c5093_NetlosspercommonstockScheduleofSecuritiesExcludedFromComputationofEarningsPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_749ba388-172c-43b6-98e1-0736d0e6e1c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2c829183-d959-479e-8001-fa7032deb7ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_749ba388-172c-43b6-98e1-0736d0e6e1c9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2c829183-d959-479e-8001-fa7032deb7ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4f3efbdf-cd66-41dc-bdbe-f375dad6d8eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_749ba388-172c-43b6-98e1-0736d0e6e1c9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4f3efbdf-cd66-41dc-bdbe-f375dad6d8eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7dee1535-ff3a-4a84-b12f-a3a45b48b26f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4f3efbdf-cd66-41dc-bdbe-f375dad6d8eb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7dee1535-ff3a-4a84-b12f-a3a45b48b26f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7dee1535-ff3a-4a84-b12f-a3a45b48b26f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7dee1535-ff3a-4a84-b12f-a3a45b48b26f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7dee1535-ff3a-4a84-b12f-a3a45b48b26f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0925d36a-c093-45e8-96c1-4b45f2141b5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7dee1535-ff3a-4a84-b12f-a3a45b48b26f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0925d36a-c093-45e8-96c1-4b45f2141b5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fbeb8767-a263-4bf6-99aa-3a8a2e08b418" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0925d36a-c093-45e8-96c1-4b45f2141b5a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fbeb8767-a263-4bf6-99aa-3a8a2e08b418" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_818484f0-b484-4022-bc6c-84754eb4f51d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0925d36a-c093-45e8-96c1-4b45f2141b5a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_818484f0-b484-4022-bc6c-84754eb4f51d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_8d011abe-b2e4-470a-80aa-ec869b3b6b54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0925d36a-c093-45e8-96c1-4b45f2141b5a" xlink:to="loc_us-gaap_EmployeeStockMember_8d011abe-b2e4-470a-80aa-ec869b3b6b54" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Incometaxes" xlink:type="simple" xlink:href="nltx-20201231.xsd#Incometaxes"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/Incometaxes" xlink:type="extended" id="i16d93801c29c4f9f95e55288310a503e_Incometaxes"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/IncometaxesTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#IncometaxesTables"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/IncometaxesTables" xlink:type="extended" id="iafd0160994c341869f69656debe71b7d_IncometaxesTables"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#IncomeTaxesScheduleofIncometaxRecoveryDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails" xlink:type="extended" id="i021fee04e5d345a19e4b1eec3148c524_IncomeTaxesScheduleofIncometaxRecoveryDetails"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/IncomeTaxesScheduleofNetLossIncomeBeforeTaxesDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#IncomeTaxesScheduleofNetLossIncomeBeforeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/IncomeTaxesScheduleofNetLossIncomeBeforeTaxesDetails" xlink:type="extended" id="ibed1bd13b6d5486cbc9b2d6cfb2c7bc3_IncomeTaxesScheduleofNetLossIncomeBeforeTaxesDetails"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails" xlink:type="extended" id="iff71de0fb72040a497cb67f180bf9572_IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="i81eac759920a4e7f9a11fd544faee007_IncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nltx_IncomeTaxesDisclosureLineItems_f1753631-95f0-4863-9916-4673811240c0" xlink:href="nltx-20201231.xsd#nltx_IncomeTaxesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary_3fc860a3-5b90-4b1c-8109-a6f4922df76d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_IncomeTaxesDisclosureLineItems_f1753631-95f0-4863-9916-4673811240c0" xlink:to="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary_3fc860a3-5b90-4b1c-8109-a6f4922df76d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_DeferredTaxAssetsTaxCreditCarryforwardsReducedDueToSaleOfForeignEntity_86657781-b895-43f9-9216-0a2f070e89f3" xlink:href="nltx-20201231.xsd#nltx_DeferredTaxAssetsTaxCreditCarryforwardsReducedDueToSaleOfForeignEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_IncomeTaxesDisclosureLineItems_f1753631-95f0-4863-9916-4673811240c0" xlink:to="loc_nltx_DeferredTaxAssetsTaxCreditCarryforwardsReducedDueToSaleOfForeignEntity_86657781-b895-43f9-9216-0a2f070e89f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_f8093805-89a7-467f-a643-dde51b531a6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_IncomeTaxesDisclosureLineItems_f1753631-95f0-4863-9916-4673811240c0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_f8093805-89a7-467f-a643-dde51b531a6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_OperatingLossCarryforwardsSubjectToExpiration_1bdf977d-4883-40f4-b0e3-4c7655d1f51e" xlink:href="nltx-20201231.xsd#nltx_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_IncomeTaxesDisclosureLineItems_f1753631-95f0-4863-9916-4673811240c0" xlink:to="loc_nltx_OperatingLossCarryforwardsSubjectToExpiration_1bdf977d-4883-40f4-b0e3-4c7655d1f51e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_OperatingLossCarryforwardsNotSubjectToExpiration_97853c9c-ee10-49c9-a1d8-ff28c3bb3313" xlink:href="nltx-20201231.xsd#nltx_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_IncomeTaxesDisclosureLineItems_f1753631-95f0-4863-9916-4673811240c0" xlink:to="loc_nltx_OperatingLossCarryforwardsNotSubjectToExpiration_97853c9c-ee10-49c9-a1d8-ff28c3bb3313" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_27456f9d-8d7d-49f4-be0e-8bdffc23af2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_IncomeTaxesDisclosureLineItems_f1753631-95f0-4863-9916-4673811240c0" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_27456f9d-8d7d-49f4-be0e-8bdffc23af2b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_6ceb23c3-1609-4ea6-b55e-49ce1b63e5dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_IncomeTaxesDisclosureLineItems_f1753631-95f0-4863-9916-4673811240c0" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_6ceb23c3-1609-4ea6-b55e-49ce1b63e5dc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_IncomeTaxesDisclosureTable_4480e7a5-3ade-4e20-8ec5-cb9392135360" xlink:href="nltx-20201231.xsd#nltx_IncomeTaxesDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nltx_IncomeTaxesDisclosureLineItems_f1753631-95f0-4863-9916-4673811240c0" xlink:to="loc_nltx_IncomeTaxesDisclosureTable_4480e7a5-3ade-4e20-8ec5-cb9392135360" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_acbb0524-c765-46fe-81f4-afb5f778480a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nltx_IncomeTaxesDisclosureTable_4480e7a5-3ade-4e20-8ec5-cb9392135360" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_acbb0524-c765-46fe-81f4-afb5f778480a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_acbb0524-c765-46fe-81f4-afb5f778480a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_acbb0524-c765-46fe-81f4-afb5f778480a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_acbb0524-c765-46fe-81f4-afb5f778480a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_02ccd010-c15e-4403-a1a8-826459dd0647" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_acbb0524-c765-46fe-81f4-afb5f778480a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_02ccd010-c15e-4403-a1a8-826459dd0647" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcqinoxCanadaMember_ce0e557f-7b6a-43fc-9fb3-97f89b5428fb" xlink:href="nltx-20201231.xsd#nltx_AcqinoxCanadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_02ccd010-c15e-4403-a1a8-826459dd0647" xlink:to="loc_nltx_AcqinoxCanadaMember_ce0e557f-7b6a-43fc-9fb3-97f89b5428fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_96d087d3-3e00-49db-ae98-a02c7331ab07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nltx_IncomeTaxesDisclosureTable_4480e7a5-3ade-4e20-8ec5-cb9392135360" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_96d087d3-3e00-49db-ae98-a02c7331ab07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_96d087d3-3e00-49db-ae98-a02c7331ab07_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_96d087d3-3e00-49db-ae98-a02c7331ab07" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_96d087d3-3e00-49db-ae98-a02c7331ab07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_f8ed2b6a-55fa-4460-989a-7372140e9b6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_96d087d3-3e00-49db-ae98-a02c7331ab07" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_f8ed2b6a-55fa-4460-989a-7372140e9b6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_6b23a0cb-7bec-44f3-bdf3-584d63f398b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f8ed2b6a-55fa-4460-989a-7372140e9b6c" xlink:to="loc_us-gaap_ResearchMember_6b23a0cb-7bec-44f3-bdf3-584d63f398b6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Licenseandpatentagreements" xlink:type="simple" xlink:href="nltx-20201231.xsd#Licenseandpatentagreements"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/Licenseandpatentagreements" xlink:type="extended" id="ia54caad8de06474cb88e472170be4554_Licenseandpatentagreements"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#LicenseandpatentagreementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails" xlink:type="extended" id="i379bdcc3f53846c1bfa90d827436629c_LicenseandpatentagreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_nltx_LicenseAndPatentAgreementsLineItems_25bc87e4-b231-49f7-a0c3-c2dcb24790ae" xlink:href="nltx-20201231.xsd#nltx_LicenseAndPatentAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_4c53a496-89ed-45db-aaf0-937ff8fafa96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_LicenseAndPatentAgreementsLineItems_25bc87e4-b231-49f7-a0c3-c2dcb24790ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_4c53a496-89ed-45db-aaf0-937ff8fafa96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_bcd83adc-bce4-4152-9c73-ab0ad40c6122" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_LicenseAndPatentAgreementsLineItems_25bc87e4-b231-49f7-a0c3-c2dcb24790ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_bcd83adc-bce4-4152-9c73-ab0ad40c6122" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_LicenseArrangementsAmountsPayableOnDevelopmentalMilestones_2ce3420f-4df7-433c-b2ec-8ac7ae8f3963" xlink:href="nltx-20201231.xsd#nltx_LicenseArrangementsAmountsPayableOnDevelopmentalMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_LicenseAndPatentAgreementsLineItems_25bc87e4-b231-49f7-a0c3-c2dcb24790ae" xlink:to="loc_nltx_LicenseArrangementsAmountsPayableOnDevelopmentalMilestones_2ce3420f-4df7-433c-b2ec-8ac7ae8f3963" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_LicenseArrangementsAmountsPayableBasedOnNetSales_4445c76b-e140-4307-9aa6-840b3385a574" xlink:href="nltx-20201231.xsd#nltx_LicenseArrangementsAmountsPayableBasedOnNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_LicenseAndPatentAgreementsLineItems_25bc87e4-b231-49f7-a0c3-c2dcb24790ae" xlink:to="loc_nltx_LicenseArrangementsAmountsPayableBasedOnNetSales_4445c76b-e140-4307-9aa6-840b3385a574" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_30bbac85-7ba5-4077-b4ce-13c2a1eb40c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_nltx_LicenseAndPatentAgreementsLineItems_25bc87e4-b231-49f7-a0c3-c2dcb24790ae" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_30bbac85-7ba5-4077-b4ce-13c2a1eb40c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_LicenseAndPatentAgreementsTable_8c37586b-0440-410a-84ee-496b3d12804d" xlink:href="nltx-20201231.xsd#nltx_LicenseAndPatentAgreementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_nltx_LicenseAndPatentAgreementsLineItems_25bc87e4-b231-49f7-a0c3-c2dcb24790ae" xlink:to="loc_nltx_LicenseAndPatentAgreementsTable_8c37586b-0440-410a-84ee-496b3d12804d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_603f510a-a4da-4159-8c9e-a62d2f5c3c78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nltx_LicenseAndPatentAgreementsTable_8c37586b-0440-410a-84ee-496b3d12804d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_603f510a-a4da-4159-8c9e-a62d2f5c3c78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_603f510a-a4da-4159-8c9e-a62d2f5c3c78_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_603f510a-a4da-4159-8c9e-a62d2f5c3c78" xlink:to="loc_us-gaap_ClassOfStockDomain_603f510a-a4da-4159-8c9e-a62d2f5c3c78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cfc48fa0-2699-4420-a8a9-dfcf4e871cbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_603f510a-a4da-4159-8c9e-a62d2f5c3c78" xlink:to="loc_us-gaap_ClassOfStockDomain_cfc48fa0-2699-4420-a8a9-dfcf4e871cbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_NonVotingConvertiblePreferredStockMember_c72e72ab-5589-45b1-94cf-7873a5924e25" xlink:href="nltx-20201231.xsd#nltx_NonVotingConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_cfc48fa0-2699-4420-a8a9-dfcf4e871cbd" xlink:to="loc_nltx_NonVotingConvertiblePreferredStockMember_c72e72ab-5589-45b1-94cf-7873a5924e25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e3228792-1253-4c9a-a40a-88ff62ac6f1f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nltx_LicenseAndPatentAgreementsTable_8c37586b-0440-410a-84ee-496b3d12804d" xlink:to="loc_srt_ProductOrServiceAxis_e3228792-1253-4c9a-a40a-88ff62ac6f1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e3228792-1253-4c9a-a40a-88ff62ac6f1f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e3228792-1253-4c9a-a40a-88ff62ac6f1f" xlink:to="loc_srt_ProductsAndServicesDomain_e3228792-1253-4c9a-a40a-88ff62ac6f1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1a2691f5-3ec9-44b0-a473-86ce7547fd82" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e3228792-1253-4c9a-a40a-88ff62ac6f1f" xlink:to="loc_srt_ProductsAndServicesDomain_1a2691f5-3ec9-44b0-a473-86ce7547fd82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndMaintenanceMember_6925c475-05b9-48f3-9f15-3eb5feb59b79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndMaintenanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a2691f5-3ec9-44b0-a473-86ce7547fd82" xlink:to="loc_us-gaap_LicenseAndMaintenanceMember_6925c475-05b9-48f3-9f15-3eb5feb59b79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_27253bf4-e3d0-4c4c-946a-889ca00005f1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nltx_LicenseAndPatentAgreementsTable_8c37586b-0440-410a-84ee-496b3d12804d" xlink:to="loc_srt_RangeAxis_27253bf4-e3d0-4c4c-946a-889ca00005f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_27253bf4-e3d0-4c4c-946a-889ca00005f1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_27253bf4-e3d0-4c4c-946a-889ca00005f1" xlink:to="loc_srt_RangeMember_27253bf4-e3d0-4c4c-946a-889ca00005f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e0c6295c-45ec-4a29-8214-52e72ec65050" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_27253bf4-e3d0-4c4c-946a-889ca00005f1" xlink:to="loc_srt_RangeMember_e0c6295c-45ec-4a29-8214-52e72ec65050" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fbc3db6d-4531-4652-9695-d5c2268ca0c9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e0c6295c-45ec-4a29-8214-52e72ec65050" xlink:to="loc_srt_MinimumMember_fbc3db6d-4531-4652-9695-d5c2268ca0c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d96b9769-dbe3-4928-9e02-0a5bd2ad8d9a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e0c6295c-45ec-4a29-8214-52e72ec65050" xlink:to="loc_srt_MaximumMember_d96b9769-dbe3-4928-9e02-0a5bd2ad8d9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5750c54a-fa4f-4209-84f5-81384c9a1f63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nltx_LicenseAndPatentAgreementsTable_8c37586b-0440-410a-84ee-496b3d12804d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5750c54a-fa4f-4209-84f5-81384c9a1f63" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5750c54a-fa4f-4209-84f5-81384c9a1f63_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5750c54a-fa4f-4209-84f5-81384c9a1f63" xlink:to="loc_us-gaap_EquityComponentDomain_5750c54a-fa4f-4209-84f5-81384c9a1f63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e7cefce8-b8d2-4abd-b202-ca6028ceed7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5750c54a-fa4f-4209-84f5-81384c9a1f63" xlink:to="loc_us-gaap_EquityComponentDomain_e7cefce8-b8d2-4abd-b202-ca6028ceed7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ee3cd48a-7528-4ba1-ae0e-b45db82b8bfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e7cefce8-b8d2-4abd-b202-ca6028ceed7f" xlink:to="loc_us-gaap_CommonStockMember_ee3cd48a-7528-4ba1-ae0e-b45db82b8bfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis_6c78f5fb-4c69-4bd3-a1e0-ea6e8d7aa9da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_nltx_LicenseAndPatentAgreementsTable_8c37586b-0440-410a-84ee-496b3d12804d" xlink:to="loc_us-gaap_EquitySecuritiesByIndustryAxis_6c78f5fb-4c69-4bd3-a1e0-ea6e8d7aa9da" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_6c78f5fb-4c69-4bd3-a1e0-ea6e8d7aa9da_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_6c78f5fb-4c69-4bd3-a1e0-ea6e8d7aa9da" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_6c78f5fb-4c69-4bd3-a1e0-ea6e8d7aa9da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_23ce423e-e20a-444c-a99d-31945f0b0f07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_6c78f5fb-4c69-4bd3-a1e0-ea6e8d7aa9da" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_23ce423e-e20a-444c-a99d-31945f0b0f07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_UniversityOfWashingtonMember_2357c35f-f4ae-4900-8ce8-ef8c3ffb5a30" xlink:href="nltx-20201231.xsd#nltx_UniversityOfWashingtonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember_23ce423e-e20a-444c-a99d-31945f0b0f07" xlink:to="loc_nltx_UniversityOfWashingtonMember_2357c35f-f4ae-4900-8ce8-ef8c3ffb5a30" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Commitmentsandcontingencies" xlink:type="simple" xlink:href="nltx-20201231.xsd#Commitmentsandcontingencies"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/Commitmentsandcontingencies" xlink:type="extended" id="i920ac749ca0f49879961d049e1c117b2_Commitmentsandcontingencies"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="i5685548ea9734ab082005f76c6264036_CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/A401kplan" xlink:type="simple" xlink:href="nltx-20201231.xsd#A401kplan"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/A401kplan" xlink:type="extended" id="ieda010dd4fe542d7bf2780828d300117_A401kplan"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/SaleofAquinoxCanada" xlink:type="simple" xlink:href="nltx-20201231.xsd#SaleofAquinoxCanada"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/SaleofAquinoxCanada" xlink:type="extended" id="iab11b0ac530c42808ce6622e022b1727_SaleofAquinoxCanada"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/SaleofAquinoxCanadaDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#SaleofAquinoxCanadaDetails"/>
  <link:definitionLink xlink:role="http://www.aqxpharma.com/role/SaleofAquinoxCanadaDetails" xlink:type="extended" id="i5a5787ac0c834e67b2ff28232a6e572d_SaleofAquinoxCanadaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_ab09f084-eb71-448a-98eb-17f2a9477f34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_ProceedsFromSaleOfStockOfSubsidiary_de2aa65f-21d0-4318-a1c2-97dd6b928870" xlink:href="nltx-20201231.xsd#nltx_ProceedsFromSaleOfStockOfSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_ab09f084-eb71-448a-98eb-17f2a9477f34" xlink:to="loc_nltx_ProceedsFromSaleOfStockOfSubsidiary_de2aa65f-21d0-4318-a1c2-97dd6b928870" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary_f74f3fdb-2a52-4caa-891d-ff23ba26dc38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_ab09f084-eb71-448a-98eb-17f2a9477f34" xlink:to="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary_f74f3fdb-2a52-4caa-891d-ff23ba26dc38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_TransactionRelatedCostIncurredForSaleOfSubsidiary_a7e9c06b-6bb2-4aea-a36e-3b3b77e5da10" xlink:href="nltx-20201231.xsd#nltx_TransactionRelatedCostIncurredForSaleOfSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_ab09f084-eb71-448a-98eb-17f2a9477f34" xlink:to="loc_nltx_TransactionRelatedCostIncurredForSaleOfSubsidiary_a7e9c06b-6bb2-4aea-a36e-3b3b77e5da10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_58ae5fb8-4e29-4614-987b-6fae4ccdc24d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_ab09f084-eb71-448a-98eb-17f2a9477f34" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_58ae5fb8-4e29-4614-987b-6fae4ccdc24d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_73ba6ce1-6afc-4441-9de3-10b5e72fab9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_58ae5fb8-4e29-4614-987b-6fae4ccdc24d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_73ba6ce1-6afc-4441-9de3-10b5e72fab9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73ba6ce1-6afc-4441-9de3-10b5e72fab9e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_73ba6ce1-6afc-4441-9de3-10b5e72fab9e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73ba6ce1-6afc-4441-9de3-10b5e72fab9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d3e6c42-449a-42a8-93f5-898119e67c5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_73ba6ce1-6afc-4441-9de3-10b5e72fab9e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d3e6c42-449a-42a8-93f5-898119e67c5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcqinoxCanadaMember_bd68fad3-ee85-4a7b-a2c6-4a542d07f153" xlink:href="nltx-20201231.xsd#nltx_AcqinoxCanadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d3e6c42-449a-42a8-93f5-898119e67c5f" xlink:to="loc_nltx_AcqinoxCanadaMember_bd68fad3-ee85-4a7b-a2c6-4a542d07f153" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>nltx-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:6019b606-66e1-49bc-8c33-d6cc15ba3335,g:b750dab7-5d48-4ebb-bb7b-41a017d885d1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_1b6024f8-8e03-4968-9f3e-755ce960d674_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease agreement, square feet of office space</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5d561c47-e729-4e18-a81d-a3c15de90d63_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c5b4ad90-2b44-44a6-a049-7c8c608dc106_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_414b5dc6-3379-455e-9c32-713662e1b9c1_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_1e0ea771-b077-4c6c-ad67-9665f3ce9857_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_280f8c9b-b63d-4cf6-80e5-4613200e1402_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at beginning of period, Aggregate intrinsic value (in dollars)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c3217d53-fae2-49c7-b591-8c777a827e96_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at end of period, Aggregate intrinsic value (in dollars)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0d515a19-b1c5-4dfc-9b3a-625fcb2e84f2_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_80c357b6-103e-4cdb-b4c1-07c53aa4e7d8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_49ff0834-f001-4cac-a460-d29f309aedba_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a4d2947f-ec2a-4d86-888a-b33c85a6f61a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_4ff1d0a3-0245-473a-8568-1c76ad33270f_verboseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In process research and development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_561f8cac-f7ae-402a-968a-b3b07cd0cfe4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_92646657-d4b9-4be9-8924-909ee8fc31b3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_e4e682a6-c20c-4905-891a-fcaa348b9476_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AcquisitionsOfAssetsFairValueOfSharesIssued_588a714a-12f1-4541-b6c7-0e3b1c4ce05e_terseLabel_en-US" xlink:label="lab_nltx_AcquisitionsOfAssetsFairValueOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_nltx_AcquisitionsOfAssetsFairValueOfSharesIssued_label_en-US" xlink:label="lab_nltx_AcquisitionsOfAssetsFairValueOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions Of Assets Fair Value Of Shares Issued</link:label>
    <link:label id="lab_nltx_AcquisitionsOfAssetsFairValueOfSharesIssued_documentation_en-US" xlink:label="lab_nltx_AcquisitionsOfAssetsFairValueOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of assets fair value of shares issued.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionsOfAssetsFairValueOfSharesIssued" xlink:href="nltx-20201231.xsd#nltx_AcquisitionsOfAssetsFairValueOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AcquisitionsOfAssetsFairValueOfSharesIssued" xlink:to="lab_nltx_AcquisitionsOfAssetsFairValueOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_94416d9f-7b71-4d11-a5cf-d2826a1c95e3_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_10591f00-0f3a-44b4-8453-29ed2b677eec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_96d64ee4-2517-4a28-9ad9-2638d73bc18f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AcquisitionOfAssetsAbstract_3d2e49bf-075b-44ff-8ee3-2a29b30a62bb_terseLabel_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Assets [Abstract]</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsAbstract_label_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Assets [Abstract]</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsAbstract_documentation_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsAbstract" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AcquisitionOfAssetsAbstract" xlink:to="lab_nltx_AcquisitionOfAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_3618796f-bf86-4819-b85d-8d7bd8e1649f_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use asset</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7d6cc2ef-bb92-422e-b727-ea83ab58ada4_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_PublicStockOfferingMember_40cfa600-c791-480d-9dbc-da0111c7204b_terseLabel_en-US" xlink:label="lab_nltx_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:label id="lab_nltx_PublicStockOfferingMember_label_en-US" xlink:label="lab_nltx_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:label id="lab_nltx_PublicStockOfferingMember_documentation_en-US" xlink:label="lab_nltx_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PublicStockOfferingMember" xlink:href="nltx-20201231.xsd#nltx_PublicStockOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_PublicStockOfferingMember" xlink:to="lab_nltx_PublicStockOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e210dc96-33a1-4040-81c3-ecb235590ff2_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_8f20862b-f4d4-4ebf-af24-2784a27cb41a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1d77f5e5-16c3-4828-97d1-f2a3928849ac_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_30a1a2a5-2209-4976-9924-f7cf55736f9d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_LeaseAgreementExtendedPeriod_bba905ec-46bf-4ab8-9224-416a4cf64dac_terseLabel_en-US" xlink:label="lab_nltx_LeaseAgreementExtendedPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease agreement extended period</link:label>
    <link:label id="lab_nltx_LeaseAgreementExtendedPeriod_label_en-US" xlink:label="lab_nltx_LeaseAgreementExtendedPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Agreement Extended Period</link:label>
    <link:label id="lab_nltx_LeaseAgreementExtendedPeriod_documentation_en-US" xlink:label="lab_nltx_LeaseAgreementExtendedPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease agreement extended period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_LeaseAgreementExtendedPeriod" xlink:href="nltx-20201231.xsd#nltx_LeaseAgreementExtendedPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_LeaseAgreementExtendedPeriod" xlink:to="lab_nltx_LeaseAgreementExtendedPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_fe86786a-fd14-4ee7-bbc1-a08a154f5509_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_46695dd4-690e-4a5f-8f85-338a5d452851_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_aa9a0f25-4d18-43f0-888a-e10c3cade686_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_43c73768-353e-42a0-87ad-e02e96ca8938_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7991a6be-046c-4789-a1b4-285b12caa672_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_5964571c-01f5-4b18-b868-0e5ccefd67cf_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_53ba8868-a957-4656-9c00-8dc3726f126d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_56229215-7f94-470e-84b4-1d37a7edf51a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7e09e58d-bada-4dc3-83d9-fed6305c72a6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_081d14c7-ab44-44d8-903a-9d1305a93f67_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanTextBlock_3af4b2bb-b834-46a2-985a-8775419dcded_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">401(k) plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTextBlock_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTextBlock" xlink:to="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AcquisitionOfAssetsAxis_0d26ca4f-6bad-4919-a284-1dbdbdaf59b6_terseLabel_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Assets [Axis]</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsAxis_5fe8ca15-68ca-47ec-9768-701b0f2db578_verboseLabel_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Assets [Axis]</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsAxis_label_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Assets [Axis]</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsAxis_documentation_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsAxis" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AcquisitionOfAssetsAxis" xlink:to="lab_nltx_AcquisitionOfAssetsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed_426384f1-16c9-4cf9-a76e-4b2ae640e3ec_totalLabel_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities assumed</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed_label_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Assets Recognized Identifiable Liabilities Assumed</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed_documentation_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of assets recognized identifiable liabilities assumed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed" xlink:to="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_89c21d73-11ec-4f40-8a9c-4aa0e7e35490_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_LicenseArrangementsAmountsPayableBasedOnNetSales_502aa7bc-6e0b-4a6d-97d0-bb5866dac22f_terseLabel_en-US" xlink:label="lab_nltx_LicenseArrangementsAmountsPayableBasedOnNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License arrangements, amounts payable based on net sales</link:label>
    <link:label id="lab_nltx_LicenseArrangementsAmountsPayableBasedOnNetSales_label_en-US" xlink:label="lab_nltx_LicenseArrangementsAmountsPayableBasedOnNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Arrangements, Amounts Payable Based On Net Sales</link:label>
    <link:label id="lab_nltx_LicenseArrangementsAmountsPayableBasedOnNetSales_documentation_en-US" xlink:label="lab_nltx_LicenseArrangementsAmountsPayableBasedOnNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Arrangements, Amounts Payable Based On Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_LicenseArrangementsAmountsPayableBasedOnNetSales" xlink:href="nltx-20201231.xsd#nltx_LicenseArrangementsAmountsPayableBasedOnNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_LicenseArrangementsAmountsPayableBasedOnNetSales" xlink:to="lab_nltx_LicenseArrangementsAmountsPayableBasedOnNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_ec3697ac-df73-4c0e-82ec-9767b3fa2237_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_ConvertiblePreferredStockToBeConverted_d85cbe3b-61f1-4b91-ac87-b512e3fda187_verboseLabel_en-US" xlink:label="lab_nltx_ConvertiblePreferredStockToBeConverted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares to be converted</link:label>
    <link:label id="lab_nltx_ConvertiblePreferredStockToBeConverted_label_en-US" xlink:label="lab_nltx_ConvertiblePreferredStockToBeConverted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock To Be Converted</link:label>
    <link:label id="lab_nltx_ConvertiblePreferredStockToBeConverted_documentation_en-US" xlink:label="lab_nltx_ConvertiblePreferredStockToBeConverted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock to be converted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_ConvertiblePreferredStockToBeConverted" xlink:href="nltx-20201231.xsd#nltx_ConvertiblePreferredStockToBeConverted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_ConvertiblePreferredStockToBeConverted" xlink:to="lab_nltx_ConvertiblePreferredStockToBeConverted" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_IncreaseDecreaseInOperatingLeaseLiabilities_7660caae-6a0b-4876-90d3-f61c32edb5ff_terseLabel_en-US" xlink:label="lab_nltx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_nltx_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_nltx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Operating Lease Liabilities</link:label>
    <link:label id="lab_nltx_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_nltx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in operating lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="nltx-20201231.xsd#nltx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_nltx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1c0710dd-e42d-4205-951b-2920fe136d53_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bd1c9874-4acd-4a70-94b0-72cdad7ce28d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fdd94169-e999-4df6-95cf-21fdc3327c02_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8195852f-89d3-4762-b25d-df29a7855beb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_0642e401-3248-4047-8df6-0e4f0f1e4e28_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2021</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_df96299d-8339-418b-a1dd-1845a02ee7bd_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December&#160;31, 2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_23eb3e81-94b5-4fa4-b24c-9b0bba8c3b0e_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7e55a4c3-04f6-427a-b097-8d4d4f5db120_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation cost (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_LicenseAgreementAbstract_35b9cc82-47c7-4968-ba25-2195650cce50_terseLabel_en-US" xlink:label="lab_nltx_LicenseAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Abstract]</link:label>
    <link:label id="lab_nltx_LicenseAgreementAbstract_label_en-US" xlink:label="lab_nltx_LicenseAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_LicenseAgreementAbstract" xlink:href="nltx-20201231.xsd#nltx_LicenseAgreementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_LicenseAgreementAbstract" xlink:to="lab_nltx_LicenseAgreementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_af075afa-7be3-480e-92a5-30cf4fd7463c_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_e60fa6da-03c0-488c-a637-9d4658e539fe_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits for research and development</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_28c237cd-b713-4e6c-a5ab-79b1663f65b4_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_3db54733-3500-4221-bf0f-690ad245c097_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_7c10c085-35a9-4c0d-a1dd-8f55396c23af_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.000001 par value per share; 5,000,000 authorized at December&#160;31, 2020 and 2019; 0 issued and outstanding at December&#160;31, 2020 and 2019</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_f6f3ff08-819f-4062-adf8-25206da0c734_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_7fa670ba-0cc2-4725-b341-42a78739b1b7_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d96558aa-2d88-4c80-8883-df9da7f71aeb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Number of options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_cb986dea-4444-42fe-92a1-abab30e5d31c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_A2020EmployeeStockPurchasePlanMember_df50ed6f-7563-469c-9a50-8d553caa60c2_terseLabel_en-US" xlink:label="lab_nltx_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_nltx_A2020EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_nltx_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_nltx_A2020EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_nltx_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_A2020EmployeeStockPurchasePlanMember" xlink:href="nltx-20201231.xsd#nltx_A2020EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_A2020EmployeeStockPurchasePlanMember" xlink:to="lab_nltx_A2020EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_eb855c74-01d8-4a94-a6be-f1fc3802d889_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment on finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_TenantImprovementAllowanceReceivable_61bd31a0-d989-4618-acd1-606fc0fe9bbf_terseLabel_en-US" xlink:label="lab_nltx_TenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvement allowance receivable</link:label>
    <link:label id="lab_nltx_TenantImprovementAllowanceReceivable_label_en-US" xlink:label="lab_nltx_TenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Allowance Receivable</link:label>
    <link:label id="lab_nltx_TenantImprovementAllowanceReceivable_documentation_en-US" xlink:label="lab_nltx_TenantImprovementAllowanceReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Element represents the carrying amount as of balance sheet date of amounts receivable related to tenant improvement allowance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_TenantImprovementAllowanceReceivable" xlink:href="nltx-20201231.xsd#nltx_TenantImprovementAllowanceReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_TenantImprovementAllowanceReceivable" xlink:to="lab_nltx_TenantImprovementAllowanceReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAndMaintenanceMember_5e4c2322-fe33-456d-bcac-493f8a4cfc43_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndMaintenanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and maintenance</link:label>
    <link:label id="lab_us-gaap_LicenseAndMaintenanceMember_label_en-US" xlink:label="lab_us-gaap_LicenseAndMaintenanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Maintenance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndMaintenanceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndMaintenanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndMaintenanceMember" xlink:to="lab_us-gaap_LicenseAndMaintenanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8b90d4ab-327d-4d5d-b50b-7d7e1f9e3cc0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_88ef920e-701b-4cf8-b662-73edaeac4853_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_22475e70-d452-4d8b-a862-0aee734858a2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contract with customer, excluding assessed tax</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_24a56b0a-6428-4d4b-a24c-4d1cf45bdfc3_negatedLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, finance lease and other liabilities assumed through the issuance of common stock</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1" xlink:to="lab_us-gaap_LiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_858c0cc5-c071-49f4-b70b-4e6aee2fe492_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_7435f65a-d3c4-4b99-9123-298efa82b5b4_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award expiration period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet_6c32b118-11ef-467c-88ee-e6981bf0bfbd_totalLabel_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets acquired</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet_label_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Assets Recognized Identifiable Assets Acquired Assets Net</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet_documentation_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of assets recognized identifiable assets acquired assets net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet" xlink:to="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_471331b2-4f47-41e2-b52c-5d9c6cc4ee88_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3949d993-8d96-4ff1-bb9b-f91af7d6e795_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Securities Excluded From Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_2d0677ec-93f0-4d11-b074-b7ed29d1f6d5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on termination of lease</link:label>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_label_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Termination of Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnTerminationOfLease" xlink:to="lab_us-gaap_GainLossOnTerminationOfLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_8a0cde28-6fa8-46d1-94c9-a639726068ec_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WA_779f2117-a1d0-4ecb-ab31-6a7fc6f9c985_terseLabel_en-US" xlink:label="lab_stpr_WA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Washington</link:label>
    <link:label id="lab_stpr_WA_label_en-US" xlink:label="lab_stpr_WA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WASHINGTON</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_WA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WA" xlink:to="lab_stpr_WA" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_cb4939b2-f006-470c-9b36-00c79effb55c_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_IncomeTaxesDisclosureLineItems_1e62813c-8866-4e8b-aa3a-5defd17f51c7_terseLabel_en-US" xlink:label="lab_nltx_IncomeTaxesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Disclosure [Line Items]</link:label>
    <link:label id="lab_nltx_IncomeTaxesDisclosureLineItems_label_en-US" xlink:label="lab_nltx_IncomeTaxesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Disclosure [Line Items]</link:label>
    <link:label id="lab_nltx_IncomeTaxesDisclosureLineItems_documentation_en-US" xlink:label="lab_nltx_IncomeTaxesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_IncomeTaxesDisclosureLineItems" xlink:href="nltx-20201231.xsd#nltx_IncomeTaxesDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_IncomeTaxesDisclosureLineItems" xlink:to="lab_nltx_IncomeTaxesDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_72d16e75-9f2e-4184-beec-dcbb8d2462fc_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_b0f05d04-f6f1-4e4f-bfd2-8817a14141c6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_ff72489f-af8f-491a-a439-76c6c6861249_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_0d511796-2132-4714-a332-04c35ad9eaba_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c1cb86af-cd37-4997-baf8-5d104892fbbe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_DeferredTaxAssetsTaxCreditCarryforwardsReducedDueToSaleOfForeignEntity_1e722832-1443-4a57-a5a9-183a735c599a_terseLabel_en-US" xlink:label="lab_nltx_DeferredTaxAssetsTaxCreditCarryforwardsReducedDueToSaleOfForeignEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax attributes no longer reflected in deferred tax assets and valuation allowance</link:label>
    <link:label id="lab_nltx_DeferredTaxAssetsTaxCreditCarryforwardsReducedDueToSaleOfForeignEntity_label_en-US" xlink:label="lab_nltx_DeferredTaxAssetsTaxCreditCarryforwardsReducedDueToSaleOfForeignEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards Reduced Due To Sale Of Foreign Entity</link:label>
    <link:label id="lab_nltx_DeferredTaxAssetsTaxCreditCarryforwardsReducedDueToSaleOfForeignEntity_documentation_en-US" xlink:label="lab_nltx_DeferredTaxAssetsTaxCreditCarryforwardsReducedDueToSaleOfForeignEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards Reduced Due To Sale Of Foreign Entity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_DeferredTaxAssetsTaxCreditCarryforwardsReducedDueToSaleOfForeignEntity" xlink:href="nltx-20201231.xsd#nltx_DeferredTaxAssetsTaxCreditCarryforwardsReducedDueToSaleOfForeignEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_DeferredTaxAssetsTaxCreditCarryforwardsReducedDueToSaleOfForeignEntity" xlink:to="lab_nltx_DeferredTaxAssetsTaxCreditCarryforwardsReducedDueToSaleOfForeignEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock_d0b7333f-8477-4f07-9052-eb68d27b50c6_terseLabel_en-US" xlink:label="lab_nltx_PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and intangibles acquired through the issuance of common stock</link:label>
    <link:label id="lab_nltx_PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock_label_en-US" xlink:label="lab_nltx_PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Equipment And Intangibles Acquired Through The Issuance Of Common Stock</link:label>
    <link:label id="lab_nltx_PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock_documentation_en-US" xlink:label="lab_nltx_PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property equipment and intangibles acquired through the issuance of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock" xlink:href="nltx-20201231.xsd#nltx_PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock" xlink:to="lab_nltx_PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_34622d4a-1eda-4e68-a88c-89430aec6fa4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_bcac796f-b9a5-4379-88a5-2f19223b4bd4_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesByIndustryAxis_eac879da-5065-4f22-b3f2-40d092bb4718_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesByIndustryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Industry Sector [Axis]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesByIndustryAxis_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesByIndustryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Industry Sector [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="lab_us-gaap_EquitySecuritiesByIndustryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f436ae60-ad2a-490e-b368-0859cb4f7f8e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_e4e4b104-c924-4bf4-a70a-3f489b982fb4_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_aea2cf2d-7984-4afd-b218-87a685496442_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common stock - basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_e71a82d6-d48e-44e5-a8d2-39fcc88c894b_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_LicenseAndPatentAgreementsTable_5f5036fe-cca4-40dc-85d9-322d1c58b2c5_terseLabel_en-US" xlink:label="lab_nltx_LicenseAndPatentAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Patent Agreements [Table]</link:label>
    <link:label id="lab_nltx_LicenseAndPatentAgreementsTable_label_en-US" xlink:label="lab_nltx_LicenseAndPatentAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Patent Agreements [Table]</link:label>
    <link:label id="lab_nltx_LicenseAndPatentAgreementsTable_documentation_en-US" xlink:label="lab_nltx_LicenseAndPatentAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Patent Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_LicenseAndPatentAgreementsTable" xlink:href="nltx-20201231.xsd#nltx_LicenseAndPatentAgreementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_LicenseAndPatentAgreementsTable" xlink:to="lab_nltx_LicenseAndPatentAgreementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AcquisitionsOfAssetsTransactionCosts_38623247-00bc-4156-a34b-f66a2e92125a_negatedTerseLabel_en-US" xlink:label="lab_nltx_AcquisitionsOfAssetsTransactionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_nltx_AcquisitionsOfAssetsTransactionCosts_label_en-US" xlink:label="lab_nltx_AcquisitionsOfAssetsTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions Of Assets Transaction Costs</link:label>
    <link:label id="lab_nltx_AcquisitionsOfAssetsTransactionCosts_documentation_en-US" xlink:label="lab_nltx_AcquisitionsOfAssetsTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of assets transaction costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionsOfAssetsTransactionCosts" xlink:href="nltx-20201231.xsd#nltx_AcquisitionsOfAssetsTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AcquisitionsOfAssetsTransactionCosts" xlink:to="lab_nltx_AcquisitionsOfAssetsTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_fe036f75-eeaa-4a55-b836-9ca86407a433_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9af8f6e3-3341-4664-bdfb-40dfd0ea8701_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_IncomeTaxesDisclosureTable_499f35e5-898c-45bf-9c7f-8df708a71b8d_terseLabel_en-US" xlink:label="lab_nltx_IncomeTaxesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Disclosure [Table]</link:label>
    <link:label id="lab_nltx_IncomeTaxesDisclosureTable_label_en-US" xlink:label="lab_nltx_IncomeTaxesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Disclosure [Table]</link:label>
    <link:label id="lab_nltx_IncomeTaxesDisclosureTable_documentation_en-US" xlink:label="lab_nltx_IncomeTaxesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_IncomeTaxesDisclosureTable" xlink:href="nltx-20201231.xsd#nltx_IncomeTaxesDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_IncomeTaxesDisclosureTable" xlink:to="lab_nltx_IncomeTaxesDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability_9d56b47e-ffd3-4005-a14b-5e69aea320e8_terseLabel_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease liability</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability_label_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Assets Recognized Identifiable Liabilities Assumed Financing Lease Liability</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability_documentation_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of assets recognized identifiable liabilities assumed, financing lease liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability" xlink:to="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_30d88708-07ad-445d-a6d8-18dcade6667c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Weighted average remaining contractual life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_652fe7a0-690e-45b4-9e0a-87d309033d7e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offering of common stock and pre-funded warrants, net of commissions of $4,575 and $5,173 in 2020 and 2019, respectively.</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_4c64dc5f-880b-434d-a881-16213e46ac87_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d365d2cb-df77-4c17-8176-afcb41550641_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AccruedClinicalExpensesCurrent_c2d30c9e-d34e-4012-b4c7-e79cf22f0cd0_terseLabel_en-US" xlink:label="lab_nltx_AccruedClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical and preclinical expenses</link:label>
    <link:label id="lab_nltx_AccruedClinicalExpensesCurrent_label_en-US" xlink:label="lab_nltx_AccruedClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Expenses Current</link:label>
    <link:label id="lab_nltx_AccruedClinicalExpensesCurrent_documentation_en-US" xlink:label="lab_nltx_AccruedClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical studies, which covers fees paid to CROs, investigative sites in connection with clinical studies and contract manufacturers in connection with the production of clinical study materials; and fees paid to vendors in connection with the preclinical development activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AccruedClinicalExpensesCurrent" xlink:href="nltx-20201231.xsd#nltx_AccruedClinicalExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AccruedClinicalExpensesCurrent" xlink:to="lab_nltx_AccruedClinicalExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_469a31b3-1fa0-46b1-9023-64f238167b8c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_833daf23-280f-404e-8aba-0e0998b2f315_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares of common stock that may be issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_39cc8f90-9ab7-4569-a964-d7315ac0d8a4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_fd580257-37c9-42fb-ae27-e4d154576d2d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_c92b1e18-e70a-4430-bcbd-b79685ced70e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_eeb16ae5-4110-4397-af9b-e33b454a8d89_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available to be granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_32f577b9-2170-449f-b29b-a575721d4112_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_SignificantAccountingPoliciesLineItems_df29c227-c3f7-4e57-9bc5-b73b3d44968f_terseLabel_en-US" xlink:label="lab_nltx_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nltx_SignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_nltx_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_nltx_SignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_nltx_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_SignificantAccountingPoliciesLineItems" xlink:href="nltx-20201231.xsd#nltx_SignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_SignificantAccountingPoliciesLineItems" xlink:to="lab_nltx_SignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ed6d5e4d-f136-4917-9f55-a98ccf93effa_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_b73ecbda-0baf-46e8-a111-0258cc99763f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_045f1477-7f31-46f8-afd8-5a3339a75d88_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_98e491ce-4c49-479f-a3ba-3da2953c3132_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_WriteOffOfRightOfUseAssetUponLeaseTermination_8aa33090-c3db-4bff-8389-75ce6ea02aef_terseLabel_en-US" xlink:label="lab_nltx_WriteOffOfRightOfUseAssetUponLeaseTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of right-of-use asset upon lease termination</link:label>
    <link:label id="lab_nltx_WriteOffOfRightOfUseAssetUponLeaseTermination_label_en-US" xlink:label="lab_nltx_WriteOffOfRightOfUseAssetUponLeaseTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write Off Of Right Of Use Asset Upon Lease Termination</link:label>
    <link:label id="lab_nltx_WriteOffOfRightOfUseAssetUponLeaseTermination_documentation_en-US" xlink:label="lab_nltx_WriteOffOfRightOfUseAssetUponLeaseTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of ROU asset upon lease termination.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_WriteOffOfRightOfUseAssetUponLeaseTermination" xlink:href="nltx-20201231.xsd#nltx_WriteOffOfRightOfUseAssetUponLeaseTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_WriteOffOfRightOfUseAssetUponLeaseTermination" xlink:to="lab_nltx_WriteOffOfRightOfUseAssetUponLeaseTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9b14bac4-0168-4579-abd2-4988858f04da_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_8926e9d9-1242-49b0-bd44-aa4588bcf3f5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Asset</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_4703401f-d5e4-4d62-9de9-68867ffc4eb0_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal of Aquinox Canada</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Business, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_6a2cbc45-d2ff-44db-9929-7562782f7c0a_terseLabel_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters of Credit</link:label>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_label_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandbyLettersOfCreditMember" xlink:to="lab_us-gaap_StandbyLettersOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6b5327c0-993c-4715-a415-cb0f9704bdec_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment unpaid at period end</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_a53c1a8b-ff9a-4b4c-a1f0-7a57424753ed_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets_9f76c820-a794-4f5b-b064-3913313000ed_terseLabel_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets_label_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Assets Recognized Identifiable Assets Acquired In Process Research And Development Assets</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets_documentation_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of assets recognized identifiable assets acquired, in process research and development asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets" xlink:to="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_a628b053-0949-4839-918f-baf0badf4fb5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a9d03ce8-e255-4697-b742-286509c001fe_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_127215f8-dfe4-4650-98c4-873baebe34d3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issuable under 2020 ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_52ade623-4b71-4509-9a57-81601cc84340_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_9d39d1e3-e1ff-419c-8830-828352d61984_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_0b0c3cd8-2911-493d-93bb-81f8ba268577_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a8097fd7-abe9-4dbd-b159-99492c4aecb9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ef80cbe8-3a8c-4a47-923d-9304c5184376_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f4b4d425-7d53-4389-a0ef-1c7b3c8fbdbd_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_39209b72-b8a9-4523-8525-60f416c38723_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Lease Expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e3e7cb61-1668-432c-9a68-fce6b512a83c_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_42514a64-4e09-44f2-89a3-7e893a4500fa_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock to University of Washington (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_f6c55105-5069-470e-a6b1-4fe0c23c0305_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for service (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_35bcd062-ef1b-4e2f-b474-0e054624a07e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_3f6983c2-fa99-49ca-8b97-2621324b28d3_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_c5e1c5a9-a1e8-4591-8b28-6ab867dcee3c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of discounts, commissions and offering expenses</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_179537c0-f404-4693-984e-42fc0a64b8b7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_880aa222-2e29-4ebc-9901-4770dc3fa2a7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_6caf54dd-2eb8-4aef-9e08-4531c3c4bd2b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_23838ace-79f5-4271-9bde-a62a8cd6f9d9_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9a1b540f-f93c-4e6e-9dac-d94a1836417e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_58830d87-1288-4f78-9338-21f6c79e746f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_49156884-e6f3-4d24-973f-05f148a7a738_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_eeaac7c6-b830-4942-9fa0-f546953b5d79_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_5d148b08-071e-47f8-b7ff-772878062bb9_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_514077c8-ccb1-40ff-bef5-e05fe35622c0_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net intangible asset</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b68b321b-3c4b-4837-b492-4d135fcb349b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset_048c6dfb-8e90-46e8-9c89-7e11e80a30fa_terseLabel_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset_label_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Of Assets Recognized Identifiable Assets Intangible Asset</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset_documentation_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of assets recognized identifiable assets acquired, Intangible asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset" xlink:to="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_SubsidiarySaleOfStockTextBlock_8bad70d5-1d1a-4716-8eed-809a58b61a03_terseLabel_en-US" xlink:label="lab_nltx_SubsidiarySaleOfStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Aquinox Canada</link:label>
    <link:label id="lab_nltx_SubsidiarySaleOfStockTextBlock_label_en-US" xlink:label="lab_nltx_SubsidiarySaleOfStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Sale of Stock [Text Block]</link:label>
    <link:label id="lab_nltx_SubsidiarySaleOfStockTextBlock_documentation_en-US" xlink:label="lab_nltx_SubsidiarySaleOfStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Sale of Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_SubsidiarySaleOfStockTextBlock" xlink:href="nltx-20201231.xsd#nltx_SubsidiarySaleOfStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_SubsidiarySaleOfStockTextBlock" xlink:to="lab_nltx_SubsidiarySaleOfStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e4d83af6-bcb7-4669-8701-6175359b2a45_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_RestructuringPlan1November62018Member_700a7097-4198-484b-b04b-0ef8f228f1f9_terseLabel_en-US" xlink:label="lab_nltx_RestructuringPlan1November62018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan, November 2018</link:label>
    <link:label id="lab_nltx_RestructuringPlan1November62018Member_label_en-US" xlink:label="lab_nltx_RestructuringPlan1November62018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan1 November62018 [Member]</link:label>
    <link:label id="lab_nltx_RestructuringPlan1November62018Member_documentation_en-US" xlink:label="lab_nltx_RestructuringPlan1November62018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan, November 6, 2018 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_RestructuringPlan1November62018Member" xlink:href="nltx-20201231.xsd#nltx_RestructuringPlan1November62018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_RestructuringPlan1November62018Member" xlink:to="lab_nltx_RestructuringPlan1November62018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_ecf76b01-7151-4729-aa52-9aa564c41160_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of credit risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_6c05edd1-99ba-426f-ad89-c954091bc4dd_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Company's Finance Lease Liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_505d1547-4dd5-4663-a7a9-0c0e7863d633_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_86969829-7f87-49e3-bef9-f3a38bf30fcd_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_b1373182-873d-4588-b0d0-4030acc02812_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeDisclosureAbstract_22c15f44-807a-4671-b61a-9a532b3c8a61_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease cost</link:label>
    <link:label id="lab_us-gaap_LesseeDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LesseeDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeDisclosureAbstract" xlink:to="lab_us-gaap_LesseeDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_3d69ff4f-6507-4e65-b7a6-25124926c736_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants_503be903-2930-4a9e-85f3-080811d7b07a_terseLabel_en-US" xlink:label="lab_nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of common stock to pre-funded warrants (in shares)</link:label>
    <link:label id="lab_nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants_label_en-US" xlink:label="lab_nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Decrease Increase During Period Shares Conversion Of Common Stock To PreFunded Warrants</link:label>
    <link:label id="lab_nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants_documentation_en-US" xlink:label="lab_nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock decrease during period conversion of common stock to&#160;pre-funded&#160;warrants shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants" xlink:href="nltx-20201231.xsd#nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants" xlink:to="lab_nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2e9778ed-9101-42c7-9c06-93369dd01ee5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation cost, weighted-average period recognized (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_155ce7df-5e31-4fc5-9033-8ad8565b5f37_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_SignificantAccountingPoliciesTable_de2fcc62-4fbb-4f8f-9a94-44dfb3dd1ccd_terseLabel_en-US" xlink:label="lab_nltx_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nltx_SignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_nltx_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_nltx_SignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_nltx_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_SignificantAccountingPoliciesTable" xlink:href="nltx-20201231.xsd#nltx_SignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_SignificantAccountingPoliciesTable" xlink:to="lab_nltx_SignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_LicenseArrangementsAmountsPayableOnDevelopmentalMilestones_4ee1375f-fed1-4e1d-b638-fb99979415d3_terseLabel_en-US" xlink:label="lab_nltx_LicenseArrangementsAmountsPayableOnDevelopmentalMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License arrangements, amounts of development milestones payment</link:label>
    <link:label id="lab_nltx_LicenseArrangementsAmountsPayableOnDevelopmentalMilestones_label_en-US" xlink:label="lab_nltx_LicenseArrangementsAmountsPayableOnDevelopmentalMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Arrangements, Amounts Payable On Developmental Milestones</link:label>
    <link:label id="lab_nltx_LicenseArrangementsAmountsPayableOnDevelopmentalMilestones_documentation_en-US" xlink:label="lab_nltx_LicenseArrangementsAmountsPayableOnDevelopmentalMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Arrangements, Amounts Payable On Developmental Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_LicenseArrangementsAmountsPayableOnDevelopmentalMilestones" xlink:href="nltx-20201231.xsd#nltx_LicenseArrangementsAmountsPayableOnDevelopmentalMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_LicenseArrangementsAmountsPayableOnDevelopmentalMilestones" xlink:to="lab_nltx_LicenseArrangementsAmountsPayableOnDevelopmentalMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0e9b356a-939f-492e-9b0f-29e11290e020_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_029adee2-faa5-422b-8a1e-980c2ca2009d_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_69b8cd31-5928-4133-b98e-cbc80f6cb4fb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income and Expense [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="lab_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AdditionalTenantImprovements_672459b1-ac51-49ae-8e94-1f76c678d620_terseLabel_en-US" xlink:label="lab_nltx_AdditionalTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional tenant improvements</link:label>
    <link:label id="lab_nltx_AdditionalTenantImprovements_label_en-US" xlink:label="lab_nltx_AdditionalTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Tenant Improvements</link:label>
    <link:label id="lab_nltx_AdditionalTenantImprovements_documentation_en-US" xlink:label="lab_nltx_AdditionalTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Tenant Improvements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AdditionalTenantImprovements" xlink:href="nltx-20201231.xsd#nltx_AdditionalTenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AdditionalTenantImprovements" xlink:to="lab_nltx_AdditionalTenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_30272b8c-9ca4-4a93-8e5b-89a3497dcbc3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_6ac4028e-bb35-4df7-84ec-ac105b423007_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_OfficeSpaceFormerPrincipalExecutiveOfficesAndLaboratoryMember_0d587af6-abc5-4ec3-859e-1d1b77afcf91_terseLabel_en-US" xlink:label="lab_nltx_OfficeSpaceFormerPrincipalExecutiveOfficesAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space, former principal executive offices and laboratory</link:label>
    <link:label id="lab_nltx_OfficeSpaceFormerPrincipalExecutiveOfficesAndLaboratoryMember_label_en-US" xlink:label="lab_nltx_OfficeSpaceFormerPrincipalExecutiveOfficesAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space, Former Principal Executive Offices and Laboratory [Member]</link:label>
    <link:label id="lab_nltx_OfficeSpaceFormerPrincipalExecutiveOfficesAndLaboratoryMember_documentation_en-US" xlink:label="lab_nltx_OfficeSpaceFormerPrincipalExecutiveOfficesAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space, Former Principal Executive Offices and Laboratory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_OfficeSpaceFormerPrincipalExecutiveOfficesAndLaboratoryMember" xlink:href="nltx-20201231.xsd#nltx_OfficeSpaceFormerPrincipalExecutiveOfficesAndLaboratoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_OfficeSpaceFormerPrincipalExecutiveOfficesAndLaboratoryMember" xlink:to="lab_nltx_OfficeSpaceFormerPrincipalExecutiveOfficesAndLaboratoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_b04bf342-d6ca-4107-8f96-a15d2efc96b0_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_a88863a6-68fb-4533-9460-91071fb5d026_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_475167e4-bba5-4139-95da-8c20d036eed6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Income, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_816526df-cc48-4d72-967a-4d5a7fae26b6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_4917f53a-1846-4e5e-91a4-d49c5da6cacb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_7647599d-e34e-4291-8292-5d1ff442d391_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_PreFundedWarrantsMember_31740cc4-c921-429f-8371-09a3876ef94f_terseLabel_en-US" xlink:label="lab_nltx_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-funded warrants</link:label>
    <link:label id="lab_nltx_PreFundedWarrantsMember_label_en-US" xlink:label="lab_nltx_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre Funded Warrants [Member]</link:label>
    <link:label id="lab_nltx_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_nltx_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre funded warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PreFundedWarrantsMember" xlink:href="nltx-20201231.xsd#nltx_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_PreFundedWarrantsMember" xlink:to="lab_nltx_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_37f0fcdf-6f67-4452-b330-c3cbfddd2e0e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of financial instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f11c8fdf-ecc6-4aa8-9674-f96cdcf8c624_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_92d4f040-5f72-4a36-9f8d-473785263509_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_20762839-0fdf-4454-894a-f23e901da712_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AcquisitionsOfAssetsConsiderationTransferred_50359e96-9270-45a9-8d72-432e05221ec6_totalLabel_en-US" xlink:label="lab_nltx_AcquisitionsOfAssetsConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_nltx_AcquisitionsOfAssetsConsiderationTransferred_label_en-US" xlink:label="lab_nltx_AcquisitionsOfAssetsConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of Assets Consideration Transferred</link:label>
    <link:label id="lab_nltx_AcquisitionsOfAssetsConsiderationTransferred_documentation_en-US" xlink:label="lab_nltx_AcquisitionsOfAssetsConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of assets consideration transferred.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionsOfAssetsConsiderationTransferred" xlink:href="nltx-20201231.xsd#nltx_AcquisitionsOfAssetsConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AcquisitionsOfAssetsConsiderationTransferred" xlink:to="lab_nltx_AcquisitionsOfAssetsConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_592b82d4-0c8e-4cf8-a9ef-70ac8e7c3a98_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_88259c78-13f9-4095-af1a-4d749a3bd647_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_02c59b14-53bf-40c2-b2d8-9f5276652e7e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e8607502-19f5-43b3-a931-610eab059822_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_5f8064cc-6059-4ca4-b0aa-7c30f83e423b_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_76345fa4-3faf-4404-949e-9deff09d0feb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_78b6152c-d634-4e79-b1a8-2f2b2aa31c0e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_1d47ecca-90fe-4c07-809c-3d7d291cec49_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_94b67cde-de99-4a04-9bf8-85ca24aab4ff_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AcquisitionOfAssetsNetCashAcquired_8bb9c9d2-e4f1-401a-a53a-363b38ca7ae2_terseLabel_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsNetCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Neoleukin Therapeutics, Inc., net of cash acquired</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsNetCashAcquired_label_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsNetCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Of Assets Net Cash Acquired</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsNetCashAcquired_documentation_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsNetCashAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of assets net cash acquired.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsNetCashAcquired" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsNetCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AcquisitionOfAssetsNetCashAcquired" xlink:to="lab_nltx_AcquisitionOfAssetsNetCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_c8bdcada-0549-4791-b950-e669a3020d0b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits_f73e725e-c64c-43a2-b054-c349078f84c2_terseLabel_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, prepayments and deposits</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits_label_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Assets Recognized Identifiable Assets Acquired Receivables Prepayments And Deposits</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits_documentation_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of assets recognized identifiable assets acquired, receivables, prepayments and deposits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits" xlink:to="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_7feb706a-157c-40dc-85a9-0b9e3f18993d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c33a41c3-75fa-46c2-b3fb-fc692f7628e8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_39f61c51-5b19-4a9b-87b7-9714bff8973c_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current lease liabilities&#8212;December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_f40c5e12-996f-454b-9b99-23c6344d4790_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock and convertible preferred stock for Former Neoleukin common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Purchase of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_028de976-baf4-45eb-889d-238921fc188d_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_9d056f1d-9f63-4f8a-821a-65ff7a6697be_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates and assumptions</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_662def2a-b0e3-4ff8-bb6c-308a59e73464_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_20f4ff52-e9f0-4275-90a0-08f2fbbae020_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December&#160;31, 2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1dd254df-c240-4f4e-b6a3-cb2a679c9817_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividends</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_5423bf00-d510-487d-bb32-2f7ef737c159_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_PercentageOfOutstandingStockPerStockholderMaximum_e3c8238a-c9c0-4910-b97a-86e2961c7286_terseLabel_en-US" xlink:label="lab_nltx_PercentageOfOutstandingStockPerStockholderMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of outstanding stock per stockholder</link:label>
    <link:label id="lab_nltx_PercentageOfOutstandingStockPerStockholderMaximum_label_en-US" xlink:label="lab_nltx_PercentageOfOutstandingStockPerStockholderMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Outstanding Stock Per Stockholder, Maximum</link:label>
    <link:label id="lab_nltx_PercentageOfOutstandingStockPerStockholderMaximum_documentation_en-US" xlink:label="lab_nltx_PercentageOfOutstandingStockPerStockholderMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Outstanding Stock Per Stockholder, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PercentageOfOutstandingStockPerStockholderMaximum" xlink:href="nltx-20201231.xsd#nltx_PercentageOfOutstandingStockPerStockholderMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_PercentageOfOutstandingStockPerStockholderMaximum" xlink:to="lab_nltx_PercentageOfOutstandingStockPerStockholderMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_4e0d6615-e602-4aa9-8033-d31bf697af8a_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_b188656c-ad4c-4c99-bcfb-12cfb92b6856_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income Tax Recovery</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_33966ad6-7fba-4ac4-ae16-aab20ab5a36c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d16a9295-28f6-4c4e-9b5d-451cb691538a_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent_7986e8e2-bc25-416a-a9d5-c28da5aada72_negatedLabel_en-US" xlink:label="lab_nltx_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration of NOLs (section 382)</link:label>
    <link:label id="lab_nltx_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent_label_en-US" xlink:label="lab_nltx_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Expiration Of Net Operating Losses, Percent</link:label>
    <link:label id="lab_nltx_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent_documentation_en-US" xlink:label="lab_nltx_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Expiration Of Net Operating Losses, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent" xlink:href="nltx-20201231.xsd#nltx_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent" xlink:to="lab_nltx_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_aede3614-90b9-4a43-8e6b-7dd086dffefb_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_90e2c7b5-4854-4692-98d3-4b4f43c4696d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a2f25584-858c-4cbb-9fa3-bc6b69af99c6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_PreFundedWarrantIssuedPricePerShare_04c1bf5d-2062-45ff-8bf7-8d070b8c8d36_terseLabel_en-US" xlink:label="lab_nltx_PreFundedWarrantIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre funded warrant issued (in dollars per share)</link:label>
    <link:label id="lab_nltx_PreFundedWarrantIssuedPricePerShare_label_en-US" xlink:label="lab_nltx_PreFundedWarrantIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre Funded Warrant Issued Price Per Share</link:label>
    <link:label id="lab_nltx_PreFundedWarrantIssuedPricePerShare_documentation_en-US" xlink:label="lab_nltx_PreFundedWarrantIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price per pre-funded warrant sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PreFundedWarrantIssuedPricePerShare" xlink:href="nltx-20201231.xsd#nltx_PreFundedWarrantIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_PreFundedWarrantIssuedPricePerShare" xlink:to="lab_nltx_PreFundedWarrantIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_444780c5-ad02-493c-a595-2d8a88f5c220_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, Shares issued upon conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_675d3dbb-627b-4fa4-bd1b-8f77dfbab2f4_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecurityDeposit_0c54c88d-ee30-4ae8-8300-fac8d916e083_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security deposit</link:label>
    <link:label id="lab_us-gaap_SecurityDeposit_label_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_e7584085-c9b9-46a7-bd8c-98c0ab0a1835_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_NonVotingConvertiblePreferredStockMember_f608f89f-4d8f-4db4-834e-7a169e10e419_terseLabel_en-US" xlink:label="lab_nltx_NonVotingConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Voting Convertible Preferred&#160;Stock</link:label>
    <link:label id="lab_nltx_NonVotingConvertiblePreferredStockMember_ae7139ab-548f-495a-85f7-9a3ee0d92074_verboseLabel_en-US" xlink:label="lab_nltx_NonVotingConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-voting convertible preferred stock</link:label>
    <link:label id="lab_nltx_NonVotingConvertiblePreferredStockMember_label_en-US" xlink:label="lab_nltx_NonVotingConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-voting convertible preferred stock [Member]</link:label>
    <link:label id="lab_nltx_NonVotingConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_nltx_NonVotingConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-voting convertible preferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_NonVotingConvertiblePreferredStockMember" xlink:href="nltx-20201231.xsd#nltx_NonVotingConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_NonVotingConvertiblePreferredStockMember" xlink:to="lab_nltx_NonVotingConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_6601014f-7ee0-4059-bf3c-70035f4409ac_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e18d5c59-6512-4526-91fb-f6f44abc7948_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_a656f8ab-96e4-4034-9608-66e273cd449f_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment1_9d4b4f2b-76dc-43d1-8099-ba5081d1df05_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revised estimates during the year</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment1_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Accrual Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:to="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_1152817a-dc5f-4837-b0bf-6366aef44e15_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_08d3ea49-417e-49ee-88fa-2c6c5606f91a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net (Loss) Income Before Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_1ddb0aa4-5c4a-4306-8096-81647232481e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_PeriodSharesReservedForIssuanceWillIncrease_a184c5a1-536c-4a3f-9704-dcff34fe95e7_terseLabel_en-US" xlink:label="lab_nltx_PeriodSharesReservedForIssuanceWillIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Years of increase in shares of common stock reserved for issuance</link:label>
    <link:label id="lab_nltx_PeriodSharesReservedForIssuanceWillIncrease_label_en-US" xlink:label="lab_nltx_PeriodSharesReservedForIssuanceWillIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Shares Reserved For Issuance Will Increase</link:label>
    <link:label id="lab_nltx_PeriodSharesReservedForIssuanceWillIncrease_documentation_en-US" xlink:label="lab_nltx_PeriodSharesReservedForIssuanceWillIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The time period over which the number of shares reserved for issuance under the stock based compensation plan will increase.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PeriodSharesReservedForIssuanceWillIncrease" xlink:href="nltx-20201231.xsd#nltx_PeriodSharesReservedForIssuanceWillIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_PeriodSharesReservedForIssuanceWillIncrease" xlink:to="lab_nltx_PeriodSharesReservedForIssuanceWillIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_edb23e7e-7e65-44e8-8f9f-3440bfafa1e1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_87c07758-ef93-4883-b49c-1b7238d8d8c9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_551c8185-ad7c-4479-a221-1eaed84953e2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_OtherCurrentAssetsAcquiredThroughTheIssuanceOfCommonStock_e80bdae5-8c87-4e3b-bfbe-943314a8dca2_terseLabel_en-US" xlink:label="lab_nltx_OtherCurrentAssetsAcquiredThroughTheIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets acquired through the issuance of common stock</link:label>
    <link:label id="lab_nltx_OtherCurrentAssetsAcquiredThroughTheIssuanceOfCommonStock_label_en-US" xlink:label="lab_nltx_OtherCurrentAssetsAcquiredThroughTheIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets Acquired Through The Issuance Of Common Stock</link:label>
    <link:label id="lab_nltx_OtherCurrentAssetsAcquiredThroughTheIssuanceOfCommonStock_documentation_en-US" xlink:label="lab_nltx_OtherCurrentAssetsAcquiredThroughTheIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables prepayments and deposits acquired through the issuance of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_OtherCurrentAssetsAcquiredThroughTheIssuanceOfCommonStock" xlink:href="nltx-20201231.xsd#nltx_OtherCurrentAssetsAcquiredThroughTheIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_OtherCurrentAssetsAcquiredThroughTheIssuanceOfCommonStock" xlink:to="lab_nltx_OtherCurrentAssetsAcquiredThroughTheIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_300f9547-8779-4b7a-a47c-4bcb197d0a68_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_817dcdbe-e427-42cb-882d-40e271252eca_negatedTerseLabel_en-US" xlink:label="lab_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Operating Lease Right Of Use Assets</link:label>
    <link:label id="lab_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in operating lease right of use assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:href="nltx-20201231.xsd#nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:to="lab_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_dbed5c9e-3e79-45d5-b7b6-99f6d5ecd991_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_a94d4794-2b61-4dc4-ad23-a90b6ba36553_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_a1168de8-ad86-4a36-b459-ba7dd26f9139_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0b4f15bc-8a10-49a6-a3eb-67e96c9fa577_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b3ecad74-8e69-4911-844a-1f431a13da65_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesIndustryMember_79d84833-aeaf-4a0a-a6c7-ce9f00f1afca_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesIndustryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Industry Sector [Domain]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesIndustryMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesIndustryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Industry Sector [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember" xlink:to="lab_us-gaap_EquitySecuritiesIndustryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_f0bafb94-f0e4-4711-9cd1-5f99e8aa5a83_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash flow Information Related to Leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a3c2ef73-1e2c-4eba-a91b-160e384816be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_607e45bc-bcbf-4154-b3af-8291444b42e0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_LaboratoryEquipmentMember_594b16be-9e93-48b9-a2f0-ec5cc4cfb405_terseLabel_en-US" xlink:label="lab_nltx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_nltx_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_nltx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_nltx_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_nltx_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_LaboratoryEquipmentMember" xlink:href="nltx-20201231.xsd#nltx_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_LaboratoryEquipmentMember" xlink:to="lab_nltx_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_af93b6bb-852d-4851-a928-c0b66a0c2d7b_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9ad6dcff-1aa5-4481-b9b2-1ac25da28996_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_OperatingLeaseLiabilityIncreaseDueToRemeasurement_5eef907f-d28c-4bd9-8ebe-7d73fd92cfb8_terseLabel_en-US" xlink:label="lab_nltx_OperatingLeaseLiabilityIncreaseDueToRemeasurement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, liability, increase due to remeasurement</link:label>
    <link:label id="lab_nltx_OperatingLeaseLiabilityIncreaseDueToRemeasurement_label_en-US" xlink:label="lab_nltx_OperatingLeaseLiabilityIncreaseDueToRemeasurement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Increase Due to Remeasurement</link:label>
    <link:label id="lab_nltx_OperatingLeaseLiabilityIncreaseDueToRemeasurement_documentation_en-US" xlink:label="lab_nltx_OperatingLeaseLiabilityIncreaseDueToRemeasurement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Increase Due to Remeasurement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_OperatingLeaseLiabilityIncreaseDueToRemeasurement" xlink:href="nltx-20201231.xsd#nltx_OperatingLeaseLiabilityIncreaseDueToRemeasurement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_OperatingLeaseLiabilityIncreaseDueToRemeasurement" xlink:to="lab_nltx_OperatingLeaseLiabilityIncreaseDueToRemeasurement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_20e3b604-3b0e-4c19-976a-38af9fed0bdc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_00676807-06ca-4a10-87a4-e63f5882fa36_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f0973d4f-db92-4def-8ea6-fcd5dc373de8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_SubsidiarySaleOfStockAbstract_label_en-US" xlink:label="lab_nltx_SubsidiarySaleOfStockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Sale Of Stock [Abstract]</link:label>
    <link:label id="lab_nltx_SubsidiarySaleOfStockAbstract_documentation_en-US" xlink:label="lab_nltx_SubsidiarySaleOfStockAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Sale Of Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_SubsidiarySaleOfStockAbstract" xlink:href="nltx-20201231.xsd#nltx_SubsidiarySaleOfStockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_SubsidiarySaleOfStockAbstract" xlink:to="lab_nltx_SubsidiarySaleOfStockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_ab902020-78e2-4044-a7cd-28fd99cd0798_verboseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f9167488-58ec-4a7b-b7d5-950e8ada2c0f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_StockConversionRatio_2f7cdb35-65e3-4e9b-a3f1-231a15de0e5e_terseLabel_en-US" xlink:label="lab_nltx_StockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock conversion ratio</link:label>
    <link:label id="lab_nltx_StockConversionRatio_label_en-US" xlink:label="lab_nltx_StockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Conversion Ratio</link:label>
    <link:label id="lab_nltx_StockConversionRatio_documentation_en-US" xlink:label="lab_nltx_StockConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock conversion ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_StockConversionRatio" xlink:href="nltx-20201231.xsd#nltx_StockConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_StockConversionRatio" xlink:to="lab_nltx_StockConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_981dfbf9-9134-4adf-9c82-b6c26f3eb599_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting for stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_DeferredTaxAssetsBeforeValuationAllowance_3be033e0-a291-4f98-bf27-a50873bc2cab_totalLabel_en-US" xlink:label="lab_nltx_DeferredTaxAssetsBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred income tax assets</link:label>
    <link:label id="lab_nltx_DeferredTaxAssetsBeforeValuationAllowance_label_en-US" xlink:label="lab_nltx_DeferredTaxAssetsBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Before Valuation Allowance</link:label>
    <link:label id="lab_nltx_DeferredTaxAssetsBeforeValuationAllowance_documentation_en-US" xlink:label="lab_nltx_DeferredTaxAssetsBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Before Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_DeferredTaxAssetsBeforeValuationAllowance" xlink:href="nltx-20201231.xsd#nltx_DeferredTaxAssetsBeforeValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_DeferredTaxAssetsBeforeValuationAllowance" xlink:to="lab_nltx_DeferredTaxAssetsBeforeValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment_228f5b8d-a452-4b8a-9f4a-156ca2a1fe97_terseLabel_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment_label_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Assets Recognized Identifiable Assets Acquired Property And Equipment</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment_documentation_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of assets recognized identifiable assets acquired, receivables, property and equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment" xlink:to="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_afd1dc9c-9727-4c36-9c4e-4f64bb07a074_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_a7d08822-e5fc-45f0-b26a-a1f777ed2fe0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Of Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_92f06e19-eb0b-4275-84d6-e65e5261cd55_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_87a68f16-414b-4a94-922d-2712d7c94122_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate&#8212;operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_8c3795e1-899a-4122-8f80-1e92b2409bc2_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_bf37ed6d-5408-494d-ba8e-293ae931ece4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_c0c4b214-1fe4-44e5-aee8-2b2f4946c832_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research&#160;&amp; development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_9214bf86-7246-4d06-bae1-1e5462d26bd9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b88fd4af-8f43-416e-970c-68c7aa553871_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3552c996-8a07-48b2-a45e-4412bce1a7d8_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_a8fa0bd4-f9df-4758-9835-4f77ee2e5b1a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_779fd8d0-19d6-4c11-a05d-13be4ec6a88e_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7b188fe4-7ef8-47d3-83fe-7aa8cb3c0081_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b39be943-9b35-469f-a47e-87d46f804e75_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_497c1879-0563-4320-a2eb-c61588942257_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_OperatingLossCarryforwardsSubjectToExpiration_51bfaf42-2010-4fdb-b159-861214c007c9_terseLabel_en-US" xlink:label="lab_nltx_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards subject to expiration</link:label>
    <link:label id="lab_nltx_OperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_nltx_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards Subject To Expiration</link:label>
    <link:label id="lab_nltx_OperatingLossCarryforwardsSubjectToExpiration_documentation_en-US" xlink:label="lab_nltx_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards subject to expiration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_OperatingLossCarryforwardsSubjectToExpiration" xlink:href="nltx-20201231.xsd#nltx_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_OperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_nltx_OperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_a584bd90-001f-4dc0-8d8a-9d56c9d680e4_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_7c0e59da-ef07-4936-9622-541b19eb8582_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of shares under public offering (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_8aed9c7c-6017-4a70-be76-151e92ec8a64_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_21eaf58d-e170-448b-a2cb-1fad152afcf2_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_3f49109b-1cc3-4f8e-a9c9-9d4c857602b8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_e4a563f0-28fc-422c-a4a8-3aa264ea13b2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_b3dd8ba3-a9f7-4669-89df-c55563144904_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted weighted average number of common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_9d31e50d-3e1d-4dfe-b137-38966e5b8685_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net of valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AcquisitionOfAssetsDisclosureTextBlock_01334cc5-8673-4975-8422-6bfeff7f7685_terseLabel_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Of Assets Disclosure [Text Block]</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsDisclosureTextBlock_documentation_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of assets disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsDisclosureTextBlock" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AcquisitionOfAssetsDisclosureTextBlock" xlink:to="lab_nltx_AcquisitionOfAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OfficeBuildingMember_c7740bdf-62e6-46ee-aefc-23378b37aa21_terseLabel_en-US" xlink:label="lab_srt_OfficeBuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office</link:label>
    <link:label id="lab_srt_OfficeBuildingMember_label_en-US" xlink:label="lab_srt_OfficeBuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OfficeBuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OfficeBuildingMember" xlink:to="lab_srt_OfficeBuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_dea082b8-504a-4a97-af58-06295c00063e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP purchase price of common stock, percent of market price</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_12ac3ef4-b057-43ce-a67a-bf8a4153ab0e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract_a769fe3f-c287-47b3-a2c0-8ebdfee06d29_terseLabel_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets acquired:</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract_label_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Assets Recognized Identifiable Assets Acquired [Abstract]</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract_documentation_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of assets recognized identifiable assets acquired.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract" xlink:to="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_d919489a-0661-46ba-8f67-582912c6b7df_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_label_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:to="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_91b43eef-09aa-4a9a-9e7a-f57f9c5e565d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AquinoxMember_3bbed951-100e-4e1a-90f4-6e1c8a01a0af_terseLabel_en-US" xlink:label="lab_nltx_AquinoxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aquinox</link:label>
    <link:label id="lab_nltx_AquinoxMember_label_en-US" xlink:label="lab_nltx_AquinoxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aquinox [Member]</link:label>
    <link:label id="lab_nltx_AquinoxMember_documentation_en-US" xlink:label="lab_nltx_AquinoxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aquinox .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AquinoxMember" xlink:href="nltx-20201231.xsd#nltx_AquinoxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AquinoxMember" xlink:to="lab_nltx_AquinoxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_04ca5cf2-d74c-4f47-b65d-6fc93b43d260_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding pre-funded warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_FinanceLeasePrincipalAndInterestPayments_8edc19b8-ff4e-4d54-9a0e-6243414d87b9_verboseLabel_en-US" xlink:label="lab_nltx_FinanceLeasePrincipalAndInterestPayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of finance lease liabilities</link:label>
    <link:label id="lab_nltx_FinanceLeasePrincipalAndInterestPayments_label_en-US" xlink:label="lab_nltx_FinanceLeasePrincipalAndInterestPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal and Interest Payments</link:label>
    <link:label id="lab_nltx_FinanceLeasePrincipalAndInterestPayments_documentation_en-US" xlink:label="lab_nltx_FinanceLeasePrincipalAndInterestPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal and Interest Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_FinanceLeasePrincipalAndInterestPayments" xlink:href="nltx-20201231.xsd#nltx_FinanceLeasePrincipalAndInterestPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_FinanceLeasePrincipalAndInterestPayments" xlink:to="lab_nltx_FinanceLeasePrincipalAndInterestPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_0b163966-783c-4fd2-a5e0-0bc10da396f3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_261810d7-425e-42bc-986e-f21129424b7c_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options cancelled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_34c1754d-61e4-4a05-88de-8a6cba7b2846_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_1d2c0c2f-9ed5-4af8-b104-51ed8de87225_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_4f675f7e-98e0-4bd9-8499-19f5cfbfdc1d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_d6542ab5-2365-4a9b-8646-f7d07bf93477_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts, commissions and offering expenses</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_122568fc-6bcc-46fc-8a9f-2d9aea75b630_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_UniversityOfWashingtonMember_a16d83ff-4f3b-4b33-93b7-71d1c0734458_terseLabel_en-US" xlink:label="lab_nltx_UniversityOfWashingtonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University Of Washington</link:label>
    <link:label id="lab_nltx_UniversityOfWashingtonMember_label_en-US" xlink:label="lab_nltx_UniversityOfWashingtonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University Of Washington [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_UniversityOfWashingtonMember" xlink:href="nltx-20201231.xsd#nltx_UniversityOfWashingtonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_UniversityOfWashingtonMember" xlink:to="lab_nltx_UniversityOfWashingtonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_938ddc4c-c2dd-471b-b6ec-3ddc8602394a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_832802d5-8807-45c0-90e8-d668bf34b46c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_d9ff122b-941f-4a9a-80ab-7ac9495964fc_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_91beb158-995a-4474-bbfc-950373a244ad_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_8f630319-243a-4a05-a25b-89ca0208283f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_48eb7d04-f6ed-4318-b8b4-59ccef8ecafb_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected terms (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_NumberOfOptionToExtendLease_f9b8d086-f252-4c88-8759-a94b9d66767b_terseLabel_en-US" xlink:label="lab_nltx_NumberOfOptionToExtendLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to extend lease</link:label>
    <link:label id="lab_nltx_NumberOfOptionToExtendLease_label_en-US" xlink:label="lab_nltx_NumberOfOptionToExtendLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Option To Extend Lease</link:label>
    <link:label id="lab_nltx_NumberOfOptionToExtendLease_documentation_en-US" xlink:label="lab_nltx_NumberOfOptionToExtendLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of option to extend lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_NumberOfOptionToExtendLease" xlink:href="nltx-20201231.xsd#nltx_NumberOfOptionToExtendLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_NumberOfOptionToExtendLease" xlink:to="lab_nltx_NumberOfOptionToExtendLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_7648c13f-9856-4734-a8c3-e229cfd27b17_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_bdd17c14-4f98-4ac1-8854-7d8d1a94bb4f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_5ec9e277-f5f5-42c3-8ab0-97ce2d2b3244_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Other Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_657a8a62-9628-4240-bfbb-03826fd747c1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0d7284f6-3ff2-46e0-86ed-dd2b6949c593_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term&#8212;operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock_c0b2126b-9738-4e99-9864-341adcbec7ff_terseLabel_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Consideration Paid</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock_label_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Of Assets Consideration Of Transaction Fair Value [Table Text Block]</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock_documentation_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of assets consideration of transaction fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock" xlink:to="lab_nltx_AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_86900a6c-cbfb-44dd-81ef-dab2d01c0d8b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_3f6d082e-2b69-4c4a-be36-6c2154ad82fa_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3cd0adb1-267f-47cd-b8af-faae4a62b64b_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_98bc480d-9b4c-42bd-84df-062c3668f6ab_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_24bea657-8203-43c3-bed2-a54c6c38f70e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_920497c5-5006-4c30-99de-cfe2ac534e21_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.000001 par value per share; 100,000,000 shares authorized at December 31, 2020 and 2019; 42,196,296 and 37,996,849 issued and outstanding at December 31, 2020 and 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fd2bcd99-7888-4091-821f-69e6b8c3fe3c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_ee2fdfce-fc03-4e28-b6e7-b405bee7d98d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_03cfeb26-ff66-442b-bf46-1dbfca4ec16f_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_fc0a2f1a-160a-4755-ae28-3e087b74281a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected amortization expense 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_FurnitureFixturesAndITEquipmentMember_4803fa31-5b15-4430-9055-170d0a866832_terseLabel_en-US" xlink:label="lab_nltx_FurnitureFixturesAndITEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture, fixtures, and IT equipment</link:label>
    <link:label id="lab_nltx_FurnitureFixturesAndITEquipmentMember_label_en-US" xlink:label="lab_nltx_FurnitureFixturesAndITEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture, Fixtures, And IT Equipment [Member]</link:label>
    <link:label id="lab_nltx_FurnitureFixturesAndITEquipmentMember_documentation_en-US" xlink:label="lab_nltx_FurnitureFixturesAndITEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture, Fixtures, And IT Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_FurnitureFixturesAndITEquipmentMember" xlink:href="nltx-20201231.xsd#nltx_FurnitureFixturesAndITEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_FurnitureFixturesAndITEquipmentMember" xlink:to="lab_nltx_FurnitureFixturesAndITEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities_f8145efa-f735-4f82-a57a-39fb2fa2678a_terseLabel_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities_label_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Assets Recognized Identifiable Liabilities Assumed Accounts Payable And Other Liabilities</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities_documentation_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of assets recognized identifiable liabilities assumed, accounts payable and other liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities" xlink:to="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_StockIncentivePlanTwoThousandFourteenMember_2d1605f0-4739-4add-9f8e-def5ad276b41_verboseLabel_en-US" xlink:label="lab_nltx_StockIncentivePlanTwoThousandFourteenMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Plan</link:label>
    <link:label id="lab_nltx_StockIncentivePlanTwoThousandFourteenMember_label_en-US" xlink:label="lab_nltx_StockIncentivePlanTwoThousandFourteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan Two Thousand Fourteen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_StockIncentivePlanTwoThousandFourteenMember" xlink:href="nltx-20201231.xsd#nltx_StockIncentivePlanTwoThousandFourteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_StockIncentivePlanTwoThousandFourteenMember" xlink:to="lab_nltx_StockIncentivePlanTwoThousandFourteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_01ef0e38-fd94-42a8-afaa-04fcc66b8f0e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Aggregate intrinsic value (in dollars)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_b77c878f-6c7e-4d73-9a38-e404eb6c2029_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_fb0ae00f-0bf4-4edd-9f45-ebc06ba6133b_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_bf432e32-6bf8-4b53-9790-5390fe8e5fde_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December&#160;31, 2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_573c32aa-285f-4ac8-af15-4f3e290a6222_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_LicenseAgreementDisclosureTextBlock_84a1a6d0-19ca-4e31-94b8-7ca046d75bf1_terseLabel_en-US" xlink:label="lab_nltx_LicenseAgreementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and patent agreements</link:label>
    <link:label id="lab_nltx_LicenseAgreementDisclosureTextBlock_label_en-US" xlink:label="lab_nltx_LicenseAgreementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Disclosure [Text Block]</link:label>
    <link:label id="lab_nltx_LicenseAgreementDisclosureTextBlock_documentation_en-US" xlink:label="lab_nltx_LicenseAgreementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_LicenseAgreementDisclosureTextBlock" xlink:href="nltx-20201231.xsd#nltx_LicenseAgreementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_LicenseAgreementDisclosureTextBlock" xlink:to="lab_nltx_LicenseAgreementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4f60b24b-946d-4cff-aa84-d088e2d04cef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_eb5a7195-5310-4ac2-a969-14acb65b472d_totalLabel_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Assets Recognized Identifiable Assets Acquired And Liabilities Assumed Net</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_documentation_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of assets recognized identifiable assets acquired and liabilities assumed net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b465bfa5-74a8-4f4a-a1de-acc2ccaba132_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_c36a3f6a-73a2-409b-a0b9-2c9690e8ea57_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1e599a62-b61b-46bf-b220-f0aa7f7ebb55_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_NumberOfDaysAdvanceNoticeMustBeGivenToTerminateTheLease_497a19cb-8c38-4770-91a9-0e14a536cb18_terseLabel_en-US" xlink:label="lab_nltx_NumberOfDaysAdvanceNoticeMustBeGivenToTerminateTheLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of days advance notice must be given to terminate the lease</link:label>
    <link:label id="lab_nltx_NumberOfDaysAdvanceNoticeMustBeGivenToTerminateTheLease_label_en-US" xlink:label="lab_nltx_NumberOfDaysAdvanceNoticeMustBeGivenToTerminateTheLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Days Advance Notice Must Be Given To Terminate The Lease</link:label>
    <link:label id="lab_nltx_NumberOfDaysAdvanceNoticeMustBeGivenToTerminateTheLease_documentation_en-US" xlink:label="lab_nltx_NumberOfDaysAdvanceNoticeMustBeGivenToTerminateTheLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Days Advance Notice Must Be Given To Terminate The Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_NumberOfDaysAdvanceNoticeMustBeGivenToTerminateTheLease" xlink:href="nltx-20201231.xsd#nltx_NumberOfDaysAdvanceNoticeMustBeGivenToTerminateTheLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_NumberOfDaysAdvanceNoticeMustBeGivenToTerminateTheLease" xlink:to="lab_nltx_NumberOfDaysAdvanceNoticeMustBeGivenToTerminateTheLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_b0aa07f6-4d12-4824-b65a-35369f6df427_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_7d035449-df70-4ea8-9778-590415e3b324_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_a76c8a18-1582-4d8a-8ddf-8ca2899e2e8b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_b7162e47-e00b-4f78-be5f-9700feb36072_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock to University of Washington</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_0b32fc52-13b9-492e-9681-b1e29e177038_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation and summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_b3434c9b-7211-42f8-aec6-083d92d48662_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_170203d9-ceca-404b-85a7-ac33ea06b742_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6d6b27b6-dbad-4519-954d-cd8cea95ad07_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_34ef6399-0bd1-447f-9937-a49de4502ab7_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of operations</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_42879916-f92a-43b1-8b23-327c53f9359b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_1b4f436b-a0e3-4f87-80bb-ef086c8d125d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_efa69b12-cd16-457d-8447-5f2736d3a49d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_TerminationFeesForLeaseTermination_ef16f1b6-a899-4b79-aecb-f6318843bf53_terseLabel_en-US" xlink:label="lab_nltx_TerminationFeesForLeaseTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination fees for lease termination</link:label>
    <link:label id="lab_nltx_TerminationFeesForLeaseTermination_label_en-US" xlink:label="lab_nltx_TerminationFeesForLeaseTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Fees For Lease Termination</link:label>
    <link:label id="lab_nltx_TerminationFeesForLeaseTermination_documentation_en-US" xlink:label="lab_nltx_TerminationFeesForLeaseTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of termination fees related to lease termination.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_TerminationFeesForLeaseTermination" xlink:href="nltx-20201231.xsd#nltx_TerminationFeesForLeaseTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_TerminationFeesForLeaseTermination" xlink:to="lab_nltx_TerminationFeesForLeaseTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_0b3eb713-ad63-4298-916f-8978b2176bd8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_568469e8-483f-413b-89aa-2b48d61cb833_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_f6515507-5b33-4ea4-b5a5-660e91bf33c0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and vacation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_a3dc56ed-8b19-4ba7-b919-611ddaec0ba7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_d89f1fc1-0224-4e96-a9eb-2b778a2d8f1b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_7f27c088-87d0-4238-ac12-35372bdbf85d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP max contribution rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5498abe7-9652-4ee1-aaa6-383270a53099_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_751425e7-04a8-48e5-a1db-790a8a7367e5_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2eb534c6-4fca-4e70-9eaf-3ac3bdac1a6a_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_09113700-5ffe-477c-b05d-2f31f57be0fc_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term&#8212;finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_fe1e5db0-a279-4a02-91a8-cc3c1c6ed427_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7e34cbf4-4219-4f11-97b5-2c88674fc8a8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_ProceedsFromSaleOfStockOfSubsidiary_aeda79d0-8fef-486e-a82e-927803e23084_terseLabel_en-US" xlink:label="lab_nltx_ProceedsFromSaleOfStockOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration from sale of assets</link:label>
    <link:label id="lab_nltx_ProceedsFromSaleOfStockOfSubsidiary_label_en-US" xlink:label="lab_nltx_ProceedsFromSaleOfStockOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Stock Of Subsidiary</link:label>
    <link:label id="lab_nltx_ProceedsFromSaleOfStockOfSubsidiary_documentation_en-US" xlink:label="lab_nltx_ProceedsFromSaleOfStockOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of stock of subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_ProceedsFromSaleOfStockOfSubsidiary" xlink:href="nltx-20201231.xsd#nltx_ProceedsFromSaleOfStockOfSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_ProceedsFromSaleOfStockOfSubsidiary" xlink:to="lab_nltx_ProceedsFromSaleOfStockOfSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_fd425fed-690f-42f3-bf65-c4e9ba6ee378_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_035bac27-81ea-431a-afec-a68d8a0e566e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_e3073db6-fd24-45ad-b3b1-4abcd717185d_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_63700093-5752-403e-92a3-9ca3620351fa_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_39d16367-9b67-4fd0-8da3-f48eac3252d8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_42977cc1-3cda-452d-ba43-1de6a6255c69_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c5ef5eb5-fb5b-4cdb-87e6-f9fa2e3ad539_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Book Value</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e2d2edfd-4688-4f14-a387-92c098a00cc7_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_af14bb40-739c-4cf2-b301-a78d52bf5acc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_1d5bb3d8-4d31-4960-ac59-b8a17f1a15a8_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_7407a1bb-d668-4db0-b508-7e084aaad1c1_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_0141c0c6-334d-4ebd-921a-5e684bf5405e_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current finance lease liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_cf784f34-764e-4e48-9c52-53d20a06d9b9_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current lease liabilities&#8212;December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear_69abd062-cac4-4f5e-b665-ecf20eeeff1c_terseLabel_en-US" xlink:label="lab_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP number of offerings per year</link:label>
    <link:label id="lab_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear_label_en-US" xlink:label="lab_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan Number Of Offering Per Year</link:label>
    <link:label id="lab_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear_documentation_en-US" xlink:label="lab_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">employee stock purchase plan number of offering per year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear" xlink:href="nltx-20201231.xsd#nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear" xlink:to="lab_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6ce89f30-53a4-4534-8293-7e8f683f18d0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_TenantImprovementAllowance_6cf5a274-2f42-408d-b1e6-3e358d7a617b_terseLabel_en-US" xlink:label="lab_nltx_TenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvement allowance</link:label>
    <link:label id="lab_nltx_TenantImprovementAllowance_label_en-US" xlink:label="lab_nltx_TenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Allowance</link:label>
    <link:label id="lab_nltx_TenantImprovementAllowance_documentation_en-US" xlink:label="lab_nltx_TenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of tenant improvement allowance pursuant to lease arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_TenantImprovementAllowance" xlink:href="nltx-20201231.xsd#nltx_TenantImprovementAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_TenantImprovementAllowance" xlink:to="lab_nltx_TenantImprovementAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_StockBasedCompensationIncreaseInCommonStockIssuancePercentage_77de4273-d74a-4350-a9a0-56849ffe44f8_terseLabel_en-US" xlink:label="lab_nltx_StockBasedCompensationIncreaseInCommonStockIssuancePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock reserved for issuance percentage</link:label>
    <link:label id="lab_nltx_StockBasedCompensationIncreaseInCommonStockIssuancePercentage_label_en-US" xlink:label="lab_nltx_StockBasedCompensationIncreaseInCommonStockIssuancePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Based Compensation Increase In Common Stock Issuance Percentage</link:label>
    <link:label id="lab_nltx_StockBasedCompensationIncreaseInCommonStockIssuancePercentage_documentation_en-US" xlink:label="lab_nltx_StockBasedCompensationIncreaseInCommonStockIssuancePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage increase in the number of authorized common shares for grant under the stock based compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_StockBasedCompensationIncreaseInCommonStockIssuancePercentage" xlink:href="nltx-20201231.xsd#nltx_StockBasedCompensationIncreaseInCommonStockIssuancePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_StockBasedCompensationIncreaseInCommonStockIssuancePercentage" xlink:to="lab_nltx_StockBasedCompensationIncreaseInCommonStockIssuancePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_977ea1a0-c1fe-422f-ae74-091b5d22bbaf_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AcqinoxCanadaMember_a05992f4-8ed2-4392-b60d-270242f60c6f_terseLabel_en-US" xlink:label="lab_nltx_AcqinoxCanadaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acqinox Canada</link:label>
    <link:label id="lab_nltx_AcqinoxCanadaMember_label_en-US" xlink:label="lab_nltx_AcqinoxCanadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acqinox Canada [Member]</link:label>
    <link:label id="lab_nltx_AcqinoxCanadaMember_documentation_en-US" xlink:label="lab_nltx_AcqinoxCanadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acqinox Canada</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcqinoxCanadaMember" xlink:href="nltx-20201231.xsd#nltx_AcqinoxCanadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AcqinoxCanadaMember" xlink:to="lab_nltx_AcqinoxCanadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_20ecc54f-8b1f-46ee-970a-edd3c99f4dd1_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2566f0df-5e4c-4d2d-b4d8-71eab7218113_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_2994edb7-0537-4595-baa7-e166ba3fa41c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_c5791fb3-f56e-41e1-b210-a8c59c2f9c02_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses carried forward for tax purposes</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_f1b6a829-57a5-487d-a3c1-5249038fb9f2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_e898b045-0a84-46b6-9e0b-5b4d320f1720_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1832a450-9dae-494b-b2db-37394317cf92_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Income Tax Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d269530a-5567-4a41-bb46-eb097580d814_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_5d06eb19-9d99-4a46-9a54-0790d7cca59d_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_fba06c84-48ec-4a56-b373-b6fa63232f23_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized foreign exchange loss and others</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_175cf0e2-9b9a-4de7-a631-538293cb9009_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_DeferredTaxAssetsLeaseLiability_6ae6bc2e-f67d-4f1d-ab33-1b107dd46cf2_terseLabel_en-US" xlink:label="lab_nltx_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Liability</link:label>
    <link:label id="lab_nltx_DeferredTaxAssetsLeaseLiability_label_en-US" xlink:label="lab_nltx_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:label id="lab_nltx_DeferredTaxAssetsLeaseLiability_documentation_en-US" xlink:label="lab_nltx_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_DeferredTaxAssetsLeaseLiability" xlink:href="nltx-20201231.xsd#nltx_DeferredTaxAssetsLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_DeferredTaxAssetsLeaseLiability" xlink:to="lab_nltx_DeferredTaxAssetsLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_ae556da8-8cf3-4e9b-8695-224af7f0be84_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_OperatingLeaseRightOfUseAssetIncreaseDueToRemeasurement_63e6d2dd-7b2f-43bb-8123-069f25145f7b_terseLabel_en-US" xlink:label="lab_nltx_OperatingLeaseRightOfUseAssetIncreaseDueToRemeasurement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, right of use asset, increase due to remeasurement</link:label>
    <link:label id="lab_nltx_OperatingLeaseRightOfUseAssetIncreaseDueToRemeasurement_label_en-US" xlink:label="lab_nltx_OperatingLeaseRightOfUseAssetIncreaseDueToRemeasurement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right of Use Asset, Increase Due to Remeasurement</link:label>
    <link:label id="lab_nltx_OperatingLeaseRightOfUseAssetIncreaseDueToRemeasurement_documentation_en-US" xlink:label="lab_nltx_OperatingLeaseRightOfUseAssetIncreaseDueToRemeasurement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right of Use Asset, Increase Due to Remeasurement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_OperatingLeaseRightOfUseAssetIncreaseDueToRemeasurement" xlink:href="nltx-20201231.xsd#nltx_OperatingLeaseRightOfUseAssetIncreaseDueToRemeasurement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_OperatingLeaseRightOfUseAssetIncreaseDueToRemeasurement" xlink:to="lab_nltx_OperatingLeaseRightOfUseAssetIncreaseDueToRemeasurement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_01e56367-19c1-4364-9ccf-28e448109b9b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock in prefunded warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0b184add-7f46-4b6a-9529-eb68db70ea02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_8183c2f5-4dbb-4214-becc-e4cc13157c94_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_4c744210-34fb-4340-bd8a-44a03aaf85e7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock and convertible preferred stock for Former Neoleukin common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_d9519b59-b435-4b59-a4e3-509155128c09_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued for acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_22c67a02-33df-4f44-a439-9fc524a499a2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents_118c8fc2-2452-447d-a1dd-24f44e16b583_terseLabel_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents_label_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Assets Recognized Identifiable Assets Acquired Cash And Cash Equivalents</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents_documentation_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of assets recognized identifiable assets acquired, cash and cash equivalents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents" xlink:to="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_c01b6153-8563-49d6-bca2-ca560ba3efc4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_fdef7101-4fd5-4cc8-9dd0-732266ed05ea_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and related cost, cost incurred to date</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f7c0d982-90d7-4277-992f-764c6132db7b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Employee Stock Purchase Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_9122f56d-f2d8-4242-829a-e94fc750ee91_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_387a5824-0e6c-4f13-99d4-c37f3f322b4e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_1072febf-eaa4-4190-b956-52b0bd1d6e8c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_3fc19e2d-c020-40cf-aa69-4115f587235e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_e21009d2-b4d4-48c2-b412-e16f8e4ce9e7_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0aef30de-b637-457f-a269-8f208a6295bc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ce76a6e-90d2-4ba2-a7ea-b13c00cc1236_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_6900361f-0f1d-4954-841e-815c5370d149_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign rate differential</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AcquisitionsOfAssetsCashConsiderationForFractionalShares_cad49800-d18a-4752-8d4d-b190cd024a1a_terseLabel_en-US" xlink:label="lab_nltx_AcquisitionsOfAssetsCashConsiderationForFractionalShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration for fractional shares</link:label>
    <link:label id="lab_nltx_AcquisitionsOfAssetsCashConsiderationForFractionalShares_label_en-US" xlink:label="lab_nltx_AcquisitionsOfAssetsCashConsiderationForFractionalShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions Of Assets Cash Consideration For Fractional Shares</link:label>
    <link:label id="lab_nltx_AcquisitionsOfAssetsCashConsiderationForFractionalShares_documentation_en-US" xlink:label="lab_nltx_AcquisitionsOfAssetsCashConsiderationForFractionalShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of assets cash consideration for fractional shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionsOfAssetsCashConsiderationForFractionalShares" xlink:href="nltx-20201231.xsd#nltx_AcquisitionsOfAssetsCashConsiderationForFractionalShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AcquisitionsOfAssetsCashConsiderationForFractionalShares" xlink:to="lab_nltx_AcquisitionsOfAssetsCashConsiderationForFractionalShares" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_LicenseAndPatentAgreementsLineItems_27c08f3e-4db9-43bf-a6f3-29be3951bcad_terseLabel_en-US" xlink:label="lab_nltx_LicenseAndPatentAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and patent agreements [Line Items]</link:label>
    <link:label id="lab_nltx_LicenseAndPatentAgreementsLineItems_label_en-US" xlink:label="lab_nltx_LicenseAndPatentAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and patent agreements [Line Items]</link:label>
    <link:label id="lab_nltx_LicenseAndPatentAgreementsLineItems_documentation_en-US" xlink:label="lab_nltx_LicenseAndPatentAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and patent agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_LicenseAndPatentAgreementsLineItems" xlink:href="nltx-20201231.xsd#nltx_LicenseAndPatentAgreementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_LicenseAndPatentAgreementsLineItems" xlink:to="lab_nltx_LicenseAndPatentAgreementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AssetAcquisitionsintangibleAssetsPolicyTextBlock_a968f074-df73-4dcc-bc61-5a08cf2de94f_verboseLabel_en-US" xlink:label="lab_nltx_AssetAcquisitionsintangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisitions/Intangible assets</link:label>
    <link:label id="lab_nltx_AssetAcquisitionsintangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_nltx_AssetAcquisitionsintangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisitionsIntangible assets [Policy Text Block]</link:label>
    <link:label id="lab_nltx_AssetAcquisitionsintangibleAssetsPolicyTextBlock_documentation_en-US" xlink:label="lab_nltx_AssetAcquisitionsintangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisitions/Intangible assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AssetAcquisitionsintangibleAssetsPolicyTextBlock" xlink:href="nltx-20201231.xsd#nltx_AssetAcquisitionsintangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AssetAcquisitionsintangibleAssetsPolicyTextBlock" xlink:to="lab_nltx_AssetAcquisitionsintangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_61c6ae67-64f2-451f-a971-1df5ee4c20e1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate&#8212;finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_decde789-3083-4987-b33e-53df7b90000a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_PreFundedCommonStockWarrantsMember_4fde5d26-7809-4e09-8a7e-2093eb1c8a49_terseLabel_en-US" xlink:label="lab_nltx_PreFundedCommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre funded common stock warrants</link:label>
    <link:label id="lab_nltx_PreFundedCommonStockWarrantsMember_label_en-US" xlink:label="lab_nltx_PreFundedCommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre Funded Common Stock Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PreFundedCommonStockWarrantsMember" xlink:href="nltx-20201231.xsd#nltx_PreFundedCommonStockWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_PreFundedCommonStockWarrantsMember" xlink:to="lab_nltx_PreFundedCommonStockWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_17a3f316-a33e-4a5c-a190-c269d55d5506_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of discounts, commissions and offering expenses (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_844cad7a-0c46-4e72-ac62-0fb9ebf6dcfd_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of shares under public offering (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_5a26e79c-141e-4de6-afeb-f91ec5988b26_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_40c448b4-768d-43c3-bef0-b0fb85d17f6a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_56b77fef-711d-4284-adbe-79aa5355e080_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible preferred stock into common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_c14cf344-c136-4fdc-a875-51f3ad659d4e_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6636947b-2528-4150-8306-8d02fdc68f65_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_c38bb4ef-eba4-41ea-8076-26b78f6d7697_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_376c88da-5d86-4ec8-aba8-8868ae2dc81d_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainOrLossOnSaleOfStockInSubsidiary_40fa38c8-636f-4bb0-bd7a-b791914134b7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of Aquinox Canada</link:label>
    <link:label id="lab_us-gaap_GainOrLossOnSaleOfStockInSubsidiary_4993d8c2-1473-4585-b5d4-ebd7c831c579_terseLabel_en-US" xlink:label="lab_us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of Aquinox Canada</link:label>
    <link:label id="lab_us-gaap_GainOrLossOnSaleOfStockInSubsidiary_label_en-US" xlink:label="lab_us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Stock in Subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:to="lab_us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_63f3d103-f8a9-4afa-8682-f9f55fbcf0c4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development deductions and credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e006a499-b089-47f6-9950-a9da4579ab55_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bcd94d0d-ce69-4453-895b-12303e1c78ee_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7e24cd8f-1594-4407-b56a-e7ec8f9e1b85_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0b964528-c7eb-4da7-80a7-2594c69ce9cd_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash, cash equivalents, and restricted cash during the year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_19fe1d58-daa6-427e-8bf5-a41c150f7a19_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_158ae4b1-5709-4676-92d6-d33005b0dec1_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_1861b7ca-09eb-411d-baf1-14ea9fc45891_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7dc8c281-5264-487e-9d31-de33720c835b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Company's Operating Lease Liability</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_6990132a-c5d6-4234-8155-ce0b036971bb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9427e7c6-26e2-410a-8f1f-cd38594b199f_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6860962c-3255-4830-8009-0b46ac1ad81f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_TransactionRelatedCostIncurredForSaleOfSubsidiary_7f23b42c-cbbb-46f9-9930-05c175a298c0_terseLabel_en-US" xlink:label="lab_nltx_TransactionRelatedCostIncurredForSaleOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction cost on sale of asset</link:label>
    <link:label id="lab_nltx_TransactionRelatedCostIncurredForSaleOfSubsidiary_label_en-US" xlink:label="lab_nltx_TransactionRelatedCostIncurredForSaleOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Related Cost Incurred For Sale Of Subsidiary</link:label>
    <link:label id="lab_nltx_TransactionRelatedCostIncurredForSaleOfSubsidiary_documentation_en-US" xlink:label="lab_nltx_TransactionRelatedCostIncurredForSaleOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction related cost incurred for sale of subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_TransactionRelatedCostIncurredForSaleOfSubsidiary" xlink:href="nltx-20201231.xsd#nltx_TransactionRelatedCostIncurredForSaleOfSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_TransactionRelatedCostIncurredForSaleOfSubsidiary" xlink:to="lab_nltx_TransactionRelatedCostIncurredForSaleOfSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_98bb1ea6-438c-46a7-a4aa-c37cc3a2b3ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options cancelled/forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_1f7bfc62-6278-4ed6-a87f-a4dc9c9c4a11_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_CommissionsOnPublicOffering_9eb2141a-a2d6-4e65-bf8f-a06dad1b549a_terseLabel_en-US" xlink:label="lab_nltx_CommissionsOnPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commissions on public offering</link:label>
    <link:label id="lab_nltx_CommissionsOnPublicOffering_label_en-US" xlink:label="lab_nltx_CommissionsOnPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commissions On Public Offering</link:label>
    <link:label id="lab_nltx_CommissionsOnPublicOffering_documentation_en-US" xlink:label="lab_nltx_CommissionsOnPublicOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission fee on public offering.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_CommissionsOnPublicOffering" xlink:href="nltx-20201231.xsd#nltx_CommissionsOnPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_CommissionsOnPublicOffering" xlink:to="lab_nltx_CommissionsOnPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_8eb28e62-f8f8-4b55-ac41-19b4be97bae2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_0a590526-b16c-45bb-a896-a123b7071c1b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_f055c1ed-f45f-45e8-aac7-362ae51aca8b_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_ba8acdf8-893e-451b-90f1-3a0c49575eae_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_aa82ab72-28df-4cb3-aa53-5e14bdffbccd_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities arising from obtaining right-of-use asset</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_68a6889c-b3be-493b-bc88-3a9fccd03d7a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_71fbceaf-f4b8-4ef2-aed3-fa5f252c96b1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected amortization expense 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_92bb359b-4d98-48de-8807-a0e3f6a10e83_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_b762b188-ac4a-4e7a-ac6c-d7c8bc1a1755_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange gains (losses)</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AcquisitionOfAssetsTable_dd381c19-d5f4-48e3-a282-472bd4325e2f_terseLabel_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Assets [Table]</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsTable_label_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsTable" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AcquisitionOfAssetsTable" xlink:to="lab_nltx_AcquisitionOfAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_edb1b3c4-d933-42bc-ade1-9e066c224bc5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a23ac44b-a517-4ebd-9ae0-882b04aecec5_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9a72b223-f995-45e2-b85e-c08c2b0b8bd5_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e984fd40-79f4-4f36-810a-7396128f3de1_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_f08717aa-ca79-4d3f-890b-5815d2692df6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_5fd75cde-e458-43f0-ade7-5881c2f9c170_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_9eb23a7f-a4f7-42a9-b61a-079aba97e743_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3d5eb4d7-c8b1-420a-9e6c-48b2aeb04622_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_72ef745a-d360-41ca-9658-26de5d01bbcb_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon exercise of options aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_cc689642-605c-4c88-8718-d293362c0c3e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_325f7971-5a7b-4c4a-984d-1083b2ebb8bc_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract_385348f4-fe07-4539-bf2b-c8eab1283c67_terseLabel_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed:</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract_label_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Assets Recognized Identifiable Liabilities Assumed [Abstract]</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract_documentation_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of assets recognized identifiable liabilities assumed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract" xlink:to="lab_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_545da995-ce5b-4a94-bfca-7637406dbca3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_305db4be-e1e7-47d0-aa5e-8f4748d06ef6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_567af7bb-e99e-4155-bbd6-dfc98aeb0543_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f83bb59e-e351-4519-a062-8eb3353d67b3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_14a6f26d-732f-4b32-8dd7-7690b9a04093_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_EquityIncentivePlanTwoThousandSixMember_11f02163-319a-4840-aa25-9ebe45104735_terseLabel_en-US" xlink:label="lab_nltx_EquityIncentivePlanTwoThousandSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2006</link:label>
    <link:label id="lab_nltx_EquityIncentivePlanTwoThousandSixMember_label_en-US" xlink:label="lab_nltx_EquityIncentivePlanTwoThousandSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan Two Thousand Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_EquityIncentivePlanTwoThousandSixMember" xlink:href="nltx-20201231.xsd#nltx_EquityIncentivePlanTwoThousandSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_EquityIncentivePlanTwoThousandSixMember" xlink:to="lab_nltx_EquityIncentivePlanTwoThousandSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_0bc39e4a-31fe-4012-b1a8-73f07f0d358f_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9270140d-3d5c-4add-a009-dc8936e063c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU Activity Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0166d12e-7130-43c3-b213-ea7bd8c5a332_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_a2ec817d-319a-45ba-98c2-91fb33ff2c30_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_8a816c86-5aa0-4348-abad-1317304c484a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_44f25db6-fc08-4325-aae5-c3bc50fff993_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_AcquisitionOfAssetsDomain_30263ec5-8c14-4eeb-88af-e7841b54862e_terseLabel_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Assets [Domain]</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsDomain_label_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Assets [Domain]</link:label>
    <link:label id="lab_nltx_AcquisitionOfAssetsDomain_documentation_en-US" xlink:label="lab_nltx_AcquisitionOfAssetsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsDomain" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_AcquisitionOfAssetsDomain" xlink:to="lab_nltx_AcquisitionOfAssetsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_a663d29f-80ca-400a-ade6-c3fd203d9ad0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_58e8830c-53dc-4b1a-9392-a7799869c11e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_OperatingLossCarryforwardsNotSubjectToExpiration_755466ae-92d6-484c-9c3b-780dcadc674a_terseLabel_en-US" xlink:label="lab_nltx_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards not subject to expiration</link:label>
    <link:label id="lab_nltx_OperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_nltx_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards Not Subject To Expiration</link:label>
    <link:label id="lab_nltx_OperatingLossCarryforwardsNotSubjectToExpiration_documentation_en-US" xlink:label="lab_nltx_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards not subject to expiration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="nltx-20201231.xsd#nltx_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_nltx_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f21740de-43b1-4761-9660-ab7b8e2cd585_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax recovery</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0908e19c-e1ad-48b0-9ff0-6995ef82e2fe_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_RestructuringPlan1July2018Member_817b67ba-572e-41d4-886c-2204b3f1b9f9_terseLabel_en-US" xlink:label="lab_nltx_RestructuringPlan1July2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan, July 2018</link:label>
    <link:label id="lab_nltx_RestructuringPlan1July2018Member_label_en-US" xlink:label="lab_nltx_RestructuringPlan1July2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan1 July2018 [Member]</link:label>
    <link:label id="lab_nltx_RestructuringPlan1July2018Member_documentation_en-US" xlink:label="lab_nltx_RestructuringPlan1July2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan 1 July 2018 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_RestructuringPlan1July2018Member" xlink:href="nltx-20201231.xsd#nltx_RestructuringPlan1July2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_RestructuringPlan1July2018Member" xlink:to="lab_nltx_RestructuringPlan1July2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_603a2219-e0d2-48f2-887c-d615cc1a6e23_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Activity, Additional Disclosure</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_234c7674-13d3-43e3-800a-874e1487f5c8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, Weighted average remaining contractual life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_14852eba-e8a0-4e38-adbb-7bb5ccf45cf7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember_71db2ed1-50d8-4519-86da-8e253abfbae0_terseLabel_en-US" xlink:label="lab_nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space, principal executive offices and laboratory</link:label>
    <link:label id="lab_nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember_label_en-US" xlink:label="lab_nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space, Principal Executive Offices and Laboratory [Member]</link:label>
    <link:label id="lab_nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember_documentation_en-US" xlink:label="lab_nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space, Principal Executive Offices and Laboratory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember" xlink:href="nltx-20201231.xsd#nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember" xlink:to="lab_nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_23ef9820-bb83-45fe-9308-4401bc7a066d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_ce555c40-b1dd-469e-aa33-aedce568edb0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_6213db1a-82b5-4f06-91d9-335c8d1618e8_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_32a6bd88-2d35-46b6-9953-e484e9fb2497_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_eab06f4b-45dd-4a60-a6dd-c5db44e5dd49_terseLabel_en-US" xlink:label="lab_nltx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information Related to Leases</link:label>
    <link:label id="lab_nltx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_label_en-US" xlink:label="lab_nltx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Supplemental Balance Sheet Information Related To Leases [Table Text Block]</link:label>
    <link:label id="lab_nltx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_documentation_en-US" xlink:label="lab_nltx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of supplemental balance sheet information related to leases for the periods presented.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:href="nltx-20201231.xsd#nltx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:to="lab_nltx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e54d12e5-c589-47c4-add8-2ae2b67bbd7d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2f690baa-727e-4ee9-afe4-c2fcd81ab0c7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_74cc90d3-582b-488b-8880-23ab3269f9ef_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common stock</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_251912f6-cec1-4924-826c-c634a6a56ab1_terseLabel_en-US" xlink:label="lab_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP offering period</link:label>
    <link:label id="lab_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_label_en-US" xlink:label="lab_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</link:label>
    <link:label id="lab_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_documentation_en-US" xlink:label="lab_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:href="nltx-20201231.xsd#nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:to="lab_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4f224599-be80-44ff-9792-289b4ae1264e_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_92924f79-ccf8-475a-a615-26e17192a38d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_e6cc4151-d69e-466f-822e-8ea6268afd6f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_040b9701-0e57-4c9f-ba88-9b599d36739e_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory federal income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_34c96ca9-6d20-49f0-8dc5-9a612bebd54b_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_3a33b0ff-ee82-4f7f-9c7a-a8f768ad8f18_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_99ffc07d-ec3d-4e73-8665-f3a0a4dd3a27_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_c1c9f000-6ea8-40a3-8ea9-7135ae77ee32_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1f84f281-6d27-4c90-9e3e-92bba206dbc4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently issued and recently adopted accounting standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_b6f851bf-634f-4fe3-99ad-8002680ed44f_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_76eaef66-c7c8-4b27-8600-2f72c518f78b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>nltx-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:6019b606-66e1-49bc-8c33-d6cc15ba3335,g:b750dab7-5d48-4ebb-bb7b-41a017d885d1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CoverPage" xlink:type="simple" xlink:href="nltx-20201231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1487a576-73fa-49f0-9f59-4a63757702f3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_DocumentType_1487a576-73fa-49f0-9f59-4a63757702f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_6783da0f-f65b-4379-993c-c8bf255bd573" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_DocumentAnnualReport_6783da0f-f65b-4379-993c-c8bf255bd573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e0d6b02b-2048-4b89-aee9-66ba14b98fdc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_DocumentPeriodEndDate_e0d6b02b-2048-4b89-aee9-66ba14b98fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_d7270b51-3bd3-44d7-9dc9-07eafab7cec0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_CurrentFiscalYearEndDate_d7270b51-3bd3-44d7-9dc9-07eafab7cec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_a2aec764-1ac8-4b31-b9c1-a1959f856751" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_DocumentTransitionReport_a2aec764-1ac8-4b31-b9c1-a1959f856751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_39b326e4-27c1-44c2-8f18-e17ee0d375db" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_EntityFileNumber_39b326e4-27c1-44c2-8f18-e17ee0d375db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_740bed62-6275-423a-a3c4-bdeeedeb686c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_EntityRegistrantName_740bed62-6275-423a-a3c4-bdeeedeb686c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5a5b26e0-b395-4999-9504-9be20a3c3565" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5a5b26e0-b395-4999-9504-9be20a3c3565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_179e9e59-ab84-4a1c-bc3d-e655f3207ff3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_EntityTaxIdentificationNumber_179e9e59-ab84-4a1c-bc3d-e655f3207ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_51edb5dd-33a1-4f61-9425-07b0e0750439" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_EntityAddressAddressLine1_51edb5dd-33a1-4f61-9425-07b0e0750439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_5dc3be43-ed8d-468d-93e8-61952f7ab5b5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_EntityAddressCityOrTown_5dc3be43-ed8d-468d-93e8-61952f7ab5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_179caafe-cfd9-449a-b4d4-38b01abbcdc5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_EntityAddressStateOrProvince_179caafe-cfd9-449a-b4d4-38b01abbcdc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_66b2cb91-22c9-49b2-be0d-2ee707e81147" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_EntityAddressPostalZipCode_66b2cb91-22c9-49b2-be0d-2ee707e81147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_1a4897be-39b2-42cb-8258-566a6a4804f0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_CityAreaCode_1a4897be-39b2-42cb-8258-566a6a4804f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_aff1f299-c5b8-4858-ab90-82147aaaaa89" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_LocalPhoneNumber_aff1f299-c5b8-4858-ab90-82147aaaaa89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_7561301f-62aa-4a39-a0a7-98368369eafa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_Security12bTitle_7561301f-62aa-4a39-a0a7-98368369eafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7eb8c65f-81b4-4882-adc0-57edf0159a07" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_TradingSymbol_7eb8c65f-81b4-4882-adc0-57edf0159a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c69ced2d-8e4d-4cbd-933e-ab999042874b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_SecurityExchangeName_c69ced2d-8e4d-4cbd-933e-ab999042874b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_b14d92e2-a111-4c50-b030-6591421b17c1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_b14d92e2-a111-4c50-b030-6591421b17c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_80f3fd83-b73d-4dda-af17-46a96efd9be8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_EntityVoluntaryFilers_80f3fd83-b73d-4dda-af17-46a96efd9be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_50f54e96-6b41-406d-a268-5bf6ea87886e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_EntityCurrentReportingStatus_50f54e96-6b41-406d-a268-5bf6ea87886e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_cbad72eb-e6a1-43b6-aaf7-80930ef417fa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_EntityInteractiveDataCurrent_cbad72eb-e6a1-43b6-aaf7-80930ef417fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_dfaa33f6-3f43-4a49-afb3-5c174ab7c2c9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_EntityFilerCategory_dfaa33f6-3f43-4a49-afb3-5c174ab7c2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_06608350-4a4a-4983-9589-1bde8cd142e7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_EntitySmallBusiness_06608350-4a4a-4983-9589-1bde8cd142e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ede7a6d1-dcd6-453e-b2bd-3a6259ab08d7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_EntityEmergingGrowthCompany_ede7a6d1-dcd6-453e-b2bd-3a6259ab08d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_e0fdaaf3-bee9-485f-9e40-c060c2bfb799" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_IcfrAuditorAttestationFlag_e0fdaaf3-bee9-485f-9e40-c060c2bfb799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_502bd0ca-f71f-44c7-bfbd-ed0fb5744196" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_EntityShellCompany_502bd0ca-f71f-44c7-bfbd-ed0fb5744196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_e204fa01-2ccd-4b28-9625-73b47713c34f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_EntityPublicFloat_e204fa01-2ccd-4b28-9625-73b47713c34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8161a858-b8f8-40d7-a683-3d9d805c6249" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_8161a858-b8f8-40d7-a683-3d9d805c6249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_27590d33-3280-422a-945d-437b63ff9a76" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_27590d33-3280-422a-945d-437b63ff9a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_73ebf195-1cef-4b83-8797-99a146c8a2e4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_AmendmentFlag_73ebf195-1cef-4b83-8797-99a146c8a2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_eb4c1245-1410-4042-88c4-9f7193e25d38" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_DocumentFiscalYearFocus_eb4c1245-1410-4042-88c4-9f7193e25d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_bc23ff49-43fb-4322-86de-4fae67229873" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_DocumentFiscalPeriodFocus_bc23ff49-43fb-4322-86de-4fae67229873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_394bf55a-3ded-4f20-90b2-702393cd8ba5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03580145-8f64-4e56-b9a4-3fa9614e9d49" xlink:to="loc_dei_EntityCentralIndexKey_394bf55a-3ded-4f20-90b2-702393cd8ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nltx-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9d144006-e61e-4f7c-8084-251f781252db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_317414c6-b373-4150-b987-cfe5a614f6e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9d144006-e61e-4f7c-8084-251f781252db" xlink:to="loc_us-gaap_AssetsAbstract_317414c6-b373-4150-b987-cfe5a614f6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_834bc54d-3548-45fc-af39-d9ab628a0803" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_317414c6-b373-4150-b987-cfe5a614f6e7" xlink:to="loc_us-gaap_AssetsCurrentAbstract_834bc54d-3548-45fc-af39-d9ab628a0803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_966920e1-8897-4ff5-9920-e106fbc58c2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_834bc54d-3548-45fc-af39-d9ab628a0803" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_966920e1-8897-4ff5-9920-e106fbc58c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_1dfd9382-f396-49ab-aa1a-4718b500e17e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_834bc54d-3548-45fc-af39-d9ab628a0803" xlink:to="loc_us-gaap_OtherAssetsCurrent_1dfd9382-f396-49ab-aa1a-4718b500e17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ff3eb2ba-6550-40c6-bc85-07a2c1e46b94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_834bc54d-3548-45fc-af39-d9ab628a0803" xlink:to="loc_us-gaap_AssetsCurrent_ff3eb2ba-6550-40c6-bc85-07a2c1e46b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_195266fb-b16e-4865-9c06-d33a2a787b61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_317414c6-b373-4150-b987-cfe5a614f6e7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_195266fb-b16e-4865-9c06-d33a2a787b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4f3f6822-cbf4-4da9-b389-188164502200" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_317414c6-b373-4150-b987-cfe5a614f6e7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4f3f6822-cbf4-4da9-b389-188164502200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0916e7c9-6dee-4a98-92e2-1174a0586cf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_317414c6-b373-4150-b987-cfe5a614f6e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0916e7c9-6dee-4a98-92e2-1174a0586cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b2ba2ee9-cce7-4d67-bbd2-26d60315172b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_317414c6-b373-4150-b987-cfe5a614f6e7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b2ba2ee9-cce7-4d67-bbd2-26d60315172b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1dc87ef5-a8a7-4cae-8123-a006cf8078be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_317414c6-b373-4150-b987-cfe5a614f6e7" xlink:to="loc_us-gaap_Assets_1dc87ef5-a8a7-4cae-8123-a006cf8078be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_14e5c031-0961-4c60-b645-70765b45971e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9d144006-e61e-4f7c-8084-251f781252db" xlink:to="loc_us-gaap_LiabilitiesAbstract_14e5c031-0961-4c60-b645-70765b45971e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_d5ddaa33-5d72-4fd8-b243-beefd93e3163" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_14e5c031-0961-4c60-b645-70765b45971e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_d5ddaa33-5d72-4fd8-b243-beefd93e3163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_a9e44e1f-ed1c-4546-95bd-94dcdc704cab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d5ddaa33-5d72-4fd8-b243-beefd93e3163" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_a9e44e1f-ed1c-4546-95bd-94dcdc704cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_913bde29-2c38-4c3d-ab5b-d3eb035723f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d5ddaa33-5d72-4fd8-b243-beefd93e3163" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_913bde29-2c38-4c3d-ab5b-d3eb035723f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_0b3f7f14-2e74-4d17-a9fd-f7fe5b25f77f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d5ddaa33-5d72-4fd8-b243-beefd93e3163" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_0b3f7f14-2e74-4d17-a9fd-f7fe5b25f77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7dd3c19a-81b5-411f-a3b7-d73b8d92ac25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d5ddaa33-5d72-4fd8-b243-beefd93e3163" xlink:to="loc_us-gaap_LiabilitiesCurrent_7dd3c19a-81b5-411f-a3b7-d73b8d92ac25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8e9a40dd-6634-40b4-b369-69fe632395ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_14e5c031-0961-4c60-b645-70765b45971e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8e9a40dd-6634-40b4-b369-69fe632395ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_dbea5f6f-bb3c-421f-ada3-34f108693a27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_14e5c031-0961-4c60-b645-70765b45971e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_dbea5f6f-bb3c-421f-ada3-34f108693a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0cb0c99b-f6b5-4a05-b418-10b3a1ab25a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_14e5c031-0961-4c60-b645-70765b45971e" xlink:to="loc_us-gaap_Liabilities_0cb0c99b-f6b5-4a05-b418-10b3a1ab25a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_d583cd3f-9cc1-461f-b98b-1b27d9e1d29d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9d144006-e61e-4f7c-8084-251f781252db" xlink:to="loc_us-gaap_StockholdersEquityAbstract_d583cd3f-9cc1-461f-b98b-1b27d9e1d29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_38241639-c84b-4ce0-a40d-5fe5b15ce474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d583cd3f-9cc1-461f-b98b-1b27d9e1d29d" xlink:to="loc_us-gaap_CommonStockValue_38241639-c84b-4ce0-a40d-5fe5b15ce474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_70ecde9f-59e5-4758-97e6-cb5d6c067242" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d583cd3f-9cc1-461f-b98b-1b27d9e1d29d" xlink:to="loc_us-gaap_PreferredStockValue_70ecde9f-59e5-4758-97e6-cb5d6c067242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f3ef9583-0daf-40f8-b4f9-3e1ef734fca3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d583cd3f-9cc1-461f-b98b-1b27d9e1d29d" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f3ef9583-0daf-40f8-b4f9-3e1ef734fca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f094edc8-71df-4959-b8a4-cd3131953d6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d583cd3f-9cc1-461f-b98b-1b27d9e1d29d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f094edc8-71df-4959-b8a4-cd3131953d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_22a06d83-c174-4105-b8d5-4ff87323493b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d583cd3f-9cc1-461f-b98b-1b27d9e1d29d" xlink:to="loc_us-gaap_StockholdersEquity_22a06d83-c174-4105-b8d5-4ff87323493b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6d4ad2fd-56f3-49df-8e7e-07a6184faed7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9d144006-e61e-4f7c-8084-251f781252db" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_6d4ad2fd-56f3-49df-8e7e-07a6184faed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nltx-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d88c8e9e-c678-4bef-ba68-732a73552177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_39880368-e8df-4106-86c4-20524a0fd3b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d88c8e9e-c678-4bef-ba68-732a73552177" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_39880368-e8df-4106-86c4-20524a0fd3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_390f1400-1725-48a9-9276-49949950d6e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d88c8e9e-c678-4bef-ba68-732a73552177" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_390f1400-1725-48a9-9276-49949950d6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e8c439ed-0f9b-4cbd-948c-f73a112738d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d88c8e9e-c678-4bef-ba68-732a73552177" xlink:to="loc_us-gaap_CommonStockSharesIssued_e8c439ed-0f9b-4cbd-948c-f73a112738d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_37da1766-8986-412d-9b94-8034fae9b8e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d88c8e9e-c678-4bef-ba68-732a73552177" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_37da1766-8986-412d-9b94-8034fae9b8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e15a0699-d867-4c82-b237-ef497ff4d59a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d88c8e9e-c678-4bef-ba68-732a73552177" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e15a0699-d867-4c82-b237-ef497ff4d59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a8b676cb-e89b-4194-9abb-b608e458ebba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d88c8e9e-c678-4bef-ba68-732a73552177" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a8b676cb-e89b-4194-9abb-b608e458ebba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_80469ca9-64f2-4b36-a7b0-9fe3047a6654" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d88c8e9e-c678-4bef-ba68-732a73552177" xlink:to="loc_us-gaap_PreferredStockSharesIssued_80469ca9-64f2-4b36-a7b0-9fe3047a6654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3b62aacb-b81c-42ad-80f8-deb9ae95bb4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d88c8e9e-c678-4bef-ba68-732a73552177" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3b62aacb-b81c-42ad-80f8-deb9ae95bb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="nltx-20201231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_830ad937-3b04-4a59-8d51-65643104cd1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_cf5e49af-22cb-48db-9fa1-c5dd27a1822c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_830ad937-3b04-4a59-8d51-65643104cd1d" xlink:to="loc_us-gaap_OperatingExpensesAbstract_cf5e49af-22cb-48db-9fa1-c5dd27a1822c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_677a3fa8-e468-48fd-a20f-54c1a27c1401" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cf5e49af-22cb-48db-9fa1-c5dd27a1822c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_677a3fa8-e468-48fd-a20f-54c1a27c1401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_0beed737-dd8b-4534-b644-ec9814640f85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cf5e49af-22cb-48db-9fa1-c5dd27a1822c" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_0beed737-dd8b-4534-b644-ec9814640f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_b87e2b6d-02c9-4765-8813-e17ea629bf75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cf5e49af-22cb-48db-9fa1-c5dd27a1822c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_b87e2b6d-02c9-4765-8813-e17ea629bf75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary_78a26913-2648-4159-836d-1db1bbf5ccf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cf5e49af-22cb-48db-9fa1-c5dd27a1822c" xlink:to="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary_78a26913-2648-4159-836d-1db1bbf5ccf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7568758d-f286-4aaa-b8b0-3c363dbfbc06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_cf5e49af-22cb-48db-9fa1-c5dd27a1822c" xlink:to="loc_us-gaap_OperatingIncomeLoss_7568758d-f286-4aaa-b8b0-3c363dbfbc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_054cd87d-e412-4e39-abe8-f6938dbdb4a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_830ad937-3b04-4a59-8d51-65643104cd1d" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_054cd87d-e412-4e39-abe8-f6938dbdb4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fad0b930-b4ec-492e-b7dd-6424394e5d88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_830ad937-3b04-4a59-8d51-65643104cd1d" xlink:to="loc_us-gaap_NetIncomeLoss_fad0b930-b4ec-492e-b7dd-6424394e5d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_237cb339-4698-4d69-b9f0-a85ddfed70ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_830ad937-3b04-4a59-8d51-65643104cd1d" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_237cb339-4698-4d69-b9f0-a85ddfed70ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3a4a8a84-73eb-46f0-a21b-dc880888ca84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_830ad937-3b04-4a59-8d51-65643104cd1d" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3a4a8a84-73eb-46f0-a21b-dc880888ca84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nltx-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f3fbed5d-17f6-4e83-938d-477f8de19381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d0f41822-6101-4576-b695-d3adfed8a50f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f3fbed5d-17f6-4e83-938d-477f8de19381" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d0f41822-6101-4576-b695-d3adfed8a50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_249bdb76-dee2-467d-81b4-de1f72e14df7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d0f41822-6101-4576-b695-d3adfed8a50f" xlink:to="loc_us-gaap_NetIncomeLoss_249bdb76-dee2-467d-81b4-de1f72e14df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_267cd34a-5483-42a2-b927-3fdb58d3febc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d0f41822-6101-4576-b695-d3adfed8a50f" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_267cd34a-5483-42a2-b927-3fdb58d3febc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_32aa38e4-cd84-4387-98a8-39f99721f9d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_267cd34a-5483-42a2-b927-3fdb58d3febc" xlink:to="loc_us-gaap_ShareBasedCompensation_32aa38e4-cd84-4387-98a8-39f99721f9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_ba6c3fe3-db16-4454-afac-257c38534f73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_267cd34a-5483-42a2-b927-3fdb58d3febc" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_ba6c3fe3-db16-4454-afac-257c38534f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_98cd94ff-7941-4e3f-9696-66d2e9d4acaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_267cd34a-5483-42a2-b927-3fdb58d3febc" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_98cd94ff-7941-4e3f-9696-66d2e9d4acaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_b3d09fff-ed68-4a75-8c28-d171981b8d80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_267cd34a-5483-42a2-b927-3fdb58d3febc" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_b3d09fff-ed68-4a75-8c28-d171981b8d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_5d098847-dd18-4e02-ba38-e53ae9d6ccd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_267cd34a-5483-42a2-b927-3fdb58d3febc" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_5d098847-dd18-4e02-ba38-e53ae9d6ccd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_WriteOffOfRightOfUseAssetUponLeaseTermination_226e1e71-2a8d-43b4-96c3-ca4c078bcbb2" xlink:href="nltx-20201231.xsd#nltx_WriteOffOfRightOfUseAssetUponLeaseTermination"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_267cd34a-5483-42a2-b927-3fdb58d3febc" xlink:to="loc_nltx_WriteOffOfRightOfUseAssetUponLeaseTermination_226e1e71-2a8d-43b4-96c3-ca4c078bcbb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_f06e42be-58e0-4cab-bb95-bfb123f4d649" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_267cd34a-5483-42a2-b927-3fdb58d3febc" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_f06e42be-58e0-4cab-bb95-bfb123f4d649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6d18280a-a37b-46d4-9ca1-6bf1c7d50b98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d0f41822-6101-4576-b695-d3adfed8a50f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6d18280a-a37b-46d4-9ca1-6bf1c7d50b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_14c8ddce-3975-47b6-8379-a48016f98dc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6d18280a-a37b-46d4-9ca1-6bf1c7d50b98" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_14c8ddce-3975-47b6-8379-a48016f98dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_b6487f76-bd39-4f74-b130-2c5966b39c78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6d18280a-a37b-46d4-9ca1-6bf1c7d50b98" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_b6487f76-bd39-4f74-b130-2c5966b39c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_a3f38d87-b598-481a-8a87-49290373605a" xlink:href="nltx-20201231.xsd#nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6d18280a-a37b-46d4-9ca1-6bf1c7d50b98" xlink:to="loc_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_a3f38d87-b598-481a-8a87-49290373605a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_IncreaseDecreaseInOperatingLeaseLiabilities_04858625-5429-4e2d-a415-696992ab82c6" xlink:href="nltx-20201231.xsd#nltx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6d18280a-a37b-46d4-9ca1-6bf1c7d50b98" xlink:to="loc_nltx_IncreaseDecreaseInOperatingLeaseLiabilities_04858625-5429-4e2d-a415-696992ab82c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b13588a3-e8d1-4b5b-a17a-e5f7c94a4359" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d0f41822-6101-4576-b695-d3adfed8a50f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b13588a3-e8d1-4b5b-a17a-e5f7c94a4359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9c48011-981c-4ffb-a260-926763457210" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f3fbed5d-17f6-4e83-938d-477f8de19381" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9c48011-981c-4ffb-a260-926763457210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsNetCashAcquired_fe6d11f1-eac4-4c2a-88a7-fde631ea32bd" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsNetCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9c48011-981c-4ffb-a260-926763457210" xlink:to="loc_nltx_AcquisitionOfAssetsNetCashAcquired_fe6d11f1-eac4-4c2a-88a7-fde631ea32bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0cb0dfb6-bfea-40e9-bdeb-707a4d456110" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9c48011-981c-4ffb-a260-926763457210" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0cb0dfb6-bfea-40e9-bdeb-707a4d456110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c443a872-c98b-4be5-b047-698ad1278039" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9c48011-981c-4ffb-a260-926763457210" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c443a872-c98b-4be5-b047-698ad1278039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_875800eb-0f7e-4d87-908d-e4ad546b541c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f3fbed5d-17f6-4e83-938d-477f8de19381" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_875800eb-0f7e-4d87-908d-e4ad546b541c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_55048cd8-ecc4-4716-9b6a-e13a5063ad1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_875800eb-0f7e-4d87-908d-e4ad546b541c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_55048cd8-ecc4-4716-9b6a-e13a5063ad1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_9a94b063-ec87-4b40-9d7d-51832e4ed208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_875800eb-0f7e-4d87-908d-e4ad546b541c" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_9a94b063-ec87-4b40-9d7d-51832e4ed208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_8cf382f9-4296-4966-9745-e81bf51696a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_875800eb-0f7e-4d87-908d-e4ad546b541c" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_8cf382f9-4296-4966-9745-e81bf51696a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_426983cf-6d33-4a16-9fcd-0b0a5765bc19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_875800eb-0f7e-4d87-908d-e4ad546b541c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_426983cf-6d33-4a16-9fcd-0b0a5765bc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_11ec0039-3759-4ae0-ae6d-8c2323073ec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_875800eb-0f7e-4d87-908d-e4ad546b541c" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_11ec0039-3759-4ae0-ae6d-8c2323073ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_baf872af-8e97-437b-891e-2dfbaf429040" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_875800eb-0f7e-4d87-908d-e4ad546b541c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_baf872af-8e97-437b-891e-2dfbaf429040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6f97fc51-4e7d-4a0c-863a-0ac225a55f92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f3fbed5d-17f6-4e83-938d-477f8de19381" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6f97fc51-4e7d-4a0c-863a-0ac225a55f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fdc5485b-a909-42a4-942b-1b8469c5a0f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f3fbed5d-17f6-4e83-938d-477f8de19381" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fdc5485b-a909-42a4-942b-1b8469c5a0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ab1fda92-89ae-4a74-91b3-c0322e4bf6da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f3fbed5d-17f6-4e83-938d-477f8de19381" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ab1fda92-89ae-4a74-91b3-c0322e4bf6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b96196da-1d60-4929-9483-5826aefa9c43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f3fbed5d-17f6-4e83-938d-477f8de19381" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b96196da-1d60-4929-9483-5826aefa9c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0db227d3-b8a5-47ed-97d6-43eb9c81b4c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f3fbed5d-17f6-4e83-938d-477f8de19381" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0db227d3-b8a5-47ed-97d6-43eb9c81b4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_OtherCurrentAssetsAcquiredThroughTheIssuanceOfCommonStock_bafd1be0-e284-4d3b-81f8-b4a82dd7d32c" xlink:href="nltx-20201231.xsd#nltx_OtherCurrentAssetsAcquiredThroughTheIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0db227d3-b8a5-47ed-97d6-43eb9c81b4c7" xlink:to="loc_nltx_OtherCurrentAssetsAcquiredThroughTheIssuanceOfCommonStock_bafd1be0-e284-4d3b-81f8-b4a82dd7d32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock_97e49fdc-89db-4563-aed1-4efa3f6d5669" xlink:href="nltx-20201231.xsd#nltx_PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0db227d3-b8a5-47ed-97d6-43eb9c81b4c7" xlink:to="loc_nltx_PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock_97e49fdc-89db-4563-aed1-4efa3f6d5669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1_459173c9-4465-4f54-87ec-d44527161bd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0db227d3-b8a5-47ed-97d6-43eb9c81b4c7" xlink:to="loc_us-gaap_LiabilitiesAssumed1_459173c9-4465-4f54-87ec-d44527161bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_af81636e-78e3-4ab4-99d5-5143dc3880da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0db227d3-b8a5-47ed-97d6-43eb9c81b4c7" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_af81636e-78e3-4ab4-99d5-5143dc3880da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c2bea1ff-ea25-441c-9cd6-9a0695506840" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0db227d3-b8a5-47ed-97d6-43eb9c81b4c7" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c2bea1ff-ea25-441c-9cd6-9a0695506840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="nltx-20201231.xsd#ConsolidatedStatementsofCashFlowsParenthetical"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_3d80f5d1-ff86-45bb-93af-ce696b769af4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_CommissionsOnPublicOffering_c1fe0c92-a3e8-49ee-8d21-895f26e27b90" xlink:href="nltx-20201231.xsd#nltx_CommissionsOnPublicOffering"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d80f5d1-ff86-45bb-93af-ce696b769af4" xlink:to="loc_nltx_CommissionsOnPublicOffering_c1fe0c92-a3e8-49ee-8d21-895f26e27b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nltx-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_983253b4-c5c7-4b48-a00e-7e2d7f0400e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_86ff619e-c21d-4c85-a6bd-cd58fbb1b93c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_983253b4-c5c7-4b48-a00e-7e2d7f0400e5" xlink:to="loc_us-gaap_StatementTable_86ff619e-c21d-4c85-a6bd-cd58fbb1b93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_04aa4728-5c00-4b51-992f-24ca2b623a4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_86ff619e-c21d-4c85-a6bd-cd58fbb1b93c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_04aa4728-5c00-4b51-992f-24ca2b623a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_578ee1b0-3238-47e7-a61c-ab6cac3b968d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_04aa4728-5c00-4b51-992f-24ca2b623a4a" xlink:to="loc_us-gaap_EquityComponentDomain_578ee1b0-3238-47e7-a61c-ab6cac3b968d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_037d2744-b130-4f77-afac-22e2055ea1e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_578ee1b0-3238-47e7-a61c-ab6cac3b968d" xlink:to="loc_us-gaap_CommonStockMember_037d2744-b130-4f77-afac-22e2055ea1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4c9b6ede-01f2-4daf-868f-641de0eabba5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_578ee1b0-3238-47e7-a61c-ab6cac3b968d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4c9b6ede-01f2-4daf-868f-641de0eabba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d415526b-1900-44bf-9566-0307a7d25358" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_578ee1b0-3238-47e7-a61c-ab6cac3b968d" xlink:to="loc_us-gaap_RetainedEarningsMember_d415526b-1900-44bf-9566-0307a7d25358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_baaa87a1-b871-48fb-b4d1-cfd3a4e1b8af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_86ff619e-c21d-4c85-a6bd-cd58fbb1b93c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_baaa87a1-b871-48fb-b4d1-cfd3a4e1b8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d9e9cbc8-422d-4bb5-bcef-1aea435fc64a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_baaa87a1-b871-48fb-b4d1-cfd3a4e1b8af" xlink:to="loc_us-gaap_ClassOfStockDomain_d9e9cbc8-422d-4bb5-bcef-1aea435fc64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_NonVotingConvertiblePreferredStockMember_c745d9ce-43bf-4dfc-8921-0d5d8fea5d14" xlink:href="nltx-20201231.xsd#nltx_NonVotingConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d9e9cbc8-422d-4bb5-bcef-1aea435fc64a" xlink:to="loc_nltx_NonVotingConvertiblePreferredStockMember_c745d9ce-43bf-4dfc-8921-0d5d8fea5d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_74539f33-5c71-4d05-86b5-4f9eb4f73ba8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_86ff619e-c21d-4c85-a6bd-cd58fbb1b93c" xlink:to="loc_us-gaap_StatementLineItems_74539f33-5c71-4d05-86b5-4f9eb4f73ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_74539f33-5c71-4d05-86b5-4f9eb4f73ba8" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_9136f30c-5cb0-4374-8c03-99cb308bbaf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_SharesOutstanding_9136f30c-5cb0-4374-8c03-99cb308bbaf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_34cf7246-c08a-45e1-8226-dc41a7dc663d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockholdersEquity_34cf7246-c08a-45e1-8226-dc41a7dc663d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_bc4c3552-7406-4917-98f5-f1976062876f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_bc4c3552-7406-4917-98f5-f1976062876f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_3ca74839-c49d-49ea-b532-77eb2811af62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_3ca74839-c49d-49ea-b532-77eb2811af62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_427fbe85-1ac4-49a5-8e95-a8640ca3a62f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_427fbe85-1ac4-49a5-8e95-a8640ca3a62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a544dd48-eda0-45e5-a1a1-ea00ef9334e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a544dd48-eda0-45e5-a1a1-ea00ef9334e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_474e31cc-8b54-4ce6-ac6c-5c94742e8bcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_474e31cc-8b54-4ce6-ac6c-5c94742e8bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_e69e6935-e1af-407c-87af-494143c6e25c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_e69e6935-e1af-407c-87af-494143c6e25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_24cdaa10-48ad-4c0d-93e5-833e6ee034ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_24cdaa10-48ad-4c0d-93e5-833e6ee034ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants_c2f384e1-ee6d-405c-8fa9-e7d8f7aaad96" xlink:href="nltx-20201231.xsd#nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants_c2f384e1-ee6d-405c-8fa9-e7d8f7aaad96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a1514162-f04f-4891-8ded-d9dae22b4936" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a1514162-f04f-4891-8ded-d9dae22b4936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ca3596d5-1c49-4b7d-98ec-43689209b90b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ca3596d5-1c49-4b7d-98ec-43689209b90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f54944ea-5754-4f58-8322-a9b07d964065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f54944ea-5754-4f58-8322-a9b07d964065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_818b9cbd-5a5f-4fac-a3c8-2ff42f952da0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_818b9cbd-5a5f-4fac-a3c8-2ff42f952da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_16363db3-09e9-4a39-b3b7-b3f11d7e97ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_16363db3-09e9-4a39-b3b7-b3f11d7e97ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a92301c8-a66f-471d-b0f1-2b150d0e0b5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a92301c8-a66f-471d-b0f1-2b150d0e0b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a143f083-0685-4b0f-a1d7-b02ce6c2e55f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_NetIncomeLoss_a143f083-0685-4b0f-a1d7-b02ce6c2e55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_d76f20e6-5add-4797-b313-9ebbdb0a7ff6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_SharesOutstanding_d76f20e6-5add-4797-b313-9ebbdb0a7ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a1758e32-2b20-4bf0-ae6d-f83046178a64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0bd1e9a1-f5f8-4775-ae5a-b09277c5cd96" xlink:to="loc_us-gaap_StockholdersEquity_a1758e32-2b20-4bf0-ae6d-f83046178a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="nltx-20201231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_39ed45da-9f95-4fb4-83af-4571a8640941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_df88e876-581d-4fed-af2d-7e95dcf5ddc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_39ed45da-9f95-4fb4-83af-4571a8640941" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_df88e876-581d-4fed-af2d-7e95dcf5ddc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Natureofoperations" xlink:type="simple" xlink:href="nltx-20201231.xsd#Natureofoperations"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/Natureofoperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8ea5c561-2453-4363-8b88-6db7b244fb2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_f046b594-e1c0-4034-bced-3ef1f8a74fa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8ea5c561-2453-4363-8b88-6db7b244fb2b" xlink:to="loc_us-gaap_NatureOfOperations_f046b594-e1c0-4034-bced-3ef1f8a74fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies" xlink:type="simple" xlink:href="nltx-20201231.xsd#Basisofpresentationandsummaryofsignificantaccountingpolicies"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ef3ce693-63b3-456d-8d64-829b5ac77f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_30185c35-3eac-49a3-b2ab-86f657fd8f18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ef3ce693-63b3-456d-8d64-829b5ac77f5f" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_30185c35-3eac-49a3-b2ab-86f657fd8f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#BasisofpresentationandsummaryofsignificantaccountingpoliciesTables"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6fe4d27a-33f8-4acd-a856-db54a9a85c82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_bd785a2c-8716-4b2f-b78b-1e50ffbc5195" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6fe4d27a-33f8-4acd-a856-db54a9a85c82" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_bd785a2c-8716-4b2f-b78b-1e50ffbc5195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_30db29f9-8a08-4344-a2b4-e6562393eff1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6fe4d27a-33f8-4acd-a856-db54a9a85c82" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_30db29f9-8a08-4344-a2b4-e6562393eff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="nltx-20201231.xsd#BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6a6b421c-2037-4b41-aab0-3c719fc8c557" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3b0a99c2-213f-4a0d-bfb4-ad7d1f0b384c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a6b421c-2037-4b41-aab0-3c719fc8c557" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3b0a99c2-213f-4a0d-bfb4-ad7d1f0b384c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_fc92ed6c-bb3e-402f-8817-cb1d38bc08cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a6b421c-2037-4b41-aab0-3c719fc8c557" xlink:to="loc_us-gaap_UseOfEstimates_fc92ed6c-bb3e-402f-8817-cb1d38bc08cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_5ad169df-1271-4f90-b9c7-8aea889c479c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a6b421c-2037-4b41-aab0-3c719fc8c557" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_5ad169df-1271-4f90-b9c7-8aea889c479c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_e8cb23af-8e80-4816-a7df-692c7d998e1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a6b421c-2037-4b41-aab0-3c719fc8c557" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_e8cb23af-8e80-4816-a7df-692c7d998e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0b4a5854-3a3f-4848-abe7-7feae6a8c112" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a6b421c-2037-4b41-aab0-3c719fc8c557" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0b4a5854-3a3f-4848-abe7-7feae6a8c112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_a615ecd9-af57-43ed-8151-e976437cba12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a6b421c-2037-4b41-aab0-3c719fc8c557" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_a615ecd9-af57-43ed-8151-e976437cba12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_9c2f8e6d-47e8-4038-bc0a-c7747b1fce13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a6b421c-2037-4b41-aab0-3c719fc8c557" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_9c2f8e6d-47e8-4038-bc0a-c7747b1fce13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AssetAcquisitionsintangibleAssetsPolicyTextBlock_b2fd9eee-27cf-4958-9888-40d46e721df1" xlink:href="nltx-20201231.xsd#nltx_AssetAcquisitionsintangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a6b421c-2037-4b41-aab0-3c719fc8c557" xlink:to="loc_nltx_AssetAcquisitionsintangibleAssetsPolicyTextBlock_b2fd9eee-27cf-4958-9888-40d46e721df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_efc43cb1-7df1-46be-90c5-8cd48fcd5649" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a6b421c-2037-4b41-aab0-3c719fc8c557" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_efc43cb1-7df1-46be-90c5-8cd48fcd5649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5983cd2b-aa62-4738-810d-f2deb7fd3620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a6b421c-2037-4b41-aab0-3c719fc8c557" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5983cd2b-aa62-4738-810d-f2deb7fd3620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8163c0a7-aeb4-49f9-b114-d3ea7a7be52e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a6b421c-2037-4b41-aab0-3c719fc8c557" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8163c0a7-aeb4-49f9-b114-d3ea7a7be52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_24ca7219-e017-4ce2-9508-67626820cfb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a6b421c-2037-4b41-aab0-3c719fc8c557" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_24ca7219-e017-4ce2-9508-67626820cfb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_48d8b509-72f2-464d-bfe8-04f4dcf47e57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a6b421c-2037-4b41-aab0-3c719fc8c557" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_48d8b509-72f2-464d-bfe8-04f4dcf47e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_de1f8225-cb93-41dc-9332-b88e2a5ae1d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a6b421c-2037-4b41-aab0-3c719fc8c557" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_de1f8225-cb93-41dc-9332-b88e2a5ae1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_caff0a65-e87e-4c6e-bac2-0ab6ec37a89c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a6b421c-2037-4b41-aab0-3c719fc8c557" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_caff0a65-e87e-4c6e-bac2-0ab6ec37a89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d07ab9d0-9929-4abb-8142-3fe03a738883" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6a6b421c-2037-4b41-aab0-3c719fc8c557" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d07ab9d0-9929-4abb-8142-3fe03a738883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ce443545-befa-4a8f-87a1-dbefad53674a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_SignificantAccountingPoliciesTable_10a12aa1-1bb2-4c33-af35-343110c81724" xlink:href="nltx-20201231.xsd#nltx_SignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ce443545-befa-4a8f-87a1-dbefad53674a" xlink:to="loc_nltx_SignificantAccountingPoliciesTable_10a12aa1-1bb2-4c33-af35-343110c81724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c449831d-fb53-4238-a658-6ba26a2ea208" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_SignificantAccountingPoliciesTable_10a12aa1-1bb2-4c33-af35-343110c81724" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c449831d-fb53-4238-a658-6ba26a2ea208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_242f8116-5f8d-4b57-b961-dda5ddf80f39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c449831d-fb53-4238-a658-6ba26a2ea208" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_242f8116-5f8d-4b57-b961-dda5ddf80f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember_13b02f0c-7806-41fd-b953-2e810e26ddcc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OfficeBuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_242f8116-5f8d-4b57-b961-dda5ddf80f39" xlink:to="loc_srt_OfficeBuildingMember_13b02f0c-7806-41fd-b953-2e810e26ddcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ba5a7a95-c23d-4a26-8d69-321fd68304c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_SignificantAccountingPoliciesTable_10a12aa1-1bb2-4c33-af35-343110c81724" xlink:to="loc_srt_RangeAxis_ba5a7a95-c23d-4a26-8d69-321fd68304c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_566a76bf-fec1-4d19-9ac6-be4ce8abdb9b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ba5a7a95-c23d-4a26-8d69-321fd68304c0" xlink:to="loc_srt_RangeMember_566a76bf-fec1-4d19-9ac6-be4ce8abdb9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3b0d6f29-49c4-4a21-ac2f-d79ef92b7424" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_566a76bf-fec1-4d19-9ac6-be4ce8abdb9b" xlink:to="loc_srt_MinimumMember_3b0d6f29-49c4-4a21-ac2f-d79ef92b7424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fa4fa825-90c9-4ade-9a19-a93fc68ab291" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_566a76bf-fec1-4d19-9ac6-be4ce8abdb9b" xlink:to="loc_srt_MaximumMember_fa4fa825-90c9-4ade-9a19-a93fc68ab291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_36c0e914-9528-48de-9248-cb0b1547459e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_SignificantAccountingPoliciesTable_10a12aa1-1bb2-4c33-af35-343110c81724" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_36c0e914-9528-48de-9248-cb0b1547459e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_448fdc76-cf2e-4e51-aeef-75dfb5931780" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_36c0e914-9528-48de-9248-cb0b1547459e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_448fdc76-cf2e-4e51-aeef-75dfb5931780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_73204ffa-0dc4-4e86-83c6-2f27c6c0ceb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_448fdc76-cf2e-4e51-aeef-75dfb5931780" xlink:to="loc_us-gaap_MoneyMarketFundsMember_73204ffa-0dc4-4e86-83c6-2f27c6c0ceb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_SignificantAccountingPoliciesLineItems_022857e3-f6a7-468c-ad39-0beba973ec2c" xlink:href="nltx-20201231.xsd#nltx_SignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_SignificantAccountingPoliciesTable_10a12aa1-1bb2-4c33-af35-343110c81724" xlink:to="loc_nltx_SignificantAccountingPoliciesLineItems_022857e3-f6a7-468c-ad39-0beba973ec2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6bcaf886-00e7-4222-abab-7f85c15515c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_SignificantAccountingPoliciesLineItems_022857e3-f6a7-468c-ad39-0beba973ec2c" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_6bcaf886-00e7-4222-abab-7f85c15515c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3eb78200-3b94-42f0-ac52-0112589865d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_SignificantAccountingPoliciesLineItems_022857e3-f6a7-468c-ad39-0beba973ec2c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3eb78200-3b94-42f0-ac52-0112589865d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_3f540be3-cbbf-4302-842a-4fdff873b4b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_SignificantAccountingPoliciesLineItems_022857e3-f6a7-468c-ad39-0beba973ec2c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_3f540be3-cbbf-4302-842a-4fdff873b4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_59d5432b-002b-446e-b46a-8b9d32e54596" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_SignificantAccountingPoliciesLineItems_022857e3-f6a7-468c-ad39-0beba973ec2c" xlink:to="loc_us-gaap_NumberOfOperatingSegments_59d5432b-002b-446e-b46a-8b9d32e54596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a3e52c60-4b62-4cce-b12c-b0064b7fd852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_SignificantAccountingPoliciesLineItems_022857e3-f6a7-468c-ad39-0beba973ec2c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a3e52c60-4b62-4cce-b12c-b0064b7fd852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesCashandcashequivalentsandrestrictedcashDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#BasisofpresentationandsummaryofsignificantaccountingpoliciesCashandcashequivalentsandrestrictedcashDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesCashandcashequivalentsandrestrictedcashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c1045985-cf0c-4df4-ae00-2c5179d69ede" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_282603ed-c0eb-4bc8-8235-674620e9426e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c1045985-cf0c-4df4-ae00-2c5179d69ede" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_282603ed-c0eb-4bc8-8235-674620e9426e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_fec4bcaa-b2b9-4736-a29f-b8f746bba87a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c1045985-cf0c-4df4-ae00-2c5179d69ede" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_fec4bcaa-b2b9-4736-a29f-b8f746bba87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a3cc3baf-9117-4266-b1c3-543bf963407a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c1045985-cf0c-4df4-ae00-2c5179d69ede" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a3cc3baf-9117-4266-b1c3-543bf963407a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsInc" xlink:type="simple" xlink:href="nltx-20201231.xsd#MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsInc"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsInc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsAbstract_423af33d-8943-4d9e-839f-c2c7f9b7b69c" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsDisclosureTextBlock_325da1fc-fe87-4bda-a155-ae66bf405e41" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsAbstract_423af33d-8943-4d9e-839f-c2c7f9b7b69c" xlink:to="loc_nltx_AcquisitionOfAssetsDisclosureTextBlock_325da1fc-fe87-4bda-a155-ae66bf405e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncTables"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsAbstract_7e3f30d4-3217-4288-a4a5-8852fe7932e4" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock_f13df819-01ae-4f42-9f24-5942e7fa08ba" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsAbstract_7e3f30d4-3217-4288-a4a5-8852fe7932e4" xlink:to="loc_nltx_AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock_f13df819-01ae-4f42-9f24-5942e7fa08ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_bc9f4163-3d34-4db9-a8d6-19b3bfa6830d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsAbstract_7e3f30d4-3217-4288-a4a5-8852fe7932e4" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_bc9f4163-3d34-4db9-a8d6-19b3bfa6830d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsAbstract_a0722809-2fc2-4979-a82a-97a370093105" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsTable_f364584b-a152-499d-9413-8eb7cf52368c" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsAbstract_a0722809-2fc2-4979-a82a-97a370093105" xlink:to="loc_nltx_AcquisitionOfAssetsTable_f364584b-a152-499d-9413-8eb7cf52368c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsAxis_02603bb6-baf4-4c96-bbcd-7db8b637bf33" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsTable_f364584b-a152-499d-9413-8eb7cf52368c" xlink:to="loc_nltx_AcquisitionOfAssetsAxis_02603bb6-baf4-4c96-bbcd-7db8b637bf33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsDomain_14c11126-a975-4bb3-8950-9c14892142d9" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsAxis_02603bb6-baf4-4c96-bbcd-7db8b637bf33" xlink:to="loc_nltx_AcquisitionOfAssetsDomain_14c11126-a975-4bb3-8950-9c14892142d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AquinoxMember_0aef0364-7e42-4594-8578-a507b94add92" xlink:href="nltx-20201231.xsd#nltx_AquinoxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsDomain_14c11126-a975-4bb3-8950-9c14892142d9" xlink:to="loc_nltx_AquinoxMember_0aef0364-7e42-4594-8578-a507b94add92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e7150dfb-bc53-4720-acd8-d90fb43fc004" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsTable_f364584b-a152-499d-9413-8eb7cf52368c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e7150dfb-bc53-4720-acd8-d90fb43fc004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ac94f9c4-ee47-42bb-a1df-229541aa2266" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e7150dfb-bc53-4720-acd8-d90fb43fc004" xlink:to="loc_us-gaap_ClassOfStockDomain_ac94f9c4-ee47-42bb-a1df-229541aa2266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_NonVotingConvertiblePreferredStockMember_dde08889-2a91-4365-bc5a-f85c7dea446a" xlink:href="nltx-20201231.xsd#nltx_NonVotingConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ac94f9c4-ee47-42bb-a1df-229541aa2266" xlink:to="loc_nltx_NonVotingConvertiblePreferredStockMember_dde08889-2a91-4365-bc5a-f85c7dea446a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b26e1e0c-2ada-479c-9dfd-4b496a422961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsTable_f364584b-a152-499d-9413-8eb7cf52368c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b26e1e0c-2ada-479c-9dfd-4b496a422961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_73413e38-2e31-49ab-ae51-9921ab21a278" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b26e1e0c-2ada-479c-9dfd-4b496a422961" xlink:to="loc_us-gaap_EquityComponentDomain_73413e38-2e31-49ab-ae51-9921ab21a278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ffb81b2f-9f68-466a-8675-65c8232ad3c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_73413e38-2e31-49ab-ae51-9921ab21a278" xlink:to="loc_us-gaap_CommonStockMember_ffb81b2f-9f68-466a-8675-65c8232ad3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5eb23d1b-0acd-4dad-b5e4-3c08cc2e8dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsTable_f364584b-a152-499d-9413-8eb7cf52368c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5eb23d1b-0acd-4dad-b5e4-3c08cc2e8dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b3c67d55-02bc-4dbd-aa3c-e276bd16e155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5eb23d1b-0acd-4dad-b5e4-3c08cc2e8dd4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b3c67d55-02bc-4dbd-aa3c-e276bd16e155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_8a9d972b-2038-4798-afa2-8bc754b87833" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b3c67d55-02bc-4dbd-aa3c-e276bd16e155" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_8a9d972b-2038-4798-afa2-8bc754b87833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1e0c20ba-9545-4728-bbfa-c83ab16202dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsTable_f364584b-a152-499d-9413-8eb7cf52368c" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1e0c20ba-9545-4728-bbfa-c83ab16202dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_d73da2f9-3bbc-4327-807e-ad92c3117530" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e0c20ba-9545-4728-bbfa-c83ab16202dd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_d73da2f9-3bbc-4327-807e-ad92c3117530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_5d17cb3b-baaf-4f09-acf0-812638042a53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e0c20ba-9545-4728-bbfa-c83ab16202dd" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_5d17cb3b-baaf-4f09-acf0-812638042a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsAbstract_9107e438-370c-48f7-8e60-5cff8a18c1c1" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsTable_2e5de5e3-c655-45fd-a837-f3dba5adf2a9" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsAbstract_9107e438-370c-48f7-8e60-5cff8a18c1c1" xlink:to="loc_nltx_AcquisitionOfAssetsTable_2e5de5e3-c655-45fd-a837-f3dba5adf2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_260656ab-50f1-438e-bba8-252066454b48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsTable_2e5de5e3-c655-45fd-a837-f3dba5adf2a9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_260656ab-50f1-438e-bba8-252066454b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6bcd58aa-6151-46c3-b2a9-8c9fd52b143b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_260656ab-50f1-438e-bba8-252066454b48" xlink:to="loc_us-gaap_EquityComponentDomain_6bcd58aa-6151-46c3-b2a9-8c9fd52b143b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5e101f8f-0321-45b9-9081-347d6bc08166" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6bcd58aa-6151-46c3-b2a9-8c9fd52b143b" xlink:to="loc_us-gaap_CommonStockMember_5e101f8f-0321-45b9-9081-347d6bc08166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_65d6e8a7-8989-4b62-9b93-149cb1ef07c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsTable_2e5de5e3-c655-45fd-a837-f3dba5adf2a9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_65d6e8a7-8989-4b62-9b93-149cb1ef07c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5fb31a9b-55ac-492c-88f0-7552d7eb9f4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_65d6e8a7-8989-4b62-9b93-149cb1ef07c5" xlink:to="loc_us-gaap_ClassOfStockDomain_5fb31a9b-55ac-492c-88f0-7552d7eb9f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_df0693a9-9416-4669-8024-1a32eb6cedd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5fb31a9b-55ac-492c-88f0-7552d7eb9f4f" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_df0693a9-9416-4669-8024-1a32eb6cedd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_NonVotingConvertiblePreferredStockMember_a259c58e-1a76-427d-8142-e52983edac4e" xlink:href="nltx-20201231.xsd#nltx_NonVotingConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5fb31a9b-55ac-492c-88f0-7552d7eb9f4f" xlink:to="loc_nltx_NonVotingConvertiblePreferredStockMember_a259c58e-1a76-427d-8142-e52983edac4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsAxis_d8af1656-b5bb-4643-beae-77b9fea31a21" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsTable_2e5de5e3-c655-45fd-a837-f3dba5adf2a9" xlink:to="loc_nltx_AcquisitionOfAssetsAxis_d8af1656-b5bb-4643-beae-77b9fea31a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsDomain_b0f59593-27cf-49e0-9b4b-2215f9a627ee" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsAxis_d8af1656-b5bb-4643-beae-77b9fea31a21" xlink:to="loc_nltx_AcquisitionOfAssetsDomain_b0f59593-27cf-49e0-9b4b-2215f9a627ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AquinoxMember_822d5f41-a354-443f-8a8e-6bc45be538dd" xlink:href="nltx-20201231.xsd#nltx_AquinoxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsDomain_b0f59593-27cf-49e0-9b4b-2215f9a627ee" xlink:to="loc_nltx_AquinoxMember_822d5f41-a354-443f-8a8e-6bc45be538dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b226ad37-73ca-4a34-b43d-dee7b1c8e35e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsTable_2e5de5e3-c655-45fd-a837-f3dba5adf2a9" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_b226ad37-73ca-4a34-b43d-dee7b1c8e35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionsOfAssetsFairValueOfSharesIssued_79d93186-a790-40fa-9601-f7ec9b972117" xlink:href="nltx-20201231.xsd#nltx_AcquisitionsOfAssetsFairValueOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b226ad37-73ca-4a34-b43d-dee7b1c8e35e" xlink:to="loc_nltx_AcquisitionsOfAssetsFairValueOfSharesIssued_79d93186-a790-40fa-9601-f7ec9b972117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionsOfAssetsCashConsiderationForFractionalShares_99c1f78f-99b8-42ac-b0c2-10442be90367" xlink:href="nltx-20201231.xsd#nltx_AcquisitionsOfAssetsCashConsiderationForFractionalShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b226ad37-73ca-4a34-b43d-dee7b1c8e35e" xlink:to="loc_nltx_AcquisitionsOfAssetsCashConsiderationForFractionalShares_99c1f78f-99b8-42ac-b0c2-10442be90367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionsOfAssetsTransactionCosts_ccdd99bb-cf1b-4409-85a2-9d058e0cbc1e" xlink:href="nltx-20201231.xsd#nltx_AcquisitionsOfAssetsTransactionCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b226ad37-73ca-4a34-b43d-dee7b1c8e35e" xlink:to="loc_nltx_AcquisitionsOfAssetsTransactionCosts_ccdd99bb-cf1b-4409-85a2-9d058e0cbc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionsOfAssetsConsiderationTransferred_4bf9327e-7abf-4073-8b9a-2db7dab2a0ba" xlink:href="nltx-20201231.xsd#nltx_AcquisitionsOfAssetsConsiderationTransferred"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b226ad37-73ca-4a34-b43d-dee7b1c8e35e" xlink:to="loc_nltx_AcquisitionsOfAssetsConsiderationTransferred_4bf9327e-7abf-4073-8b9a-2db7dab2a0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_60ab0255-246c-4391-a8a0-1541902a91a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b226ad37-73ca-4a34-b43d-dee7b1c8e35e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_60ab0255-246c-4391-a8a0-1541902a91a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsAbstract_8bb7ba27-1183-43fb-8fe3-53a4f5a26f91" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsTable_e34bc850-eaea-4b6a-8152-d1bb43cf6c81" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsAbstract_8bb7ba27-1183-43fb-8fe3-53a4f5a26f91" xlink:to="loc_nltx_AcquisitionOfAssetsTable_e34bc850-eaea-4b6a-8152-d1bb43cf6c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsAxis_f26d5c30-636e-4f5a-9467-7fb1e621f69b" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsTable_e34bc850-eaea-4b6a-8152-d1bb43cf6c81" xlink:to="loc_nltx_AcquisitionOfAssetsAxis_f26d5c30-636e-4f5a-9467-7fb1e621f69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsDomain_623c7787-e017-4cee-b199-64c13742a5e0" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsAxis_f26d5c30-636e-4f5a-9467-7fb1e621f69b" xlink:to="loc_nltx_AcquisitionOfAssetsDomain_623c7787-e017-4cee-b199-64c13742a5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AquinoxMember_591e53ce-c607-49ae-a8c3-dad39589b21d" xlink:href="nltx-20201231.xsd#nltx_AquinoxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsDomain_623c7787-e017-4cee-b199-64c13742a5e0" xlink:to="loc_nltx_AquinoxMember_591e53ce-c607-49ae-a8c3-dad39589b21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_def8d204-cf61-4689-994a-76a2e7273046" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsTable_e34bc850-eaea-4b6a-8152-d1bb43cf6c81" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_def8d204-cf61-4689-994a-76a2e7273046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract_1daa4abd-86d1-4f37-a346-8a1e0650eaa7" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_def8d204-cf61-4689-994a-76a2e7273046" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract_1daa4abd-86d1-4f37-a346-8a1e0650eaa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents_31430b50-e0d6-4e69-a834-dae1efda8bda" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract_1daa4abd-86d1-4f37-a346-8a1e0650eaa7" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents_31430b50-e0d6-4e69-a834-dae1efda8bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits_103f626e-b0ad-471b-bd75-5ffbc18feb04" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract_1daa4abd-86d1-4f37-a346-8a1e0650eaa7" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits_103f626e-b0ad-471b-bd75-5ffbc18feb04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment_5d47f4eb-ea88-4b7c-9b29-1998cfa9ae68" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract_1daa4abd-86d1-4f37-a346-8a1e0650eaa7" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment_5d47f4eb-ea88-4b7c-9b29-1998cfa9ae68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets_df6cadab-521c-491f-9c46-9b96be01dd9f" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract_1daa4abd-86d1-4f37-a346-8a1e0650eaa7" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets_df6cadab-521c-491f-9c46-9b96be01dd9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset_6982a497-be72-40a3-959d-8d666622a4f8" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract_1daa4abd-86d1-4f37-a346-8a1e0650eaa7" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset_6982a497-be72-40a3-959d-8d666622a4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet_1651cae6-f186-491c-bdc6-7aa04ae6e079" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract_1daa4abd-86d1-4f37-a346-8a1e0650eaa7" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet_1651cae6-f186-491c-bdc6-7aa04ae6e079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract_859e989c-21b6-4a77-9285-d26231ca782d" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_def8d204-cf61-4689-994a-76a2e7273046" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract_859e989c-21b6-4a77-9285-d26231ca782d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities_24fe6f52-575c-4bbd-8f0b-716fa2111594" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract_859e989c-21b6-4a77-9285-d26231ca782d" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities_24fe6f52-575c-4bbd-8f0b-716fa2111594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability_0f11b068-f0a5-4a99-9a8d-eca1ca3196ff" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract_859e989c-21b6-4a77-9285-d26231ca782d" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability_0f11b068-f0a5-4a99-9a8d-eca1ca3196ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed_27ec48cc-0f75-4699-9b27-063a4a7bfc17" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract_859e989c-21b6-4a77-9285-d26231ca782d" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed_27ec48cc-0f75-4699-9b27-063a4a7bfc17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_809d83c3-c05d-4860-becf-bc7d6a6ae4b3" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_def8d204-cf61-4689-994a-76a2e7273046" xlink:to="loc_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_809d83c3-c05d-4860-becf-bc7d6a6ae4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Propertyandequipmentnet" xlink:type="simple" xlink:href="nltx-20201231.xsd#Propertyandequipmentnet"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/Propertyandequipmentnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c72a7a3c-257e-4d0c-b5b3-734bce089bb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_4de1a200-ed78-4ae7-a33f-64cd2b032f8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c72a7a3c-257e-4d0c-b5b3-734bce089bb9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_4de1a200-ed78-4ae7-a33f-64cd2b032f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/PropertyandequipmentnetTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#PropertyandequipmentnetTables"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/PropertyandequipmentnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ca68a3f2-ca87-46b2-843a-0bf07a311a76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_42f89b57-cc2f-4044-9631-92901cb78629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ca68a3f2-ca87-46b2-843a-0bf07a311a76" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_42f89b57-cc2f-4044-9631-92901cb78629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#PropertyandequipmentnetScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9e29a870-ead6-4703-bbed-27b39978cd95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d4b476f4-543c-4d31-8488-f64a819072de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9e29a870-ead6-4703-bbed-27b39978cd95" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d4b476f4-543c-4d31-8488-f64a819072de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7d75d37f-9a27-4bae-9737-df5612f660f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d4b476f4-543c-4d31-8488-f64a819072de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7d75d37f-9a27-4bae-9737-df5612f660f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_83aa278f-6bdb-41de-9e5f-8467b07a7de0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7d75d37f-9a27-4bae-9737-df5612f660f4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_83aa278f-6bdb-41de-9e5f-8467b07a7de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_7874713d-4752-4ff7-b94d-827851dfcbea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_83aa278f-6bdb-41de-9e5f-8467b07a7de0" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_7874713d-4752-4ff7-b94d-827851dfcbea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_LaboratoryEquipmentMember_b6a19afb-5620-41e6-8299-7940bd4ab25f" xlink:href="nltx-20201231.xsd#nltx_LaboratoryEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_83aa278f-6bdb-41de-9e5f-8467b07a7de0" xlink:to="loc_nltx_LaboratoryEquipmentMember_b6a19afb-5620-41e6-8299-7940bd4ab25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_FurnitureFixturesAndITEquipmentMember_62672387-73da-439b-b264-c54245ecca2d" xlink:href="nltx-20201231.xsd#nltx_FurnitureFixturesAndITEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_83aa278f-6bdb-41de-9e5f-8467b07a7de0" xlink:to="loc_nltx_FurnitureFixturesAndITEquipmentMember_62672387-73da-439b-b264-c54245ecca2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_630e8867-2774-4613-af54-e7d4962a9f5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d4b476f4-543c-4d31-8488-f64a819072de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_630e8867-2774-4613-af54-e7d4962a9f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_56ee91c8-a765-412b-987f-e2632cfe9333" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_630e8867-2774-4613-af54-e7d4962a9f5e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_56ee91c8-a765-412b-987f-e2632cfe9333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_cf744b6c-611c-4a5b-8ba1-2c21c3f945a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_630e8867-2774-4613-af54-e7d4962a9f5e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_cf744b6c-611c-4a5b-8ba1-2c21c3f945a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_506feee2-19ba-43c4-beb6-f2a63046e740" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_630e8867-2774-4613-af54-e7d4962a9f5e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_506feee2-19ba-43c4-beb6-f2a63046e740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/PropertyandequipmentnetAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#PropertyandequipmentnetAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/PropertyandequipmentnetAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_34ee16f6-971b-41db-8094-ece3eeb9919b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_b7769769-eb93-4e97-a728-07ef8a6f54b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_34ee16f6-971b-41db-8094-ece3eeb9919b" xlink:to="loc_us-gaap_Depreciation_b7769769-eb93-4e97-a728-07ef8a6f54b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Intangibleassetnet" xlink:type="simple" xlink:href="nltx-20201231.xsd#Intangibleassetnet"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/Intangibleassetnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4181ce9a-a096-40ad-9df1-d6ef41a7b79a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_c2ddfc4b-fbd2-4963-8abe-a6697c8c3dea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4181ce9a-a096-40ad-9df1-d6ef41a7b79a" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_c2ddfc4b-fbd2-4963-8abe-a6697c8c3dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/IntangibleassetnetTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#IntangibleassetnetTables"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/IntangibleassetnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c41f458b-7068-4e42-bad6-b849f984c0cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_90c616cf-9a4a-4786-8c4b-e2287bdc8329" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c41f458b-7068-4e42-bad6-b849f984c0cc" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_90c616cf-9a4a-4786-8c4b-e2287bdc8329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/IntangibleassetnetSummaryofIntangibleAssetDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#IntangibleassetnetSummaryofIntangibleAssetDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/IntangibleassetnetSummaryofIntangibleAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_816547a0-723a-4aaf-a930-c8585df74138" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_eaa4d5e2-23d9-4050-90f5-40bf0d0b253f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_816547a0-723a-4aaf-a930-c8585df74138" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_eaa4d5e2-23d9-4050-90f5-40bf0d0b253f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_43803dc6-2422-4fa7-b448-73be2e3f5173" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_816547a0-723a-4aaf-a930-c8585df74138" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_43803dc6-2422-4fa7-b448-73be2e3f5173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6b6c8b71-1b4f-4b41-be8c-b8a0de25411c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_816547a0-723a-4aaf-a930-c8585df74138" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6b6c8b71-1b4f-4b41-be8c-b8a0de25411c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_565efb15-ad7a-47bc-a250-061587ab5c8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_816547a0-723a-4aaf-a930-c8585df74138" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_565efb15-ad7a-47bc-a250-061587ab5c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1a205972-7c77-4e11-aa2b-a52b7a52150f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_816547a0-723a-4aaf-a930-c8585df74138" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1a205972-7c77-4e11-aa2b-a52b7a52150f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_db8a59ee-addf-4f61-bd36-aa8dae00ff52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_816547a0-723a-4aaf-a930-c8585df74138" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_db8a59ee-addf-4f61-bd36-aa8dae00ff52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Accountspayableandotherliabilities" xlink:type="simple" xlink:href="nltx-20201231.xsd#Accountspayableandotherliabilities"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/Accountspayableandotherliabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_76748562-1900-4ad3-820c-c8b8b77337bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_4d666cd4-50d3-46c9-ab5e-815658b1171f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_76748562-1900-4ad3-820c-c8b8b77337bf" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_4d666cd4-50d3-46c9-ab5e-815658b1171f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#AccountspayableandotherliabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_673ae228-802f-46a4-8f15-e7d0381817aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_af9bfef2-cb00-4a44-8d9d-be1b257f33c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_673ae228-802f-46a4-8f15-e7d0381817aa" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_af9bfef2-cb00-4a44-8d9d-be1b257f33c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#AccountspayableandotherliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_275af0b9-8e96-4655-805c-79d7ba095468" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_5b771bf2-4a97-4ace-9cf7-b570a303748c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_275af0b9-8e96-4655-805c-79d7ba095468" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_5b771bf2-4a97-4ace-9cf7-b570a303748c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AccruedClinicalExpensesCurrent_3ce3cf4e-ced7-46e0-8c55-a69470a7366e" xlink:href="nltx-20201231.xsd#nltx_AccruedClinicalExpensesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_275af0b9-8e96-4655-805c-79d7ba095468" xlink:to="loc_nltx_AccruedClinicalExpensesCurrent_3ce3cf4e-ced7-46e0-8c55-a69470a7366e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4c881081-7b78-4a47-becb-cb400b409c14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_275af0b9-8e96-4655-805c-79d7ba095468" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4c881081-7b78-4a47-becb-cb400b409c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a3bb4977-3bcc-4051-9c4c-1d0a2a69ae39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_275af0b9-8e96-4655-805c-79d7ba095468" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a3bb4977-3bcc-4051-9c4c-1d0a2a69ae39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_93ae99d2-2627-4a42-95a6-81b32ac34c52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_275af0b9-8e96-4655-805c-79d7ba095468" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_93ae99d2-2627-4a42-95a6-81b32ac34c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Leases" xlink:type="simple" xlink:href="nltx-20201231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ca9e8932-6a1e-4796-8088-1b4c8ab666fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_4a2c169c-afe3-486f-bbe1-6f552e02dc22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ca9e8932-6a1e-4796-8088-1b4c8ab666fa" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_4a2c169c-afe3-486f-bbe1-6f552e02dc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_fcc39d52-68be-4d41-b57b-88c5d28b21d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ca9e8932-6a1e-4796-8088-1b4c8ab666fa" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_fcc39d52-68be-4d41-b57b-88c5d28b21d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c56d1f39-a0d5-4bab-ba43-53976e11882a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_ffda14d5-f857-4de2-9ccc-80da6bcdf194" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c56d1f39-a0d5-4bab-ba43-53976e11882a" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_ffda14d5-f857-4de2-9ccc-80da6bcdf194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_87b68d31-bbdf-4e59-84d3-d8ebd86268a9" xlink:href="nltx-20201231.xsd#nltx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c56d1f39-a0d5-4bab-ba43-53976e11882a" xlink:to="loc_nltx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock_87b68d31-bbdf-4e59-84d3-d8ebd86268a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_2ea228b8-3dc3-424c-8070-8cbf3732dc65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c56d1f39-a0d5-4bab-ba43-53976e11882a" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_2ea228b8-3dc3-424c-8070-8cbf3732dc65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_39c39f01-5301-434f-99cc-ce11ddba0d40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c56d1f39-a0d5-4bab-ba43-53976e11882a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_39c39f01-5301-434f-99cc-ce11ddba0d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_d73fd1fc-5873-4896-9f35-c543e6b92b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c56d1f39-a0d5-4bab-ba43-53976e11882a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_d73fd1fc-5873-4896-9f35-c543e6b92b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a4bede02-c5a1-44f8-9506-a1d50272646e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_eee9fffe-0a59-48eb-9c5e-90941040468b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a4bede02-c5a1-44f8-9506-a1d50272646e" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_eee9fffe-0a59-48eb-9c5e-90941040468b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_32731f6c-9d32-4497-b2f3-e254fdfd8a70" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_eee9fffe-0a59-48eb-9c5e-90941040468b" xlink:to="loc_srt_StatementGeographicalAxis_32731f6c-9d32-4497-b2f3-e254fdfd8a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d20b270d-1dd1-4e73-bcb3-5234650136dc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_32731f6c-9d32-4497-b2f3-e254fdfd8a70" xlink:to="loc_srt_SegmentGeographicalDomain_d20b270d-1dd1-4e73-bcb3-5234650136dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA_40aef1bc-716d-4a8d-8772-6565f5cc8dc1" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_WA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d20b270d-1dd1-4e73-bcb3-5234650136dc" xlink:to="loc_stpr_WA_40aef1bc-716d-4a8d-8772-6565f5cc8dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_50a53e23-acaf-4eb3-9d8a-9009a3cd81d0" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d20b270d-1dd1-4e73-bcb3-5234650136dc" xlink:to="loc_country_CA_50a53e23-acaf-4eb3-9d8a-9009a3cd81d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4140ca1e-d894-45b0-b520-fc5a5aa38522" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_eee9fffe-0a59-48eb-9c5e-90941040468b" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4140ca1e-d894-45b0-b520-fc5a5aa38522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f6d04937-0db7-4fc2-8ac8-ae5cbba38c35" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4140ca1e-d894-45b0-b520-fc5a5aa38522" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f6d04937-0db7-4fc2-8ac8-ae5cbba38c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember_c8d5d5ad-4e93-4193-9c49-ab3dc3b8b749" xlink:href="nltx-20201231.xsd#nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f6d04937-0db7-4fc2-8ac8-ae5cbba38c35" xlink:to="loc_nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember_c8d5d5ad-4e93-4193-9c49-ab3dc3b8b749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_OfficeSpaceFormerPrincipalExecutiveOfficesAndLaboratoryMember_cd1e3d5c-7ff0-4eec-9d1f-af66c0e9c49f" xlink:href="nltx-20201231.xsd#nltx_OfficeSpaceFormerPrincipalExecutiveOfficesAndLaboratoryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_f6d04937-0db7-4fc2-8ac8-ae5cbba38c35" xlink:to="loc_nltx_OfficeSpaceFormerPrincipalExecutiveOfficesAndLaboratoryMember_cd1e3d5c-7ff0-4eec-9d1f-af66c0e9c49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_62fc71f7-2ebd-48da-b25f-f3147fcd6380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_eee9fffe-0a59-48eb-9c5e-90941040468b" xlink:to="loc_us-gaap_CreditFacilityAxis_62fc71f7-2ebd-48da-b25f-f3147fcd6380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d67d3c49-cccb-4146-827f-bafac951602a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_62fc71f7-2ebd-48da-b25f-f3147fcd6380" xlink:to="loc_us-gaap_CreditFacilityDomain_d67d3c49-cccb-4146-827f-bafac951602a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_1b2b81a2-0320-4e56-8dc6-f0b9573e8752" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_d67d3c49-cccb-4146-827f-bafac951602a" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_1b2b81a2-0320-4e56-8dc6-f0b9573e8752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_eee9fffe-0a59-48eb-9c5e-90941040468b" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_c9f1f3a0-a735-43f7-8280-f4bfa59a4713" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_c9f1f3a0-a735-43f7-8280-f4bfa59a4713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_e50a5b7d-907c-45ea-9d3e-42fc7d9aeb95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_us-gaap_SecurityDeposit_e50a5b7d-907c-45ea-9d3e-42fc7d9aeb95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_NumberOfOptionToExtendLease_93774220-c364-40c7-94c4-659a1a08773a" xlink:href="nltx-20201231.xsd#nltx_NumberOfOptionToExtendLease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_nltx_NumberOfOptionToExtendLease_93774220-c364-40c7-94c4-659a1a08773a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_LeaseAgreementExtendedPeriod_7f6087b2-a04b-47bb-85ac-f7bf9a573f63" xlink:href="nltx-20201231.xsd#nltx_LeaseAgreementExtendedPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_nltx_LeaseAgreementExtendedPeriod_7f6087b2-a04b-47bb-85ac-f7bf9a573f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_TenantImprovementAllowance_daff0918-6553-4a0b-96f5-bc06aee8df29" xlink:href="nltx-20201231.xsd#nltx_TenantImprovementAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_nltx_TenantImprovementAllowance_daff0918-6553-4a0b-96f5-bc06aee8df29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AdditionalTenantImprovements_ca0de8b7-b822-4115-8d44-64ddd37d279a" xlink:href="nltx-20201231.xsd#nltx_AdditionalTenantImprovements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_nltx_AdditionalTenantImprovements_ca0de8b7-b822-4115-8d44-64ddd37d279a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_OperatingLeaseRightOfUseAssetIncreaseDueToRemeasurement_bc612983-cf30-48b3-be79-751f87b45f88" xlink:href="nltx-20201231.xsd#nltx_OperatingLeaseRightOfUseAssetIncreaseDueToRemeasurement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_nltx_OperatingLeaseRightOfUseAssetIncreaseDueToRemeasurement_bc612983-cf30-48b3-be79-751f87b45f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_OperatingLeaseLiabilityIncreaseDueToRemeasurement_cd070e32-a705-459e-bdb6-97e206f4210e" xlink:href="nltx-20201231.xsd#nltx_OperatingLeaseLiabilityIncreaseDueToRemeasurement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_nltx_OperatingLeaseLiabilityIncreaseDueToRemeasurement_cd070e32-a705-459e-bdb6-97e206f4210e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_TenantImprovementAllowanceReceivable_d12a0431-a96d-4f61-bf13-797b93b7f490" xlink:href="nltx-20201231.xsd#nltx_TenantImprovementAllowanceReceivable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_nltx_TenantImprovementAllowanceReceivable_d12a0431-a96d-4f61-bf13-797b93b7f490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_NumberOfDaysAdvanceNoticeMustBeGivenToTerminateTheLease_53e9d3d8-c8b9-4486-9154-838391e99bb5" xlink:href="nltx-20201231.xsd#nltx_NumberOfDaysAdvanceNoticeMustBeGivenToTerminateTheLease"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_nltx_NumberOfDaysAdvanceNoticeMustBeGivenToTerminateTheLease_53e9d3d8-c8b9-4486-9154-838391e99bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_TerminationFeesForLeaseTermination_9fe1df5f-773e-46b5-8dc0-b16ae0624e50" xlink:href="nltx-20201231.xsd#nltx_TerminationFeesForLeaseTermination"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_nltx_TerminationFeesForLeaseTermination_9fe1df5f-773e-46b5-8dc0-b16ae0624e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_1a863cab-7460-481e-8c78-de1a6ec9f523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_1a863cab-7460-481e-8c78-de1a6ec9f523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4faa977c-ab92-4988-8c0f-d4189d5f2efa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4faa977c-ab92-4988-8c0f-d4189d5f2efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1dfe744d-92fd-487d-97a1-604f83c2a23d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1dfe744d-92fd-487d-97a1-604f83c2a23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_4742a072-8fe2-46bd-b903-15eb7948c60f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_87fb0f62-b330-407d-b370-b87ace36368f" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_4742a072-8fe2-46bd-b903-15eb7948c60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#LeasesScheduleofComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8d14b489-50e3-4b13-899a-dd42ae671243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_fe6ac629-3e6f-4232-85f3-d7a26ad2b156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8d14b489-50e3-4b13-899a-dd42ae671243" xlink:to="loc_us-gaap_LesseeDisclosureAbstract_fe6ac629-3e6f-4232-85f3-d7a26ad2b156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_0a808b78-e635-49a3-b572-725d5406742c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_fe6ac629-3e6f-4232-85f3-d7a26ad2b156" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_0a808b78-e635-49a3-b572-725d5406742c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_000f270c-5a2a-4613-938d-987467fc0070" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_fe6ac629-3e6f-4232-85f3-d7a26ad2b156" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_000f270c-5a2a-4613-938d-987467fc0070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_7bc89e4b-8dd7-4df1-acbc-1ba74720d7f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8d14b489-50e3-4b13-899a-dd42ae671243" xlink:to="loc_us-gaap_OperatingLeaseCost_7bc89e4b-8dd7-4df1-acbc-1ba74720d7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_0ffb7761-7856-4b91-bf50-e9cd13984efd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8d14b489-50e3-4b13-899a-dd42ae671243" xlink:to="loc_us-gaap_ShortTermLeaseCost_0ffb7761-7856-4b91-bf50-e9cd13984efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_5672177c-6150-4ec0-ac69-d23fa3f746b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8d14b489-50e3-4b13-899a-dd42ae671243" xlink:to="loc_us-gaap_VariableLeaseCost_5672177c-6150-4ec0-ac69-d23fa3f746b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_12cd0473-2b1b-4b5e-8c28-3aaba9db5d2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8d14b489-50e3-4b13-899a-dd42ae671243" xlink:to="loc_us-gaap_LeaseCost_12cd0473-2b1b-4b5e-8c28-3aaba9db5d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_ad4e6596-cc51-4a41-b184-effaf0400a9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8d14b489-50e3-4b13-899a-dd42ae671243" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_ad4e6596-cc51-4a41-b184-effaf0400a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b10add69-3522-4246-b67c-a0b4f5154355" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8d14b489-50e3-4b13-899a-dd42ae671243" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b10add69-3522-4246-b67c-a0b4f5154355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_ba2c3287-c404-4aea-9906-0e39a53b6115" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8d14b489-50e3-4b13-899a-dd42ae671243" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_ba2c3287-c404-4aea-9906-0e39a53b6115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f6d6464d-e0c1-4786-9706-055d47d2e9a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8d14b489-50e3-4b13-899a-dd42ae671243" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f6d6464d-e0c1-4786-9706-055d47d2e9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/LeasesSupplementalCashflowInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#LeasesSupplementalCashflowInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/LeasesSupplementalCashflowInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_eeb3b979-d5be-4c07-b0cb-07f8a9b8fc04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_4677f73b-dc71-41b1-a902-f7acf8aacf78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_eeb3b979-d5be-4c07-b0cb-07f8a9b8fc04" xlink:to="loc_us-gaap_OperatingLeasePayments_4677f73b-dc71-41b1-a902-f7acf8aacf78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_FinanceLeasePrincipalAndInterestPayments_934f5569-84c7-4886-81fe-c13a7ad1f308" xlink:href="nltx-20201231.xsd#nltx_FinanceLeasePrincipalAndInterestPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_eeb3b979-d5be-4c07-b0cb-07f8a9b8fc04" xlink:to="loc_nltx_FinanceLeasePrincipalAndInterestPayments_934f5569-84c7-4886-81fe-c13a7ad1f308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cb3a2f4d-c67e-45b6-a50c-c18424efba14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_906eb46e-9e31-4c0e-af8d-47b048c0b5d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cb3a2f4d-c67e-45b6-a50c-c18424efba14" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_906eb46e-9e31-4c0e-af8d-47b048c0b5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_f4159f67-4a4d-466c-9285-4e51d35611bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_906eb46e-9e31-4c0e-af8d-47b048c0b5d6" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_f4159f67-4a4d-466c-9285-4e51d35611bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_075e8b21-ac18-46e8-9c93-76cdb9f64e97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_906eb46e-9e31-4c0e-af8d-47b048c0b5d6" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_075e8b21-ac18-46e8-9c93-76cdb9f64e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_ca1eb644-2616-4818-8a5d-a881abdbc4b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_906eb46e-9e31-4c0e-af8d-47b048c0b5d6" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_ca1eb644-2616-4818-8a5d-a881abdbc4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_1aeee3b3-37e8-4871-bdc2-d9c37c8f8db5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_906eb46e-9e31-4c0e-af8d-47b048c0b5d6" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_1aeee3b3-37e8-4871-bdc2-d9c37c8f8db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_8231fdfd-fe7b-475f-8eaa-40eafe6657e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_906eb46e-9e31-4c0e-af8d-47b048c0b5d6" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_8231fdfd-fe7b-475f-8eaa-40eafe6657e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_9559fa80-5d71-4e91-aa75-252ab28b0ac0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_906eb46e-9e31-4c0e-af8d-47b048c0b5d6" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_9559fa80-5d71-4e91-aa75-252ab28b0ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_27e88297-4bad-47d3-8f73-6b7872140f23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_906eb46e-9e31-4c0e-af8d-47b048c0b5d6" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_27e88297-4bad-47d3-8f73-6b7872140f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_1cd0ffa6-2a78-4d42-824b-54518fd05539" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_906eb46e-9e31-4c0e-af8d-47b048c0b5d6" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_1cd0ffa6-2a78-4d42-824b-54518fd05539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_f1ee335f-84c5-411b-86c2-e7208d4ea6e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_906eb46e-9e31-4c0e-af8d-47b048c0b5d6" xlink:to="loc_us-gaap_FinanceLeaseLiability_f1ee335f-84c5-411b-86c2-e7208d4ea6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_aab4b896-c973-4f98-8e7c-921f300eaa9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_906eb46e-9e31-4c0e-af8d-47b048c0b5d6" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_aab4b896-c973-4f98-8e7c-921f300eaa9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_72233257-c78f-435f-a8c0-a2d5e98f7e16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_906eb46e-9e31-4c0e-af8d-47b048c0b5d6" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_72233257-c78f-435f-a8c0-a2d5e98f7e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0d7ba3f8-063c-4ca4-9310-617f2f44c4cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cb3a2f4d-c67e-45b6-a50c-c18424efba14" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0d7ba3f8-063c-4ca4-9310-617f2f44c4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8895b63f-29e3-4b79-8f97-684b2cab10e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0d7ba3f8-063c-4ca4-9310-617f2f44c4cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8895b63f-29e3-4b79-8f97-684b2cab10e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2267709b-d21a-4e2e-9ef7-53ff54948111" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0d7ba3f8-063c-4ca4-9310-617f2f44c4cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2267709b-d21a-4e2e-9ef7-53ff54948111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_af3a0ee7-027f-47cb-8275-91ab7ab92cd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0d7ba3f8-063c-4ca4-9310-617f2f44c4cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_af3a0ee7-027f-47cb-8275-91ab7ab92cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bd070e5a-552f-4101-88d3-29875d6a69a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0d7ba3f8-063c-4ca4-9310-617f2f44c4cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bd070e5a-552f-4101-88d3-29875d6a69a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_aaa427b0-b01b-4656-ba66-bf4a7c614b84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0d7ba3f8-063c-4ca4-9310-617f2f44c4cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_aaa427b0-b01b-4656-ba66-bf4a7c614b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_fba2c6c6-a93f-4e31-8d23-2ca15de378db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0d7ba3f8-063c-4ca4-9310-617f2f44c4cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_fba2c6c6-a93f-4e31-8d23-2ca15de378db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_28aaddd0-c3b1-4128-aef1-368e36e90d8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0d7ba3f8-063c-4ca4-9310-617f2f44c4cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_28aaddd0-c3b1-4128-aef1-368e36e90d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2676004c-18de-484e-8cdc-df86e47e7a41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0d7ba3f8-063c-4ca4-9310-617f2f44c4cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2676004c-18de-484e-8cdc-df86e47e7a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f18cd955-55cb-4e57-b351-3af0cebc46f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0d7ba3f8-063c-4ca4-9310-617f2f44c4cb" xlink:to="loc_us-gaap_OperatingLeaseLiability_f18cd955-55cb-4e57-b351-3af0cebc46f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6ab6966e-c0b7-404c-bc43-79d00d73636e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0d7ba3f8-063c-4ca4-9310-617f2f44c4cb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6ab6966e-c0b7-404c-bc43-79d00d73636e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4e244277-be50-4fc7-99d9-b5273feaa951" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0d7ba3f8-063c-4ca4-9310-617f2f44c4cb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4e244277-be50-4fc7-99d9-b5273feaa951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="nltx-20201231.xsd#LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Stockholdersequity" xlink:type="simple" xlink:href="nltx-20201231.xsd#Stockholdersequity"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/Stockholdersequity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8b976993-7990-4011-b11c-02dec5b332fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1f50bb4c-606a-4bb7-bd67-85be8069a4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8b976993-7990-4011-b11c-02dec5b332fb" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1f50bb4c-606a-4bb7-bd67-85be8069a4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/StockholdersequityTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#StockholdersequityTables"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/StockholdersequityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_09a1adea-272f-42e9-8654-ab732f95a984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4c77cf7a-f246-48ab-919a-d61fcd03d285" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_09a1adea-272f-42e9-8654-ab732f95a984" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4c77cf7a-f246-48ab-919a-d61fcd03d285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7a5c8eda-8a7d-451c-bedf-c8cbacacf9ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_09a1adea-272f-42e9-8654-ab732f95a984" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_7a5c8eda-8a7d-451c-bedf-c8cbacacf9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_ab762449-2a1c-45dd-b778-2d33387fcc13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_09a1adea-272f-42e9-8654-ab732f95a984" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_ab762449-2a1c-45dd-b778-2d33387fcc13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7db5cb73-61f9-402f-909e-c4d0f78f1f2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_09a1adea-272f-42e9-8654-ab732f95a984" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7db5cb73-61f9-402f-909e-c4d0f78f1f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#StockholdersequityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_bfab91a2-ac29-4e6e-8fcb-e72b5fed1ba1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2621c5a-c6a1-4b2b-b2f8-c85d4e30718c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bfab91a2-ac29-4e6e-8fcb-e72b5fed1ba1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2621c5a-c6a1-4b2b-b2f8-c85d4e30718c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_bd16f878-e0c0-431c-88e5-ac52c49c8247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2621c5a-c6a1-4b2b-b2f8-c85d4e30718c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_bd16f878-e0c0-431c-88e5-ac52c49c8247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2bbb006-54eb-4807-ad3c-19eba93c52d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bd16f878-e0c0-431c-88e5-ac52c49c8247" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2bbb006-54eb-4807-ad3c-19eba93c52d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PublicStockOfferingMember_0b54056a-d192-44be-8da4-e409d27fc55a" xlink:href="nltx-20201231.xsd#nltx_PublicStockOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2bbb006-54eb-4807-ad3c-19eba93c52d4" xlink:to="loc_nltx_PublicStockOfferingMember_0b54056a-d192-44be-8da4-e409d27fc55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_114488b2-3155-4219-adbb-d29a8f8fe5b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2621c5a-c6a1-4b2b-b2f8-c85d4e30718c" xlink:to="loc_us-gaap_AwardTypeAxis_114488b2-3155-4219-adbb-d29a8f8fe5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8231e91-a4a6-42a7-a6d8-6657bdcf01d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_114488b2-3155-4219-adbb-d29a8f8fe5b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8231e91-a4a6-42a7-a6d8-6657bdcf01d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PreFundedWarrantsMember_064a7499-7bfc-4217-a3cf-c5e0eb2a55ea" xlink:href="nltx-20201231.xsd#nltx_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8231e91-a4a6-42a7-a6d8-6657bdcf01d3" xlink:to="loc_nltx_PreFundedWarrantsMember_064a7499-7bfc-4217-a3cf-c5e0eb2a55ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_0bd53865-6b53-4c07-91dd-0a460acc0d30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b8231e91-a4a6-42a7-a6d8-6657bdcf01d3" xlink:to="loc_us-gaap_EmployeeStockMember_0bd53865-6b53-4c07-91dd-0a460acc0d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsAxis_77c48069-b23d-4752-a87e-bf18eea8b9f8" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2621c5a-c6a1-4b2b-b2f8-c85d4e30718c" xlink:to="loc_nltx_AcquisitionOfAssetsAxis_77c48069-b23d-4752-a87e-bf18eea8b9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcquisitionOfAssetsDomain_8ed3d052-d5cf-4d39-9612-31ada8a15584" xlink:href="nltx-20201231.xsd#nltx_AcquisitionOfAssetsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsAxis_77c48069-b23d-4752-a87e-bf18eea8b9f8" xlink:to="loc_nltx_AcquisitionOfAssetsDomain_8ed3d052-d5cf-4d39-9612-31ada8a15584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AquinoxMember_f59d7e8e-0f74-4897-9128-77db59cbe1d3" xlink:href="nltx-20201231.xsd#nltx_AquinoxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_AcquisitionOfAssetsDomain_8ed3d052-d5cf-4d39-9612-31ada8a15584" xlink:to="loc_nltx_AquinoxMember_f59d7e8e-0f74-4897-9128-77db59cbe1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e88355ab-c34b-43d6-8c3c-c5668c097572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2621c5a-c6a1-4b2b-b2f8-c85d4e30718c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e88355ab-c34b-43d6-8c3c-c5668c097572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_224cf3c1-e4d1-45f1-a4ed-bc896c06669d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e88355ab-c34b-43d6-8c3c-c5668c097572" xlink:to="loc_us-gaap_EquityComponentDomain_224cf3c1-e4d1-45f1-a4ed-bc896c06669d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c70aa67c-2539-45f3-b85a-7e2cd28e8d22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_224cf3c1-e4d1-45f1-a4ed-bc896c06669d" xlink:to="loc_us-gaap_CommonStockMember_c70aa67c-2539-45f3-b85a-7e2cd28e8d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_be6368f5-be05-46b6-bc95-6b3aea800dfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2621c5a-c6a1-4b2b-b2f8-c85d4e30718c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_be6368f5-be05-46b6-bc95-6b3aea800dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d87f3ab5-85e2-4c44-99ee-40b106f6d1a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_be6368f5-be05-46b6-bc95-6b3aea800dfc" xlink:to="loc_us-gaap_ClassOfStockDomain_d87f3ab5-85e2-4c44-99ee-40b106f6d1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_NonVotingConvertiblePreferredStockMember_a113bb7d-ec84-4b7b-8349-fc1ed10dd9f9" xlink:href="nltx-20201231.xsd#nltx_NonVotingConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d87f3ab5-85e2-4c44-99ee-40b106f6d1a5" xlink:to="loc_nltx_NonVotingConvertiblePreferredStockMember_a113bb7d-ec84-4b7b-8349-fc1ed10dd9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PreFundedCommonStockWarrantsMember_1dcfd567-ee0c-4409-9a78-b173e8b279ee" xlink:href="nltx-20201231.xsd#nltx_PreFundedCommonStockWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d87f3ab5-85e2-4c44-99ee-40b106f6d1a5" xlink:to="loc_nltx_PreFundedCommonStockWarrantsMember_1dcfd567-ee0c-4409-9a78-b173e8b279ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4db84f37-1f0c-4217-9fc2-7947a3d72df5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2621c5a-c6a1-4b2b-b2f8-c85d4e30718c" xlink:to="loc_us-gaap_PlanNameAxis_4db84f37-1f0c-4217-9fc2-7947a3d72df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c94c97d4-9653-4d31-bbb6-7165fcf17d99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4db84f37-1f0c-4217-9fc2-7947a3d72df5" xlink:to="loc_us-gaap_PlanNameDomain_c94c97d4-9653-4d31-bbb6-7165fcf17d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_StockIncentivePlanTwoThousandFourteenMember_f9c685f9-afea-42b4-a3b0-fd5168d140ea" xlink:href="nltx-20201231.xsd#nltx_StockIncentivePlanTwoThousandFourteenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c94c97d4-9653-4d31-bbb6-7165fcf17d99" xlink:to="loc_nltx_StockIncentivePlanTwoThousandFourteenMember_f9c685f9-afea-42b4-a3b0-fd5168d140ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_EquityIncentivePlanTwoThousandSixMember_2f86158c-f702-47a1-93c0-7012ed793a6a" xlink:href="nltx-20201231.xsd#nltx_EquityIncentivePlanTwoThousandSixMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c94c97d4-9653-4d31-bbb6-7165fcf17d99" xlink:to="loc_nltx_EquityIncentivePlanTwoThousandSixMember_2f86158c-f702-47a1-93c0-7012ed793a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_A2020EmployeeStockPurchasePlanMember_e89daf55-672b-404f-9a7b-827c2cd6a1f2" xlink:href="nltx-20201231.xsd#nltx_A2020EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c94c97d4-9653-4d31-bbb6-7165fcf17d99" xlink:to="loc_nltx_A2020EmployeeStockPurchasePlanMember_e89daf55-672b-404f-9a7b-827c2cd6a1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e85f9319-8ab5-4857-92df-9ebd065431f4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2621c5a-c6a1-4b2b-b2f8-c85d4e30718c" xlink:to="loc_srt_RangeAxis_e85f9319-8ab5-4857-92df-9ebd065431f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_93c2474c-a6df-4211-8094-43cedf51cc7d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e85f9319-8ab5-4857-92df-9ebd065431f4" xlink:to="loc_srt_RangeMember_93c2474c-a6df-4211-8094-43cedf51cc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7d2e8643-2702-4c29-804d-c801f258ce46" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_93c2474c-a6df-4211-8094-43cedf51cc7d" xlink:to="loc_srt_MinimumMember_7d2e8643-2702-4c29-804d-c801f258ce46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_13b2f6ff-aa4c-4c5d-b0df-a547884b81d6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_93c2474c-a6df-4211-8094-43cedf51cc7d" xlink:to="loc_srt_MaximumMember_13b2f6ff-aa4c-4c5d-b0df-a547884b81d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b2621c5a-c6a1-4b2b-b2f8-c85d4e30718c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2f73bc91-e444-4962-b6d1-01a13da948d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2f73bc91-e444-4962-b6d1-01a13da948d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c4f46429-cc45-4b69-8752-f339985d2cba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c4f46429-cc45-4b69-8752-f339985d2cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_69b4c5b7-25d6-41a3-bb01-6ccea805d4da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_CommonStockSharesIssued_69b4c5b7-25d6-41a3-bb01-6ccea805d4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_19f0a786-476d-4a0e-acb0-b67951432015" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_19f0a786-476d-4a0e-acb0-b67951432015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8a7924f3-12bc-49d2-b141-92d1d3c9daca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8a7924f3-12bc-49d2-b141-92d1d3c9daca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_144944d2-c862-4ecc-84bb-9d0523ef5693" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_144944d2-c862-4ecc-84bb-9d0523ef5693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5a1d898f-2014-4dd4-a8d4-cf5497459ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5a1d898f-2014-4dd4-a8d4-cf5497459ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PreFundedWarrantIssuedPricePerShare_56c91886-16d9-4d0f-8b2c-cbf78d114c26" xlink:href="nltx-20201231.xsd#nltx_PreFundedWarrantIssuedPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_nltx_PreFundedWarrantIssuedPricePerShare_56c91886-16d9-4d0f-8b2c-cbf78d114c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d9134b12-9cdc-4b92-a92a-1125f8494c00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d9134b12-9cdc-4b92-a92a-1125f8494c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2e75745d-6d88-4b21-bca4-0c20f1f38de7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2e75745d-6d88-4b21-bca4-0c20f1f38de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_2c48a1bc-994d-407a-a20a-f9bc2315ff08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_2c48a1bc-994d-407a-a20a-f9bc2315ff08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_85b78195-160c-4244-b6e5-2609e07000b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_85b78195-160c-4244-b6e5-2609e07000b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8400fdd8-fd56-466f-9921-4b0916912ad3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8400fdd8-fd56-466f-9921-4b0916912ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_74c01bc9-5365-41d6-bbf9-72b8f0c39459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_PreferredStockSharesIssued_74c01bc9-5365-41d6-bbf9-72b8f0c39459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_8f88ef43-c4fd-4e61-b63f-b428267273f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_8f88ef43-c4fd-4e61-b63f-b428267273f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_e98a8781-ce6a-47e0-9b0f-9336bf5c31f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_e98a8781-ce6a-47e0-9b0f-9336bf5c31f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_StockConversionRatio_ace464e5-22be-4cbd-9932-babb2431cf8a" xlink:href="nltx-20201231.xsd#nltx_StockConversionRatio"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_nltx_StockConversionRatio_ace464e5-22be-4cbd-9932-babb2431cf8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_ConvertiblePreferredStockToBeConverted_1192ea42-7f0b-457f-81eb-2ae534209f9f" xlink:href="nltx-20201231.xsd#nltx_ConvertiblePreferredStockToBeConverted"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_nltx_ConvertiblePreferredStockToBeConverted_1192ea42-7f0b-457f-81eb-2ae534209f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2319fec8-9b8f-44be-a675-f66bf92b2f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2319fec8-9b8f-44be-a675-f66bf92b2f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants_7a1ac86c-3492-41c8-b91f-6b0e1bd177ee" xlink:href="nltx-20201231.xsd#nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants_7a1ac86c-3492-41c8-b91f-6b0e1bd177ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PercentageOfOutstandingStockPerStockholderMaximum_29c7c25d-aba8-4257-9b49-f82dc7b0dfd6" xlink:href="nltx-20201231.xsd#nltx_PercentageOfOutstandingStockPerStockholderMaximum"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_nltx_PercentageOfOutstandingStockPerStockholderMaximum_29c7c25d-aba8-4257-9b49-f82dc7b0dfd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_70e576f0-4d09-4b53-bef3-ef038858776c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_70e576f0-4d09-4b53-bef3-ef038858776c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fe3e5dff-9232-4dbc-b4d1-432ca4018781" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fe3e5dff-9232-4dbc-b4d1-432ca4018781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_PeriodSharesReservedForIssuanceWillIncrease_c060f226-43be-4c70-a0f6-f117c5fe454d" xlink:href="nltx-20201231.xsd#nltx_PeriodSharesReservedForIssuanceWillIncrease"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_nltx_PeriodSharesReservedForIssuanceWillIncrease_c060f226-43be-4c70-a0f6-f117c5fe454d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_StockBasedCompensationIncreaseInCommonStockIssuancePercentage_fb087a87-2aff-4c63-9012-92eee74713cb" xlink:href="nltx-20201231.xsd#nltx_StockBasedCompensationIncreaseInCommonStockIssuancePercentage"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_nltx_StockBasedCompensationIncreaseInCommonStockIssuancePercentage_fb087a87-2aff-4c63-9012-92eee74713cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b536783e-9d91-40b6-a4cf-50e5dc119992" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b536783e-9d91-40b6-a4cf-50e5dc119992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_71e3e3a8-adc3-479f-a44d-1738be072946" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_71e3e3a8-adc3-479f-a44d-1738be072946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2b086514-436a-4595-aadc-1441a33c8085" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2b086514-436a-4595-aadc-1441a33c8085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_86387f88-8a41-4797-819d-48aab6eef0ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_86387f88-8a41-4797-819d-48aab6eef0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ffb60704-eb4c-4d6f-b10f-1b786e47279e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ffb60704-eb4c-4d6f-b10f-1b786e47279e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_bdacb67a-a6fa-4ba2-b2d3-8134728ff91b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_bdacb67a-a6fa-4ba2-b2d3-8134728ff91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_99801b40-dbc9-4ecf-8e6a-a10cc852a552" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_99801b40-dbc9-4ecf-8e6a-a10cc852a552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_88d246ba-4c10-444c-a859-c62e6d1f0516" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_88d246ba-4c10-444c-a859-c62e6d1f0516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a10d2109-abf1-4f03-a04e-8f3fe351f19a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a10d2109-abf1-4f03-a04e-8f3fe351f19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7980ac42-ecdb-4fcd-9702-542e8bb9630b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7980ac42-ecdb-4fcd-9702-542e8bb9630b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_3b136227-59c9-4765-86d0-de965ab93409" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_3b136227-59c9-4765-86d0-de965ab93409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_b2c386ef-e359-41a5-8944-a9262f762dfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_b2c386ef-e359-41a5-8944-a9262f762dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear_7241e565-bf52-47b7-8de0-6750de33c637" xlink:href="nltx-20201231.xsd#nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear_7241e565-bf52-47b7-8de0-6750de33c637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_903027df-323c-42e4-9a5d-ff8a4ba8bc81" xlink:href="nltx-20201231.xsd#nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_903027df-323c-42e4-9a5d-ff8a4ba8bc81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6f98a447-f19e-4700-b54b-8e0974d9d177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6f98a447-f19e-4700-b54b-8e0974d9d177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3780dd2a-a3ce-4a9e-b58f-966af4b51804" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dc8a2558-adc0-42e7-9c32-84e2aa92407b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_3780dd2a-a3ce-4a9e-b58f-966af4b51804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/StockholdersequityScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#StockholdersequityScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/StockholdersequityScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_80d7d79c-fb80-41fc-904f-ab0250fc64f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a7620866-1cb9-449a-bbdb-cc3d5bbad730" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_80d7d79c-fb80-41fc-904f-ab0250fc64f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a7620866-1cb9-449a-bbdb-cc3d5bbad730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c447d621-610e-4883-b5b9-5ff0ba6696dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a7620866-1cb9-449a-bbdb-cc3d5bbad730" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c447d621-610e-4883-b5b9-5ff0ba6696dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_647c5262-b29b-409a-b26e-de68eb3967c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a7620866-1cb9-449a-bbdb-cc3d5bbad730" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_647c5262-b29b-409a-b26e-de68eb3967c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4837b04b-2132-4bb3-b282-4c586186b685" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a7620866-1cb9-449a-bbdb-cc3d5bbad730" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4837b04b-2132-4bb3-b282-4c586186b685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_88e0cc11-9d6d-4950-8906-dfe010598c26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a7620866-1cb9-449a-bbdb-cc3d5bbad730" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_88e0cc11-9d6d-4950-8906-dfe010598c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8a8b476b-4bb9-41de-9f5c-b65995936aac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a7620866-1cb9-449a-bbdb-cc3d5bbad730" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8a8b476b-4bb9-41de-9f5c-b65995936aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6f7c7b14-cf94-48de-825c-d55a42b3bff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_80d7d79c-fb80-41fc-904f-ab0250fc64f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6f7c7b14-cf94-48de-825c-d55a42b3bff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8b154d53-f7f2-4965-aadf-50a522be7bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6f7c7b14-cf94-48de-825c-d55a42b3bff9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8b154d53-f7f2-4965-aadf-50a522be7bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_aff5c0f0-cde0-4cc7-a2e8-e7fd9e7691ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6f7c7b14-cf94-48de-825c-d55a42b3bff9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_aff5c0f0-cde0-4cc7-a2e8-e7fd9e7691ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_306a8d46-a4b9-4398-a02a-32115001b007" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6f7c7b14-cf94-48de-825c-d55a42b3bff9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_306a8d46-a4b9-4398-a02a-32115001b007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_bcb387ec-53e7-47a8-9e68-4b7baede7ef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6f7c7b14-cf94-48de-825c-d55a42b3bff9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_bcb387ec-53e7-47a8-9e68-4b7baede7ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eb75da3f-14fd-4280-b2d7-9f2180f1926e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6f7c7b14-cf94-48de-825c-d55a42b3bff9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eb75da3f-14fd-4280-b2d7-9f2180f1926e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8dd43fcd-4f29-4fe7-86a2-16b0042da0db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_80d7d79c-fb80-41fc-904f-ab0250fc64f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8dd43fcd-4f29-4fe7-86a2-16b0042da0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7bd5866e-4617-471d-b283-9923e1d24931" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8dd43fcd-4f29-4fe7-86a2-16b0042da0db" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7bd5866e-4617-471d-b283-9923e1d24931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3e82eecd-d23c-4b2c-8722-7343cb0b26bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8dd43fcd-4f29-4fe7-86a2-16b0042da0db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3e82eecd-d23c-4b2c-8722-7343cb0b26bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9f47a608-3859-4f28-99e7-96e4daad6706" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8dd43fcd-4f29-4fe7-86a2-16b0042da0db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9f47a608-3859-4f28-99e7-96e4daad6706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_af81f91c-1d7f-40c2-98c5-040e5b98fa81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8dd43fcd-4f29-4fe7-86a2-16b0042da0db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_af81f91c-1d7f-40c2-98c5-040e5b98fa81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_30f26266-53de-4120-8a78-772312c3f4c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8dd43fcd-4f29-4fe7-86a2-16b0042da0db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_30f26266-53de-4120-8a78-772312c3f4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_72c29997-4d4b-4485-afcf-a09c2aeed5ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8dd43fcd-4f29-4fe7-86a2-16b0042da0db" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_72c29997-4d4b-4485-afcf-a09c2aeed5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5ffb3a34-679b-418a-8030-9fb719175ebb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_8dd43fcd-4f29-4fe7-86a2-16b0042da0db" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5ffb3a34-679b-418a-8030-9fb719175ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/StockholdersequityScheduleofWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#StockholdersequityScheduleofWeightedAverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/StockholdersequityScheduleofWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8ace742a-c778-4073-873b-79ab7cebb248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7fe159e1-a86c-4e3c-bcbe-1eb5a5bd0a52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8ace742a-c778-4073-873b-79ab7cebb248" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7fe159e1-a86c-4e3c-bcbe-1eb5a5bd0a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f226dfe8-6b3e-4033-8999-2c87abadcd11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8ace742a-c778-4073-873b-79ab7cebb248" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f226dfe8-6b3e-4033-8999-2c87abadcd11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_910f4861-15f6-4a7d-af95-0b0baca4d69a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8ace742a-c778-4073-873b-79ab7cebb248" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_910f4861-15f6-4a7d-af95-0b0baca4d69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_57cf491f-dbf1-43dc-b551-d0e25cff863b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8ace742a-c778-4073-873b-79ab7cebb248" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_57cf491f-dbf1-43dc-b551-d0e25cff863b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/StockholdersequityScheduleofRSUActivityDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#StockholdersequityScheduleofRSUActivityDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/StockholdersequityScheduleofRSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_27d40472-9298-4da7-9bc0-fdd698b7c2b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9f822180-b41c-48e6-a4a6-afb25ad8444a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_27d40472-9298-4da7-9bc0-fdd698b7c2b2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9f822180-b41c-48e6-a4a6-afb25ad8444a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6055318b-9ed2-4a2e-91ea-ea2cd22b8a94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9f822180-b41c-48e6-a4a6-afb25ad8444a" xlink:to="loc_us-gaap_AwardTypeAxis_6055318b-9ed2-4a2e-91ea-ea2cd22b8a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c6ee62e-d939-4910-b3bd-81b7b5316495" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6055318b-9ed2-4a2e-91ea-ea2cd22b8a94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c6ee62e-d939-4910-b3bd-81b7b5316495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_041b5af7-1884-4837-9c0e-3308b212cf9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c6ee62e-d939-4910-b3bd-81b7b5316495" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_041b5af7-1884-4837-9c0e-3308b212cf9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fdb39b71-da26-486c-bc36-f80e12349fc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9f822180-b41c-48e6-a4a6-afb25ad8444a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fdb39b71-da26-486c-bc36-f80e12349fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0cbdde5-a5a8-49a1-bb76-3d9502e27218" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fdb39b71-da26-486c-bc36-f80e12349fc5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0cbdde5-a5a8-49a1-bb76-3d9502e27218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_59fecea0-2c4f-4c75-96ea-0c9913b2c2c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0cbdde5-a5a8-49a1-bb76-3d9502e27218" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_59fecea0-2c4f-4c75-96ea-0c9913b2c2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_eb5f71ab-dbcb-406f-b2f3-ba429ab90c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0cbdde5-a5a8-49a1-bb76-3d9502e27218" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_eb5f71ab-dbcb-406f-b2f3-ba429ab90c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6ae267cb-e5bd-4ccf-88c2-416f174138bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0cbdde5-a5a8-49a1-bb76-3d9502e27218" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6ae267cb-e5bd-4ccf-88c2-416f174138bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_072f9e81-aa31-47ff-b2a0-f6a590047423" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0cbdde5-a5a8-49a1-bb76-3d9502e27218" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_072f9e81-aa31-47ff-b2a0-f6a590047423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1cc3d7d3-b767-480c-aa83-0b4202795fb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_e0cbdde5-a5a8-49a1-bb76-3d9502e27218" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1cc3d7d3-b767-480c-aa83-0b4202795fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b5eac660-fd50-4804-a3a4-a41f324cdd0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fdb39b71-da26-486c-bc36-f80e12349fc5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b5eac660-fd50-4804-a3a4-a41f324cdd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cfb69c38-4a4e-4a94-86ea-cbd791b2d87c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b5eac660-fd50-4804-a3a4-a41f324cdd0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cfb69c38-4a4e-4a94-86ea-cbd791b2d87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9f643b9a-0b9d-4eef-b17d-626946556367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b5eac660-fd50-4804-a3a4-a41f324cdd0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9f643b9a-0b9d-4eef-b17d-626946556367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3d535ff5-0bd3-4a88-9fbd-8b73532a6f9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b5eac660-fd50-4804-a3a4-a41f324cdd0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3d535ff5-0bd3-4a88-9fbd-8b73532a6f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f2b49b6e-5ca9-4cfc-8eec-8a8a8b3c4b72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b5eac660-fd50-4804-a3a4-a41f324cdd0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f2b49b6e-5ca9-4cfc-8eec-8a8a8b3c4b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a9de4481-08bd-4d1f-b4a0-fcb8d94dc4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b5eac660-fd50-4804-a3a4-a41f324cdd0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a9de4481-08bd-4d1f-b4a0-fcb8d94dc4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/StockholdersequitySummaryofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#StockholdersequitySummaryofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/StockholdersequitySummaryofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c6f45b8f-a03f-4b4f-95a0-3dddb44a8a13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e94f28c2-21e0-4c05-917d-0617123c5fed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c6f45b8f-a03f-4b4f-95a0-3dddb44a8a13" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e94f28c2-21e0-4c05-917d-0617123c5fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_24d2e19c-257e-4164-869f-a8c5adc14e86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e94f28c2-21e0-4c05-917d-0617123c5fed" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_24d2e19c-257e-4164-869f-a8c5adc14e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2d35cfa8-9ba0-43de-8c5e-da17e2bfd4a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_24d2e19c-257e-4164-869f-a8c5adc14e86" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2d35cfa8-9ba0-43de-8c5e-da17e2bfd4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_35acfedd-46f9-4a3a-b7aa-084727ddc7b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2d35cfa8-9ba0-43de-8c5e-da17e2bfd4a1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_35acfedd-46f9-4a3a-b7aa-084727ddc7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1f9ecfa1-dd0b-47cf-819f-19f8f94a864e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2d35cfa8-9ba0-43de-8c5e-da17e2bfd4a1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1f9ecfa1-dd0b-47cf-819f-19f8f94a864e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e359938-5a3f-4cdc-9a0d-25af9acf9648" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e94f28c2-21e0-4c05-917d-0617123c5fed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e359938-5a3f-4cdc-9a0d-25af9acf9648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b45bfcaa-3427-4ef6-abc7-256c40452d19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e359938-5a3f-4cdc-9a0d-25af9acf9648" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b45bfcaa-3427-4ef6-abc7-256c40452d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Restructuring" xlink:type="simple" xlink:href="nltx-20201231.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6f9a6874-7215-49f4-8dec-7003fead453b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_51350f07-0735-47c6-8af3-3b2fa1dbde2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6f9a6874-7215-49f4-8dec-7003fead453b" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_51350f07-0735-47c6-8af3-3b2fa1dbde2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/RestructuringAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#RestructuringAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/RestructuringAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ba847449-2337-4b67-bd41-a08d5317cdfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5c9a0262-e865-42f0-9c54-eb836003f7af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ba847449-2337-4b67-bd41-a08d5317cdfa" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5c9a0262-e865-42f0-9c54-eb836003f7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_42680315-72b9-4583-b0d4-d0609e07ecf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5c9a0262-e865-42f0-9c54-eb836003f7af" xlink:to="loc_us-gaap_RestructuringPlanAxis_42680315-72b9-4583-b0d4-d0609e07ecf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_b1eeeb9e-c32f-4a7b-9314-45b445a10bb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_42680315-72b9-4583-b0d4-d0609e07ecf9" xlink:to="loc_us-gaap_RestructuringPlanDomain_b1eeeb9e-c32f-4a7b-9314-45b445a10bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_RestructuringPlan1July2018Member_011e2a49-1bb3-4cb1-bff4-cf2a40d3051b" xlink:href="nltx-20201231.xsd#nltx_RestructuringPlan1July2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_b1eeeb9e-c32f-4a7b-9314-45b445a10bb8" xlink:to="loc_nltx_RestructuringPlan1July2018Member_011e2a49-1bb3-4cb1-bff4-cf2a40d3051b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_RestructuringPlan1November62018Member_4602221f-bc96-4fd9-a910-7f3bdbfabe1a" xlink:href="nltx-20201231.xsd#nltx_RestructuringPlan1November62018Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_b1eeeb9e-c32f-4a7b-9314-45b445a10bb8" xlink:to="loc_nltx_RestructuringPlan1November62018Member_4602221f-bc96-4fd9-a910-7f3bdbfabe1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ddae4b0f-d042-49b7-bf3e-c014266896af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5c9a0262-e865-42f0-9c54-eb836003f7af" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ddae4b0f-d042-49b7-bf3e-c014266896af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_37bac6ce-52ed-4c9a-a08e-94b02e973097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ddae4b0f-d042-49b7-bf3e-c014266896af" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_37bac6ce-52ed-4c9a-a08e-94b02e973097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ccac093f-238e-403e-8f90-c21e4959378a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_37bac6ce-52ed-4c9a-a08e-94b02e973097" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ccac093f-238e-403e-8f90-c21e4959378a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8c7da214-9a40-40f5-8361-a44d5fc8e6b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_37bac6ce-52ed-4c9a-a08e-94b02e973097" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8c7da214-9a40-40f5-8361-a44d5fc8e6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_50ee28c3-fc88-4d86-80e6-2b862629793a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5c9a0262-e865-42f0-9c54-eb836003f7af" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_50ee28c3-fc88-4d86-80e6-2b862629793a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_b3dcecde-93d4-415d-8f10-0214ca3a674b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50ee28c3-fc88-4d86-80e6-2b862629793a" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_b3dcecde-93d4-415d-8f10-0214ca3a674b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_3b55271f-4c11-4fe4-a57a-56d5a6fd1269" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50ee28c3-fc88-4d86-80e6-2b862629793a" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_3b55271f-4c11-4fe4-a57a-56d5a6fd1269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_0bb2adc7-470e-4d1e-b62f-5b06980cea9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50ee28c3-fc88-4d86-80e6-2b862629793a" xlink:to="loc_us-gaap_RestructuringReserve_0bb2adc7-470e-4d1e-b62f-5b06980cea9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_fa36d119-ae1c-49f8-9df9-81e980786a03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50ee28c3-fc88-4d86-80e6-2b862629793a" xlink:to="loc_us-gaap_RestructuringCharges_fa36d119-ae1c-49f8-9df9-81e980786a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Otherincomenet" xlink:type="simple" xlink:href="nltx-20201231.xsd#Otherincomenet"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/Otherincomenet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_4ce1fa21-4f84-4eca-9a4e-b042eb227e00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_6e2d498c-9e3a-49fb-bd45-8b5e56edabdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_4ce1fa21-4f84-4eca-9a4e-b042eb227e00" xlink:to="loc_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_6e2d498c-9e3a-49fb-bd45-8b5e56edabdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/OtherincomenetTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#OtherincomenetTables"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/OtherincomenetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_79c8c608-154f-46ed-9d1b-86fdcdf4b7b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_037b142a-d3b4-4673-a96f-d81141ee837a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_79c8c608-154f-46ed-9d1b-86fdcdf4b7b2" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_037b142a-d3b4-4673-a96f-d81141ee837a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/OtherincomenetScheduleofOtherIncomeNetDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#OtherincomenetScheduleofOtherIncomeNetDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/OtherincomenetScheduleofOtherIncomeNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_f11b8ed3-3213-44b2-891c-5e62b630bf11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_0ebf2c7b-707e-4c40-923f-52f02a27bda0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_f11b8ed3-3213-44b2-891c-5e62b630bf11" xlink:to="loc_us-gaap_InvestmentIncomeNet_0ebf2c7b-707e-4c40-923f-52f02a27bda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_3eeda284-abac-4325-bd51-38d8f0c012c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_f11b8ed3-3213-44b2-891c-5e62b630bf11" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_3eeda284-abac-4325-bd51-38d8f0c012c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_18d09766-aefa-403c-abb3-e44a0d123994" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_f11b8ed3-3213-44b2-891c-5e62b630bf11" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_18d09766-aefa-403c-abb3-e44a0d123994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7b54d94a-d547-461e-a699-c25036339395" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_f11b8ed3-3213-44b2-891c-5e62b630bf11" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_7b54d94a-d547-461e-a699-c25036339395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Netlosspercommonstock" xlink:type="simple" xlink:href="nltx-20201231.xsd#Netlosspercommonstock"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/Netlosspercommonstock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_19750274-bad0-498f-bb75-530ebdd28810" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_16995385-c401-4a85-bcdd-676998266a56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_19750274-bad0-498f-bb75-530ebdd28810" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_16995385-c401-4a85-bcdd-676998266a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/NetlosspercommonstockTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#NetlosspercommonstockTables"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/NetlosspercommonstockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d547ca35-501a-40f1-9e1d-ae5946b47e4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c15694a5-3134-4961-bef6-6461a79abb65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d547ca35-501a-40f1-9e1d-ae5946b47e4b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c15694a5-3134-4961-bef6-6461a79abb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/NetlosspercommonstockScheduleofSecuritiesExcludedFromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#NetlosspercommonstockScheduleofSecuritiesExcludedFromComputationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/NetlosspercommonstockScheduleofSecuritiesExcludedFromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_cc74ce8f-a17a-47e2-9943-c5c215778ee1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4f3efbdf-cd66-41dc-bdbe-f375dad6d8eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cc74ce8f-a17a-47e2-9943-c5c215778ee1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4f3efbdf-cd66-41dc-bdbe-f375dad6d8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7dee1535-ff3a-4a84-b12f-a3a45b48b26f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4f3efbdf-cd66-41dc-bdbe-f375dad6d8eb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7dee1535-ff3a-4a84-b12f-a3a45b48b26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0925d36a-c093-45e8-96c1-4b45f2141b5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7dee1535-ff3a-4a84-b12f-a3a45b48b26f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0925d36a-c093-45e8-96c1-4b45f2141b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fbeb8767-a263-4bf6-99aa-3a8a2e08b418" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0925d36a-c093-45e8-96c1-4b45f2141b5a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fbeb8767-a263-4bf6-99aa-3a8a2e08b418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_818484f0-b484-4022-bc6c-84754eb4f51d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0925d36a-c093-45e8-96c1-4b45f2141b5a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_818484f0-b484-4022-bc6c-84754eb4f51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_8d011abe-b2e4-470a-80aa-ec869b3b6b54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0925d36a-c093-45e8-96c1-4b45f2141b5a" xlink:to="loc_us-gaap_EmployeeStockMember_8d011abe-b2e4-470a-80aa-ec869b3b6b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_749ba388-172c-43b6-98e1-0736d0e6e1c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4f3efbdf-cd66-41dc-bdbe-f375dad6d8eb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_749ba388-172c-43b6-98e1-0736d0e6e1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2c829183-d959-479e-8001-fa7032deb7ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_749ba388-172c-43b6-98e1-0736d0e6e1c9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2c829183-d959-479e-8001-fa7032deb7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Incometaxes" xlink:type="simple" xlink:href="nltx-20201231.xsd#Incometaxes"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/Incometaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_08c95205-2802-4824-a1b2-e0fb3bdedcd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_dcf74b23-34dc-4a2a-86f3-5728cf53cf39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_08c95205-2802-4824-a1b2-e0fb3bdedcd0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_dcf74b23-34dc-4a2a-86f3-5728cf53cf39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/IncometaxesTables" xlink:type="simple" xlink:href="nltx-20201231.xsd#IncometaxesTables"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/IncometaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_37f59524-417c-4a22-9dda-1a3a416c4d26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3a2902ac-a61d-438c-b49f-fbf242203d8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_37f59524-417c-4a22-9dda-1a3a416c4d26" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3a2902ac-a61d-438c-b49f-fbf242203d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_8cb2dadf-40cd-4a6e-97ee-43b53b760da8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_37f59524-417c-4a22-9dda-1a3a416c4d26" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_8cb2dadf-40cd-4a6e-97ee-43b53b760da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_a114fd1f-7ce5-45b1-965b-299553c3d207" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_37f59524-417c-4a22-9dda-1a3a416c4d26" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_a114fd1f-7ce5-45b1-965b-299553c3d207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#IncomeTaxesScheduleofIncometaxRecoveryDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c9dbba0a-429a-4256-97bd-555ee3247e7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d1bdcefe-b534-477d-adf2-5c03f91a3452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c9dbba0a-429a-4256-97bd-555ee3247e7b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d1bdcefe-b534-477d-adf2-5c03f91a3452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_920f46b6-c9ff-4454-b9b7-45c83b13f6f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c9dbba0a-429a-4256-97bd-555ee3247e7b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_920f46b6-c9ff-4454-b9b7-45c83b13f6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_19fd91e4-7292-49e0-8bcb-0b46efa77d14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c9dbba0a-429a-4256-97bd-555ee3247e7b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_19fd91e4-7292-49e0-8bcb-0b46efa77d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_a78b98c4-57c5-46c0-8483-2ba7264239c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c9dbba0a-429a-4256-97bd-555ee3247e7b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_a78b98c4-57c5-46c0-8483-2ba7264239c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_6cd3b165-142a-4cf3-a718-2ae7e0c5f451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c9dbba0a-429a-4256-97bd-555ee3247e7b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_6cd3b165-142a-4cf3-a718-2ae7e0c5f451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_84d668c6-f598-425b-9071-26cd80a67ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c9dbba0a-429a-4256-97bd-555ee3247e7b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_84d668c6-f598-425b-9071-26cd80a67ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_da716f93-ac6a-4942-aaaf-910a76b1dcec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c9dbba0a-429a-4256-97bd-555ee3247e7b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_da716f93-ac6a-4942-aaaf-910a76b1dcec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_079f2598-d37f-402e-b8cb-744d99f681ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c9dbba0a-429a-4256-97bd-555ee3247e7b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_079f2598-d37f-402e-b8cb-744d99f681ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent_f9477842-058c-428e-a489-74223479d5cc" xlink:href="nltx-20201231.xsd#nltx_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c9dbba0a-429a-4256-97bd-555ee3247e7b" xlink:to="loc_nltx_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent_f9477842-058c-428e-a489-74223479d5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_035709eb-e495-4d0d-b985-d5c198a8e07b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c9dbba0a-429a-4256-97bd-555ee3247e7b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_035709eb-e495-4d0d-b985-d5c198a8e07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_44cdfa44-10c7-4b9a-877c-ce0516c75a60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c9dbba0a-429a-4256-97bd-555ee3247e7b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_44cdfa44-10c7-4b9a-877c-ce0516c75a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7568954e-592c-4841-9aa7-9ad53d0acbec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c9dbba0a-429a-4256-97bd-555ee3247e7b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7568954e-592c-4841-9aa7-9ad53d0acbec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/IncomeTaxesScheduleofNetLossIncomeBeforeTaxesDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#IncomeTaxesScheduleofNetLossIncomeBeforeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/IncomeTaxesScheduleofNetLossIncomeBeforeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0349d12e-3612-4775-9c27-8d9b1f73d6a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_8f6b5bf7-9ae0-4d16-9efa-781ef7a97dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0349d12e-3612-4775-9c27-8d9b1f73d6a0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_8f6b5bf7-9ae0-4d16-9efa-781ef7a97dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_bedad325-b685-4e1a-bb4c-bd0807c2dc47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0349d12e-3612-4775-9c27-8d9b1f73d6a0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_bedad325-b685-4e1a-bb4c-bd0807c2dc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_298fce56-f4b0-4752-b929-e8f33beeedff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0349d12e-3612-4775-9c27-8d9b1f73d6a0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_298fce56-f4b0-4752-b929-e8f33beeedff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7037779b-8ecc-4c10-9650-ea0a3e67a2ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_34f4369d-5188-4a6b-a53d-797e807694e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7037779b-8ecc-4c10-9650-ea0a3e67a2ea" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_34f4369d-5188-4a6b-a53d-797e807694e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_aa6e7cc2-06ae-49fd-9e6c-9c4f5382688b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_34f4369d-5188-4a6b-a53d-797e807694e8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_aa6e7cc2-06ae-49fd-9e6c-9c4f5382688b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_0fd8b3a3-6d79-4dbd-9a64-073ee45a81de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_34f4369d-5188-4a6b-a53d-797e807694e8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_0fd8b3a3-6d79-4dbd-9a64-073ee45a81de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_499a5341-040a-4733-9599-4e9f81336b7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_34f4369d-5188-4a6b-a53d-797e807694e8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_499a5341-040a-4733-9599-4e9f81336b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_6538298b-43d9-4698-99e5-c373d952637e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_34f4369d-5188-4a6b-a53d-797e807694e8" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_6538298b-43d9-4698-99e5-c373d952637e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_DeferredTaxAssetsLeaseLiability_83f7bf89-3d13-4bfc-8370-ce3ce536ea89" xlink:href="nltx-20201231.xsd#nltx_DeferredTaxAssetsLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_34f4369d-5188-4a6b-a53d-797e807694e8" xlink:to="loc_nltx_DeferredTaxAssetsLeaseLiability_83f7bf89-3d13-4bfc-8370-ce3ce536ea89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c43d9476-5c3f-4afb-9760-8c0809768952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_34f4369d-5188-4a6b-a53d-797e807694e8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c43d9476-5c3f-4afb-9760-8c0809768952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_f653a785-7901-49a4-b236-bd1b3958bc86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_34f4369d-5188-4a6b-a53d-797e807694e8" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_f653a785-7901-49a4-b236-bd1b3958bc86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_30ce35bb-2a49-44bd-bc29-fafe1a4f7417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_34f4369d-5188-4a6b-a53d-797e807694e8" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_30ce35bb-2a49-44bd-bc29-fafe1a4f7417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_266df33e-8002-4e2d-9c40-57a55862aef1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7037779b-8ecc-4c10-9650-ea0a3e67a2ea" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_266df33e-8002-4e2d-9c40-57a55862aef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2796fe3b-35d9-48bc-9703-7f6c69ab7d5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_266df33e-8002-4e2d-9c40-57a55862aef1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2796fe3b-35d9-48bc-9703-7f6c69ab7d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_0efacfa4-9dbb-48aa-a206-a51adaa0531c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_266df33e-8002-4e2d-9c40-57a55862aef1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_0efacfa4-9dbb-48aa-a206-a51adaa0531c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_3b589273-8e3f-4e81-a852-f1ff94e41d13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_266df33e-8002-4e2d-9c40-57a55862aef1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_3b589273-8e3f-4e81-a852-f1ff94e41d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_DeferredTaxAssetsBeforeValuationAllowance_5fc16846-de18-459c-81ea-d2ed286c996e" xlink:href="nltx-20201231.xsd#nltx_DeferredTaxAssetsBeforeValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7037779b-8ecc-4c10-9650-ea0a3e67a2ea" xlink:to="loc_nltx_DeferredTaxAssetsBeforeValuationAllowance_5fc16846-de18-459c-81ea-d2ed286c996e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c89bb88d-0635-414c-8e14-7003209996bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7037779b-8ecc-4c10-9650-ea0a3e67a2ea" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c89bb88d-0635-414c-8e14-7003209996bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_01115c10-7e9a-4465-9645-118bd974a46b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7037779b-8ecc-4c10-9650-ea0a3e67a2ea" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_01115c10-7e9a-4465-9645-118bd974a46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5a755d44-0ecf-472f-a9ec-90e3ba0871e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_IncomeTaxesDisclosureTable_4480e7a5-3ade-4e20-8ec5-cb9392135360" xlink:href="nltx-20201231.xsd#nltx_IncomeTaxesDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5a755d44-0ecf-472f-a9ec-90e3ba0871e9" xlink:to="loc_nltx_IncomeTaxesDisclosureTable_4480e7a5-3ade-4e20-8ec5-cb9392135360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_acbb0524-c765-46fe-81f4-afb5f778480a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_IncomeTaxesDisclosureTable_4480e7a5-3ade-4e20-8ec5-cb9392135360" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_acbb0524-c765-46fe-81f4-afb5f778480a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_02ccd010-c15e-4403-a1a8-826459dd0647" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_acbb0524-c765-46fe-81f4-afb5f778480a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_02ccd010-c15e-4403-a1a8-826459dd0647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcqinoxCanadaMember_ce0e557f-7b6a-43fc-9fb3-97f89b5428fb" xlink:href="nltx-20201231.xsd#nltx_AcqinoxCanadaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_02ccd010-c15e-4403-a1a8-826459dd0647" xlink:to="loc_nltx_AcqinoxCanadaMember_ce0e557f-7b6a-43fc-9fb3-97f89b5428fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_96d087d3-3e00-49db-ae98-a02c7331ab07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_IncomeTaxesDisclosureTable_4480e7a5-3ade-4e20-8ec5-cb9392135360" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_96d087d3-3e00-49db-ae98-a02c7331ab07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_f8ed2b6a-55fa-4460-989a-7372140e9b6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_96d087d3-3e00-49db-ae98-a02c7331ab07" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_f8ed2b6a-55fa-4460-989a-7372140e9b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_6b23a0cb-7bec-44f3-bdf3-584d63f398b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_f8ed2b6a-55fa-4460-989a-7372140e9b6c" xlink:to="loc_us-gaap_ResearchMember_6b23a0cb-7bec-44f3-bdf3-584d63f398b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_IncomeTaxesDisclosureLineItems_f1753631-95f0-4863-9916-4673811240c0" xlink:href="nltx-20201231.xsd#nltx_IncomeTaxesDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_IncomeTaxesDisclosureTable_4480e7a5-3ade-4e20-8ec5-cb9392135360" xlink:to="loc_nltx_IncomeTaxesDisclosureLineItems_f1753631-95f0-4863-9916-4673811240c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary_3fc860a3-5b90-4b1c-8109-a6f4922df76d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_IncomeTaxesDisclosureLineItems_f1753631-95f0-4863-9916-4673811240c0" xlink:to="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary_3fc860a3-5b90-4b1c-8109-a6f4922df76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_DeferredTaxAssetsTaxCreditCarryforwardsReducedDueToSaleOfForeignEntity_86657781-b895-43f9-9216-0a2f070e89f3" xlink:href="nltx-20201231.xsd#nltx_DeferredTaxAssetsTaxCreditCarryforwardsReducedDueToSaleOfForeignEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_IncomeTaxesDisclosureLineItems_f1753631-95f0-4863-9916-4673811240c0" xlink:to="loc_nltx_DeferredTaxAssetsTaxCreditCarryforwardsReducedDueToSaleOfForeignEntity_86657781-b895-43f9-9216-0a2f070e89f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_f8093805-89a7-467f-a643-dde51b531a6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_IncomeTaxesDisclosureLineItems_f1753631-95f0-4863-9916-4673811240c0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_f8093805-89a7-467f-a643-dde51b531a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_OperatingLossCarryforwardsSubjectToExpiration_1bdf977d-4883-40f4-b0e3-4c7655d1f51e" xlink:href="nltx-20201231.xsd#nltx_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_IncomeTaxesDisclosureLineItems_f1753631-95f0-4863-9916-4673811240c0" xlink:to="loc_nltx_OperatingLossCarryforwardsSubjectToExpiration_1bdf977d-4883-40f4-b0e3-4c7655d1f51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_OperatingLossCarryforwardsNotSubjectToExpiration_97853c9c-ee10-49c9-a1d8-ff28c3bb3313" xlink:href="nltx-20201231.xsd#nltx_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_IncomeTaxesDisclosureLineItems_f1753631-95f0-4863-9916-4673811240c0" xlink:to="loc_nltx_OperatingLossCarryforwardsNotSubjectToExpiration_97853c9c-ee10-49c9-a1d8-ff28c3bb3313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_27456f9d-8d7d-49f4-be0e-8bdffc23af2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_IncomeTaxesDisclosureLineItems_f1753631-95f0-4863-9916-4673811240c0" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_27456f9d-8d7d-49f4-be0e-8bdffc23af2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_6ceb23c3-1609-4ea6-b55e-49ce1b63e5dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_IncomeTaxesDisclosureLineItems_f1753631-95f0-4863-9916-4673811240c0" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_6ceb23c3-1609-4ea6-b55e-49ce1b63e5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Licenseandpatentagreements" xlink:type="simple" xlink:href="nltx-20201231.xsd#Licenseandpatentagreements"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/Licenseandpatentagreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nltx_LicenseAgreementAbstract_723896d2-9fe8-49bc-ae1e-945df0ba9bf7" xlink:href="nltx-20201231.xsd#nltx_LicenseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_LicenseAgreementDisclosureTextBlock_59e7536c-de7b-4c2b-ad3e-f54401488af6" xlink:href="nltx-20201231.xsd#nltx_LicenseAgreementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_LicenseAgreementAbstract_723896d2-9fe8-49bc-ae1e-945df0ba9bf7" xlink:to="loc_nltx_LicenseAgreementDisclosureTextBlock_59e7536c-de7b-4c2b-ad3e-f54401488af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#LicenseandpatentagreementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nltx_LicenseAgreementAbstract_2351621c-722f-461b-87a2-c10b32ff03ad" xlink:href="nltx-20201231.xsd#nltx_LicenseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_LicenseAndPatentAgreementsTable_8c37586b-0440-410a-84ee-496b3d12804d" xlink:href="nltx-20201231.xsd#nltx_LicenseAndPatentAgreementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_LicenseAgreementAbstract_2351621c-722f-461b-87a2-c10b32ff03ad" xlink:to="loc_nltx_LicenseAndPatentAgreementsTable_8c37586b-0440-410a-84ee-496b3d12804d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_603f510a-a4da-4159-8c9e-a62d2f5c3c78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_LicenseAndPatentAgreementsTable_8c37586b-0440-410a-84ee-496b3d12804d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_603f510a-a4da-4159-8c9e-a62d2f5c3c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cfc48fa0-2699-4420-a8a9-dfcf4e871cbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_603f510a-a4da-4159-8c9e-a62d2f5c3c78" xlink:to="loc_us-gaap_ClassOfStockDomain_cfc48fa0-2699-4420-a8a9-dfcf4e871cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_NonVotingConvertiblePreferredStockMember_c72e72ab-5589-45b1-94cf-7873a5924e25" xlink:href="nltx-20201231.xsd#nltx_NonVotingConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_cfc48fa0-2699-4420-a8a9-dfcf4e871cbd" xlink:to="loc_nltx_NonVotingConvertiblePreferredStockMember_c72e72ab-5589-45b1-94cf-7873a5924e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e3228792-1253-4c9a-a40a-88ff62ac6f1f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_LicenseAndPatentAgreementsTable_8c37586b-0440-410a-84ee-496b3d12804d" xlink:to="loc_srt_ProductOrServiceAxis_e3228792-1253-4c9a-a40a-88ff62ac6f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1a2691f5-3ec9-44b0-a473-86ce7547fd82" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e3228792-1253-4c9a-a40a-88ff62ac6f1f" xlink:to="loc_srt_ProductsAndServicesDomain_1a2691f5-3ec9-44b0-a473-86ce7547fd82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndMaintenanceMember_6925c475-05b9-48f3-9f15-3eb5feb59b79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndMaintenanceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a2691f5-3ec9-44b0-a473-86ce7547fd82" xlink:to="loc_us-gaap_LicenseAndMaintenanceMember_6925c475-05b9-48f3-9f15-3eb5feb59b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_27253bf4-e3d0-4c4c-946a-889ca00005f1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_LicenseAndPatentAgreementsTable_8c37586b-0440-410a-84ee-496b3d12804d" xlink:to="loc_srt_RangeAxis_27253bf4-e3d0-4c4c-946a-889ca00005f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e0c6295c-45ec-4a29-8214-52e72ec65050" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_27253bf4-e3d0-4c4c-946a-889ca00005f1" xlink:to="loc_srt_RangeMember_e0c6295c-45ec-4a29-8214-52e72ec65050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fbc3db6d-4531-4652-9695-d5c2268ca0c9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e0c6295c-45ec-4a29-8214-52e72ec65050" xlink:to="loc_srt_MinimumMember_fbc3db6d-4531-4652-9695-d5c2268ca0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d96b9769-dbe3-4928-9e02-0a5bd2ad8d9a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e0c6295c-45ec-4a29-8214-52e72ec65050" xlink:to="loc_srt_MaximumMember_d96b9769-dbe3-4928-9e02-0a5bd2ad8d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5750c54a-fa4f-4209-84f5-81384c9a1f63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_LicenseAndPatentAgreementsTable_8c37586b-0440-410a-84ee-496b3d12804d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5750c54a-fa4f-4209-84f5-81384c9a1f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e7cefce8-b8d2-4abd-b202-ca6028ceed7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5750c54a-fa4f-4209-84f5-81384c9a1f63" xlink:to="loc_us-gaap_EquityComponentDomain_e7cefce8-b8d2-4abd-b202-ca6028ceed7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ee3cd48a-7528-4ba1-ae0e-b45db82b8bfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e7cefce8-b8d2-4abd-b202-ca6028ceed7f" xlink:to="loc_us-gaap_CommonStockMember_ee3cd48a-7528-4ba1-ae0e-b45db82b8bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis_6c78f5fb-4c69-4bd3-a1e0-ea6e8d7aa9da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_LicenseAndPatentAgreementsTable_8c37586b-0440-410a-84ee-496b3d12804d" xlink:to="loc_us-gaap_EquitySecuritiesByIndustryAxis_6c78f5fb-4c69-4bd3-a1e0-ea6e8d7aa9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_23ce423e-e20a-444c-a99d-31945f0b0f07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_6c78f5fb-4c69-4bd3-a1e0-ea6e8d7aa9da" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_23ce423e-e20a-444c-a99d-31945f0b0f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_UniversityOfWashingtonMember_2357c35f-f4ae-4900-8ce8-ef8c3ffb5a30" xlink:href="nltx-20201231.xsd#nltx_UniversityOfWashingtonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember_23ce423e-e20a-444c-a99d-31945f0b0f07" xlink:to="loc_nltx_UniversityOfWashingtonMember_2357c35f-f4ae-4900-8ce8-ef8c3ffb5a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_LicenseAndPatentAgreementsLineItems_25bc87e4-b231-49f7-a0c3-c2dcb24790ae" xlink:href="nltx-20201231.xsd#nltx_LicenseAndPatentAgreementsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_LicenseAndPatentAgreementsTable_8c37586b-0440-410a-84ee-496b3d12804d" xlink:to="loc_nltx_LicenseAndPatentAgreementsLineItems_25bc87e4-b231-49f7-a0c3-c2dcb24790ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_4c53a496-89ed-45db-aaf0-937ff8fafa96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_LicenseAndPatentAgreementsLineItems_25bc87e4-b231-49f7-a0c3-c2dcb24790ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_4c53a496-89ed-45db-aaf0-937ff8fafa96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_bcd83adc-bce4-4152-9c73-ab0ad40c6122" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_LicenseAndPatentAgreementsLineItems_25bc87e4-b231-49f7-a0c3-c2dcb24790ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_bcd83adc-bce4-4152-9c73-ab0ad40c6122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_LicenseArrangementsAmountsPayableOnDevelopmentalMilestones_2ce3420f-4df7-433c-b2ec-8ac7ae8f3963" xlink:href="nltx-20201231.xsd#nltx_LicenseArrangementsAmountsPayableOnDevelopmentalMilestones"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_LicenseAndPatentAgreementsLineItems_25bc87e4-b231-49f7-a0c3-c2dcb24790ae" xlink:to="loc_nltx_LicenseArrangementsAmountsPayableOnDevelopmentalMilestones_2ce3420f-4df7-433c-b2ec-8ac7ae8f3963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_LicenseArrangementsAmountsPayableBasedOnNetSales_4445c76b-e140-4307-9aa6-840b3385a574" xlink:href="nltx-20201231.xsd#nltx_LicenseArrangementsAmountsPayableBasedOnNetSales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_LicenseAndPatentAgreementsLineItems_25bc87e4-b231-49f7-a0c3-c2dcb24790ae" xlink:to="loc_nltx_LicenseArrangementsAmountsPayableBasedOnNetSales_4445c76b-e140-4307-9aa6-840b3385a574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_30bbac85-7ba5-4077-b4ce-13c2a1eb40c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_LicenseAndPatentAgreementsLineItems_25bc87e4-b231-49f7-a0c3-c2dcb24790ae" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_30bbac85-7ba5-4077-b4ce-13c2a1eb40c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/Commitmentsandcontingencies" xlink:type="simple" xlink:href="nltx-20201231.xsd#Commitmentsandcontingencies"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/Commitmentsandcontingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a4ff0f6a-943f-49da-9c8a-c5e8f4230480" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f907fffa-ca6c-4e98-8eb1-09f1621b97b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a4ff0f6a-943f-49da-9c8a-c5e8f4230480" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f907fffa-ca6c-4e98-8eb1-09f1621b97b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8bf9258f-54b0-49da-9f22-8a4dde8510aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_343464ca-f141-44af-bbdb-c50d1cab6009" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8bf9258f-54b0-49da-9f22-8a4dde8510aa" xlink:to="loc_us-gaap_PurchaseObligation_343464ca-f141-44af-bbdb-c50d1cab6009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/A401kplan" xlink:type="simple" xlink:href="nltx-20201231.xsd#A401kplan"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/A401kplan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_52bf8c43-4391-4231-af61-1f1a76ae2be2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTextBlock_5925572e-70a7-4e79-ae1b-e4bbcfe1b0ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_52bf8c43-4391-4231-af61-1f1a76ae2be2" xlink:to="loc_us-gaap_DefinedContributionPlanTextBlock_5925572e-70a7-4e79-ae1b-e4bbcfe1b0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/SaleofAquinoxCanada" xlink:type="simple" xlink:href="nltx-20201231.xsd#SaleofAquinoxCanada"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/SaleofAquinoxCanada" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nltx_SubsidiarySaleOfStockAbstract_32d2dd92-0420-4cf7-9646-008443854ebb" xlink:href="nltx-20201231.xsd#nltx_SubsidiarySaleOfStockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_SubsidiarySaleOfStockTextBlock_04045e57-e0c7-4e47-a8a4-beec4518460b" xlink:href="nltx-20201231.xsd#nltx_SubsidiarySaleOfStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_SubsidiarySaleOfStockAbstract_32d2dd92-0420-4cf7-9646-008443854ebb" xlink:to="loc_nltx_SubsidiarySaleOfStockTextBlock_04045e57-e0c7-4e47-a8a4-beec4518460b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.aqxpharma.com/role/SaleofAquinoxCanadaDetails" xlink:type="simple" xlink:href="nltx-20201231.xsd#SaleofAquinoxCanadaDetails"/>
  <link:presentationLink xlink:role="http://www.aqxpharma.com/role/SaleofAquinoxCanadaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_nltx_SubsidiarySaleOfStockAbstract_dd755b79-50d1-4af0-b0fe-a1fe5fa90777" xlink:href="nltx-20201231.xsd#nltx_SubsidiarySaleOfStockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_58ae5fb8-4e29-4614-987b-6fae4ccdc24d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nltx_SubsidiarySaleOfStockAbstract_dd755b79-50d1-4af0-b0fe-a1fe5fa90777" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_58ae5fb8-4e29-4614-987b-6fae4ccdc24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_73ba6ce1-6afc-4441-9de3-10b5e72fab9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_58ae5fb8-4e29-4614-987b-6fae4ccdc24d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_73ba6ce1-6afc-4441-9de3-10b5e72fab9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d3e6c42-449a-42a8-93f5-898119e67c5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_73ba6ce1-6afc-4441-9de3-10b5e72fab9e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d3e6c42-449a-42a8-93f5-898119e67c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_AcqinoxCanadaMember_bd68fad3-ee85-4a7b-a2c6-4a542d07f153" xlink:href="nltx-20201231.xsd#nltx_AcqinoxCanadaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d3e6c42-449a-42a8-93f5-898119e67c5f" xlink:to="loc_nltx_AcqinoxCanadaMember_bd68fad3-ee85-4a7b-a2c6-4a542d07f153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_ab09f084-eb71-448a-98eb-17f2a9477f34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_58ae5fb8-4e29-4614-987b-6fae4ccdc24d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_ab09f084-eb71-448a-98eb-17f2a9477f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_ProceedsFromSaleOfStockOfSubsidiary_de2aa65f-21d0-4318-a1c2-97dd6b928870" xlink:href="nltx-20201231.xsd#nltx_ProceedsFromSaleOfStockOfSubsidiary"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_ab09f084-eb71-448a-98eb-17f2a9477f34" xlink:to="loc_nltx_ProceedsFromSaleOfStockOfSubsidiary_de2aa65f-21d0-4318-a1c2-97dd6b928870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary_f74f3fdb-2a52-4caa-891d-ff23ba26dc38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_ab09f084-eb71-448a-98eb-17f2a9477f34" xlink:to="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary_f74f3fdb-2a52-4caa-891d-ff23ba26dc38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nltx_TransactionRelatedCostIncurredForSaleOfSubsidiary_a7e9c06b-6bb2-4aea-a36e-3b3b77e5da10" xlink:href="nltx-20201231.xsd#nltx_TransactionRelatedCostIncurredForSaleOfSubsidiary"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_ab09f084-eb71-448a-98eb-17f2a9477f34" xlink:to="loc_nltx_TransactionRelatedCostIncurredForSaleOfSubsidiary_a7e9c06b-6bb2-4aea-a36e-3b3b77e5da10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>nltx-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nltx="http://www.aqxpharma.com/20201231"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nltx-20201231.xsd" xlink:type="simple"/>
    <context id="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic2b26b0a70bd4921be8f5b71cba81d62_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="idd7a0891c771440993dddc18188b0907_I20210322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <instant>2021-03-22</instant>
        </period>
    </context>
    <context id="i2e2fcca578804ccebdb1444503987c24_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9532edde7a4d48b5887af8007e83465c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i049d641cdc3c4012850e2abee7d5fe17_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i732d643094fe48eabda3a3bdcda606d7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5cf36246e64844f0999cee0b4685f134_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibc7d097a895f4d19ad4225c8b7a363e3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ia5203423d3b74826a3d7fe380aabf55b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4f9b47e6f171422bb275e6ef86e39725_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9b5b9988d4e248bc863b2725dbedccc0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nltx:NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie40aff3f920a4fa49c187c3ad3974bfb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nltx:NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0d6e4cb98c3641c0b1a872248ed13060_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9394470fa9e045eaaa71a62dee88a970_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i85f0f44c55744942ad3e1471a8246db3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9cc2885987c54d929541504d3cf066e4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib2b7aa4965884327b321e9713f816fca_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i815e5dda4d8349a9beb806cdf5433517_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i54fb527f851045fcb24b611005c9b2a2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8c771818b1a2410cbe3be150df63decf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i64550577bf6444d791bf8bd32d649edd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i277fa222473b45ceb75d3af3ec082271_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d1ecd6573694fdfb6e3cad48ebf1c3c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6af04cfacce4158ab34277a1960ae3a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iae8ed78b63224fe9a7fae1f526fde05d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie23ad3f47f044a12afefd67475b342f7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibe8d18d31bb743bea079e6b2de6ec19a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i40320493bb114b7b9790c7199d64f1a0_D20190808-20190808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nltx:AcquisitionOfAssetsAxis">nltx:AquinoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-08</startDate>
            <endDate>2019-08-08</endDate>
        </period>
    </context>
    <context id="ib1005fcc8fe5417da0ed149702b76a6f_D20190808-20190808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nltx:NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nltx:AcquisitionOfAssetsAxis">nltx:AquinoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-08</startDate>
            <endDate>2019-08-08</endDate>
        </period>
    </context>
    <context id="i562c09437d76488daa016091ce08fa2a_D20190808-20190808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <startDate>2019-08-08</startDate>
            <endDate>2019-08-08</endDate>
        </period>
    </context>
    <context id="i6bb0f20de0234580abbe24e6025eeb91_D20190808-20190808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="nltx:AcquisitionOfAssetsAxis">nltx:AquinoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-08</startDate>
            <endDate>2019-08-08</endDate>
        </period>
    </context>
    <context id="icc0c497a9b7e42ff89e71ed4e700c005_D20190808-20190808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-08</startDate>
            <endDate>2019-08-08</endDate>
        </period>
    </context>
    <context id="i99076ffdc9d3414f812225c38a835667_I20190808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="nltx:AcquisitionOfAssetsAxis">nltx:AquinoxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-08</instant>
        </period>
    </context>
    <context id="ia47d5cee66404f7cbae1aeec9577fc50_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nltx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if7459e4cc288446f840ea60d80fbb934_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nltx:FurnitureFixturesAndITEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1a680cc9adc946558b7938da05a43e34_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i15d940e5d2f149acbb5357be4a7e366f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nltx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2208e67d526547b5819db3624bbe011a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nltx:FurnitureFixturesAndITEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4705a5c4b4bc44d6bb8ba59262f94449_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nltx:OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id6e7ca6980e0434682af1d48cf353254_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="idf105168c8db4aaca79efa56d6480d67_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nltx:OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5ed3c72fdd5244ab8974717f9b77a301_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nltx:OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="icc93ba96caae41caaf0f462dced9d9f5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nltx:OfficeSpaceFormerPrincipalExecutiveOfficesAndLaboratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i551bbb0f39284233bd2bc07a764f6743_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">nltx:OfficeSpaceFormerPrincipalExecutiveOfficesAndLaboratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i33f7bbfc02b54beb8163ea39433e3cad_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i23ddd03e1fc94695ab704c560ff13b1a_D20200630-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <startDate>2020-06-30</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2bfb640b4f9448db81cd2eda573a733f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iacf40562c9644cc9828d02f05554823f_D20200707-20200707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nltx:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-07</startDate>
            <endDate>2020-07-07</endDate>
        </period>
    </context>
    <context id="ia289d260d3db4da2aacbed8339f37590_I20200707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nltx:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-07</instant>
        </period>
    </context>
    <context id="i3397ebe8ae644e4aabdacd910f7b5d9e_I20200707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">nltx:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-07</instant>
        </period>
    </context>
    <context id="ibcd7f5cd1b2a4a29a2a3ab167bb32bce_D20200707-20200707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <startDate>2020-07-07</startDate>
            <endDate>2020-07-07</endDate>
        </period>
    </context>
    <context id="i4106335c2a9e4f65a3bf48b670d2780f_D20191220-20191220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nltx:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-20</startDate>
            <endDate>2019-12-20</endDate>
        </period>
    </context>
    <context id="i244aa6bc78a741be9d0e8aafa2725d77_I20191220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nltx:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-20</instant>
        </period>
    </context>
    <context id="ib79c600c3cf14f96b3f11cb86e2c6fe1_D20191220-20191220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <startDate>2019-12-20</startDate>
            <endDate>2019-12-20</endDate>
        </period>
    </context>
    <context id="iff8af19eb46e4d98bfc328b1fb63531e_D20191112-20191112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nltx:NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-12</startDate>
            <endDate>2019-11-12</endDate>
        </period>
    </context>
    <context id="id6d4eed2171d4fda82da0d88564149d9_I20191112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-12</instant>
        </period>
    </context>
    <context id="ie4a634a968e049b7b556b6104f5c0ae5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nltx:NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1913c226c2e2462ba6fe703cb86f64c8_D20191217-20191217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
        </entity>
        <period>
            <startDate>2019-12-17</startDate>
            <endDate>2019-12-17</endDate>
        </period>
    </context>
    <context id="i5612b1ceb0074b538a341f49adc28d80_I20191217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nltx:PreFundedCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-17</instant>
        </period>
    </context>
    <context id="ifb2fe74f8fec43409b383c349c9d583a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nltx:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5126c731497844cf82463ebd9ba0ec2c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nltx:EquityIncentivePlanTwoThousandSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iceb04586e32a40cc920160798f9ddce9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nltx:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i40473cfe46a34de087cfebd3e2af1629_D20191112-20191112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nltx:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-12</startDate>
            <endDate>2019-11-12</endDate>
        </period>
    </context>
    <context id="i56d428d107ab495dbcb789afcb67f7ac_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nltx:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icd60841f3d0c4c839e994b21197a5e5a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icf570f55902f4cc28e0254cce74d57f7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i519925c39cf4455091866ca196cf1161_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i98de22e11051465b8dcdb754ab88181e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4ded9a42fb4c43d59acd21cbb286e7ab_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib836d4e8cc0846f3aae456d3e9c5c4a1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3bf297e89d3a4439826cf1221fa7077e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic094ebf448aa42ca8ddd6b528bd22183_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nltx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6ce8a1775eab43619ee74ee567323a06_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nltx:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9458a61fcd5441b4a06f3867c7b43644_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i71f76aa20b85452986373dda65e0d335_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nltx:RestructuringPlan1July2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if5d6fef6a34b42589a5f9af4fd295376_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nltx:RestructuringPlan1July2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i8b0667298aca423a94e3af1049753d11_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nltx:RestructuringPlan1July2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie44b93451c7140eaadb4a1b1ad21f5a2_I20181106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nltx:RestructuringPlan1November62018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-06</instant>
        </period>
    </context>
    <context id="i683ab08d4e50424b957c9a94c07b61de_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">nltx:RestructuringPlan1November62018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i114d11c2e9f14956aaff2d2291a3bb3c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0287eaf6edad4bca9a12a64c9fd6bfd3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib0fb710a1248468f89148e8f321466cd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i716d60022b294375af6a54233d5dafb2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ided3ec02dff84702acaa7ae1e47b2e5f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i96ba60c113044d799a3a4c62cb49aed1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i74a1d2bd4a394b7b96915526dbf4b948_D20200731-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nltx:AcqinoxCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-31</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i99c20b1ea8274dc9b108a3b0bd76f6b1_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">nltx:AcqinoxCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i342b1069b9d04ed099561a06485fbac8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i263816d2f8ea45e08a1dadaf18225ac9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i40d4ac81f67244daa74169c591a76a81_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">nltx:UniversityOfWashingtonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0e261bc82ccb41c588ae441128cc8612_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">nltx:UniversityOfWashingtonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6db8900a02d94ac0b3d9b45c02322b98_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">nltx:UniversityOfWashingtonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">nltx:NonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2d0273c0483c4e869c87c35dd362ea8b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">nltx:UniversityOfWashingtonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4b9bb655d75545a397e6154c4fb4f637_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">nltx:UniversityOfWashingtonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i73035a213d0243978324cca10be3c694_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">nltx:UniversityOfWashingtonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>nltx:segment</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="option">
        <measure>nltx:option</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="offering">
        <measure>nltx:offering</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl80L2ZyYWc6OTcwY2NkMzllZmM3NDU5Njk3YzNlNTQ3MjU5YjI3ZDYvdGFibGU6OGQ0NjM4ZGZhNDg3NDk3MzlkMjQwMTY1ZTU5ZDI5OWQvdGFibGVyYW5nZTo4ZDQ2MzhkZmE0ODc0OTczOWQyNDAxNjVlNTlkMjk5ZF81LTEtMS0xLTA_ff210ed3-2065-4d13-bde0-eb6d2f64bcd8">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl80L2ZyYWc6OTcwY2NkMzllZmM3NDU5Njk3YzNlNTQ3MjU5YjI3ZDYvdGFibGU6OGQ0NjM4ZGZhNDg3NDk3MzlkMjQwMTY1ZTU5ZDI5OWQvdGFibGVyYW5nZTo4ZDQ2MzhkZmE0ODc0OTczOWQyNDAxNjVlNTlkMjk5ZF83LTEtMS0xLTA_07fccfa7-0691-4217-8171-75551638c780">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl80L2ZyYWc6OTcwY2NkMzllZmM3NDU5Njk3YzNlNTQ3MjU5YjI3ZDYvdGFibGU6OGQ0NjM4ZGZhNDg3NDk3MzlkMjQwMTY1ZTU5ZDI5OWQvdGFibGVyYW5nZTo4ZDQ2MzhkZmE0ODc0OTczOWQyNDAxNjVlNTlkMjk5ZF84LTEtMS0xLTA_51017142-e3df-4890-8a5d-69e995c83fea">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl80L2ZyYWc6OTcwY2NkMzllZmM3NDU5Njk3YzNlNTQ3MjU5YjI3ZDYvdGFibGU6OGQ0NjM4ZGZhNDg3NDk3MzlkMjQwMTY1ZTU5ZDI5OWQvdGFibGVyYW5nZTo4ZDQ2MzhkZmE0ODc0OTczOWQyNDAxNjVlNTlkMjk5ZF8xMS0xLTEtMS0w_cd8ce717-e05d-43cf-ac37-d11c10d5dd2a">0001404644</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if6af04cfacce4158ab34277a1960ae3a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzE2NDkyNjc0OTYxNDk_956254c7-b20d-4861-9cc1-c72b39fa063a">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="if6af04cfacce4158ab34277a1960ae3a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTM5ODM_38a5a479-ddde-4ba0-9188-8ce886f75bc3">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:RestructuringCharges
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xODE5L2ZyYWc6Njk3M2M5ZGFkMDU5NGQ5MDhmNTlhMmE1YmY4Mjg4MDQvdGV4dHJlZ2lvbjo2OTczYzlkYWQwNTk0ZDkwOGY1OWEyYTViZjgyODgwNF8xNjQ5MjY3NDQxOTY2_fa932cf2-6672-4c35-bc8a-4bfcc47229be"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <dei:DocumentType
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1NTAw_80d8d92c-afa6-46a9-b544-1697f7ad02b5">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGFibGU6YTJiYjVkZGVhOGE5NDA1Mzk5ODE2OGRhMDU5MmU4NjQvdGFibGVyYW5nZTphMmJiNWRkZWE4YTk0MDUzOTk4MTY4ZGEwNTkyZTg2NF8wLTAtMS0xLTU5OA_9804787c-4767-4378-9674-3973c9180a1d">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8yMTk5MDIzMjU5NTIy_1734cedc-b410-4fab-8722-1c42b3d42e33">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8yMTk5MDIzMjU5NTIy_b7418163-a443-4aa1-88dd-4a4ee8d15f9d">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGFibGU6NjU5NjYxZmFkYzUxNDhjNGJmY2QxOTMxNTFlZGI2ZTAvdGFibGVyYW5nZTo2NTk2NjFmYWRjNTE0OGM0YmZjZDE5MzE1MWVkYjZlMF8wLTAtMS0xLTYwMA_77889dd8-557b-4e2d-85b1-ef7f7d1b5650">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1NTAx_8e46ba7b-cdf1-4423-97cd-9797e638c918">001-36327</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1NTA0_5f76358b-6e90-4915-bbbb-2f2d442ca9b3">Neoleukin Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGFibGU6MTQ2ZWFhNjlkNGU1NGVmM2E5ZjIxYTlhOGYwMTMzMTgvdGFibGVyYW5nZToxNDZlYWE2OWQ0ZTU0ZWYzYTlmMjFhOWE4ZjAxMzMxOF8wLTAtMS0xLTc3Nw_0f294580-1cb5-40bd-8b9b-30c101989ebe">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGFibGU6MTQ2ZWFhNjlkNGU1NGVmM2E5ZjIxYTlhOGYwMTMzMTgvdGFibGVyYW5nZToxNDZlYWE2OWQ0ZTU0ZWYzYTlmMjFhOWE4ZjAxMzMxOF8wLTEtMS0xLTU0Mjg_186bee8e-3cd9-4327-947b-30041e2c11fc">98-0542593</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1NTA2_04c74e32-6751-4f18-abae-d594af0a6ace">188 East Blaine Street, Suite 450</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1NTA3_8f75b94a-c2db-4230-ae19-2dc750412493">Seattle</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1NTA4_c04ce68a-f969-4b56-807c-aa6b0eebf305">WA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1NTM5_7c731bc2-d9b0-4888-b18e-19ab56a96fa9">98102</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1ODYz_d61a9920-5cee-44bf-bf25-3bb477beb9d1">866</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1ODY3_e27df6da-0eeb-4e69-969d-7183b0c0d4c1">245-0312</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGFibGU6ZWRiNWUzYjA0ZjI4NDBiMWE3YzJmMGFkODE1MmE0OTQvdGFibGVyYW5nZTplZGI1ZTNiMDRmMjg0MGIxYTdjMmYwYWQ4MTUyYTQ5NF8xLTAtMS0xLTY3Nw_eec5e90c-e62d-48df-b07d-8dff9b35fc92">Common Stock, par value $0.000001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGFibGU6ZWRiNWUzYjA0ZjI4NDBiMWE3YzJmMGFkODE1MmE0OTQvdGFibGVyYW5nZTplZGI1ZTNiMDRmMjg0MGIxYTdjMmYwYWQ4MTUyYTQ5NF8xLTItMS0xLTY3OQ_ea9e2d14-0d06-4657-bac2-f4edc7cd986c">NLTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGFibGU6ZWRiNWUzYjA0ZjI4NDBiMWE3YzJmMGFkODE1MmE0OTQvdGFibGVyYW5nZTplZGI1ZTNiMDRmMjg0MGIxYTdjMmYwYWQ4MTUyYTQ5NF8xLTQtMS0xLTY4MQ_89a13257-a401-440e-b1af-1b9aec3f9554">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1NTUz_fc49f268-ea8f-40bf-a706-706cb5e92751">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1NTU0_6b8b7465-e006-4bbb-9bbf-618013e7b033">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1NTU1_506acf96-1b64-404f-a922-267e54518107">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1NTU2_4c662f6e-a5da-4ef7-9464-96ea26d108d8">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGFibGU6NzgxZDhhZmM1NzQ0NDIzY2IwNTVlNGE5MDYwMzlkMTIvdGFibGVyYW5nZTo3ODFkOGFmYzU3NDQ0MjNjYjA1NWU0YTkwNjAzOWQxMl8yLTAtMS0xLTEwNDc_16eabc4a-30f0-4dc0-b7ac-9ff261a04fdb">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGFibGU6NzgxZDhhZmM1NzQ0NDIzY2IwNTVlNGE5MDYwMzlkMTIvdGFibGVyYW5nZTo3ODFkOGFmYzU3NDQ0MjNjYjA1NWU0YTkwNjAzOWQxMl8yLTQtMS0xLTcxMw_acab4d48-cfa0-4cbe-9912-400d8e1c5efd">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGFibGU6NzgxZDhhZmM1NzQ0NDIzY2IwNTVlNGE5MDYwMzlkMTIvdGFibGVyYW5nZTo3ODFkOGFmYzU3NDQ0MjNjYjA1NWU0YTkwNjAzOWQxMl80LTQtMS0xLTcxNQ_75cc73d5-04a3-4d94-b2c0-d68ad524a18b">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ3NzAy_e8fb0f21-590d-48d2-b197-b3c67abb922f">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xMTU0NDg3MjA5NzEyNQ_8cbad84f-e580-4188-9392-3291d88540fd">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ic2b26b0a70bd4921be8f5b71cba81d62_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1NTYx_eb601cff-7955-40d5-8631-7be023ca01ca"
      unitRef="usd">546000000.0</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="idd7a0891c771440993dddc18188b0907_I20210322"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8zMjk4NTM0ODg3NDIw_ae95f874-bd96-4bf7-b4f8-6fe8fdacb11f"
      unitRef="shares">42326033</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xL2ZyYWc6M2Q3MDlkYTYwZGUwNGQ5ZWE2OWU3YTQ5M2U5MTliNWYvdGV4dHJlZ2lvbjozZDcwOWRhNjBkZTA0ZDllYTY5ZTdhNDkzZTkxOWI1Zl8xNjQ5MjY3NDQ1NTg5_6b3c61ca-dd6e-4743-8439-de36bb7d66c3">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Part III incorporates information by reference from the registrant&#x2019;s definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, in connection with the registrant&#x2019;s 2021 Annual Meeting of Stockholders (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Proxy Statement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;).&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMy0xLTEtMS0w_1eb37097-c7b3-4171-8942-3c7f2d6db01d"
      unitRef="usd">192556000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMy0zLTEtMS0w_4e6fc524-329b-4514-a547-c84471464826"
      unitRef="usd">143093000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsCurrent
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfNC0xLTEtMS0w_46a467b5-e0d5-41c0-a1fa-e59bc33d33bf"
      unitRef="usd">1966000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfNC0zLTEtMS0w_b1ebb3e6-87df-4815-a43d-4970f20754f1"
      unitRef="usd">503000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfNS0xLTEtMS0w_38e0728f-fb95-4308-be02-333829de2806"
      unitRef="usd">194522000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfNS0zLTEtMS0w_c2025281-97d4-42cd-a953-2a849706bbc8"
      unitRef="usd">143596000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfNi0xLTEtMS0w_16b5d318-1772-4b6b-a789-effcbcb146bc"
      unitRef="usd">3570000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfNi0zLTEtMS0w_9d539945-cf1a-47c4-acae-7dd64c1ede26"
      unitRef="usd">2060000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfNy0xLTEtMS0w_bcd9d49a-c45e-4dcc-92c4-a70d815ac8a9"
      unitRef="usd">10154000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfNy0zLTEtMS0w_c8ecb5a2-0727-47f1-b8a4-4feefbfe6368"
      unitRef="usd">770000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfOC0xLTEtMS0w_8c2e71ea-2e74-4c9e-81f1-0d6ac2b49427"
      unitRef="usd">347000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfOC0zLTEtMS0w_7ae6e8ee-961c-490a-81ec-d526be9f06f9"
      unitRef="usd">567000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfOS0xLTEtMS0w_c23128fe-2328-4f0a-9a8a-fc76504eece8"
      unitRef="usd">1926000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfOS0zLTEtMS0w_de4f39e1-3be4-4746-95bc-dad3150e3604"
      unitRef="usd">30000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTAtMS0xLTEtMA_00d374d0-b3c4-4442-afb5-dfe706c668a2"
      unitRef="usd">210519000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTAtMy0xLTEtMA_861549b3-4096-41a2-9bbc-15d203b25a5f"
      unitRef="usd">147023000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTMtMS0xLTEtMA_09d76391-88f4-4e1f-9e18-a09749a625b2"
      unitRef="usd">7181000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTMtMy0xLTEtMA_e78d7825-7c02-4b20-8a47-feee48cd69eb"
      unitRef="usd">4125000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTQtMS0xLTEtMA_8b4b0848-c4a2-406a-aaec-65fbf0d09927"
      unitRef="usd">659000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTQtMy0xLTEtMA_e33c0997-09e1-406a-b3a3-5210fe0f126d"
      unitRef="usd">556000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTUtMS0xLTEtMA_97fd0e40-293e-4ffb-bfa9-9be6505f504e"
      unitRef="usd">49000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTUtMy0xLTEtMA_c4041c71-61fc-4106-903a-0307ab620c8e"
      unitRef="usd">62000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTYtMS0xLTEtMA_cdc9b334-3ffb-404a-9f44-931eb3492ef0"
      unitRef="usd">7889000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTYtMy0xLTEtMA_85a8b246-6800-4058-964f-399f214c6ab6"
      unitRef="usd">4743000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTctMS0xLTEtMA_2e968ffa-cfd3-4132-a31c-1d409a4549d5"
      unitRef="usd">11306000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTctMy0xLTEtMA_661098f9-e172-4cb4-83bc-eae90de1dd4a"
      unitRef="usd">447000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTgtMS0xLTEtMA_b82fe168-c82c-41bf-bbf6-3ef4d662b5d8"
      unitRef="usd">108000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMTgtMy0xLTEtMA_a9eb4465-00ba-406a-9f10-ee851c3df4bd"
      unitRef="usd">146000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjAtMS0xLTEtMA_b9708867-d788-4532-8280-086535cc4941"
      unitRef="usd">19303000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjAtMy0xLTEtMA_55bad94e-dd2f-4d5a-a270-806bdf8759f9"
      unitRef="usd">5336000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjQtMC0xLTEtNDkxL3RleHRyZWdpb246MTZmMjUwMzI5NTNkNDg5N2I2YjM3NWU5ODY3NTMwY2RfMjE5OTAyMzI1NTc2NA_028e48b7-1749-4196-a8da-8a94ebd15432"
      unitRef="usdPerShare">0.000001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjQtMC0xLTEtNDkxL3RleHRyZWdpb246MTZmMjUwMzI5NTNkNDg5N2I2YjM3NWU5ODY3NTMwY2RfMjE5OTAyMzI1NTc2NA_f906b5fd-c6a4-45d4-a1ef-fb1c70e67cc9"
      unitRef="usdPerShare">0.000001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjQtMC0xLTEtNDkxL3RleHRyZWdpb246MTZmMjUwMzI5NTNkNDg5N2I2YjM3NWU5ODY3NTMwY2RfMjE5OTAyMzI1NTc4MA_c3c00584-7be7-4811-885b-2fdf551ddf7f"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjQtMC0xLTEtNDkxL3RleHRyZWdpb246MTZmMjUwMzI5NTNkNDg5N2I2YjM3NWU5ODY3NTMwY2RfMjE5OTAyMzI1NTc4MA_e41f3c56-ea49-41d1-99a5-d6bfeeecbb33"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjQtMC0xLTEtNDkxL3RleHRyZWdpb246MTZmMjUwMzI5NTNkNDg5N2I2YjM3NWU5ODY3NTMwY2RfMjE5OTAyMzI1NTc5Mw_34274fda-2f6e-4165-9a37-c5f5a6189524"
      unitRef="shares">42196296</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjQtMC0xLTEtNDkxL3RleHRyZWdpb246MTZmMjUwMzI5NTNkNDg5N2I2YjM3NWU5ODY3NTMwY2RfMjE5OTAyMzI1NTc5Mw_85803062-0bf2-408b-a359-0c4e3ebfb649"
      unitRef="shares">42196296</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjQtMC0xLTEtNDkxL3RleHRyZWdpb246MTZmMjUwMzI5NTNkNDg5N2I2YjM3NWU5ODY3NTMwY2RfMjE5OTAyMzI1NTgwNg_91754555-285a-49b3-8a4b-f0220d737ee3"
      unitRef="shares">37996849</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjQtMC0xLTEtNDkxL3RleHRyZWdpb246MTZmMjUwMzI5NTNkNDg5N2I2YjM3NWU5ODY3NTMwY2RfMjE5OTAyMzI1NTgwNg_d03035ae-1c67-4171-9965-475feb0ca4fc"
      unitRef="shares">37996849</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjQtMS0xLTEtMA_ccaf4725-2433-4274-a403-f7dd389c092b"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjQtMy0xLTEtMA_655c9b22-56c4-4495-be59-7c784c366631"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjUtMC0xLTEtNDkxL3RleHRyZWdpb246ZDYwMWZjMDNhOTQ1NDdjZDlmNWI2NDQwNWJmYjJhNTRfMjE5OTAyMzI1NTcyMw_65436cc9-6be5-4208-aac4-53ce7e6ee591"
      unitRef="usdPerShare">0.000001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjUtMC0xLTEtNDkxL3RleHRyZWdpb246ZDYwMWZjMDNhOTQ1NDdjZDlmNWI2NDQwNWJmYjJhNTRfMjE5OTAyMzI1NTcyMw_a8c39275-f1b9-4303-8469-b621fd84ad52"
      unitRef="usdPerShare">0.000001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjUtMC0xLTEtNDkxL3RleHRyZWdpb246ZDYwMWZjMDNhOTQ1NDdjZDlmNWI2NDQwNWJmYjJhNTRfMjE5OTAyMzI1NTczNw_2cd676a0-2a33-4e24-8cd5-c606378f7154"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjUtMC0xLTEtNDkxL3RleHRyZWdpb246ZDYwMWZjMDNhOTQ1NDdjZDlmNWI2NDQwNWJmYjJhNTRfMjE5OTAyMzI1NTczNw_7599d89c-cd61-4be9-a0ef-88b32eafe41c"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjUtMC0xLTEtNDkxL3RleHRyZWdpb246ZDYwMWZjMDNhOTQ1NDdjZDlmNWI2NDQwNWJmYjJhNTRfMjE5OTAyMzI1NTc0NA_1afa781f-f218-436d-8093-e9a142ff4e78"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjUtMC0xLTEtNDkxL3RleHRyZWdpb246ZDYwMWZjMDNhOTQ1NDdjZDlmNWI2NDQwNWJmYjJhNTRfMjE5OTAyMzI1NTc0NA_4a680058-2ace-4aaa-aa06-fbe892125b2b"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjUtMC0xLTEtNDkxL3RleHRyZWdpb246ZDYwMWZjMDNhOTQ1NDdjZDlmNWI2NDQwNWJmYjJhNTRfMjE5OTAyMzI1NTc0NA_9fab9556-aedf-495d-9b3b-4bd341e123b8"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjUtMC0xLTEtNDkxL3RleHRyZWdpb246ZDYwMWZjMDNhOTQ1NDdjZDlmNWI2NDQwNWJmYjJhNTRfMjE5OTAyMzI1NTc0NA_af749fa3-edb3-4ad0-8232-70dc9c19e3ea"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjUtMS0xLTEtMA_e9417bdf-6f72-4a49-86f0-dbccb3b4ac26"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjUtMy0xLTEtMA_e9c833a3-ddea-4071-83eb-52c0aa7e330b"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjYtMS0xLTEtMA_18221191-f085-489e-a030-10d6fd4926a0"
      unitRef="usd">524022000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjYtMy0xLTEtMA_43376d90-d29c-41f5-b54d-4984c0ad785e"
      unitRef="usd">441216000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjctMS0xLTEtMA_d7a812a7-5307-4683-81a9-e0d8cee812c3"
      unitRef="usd">-332806000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjctMy0xLTEtMA_3f117a4a-91d3-42fe-a37a-cff2ac279059"
      unitRef="usd">-299529000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjgtMS0xLTEtMA_a978a4fd-2b25-41af-ad14-b1c42f363b2c"
      unitRef="usd">191216000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjgtMy0xLTEtMA_015ce860-2b3c-4a8e-8e9c-723f8259abfb"
      unitRef="usd">141687000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjktMS0xLTEtMA_1f50cb4a-e50e-46b7-a2d0-8540ab9efa42"
      unitRef="usd">210519000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl84NS9mcmFnOjQ0ZjYxMjRmMjBjNjQ1MzhiYjYwMzgxMDc0OGQ2NGZjL3RhYmxlOmQzYWQ5YTcxMDBjODQzZjBhYzhkOWU4ZTQwMThhNDRiL3RhYmxlcmFuZ2U6ZDNhZDlhNzEwMGM4NDNmMGFjOGQ5ZThlNDAxOGE0NGJfMjktMy0xLTEtMA_8408006d-f181-4aad-a217-ced04fd9fa6a"
      unitRef="usd">147023000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfNC0xLTEtMS0w_d1b47021-dec6-4495-aa79-67dd40aa1102"
      unitRef="usd">24344000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfNC0zLTEtMS0w_6c51e519-2541-4b67-9965-393a3abe92a3"
      unitRef="usd">4417000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfNS0xLTEtMS0w_9ff7e493-dea9-4085-9738-64b818573515"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfNS0zLTEtMS0w_4b0f97ba-bfed-4e4e-b387-373ab13255ff"
      unitRef="usd">47716000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfNi0xLTEtMS0w_a2525821-968f-46fc-a48b-8511f6745fd4"
      unitRef="usd">17210000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfNi0zLTEtMS0w_fbefd4c9-821b-4496-b775-937f07fdba39"
      unitRef="usd">18826000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GainOrLossOnSaleOfStockInSubsidiary
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfNi0xLTEtMS0xNTg5_cbb5ca22-94e6-4840-9d60-78c35ef55cd5"
      unitRef="usd">7826000</us-gaap:GainOrLossOnSaleOfStockInSubsidiary>
    <us-gaap:GainOrLossOnSaleOfStockInSubsidiary
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfNi0zLTEtMS0xNTkx_d85d9d2a-fcd0-46f3-be91-3136976a83f3"
      unitRef="usd">0</us-gaap:GainOrLossOnSaleOfStockInSubsidiary>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfNy0xLTEtMS0w_241ebce6-04c2-4253-958d-a3b876c26521"
      unitRef="usd">-33728000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfNy0zLTEtMS0w_99393d35-bb1a-4394-9ccc-922974c7364d"
      unitRef="usd">-70959000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfMTItMS0xLTEtMA_ec2d13be-3b15-4bcd-9a2f-22548585870d"
      unitRef="usd">451000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfMTItMy0xLTEtMA_e19910af-4827-43f7-82a3-8b6d3e068ae0"
      unitRef="usd">1517000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfMTMtMS0xLTEtMA_57c34d90-ca3e-4acf-a287-a2bfdbc665db"
      unitRef="usd">-33277000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfMTMtMy0xLTEtMA_f85333c4-a0ce-4c0e-a9a8-ee53b469b1d3"
      unitRef="usd">-69442000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfMTQtMS0xLTEtMA_b024699e-89e8-4213-ade4-cba0ed704d2d"
      unitRef="usdPerShare">-0.64</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfMTQtMy0xLTEtMA_72eabc4d-5b0f-4b10-a08c-4386d7550a8b"
      unitRef="usdPerShare">-2.57</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfMTUtMS0xLTEtMA_51655bdb-a367-4fff-b886-8795a716da9d"
      unitRef="shares">51825022</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85MS9mcmFnOjdlYWY4ZDhmZWNmZDQ5ZDA4ODVmNzMxMDMxMmE0NTgwL3RhYmxlOmQ2NGRiYjk1ODNmNzQzNGU5YjczMWZjZWMyNTUwNzI2L3RhYmxlcmFuZ2U6ZDY0ZGJiOTU4M2Y3NDM0ZTliNzMxZmNlYzI1NTA3MjZfMTUtMy0xLTEtMA_cf1e63c0-b6b1-4b30-b45e-2c83a25fd016"
      unitRef="shares">27030355</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMy0xLTEtMS0w_c49e78dc-0107-4249-be6b-b95eb4b4bfcf"
      unitRef="usd">-33277000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMy0zLTEtMS0w_e0a6f0e5-e93b-4b06-a308-8475e81127c0"
      unitRef="usd">-69442000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfNS0xLTEtMS0w_3a06ff08-0723-4763-95fe-92041a474bb7"
      unitRef="usd">5622000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfNS0zLTEtMS0w_3c877a36-d62c-4825-916e-d27a043bb608"
      unitRef="usd">7683000</us-gaap:ShareBasedCompensation>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfNi0xLTEtMS0w_c1420d31-b13c-4fc5-ad4e-6741e253c7d4"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfNi0zLTEtMS0w_b9b6d720-b669-4f63-88da-9fa2895d9811"
      unitRef="usd">47716000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfNy0xLTEtMS0w_68f17cd8-9e7f-4e19-ac42-68a322dc718c"
      unitRef="usd">785000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfNy0zLTEtMS0w_e858e887-039a-4c67-9e92-2351efe067a5"
      unitRef="usd">340000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfOC0xLTEtMS00NTQ3_bbd75940-2e3d-488a-9e6f-4432ffc9d989"
      unitRef="usd">-180000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfOC0zLTEtMS00NTYx_ea66c710-56ea-4251-aba3-b8ead1114cc7"
      unitRef="usd">-5000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfOS0xLTEtMS00NTQ3_4aa0a599-f1bb-4b09-bb31-531c38670ddd"
      unitRef="usd">1036000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfOS0zLTEtMS00NTYx_95ffc336-0ecd-4797-a5ba-8a6baaf09627"
      unitRef="usd">188000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <nltx:WriteOffOfRightOfUseAssetUponLeaseTermination
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTAtMS0xLTEtNDU0Nw_25057abf-20d0-481b-a83f-3546eec34d80"
      unitRef="usd">113000</nltx:WriteOffOfRightOfUseAssetUponLeaseTermination>
    <nltx:WriteOffOfRightOfUseAssetUponLeaseTermination
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTAtMy0xLTEtNDU2MQ_06c66f48-15be-4ac4-86fe-03733d4db164"
      unitRef="usd">0</nltx:WriteOffOfRightOfUseAssetUponLeaseTermination>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTEtMS0xLTEtNTQyMA_121ee386-f926-4b8f-b9cb-3eb34892f4ce"
      unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTEtMy0xLTEtNTQyMA_a0475924-9bdf-43c2-a81f-3771d9bbbcc5"
      unitRef="usd">-70000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTAtMS0xLTEtMA_340edc96-f1e1-4576-9e26-281143f0b50d"
      unitRef="usd">2481000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTAtMy0xLTEtMA_251b4722-bb81-4dbf-88c0-768aa9ab4f8f"
      unitRef="usd">-290000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTEtMS0xLTEtMA_c89c6e2e-cb20-404c-b688-9e467ae411e7"
      unitRef="usd">3018000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTEtMy0xLTEtMA_5a7fd794-3221-4fc9-b149-6b29f4905fce"
      unitRef="usd">-2007000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <nltx:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTQtMS0xLTEtNDU1Nw_76daa806-9fb9-4842-aa00-471835248bda"
      unitRef="usd">169000</nltx:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <nltx:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTQtMy0xLTEtNDU1Nw_95087ddb-3995-4ef6-8ecd-39ac7a909a32"
      unitRef="usd">0</nltx:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <nltx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTUtMS0xLTEtNDU1Nw_bf0a6010-a91d-4260-9278-435b4ead8e97"
      unitRef="usd">598000</nltx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <nltx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTUtMy0xLTEtNDU1Nw_1feaaca0-f7b4-43a2-aeca-b3ddec85faac"
      unitRef="usd">-237000</nltx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTItMS0xLTEtMA_bfa54c11-0934-40ba-aa8b-d578d3f02dc7"
      unitRef="usd">-24575000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTItMy0xLTEtMA_10e76793-2702-4337-a987-e94158d4228a"
      unitRef="usd">-15394000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <nltx:AcquisitionOfAssetsNetCashAcquired
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTQtMS0xLTEtMA_14a12441-6edd-4ff1-9fb7-b40bc499d63d"
      unitRef="usd">0</nltx:AcquisitionOfAssetsNetCashAcquired>
    <nltx:AcquisitionOfAssetsNetCashAcquired
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTQtMy0xLTEtMA_f42c2c7c-643e-40bf-9cc5-59ed62140c31"
      unitRef="usd">191000</nltx:AcquisitionOfAssetsNetCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTctMS0xLTEtMA_984419c9-0e07-47ea-b463-1c8052ba7bcb"
      unitRef="usd">2219000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTctMy0xLTEtMA_d4ab8ea3-abd6-4025-a206-f6b70bf76f85"
      unitRef="usd">879000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTgtMS0xLTEtMA_4d731e0a-46fe-4be4-904d-295c5b430116"
      unitRef="usd">-2219000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMTgtMy0xLTEtMA_d62b0348-e26d-4549-8a02-3e846d1ac9cd"
      unitRef="usd">-688000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <nltx:CommissionsOnPublicOffering
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjAtMC0xLTEtNDg0L3RleHRyZWdpb246MzBlYWVhMjYxZTQwNDZiYTkxMDdhMDI1MjFjYzJiNmJfMjE5OTAyMzI1NTcwNA_4897014c-1ff0-4e59-8e44-c0aa50297f7d"
      unitRef="usd">4575000</nltx:CommissionsOnPublicOffering>
    <nltx:CommissionsOnPublicOffering
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjAtMC0xLTEtNDg0L3RleHRyZWdpb246MzBlYWVhMjYxZTQwNDZiYTkxMDdhMDI1MjFjYzJiNmJfMjE5OTAyMzI1NTcxNA_576c545e-774e-4705-9d6a-38ede703e78e"
      unitRef="usd">5173000</nltx:CommissionsOnPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjAtMS0xLTEtMA_6b2231aa-ca53-43cf-bd2b-4136a1a143b7"
      unitRef="usd">71675000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjAtMy0xLTEtMA_53bd2c63-a4c3-411e-85d9-20bb89103256"
      unitRef="usd">81043000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjEtMS0xLTEtMA_1b0731fd-5d1f-4016-9821-3aefbd1c28b0"
      unitRef="usd">355000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjEtMy0xLTEtMA_67da3976-392a-4109-a1aa-5f6175b3e85a"
      unitRef="usd">352000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjItMS0xLTEtMA_e2512171-8117-4599-bf8c-485657b2c4c0"
      unitRef="usd">5665000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjItMy0xLTEtMA_d598e290-5e73-4447-b767-b1220f1e2e57"
      unitRef="usd">1555000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjYtMS0xLTEtNTQ4Ng_fe57a009-f44f-47d7-8be2-0bd7d80e3dc9"
      unitRef="usd">199000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjYtMy0xLTEtNTQ4Ng_7856ba3d-62b0-47b9-8c49-de86533b912a"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjMtMS0xLTEtMA_06c6a63a-8ccb-4141-9fdd-e3d906930561"
      unitRef="usd">49000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjMtMy0xLTEtMA_b4f9aa36-7efd-4c1d-ad3a-7e810ef73a30"
      unitRef="usd">9000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjQtMS0xLTEtMA_a86b8352-2e60-41f6-9f4f-9bc11aeb9160"
      unitRef="usd">77135000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjQtMy0xLTEtMA_afe3250a-daff-421e-9bd7-20692ff7a3d2"
      unitRef="usd">82237000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjUtMS0xLTEtMA_27cd6ed7-f6d1-4484-b991-5e011232f333"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjUtMy0xLTEtMA_3963e615-9cb5-4603-8d7c-4bb042c947d1"
      unitRef="usd">10000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjYtMS0xLTEtMA_78c043d1-8635-4bdd-98e9-6d26c24fd740"
      unitRef="usd">50341000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjYtMy0xLTEtMA_65367329-117b-4f3a-86e3-962598c428a5"
      unitRef="usd">66165000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjctMS0xLTEtMA_b241fea7-b27c-4c37-81ae-466898f8fd42"
      unitRef="usd">143093000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i049d641cdc3c4012850e2abee7d5fe17_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjctMy0xLTEtMA_46582ef1-70e6-4c4f-b669-f40b4ed26410"
      unitRef="usd">76928000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjgtMS0xLTEtMA_1c685bb2-7e06-45d9-a123-dd885a6ef670"
      unitRef="usd">193434000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMjgtMy0xLTEtMA_6ca783b7-55bd-4228-81b3-d3f245d0ce90"
      unitRef="usd">143093000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <nltx:OtherCurrentAssetsAcquiredThroughTheIssuanceOfCommonStock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMzMtMS0xLTEtMA_b85a593f-8841-4590-924d-341f601cfd77"
      unitRef="usd">0</nltx:OtherCurrentAssetsAcquiredThroughTheIssuanceOfCommonStock>
    <nltx:OtherCurrentAssetsAcquiredThroughTheIssuanceOfCommonStock
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMzMtMy0xLTEtMA_0e7f9051-a3cc-4ee7-a11f-5dfa7da98c23"
      unitRef="usd">560000</nltx:OtherCurrentAssetsAcquiredThroughTheIssuanceOfCommonStock>
    <nltx:PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMzQtMS0xLTEtMA_9600d164-4fea-4d9f-9aba-2604f8c870ef"
      unitRef="usd">0</nltx:PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock>
    <nltx:PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMzQtMy0xLTEtMA_3ddae8bc-42c4-46dc-9cd6-c7dbe480951d"
      unitRef="usd">1693000</nltx:PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock>
    <us-gaap:LiabilitiesAssumed1
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMzUtMS0xLTEtMA_8f356fc8-198b-4f18-8f9a-6759dbb9db92"
      unitRef="usd">0</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMzUtMy0xLTEtMA_03d186dd-6f5f-4703-8935-246670b448ad"
      unitRef="usd">1673000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMzYtMS0xLTEtMA_82c7c30e-214e-4c18-8770-01b3e6dab9f3"
      unitRef="usd">10364000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMzYtMy0xLTEtMA_b571c4e4-4150-4fb8-b791-18243dd0d3c5"
      unitRef="usd">1182000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMzMtMS0xLTEtNDQzMw_87402e12-5914-4737-b5f1-71cb84864cbb"
      unitRef="usd">36000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85NC9mcmFnOmMwMzk2NDIyNGFhMzQ2NWQ4Yjg1MzMwMDE1Mzg1YzNmL3RhYmxlOjc4ZGY0OTRhZWQ5NTRlYWQ5ZTc3Yzg4Y2Q5Y2NlYTMwL3RhYmxlcmFuZ2U6NzhkZjQ5NGFlZDk1NGVhZDllNzdjODhjZDljY2VhMzBfMzMtMy0xLTEtNDQzMw_4ec46b06-cc0c-4cd4-ad76-7685199ce953"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:SharesOutstanding
      contextRef="i732d643094fe48eabda3a3bdcda606d7_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfOS0xLTEtMS0w_60c7667d-6b27-4941-99e7-41d35ae3e47c"
      unitRef="shares">23537368</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5cf36246e64844f0999cee0b4685f134_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfOS05LTEtMS0w_39f15b98-80e5-4ea9-96a1-2865d33ed722"
      unitRef="usd">302759000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibc7d097a895f4d19ad4225c8b7a363e3_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfOS0xMS0xLTEtMA_39b570dd-85ad-4a9b-8015-89a4f3543544"
      unitRef="usd">-230087000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i049d641cdc3c4012850e2abee7d5fe17_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMi0xNS0xLTEtMjgwMw_dbdeb4f2-bc2c-4a79-a9c9-52ab4f29577f"
      unitRef="usd">72672000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="ia5203423d3b74826a3d7fe380aabf55b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTAtMS0xLTEtMA_98cbf324-3251-497e-af42-dc0c2c3fc8ce"
      unitRef="shares">4589771</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="i4f9b47e6f171422bb275e6ef86e39725_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTAtOS0xLTEtMA_dd17aa7e-dbf2-4435-a8c9-0d1ac688e157"
      unitRef="usd">15055000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMy0xNS0xLTEtMjgwMw_903629f0-d577-4066-aef4-af35d96b648e"
      unitRef="usd">15055000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="i9b5b9988d4e248bc863b2725dbedccc0_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTEtNS0xLTEtMA_a885b0ef-275d-4ae3-9316-52b4d182cf7c"
      unitRef="shares">102000</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="ie40aff3f920a4fa49c187c3ad3974bfb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTEtOS0xLTEtMA_511dea10-e841-400c-b55e-a36539021e1c"
      unitRef="usd">33432000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="i9b5b9988d4e248bc863b2725dbedccc0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfNC0xNS0xLTEtMjgwMw_4ec74324-29d2-4c82-828f-9a1a5d80093a"
      unitRef="usd">33432000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ia5203423d3b74826a3d7fe380aabf55b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfNS0xLTEtMS0yNzYy_471a4ec7-9638-4550-a397-4af09dc41164"
      unitRef="shares">10192700</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i9b5b9988d4e248bc863b2725dbedccc0_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfNS01LTEtMS0yNzkx_724ed378-905b-45a4-9e7a-3bfda5234d77"
      unitRef="shares">-102000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfNi0wLTEtMS0yNzU0L3RleHRyZWdpb246ZTAxZjYwOTEwM2I0NDUyYzg2MDkxNTRkNGZiOWY0ZWNfMjE5OTAyMzI1NTY4NQ_b3f1633c-d58c-4abc-944f-3cb15ba4e73f"
      unitRef="usd">5525000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia5203423d3b74826a3d7fe380aabf55b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfNi0xLTEtMS0yNzYy_49bd2e87-8808-4769-805f-880ac31b225b"
      unitRef="shares">10263750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4f9b47e6f171422bb275e6ef86e39725_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfNi05LTEtMS0yNzkx_a1362e06-5a9d-4c5c-876a-d76a2ac3d657"
      unitRef="usd">80691000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfNi0xNS0xLTEtMjgwMw_7c3ebd7a-3110-44ca-8626-9ba80e528e78"
      unitRef="usd">80691000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="ia5203423d3b74826a3d7fe380aabf55b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfNy0xLTEtMS0yNzYy_8a71c310-5457-4672-af02-efaa5edc8320"
      unitRef="shares">12647</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i4f9b47e6f171422bb275e6ef86e39725_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfNy05LTEtMS0yNzkx_2d4e93ec-2d7a-45b1-8b5e-a617fb1b1a03"
      unitRef="usd">41000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfNy0xNS0xLTEtMjgwMw_55a87377-9a40-4556-9dde-57619b6d0618"
      unitRef="usd">41000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <nltx:StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants
      contextRef="ia5203423d3b74826a3d7fe380aabf55b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfOC0xLTEtMS0yNzYy_5683ffda-3614-427c-b26b-4b00d0a9aecb"
      unitRef="shares">-10925481</nltx:StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia5203423d3b74826a3d7fe380aabf55b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfOS0xLTEtMS0yNzYy_1a3330dc-5028-490c-bea5-678256e3034f"
      unitRef="shares">326094</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4f9b47e6f171422bb275e6ef86e39725_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfOS05LTEtMS0yNzkx_a5d0c58b-fec6-4539-9858-14aeb3e8840e"
      unitRef="usd">1555000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfOS0xNS0xLTEtMjgwMw_ee1bf612-ee1a-4566-bb2e-b6170a562359"
      unitRef="usd">1555000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4f9b47e6f171422bb275e6ef86e39725_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTItOS0xLTEtMA_33fc7bc4-d7f3-4420-a95b-685295d4e024"
      unitRef="usd">7683000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTAtMTUtMS0xLTI4MDM_044c8fad-1aac-43f3-be0c-09e323dfe00f"
      unitRef="usd">7683000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i0d6e4cb98c3641c0b1a872248ed13060_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTMtMTEtMS0xLTA_22ade35a-1332-414a-b908-88649511d19e"
      unitRef="usd">-69442000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTEtMTUtMS0xLTI4MDM_9f947dd2-5338-460d-839c-c21b037e69ff"
      unitRef="usd">-69442000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i9394470fa9e045eaaa71a62dee88a970_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTQtMS0xLTEtMA_4ccd3809-aa70-42b2-bb6b-4c77ea6d2a25"
      unitRef="shares">37996849</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i85f0f44c55744942ad3e1471a8246db3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTQtOS0xLTEtMA_adc4c33e-8834-4019-9a7f-e925ad26edd4"
      unitRef="usd">441216000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9cc2885987c54d929541504d3cf066e4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTQtMTEtMS0xLTA_b7320ea0-bd3b-42bb-be7a-14b0876e1803"
      unitRef="usd">-299529000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTItMTUtMS0xLTI4MDM_36c47b8f-d18b-420b-b323-39e87ab63f69"
      unitRef="usd">141687000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfOC0wLTEtMS0xNjM1L3RleHRyZWdpb246YmQzMzk4MjkyZmYyNGNhMWIwZTQ5MjMwNWQ1YzI0ZDdfMjE5OTAyMzI1NTY4Mg_12197f47-d898-4e5e-af0b-f485b705bc55"
      unitRef="usd">4930000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib2b7aa4965884327b321e9713f816fca_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfOC0xLTEtMS0xNjAx_7bc58a16-9987-4798-8c38-cf903b3101d8"
      unitRef="shares">3262471</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i815e5dda4d8349a9beb806cdf5433517_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfOC05LTEtMS0xNjAz_122dfc0b-75ea-4b01-996a-12c58d6efd4f"
      unitRef="usd">71320000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTMtMTUtMS0xLTI4MDM_91b42a54-b1cc-4fba-96f9-d326288aac54"
      unitRef="usd">71320000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ib2b7aa4965884327b321e9713f816fca_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfOS0xLTEtMS0xNjE1_0ad3e24c-b4e6-420e-bb44-ee289c8be259"
      unitRef="shares">882624</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i815e5dda4d8349a9beb806cdf5433517_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfOS05LTEtMS0xNjE5_b27e2af3-9bdb-4043-97e0-4512aeb25eed"
      unitRef="usd">5665000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTQtMTUtMS0xLTI4MDM_095f740e-b734-49a8-b2c8-8fda4e75c879"
      unitRef="usd">5665000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ib2b7aa4965884327b321e9713f816fca_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMjEtMS0xLTEtMA_4c29ad36-8132-49c2-98d1-b0cd688bd04c"
      unitRef="shares">36000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ib2b7aa4965884327b321e9713f816fca_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTYtMS0xLTEtNDQwOA_84684cec-e41e-48ff-8b56-89cf81afd9cb"
      unitRef="shares">18352</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i815e5dda4d8349a9beb806cdf5433517_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTYtOS0xLTEtNDQwOA_a8a516d3-f6a4-419e-a0f2-bf17efb20a06"
      unitRef="usd">199000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTYtMTUtMS0xLTQ0MDg_a9001011-59c8-4eae-8dd2-f800e4a7589e"
      unitRef="usd">199000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i815e5dda4d8349a9beb806cdf5433517_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMjItOS0xLTEtMA_1d204a36-a27d-4c8a-9068-9c7c27f3ed1e"
      unitRef="usd">5622000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i815e5dda4d8349a9beb806cdf5433517_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMjItOS0xLTEtMA_31455b16-498c-411e-b2de-b85c1d8d83b7"
      unitRef="usd">5622000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTYtMTUtMS0xLTI4MDM_20f7b2e1-c644-4744-89bb-be9d1b86d402"
      unitRef="usd">5622000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTYtMTUtMS0xLTI4MDM_8ef4d7c4-2af4-482a-9224-ac23b06dc3f5"
      unitRef="usd">5622000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i54fb527f851045fcb24b611005c9b2a2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMjMtMTEtMS0xLTA_1d0b8816-bcf0-46d7-bc0b-9249d192d16e"
      unitRef="usd">-33277000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i54fb527f851045fcb24b611005c9b2a2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMjMtMTEtMS0xLTA_ddc33729-142d-4220-9c9b-9ea5fa96ef5d"
      unitRef="usd">-33277000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTctMTUtMS0xLTI4MDM_2f4b8e2a-5461-449c-80e4-0dc9fe9ac554"
      unitRef="usd">-33277000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTctMTUtMS0xLTI4MDM_b024471e-6be8-4bda-bee4-5ca765a34696"
      unitRef="usd">-33277000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i8c771818b1a2410cbe3be150df63decf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMjQtMS0xLTEtMA_3fc1559d-f5da-42e1-922b-e1b03257ced4"
      unitRef="shares">42196296</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="i8c771818b1a2410cbe3be150df63decf_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMjQtMS0xLTEtMA_d4019ef7-64de-44f6-8d81-81df59c53f9b"
      unitRef="shares">42196296</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i64550577bf6444d791bf8bd32d649edd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMjQtOS0xLTEtMA_6df19335-e354-4500-9a94-bb7e010c0eb2"
      unitRef="usd">524022000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i64550577bf6444d791bf8bd32d649edd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMjQtOS0xLTEtMA_9efe793b-61aa-41d5-97e2-cf0465946199"
      unitRef="usd">524022000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i277fa222473b45ceb75d3af3ec082271_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMjQtMTEtMS0xLTA_428c4ed6-9344-41e4-8d3d-df9f01a2046a"
      unitRef="usd">-332806000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i277fa222473b45ceb75d3af3ec082271_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMjQtMTEtMS0xLTA_9d31cb3f-dbc9-433d-be9e-2a7c8d073467"
      unitRef="usd">-332806000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTgtMTUtMS0xLTI4MDM_2ad84739-67d9-4fe3-a8a7-bef05033b0fa"
      unitRef="usd">191216000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl85Ny9mcmFnOjFhZmUwM2Y3ODllMjQ2MmU5NmZiYTMyYzhhNmNlZWM5L3RhYmxlOmJmMzhkMDQ3NTE1YzQwOGRiZTczYWRhODFiYTMyNTI2L3RhYmxlcmFuZ2U6YmYzOGQwNDc1MTVjNDA4ZGJlNzNhZGE4MWJhMzI1MjZfMTgtMTUtMS0xLTI4MDM_65f02429-c69d-424c-bc2d-562985bd861f"
      unitRef="usd">191216000</us-gaap:StockholdersEquity>
    <us-gaap:NatureOfOperations
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDYvZnJhZzoxYzFkYjVkNjlkZDc0OGYwYTYzMWIwODgyNDlmNWNmOC90ZXh0cmVnaW9uOjFjMWRiNWQ2OWRkNzQ4ZjBhNjMxYjA4ODI0OWY1Y2Y4XzEyMjQ_5388df32-f995-47c5-be14-efcb0a912a7d">Nature of operations&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Neoleukin Therapeutics, Inc. (&#x201c;Neoleukin&#x201d; or &#x201c;the Company&#x201d;) is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;de novo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; protein design technology. Neoleukin uses sophisticated computational methods to design&#160;proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.&#160;The Company&#x2019;s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.&lt;/span&gt;</us-gaap:NatureOfOperations>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMzAy_8c35e1a6-7574-4460-9077-a276445653cb">Basis of presentation and summary of significant accounting policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(a) Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements are presented in United States (&#x201c;U.S.&#x201d;) dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). The financial results are presented on a consolidated basis. All intercompany transactions are eliminated on consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, the Company sold all of the issued and outstanding capital stock of Aquinox Pharmaceuticals (Canada) (&#x201c;Aquinox Canada&#x201d;) to an unrelated third party, as further described in Note 16, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sale of Aquinox Canada&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. On December 31, 2020, Neoleukin Corporation, the Company's wholly owned subsidiary, was merged into the Company. As a result, the Company consists of a single operating company without any subsidiaries at December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(b) Use of estimates and assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant areas requiring estimates include valuation and recognition of stock-based compensation, the incremental borrowing rate utilized in the measurement of operating and finance lease liabilities, amortization and depreciation of property, plant and equipment and intangible assets, and pre-clinical, clinical, and other accruals. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(c) Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reclassified amounts related to prior year amortization of operating lease right-of-use assets, loss on disposal of property and equipment, changes in operating lease liabilities, and payment of offering costs in the consolidated statements of cash flows to conform to current year presentation. This reclassification had no effect on cash used in operating activities or cash provided by financing activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(d) Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company determines if the contract is or contains a lease. Lease liabilities are recognized on the lease commencement date based on the estimated present value of lease payments over the lease term. To determine the present value of the lease payments, the Company utilizes its estimated incremental borrowing rate based on information available at the lease commencement date as the interest rate implicit in the lease is typically not readily determinable. The related right-of-use assets are recorded net of any lease incentives received. Variable lease cost primarily includes building operating expenses as charged to the Company by its landlords.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We include options to extend the lease in our lease liability and right-of-use asset when it is reasonably certain that we will exercise that option. None of our options to extend the rental term of any existing leases were considered reasonably certain as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For leases of office space, the Company has elected to not separate the lease components from the non-lease components.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For leases of office space with a lease term of 12 months or less and which do not include an option to purchase the underlying asset, the Company has elected to recognize the lease payments in the statement of operations on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(e) Cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All highly liquid investments with maturities of three months or less at the date of acquisition are considered to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash, included in Other non-current assets in the consolidated balance sheets, includes cash deposits the Company maintains with its bank as collateral for the irrevocable letters of credits related to its lease obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(f) Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost and are amortized using the straight-line basis over a range of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzE2NDkyNjc0OTYxNDk_956254c7-b20d-4861-9cc1-c72b39fa063a"&gt;three&lt;/span&gt; to seven years. Expenditures for improvements to the Company&#x2019;s office spaces are capitalized and expenditures for maintenance and repairs are expensed as incurred. Leasehold improvements are amortized over the lesser of useful life and term of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews the carrying value of property and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition, and other economic factors. Based on management&#x2019;s assessment there were no indicators of impairment of property and equipment as at December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(g) Earnings (loss) per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Common stock equivalents are included in the calculation of diluted earnings per share only in periods of net income. Such common stock equivalents are excluded in the calculation of diluted net loss per share in periods of net loss as inclusion of such amounts would be anti-dilutive. Outstanding pre-funded warrants as of December&#160;31, 2020 of 12,663,010 are considered outstanding as of their issuance date and are included in the basic and diluted net loss per share calculation because they are fully vested and exercisable at any time for a nominal cash consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(h) Asset acquisitions/Intangible assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the time of acquisition, the Company determines if a transaction should be accounted for as a business combination or acquisition of assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For an acquisition of assets, the cost of acquiring the asset group, including transaction costs, is allocated to the acquired assets and assumed liabilities based on their relative fair values without giving rise to goodwill. Acquired in-process research and development assets are expensed if management determines that the assets do not have an alternative future use. Other long-lived intangible assets are recorded at the acquired cost and amortized using the straight-line method over their estimated useful life. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intangible asset is tested for impairment when events or changes in circumstances indicate that the carrying value of the asset may not be recoverable.&#160;The Company recognizes an impairment loss when carrying amount is not recoverable and the estimated fair value of the intangible asset is less than its carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(i) Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the differences between events that have been recognized in the Company&#x2019;s consolidated financial statements and the tax bases of assets and liabilities recognized at enacted tax rates. In estimating future tax consequences, Accounting Standards Codification ("ASC") 740 generally considers all expected future events other than enactments of and changes in the tax law or rates. The measurement of deferred tax assets is reduced, if necessary, by the extent of the valuation allowance. We will establish a valuation allowance for deferred tax assets if it is more likely than not that these items will expire before we are able to realize their benefits or that future deductibility is uncertain. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investment tax credits relating to scientific research and experimental development are accounted for as a reduction in operating expenses. They are recorded in the period when there is reasonable assurance the credits will be realized. If investment tax credit amounts subsequently received are less or more than originally recorded, the difference is treated as a change in estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(j) Research and development costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to expense as incurred and include items such as: employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations that conduct clinical trials and preclinical studies, the cost of acquiring, developing and manufacturing clinical trial materials, facilities, and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, and other supplies and costs associated with clinical trials, preclinical activities, and regulatory operations. Restructuring costs associated with the termination of research and development programs and related employees are included in research and development costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Development costs are expensed in the period incurred unless management believes a development project meets generally accepted accounting criteria for deferral and amortization. No product development expenditures have been deferred to date. The Company records costs for certain development activities based on management&#x2019;s evaluation of the progress to completion of specific tasks or information provided to the Company by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(k) Accounting for stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has issued stock options and restricted stock units (&#x201c;RSUs&#x201d;). The Company measures the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The cost of such award is recognized on a straight-line basis over the requisite service period, which is generally the vesting period. The Company accounts for forfeitures as they occur. We utilize newly issued shares to satisfy option exercises.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of options using the Black-Scholes option pricing model on the grant date. This approximation uses assumptions regarding a number of inputs that requires management to make significant estimates and judgments. The expected term represents the period that the Company&#x2019;s stock-based awards are expected to be outstanding. As the Company does not have sufficient historical experience for determining the expected term of the stock option awards granted, the Company has based its expected term for awards issued to employees on the simplified method, which represents the average period from vesting to the expiration of the stock option. In addition, the Company does not have sufficient trading history for the Company&#x2019;s common stock, and therefore, the expected stock price volatility for the Company&#x2019;s common stock was estimated by taking the average historical price volatility for industry peers. The Company has never declared or paid any cash dividends to common stockholders and does not presently plan to pay cash dividends in the foreseeable future. Consequently, the Company used an expected dividend yield of zero. The risk-free interest rate was based on the yields of treasury securities with maturities similar to the expected term of the options for each option group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each RSU is measured using the closing price of the Company&#x2019;s common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(l) Restructuring costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for restructuring costs in accordance with ASC 420,&#160;Exit or Disposal Cost Obligations. ASC 420 specifies that a liability for a cost associated with an exit or disposal activity be recognized when the liability is incurred, except for a liability where employees are required to render service until they are terminated in order to receive termination benefits and will be retained to render service beyond the minimum retention period. A liability for such one-time termination benefits shall be measured initially at the communication date based on the fair value of the liability as of the termination date and recognized ratably over the future service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The charges that the Company expects to incur in connection with the restructuring are subject to a number of assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the restructuring plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(m) Segment reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in one segment, the research and development of&#160;de novo&#160;protein therapeutics using sophisticated computational algorithms and methods to address unmet medical needs. Our primary areas of focus are in oncology, inflammation, and autoimmunity. The Company&#x2019;s operations and its assets are held in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(n) Fair value of financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of certain of the Company&#x2019;s financial instruments, including cash, cash equivalents, receivables, accounts payable and other liabilities, approximate their fair values because of their nature and/or short maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, and December&#160;31, 2019, the Company had $108.3 million and $40.0 million in money market funds, respectively. Money market funds are level one financial instruments as their pricing can be obtained from an actively traded exchange.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(o) Concentration of credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents. Cash and cash equivalents are invested in accordance with the Company&#x2019;s investment policy. The primary objective for the Company&#x2019;s investment portfolio is the preservation of capital and maintenance of liquidity and includes guidelines on the quality of financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(p) Recently issued and recently adopted accounting standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12 &#x201c;Simplifying the Accounting for Income Taxes.&#x201d; The objective of the standard is to improve areas of GAAP by removing certain exceptions permitted by ASC Topic 740-- Income Taxes and clarifying existing guidance to facilitate consistent application. ASU 2019-12 is effective for fiscal years and interim periods beginning after December&#160;15, 2020. The Company has incurred net losses since its inception and maintains a full valuation allowance on the net deferred tax assets. As such, the Company does not expect the adoption of this standard to have a material impact on the financial condition, results of operations and cash flows, or financial statement disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued &#x201c;ASU 2018-15, Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.&#x201d; The objective of the standard is to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The Company adopted this standard on January 1, 2020 on a prospective basis. The adoption of this ASU did not have a material impact on the Company&#x2019;s financial condition, results of operations, cash flows, and financial statement disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMjk2_5267e6c3-380a-4e0a-8a7a-66d809122fc5">Basis of presentationThe accompanying consolidated financial statements are presented in United States (&#x201c;U.S.&#x201d;) dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). The financial results are presented on a consolidated basis. All intercompany transactions are eliminated on consolidation. &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, the Company sold all of the issued and outstanding capital stock of Aquinox Pharmaceuticals (Canada) (&#x201c;Aquinox Canada&#x201d;) to an unrelated third party, as further described in Note 16, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sale of Aquinox Canada&lt;/span&gt;. On December 31, 2020, Neoleukin Corporation, the Company's wholly owned subsidiary, was merged into the Company. As a result, the Company consists of a single operating company without any subsidiaries at December 31, 2020.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMjk4_f2ac624c-4ac9-466c-bfaf-1b913083916c">Use of estimates and assumptionsThe preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant areas requiring estimates include valuation and recognition of stock-based compensation, the incremental borrowing rate utilized in the measurement of operating and finance lease liabilities, amortization and depreciation of property, plant and equipment and intangible assets, and pre-clinical, clinical, and other accruals. Actual results could differ from those estimates.</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzE2NDkyNjc0OTYxMzA_402fb23d-e6a3-4502-b43a-a67de8da1101">ReclassificationThe Company reclassified amounts related to prior year amortization of operating lease right-of-use assets, loss on disposal of property and equipment, changes in operating lease liabilities, and payment of offering costs in the consolidated statements of cash flows to conform to current year presentation. This reclassification had no effect on cash used in operating activities or cash provided by financing activities.</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzE2NDkyNjc0OTYxMzI_1d4c154a-0570-42dc-8e36-a715f8a5f310">Leases&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company determines if the contract is or contains a lease. Lease liabilities are recognized on the lease commencement date based on the estimated present value of lease payments over the lease term. To determine the present value of the lease payments, the Company utilizes its estimated incremental borrowing rate based on information available at the lease commencement date as the interest rate implicit in the lease is typically not readily determinable. The related right-of-use assets are recorded net of any lease incentives received. Variable lease cost primarily includes building operating expenses as charged to the Company by its landlords.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We include options to extend the lease in our lease liability and right-of-use asset when it is reasonably certain that we will exercise that option. None of our options to extend the rental term of any existing leases were considered reasonably certain as of December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For leases of office space, the Company has elected to not separate the lease components from the non-lease components.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For leases of office space with a lease term of 12 months or less and which do not include an option to purchase the underlying asset, the Company has elected to recognize the lease payments in the statement of operations on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i3d1ecd6573694fdfb6e3cad48ebf1c3c_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzE2NDkyNjc0OTYxOTA_3deef86e-d0dc-4596-a42e-acbce0b95d44">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMjk5_e748e1ad-1829-4f75-8de1-98076eac4eb4">Cash, cash equivalents, and restricted cash&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All highly liquid investments with maturities of three months or less at the date of acquisition are considered to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash, included in Other non-current assets in the consolidated balance sheets, includes cash deposits the Company maintains with its bank as collateral for the irrevocable letters of credits related to its lease obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzE2NDkyNjc1MjI2NzQ_c3c50190-8c2b-4792-b5cf-acfdeae21e40">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzE2NDkyNjc1MjI2NzQ_f722fb9b-fcad-4ad8-b15a-55afc3a828c3">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.867%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90YWJsZTplZGFkMjdhNDE5MWQ0NWYzYjRiZTEzYWEzZTIwNTllOS90YWJsZXJhbmdlOmVkYWQyN2E0MTkxZDQ1ZjNiNGJlMTNhYTNlMjA1OWU5XzEtMS0xLTEtNTU0OA_73db0383-9df1-4ff4-b276-7b48ebc1a76c"
      unitRef="usd">192556000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90YWJsZTplZGFkMjdhNDE5MWQ0NWYzYjRiZTEzYWEzZTIwNTllOS90YWJsZXJhbmdlOmVkYWQyN2E0MTkxZDQ1ZjNiNGJlMTNhYTNlMjA1OWU5XzEtMy0xLTEtNTU1MA_bdfabd21-1796-4633-9ec5-5d60d0529917"
      unitRef="usd">143093000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90YWJsZTplZGFkMjdhNDE5MWQ0NWYzYjRiZTEzYWEzZTIwNTllOS90YWJsZXJhbmdlOmVkYWQyN2E0MTkxZDQ1ZjNiNGJlMTNhYTNlMjA1OWU5XzItMS0xLTEtNTU0OA_45160e56-974e-43c7-ae0b-ffda4df4ad6b"
      unitRef="usd">878000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90YWJsZTplZGFkMjdhNDE5MWQ0NWYzYjRiZTEzYWEzZTIwNTllOS90YWJsZXJhbmdlOmVkYWQyN2E0MTkxZDQ1ZjNiNGJlMTNhYTNlMjA1OWU5XzItMy0xLTEtNTU1MA_b796134a-d580-4101-9f2c-3999a9f1b523"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90YWJsZTplZGFkMjdhNDE5MWQ0NWYzYjRiZTEzYWEzZTIwNTllOS90YWJsZXJhbmdlOmVkYWQyN2E0MTkxZDQ1ZjNiNGJlMTNhYTNlMjA1OWU5XzMtMS0xLTEtNTU0OA_54a9dc28-9049-47c8-9f71-7f4c8cede975"
      unitRef="usd">193434000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90YWJsZTplZGFkMjdhNDE5MWQ0NWYzYjRiZTEzYWEzZTIwNTllOS90YWJsZXJhbmdlOmVkYWQyN2E0MTkxZDQ1ZjNiNGJlMTNhYTNlMjA1OWU5XzMtMy0xLTEtNTU1MA_c907007f-befb-40fa-8074-d796c35fda74"
      unitRef="usd">143093000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMzEx_a120f076-3793-44a3-93c7-382a4e07ee37">Property and equipment&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost and are amortized using the straight-line basis over a range of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzE2NDkyNjc0OTYxNDk_956254c7-b20d-4861-9cc1-c72b39fa063a"&gt;three&lt;/span&gt; to seven years. Expenditures for improvements to the Company&#x2019;s office spaces are capitalized and expenditures for maintenance and repairs are expensed as incurred. Leasehold improvements are amortized over the lesser of useful life and term of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews the carrying value of property and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition, and other economic factors. Based on management&#x2019;s assessment there were no indicators of impairment of property and equipment as at December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iae8ed78b63224fe9a7fae1f526fde05d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzE2NDkyNjc0OTYxNjE_516bf8ec-1d6d-4c7b-81f2-42056e758e10">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzE2NDkyNjc0OTYxNDc_d9cbd895-53af-4f6c-87c5-a9aaac69a8ef">Earnings (loss) per shareBasic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Common stock equivalents are included in the calculation of diluted earnings per share only in periods of net income. Such common stock equivalents are excluded in the calculation of diluted net loss per share in periods of net loss as inclusion of such amounts would be anti-dilutive. Outstanding pre-funded warrants as of December&#160;31, 2020 of 12,663,010 are considered outstanding as of their issuance date and are included in the basic and diluted net loss per share calculation because they are fully vested and exercisable at any time for a nominal cash consideration.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzMyOTg1MzQ5NTk1Mzk_19ccbf22-60b4-4acf-b6c5-22c1926bc300"
      unitRef="shares">12663010</us-gaap:ClassOfWarrantOrRightOutstanding>
    <nltx:AssetAcquisitionsintangibleAssetsPolicyTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMzEy_8692fe03-a166-4c0a-94a6-b5eb2edc7ae7">Asset acquisitions/Intangible assets&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the time of acquisition, the Company determines if a transaction should be accounted for as a business combination or acquisition of assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For an acquisition of assets, the cost of acquiring the asset group, including transaction costs, is allocated to the acquired assets and assumed liabilities based on their relative fair values without giving rise to goodwill. Acquired in-process research and development assets are expensed if management determines that the assets do not have an alternative future use. Other long-lived intangible assets are recorded at the acquired cost and amortized using the straight-line method over their estimated useful life. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intangible asset is tested for impairment when events or changes in circumstances indicate that the carrying value of the asset may not be recoverable.&#160;The Company recognizes an impairment loss when carrying amount is not recoverable and the estimated fair value of the intangible asset is less than its carrying value.&lt;/span&gt;&lt;/div&gt;</nltx:AssetAcquisitionsintangibleAssetsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMzEz_4729c5e1-ec8f-40f0-84ec-34ff391b5046">Income taxes&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the differences between events that have been recognized in the Company&#x2019;s consolidated financial statements and the tax bases of assets and liabilities recognized at enacted tax rates. In estimating future tax consequences, Accounting Standards Codification ("ASC") 740 generally considers all expected future events other than enactments of and changes in the tax law or rates. The measurement of deferred tax assets is reduced, if necessary, by the extent of the valuation allowance. We will establish a valuation allowance for deferred tax assets if it is more likely than not that these items will expire before we are able to realize their benefits or that future deductibility is uncertain. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investment tax credits relating to scientific research and experimental development are accounted for as a reduction in operating expenses. They are recorded in the period when there is reasonable assurance the credits will be realized. If investment tax credit amounts subsequently received are less or more than originally recorded, the difference is treated as a change in estimate.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMzE0_1526cf6a-012b-4e8c-850d-328b323969c5">Research and development costs&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are charged to expense as incurred and include items such as: employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations that conduct clinical trials and preclinical studies, the cost of acquiring, developing and manufacturing clinical trial materials, facilities, and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, and other supplies and costs associated with clinical trials, preclinical activities, and regulatory operations. Restructuring costs associated with the termination of research and development programs and related employees are included in research and development costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Development costs are expensed in the period incurred unless management believes a development project meets generally accepted accounting criteria for deferral and amortization. No product development expenditures have been deferred to date. The Company records costs for certain development activities based on management&#x2019;s evaluation of the progress to completion of specific tasks or information provided to the Company by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMzE1_35240b48-b22a-4eb6-8ccd-e2346a9b1fb2">Accounting for stock-based compensation&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has issued stock options and restricted stock units (&#x201c;RSUs&#x201d;). The Company measures the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The cost of such award is recognized on a straight-line basis over the requisite service period, which is generally the vesting period. The Company accounts for forfeitures as they occur. We utilize newly issued shares to satisfy option exercises.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of options using the Black-Scholes option pricing model on the grant date. This approximation uses assumptions regarding a number of inputs that requires management to make significant estimates and judgments. The expected term represents the period that the Company&#x2019;s stock-based awards are expected to be outstanding. As the Company does not have sufficient historical experience for determining the expected term of the stock option awards granted, the Company has based its expected term for awards issued to employees on the simplified method, which represents the average period from vesting to the expiration of the stock option. In addition, the Company does not have sufficient trading history for the Company&#x2019;s common stock, and therefore, the expected stock price volatility for the Company&#x2019;s common stock was estimated by taking the average historical price volatility for industry peers. The Company has never declared or paid any cash dividends to common stockholders and does not presently plan to pay cash dividends in the foreseeable future. Consequently, the Company used an expected dividend yield of zero. The risk-free interest rate was based on the yields of treasury securities with maturities similar to the expected term of the options for each option group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each RSU is measured using the closing price of the Company&#x2019;s common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMzA3_9877ced6-1adb-484a-833a-6003aae52124">Restructuring costs&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for restructuring costs in accordance with ASC 420,&#160;Exit or Disposal Cost Obligations. ASC 420 specifies that a liability for a cost associated with an exit or disposal activity be recognized when the liability is incurred, except for a liability where employees are required to render service until they are terminated in order to receive termination benefits and will be retained to render service beyond the minimum retention period. A liability for such one-time termination benefits shall be measured initially at the communication date based on the fair value of the liability as of the termination date and recognized ratably over the future service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The charges that the Company expects to incur in connection with the restructuring are subject to a number of assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the restructuring plan.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMjk0_fc181b10-4218-4b9e-9661-b14100231945">Segment reportingThe Company operates in one segment, the research and development of&#160;de novo&#160;protein therapeutics using sophisticated computational algorithms and methods to address unmet medical needs. Our primary areas of focus are in oncology, inflammation, and autoimmunity. The Company&#x2019;s operations and its assets are held in the United States.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzE2NDkyNjc1MjU4ODA_57cbdc7a-b466-4f2b-887f-079550689f6a"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMzEw_3d153df4-9a0e-4de5-aff3-01551939af36">Fair value of financial instrumentsThe carrying amounts of certain of the Company&#x2019;s financial instruments, including cash, cash equivalents, receivables, accounts payable and other liabilities, approximate their fair values because of their nature and/or short maturities.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie23ad3f47f044a12afefd67475b342f7_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzMyOTg1MzQ5MzUwODk_d5e601f3-f781-40bf-9f93-aefdd7929fdb"
      unitRef="usd">108300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibe8d18d31bb743bea079e6b2de6ec19a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzMyOTg1MzQ5MzUwOTg_bceb6c0e-866a-46f5-aaf8-c58490f0ffb2"
      unitRef="usd">40000000.0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMjk1_bfeeeeca-b5d5-4f0c-aee8-7e4dd8e10ffa">Concentration of credit riskFinancial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents. Cash and cash equivalents are invested in accordance with the Company&#x2019;s investment policy. The primary objective for the Company&#x2019;s investment portfolio is the preservation of capital and maintenance of liquidity and includes guidelines on the quality of financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzIxMzA5_40d220ca-a5ca-491b-a3a6-64bbe9e2af7e">Recently issued and recently adopted accounting standards&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12 &#x201c;Simplifying the Accounting for Income Taxes.&#x201d; The objective of the standard is to improve areas of GAAP by removing certain exceptions permitted by ASC Topic 740-- Income Taxes and clarifying existing guidance to facilitate consistent application. ASU 2019-12 is effective for fiscal years and interim periods beginning after December&#160;15, 2020. The Company has incurred net losses since its inception and maintains a full valuation allowance on the net deferred tax assets. As such, the Company does not expect the adoption of this standard to have a material impact on the financial condition, results of operations and cash flows, or financial statement disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued &#x201c;ASU 2018-15, Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.&#x201d; The objective of the standard is to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The Company adopted this standard on January 1, 2020 on a prospective basis. The adoption of this ASU did not have a material impact on the Company&#x2019;s financial condition, results of operations, cash flows, and financial statement disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <nltx:AcquisitionOfAssetsDisclosureTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90ZXh0cmVnaW9uOmIxMTU2ODgxNDdhYTQ5N2NiOGE2ZWFjZTVjOTg1YTczXzEyNDU_9ef3d3f3-cbc4-42ad-8ba1-8306f9fb2fea">Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc.&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;8, 2019, Neoleukin Therapeutics, Inc., or Former Neoleukin, and Aquinox Pharmaceuticals, Inc., or Aquinox, completed a transaction pursuant to the Agreement and Plan of Merger dated August&#160;5, 2019. Former Neoleukin became a wholly owned subsidiary of Aquinox and Aquinox subsequently changed its name to Neoleukin Therapeutics, Inc. All of the outstanding shares of common stock of the Former Neoleukin were exchanged for 4,589,771 shares of common stock of the Company and 101,927 shares of non-voting convertible preferred stock of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total consideration paid was $51.6 million and consisted of (in thousands, except share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of 4,589,771 Aquinox common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of 101,927 Aquinox convertible preferred stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash consideration for fractional shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Aquinox securities issued to stockholders of Former Neoleukin was based on the closing stock price on August&#160;7, 2019, the last day of trading prior to the completion of the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction was accounted for as an asset acquisition as Former Neoleukin did not meet the definition of a business as substantially all of the value was in the In-Process Research&#160;&amp;amp; Development (&#x201c;IPR&amp;amp;D&#x201d;) asset. The estimated fair value of the IPR&amp;amp;D asset of $47.7 million was expensed as the Company determined that the asset has no alternative future use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the assets acquired and liabilities assumed (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables, prepayments and deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nltx:AcquisitionOfAssetsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="i40320493bb114b7b9790c7199d64f1a0_D20190808-20190808"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90ZXh0cmVnaW9uOmIxMTU2ODgxNDdhYTQ5N2NiOGE2ZWFjZTVjOTg1YTczXzMyOTg1MzQ4ODUzMzM_8e01ca8d-511b-4c42-adcb-06d7a1d705da"
      unitRef="shares">4589771</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="ib1005fcc8fe5417da0ed149702b76a6f_D20190808-20190808"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90ZXh0cmVnaW9uOmIxMTU2ODgxNDdhYTQ5N2NiOGE2ZWFjZTVjOTg1YTczXzMyOTg1MzQ4ODUzMzc_852e98a0-96ab-409e-b12e-b53ebf80478e"
      unitRef="shares">101927</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <nltx:AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90ZXh0cmVnaW9uOmIxMTU2ODgxNDdhYTQ5N2NiOGE2ZWFjZTVjOTg1YTczXzEyNDY_2a66be7a-b3f9-4ac9-b291-81c59db97c69">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total consideration paid was $51.6 million and consisted of (in thousands, except share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of 4,589,771 Aquinox common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of 101,927 Aquinox convertible preferred stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash consideration for fractional shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nltx:AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock>
    <nltx:AcquisitionsOfAssetsConsiderationTransferred
      contextRef="i562c09437d76488daa016091ce08fa2a_D20190808-20190808"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90ZXh0cmVnaW9uOmIxMTU2ODgxNDdhYTQ5N2NiOGE2ZWFjZTVjOTg1YTczXzMyOTg1MzQ4ODUzNDE_d9c7c7c2-12dc-47ff-9d51-3145b567fa1a"
      unitRef="usd">51600000</nltx:AcquisitionsOfAssetsConsiderationTransferred>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="i40320493bb114b7b9790c7199d64f1a0_D20190808-20190808"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozNTkxNGZlMjY2ODE0YTI1Yjk1NDY3NjI4NjY1ZGI0Yy90YWJsZXJhbmdlOjM1OTE0ZmUyNjY4MTRhMjViOTU0Njc2Mjg2NjVkYjRjXzEtMC0xLTEtNTcwL3RleHRyZWdpb246MjgxMTc5ZDg0NTU0NDY1M2IyOTQ0NTdhYWJjMjM1NjFfMjE5OTAyMzI1NTYwOQ_2725e9e3-b372-4ead-b9a1-fc383837dc4f"
      unitRef="shares">4589771</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <nltx:AcquisitionsOfAssetsFairValueOfSharesIssued
      contextRef="i40320493bb114b7b9790c7199d64f1a0_D20190808-20190808"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozNTkxNGZlMjY2ODE0YTI1Yjk1NDY3NjI4NjY1ZGI0Yy90YWJsZXJhbmdlOjM1OTE0ZmUyNjY4MTRhMjViOTU0Njc2Mjg2NjVkYjRjXzEtMS0xLTEtMA_577865ca-0b76-452c-b42d-f2eae76ede0c"
      unitRef="usd">15055000</nltx:AcquisitionsOfAssetsFairValueOfSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="ib1005fcc8fe5417da0ed149702b76a6f_D20190808-20190808"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozNTkxNGZlMjY2ODE0YTI1Yjk1NDY3NjI4NjY1ZGI0Yy90YWJsZXJhbmdlOjM1OTE0ZmUyNjY4MTRhMjViOTU0Njc2Mjg2NjVkYjRjXzItMC0xLTEtNTcwL3RleHRyZWdpb246MTE1ZTIwNDFjMWQzNDkwZWJlOGM5OTFmY2VmZjhhNjRfMjE5OTAyMzI1NTYyMA_476d9918-e7d8-4086-bb75-f0eda1119ad1"
      unitRef="shares">101927</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <nltx:AcquisitionsOfAssetsFairValueOfSharesIssued
      contextRef="i6bb0f20de0234580abbe24e6025eeb91_D20190808-20190808"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozNTkxNGZlMjY2ODE0YTI1Yjk1NDY3NjI4NjY1ZGI0Yy90YWJsZXJhbmdlOjM1OTE0ZmUyNjY4MTRhMjViOTU0Njc2Mjg2NjVkYjRjXzItMS0xLTEtMA_3fe1c925-dfd2-4da1-916e-8be052d0a940"
      unitRef="usd">33432000</nltx:AcquisitionsOfAssetsFairValueOfSharesIssued>
    <nltx:AcquisitionsOfAssetsCashConsiderationForFractionalShares
      contextRef="i562c09437d76488daa016091ce08fa2a_D20190808-20190808"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozNTkxNGZlMjY2ODE0YTI1Yjk1NDY3NjI4NjY1ZGI0Yy90YWJsZXJhbmdlOjM1OTE0ZmUyNjY4MTRhMjViOTU0Njc2Mjg2NjVkYjRjXzMtMS0xLTEtMA_3b5c4c94-31fb-40b7-bbe1-d24c04b53e9d"
      unitRef="usd">5000</nltx:AcquisitionsOfAssetsCashConsiderationForFractionalShares>
    <nltx:AcquisitionsOfAssetsTransactionCosts
      contextRef="i562c09437d76488daa016091ce08fa2a_D20190808-20190808"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozNTkxNGZlMjY2ODE0YTI1Yjk1NDY3NjI4NjY1ZGI0Yy90YWJsZXJhbmdlOjM1OTE0ZmUyNjY4MTRhMjViOTU0Njc2Mjg2NjVkYjRjXzQtMS0xLTEtMA_f955aa77-0524-4348-b446-cc43a9fc8e54"
      unitRef="usd">-3086000</nltx:AcquisitionsOfAssetsTransactionCosts>
    <nltx:AcquisitionsOfAssetsConsiderationTransferred
      contextRef="i562c09437d76488daa016091ce08fa2a_D20190808-20190808"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozNTkxNGZlMjY2ODE0YTI1Yjk1NDY3NjI4NjY1ZGI0Yy90YWJsZXJhbmdlOjM1OTE0ZmUyNjY4MTRhMjViOTU0Njc2Mjg2NjVkYjRjXzUtMS0xLTEtMA_6aa5e9e1-259c-471b-963e-18b16ddd138e"
      unitRef="usd">51578000</nltx:AcquisitionsOfAssetsConsiderationTransferred>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="icc0c497a9b7e42ff89e71ed4e700c005_D20190808-20190808"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90ZXh0cmVnaW9uOmIxMTU2ODgxNDdhYTQ5N2NiOGE2ZWFjZTVjOTg1YTczXzMyOTg1MzQ4ODUzNTM_4019c192-7bac-489f-8e41-9d6ebe257b36"
      unitRef="usd">47700000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90ZXh0cmVnaW9uOmIxMTU2ODgxNDdhYTQ5N2NiOGE2ZWFjZTVjOTg1YTczXzEyNDc_f72d780a-65de-411d-bf1c-e23e23e3a025">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the assets acquired and liabilities assumed (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables, prepayments and deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <nltx:AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents
      contextRef="i99076ffdc9d3414f812225c38a835667_I20190808"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozMWZlYzExNzA3MDI0M2Y1YTJiN2RhNTA5OWRiOTJjYS90YWJsZXJhbmdlOjMxZmVjMTE3MDcwMjQzZjVhMmI3ZGE1MDk5ZGI5MmNhXzItMS0xLTEtMA_4e1c844e-a3d2-46bf-b1e7-c66082bc9df7"
      unitRef="usd">3282000</nltx:AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents>
    <nltx:AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits
      contextRef="i99076ffdc9d3414f812225c38a835667_I20190808"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozMWZlYzExNzA3MDI0M2Y1YTJiN2RhNTA5OWRiOTJjYS90YWJsZXJhbmdlOjMxZmVjMTE3MDcwMjQzZjVhMmI3ZGE1MDk5ZGI5MmNhXzMtMS0xLTEtMA_c04be4c3-5354-4542-bf54-d58c4754b681"
      unitRef="usd">560000</nltx:AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits>
    <nltx:AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment
      contextRef="i99076ffdc9d3414f812225c38a835667_I20190808"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozMWZlYzExNzA3MDI0M2Y1YTJiN2RhNTA5OWRiOTJjYS90YWJsZXJhbmdlOjMxZmVjMTE3MDcwMjQzZjVhMmI3ZGE1MDk5ZGI5MmNhXzQtMS0xLTEtMA_090fec62-df38-4434-adfb-18679493967d"
      unitRef="usd">1034000</nltx:AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment>
    <nltx:AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets
      contextRef="i99076ffdc9d3414f812225c38a835667_I20190808"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozMWZlYzExNzA3MDI0M2Y1YTJiN2RhNTA5OWRiOTJjYS90YWJsZXJhbmdlOjMxZmVjMTE3MDcwMjQzZjVhMmI3ZGE1MDk5ZGI5MmNhXzUtMS0xLTEtMA_a2b1a764-8005-419b-b829-7b74d86b9e8c"
      unitRef="usd">47716000</nltx:AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets>
    <nltx:AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset
      contextRef="i99076ffdc9d3414f812225c38a835667_I20190808"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozMWZlYzExNzA3MDI0M2Y1YTJiN2RhNTA5OWRiOTJjYS90YWJsZXJhbmdlOjMxZmVjMTE3MDcwMjQzZjVhMmI3ZGE1MDk5ZGI5MmNhXzYtMS0xLTEtMA_076e1a1d-4253-4fe6-93ad-03d4bbf9beb5"
      unitRef="usd">659000</nltx:AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset>
    <nltx:AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet
      contextRef="i99076ffdc9d3414f812225c38a835667_I20190808"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozMWZlYzExNzA3MDI0M2Y1YTJiN2RhNTA5OWRiOTJjYS90YWJsZXJhbmdlOjMxZmVjMTE3MDcwMjQzZjVhMmI3ZGE1MDk5ZGI5MmNhXzctMS0xLTEtMA_847c1ce0-a7cd-4468-99db-4157514cace3"
      unitRef="usd">53251000</nltx:AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet>
    <nltx:AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities
      contextRef="i99076ffdc9d3414f812225c38a835667_I20190808"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozMWZlYzExNzA3MDI0M2Y1YTJiN2RhNTA5OWRiOTJjYS90YWJsZXJhbmdlOjMxZmVjMTE3MDcwMjQzZjVhMmI3ZGE1MDk5ZGI5MmNhXzktMS0xLTEtMA_0865e4fa-4d45-40c3-b2c9-186645b8049d"
      unitRef="usd">1472000</nltx:AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities>
    <nltx:AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability
      contextRef="i99076ffdc9d3414f812225c38a835667_I20190808"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozMWZlYzExNzA3MDI0M2Y1YTJiN2RhNTA5OWRiOTJjYS90YWJsZXJhbmdlOjMxZmVjMTE3MDcwMjQzZjVhMmI3ZGE1MDk5ZGI5MmNhXzEwLTEtMS0xLTA_a14713d7-2d7c-4504-8627-8a188a88a003"
      unitRef="usd">201000</nltx:AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability>
    <nltx:AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed
      contextRef="i99076ffdc9d3414f812225c38a835667_I20190808"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozMWZlYzExNzA3MDI0M2Y1YTJiN2RhNTA5OWRiOTJjYS90YWJsZXJhbmdlOjMxZmVjMTE3MDcwMjQzZjVhMmI3ZGE1MDk5ZGI5MmNhXzExLTEtMS0xLTA_2abc6242-1116-46d2-822a-a1fec8d1d752"
      unitRef="usd">1673000</nltx:AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed>
    <nltx:AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i99076ffdc9d3414f812225c38a835667_I20190808"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTIvZnJhZzpiMTE1Njg4MTQ3YWE0OTdjYjhhNmVhY2U1Yzk4NWE3My90YWJsZTozMWZlYzExNzA3MDI0M2Y1YTJiN2RhNTA5OWRiOTJjYS90YWJsZXJhbmdlOjMxZmVjMTE3MDcwMjQzZjVhMmI3ZGE1MDk5ZGI5MmNhXzEyLTEtMS0xLTA_bd85a82a-d275-4670-872c-119b28e7945f"
      unitRef="usd">51578000</nltx:AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90ZXh0cmVnaW9uOjE1NGQ0YmFjYzI4ZTQzZTk5ZmJjMWJiOWIwZmQxYzlmXzE1Ng_bf399520-a5bf-43c9-8db7-c334f48747fc">Property and equipment, net&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Book Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture, fixtures, and IT equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Book Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture, fixtures, and IT equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense on property and equipment totaled $0.6 million and $0.2 million for the years ended December&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90ZXh0cmVnaW9uOjE1NGQ0YmFjYzI4ZTQzZTk5ZmJjMWJiOWIwZmQxYzlmXzE1Nw_09c36d70-83e7-462b-b7cb-bc64dea5b622">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Book Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture, fixtures, and IT equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Book Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furniture, fixtures, and IT equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia47d5cee66404f7cbae1aeec9577fc50_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZToyMDYzNWM4YzA1OGU0MTA3OTU3YzU0N2FjZDQyNGNiYy90YWJsZXJhbmdlOjIwNjM1YzhjMDU4ZTQxMDc5NTdjNTQ3YWNkNDI0Y2JjXzMtMS0xLTEtMA_ed690952-dbd2-40e2-b1a0-ddd892c5c429"
      unitRef="usd">3402000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ia47d5cee66404f7cbae1aeec9577fc50_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZToyMDYzNWM4YzA1OGU0MTA3OTU3YzU0N2FjZDQyNGNiYy90YWJsZXJhbmdlOjIwNjM1YzhjMDU4ZTQxMDc5NTdjNTQ3YWNkNDI0Y2JjXzMtMy0xLTEtMA_aca1a085-5829-4476-97c5-0ac81ccfac71"
      unitRef="usd">426000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia47d5cee66404f7cbae1aeec9577fc50_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZToyMDYzNWM4YzA1OGU0MTA3OTU3YzU0N2FjZDQyNGNiYy90YWJsZXJhbmdlOjIwNjM1YzhjMDU4ZTQxMDc5NTdjNTQ3YWNkNDI0Y2JjXzMtNS0xLTEtMA_20e64744-45b7-4f21-b912-96fed248b944"
      unitRef="usd">2976000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if7459e4cc288446f840ea60d80fbb934_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZToyMDYzNWM4YzA1OGU0MTA3OTU3YzU0N2FjZDQyNGNiYy90YWJsZXJhbmdlOjIwNjM1YzhjMDU4ZTQxMDc5NTdjNTQ3YWNkNDI0Y2JjXzQtMS0xLTEtMA_07f412e6-0da9-431a-a9a9-73214570b23b"
      unitRef="usd">753000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="if7459e4cc288446f840ea60d80fbb934_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZToyMDYzNWM4YzA1OGU0MTA3OTU3YzU0N2FjZDQyNGNiYy90YWJsZXJhbmdlOjIwNjM1YzhjMDU4ZTQxMDc5NTdjNTQ3YWNkNDI0Y2JjXzQtMy0xLTEtMA_5c534ebc-bf6f-4a30-ac16-8137a3258faa"
      unitRef="usd">159000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if7459e4cc288446f840ea60d80fbb934_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZToyMDYzNWM4YzA1OGU0MTA3OTU3YzU0N2FjZDQyNGNiYy90YWJsZXJhbmdlOjIwNjM1YzhjMDU4ZTQxMDc5NTdjNTQ3YWNkNDI0Y2JjXzQtNS0xLTEtMA_10ede25d-4968-4a14-b2aa-20c2561521a4"
      unitRef="usd">594000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZToyMDYzNWM4YzA1OGU0MTA3OTU3YzU0N2FjZDQyNGNiYy90YWJsZXJhbmdlOjIwNjM1YzhjMDU4ZTQxMDc5NTdjNTQ3YWNkNDI0Y2JjXzUtMS0xLTEtMA_7c30e9eb-e009-4169-970e-8cf2bc3fa2a1"
      unitRef="usd">4155000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZToyMDYzNWM4YzA1OGU0MTA3OTU3YzU0N2FjZDQyNGNiYy90YWJsZXJhbmdlOjIwNjM1YzhjMDU4ZTQxMDc5NTdjNTQ3YWNkNDI0Y2JjXzUtMy0xLTEtMA_c925a16a-1d23-46af-86e2-b591e7563272"
      unitRef="usd">585000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZToyMDYzNWM4YzA1OGU0MTA3OTU3YzU0N2FjZDQyNGNiYy90YWJsZXJhbmdlOjIwNjM1YzhjMDU4ZTQxMDc5NTdjNTQ3YWNkNDI0Y2JjXzUtNS0xLTEtMA_13df2528-c7dd-4952-90fa-24b585bd88b9"
      unitRef="usd">3570000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1a680cc9adc946558b7938da05a43e34_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZTo1NzRjNDczMDgxMDY0NTU0OTMwNTJjNGE5MTZmYmM1MC90YWJsZXJhbmdlOjU3NGM0NzMwODEwNjQ1NTQ5MzA1MmM0YTkxNmZiYzUwXzItMS0xLTEtMA_4556ef02-976b-40b8-be71-aab30d5a62e6"
      unitRef="usd">490000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i1a680cc9adc946558b7938da05a43e34_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZTo1NzRjNDczMDgxMDY0NTU0OTMwNTJjNGE5MTZmYmM1MC90YWJsZXJhbmdlOjU3NGM0NzMwODEwNjQ1NTQ5MzA1MmM0YTkxNmZiYzUwXzItMy0xLTEtMA_57585b99-057e-4a47-8e5a-afd8afb5e347"
      unitRef="usd">333000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1a680cc9adc946558b7938da05a43e34_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZTo1NzRjNDczMDgxMDY0NTU0OTMwNTJjNGE5MTZmYmM1MC90YWJsZXJhbmdlOjU3NGM0NzMwODEwNjQ1NTQ5MzA1MmM0YTkxNmZiYzUwXzItNS0xLTEtMA_fd2bdd56-eb53-43fe-8fdb-9c474d176d5a"
      unitRef="usd">157000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i15d940e5d2f149acbb5357be4a7e366f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZTo1NzRjNDczMDgxMDY0NTU0OTMwNTJjNGE5MTZmYmM1MC90YWJsZXJhbmdlOjU3NGM0NzMwODEwNjQ1NTQ5MzA1MmM0YTkxNmZiYzUwXzMtMS0xLTEtMjE4_62c354c2-f050-47f1-9b25-c30b64614a30"
      unitRef="usd">1515000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i15d940e5d2f149acbb5357be4a7e366f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZTo1NzRjNDczMDgxMDY0NTU0OTMwNTJjNGE5MTZmYmM1MC90YWJsZXJhbmdlOjU3NGM0NzMwODEwNjQ1NTQ5MzA1MmM0YTkxNmZiYzUwXzMtMy0xLTEtMjE4_0fbe8576-da00-4ffd-97a2-4af9a705c950"
      unitRef="usd">62000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i15d940e5d2f149acbb5357be4a7e366f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZTo1NzRjNDczMDgxMDY0NTU0OTMwNTJjNGE5MTZmYmM1MC90YWJsZXJhbmdlOjU3NGM0NzMwODEwNjQ1NTQ5MzA1MmM0YTkxNmZiYzUwXzMtNS0xLTEtMjE4_22a506ce-d593-4d92-a42b-3538b61a5828"
      unitRef="usd">1453000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2208e67d526547b5819db3624bbe011a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZTo1NzRjNDczMDgxMDY0NTU0OTMwNTJjNGE5MTZmYmM1MC90YWJsZXJhbmdlOjU3NGM0NzMwODEwNjQ1NTQ5MzA1MmM0YTkxNmZiYzUwXzMtMS0xLTEtMA_11325f68-1477-440d-a377-690e45f9a1db"
      unitRef="usd">743000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i2208e67d526547b5819db3624bbe011a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZTo1NzRjNDczMDgxMDY0NTU0OTMwNTJjNGE5MTZmYmM1MC90YWJsZXJhbmdlOjU3NGM0NzMwODEwNjQ1NTQ5MzA1MmM0YTkxNmZiYzUwXzMtMy0xLTEtMA_31195fef-c4ae-4908-be3b-34385df72785"
      unitRef="usd">293000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2208e67d526547b5819db3624bbe011a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZTo1NzRjNDczMDgxMDY0NTU0OTMwNTJjNGE5MTZmYmM1MC90YWJsZXJhbmdlOjU3NGM0NzMwODEwNjQ1NTQ5MzA1MmM0YTkxNmZiYzUwXzMtNS0xLTEtMA_61ba8cc6-3cda-40aa-bd66-cc2a8173e200"
      unitRef="usd">450000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZTo1NzRjNDczMDgxMDY0NTU0OTMwNTJjNGE5MTZmYmM1MC90YWJsZXJhbmdlOjU3NGM0NzMwODEwNjQ1NTQ5MzA1MmM0YTkxNmZiYzUwXzQtMS0xLTEtMA_4155eea7-2ccc-4d7b-8312-1a25d23260ca"
      unitRef="usd">2748000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZTo1NzRjNDczMDgxMDY0NTU0OTMwNTJjNGE5MTZmYmM1MC90YWJsZXJhbmdlOjU3NGM0NzMwODEwNjQ1NTQ5MzA1MmM0YTkxNmZiYzUwXzQtMy0xLTEtMA_3bdc7330-0878-4269-a8c5-4e3b293c12c2"
      unitRef="usd">688000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90YWJsZTo1NzRjNDczMDgxMDY0NTU0OTMwNTJjNGE5MTZmYmM1MC90YWJsZXJhbmdlOjU3NGM0NzMwODEwNjQ1NTQ5MzA1MmM0YTkxNmZiYzUwXzQtNS0xLTEtMA_cf46e4af-7623-462e-95e2-aca9daa8e88c"
      unitRef="usd">2060000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90ZXh0cmVnaW9uOjE1NGQ0YmFjYzI4ZTQzZTk5ZmJjMWJiOWIwZmQxYzlmXzk1_61df6079-c545-478a-bf7d-5d2edfe0d20a"
      unitRef="usd">600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMTgvZnJhZzoxNTRkNGJhY2MyOGU0M2U5OWZiYzFiYjliMGZkMWM5Zi90ZXh0cmVnaW9uOjE1NGQ0YmFjYzI4ZTQzZTk5ZmJjMWJiOWIwZmQxYzlmXzk5_8c2388a1-1fd2-491e-a405-398815f25f2e"
      unitRef="usd">200000</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjEvZnJhZzo5ZGMzNTA1OTVkNjc0MmY5YWU5ZWE5OTBmNDg4ZGU0OS90ZXh0cmVnaW9uOjlkYzM1MDU5NWQ2NzQyZjlhZTllYTk5MGY0ODhkZTQ5XzMx_2a134d28-935e-44a5-bb14-34e3452eac37">Intangible asset, net&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes intangible asset (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Merger as discussed in Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, an assembled workforce was acquired. In an asset acquisition, an assembled workforce meets the asset recognition criteria and is separately recognized as an intangible asset and amortized over its expected life. The amortization period has been established as 3 years based on management's judgement. The Company will recognize $0.2 million and $0.1 million of amortization expense in fiscal years 2021 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjEvZnJhZzo5ZGMzNTA1OTVkNjc0MmY5YWU5ZWE5OTBmNDg4ZGU0OS90ZXh0cmVnaW9uOjlkYzM1MDU5NWQ2NzQyZjlhZTllYTk5MGY0ODhkZTQ5XzMy_4f3cca30-f3c2-44a9-badd-8dfc69f79e86">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes intangible asset (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjEvZnJhZzo5ZGMzNTA1OTVkNjc0MmY5YWU5ZWE5OTBmNDg4ZGU0OS90YWJsZTozZWRiMzIyMzQ2ODM0ZmUwOGJkODIxMWUwYjVhZjAzMS90YWJsZXJhbmdlOjNlZGIzMjIzNDY4MzRmZTA4YmQ4MjExZTBiNWFmMDMxXzEtMS0xLTEtMA_5f2c9898-90bf-427d-b8b6-a869a1705ce8"
      unitRef="usd">659000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjEvZnJhZzo5ZGMzNTA1OTVkNjc0MmY5YWU5ZWE5OTBmNDg4ZGU0OS90YWJsZTozZWRiMzIyMzQ2ODM0ZmUwOGJkODIxMWUwYjVhZjAzMS90YWJsZXJhbmdlOjNlZGIzMjIzNDY4MzRmZTA4YmQ4MjExZTBiNWFmMDMxXzEtMy0xLTEtMA_0b13dcb5-f91f-4833-bdaf-14301abfa085"
      unitRef="usd">659000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjEvZnJhZzo5ZGMzNTA1OTVkNjc0MmY5YWU5ZWE5OTBmNDg4ZGU0OS90YWJsZTozZWRiMzIyMzQ2ODM0ZmUwOGJkODIxMWUwYjVhZjAzMS90YWJsZXJhbmdlOjNlZGIzMjIzNDY4MzRmZTA4YmQ4MjExZTBiNWFmMDMxXzItMS0xLTEtMA_50a492d2-6d0c-4d87-8241-e63d3b561904"
      unitRef="usd">312000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjEvZnJhZzo5ZGMzNTA1OTVkNjc0MmY5YWU5ZWE5OTBmNDg4ZGU0OS90YWJsZTozZWRiMzIyMzQ2ODM0ZmUwOGJkODIxMWUwYjVhZjAzMS90YWJsZXJhbmdlOjNlZGIzMjIzNDY4MzRmZTA4YmQ4MjExZTBiNWFmMDMxXzItMy0xLTEtMA_acf7025f-6ebc-441c-a6e9-2a9afc32ccf0"
      unitRef="usd">92000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjEvZnJhZzo5ZGMzNTA1OTVkNjc0MmY5YWU5ZWE5OTBmNDg4ZGU0OS90YWJsZTozZWRiMzIyMzQ2ODM0ZmUwOGJkODIxMWUwYjVhZjAzMS90YWJsZXJhbmdlOjNlZGIzMjIzNDY4MzRmZTA4YmQ4MjExZTBiNWFmMDMxXzMtMS0xLTEtMA_61f898ec-22c4-4cc2-a405-5d5aa06c9f60"
      unitRef="usd">347000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjEvZnJhZzo5ZGMzNTA1OTVkNjc0MmY5YWU5ZWE5OTBmNDg4ZGU0OS90YWJsZTozZWRiMzIyMzQ2ODM0ZmUwOGJkODIxMWUwYjVhZjAzMS90YWJsZXJhbmdlOjNlZGIzMjIzNDY4MzRmZTA4YmQ4MjExZTBiNWFmMDMxXzMtMy0xLTEtMA_42a2f48f-6459-4cf5-ac13-4700413a6529"
      unitRef="usd">567000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjEvZnJhZzo5ZGMzNTA1OTVkNjc0MmY5YWU5ZWE5OTBmNDg4ZGU0OS90ZXh0cmVnaW9uOjlkYzM1MDU5NWQ2NzQyZjlhZTllYTk5MGY0ODhkZTQ5XzE2NDkyNjc0NDIwNTY_6b624b79-7e31-4262-a8ee-24e5bec50b1a">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjEvZnJhZzo5ZGMzNTA1OTVkNjc0MmY5YWU5ZWE5OTBmNDg4ZGU0OS90ZXh0cmVnaW9uOjlkYzM1MDU5NWQ2NzQyZjlhZTllYTk5MGY0ODhkZTQ5XzIxOTkwMjMyNTY3ODA_9b00d72a-5925-491d-8692-849a218190cc"
      unitRef="usd">200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjEvZnJhZzo5ZGMzNTA1OTVkNjc0MmY5YWU5ZWE5OTBmNDg4ZGU0OS90ZXh0cmVnaW9uOjlkYzM1MDU5NWQ2NzQyZjlhZTllYTk5MGY0ODhkZTQ5XzIxOTkwMjMyNTY3ODg_2ab8ce98-8e71-4074-9c81-8edfa53d43c8"
      unitRef="usd">100000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjQvZnJhZzo0NzQ2MmIzMjNlZTA0Mjk0OGUyZTVkYmNmMGYwMmZiMi90ZXh0cmVnaW9uOjQ3NDYyYjMyM2VlMDQyOTQ4ZTJlNWRiY2YwZjAyZmIyXzQ4_3a009772-be25-41b9-9184-4bf562a1c707">Accounts payable and other liabilities&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical and preclinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and vacation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjQvZnJhZzo0NzQ2MmIzMjNlZTA0Mjk0OGUyZTVkYmNmMGYwMmZiMi90ZXh0cmVnaW9uOjQ3NDYyYjMyM2VlMDQyOTQ4ZTJlNWRiY2YwZjAyZmIyXzQ5_c19cdc18-ad57-431d-b907-2a592e9e9976">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical and preclinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and vacation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjQvZnJhZzo0NzQ2MmIzMjNlZTA0Mjk0OGUyZTVkYmNmMGYwMmZiMi90YWJsZTplZjg5MzY2NmE4MTA0MmM0ODVlMmEwNGQ4NWY2NDFmZC90YWJsZXJhbmdlOmVmODkzNjY2YTgxMDQyYzQ4NWUyYTA0ZDg1ZjY0MWZkXzEtMS0xLTEtMA_3d9c9347-07ab-40da-842b-8b7dc050ed58"
      unitRef="usd">1323000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjQvZnJhZzo0NzQ2MmIzMjNlZTA0Mjk0OGUyZTVkYmNmMGYwMmZiMi90YWJsZTplZjg5MzY2NmE4MTA0MmM0ODVlMmEwNGQ4NWY2NDFmZC90YWJsZXJhbmdlOmVmODkzNjY2YTgxMDQyYzQ4NWUyYTA0ZDg1ZjY0MWZkXzEtMy0xLTEtMA_babb1c24-a522-4ac9-95ad-d7afd102d14b"
      unitRef="usd">1604000</us-gaap:AccountsPayableTradeCurrent>
    <nltx:AccruedClinicalExpensesCurrent
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjQvZnJhZzo0NzQ2MmIzMjNlZTA0Mjk0OGUyZTVkYmNmMGYwMmZiMi90YWJsZTplZjg5MzY2NmE4MTA0MmM0ODVlMmEwNGQ4NWY2NDFmZC90YWJsZXJhbmdlOmVmODkzNjY2YTgxMDQyYzQ4NWUyYTA0ZDg1ZjY0MWZkXzItMS0xLTEtMA_fafd72fd-1bb7-47ea-aa3e-a4bcb106612e"
      unitRef="usd">1687000</nltx:AccruedClinicalExpensesCurrent>
    <nltx:AccruedClinicalExpensesCurrent
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjQvZnJhZzo0NzQ2MmIzMjNlZTA0Mjk0OGUyZTVkYmNmMGYwMmZiMi90YWJsZTplZjg5MzY2NmE4MTA0MmM0ODVlMmEwNGQ4NWY2NDFmZC90YWJsZXJhbmdlOmVmODkzNjY2YTgxMDQyYzQ4NWUyYTA0ZDg1ZjY0MWZkXzItMy0xLTEtMA_dabf47c3-8f36-40d9-9c79-4028d08065a9"
      unitRef="usd">944000</nltx:AccruedClinicalExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjQvZnJhZzo0NzQ2MmIzMjNlZTA0Mjk0OGUyZTVkYmNmMGYwMmZiMi90YWJsZTplZjg5MzY2NmE4MTA0MmM0ODVlMmEwNGQ4NWY2NDFmZC90YWJsZXJhbmdlOmVmODkzNjY2YTgxMDQyYzQ4NWUyYTA0ZDg1ZjY0MWZkXzMtMS0xLTEtMA_3a04c649-9496-492c-8b17-c5acd221ba7f"
      unitRef="usd">3244000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjQvZnJhZzo0NzQ2MmIzMjNlZTA0Mjk0OGUyZTVkYmNmMGYwMmZiMi90YWJsZTplZjg5MzY2NmE4MTA0MmM0ODVlMmEwNGQ4NWY2NDFmZC90YWJsZXJhbmdlOmVmODkzNjY2YTgxMDQyYzQ4NWUyYTA0ZDg1ZjY0MWZkXzMtMy0xLTEtMA_9d6b775c-dde4-4d64-90d2-f01256406c75"
      unitRef="usd">1238000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjQvZnJhZzo0NzQ2MmIzMjNlZTA0Mjk0OGUyZTVkYmNmMGYwMmZiMi90YWJsZTplZjg5MzY2NmE4MTA0MmM0ODVlMmEwNGQ4NWY2NDFmZC90YWJsZXJhbmdlOmVmODkzNjY2YTgxMDQyYzQ4NWUyYTA0ZDg1ZjY0MWZkXzQtMS0xLTEtMA_bb9b17ad-6dd7-4d5a-b1c9-1b9cb19e65b0"
      unitRef="usd">927000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjQvZnJhZzo0NzQ2MmIzMjNlZTA0Mjk0OGUyZTVkYmNmMGYwMmZiMi90YWJsZTplZjg5MzY2NmE4MTA0MmM0ODVlMmEwNGQ4NWY2NDFmZC90YWJsZXJhbmdlOmVmODkzNjY2YTgxMDQyYzQ4NWUyYTA0ZDg1ZjY0MWZkXzQtMy0xLTEtMA_ab14a8a8-b52e-4aa3-ad38-5109af448273"
      unitRef="usd">339000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjQvZnJhZzo0NzQ2MmIzMjNlZTA0Mjk0OGUyZTVkYmNmMGYwMmZiMi90YWJsZTplZjg5MzY2NmE4MTA0MmM0ODVlMmEwNGQ4NWY2NDFmZC90YWJsZXJhbmdlOmVmODkzNjY2YTgxMDQyYzQ4NWUyYTA0ZDg1ZjY0MWZkXzUtMS0xLTEtMA_3e163eb9-d03e-424a-a44b-4a4c8ae9ba00"
      unitRef="usd">7181000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjQvZnJhZzo0NzQ2MmIzMjNlZTA0Mjk0OGUyZTVkYmNmMGYwMmZiMi90YWJsZTplZjg5MzY2NmE4MTA0MmM0ODVlMmEwNGQ4NWY2NDFmZC90YWJsZXJhbmdlOmVmODkzNjY2YTgxMDQyYzQ4NWUyYTA0ZDg1ZjY0MWZkXzUtMy0xLTEtMA_b357eb69-73dc-44b2-9785-4b2155bc03b9"
      unitRef="usd">4125000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzM1NDI_716cdb4e-6b42-4612-98e6-d79e891cb7d4">Leases&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into lease arrangements for its facilities as well as certain equipment, classified either as operating or finance leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a lease agreement for approximately 33,300 square feet of office space in Seattle, Washington for the Company&#x2019;s principal executive offices, a laboratory for research and development and related uses (the "Blaine lease"). In January 2020, the Company issued an irrevocable letter of credit in the amount of $0.5 million for the security deposit in accordance with the terms of the lease. The lease commenced on January 15, 2020 and rent obligations were scheduled to commence on December 1, 2020. The Company will also be responsible for the payment of additional rent to cover the Company&#x2019;s share of the annual operating and tax expenses and utilities costs for the building. The lease was originally scheduled to expire on December 1, 2028, with the option to extend the lease for two five-year terms.  The lease provides for a tenant improvement allowance of $8.0 million, which is included in the base rent, and an optional additional tenant improvement allowance with a maximum amount of $1.5 million, which will result, if elected, in additional rent expense recognized over the term of the lease. In September 2020, the Company elected to utilize this additional tenant improvement allowance. This resulted in a remeasurement of the lease liability due to an increase in lease payments over the term of the lease. The Company recorded an increase to the lease liability and related right-of-use asset of $1.0 million.  In November 2020, the Company executed an amendment to this lease that extends the scheduled rent commencement date to February 1, 2021 and the base term expiration to February 1, 2029. This amendment was accounted for as a modification to the lease and resulted in an immaterial reduction of the lease liability and related right-of-use asset.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31,2020, there was a tenant improvement allowance receivable of $0.9 million recorded in other current assets on the consolidated balance sheets related to reimbursable build-out costs incurred by the Company.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a lease agreement&#160;for approximately 6,272 square feet of office space in Seattle, Washington, for the Company&#x2019;s former principal executive offices, a laboratory for research and development and related uses. In June 2020, the Company executed an amendment to this lease pursuant to which the Company has the option to terminate the lease, without penalty, at any point subsequent to November 1, 2020 with 45 days advance written notice. At December 31, 2020, the Company determined that it is reasonably certain to not exercise this termination option. On March 24, 2021, the Company executed a second amendment to this lease, pursuant to which the term of the lease is extended through September 30, 2026. This will result in an increase in fixed rental payments over the updated term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 30, 2020, the Company terminated its lease agreement for 10,946 square feet of office space in Vancouver, Canada. The lease termination resulted in an extinguishment of the lease liability and the write-off of the related right-of-use asset. After incurring additional expenses included in the termination fee of $0.5 million, the Company recognized a loss of $0.3 million on the termination of the lease, which was recorded in general and administrative expenses in June 2020. In addition, the Company wrote-off leasehold improvements and other property and equipment associated with the lease and incurred a loss on disposal of $0.2 million in June 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, and December&#160;31, 2019, the Company&#x2019;s operating lease right-of-use assets were $10.2 million and $0.8 million, respectively. As of December&#160;31, 2020, and December&#160;31, 2019, the Company's&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;finance lease right-of use-assets, included within property and equipment on the consolidated balance sheet, were $0.3 million and $0.3&#160;million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the lease expense were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease term&#x2014;finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.33 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease term&#x2014;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.97 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.83 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average discount rate&#x2014;finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.11%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.11%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average discount rate&#x2014;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.37%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculation of the present value of the operating lease payments for the Blaine lease did not include the option to extend the lease for two five year terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, the future payments under the Company&#x2019;s operating and finance lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance Lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,572)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(659)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current lease liabilities&#x2014;December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzM1NDI_b4de3fe8-3f60-4ebd-9fb8-a05255fdea59">Leases&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into lease arrangements for its facilities as well as certain equipment, classified either as operating or finance leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a lease agreement for approximately 33,300 square feet of office space in Seattle, Washington for the Company&#x2019;s principal executive offices, a laboratory for research and development and related uses (the "Blaine lease"). In January 2020, the Company issued an irrevocable letter of credit in the amount of $0.5 million for the security deposit in accordance with the terms of the lease. The lease commenced on January 15, 2020 and rent obligations were scheduled to commence on December 1, 2020. The Company will also be responsible for the payment of additional rent to cover the Company&#x2019;s share of the annual operating and tax expenses and utilities costs for the building. The lease was originally scheduled to expire on December 1, 2028, with the option to extend the lease for two five-year terms.  The lease provides for a tenant improvement allowance of $8.0 million, which is included in the base rent, and an optional additional tenant improvement allowance with a maximum amount of $1.5 million, which will result, if elected, in additional rent expense recognized over the term of the lease. In September 2020, the Company elected to utilize this additional tenant improvement allowance. This resulted in a remeasurement of the lease liability due to an increase in lease payments over the term of the lease. The Company recorded an increase to the lease liability and related right-of-use asset of $1.0 million.  In November 2020, the Company executed an amendment to this lease that extends the scheduled rent commencement date to February 1, 2021 and the base term expiration to February 1, 2029. This amendment was accounted for as a modification to the lease and resulted in an immaterial reduction of the lease liability and related right-of-use asset.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31,2020, there was a tenant improvement allowance receivable of $0.9 million recorded in other current assets on the consolidated balance sheets related to reimbursable build-out costs incurred by the Company.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a lease agreement&#160;for approximately 6,272 square feet of office space in Seattle, Washington, for the Company&#x2019;s former principal executive offices, a laboratory for research and development and related uses. In June 2020, the Company executed an amendment to this lease pursuant to which the Company has the option to terminate the lease, without penalty, at any point subsequent to November 1, 2020 with 45 days advance written notice. At December 31, 2020, the Company determined that it is reasonably certain to not exercise this termination option. On March 24, 2021, the Company executed a second amendment to this lease, pursuant to which the term of the lease is extended through September 30, 2026. This will result in an increase in fixed rental payments over the updated term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 30, 2020, the Company terminated its lease agreement for 10,946 square feet of office space in Vancouver, Canada. The lease termination resulted in an extinguishment of the lease liability and the write-off of the related right-of-use asset. After incurring additional expenses included in the termination fee of $0.5 million, the Company recognized a loss of $0.3 million on the termination of the lease, which was recorded in general and administrative expenses in June 2020. In addition, the Company wrote-off leasehold improvements and other property and equipment associated with the lease and incurred a loss on disposal of $0.2 million in June 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, and December&#160;31, 2019, the Company&#x2019;s operating lease right-of-use assets were $10.2 million and $0.8 million, respectively. As of December&#160;31, 2020, and December&#160;31, 2019, the Company's&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;finance lease right-of use-assets, included within property and equipment on the consolidated balance sheet, were $0.3 million and $0.3&#160;million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the lease expense were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease term&#x2014;finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.33 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease term&#x2014;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.97 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.83 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average discount rate&#x2014;finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.11%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.11%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average discount rate&#x2014;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.37%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculation of the present value of the operating lease payments for the Blaine lease did not include the option to extend the lease for two five year terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, the future payments under the Company&#x2019;s operating and finance lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance Lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,572)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(659)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current lease liabilities&#x2014;December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i4705a5c4b4bc44d6bb8ba59262f94449_I20201231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzE2NDkyNjc0NjgxNzE_ba89107b-37aa-4d23-8250-cbebd814e9b2"
      unitRef="sqft">33300</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:SecurityDeposit
      contextRef="id6e7ca6980e0434682af1d48cf353254_I20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzMyOTg1MzQ5MDg2Mzg_52303418-5606-4d7c-8458-9c5098e6438d"
      unitRef="usd">500000</us-gaap:SecurityDeposit>
    <nltx:NumberOfOptionToExtendLease
      contextRef="idf105168c8db4aaca79efa56d6480d67_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzE2NDkyNjc0NjgxNzg_e7e761ee-a6e2-4434-8d34-910b53dafcc2"
      unitRef="option">2</nltx:NumberOfOptionToExtendLease>
    <nltx:LeaseAgreementExtendedPeriod
      contextRef="idf105168c8db4aaca79efa56d6480d67_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzE2NDkyNjc0NjkwMzU_cf7ce2bf-5ae6-4e94-9f64-ca66632cd28f">P5Y</nltx:LeaseAgreementExtendedPeriod>
    <nltx:TenantImprovementAllowance
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzMyOTg1MzQ5MDg2NDU_fd842326-4504-45c0-884f-bdfe0564aa27"
      unitRef="usd">8000000.0</nltx:TenantImprovementAllowance>
    <nltx:AdditionalTenantImprovements
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzIxOTkwMjMyODExMjA_8da8b72a-f532-4886-a154-9f2a338725f0"
      unitRef="usd">1500000</nltx:AdditionalTenantImprovements>
    <nltx:OperatingLeaseRightOfUseAssetIncreaseDueToRemeasurement
      contextRef="i5ed3c72fdd5244ab8974717f9b77a301_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzMyOTg1MzQ5MDg2NjE_d5223fc6-c357-4c59-8fa1-10207b3c9565"
      unitRef="usd">1000000.0</nltx:OperatingLeaseRightOfUseAssetIncreaseDueToRemeasurement>
    <nltx:OperatingLeaseLiabilityIncreaseDueToRemeasurement
      contextRef="i5ed3c72fdd5244ab8974717f9b77a301_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzMyOTg1MzQ5MDg2NjE_fed2c2b9-98dd-4c85-9bd1-18cf542bb3be"
      unitRef="usd">1000000.0</nltx:OperatingLeaseLiabilityIncreaseDueToRemeasurement>
    <nltx:TenantImprovementAllowanceReceivable
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzIxOTkwMjMyODExMjU_79f98d52-d152-4fac-9c44-d49b1f270e2c"
      unitRef="usd">900000</nltx:TenantImprovementAllowanceReceivable>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="icc93ba96caae41caaf0f462dced9d9f5_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzExMg_4c570e1c-004b-4725-8abd-4ff2dfb08aa9"
      unitRef="sqft">6272</us-gaap:AreaOfRealEstateProperty>
    <nltx:NumberOfDaysAdvanceNoticeMustBeGivenToTerminateTheLease
      contextRef="i551bbb0f39284233bd2bc07a764f6743_D20200601-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzE2NDkyNjc0NjkwMzk_67dc90c4-8b38-42f8-8187-efc4c51776ce">P45D</nltx:NumberOfDaysAdvanceNoticeMustBeGivenToTerminateTheLease>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i33f7bbfc02b54beb8163ea39433e3cad_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzYzNw_4a8805e3-a15f-4ec6-8761-85cadcb56dab"
      unitRef="sqft">10946</us-gaap:AreaOfRealEstateProperty>
    <nltx:TerminationFeesForLeaseTermination
      contextRef="i23ddd03e1fc94695ab704c560ff13b1a_D20200630-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzMyOTg1MzQ5MDg2ODk_f6c0e0f8-c447-4e10-b6ba-74eb62a9abd6"
      unitRef="usd">500000</nltx:TerminationFeesForLeaseTermination>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="i23ddd03e1fc94695ab704c560ff13b1a_D20200630-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzMyOTg1MzQ5MDg2NzU_cfc62a6d-51ce-4d0a-9e74-dd8864d97376"
      unitRef="usd">-300000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i23ddd03e1fc94695ab704c560ff13b1a_D20200630-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzMyOTg1MzQ5MDg2ODI_133cbde2-83c0-4257-986d-ad6b2dc01928"
      unitRef="usd">-200000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzE0OTU_47fd67c5-91e1-42a9-9ed5-a6891f7b57a2"
      unitRef="usd">10200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzMyOTg1MzQ5MDg3MTY_22c89cf1-bee8-4926-985d-d6dc6f9a1ba3"
      unitRef="usd">800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzE1NDM_65945406-5de0-4323-9779-cd8f042a137c"
      unitRef="usd">300000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzE2NDkyNjc0NjgxOTk_dbe04eb0-368c-4114-a9d9-fb9a02acc8f4"
      unitRef="usd">300000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzM1NDM_19d41a45-ffa1-4946-b14b-fe6ab8b44553">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the lease expense were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total net lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjYjdkOGQ5OWQ3OTg0YjRhOWJkZTY4YmQzY2NiMDg1My90YWJsZXJhbmdlOmNiN2Q4ZDk5ZDc5ODRiNGE5YmRlNjhiZDNjY2IwODUzXzItMS0xLTEtMA_b620c4db-c41f-48ac-b2d8-95d7016ce434"
      unitRef="usd">46000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjYjdkOGQ5OWQ3OTg0YjRhOWJkZTY4YmQzY2NiMDg1My90YWJsZXJhbmdlOmNiN2Q4ZDk5ZDc5ODRiNGE5YmRlNjhiZDNjY2IwODUzXzItMy0xLTEtNTg0OQ_3bbc698f-ade9-4118-bfb9-82fb900bc406"
      unitRef="usd">19000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjYjdkOGQ5OWQ3OTg0YjRhOWJkZTY4YmQzY2NiMDg1My90YWJsZXJhbmdlOmNiN2Q4ZDk5ZDc5ODRiNGE5YmRlNjhiZDNjY2IwODUzXzMtMS0xLTEtMA_822431e8-757e-4a57-9077-120526d06232"
      unitRef="usd">14000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjYjdkOGQ5OWQ3OTg0YjRhOWJkZTY4YmQzY2NiMDg1My90YWJsZXJhbmdlOmNiN2Q4ZDk5ZDc5ODRiNGE5YmRlNjhiZDNjY2IwODUzXzMtMy0xLTEtNTg0OQ_9351ec0d-5029-4f5a-be41-0d455720a1a3"
      unitRef="usd">0</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:OperatingLeaseCost
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjYjdkOGQ5OWQ3OTg0YjRhOWJkZTY4YmQzY2NiMDg1My90YWJsZXJhbmdlOmNiN2Q4ZDk5ZDc5ODRiNGE5YmRlNjhiZDNjY2IwODUzXzQtMS0xLTEtMA_f8812169-2fe5-4f59-8fe3-dc6cc0311937"
      unitRef="usd">2368000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjYjdkOGQ5OWQ3OTg0YjRhOWJkZTY4YmQzY2NiMDg1My90YWJsZXJhbmdlOmNiN2Q4ZDk5ZDc5ODRiNGE5YmRlNjhiZDNjY2IwODUzXzQtMy0xLTEtNTg0OQ_2776dd32-3c9c-4fd3-98f6-2ed11e1b296c"
      unitRef="usd">197000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjYjdkOGQ5OWQ3OTg0YjRhOWJkZTY4YmQzY2NiMDg1My90YWJsZXJhbmdlOmNiN2Q4ZDk5ZDc5ODRiNGE5YmRlNjhiZDNjY2IwODUzXzUtMS0xLTEtMA_73e1a276-8a3c-4589-b50d-7590a33fe4fb"
      unitRef="usd">348000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjYjdkOGQ5OWQ3OTg0YjRhOWJkZTY4YmQzY2NiMDg1My90YWJsZXJhbmdlOmNiN2Q4ZDk5ZDc5ODRiNGE5YmRlNjhiZDNjY2IwODUzXzUtMy0xLTEtNTg0OQ_28c2af51-67d5-4d81-b15e-f2522f27ef55"
      unitRef="usd">105000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjYjdkOGQ5OWQ3OTg0YjRhOWJkZTY4YmQzY2NiMDg1My90YWJsZXJhbmdlOmNiN2Q4ZDk5ZDc5ODRiNGE5YmRlNjhiZDNjY2IwODUzXzYtMS0xLTEtMA_114dec38-ccdb-4dc1-a7fd-87a91a0f02ea"
      unitRef="usd">321000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjYjdkOGQ5OWQ3OTg0YjRhOWJkZTY4YmQzY2NiMDg1My90YWJsZXJhbmdlOmNiN2Q4ZDk5ZDc5ODRiNGE5YmRlNjhiZDNjY2IwODUzXzYtMy0xLTEtNTg0OQ_0553a004-2991-4d0d-85db-12ee2a29c827"
      unitRef="usd">181000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjYjdkOGQ5OWQ3OTg0YjRhOWJkZTY4YmQzY2NiMDg1My90YWJsZXJhbmdlOmNiN2Q4ZDk5ZDc5ODRiNGE5YmRlNjhiZDNjY2IwODUzXzctMS0xLTEtMA_e7b64449-1acf-470f-aa41-2dd2ad6d5cf5"
      unitRef="usd">3097000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjYjdkOGQ5OWQ3OTg0YjRhOWJkZTY4YmQzY2NiMDg1My90YWJsZXJhbmdlOmNiN2Q4ZDk5ZDc5ODRiNGE5YmRlNjhiZDNjY2IwODUzXzctMy0xLTEtNTg0OQ_733ebd4c-2600-4eb8-baa1-c8f62a745711"
      unitRef="usd">502000</us-gaap:LeaseCost>
    <nltx:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzM1NDQ_d641632c-45cd-49e5-9461-313193da2b92">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease term&#x2014;finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.33 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average remaining lease term&#x2014;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.97 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.83 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average discount rate&#x2014;finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.11%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.11%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average discount rate&#x2014;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.37%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nltx:ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpmN2JkZjc0YzE5YmE0ZWExYmE3M2NjZGY5YjAxZGI4YS90YWJsZXJhbmdlOmY3YmRmNzRjMTliYTRlYTFiYTczY2NkZjliMDFkYjhhXzEtMS0xLTEtMA_92906772-dfcf-4cde-b7ed-4ff7f28daec1">P2Y5M12D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpmN2JkZjc0YzE5YmE0ZWExYmE3M2NjZGY5YjAxZGI4YS90YWJsZXJhbmdlOmY3YmRmNzRjMTliYTRlYTFiYTczY2NkZjliMDFkYjhhXzEtMy0xLTEtNTg2Mg_e77c916c-e868-48fd-aeba-0aeb6a7fd2ed">P3Y3M29D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpmN2JkZjc0YzE5YmE0ZWExYmE3M2NjZGY5YjAxZGI4YS90YWJsZXJhbmdlOmY3YmRmNzRjMTliYTRlYTFiYTczY2NkZjliMDFkYjhhXzItMS0xLTEtMA_c69787e5-e43b-4edd-a0ce-9450dd4009e3">P7Y11M19D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpmN2JkZjc0YzE5YmE0ZWExYmE3M2NjZGY5YjAxZGI4YS90YWJsZXJhbmdlOmY3YmRmNzRjMTliYTRlYTFiYTczY2NkZjliMDFkYjhhXzItMy0xLTEtNTg2Mg_9d7da0c1-c990-4247-ab98-3c21a830fce2">P1Y9M29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpmN2JkZjc0YzE5YmE0ZWExYmE3M2NjZGY5YjAxZGI4YS90YWJsZXJhbmdlOmY3YmRmNzRjMTliYTRlYTFiYTczY2NkZjliMDFkYjhhXzMtMS0xLTEtMA_669236c0-c46f-48bd-8ee0-6ca2e00ee2fb"
      unitRef="number">0.0711</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpmN2JkZjc0YzE5YmE0ZWExYmE3M2NjZGY5YjAxZGI4YS90YWJsZXJhbmdlOmY3YmRmNzRjMTliYTRlYTFiYTczY2NkZjliMDFkYjhhXzMtMy0xLTEtNTg2Mg_27559146-c085-46f2-a2d4-6e748f540ef1"
      unitRef="number">0.0711</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpmN2JkZjc0YzE5YmE0ZWExYmE3M2NjZGY5YjAxZGI4YS90YWJsZXJhbmdlOmY3YmRmNzRjMTliYTRlYTFiYTczY2NkZjliMDFkYjhhXzQtMS0xLTEtMA_57cd2d8a-b2d8-4a18-ad2c-1f99877069be"
      unitRef="number">0.1288</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpmN2JkZjc0YzE5YmE0ZWExYmE3M2NjZGY5YjAxZGI4YS90YWJsZXJhbmdlOmY3YmRmNzRjMTliYTRlYTFiYTczY2NkZjliMDFkYjhhXzQtMy0xLTEtNTg2Mg_4f681041-ff19-446f-b90e-3cd0e65f4bf7"
      unitRef="number">0.0537</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzM1NDU_e88c800a-5c34-412b-92b2-865ebadd1d24">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjMjNhMWMyYWY4MjA0NTg3YjgxZTkxYjY3ZmJkZGM3OC90YWJsZXJhbmdlOmMyM2ExYzJhZjgyMDQ1ODdiODFlOTFiNjdmYmRkYzc4XzEtMS0xLTEtMA_031194d1-fadf-4999-b4e7-8031c0848630"
      unitRef="usd">460000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjMjNhMWMyYWY4MjA0NTg3YjgxZTkxYjY3ZmJkZGM3OC90YWJsZXJhbmdlOmMyM2ExYzJhZjgyMDQ1ODdiODFlOTFiNjdmYmRkYzc4XzEtMy0xLTEtNTg3Mg_7fa92ca2-aeae-4c5c-9b6e-42e294454cee"
      unitRef="usd">236000</us-gaap:OperatingLeasePayments>
    <nltx:FinanceLeasePrincipalAndInterestPayments
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjMjNhMWMyYWY4MjA0NTg3YjgxZTkxYjY3ZmJkZGM3OC90YWJsZXJhbmdlOmMyM2ExYzJhZjgyMDQ1ODdiODFlOTFiNjdmYmRkYzc4XzItMS0xLTEtMA_6dc8b98c-3d02-44c3-b843-c72f41bff0f8"
      unitRef="usd">60000</nltx:FinanceLeasePrincipalAndInterestPayments>
    <nltx:FinanceLeasePrincipalAndInterestPayments
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTpjMjNhMWMyYWY4MjA0NTg3YjgxZTkxYjY3ZmJkZGM3OC90YWJsZXJhbmdlOmMyM2ExYzJhZjgyMDQ1ODdiODFlOTFiNjdmYmRkYzc4XzItMy0xLTEtNTg3Mg_bbc1d5b0-cc03-4246-957a-099e1ef74e58"
      unitRef="usd">9000</nltx:FinanceLeasePrincipalAndInterestPayments>
    <nltx:NumberOfOptionToExtendLease
      contextRef="i2bfb640b4f9448db81cd2eda573a733f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzE2NDkyNjc0NjgyMTI_946fa64f-ed78-409e-ace3-d7c2d3efd809"
      unitRef="option">2</nltx:NumberOfOptionToExtendLease>
    <nltx:LeaseAgreementExtendedPeriod
      contextRef="i2bfb640b4f9448db81cd2eda573a733f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzE2NDkyNjc0NjkwMzg_03bd2101-ee55-45b1-96b9-0da5252d973e">P5Y</nltx:LeaseAgreementExtendedPeriod>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzM1NDA_cf2e3e32-5ea7-4f0a-b34e-68e2fb0c4a32">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, the future payments under the Company&#x2019;s operating and finance lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance Lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,572)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(659)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current lease liabilities&#x2014;December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90ZXh0cmVnaW9uOjNhMmZhMzFiNTE3ZTRkZmNiZjkyNzhjZDMyMDE4M2U0XzM1NDY_9f46fce0-4846-48af-8593-757f1ab72d4a">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, the future payments under the Company&#x2019;s operating and finance lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance Lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,572)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(659)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current lease liabilities&#x2014;December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzEtMS0xLTEtMA_ad90361d-deae-4b2f-8166-b9ee806c714f"
      unitRef="usd">60000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzEtMy0xLTEtMA_faf2b1b0-45c6-4654-a96c-b49e182c48c5"
      unitRef="usd">2161000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzItMS0xLTEtMA_656fe15e-afa7-4f2f-aabb-fb2203a8c50d"
      unitRef="usd">60000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzItMy0xLTEtMA_d74bd0b6-ea88-473a-b204-40492bc3c458"
      unitRef="usd">2289000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzMtMS0xLTEtMA_d2b02234-c540-424e-af42-a5cbcf9491d2"
      unitRef="usd">60000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzMtMy0xLTEtMA_02a5689a-3ac0-428f-be76-6b7016fa37f4"
      unitRef="usd">2341000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzQtMS0xLTEtMA_b3f70a0e-032e-4773-981c-787a4685d376"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzQtMy0xLTEtMA_648c4ae2-96a9-4483-aff8-0d0078947cac"
      unitRef="usd">2394000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzUtMS0xLTEtMzUzMw_d6b128a2-66db-4f9f-a8b1-a2843768554a"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzUtMy0xLTEtMzUzMw_8e28b605-9a06-4999-807f-758af2f43765"
      unitRef="usd">2448000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzYtMS0xLTEtMzUzMw_a12ba635-3e67-4007-b466-59e4046654ab"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzYtMy0xLTEtMzUzMw_b913d427-07c3-47ad-bd69-24de45400322"
      unitRef="usd">7904000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzUtMS0xLTEtMA_3a59d0d6-323d-4cb4-af39-82037c9a5062"
      unitRef="usd">180000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzUtMy0xLTEtMA_60e8114b-c1e4-4fb8-9898-1c196e0d32d4"
      unitRef="usd">19537000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzYtMS0xLTEtMA_d1031294-fa3e-4fe2-a4de-ccab2d1d4d72"
      unitRef="usd">23000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzYtMy0xLTEtMA_9679fb61-8f99-4707-8e69-ab020cb213c6"
      unitRef="usd">7572000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzctMS0xLTEtMA_6a1b1afe-ebd5-40fc-97a4-4905278c77b5"
      unitRef="usd">157000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzctMy0xLTEtMA_0aa7bff9-f615-40f0-a6b8-79cbf4de8602"
      unitRef="usd">11965000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzgtMS0xLTEtMA_f7c7b9d4-3425-4023-afe3-12ea13d0acef"
      unitRef="usd">49000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzgtMy0xLTEtMA_75aa2db2-529d-437e-a427-eed3f3981f63"
      unitRef="usd">659000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzktMS0xLTEtMA_4982a6ab-14b8-4cf1-abe3-db65a35a5d1e"
      unitRef="usd">108000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMjcvZnJhZzozYTJmYTMxYjUxN2U0ZGZjYmY5Mjc4Y2QzMjAxODNlNC90YWJsZTowNjQ5ODc2ZWZkM2U0NjkwYjA5MDc1Yjk3NGYyMzI5NS90YWJsZXJhbmdlOjA2NDk4NzZlZmQzZTQ2OTBiMDkwNzViOTc0ZjIzMjk1XzktMy0xLTEtMA_fe41bf05-4f0e-4cc9-b821-92a208e77e90"
      unitRef="usd">11306000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTQwNTg_7e2cd63f-e7eb-4717-bb62-032ccc33df8a">Stockholders&#x2019; equity&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(a) Common stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue 100,000,000 shares of common stock with a par value of $0.000001 per share as of December&#160;31, 2020. As of December&#160;31, 2020, and 2019, the total number of shares of common stock issued and outstanding was 42,196,296, and 37,996,849, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 7, 2020, the Company completed an underwritten public offering of 3,262,471 shares of its common stock at a price of $15.25 per share and pre-funded warrants to purchase 1,737,529 shares of its common stock at a price of $15.249999 per prefunded warrant.  The pre-funded warrants can be exercised at any time after issuance for an exercise price of $0.000001 per share. The aggregate net proceeds received by the Company from the offering were $71.3&#160;million, net of underwriting discounts, commissions, and offering costs of approximately $4.9&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 20, 2019, the Company completed an underwritten public offering of 10,263,750 shares of its common stock at a price to the public of $8.40 per share. The aggregate net proceeds received by the Company from the offering, net of underwriting discounts, commissions, and offering costs of approximately $5.5&#160;million, were $80.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(b) Preferred stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue 5,000,000 shares of preferred stock with a par value of $0.000001 per share. As of December&#160;31, 2020 and December&#160;31, 2019, 0 shares of preferred stock were issued or outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(c) Merger with Former Neoleukin&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;8, 2019, the Company issued 4,589,771 shares of common stock and 101,927 shares of non-voting convertible preferred stock as consideration in the Merger among Aquinox, Former Neoleukin and Apollo Merger Inc. (see Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). Each share of non-voting convertible preferred stock was convertible into 100 shares of common stock and was entitled to receive dividends, on an as-is converted to common stock basis, when dividends are paid to common stockholders. The holders of preferred stock were only entitled to vote when it impacts the rights of the preferred stockholder.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;12, 2019, the Company&#x2019;s stockholders approved the conversion of 101,927 shares of non-voting convertible preferred stock into 10,192,700 shares of the Company&#x2019;s common stock. As of December&#160;31, 2020, the Company did not have any outstanding non-voting convertible preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(d) December 2019 pre-funded common stock warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;17, 2019, Neoleukin entered into an exchange agreement (the &#x201c;Exchange Agreement&#x201d;) with certain stockholders, pursuant to which the Company exchanged an aggregate of 10,925,481 shares of common stock held by the stockholders&#160;for&#160;pre-funded&#160;warrants&#160;(the &#x201c;Exchange Warrants&#x201d;) to purchase an aggregate of 10,925,481 shares of common stock (subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting common stock), with an exercise price of $0.000001 per share. The Exchange Warrants may be exercised at any time after the date of issuance, except that the Exchange Warrants cannot be exercised by the stockholders if, after giving effect thereto, the stockholders would beneficially own more than 9.99% of the outstanding common stock, subject to certain exceptions. The holders of the Exchange Warrants will not have the right to vote on any matter except to the extent required by Delaware law.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the Exchange Warrants meet the conditions for equity classification, the proceeds previously received for the shares of common stock will remain in additional paid-in capital. Upon the exercise of the warrants the proceeds received along with the exercise price will be recorded in common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(e) Stock option plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2014, the Company&#x2019;s stockholders approved the 2014 Equity Incentive Plan (&#x201c;2014 Plan&#x201d;) which became effective in March 2014. The 2014 Plan is the successor to and continuation of the Joint Canadian Stock Option Plan (the &#x201c;2006 Plan&#x201d;). No further grants will be made under the 2006 Plan. The 2014 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards, and other forms of equity awards to employees, directors, and consultants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, the maximum number of shares of common stock that may be issued under the 2014 Plan was 9,786,363. The number of shares of common stock reserved for issuance under the 2014 Plan will be increased by the number of shares subject to stock options granted under the 2006 Plan that would have otherwise returned to the 2006 Plan, such as upon the expiration or termination of a stock award prior to vesting. As of December&#160;31, 2020, there were  23,958  shares subject to stock options granted under the 2006 Plan. Additionally, the number of shares of common stock reserved for issuance under the 2014 Plan will automatically increase on January&#160;1 of each year for a period of up to 10 years, beginning on January&#160;1, 2015 and ending on and including January&#160;1, 2024, by 4.00% of the total number of shares of capital stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;outstanding on December&#160;31 of the preceding calendar year, or a lesser number of shares determined by the board of directors. On November&#160;12, 2019, the Company&#x2019;s stockholders approved the increase in the number of shares reserved from issuance under the 2014 Plan by 4,500,000 shares. All awards granted pursuant to the 2014 Plan have a contractual term of ten years. All awards granted to date are equity classified and subject to service based vesting, typically over a period of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTM5ODM_38a5a479-ddde-4ba0-9188-8ce886f75bc3"&gt;one&lt;/span&gt; to four years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of shares available to be granted under the 2014 Plan was 6,037,532 and 6,556,534 as of December&#160;31, 2020 and 2019 respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company's stock option activity and related information for the year ended December&#160;31, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life&lt;br/&gt;(In Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value   &lt;br/&gt;(In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,840,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,404,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(882,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(515,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,846,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,878,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2020, 882,624 shares of common stock were issued upon exercise of options with an aggregate intrinsic value of $6.0 million. During the year ended December&#160;31, 2019, 326,094 shares of common stock were issued upon exercise of options with an aggregate intrinsic value of $1.3 million. The weighted-average grant date fair value of options granted during the years ended December&#160;31, 2020 and December&#160;31, 2019 was $8.70 and $2.17 per share, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted is estimated using the Black-Scholes option pricing model with the following weighted average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected terms (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company's restricted stock unit activity and related information for the year ended December&#160;31, 2020 is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.26&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.47&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.47&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(f) Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense is classified in the consolidated statements of operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.758%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total unrecognized compensation for all stock-based compensation was $24.9 million as of December&#160;31, 2020, which is expected to be recognized over a weighted-average period of 3.15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(g) Employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s 2020 Employee Stock Purchase Plan (&#x201c;2020 ESPP&#x201d;) was adopted by the Company&#x2019;s Board of Directors in March 2020 and approved by the Company&#x2019;s stockholders in May 2020. A total of 759,936 shares of common stock have been reserved for issuance under the 2020 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to share and dollar limits as described in the plan, the 2020 ESPP allows eligible employees to contribute, through payroll deductions, up to 15% of their earnings for the purchase of the Company&#x2019;s shares of common stock at the lower of 85% of the closing price of the Company&#x2019;s common stock on the first trading day of the offering period or 85% of the closing price of the Company&#x2019;s common stock on the last trading day of the offering period. There are two six-month offering periods during each fiscal year, ending on May 15 and November 15. &lt;/span&gt;&lt;/div&gt;During the year ended December&#160;31, 2020, the Company issued 18,352 shares of common stock at a price per share of $10.84 under the 2020 ESPP. Cash received from the purchases under the 2020 ESPP for the year ended December&#160;31, 2020 was $0.2 million.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzgyNDYzMzcyNjY1Mzc_44466627-6451-4b3b-9386-099fa25796c9"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzgyNDYzMzcyNjY1Mzc_de942fe3-b730-4692-a6bb-3fb9c9967470"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzgyNDYzMzcyNjY1ODQ_8a960b14-2d2e-4604-bf51-7656992adf92"
      unitRef="usdPerShare">0.000001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzgyNDYzMzcyNjY1ODQ_cc94f43b-3f60-4789-ab5a-6150474f4854"
      unitRef="usdPerShare">0.000001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzgyNDYzMzcyNjY2OTk_5ba54886-df5e-46ef-95ed-fa243be936f2"
      unitRef="shares">42196296</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzgyNDYzMzcyNjY2OTk_c815da13-5d1f-45b8-96b2-4b991d7a7cf8"
      unitRef="shares">42196296</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzgyNDYzMzcyNjY3MDg_8d85fa0f-776a-41ab-8309-a6dc92eacd79"
      unitRef="shares">37996849</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzgyNDYzMzcyNjY3MDg_efe039d2-001f-4228-8c1c-9219ce8b600f"
      unitRef="shares">37996849</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="iacf40562c9644cc9828d02f05554823f_D20200707-20200707"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MDI0MTY_51191d58-4f1a-4e24-b7b4-2801764dcfbf"
      unitRef="shares">3262471</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="ia289d260d3db4da2aacbed8339f37590_I20200707"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MDI0NjE_039a2e63-3732-41a1-88d3-e195db08a3ce"
      unitRef="usdPerShare">15.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i3397ebe8ae644e4aabdacd910f7b5d9e_I20200707"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MDI1MTE_c84a4844-7da1-4605-b361-e48d65b0c2e2"
      unitRef="shares">1737529</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <nltx:PreFundedWarrantIssuedPricePerShare
      contextRef="i3397ebe8ae644e4aabdacd910f7b5d9e_I20200707"
      decimals="6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MDI1NTY_26d951bf-6888-4f88-8914-1646d04b0ae2"
      unitRef="usdPerShare">15.249999</nltx:PreFundedWarrantIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i3397ebe8ae644e4aabdacd910f7b5d9e_I20200707"
      decimals="6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MDI2Nzg_caaf3478-e61e-492c-855d-c8c6899413b4"
      unitRef="usdPerShare">0.000001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ibcd7f5cd1b2a4a29a2a3ab167bb32bce_D20200707-20200707"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTM5MjA_e05dec0d-02b6-4668-b4e2-3cf35d5c88a7"
      unitRef="usd">71300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ibcd7f5cd1b2a4a29a2a3ab167bb32bce_D20200707-20200707"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MDI4NjQ_682ad3e4-9b9f-4d43-990a-61e067237dea"
      unitRef="usd">4900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i4106335c2a9e4f65a3bf48b670d2780f_D20191220-20191220"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTM5MzU_7b871b57-51b0-4c28-b48e-028799c6de7b"
      unitRef="shares">10263750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i244aa6bc78a741be9d0e8aafa2725d77_I20191220"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTM5NDc_e14f65a8-ca88-4ee2-8ac9-f47343c5dd89"
      unitRef="usdPerShare">8.40</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ib79c600c3cf14f96b3f11cb86e2c6fe1_D20191220-20191220"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTM5NTQ_3f7d13db-d24f-416d-a132-1e11cf0837dc"
      unitRef="usd">5500000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ib79c600c3cf14f96b3f11cb86e2c6fe1_D20191220-20191220"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTM5Njg_656196b7-9072-4a6d-93e9-07d117b53270"
      unitRef="usd">80700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MDc2ODk_245d5181-84f7-4d60-a622-e07a9c641e75"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MDc2ODk_c6fa0fd6-c3ee-4d15-9b60-70f95886be3f"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MDc2OTQ_22a74ae7-629c-44e3-8d2d-7b1437dd6dbf"
      unitRef="usdPerShare">0.000001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MDc2OTQ_e4047a3f-673d-45d2-a163-d2f816bc2860"
      unitRef="usdPerShare">0.000001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0NTUyNzg_1e63d879-865e-423b-bdbf-7b251eff12d0"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0NTUyNzg_23ae5e15-e6a1-4c7b-b7c4-d698abeda481"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0NTUyNzg_517e14f3-5c95-449f-b17f-5d9c58b94664"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0NTUyNzg_f3006b77-4cfd-463e-852f-97161cf8c368"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="i40320493bb114b7b9790c7199d64f1a0_D20190808-20190808"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzY0NQ_f77eb730-7ad0-43bc-8175-a412a5f20086"
      unitRef="shares">4589771</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="ib1005fcc8fe5417da0ed149702b76a6f_D20190808-20190808"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzY3NQ_be04afbc-3646-475b-a2c1-b27f891063ce"
      unitRef="shares">101927</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <nltx:StockConversionRatio
      contextRef="i562c09437d76488daa016091ce08fa2a_D20190808-20190808"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzkwMQ_7bb3de92-0434-457e-b703-770bf72b4247"
      unitRef="shares">100</nltx:StockConversionRatio>
    <nltx:ConvertiblePreferredStockToBeConverted
      contextRef="iff8af19eb46e4d98bfc328b1fb63531e_D20191112-20191112"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzEyNTA_07eae89b-a7f3-49c3-8f05-21ccf3796611"
      unitRef="shares">101927</nltx:ConvertiblePreferredStockToBeConverted>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="id6d4eed2171d4fda82da0d88564149d9_I20191112"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzEzMDc_4293a08e-fb7d-4a5b-9119-de91149c9933"
      unitRef="shares">10192700</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ie4a634a968e049b7b556b6104f5c0ae5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0NTUzODc_91e091aa-0b0b-41df-ac96-bde471aef18d"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <nltx:StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants
      contextRef="i1913c226c2e2462ba6fe703cb86f64c8_D20191217-20191217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NTM_daa1af63-f7ad-42b5-985f-465b85d26731"
      unitRef="shares">10925481</nltx:StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i5612b1ceb0074b538a341f49adc28d80_I20191217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE3ODI_38fd2daf-37e7-4578-9027-6a4b1d065b63"
      unitRef="shares">10925481</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i5612b1ceb0074b538a341f49adc28d80_I20191217"
      decimals="6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE5NTU_193370b2-254d-4ac5-ad2f-00afdc5c2660"
      unitRef="usdPerShare">0.000001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <nltx:PercentageOfOutstandingStockPerStockholderMaximum
      contextRef="i1913c226c2e2462ba6fe703cb86f64c8_D20191217-20191217"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzIyMDU_0aad6df8-c17d-445b-8b5b-1a97006e622a"
      unitRef="number">0.0999</nltx:PercentageOfOutstandingStockPerStockholderMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ifb2fe74f8fec43409b383c349c9d583a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MTM4ODg_c7d440dc-db1b-4d64-942d-9a31c7694914"
      unitRef="shares">9786363</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5126c731497844cf82463ebd9ba0ec2c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzIxOTkwMjMyODkzNDU_8f6c0817-734f-47d7-a6b7-a787310f076a"
      unitRef="shares">23958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <nltx:PeriodSharesReservedForIssuanceWillIncrease
      contextRef="iceb04586e32a40cc920160798f9ddce9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MTM4MzI_bc5bfa60-5d47-4afd-b95d-6c6ea3b05e93">P10Y</nltx:PeriodSharesReservedForIssuanceWillIncrease>
    <nltx:StockBasedCompensationIncreaseInCommonStockIssuancePercentage
      contextRef="iceb04586e32a40cc920160798f9ddce9_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MTM4Mjg_e38d7607-6499-4c03-9df3-d153d5e8ad25"
      unitRef="number">0.0400</nltx:StockBasedCompensationIncreaseInCommonStockIssuancePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i40473cfe46a34de087cfebd3e2af1629_D20191112-20191112"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MTExNTY_b2539715-6355-4c65-b2a2-55bc2580decb"
      unitRef="shares">4500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="iceb04586e32a40cc920160798f9ddce9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTQwMTA_677ada03-71d0-4082-9bfd-2b9fc8f9202b">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iae8ed78b63224fe9a7fae1f526fde05d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTM5ODQ_a426f920-3fde-422d-8114-9a4fea25be42">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ifb2fe74f8fec43409b383c349c9d583a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzIxOTkwMjMyODkzNDE_8371e81f-73c5-40a0-aac6-e9d94c8232a4"
      unitRef="shares">6037532</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i56d428d107ab495dbcb789afcb67f7ac_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MTM4NDU_1c050846-45e1-4049-bea7-7594ea25ac05"
      unitRef="shares">6556534</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTQwMjU_8afb1f71-c9a2-4f02-83e5-e0b8386e6d35">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company's stock option activity and related information for the year ended December&#160;31, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Life&lt;br/&gt;(In Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value   &lt;br/&gt;(In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,840,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,404,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(882,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(515,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,846,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,878,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzEtMS0xLTEtMzkyNw_96596da2-addd-4c03-985a-e2d8d47d0b4d"
      unitRef="shares">5840538</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzEtMy0xLTEtMzkyNw_f1805625-95f4-4d8e-9dd9-2b026aae17a2"
      unitRef="usdPerShare">5.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzEtNS0xLTEtMzkyNw_f8ccf464-172c-42b1-ba44-c2245de4f52b">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzEtNy0xLTEtMzkyNw_6b941d05-4e69-4938-a969-c79eb8b47d45"
      unitRef="usd">45037000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzItMS0xLTEtMzkyNw_e0ec3fae-f17b-4669-b52e-b5cb283c3f57"
      unitRef="shares">2404300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzItMy0xLTEtMzkyNw_18baec90-c8da-46f3-946d-80107b6561b7"
      unitRef="usdPerShare">11.6</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzMtMS0xLTEtMzkyNw_af06e5d5-784a-4ae3-a97e-af1b0bef199d"
      unitRef="shares">882624</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzMtMy0xLTEtMzkyNw_2c549bb9-a171-4c24-8e24-598220cbfce1"
      unitRef="usdPerShare">6.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzQtMS0xLTEtMzkyNw_c34a4768-6fe5-471d-aac9-00af1f6726f9"
      unitRef="shares">515925</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzQtMy0xLTEtMzkyNw_e9624ba4-473d-4cdf-baca-655df3de8e1a"
      unitRef="usdPerShare">15.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzUtMS0xLTEtMzkyNw_0ed10cbd-df25-45d7-9bae-4909749110f0"
      unitRef="shares">6846289</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzUtMy0xLTEtMzkyNw_6712b20b-c6a4-47ed-8502-0b8234512acb"
      unitRef="usdPerShare">6.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzUtNS0xLTEtMzkyNw_7374b899-9cd9-48a7-98bf-b2bbd7056cea">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzUtNy0xLTEtMzkyNw_90d70661-a1e4-4858-b869-51a2b2c10398"
      unitRef="usd">53127000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzYtMS0xLTEtNTgxNQ_f8955dbd-b1d9-4cc4-8efa-e4e4eb1c0b67"
      unitRef="shares">1878082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzYtMy0xLTEtNTgxNQ_da2e9e67-2937-46e4-a16d-3c4e5bcedcfa"
      unitRef="usdPerShare">5.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzYtNS0xLTEtNTgxNQ_caa24c43-3bad-41d0-916d-1ab8fc254e90">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo4ODEwYWU1MGE1Yzk0Nzg3YWU3Yzc3NGM1OTI2ZWU1NS90YWJsZXJhbmdlOjg4MTBhZTUwYTVjOTQ3ODdhZTdjNzc0YzU5MjZlZTU1XzYtNy0xLTEtNTgxNQ_3247c4d1-4ab2-45d5-8733-cd515a180e64"
      unitRef="usd">17547000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ib2b7aa4965884327b321e9713f816fca_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzcxNDY4MjU2MTIzNzE_eb1e322c-c1c5-4950-a5b5-c7368d8c23e7"
      unitRef="shares">882624</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MTQ2NjI_2cdef402-dbef-4b56-8f09-7b8471c0e135"
      unitRef="usd">6000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia5203423d3b74826a3d7fe380aabf55b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MTQ2Nzg_442ce288-60f1-4646-bae5-60629b731f87"
      unitRef="shares">326094</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MTQ2NzQ_7875da96-6154-473e-bdf0-78983aa39c36"
      unitRef="usd">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzI3NDg3NzkxMTg3NDk_a9e785a5-6f89-4a0c-b817-27c821187dfe"
      unitRef="usdPerShare">8.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzI3NDg3NzkxMTg3NTc_e3516621-ad14-4e41-ab80-2531244f0ea1"
      unitRef="usdPerShare">2.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc1MDEzNTM_d8449650-4dc9-4349-be1c-723357b28c21">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted is estimated using the Black-Scholes option pricing model with the following weighted average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected terms (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZToyMDhjYzYyYmRmNGY0ZWJiOThhNTI2ZWZhMjdmMmFlYi90YWJsZXJhbmdlOjIwOGNjNjJiZGY0ZjRlYmI5OGE1MjZlZmEyN2YyYWViXzItMS0xLTEtNzEwNw_f0f04864-2488-4b5d-9c7e-1c46f9f6f7bb"
      unitRef="number">0.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZToyMDhjYzYyYmRmNGY0ZWJiOThhNTI2ZWZhMjdmMmFlYi90YWJsZXJhbmdlOjIwOGNjNjJiZGY0ZjRlYmI5OGE1MjZlZmEyN2YyYWViXzItMy0xLTEtNzEwNw_7cdad612-d78e-47bb-aa5b-a17416c8d8a5"
      unitRef="number">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZToyMDhjYzYyYmRmNGY0ZWJiOThhNTI2ZWZhMjdmMmFlYi90YWJsZXJhbmdlOjIwOGNjNjJiZGY0ZjRlYmI5OGE1MjZlZmEyN2YyYWViXzMtMS0xLTEtNzEwNw_9f36f7f3-ff13-43e2-874b-e517d87ccdb4"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZToyMDhjYzYyYmRmNGY0ZWJiOThhNTI2ZWZhMjdmMmFlYi90YWJsZXJhbmdlOjIwOGNjNjJiZGY0ZjRlYmI5OGE1MjZlZmEyN2YyYWViXzMtMy0xLTEtNzEwNw_538f2076-5818-460b-89d2-a6f1a986fb32"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZToyMDhjYzYyYmRmNGY0ZWJiOThhNTI2ZWZhMjdmMmFlYi90YWJsZXJhbmdlOjIwOGNjNjJiZGY0ZjRlYmI5OGE1MjZlZmEyN2YyYWViXzQtMS0xLTEtNzEwNw_9ba57496-c5fe-49fa-b54c-038523ef666f">P6Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZToyMDhjYzYyYmRmNGY0ZWJiOThhNTI2ZWZhMjdmMmFlYi90YWJsZXJhbmdlOjIwOGNjNjJiZGY0ZjRlYmI5OGE1MjZlZmEyN2YyYWViXzQtMy0xLTEtNzEwNw_2402e15c-de3b-4ea1-9275-f35edfc119ed">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZToyMDhjYzYyYmRmNGY0ZWJiOThhNTI2ZWZhMjdmMmFlYi90YWJsZXJhbmdlOjIwOGNjNjJiZGY0ZjRlYmI5OGE1MjZlZmEyN2YyYWViXzUtMS0xLTEtNzEwNw_10168e3f-fad5-4047-b9e8-75cde30a01d6"
      unitRef="number">0.0042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZToyMDhjYzYyYmRmNGY0ZWJiOThhNTI2ZWZhMjdmMmFlYi90YWJsZXJhbmdlOjIwOGNjNjJiZGY0ZjRlYmI5OGE1MjZlZmEyN2YyYWViXzUtMy0xLTEtNzEwNw_1092cadf-cf36-4d3d-a71c-f3f805e24b29"
      unitRef="number">0.0143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTQwMjc_b2724ed2-6e77-4198-8d9e-a2aa652c8772">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company's restricted stock unit activity and related information for the year ended December&#160;31, 2020 is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.320%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.26&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.47&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.47&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="icd60841f3d0c4c839e994b21197a5e5a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo5ZjUwYmZiZjc1NWI0NmU4YTFhMmQzNzcxNmM0YmM5Yi90YWJsZXJhbmdlOjlmNTBiZmJmNzU1YjQ2ZThhMWEyZDM3NzE2YzRiYzliXzEtMS0xLTEtNDgxOA_ee18b8cc-1769-432f-b9ad-710231a0b50c"
      unitRef="shares">72000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="icd60841f3d0c4c839e994b21197a5e5a_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo5ZjUwYmZiZjc1NWI0NmU4YTFhMmQzNzcxNmM0YmM5Yi90YWJsZXJhbmdlOjlmNTBiZmJmNzU1YjQ2ZThhMWEyZDM3NzE2YzRiYzliXzEtMy0xLTEtNDgxOA_7a3930bd-470b-4f5a-940d-244337b53d0a"
      unitRef="usdPerShare">3.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="icf570f55902f4cc28e0254cce74d57f7_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo5ZjUwYmZiZjc1NWI0NmU4YTFhMmQzNzcxNmM0YmM5Yi90YWJsZXJhbmdlOjlmNTBiZmJmNzU1YjQ2ZThhMWEyZDM3NzE2YzRiYzliXzItMS0xLTEtNDgxOA_d989839a-d54c-42a4-aaf9-7bada97c5d28"
      unitRef="shares">152000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="icf570f55902f4cc28e0254cce74d57f7_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo5ZjUwYmZiZjc1NWI0NmU4YTFhMmQzNzcxNmM0YmM5Yi90YWJsZXJhbmdlOjlmNTBiZmJmNzU1YjQ2ZThhMWEyZDM3NzE2YzRiYzliXzItMy0xLTEtNDgxOA_2340c84e-1902-4286-898e-450f69ea7216"
      unitRef="usdPerShare">9.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="icf570f55902f4cc28e0254cce74d57f7_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo5ZjUwYmZiZjc1NWI0NmU4YTFhMmQzNzcxNmM0YmM5Yi90YWJsZXJhbmdlOjlmNTBiZmJmNzU1YjQ2ZThhMWEyZDM3NzE2YzRiYzliXzMtMS0xLTEtNDgxOA_e551c4df-81c1-45c2-bfdd-198a5dae7832"
      unitRef="shares">36000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="icf570f55902f4cc28e0254cce74d57f7_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo5ZjUwYmZiZjc1NWI0NmU4YTFhMmQzNzcxNmM0YmM5Yi90YWJsZXJhbmdlOjlmNTBiZmJmNzU1YjQ2ZThhMWEyZDM3NzE2YzRiYzliXzMtMy0xLTEtNDgxOA_da8ceb16-b807-4261-8aaa-d55467aa4e7e"
      unitRef="usdPerShare">3.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="icf570f55902f4cc28e0254cce74d57f7_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo5ZjUwYmZiZjc1NWI0NmU4YTFhMmQzNzcxNmM0YmM5Yi90YWJsZXJhbmdlOjlmNTBiZmJmNzU1YjQ2ZThhMWEyZDM3NzE2YzRiYzliXzQtMS0xLTEtNDgxOA_b9376e12-a3b4-4014-812a-ffee0e25bf23"
      unitRef="shares">1500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="icf570f55902f4cc28e0254cce74d57f7_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo5ZjUwYmZiZjc1NWI0NmU4YTFhMmQzNzcxNmM0YmM5Yi90YWJsZXJhbmdlOjlmNTBiZmJmNzU1YjQ2ZThhMWEyZDM3NzE2YzRiYzliXzQtMy0xLTEtNDgxOA_5fab42df-0f8c-4eec-ba7e-bdad4cc40b62"
      unitRef="usdPerShare">3.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i519925c39cf4455091866ca196cf1161_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo5ZjUwYmZiZjc1NWI0NmU4YTFhMmQzNzcxNmM0YmM5Yi90YWJsZXJhbmdlOjlmNTBiZmJmNzU1YjQ2ZThhMWEyZDM3NzE2YzRiYzliXzUtMS0xLTEtNDgxOA_0dbe508e-4679-4a32-9436-2f69c63ca0ae"
      unitRef="shares">186500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i519925c39cf4455091866ca196cf1161_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo5ZjUwYmZiZjc1NWI0NmU4YTFhMmQzNzcxNmM0YmM5Yi90YWJsZXJhbmdlOjlmNTBiZmJmNzU1YjQ2ZThhMWEyZDM3NzE2YzRiYzliXzUtMy0xLTEtNDgxOA_e3be6fa6-de1f-49d6-a85c-407c31252f84"
      unitRef="usdPerShare">8.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTQwMjg_6a3d548e-6356-4177-adf4-8f9daa0da626">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense is classified in the consolidated statements of operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.758%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i98de22e11051465b8dcdb754ab88181e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo0MmQzZjQxYjE4OWY0ZmMxYmQ0YTAwOWJiYjkyNmM1My90YWJsZXJhbmdlOjQyZDNmNDFiMTg5ZjRmYzFiZDRhMDA5YmJiOTI2YzUzXzItMS0xLTEtMzcwNQ_ed08f034-24cc-43d0-ac6f-f067825c6fce"
      unitRef="usd">1999000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4ded9a42fb4c43d59acd21cbb286e7ab_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo0MmQzZjQxYjE4OWY0ZmMxYmQ0YTAwOWJiYjkyNmM1My90YWJsZXJhbmdlOjQyZDNmNDFiMTg5ZjRmYzFiZDRhMDA5YmJiOTI2YzUzXzItMy0xLTEtMzcwNQ_19771a77-ce42-459b-b98a-882f179dc9b5"
      unitRef="usd">486000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib836d4e8cc0846f3aae456d3e9c5c4a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo0MmQzZjQxYjE4OWY0ZmMxYmQ0YTAwOWJiYjkyNmM1My90YWJsZXJhbmdlOjQyZDNmNDFiMTg5ZjRmYzFiZDRhMDA5YmJiOTI2YzUzXzMtMS0xLTEtMzcwNQ_eaa2e79e-1999-4bc3-b925-19f4bc7d6232"
      unitRef="usd">3623000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3bf297e89d3a4439826cf1221fa7077e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo0MmQzZjQxYjE4OWY0ZmMxYmQ0YTAwOWJiYjkyNmM1My90YWJsZXJhbmdlOjQyZDNmNDFiMTg5ZjRmYzFiZDRhMDA5YmJiOTI2YzUzXzMtMy0xLTEtMzcwNQ_62212570-b3cf-4626-9660-0c513a497bf9"
      unitRef="usd">7197000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo0MmQzZjQxYjE4OWY0ZmMxYmQ0YTAwOWJiYjkyNmM1My90YWJsZXJhbmdlOjQyZDNmNDFiMTg5ZjRmYzFiZDRhMDA5YmJiOTI2YzUzXzQtMS0xLTEtMzcwNQ_5d330255-9828-4672-81db-76fc73e87219"
      unitRef="usd">5622000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90YWJsZTo0MmQzZjQxYjE4OWY0ZmMxYmQ0YTAwOWJiYjkyNmM1My90YWJsZXJhbmdlOjQyZDNmNDFiMTg5ZjRmYzFiZDRhMDA5YmJiOTI2YzUzXzQtMy0xLTEtMzcwNQ_bc7b4a0d-b15b-4399-864b-86098e2e7378"
      unitRef="usd">7683000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MDY5NzI_fab9c19a-983f-449b-a14a-4cfb433669f7"
      unitRef="usd">24900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzMyOTg1MzQ5MDcwMzA_0ac18e79-ebc2-4ad0-ad79-b168ee5b8e76">P3Y1M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ic094ebf448aa42ca8ddd6b528bd22183_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzcxNDY4MjU2MTIzNjc_e31b7c62-d9b9-4544-8a56-36b82d20aa90"
      unitRef="shares">759936</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="ic094ebf448aa42ca8ddd6b528bd22183_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc1MDEzNTY_54d6c4f7-1680-485f-a883-9151f511e578"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="ic094ebf448aa42ca8ddd6b528bd22183_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc1MDEzNTY_9b19ce78-ef4f-457a-b6d1-25abf744cb90"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i6ce8a1775eab43619ee74ee567323a06_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTQwNDg_ca48909a-b266-40dd-af7b-f6287f28a660"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i6ce8a1775eab43619ee74ee567323a06_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTQwNTM_2035434f-c011-43bd-ab9e-9e7b24e5b5c5"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <nltx:EmployeeStockPurchasePlanNumberOfOfferingPerYear
      contextRef="i6ce8a1775eab43619ee74ee567323a06_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTQwMzA_e45e1e14-dec5-4eff-b069-03d12ccdf15f"
      unitRef="offering">2</nltx:EmployeeStockPurchasePlanNumberOfOfferingPerYear>
    <nltx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod
      contextRef="i6ce8a1775eab43619ee74ee567323a06_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTQwNDU_b1afcb1c-8209-4999-b9f3-4b723b76fa80">P6M</nltx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzgyNDYzMzcyNTY0ODY_47289b9d-e40c-41ca-96e9-0e31ee4d39e4"
      unitRef="shares">18352</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i9458a61fcd5441b4a06f3867c7b43644_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzgyNDYzMzcyNTY0OTI_1bcf3adc-27f2-4478-bec9-3d4d41d9d9a8"
      unitRef="usdPerShare">10.84</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzgyNDYzMzcyNTY0OTg_e4c599e6-615d-4109-a3fe-dcdc4ab24f72"
      unitRef="usd">200000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNDUvZnJhZzo5YmYyYTkwODMzNWQ0NzZjOGFhZGMyZDM4ZWFlNjQ5OS90ZXh0cmVnaW9uOjliZjJhOTA4MzM1ZDQ3NmM4YWFkYzJkMzhlYWU2NDk5XzI1MTc_23292033-e02e-4370-b376-5dadbbff0fd1">Restructuring&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2018, the Company&#x2019;s Board of Directors approved a restructuring plan to reduce operating costs and better align the Company&#x2019;s workforce with the needs of its business following the June&#160;27, 2018 announcement that its Phase 3 Leadership 301 clinical trial evaluating once-daily, oral rosiptor for the treatment of IC/BPS failed to meet its primary endpoint. The Company has halted all further development activities with rosiptor. In 2018 and 2019, the Company incurred and paid aggregate restructuring charges of $7.4 million related to clinical trial closing costs, contract cancellations, closing of its office in San Bruno, California, severance payments and other employee-related costs. During the second quarter of 2019, the Company revised its original estimate of aggregate restructuring charges lower by $2.0&#160;million based upon updated information from its vendors related to a completed project. There were no amounts accrued as of December&#160;31, 2020 or December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;6, 2018, the Company&#x2019;s Board of Directors approved an additional restructuring plan to further reduce operating costs.  The Company incurred and paid aggregate restructuring charges of $1.6&#160;million related to severance payments and other employee-related costs.  There were no amounts accrued as of December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2020, the Company incurred and paid an immaterial amount of restructuring charges. For the year ended December&#160;31, 2019, restructuring recoveries of $1.9&#160;million were recorded in research and development expenses and restructuring costs of $0.7&#160;million were recorded in general and administrative expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i71f76aa20b85452986373dda65e0d335_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNDUvZnJhZzo5YmYyYTkwODMzNWQ0NzZjOGFhZGMyZDM4ZWFlNjQ5OS90ZXh0cmVnaW9uOjliZjJhOTA4MzM1ZDQ3NmM4YWFkYzJkMzhlYWU2NDk5XzMyOTg1MzQ4OTQzNzY_318de1a1-2008-4763-b6d4-cf0bb0cbf4b0"
      unitRef="usd">7400000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringReserveAccrualAdjustment1
      contextRef="if5d6fef6a34b42589a5f9af4fd295376_D20190401-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNDUvZnJhZzo5YmYyYTkwODMzNWQ0NzZjOGFhZGMyZDM4ZWFlNjQ5OS90ZXh0cmVnaW9uOjliZjJhOTA4MzM1ZDQ3NmM4YWFkYzJkMzhlYWU2NDk5XzE2NDkyNjc0NTI5Mzc_0afe0b3b-c8c5-4415-8b0e-ce8e3650e27f"
      unitRef="usd">-2000000.0</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:RestructuringReserve
      contextRef="i71f76aa20b85452986373dda65e0d335_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNDUvZnJhZzo5YmYyYTkwODMzNWQ0NzZjOGFhZGMyZDM4ZWFlNjQ5OS90ZXh0cmVnaW9uOjliZjJhOTA4MzM1ZDQ3NmM4YWFkYzJkMzhlYWU2NDk5XzE2NDkyNjc0NTI5OTM_2c09c414-7848-4b97-8d6c-9fd0b0bec6bf"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i8b0667298aca423a94e3af1049753d11_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNDUvZnJhZzo5YmYyYTkwODMzNWQ0NzZjOGFhZGMyZDM4ZWFlNjQ5OS90ZXh0cmVnaW9uOjliZjJhOTA4MzM1ZDQ3NmM4YWFkYzJkMzhlYWU2NDk5XzE2NDkyNjc0NTI5OTM_e021b6d4-f612-419b-9539-e3caef3b4e25"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="ie44b93451c7140eaadb4a1b1ad21f5a2_I20181106"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNDUvZnJhZzo5YmYyYTkwODMzNWQ0NzZjOGFhZGMyZDM4ZWFlNjQ5OS90ZXh0cmVnaW9uOjliZjJhOTA4MzM1ZDQ3NmM4YWFkYzJkMzhlYWU2NDk5XzE2NDkyNjc0NTI5NTE_ae00a1d1-0304-4079-b613-d05f04436e45"
      unitRef="usd">1600000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringReserve
      contextRef="i683ab08d4e50424b957c9a94c07b61de_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNDUvZnJhZzo5YmYyYTkwODMzNWQ0NzZjOGFhZGMyZDM4ZWFlNjQ5OS90ZXh0cmVnaW9uOjliZjJhOTA4MzM1ZDQ3NmM4YWFkYzJkMzhlYWU2NDk5XzE2NDkyNjc0NTI5NjQ_671686f5-86b1-4280-8e7d-93d3911270ec"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i4ded9a42fb4c43d59acd21cbb286e7ab_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNDUvZnJhZzo5YmYyYTkwODMzNWQ0NzZjOGFhZGMyZDM4ZWFlNjQ5OS90ZXh0cmVnaW9uOjliZjJhOTA4MzM1ZDQ3NmM4YWFkYzJkMzhlYWU2NDk5XzE2NDkyNjc0NTI5NjY_ba1198c4-56a6-408c-87c5-6a489638616a"
      unitRef="usd">-1900000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i3bf297e89d3a4439826cf1221fa7077e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNDUvZnJhZzo5YmYyYTkwODMzNWQ0NzZjOGFhZGMyZDM4ZWFlNjQ5OS90ZXh0cmVnaW9uOjliZjJhOTA4MzM1ZDQ3NmM4YWFkYzJkMzhlYWU2NDk5XzE2NDkyNjc0NTI5ODA_831dedce-dec8-4122-815d-efebf0ce44ba"
      unitRef="usd">700000</us-gaap:RestructuringCharges>
    <us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTEvZnJhZzo1OWNkZmE1NTEyOTY0MjYzOGNlMDhlNGVmODhiMTM1NC90ZXh0cmVnaW9uOjU5Y2RmYTU1MTI5NjQyNjM4Y2UwOGU0ZWY4OGIxMzU0XzI4_26e3dd8f-c5aa-4399-837b-ce312b79892c">Other income, net&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other income is presented for all periods (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign exchange gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTEvZnJhZzo1OWNkZmE1NTEyOTY0MjYzOGNlMDhlNGVmODhiMTM1NC90ZXh0cmVnaW9uOjU5Y2RmYTU1MTI5NjQyNjM4Y2UwOGU0ZWY4OGIxMzU0XzI5_5f533d96-4664-4b6d-8af6-ddd847016b25">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other income is presented for all periods (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign exchange gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeNet
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTEvZnJhZzo1OWNkZmE1NTEyOTY0MjYzOGNlMDhlNGVmODhiMTM1NC90YWJsZTo0NDBkMmY4ZjY1Y2U0ZmM4ODcxOTAxYzFkYWYzMGFhZC90YWJsZXJhbmdlOjQ0MGQyZjhmNjVjZTRmYzg4NzE5MDFjMWRhZjMwYWFkXzItMS0xLTEtMA_7093468a-0040-4eeb-a363-3fbe76c6a011"
      unitRef="usd">490000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTEvZnJhZzo1OWNkZmE1NTEyOTY0MjYzOGNlMDhlNGVmODhiMTM1NC90YWJsZTo0NDBkMmY4ZjY1Y2U0ZmM4ODcxOTAxYzFkYWYzMGFhZC90YWJsZXJhbmdlOjQ0MGQyZjhmNjVjZTRmYzg4NzE5MDFjMWRhZjMwYWFkXzItMy0xLTEtMA_8923e99e-177e-483c-9c5a-10d88f22efcb"
      unitRef="usd">1542000</us-gaap:InvestmentIncomeNet>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTEvZnJhZzo1OWNkZmE1NTEyOTY0MjYzOGNlMDhlNGVmODhiMTM1NC90YWJsZTo0NDBkMmY4ZjY1Y2U0ZmM4ODcxOTAxYzFkYWYzMGFhZC90YWJsZXJhbmdlOjQ0MGQyZjhmNjVjZTRmYzg4NzE5MDFjMWRhZjMwYWFkXzMtMS0xLTEtMA_2173bb16-34d4-4b37-b0fc-b3470261f3b9"
      unitRef="usd">5000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTEvZnJhZzo1OWNkZmE1NTEyOTY0MjYzOGNlMDhlNGVmODhiMTM1NC90YWJsZTo0NDBkMmY4ZjY1Y2U0ZmM4ODcxOTAxYzFkYWYzMGFhZC90YWJsZXJhbmdlOjQ0MGQyZjhmNjVjZTRmYzg4NzE5MDFjMWRhZjMwYWFkXzMtMy0xLTEtMA_7613dab0-9e5a-4575-a12e-10087087bac4"
      unitRef="usd">-16000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTEvZnJhZzo1OWNkZmE1NTEyOTY0MjYzOGNlMDhlNGVmODhiMTM1NC90YWJsZTo0NDBkMmY4ZjY1Y2U0ZmM4ODcxOTAxYzFkYWYzMGFhZC90YWJsZXJhbmdlOjQ0MGQyZjhmNjVjZTRmYzg4NzE5MDFjMWRhZjMwYWFkXzQtMS0xLTEtMA_84ce4ad8-61ad-47d3-a11c-5e3177c1e3ea"
      unitRef="usd">-44000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTEvZnJhZzo1OWNkZmE1NTEyOTY0MjYzOGNlMDhlNGVmODhiMTM1NC90YWJsZTo0NDBkMmY4ZjY1Y2U0ZmM4ODcxOTAxYzFkYWYzMGFhZC90YWJsZXJhbmdlOjQ0MGQyZjhmNjVjZTRmYzg4NzE5MDFjMWRhZjMwYWFkXzQtMy0xLTEtMA_66fae3dc-2ec6-43ac-9e29-a539487b2975"
      unitRef="usd">-9000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTEvZnJhZzo1OWNkZmE1NTEyOTY0MjYzOGNlMDhlNGVmODhiMTM1NC90YWJsZTo0NDBkMmY4ZjY1Y2U0ZmM4ODcxOTAxYzFkYWYzMGFhZC90YWJsZXJhbmdlOjQ0MGQyZjhmNjVjZTRmYzg4NzE5MDFjMWRhZjMwYWFkXzUtMS0xLTEtMA_c6934b52-931a-4002-b70f-26f49fe0b1f2"
      unitRef="usd">451000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTEvZnJhZzo1OWNkZmE1NTEyOTY0MjYzOGNlMDhlNGVmODhiMTM1NC90YWJsZTo0NDBkMmY4ZjY1Y2U0ZmM4ODcxOTAxYzFkYWYzMGFhZC90YWJsZXJhbmdlOjQ0MGQyZjhmNjVjZTRmYzg4NzE5MDFjMWRhZjMwYWFkXzUtMy0xLTEtMA_cc899a81-b9e9-4a96-a8e6-98b76ccb609e"
      unitRef="usd">1517000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTQvZnJhZzo0YjFlOGQwYWY3YTY0OWFmYWEzYjAzMjAyYTNkZGUyMS90ZXh0cmVnaW9uOjRiMWU4ZDBhZjdhNjQ5YWZhYTNiMDMyMDJhM2RkZTIxXzQwMA_71c6bfa4-94a4-4a09-ba3c-a5145b5a54cf">Net loss per common stock&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company excluded the following potentially dilutive shares from diluted net loss per share as the effect would have been anti-dilutive for all periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;YEARS ENDED &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,848,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,840,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issuable under 2020 ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,057,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,912,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTQvZnJhZzo0YjFlOGQwYWY3YTY0OWFmYWEzYjAzMjAyYTNkZGUyMS90ZXh0cmVnaW9uOjRiMWU4ZDBhZjdhNjQ5YWZhYTNiMDMyMDJhM2RkZTIxXzM5OQ_28c0f5cc-1fa2-4032-afbb-6441b9c9b878">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company excluded the following potentially dilutive shares from diluted net loss per share as the effect would have been anti-dilutive for all periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;YEARS ENDED &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,848,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,840,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issuable under 2020 ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,057,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,912,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i114d11c2e9f14956aaff2d2291a3bb3c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTQvZnJhZzo0YjFlOGQwYWY3YTY0OWFmYWEzYjAzMjAyYTNkZGUyMS90YWJsZTo0NTZlMDYxY2NjYWQ0NDA5Yjg5MDNmZjgxM2UxZDQxYS90YWJsZXJhbmdlOjQ1NmUwNjFjY2NhZDQ0MDliODkwM2ZmODEzZTFkNDFhXzItMS0xLTEtMA_427ec367-ab32-4180-b20b-164110887e7c"
      unitRef="shares">6848289</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0287eaf6edad4bca9a12a64c9fd6bfd3_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTQvZnJhZzo0YjFlOGQwYWY3YTY0OWFmYWEzYjAzMjAyYTNkZGUyMS90YWJsZTo0NTZlMDYxY2NjYWQ0NDA5Yjg5MDNmZjgxM2UxZDQxYS90YWJsZXJhbmdlOjQ1NmUwNjFjY2NhZDQ0MDliODkwM2ZmODEzZTFkNDFhXzItMy0xLTEtMA_8db27ed9-6a25-472d-a69d-64b5b44f61a9"
      unitRef="shares">5840538</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib0fb710a1248468f89148e8f321466cd_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTQvZnJhZzo0YjFlOGQwYWY3YTY0OWFmYWEzYjAzMjAyYTNkZGUyMS90YWJsZTo0NTZlMDYxY2NjYWQ0NDA5Yjg5MDNmZjgxM2UxZDQxYS90YWJsZXJhbmdlOjQ1NmUwNjFjY2NhZDQ0MDliODkwM2ZmODEzZTFkNDFhXzMtMS0xLTEtMA_360303f4-bef6-4727-97b5-493fe0c9b9f7"
      unitRef="shares">186500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i716d60022b294375af6a54233d5dafb2_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTQvZnJhZzo0YjFlOGQwYWY3YTY0OWFmYWEzYjAzMjAyYTNkZGUyMS90YWJsZTo0NTZlMDYxY2NjYWQ0NDA5Yjg5MDNmZjgxM2UxZDQxYS90YWJsZXJhbmdlOjQ1NmUwNjFjY2NhZDQ0MDliODkwM2ZmODEzZTFkNDFhXzMtMy0xLTEtMA_cdf6afec-167e-48e8-baba-4fe8dbe074c9"
      unitRef="shares">72000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ided3ec02dff84702acaa7ae1e47b2e5f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTQvZnJhZzo0YjFlOGQwYWY3YTY0OWFmYWEzYjAzMjAyYTNkZGUyMS90YWJsZTo0NTZlMDYxY2NjYWQ0NDA5Yjg5MDNmZjgxM2UxZDQxYS90YWJsZXJhbmdlOjQ1NmUwNjFjY2NhZDQ0MDliODkwM2ZmODEzZTFkNDFhXzQtMS0xLTEtNDc1OA_cb9febcb-7eac-4684-a76c-8c858d912aa1"
      unitRef="shares">22521</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i96ba60c113044d799a3a4c62cb49aed1_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTQvZnJhZzo0YjFlOGQwYWY3YTY0OWFmYWEzYjAzMjAyYTNkZGUyMS90YWJsZTo0NTZlMDYxY2NjYWQ0NDA5Yjg5MDNmZjgxM2UxZDQxYS90YWJsZXJhbmdlOjQ1NmUwNjFjY2NhZDQ0MDliODkwM2ZmODEzZTFkNDFhXzQtMy0xLTEtNDc1OA_52c4ef8d-1a64-48d4-b9f8-2544ef31b425"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTQvZnJhZzo0YjFlOGQwYWY3YTY0OWFmYWEzYjAzMjAyYTNkZGUyMS90YWJsZTo0NTZlMDYxY2NjYWQ0NDA5Yjg5MDNmZjgxM2UxZDQxYS90YWJsZXJhbmdlOjQ1NmUwNjFjY2NhZDQ0MDliODkwM2ZmODEzZTFkNDFhXzQtMS0xLTEtMA_eb546186-73b7-4361-8b2b-dde817000f45"
      unitRef="shares">7057310</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTQvZnJhZzo0YjFlOGQwYWY3YTY0OWFmYWEzYjAzMjAyYTNkZGUyMS90YWJsZTo0NTZlMDYxY2NjYWQ0NDA5Yjg5MDNmZjgxM2UxZDQxYS90YWJsZXJhbmdlOjQ1NmUwNjFjY2NhZDQ0MDliODkwM2ZmODEzZTFkNDFhXzQtMy0xLTEtMA_cd5145ae-8213-497d-b602-5021d3f5d436"
      unitRef="shares">5912538</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzM3OTk_d3f4975d-7b70-4dc4-960e-62af4bf24f5c">Income taxes&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax recovery varies from the amounts that would be computed by applying the expected U.S. federal income tax rate (21%) as shown in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Statutory federal income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired in-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Disposal of Aquinox Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expiration of NOLs (section 382)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax recovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net loss before taxes (in thousands):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(522)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,442)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income tax assets and liabilities result from the temporary differences between the amount of assets and liabilities recognized for financial statement and income tax purposes. The significant components of the deferred income tax assets are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canadian net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development deductions and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,893)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 31, 2020, the Company sold all issued and outstanding capital stock of its Canadian subsidiary, Aquinox Canada, to an unrelated third party for cash consideration. As of the date of sale, Aquinox Canada&#x2019;s remaining assets included intellectual property and other assets developed through past research and development activities, all of which had no book value. The transaction resulted in a net gain on sale of $7.8&#160;million. The sale of Aquinox Canada triggered a significant capital loss carryforward for tax purposes. However, most of the capital loss carryforward is limited by the prior ownership change under Section 382.  The remaining unlimited portion of the capital loss carryforward will be subject to a full valuation allowance as the Company has determined that it is more likely than not that the benefit of the loss will not be realized. After the sale, Aquinox Canada's tax attributes of $51.7&#160;million including the net operating losses, scientific research and experimental development expenditures and investment tax credits are no longer reflected in the deferred tax assets and valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020 and December&#160;31, 2019, the Company had U.S. federal net operating losses ("NOL") carryforwards for tax purposes of approximately $58.1 million and $25.5 million, respectively, which were available to reduce taxable income. Of the $58.1 million of federal NOL carryforwards, $1.7 million will expire between the years 2028 and 2037 and the remaining $56.4 million are indefinite. The Company also has U.S. federal research &amp;amp; development tax credits of $1.0 million and $0.2 million as of December&#160;31, 2020 and December&#160;31, 2019, respectively, that begin to expire in 2039. The Company completed a formal study under IRC Section 382 through 2019  to determine the U.S. tax attributes available for use.  The U.S. attributes disclosed reflect the conclusion of that study. However, subsequent ownership changes may further affect the limitation in future years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company maintains a full valuation allowance on its net U.S. deferred tax assets. The assessment regarding whether a valuation allowance is required considers both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. In making this assessment, significant weight is given to evidence that can be objectively verified. In its evaluation, the Company considered its cumulative losses and its forecasted losses in the near-term as significant negative evidence. Therefore, the Company determined that the negative evidence outweighed the positive evidence and a full valuation allowance on its assets will be maintained. The Company will continue to assess the realizability of its assets going forward and will adjust the valuation allowance as needed. The valuation allowance decreased by $42.9&#160;million for the year ended December&#160;31, 2020. The decrease is primarily due to the sale of Aquinox Canada and the write-off of the related tax attributes, and partially offset by an increase in US net operating losses and research and development tax credits. The valuation allowance increased by $0.6&#160;million for the year ended December&#160;31, 2019. The increase is primarily related to an increase in deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies judgment in the determination of the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. As of December&#160;31, 2020, the Company had no uncertain tax positions.&lt;/span&gt;&lt;/div&gt;The Company currently files income tax returns in the United States, the jurisdictions in which the Company believes that it is subject to tax. Further, while the statute of limitations in each jurisdiction where an income tax return has been filed generally limits the examination period, as a result of loss carryforwards, the limitation period for examination generally does not expire until several years after the loss carryforwards are utilized. Other than routine audits by tax authorities for tax credits and tax refunds that the Company has claimed, the Company is not aware of any other material income tax examination currently in progress by any taxing jurisdiction.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzM4MDA_48c581ef-1192-43c3-ab7d-4424cab276fd">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax recovery varies from the amounts that would be computed by applying the expected U.S. federal income tax rate (21%) as shown in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Statutory federal income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired in-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Disposal of Aquinox Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expiration of NOLs (section 382)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax Credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax recovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzItMS0xLTEtMA_4f28c16e-e164-47a8-9e95-9a7b0d38ba69"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzItMy0xLTEtMA_5bb8986a-4bb7-4d70-97f5-77dbdc909f08"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzMtMS0xLTEtMA_31dd0e4c-b718-46e0-837e-016179983142"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzMtMy0xLTEtMA_5c671a26-be99-4a49-baae-54b49ba87adf"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzQtMS0xLTEtMA_90a309ed-81f0-494e-ae8c-547072316624"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzQtMy0xLTEtMA_1abc5a88-67b4-4c20-8436-667af39dbed1"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzUtMS0xLTEtMA_775788bc-3482-4191-84f8-e37d0bb6d81c"
      unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzUtMy0xLTEtMA_2f1a702b-2c11-4db9-9579-95c3fab35b72"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzYtMS0xLTEtMA_c0a6b8e9-1c17-402f-8473-c46d39dc4fbd"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzYtMy0xLTEtMA_7de8b897-56f1-48e2-b9db-ba53fa321225"
      unitRef="number">-0.144</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzctMS0xLTEtMA_ef1429cd-6747-4e1d-ad62-d3a3dfe16cc9"
      unitRef="number">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzctMy0xLTEtMA_0e56075b-2cb0-4eaf-bd5d-c63cec7f3b50"
      unitRef="number">-0.026</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzgtMS0xLTEtNzM4Mg_267bb732-830b-407a-b80d-d8d8133a8743"
      unitRef="number">0.052</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzgtMy0xLTEtNzM4NQ_56ab3832-7f2c-447f-a166-c2615f6bce4a"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzgtMS0xLTEtMA_fb5b1301-dc6f-42e2-8f48-2e8de8b3b4c6"
      unitRef="number">-0.265</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzgtMy0xLTEtMA_8ab91791-079c-4b8c-a975-43bfbfef0466"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <nltx:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzktMS0xLTEtMA_4e3dcfa6-b316-4a27-b4bd-88ae5abb71ca"
      unitRef="number">-0.005</nltx:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent>
    <nltx:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzktMy0xLTEtMA_7f188313-9293-4595-b271-dbc88f0f6bba"
      unitRef="number">-0.054</nltx:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzExLTEtMS0xLTczODk_9c7798ab-87bb-4e50-b821-56c55f06ba4a"
      unitRef="number">-0.025</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzExLTMtMS0xLTczOTI_f5e48f49-1229-4044-9f1b-7710df4af0f7"
      unitRef="number">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzExLTEtMS0xLTA_a17680b1-b06b-4da1-8356-bcd8a3cdff15"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzExLTMtMS0xLTA_45c441e9-65e4-4026-b23c-1f9edf2cd1bc"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzEyLTEtMS0xLTA_75dc547a-bc34-4515-80c0-e2fb472f0a90"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTo3NzQ0YWM2YmM1MTc0ZDI4YTQ4NjQzYmU5OGY3YzM3Yi90YWJsZXJhbmdlOjc3NDRhYzZiYzUxNzRkMjhhNDg2NDNiZTk4ZjdjMzdiXzEyLTMtMS0xLTA_63ca0f5f-a807-4d25-be44-7c6ac02106af"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzM4MDE_c556491a-315c-4e38-86f5-f3b89fdae554">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net loss before taxes (in thousands):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(522)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,442)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZToxYjAzNDRiNjFjMDE0M2YxYjM3YTc0MDQ4ZDBhMzQxMi90YWJsZXJhbmdlOjFiMDM0NGI2MWMwMTQzZjFiMzdhNzQwNDhkMGEzNDEyXzItMS0xLTEtMA_ad6aedc5-5301-45b0-955b-ef2d7cc7fa06"
      unitRef="usd">-522000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZToxYjAzNDRiNjFjMDE0M2YxYjM3YTc0MDQ4ZDBhMzQxMi90YWJsZXJhbmdlOjFiMDM0NGI2MWMwMTQzZjFiMzdhNzQwNDhkMGEzNDEyXzItMy0xLTEtMA_f878df52-1529-4581-916c-4eacfc49eb7f"
      unitRef="usd">-2129000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZToxYjAzNDRiNjFjMDE0M2YxYjM3YTc0MDQ4ZDBhMzQxMi90YWJsZXJhbmdlOjFiMDM0NGI2MWMwMTQzZjFiMzdhNzQwNDhkMGEzNDEyXzMtMS0xLTEtMA_28f7fd2f-b70f-45dc-b230-0b98d19ac7b6"
      unitRef="usd">-32755000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZToxYjAzNDRiNjFjMDE0M2YxYjM3YTc0MDQ4ZDBhMzQxMi90YWJsZXJhbmdlOjFiMDM0NGI2MWMwMTQzZjFiMzdhNzQwNDhkMGEzNDEyXzMtMy0xLTEtMA_43a81f65-3946-464e-b1f6-ef2c32d71b44"
      unitRef="usd">-67313000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZToxYjAzNDRiNjFjMDE0M2YxYjM3YTc0MDQ4ZDBhMzQxMi90YWJsZXJhbmdlOjFiMDM0NGI2MWMwMTQzZjFiMzdhNzQwNDhkMGEzNDEyXzQtMS0xLTEtMA_9dc91805-8412-4688-afea-eb8ad4fd835d"
      unitRef="usd">-33277000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZToxYjAzNDRiNjFjMDE0M2YxYjM3YTc0MDQ4ZDBhMzQxMi90YWJsZXJhbmdlOjFiMDM0NGI2MWMwMTQzZjFiMzdhNzQwNDhkMGEzNDEyXzQtMy0xLTEtMA_d2138324-a847-42c4-a3d3-705d0798d761"
      unitRef="usd">-69442000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzM3OTg_c95fe53d-a77e-455c-b2c6-031e8414ec65">The significant components of the deferred income tax assets are as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canadian net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development deductions and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,893)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzMtMS0xLTEtNzQzNQ_9f410e7d-f021-4fce-8f5c-8bafc78a0d79"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzMtMy0xLTEtNzQ0MQ_6a108185-5d44-4dcf-878f-f3ecb792d5bb"
      unitRef="usd">39574000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzQtMS0xLTEtNzQzNQ_ff5e9b68-c007-47d2-9dec-e6dcb9c6a990"
      unitRef="usd">12328000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzQtMy0xLTEtNzQ0MQ_dc6e815d-2813-4f1a-9a4a-35adf6d212c0"
      unitRef="usd">5347000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzUtMS0xLTEtNzQzNQ_a76e8fe3-8e18-4136-8fc6-987f17bf5b7e"
      unitRef="usd">1040000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzUtMy0xLTEtNzQ0MQ_3b25f7a0-b84b-4f67-8299-8bb9f21cc3d1"
      unitRef="usd">11062000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzYtMS0xLTEtNzQzNQ_6ff6b5ba-b2f0-4da4-93a4-ae3fffd505eb"
      unitRef="usd">422000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzYtMy0xLTEtNzQ0MQ_a87bf78e-c5f7-4554-a8b8-556658fe2a4b"
      unitRef="usd">1189000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <nltx:DeferredTaxAssetsLeaseLiability
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzctMS0xLTEtNzQzNQ_30684683-6c4d-4695-9504-b5496bd0aa1f"
      unitRef="usd">2513000</nltx:DeferredTaxAssetsLeaseLiability>
    <nltx:DeferredTaxAssetsLeaseLiability
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzctMy0xLTEtNzQ0MQ_1d6fc871-0f3d-4f52-bc8e-75b9b641a91d"
      unitRef="usd">233000</nltx:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzgtMS0xLTEtNzQzNQ_e85d8c4b-2d93-4464-8164-9600e0a888fb"
      unitRef="usd">717000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzgtMy0xLTEtNzQ0MQ_1a896e75-5ef0-454e-91a2-0e946b60af99"
      unitRef="usd">309000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzktMS0xLTEtNzQzNQ_6bbbe1e4-3e25-450c-8061-1e1d40d8b8fb"
      unitRef="usd">162000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzktMy0xLTEtNzQ0MQ_541ca0ba-ecdb-4741-96c9-6dfcf3fa66c3"
      unitRef="usd">330000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzEwLTEtMS0xLTc0MzU_564e7512-f1a1-42e9-bf8e-e72fee775937"
      unitRef="usd">17182000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzEwLTMtMS0xLTc0NDE_bc7261d5-3cda-4348-9417-79806e15f062"
      unitRef="usd">58044000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzMtMS0xLTEtMA_2faa76e6-ea20-4f21-b55e-035016807dd7"
      unitRef="usd">2132000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzMtMy0xLTEtMA_c12a073c-e474-4c91-af4b-b6070cb767f7"
      unitRef="usd">169000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzQtMS0xLTEtMA_2767ca02-a841-4d09-a4bf-b0a396636051"
      unitRef="usd">157000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzQtMy0xLTEtMA_19f32be5-4e7b-43f4-bc36-3fab58363f9c"
      unitRef="usd">60000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzUtMS0xLTEtMA_8dc59654-a02d-4f4c-a91f-7d5570d9786e"
      unitRef="usd">2289000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzUtMy0xLTEtMA_60756f99-3fb7-431e-a7c2-448d84fc89e9"
      unitRef="usd">229000</us-gaap:DeferredIncomeTaxLiabilities>
    <nltx:DeferredTaxAssetsBeforeValuationAllowance
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzYtMS0xLTEtMA_9ea263a7-9148-41dc-927d-aae9fdb7269f"
      unitRef="usd">14893000</nltx:DeferredTaxAssetsBeforeValuationAllowance>
    <nltx:DeferredTaxAssetsBeforeValuationAllowance
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzYtMy0xLTEtMA_37c5618b-5495-44c7-923b-be9c58778cc0"
      unitRef="usd">57815000</nltx:DeferredTaxAssetsBeforeValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzE2LTEtMS0xLTc0MzU_309c386c-a77c-4631-8e34-2615ed6ec35f"
      unitRef="usd">14893000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzE2LTMtMS0xLTc0NDE_8bb12743-25cb-481f-8398-e57a4c633bab"
      unitRef="usd">57815000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzE3LTEtMS0xLTc0MzU_0407869c-5a7d-44fa-9caf-16b27a7d3356"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90YWJsZTpmY2QzOWZkNjUxN2I0MDBiYjc2ZjI2ZmFmZGRjMmIzNC90YWJsZXJhbmdlOmZjZDM5ZmQ2NTE3YjQwMGJiNzZmMjZmYWZkZGMyYjM0XzE3LTMtMS0xLTc0NDE_be1b6c91-f5d9-4e10-bf43-50e5adc1669b"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:GainOrLossOnSaleOfStockInSubsidiary
      contextRef="i74a1d2bd4a394b7b96915526dbf4b948_D20200731-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzE2NDkyNjc0NTY1Njk_45c558f9-55d4-4da6-a9fd-a423d135009a"
      unitRef="usd">7800000</us-gaap:GainOrLossOnSaleOfStockInSubsidiary>
    <nltx:DeferredTaxAssetsTaxCreditCarryforwardsReducedDueToSaleOfForeignEntity
      contextRef="i99c20b1ea8274dc9b108a3b0bd76f6b1_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzE2NDkyNjc0NTY1ODM_d41a19fe-7153-45cf-85d8-a3767a172428"
      unitRef="usd">51700000</nltx:DeferredTaxAssetsTaxCreditCarryforwardsReducedDueToSaleOfForeignEntity>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzE0ODA_e28da804-5337-47af-9570-452e6791d8d9"
      unitRef="usd">58100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i9532edde7a4d48b5887af8007e83465c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzE1MDE_d34195cb-39f1-46d2-8b4a-995c5afa6571"
      unitRef="usd">25500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzIxOTkwMjMyNjIyMjg_e28da804-5337-47af-9570-452e6791d8d9"
      unitRef="usd">58100000</us-gaap:OperatingLossCarryforwards>
    <nltx:OperatingLossCarryforwardsSubjectToExpiration
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzE2MzU_50fcee55-d2db-4dd7-b5b2-128a6c75d741"
      unitRef="usd">1700000</nltx:OperatingLossCarryforwardsSubjectToExpiration>
    <nltx:OperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzE2OTY_a1e9224f-13b3-4251-8306-dd69c349f0c3"
      unitRef="usd">56400000</nltx:OperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i342b1069b9d04ed099561a06485fbac8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzIxOTkwMjMyNjM1MTY_2e5eb869-1b81-4a9c-8e91-b72cfc28926d"
      unitRef="usd">1000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i263816d2f8ea45e08a1dadaf18225ac9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzIxOTkwMjMyNjM1MzU_1f8ace37-225e-49e3-90f1-afe90a2fc602"
      unitRef="usd">200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzgyNDYzMzcyMjQ0MDA_916cdf4a-8d39-40d8-8084-6f1bfd828bd9"
      unitRef="usd">-42900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="id1ec05f7f83e48299dded0ae7b6e5cf1_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNTcvZnJhZzphNTBhODFjNmJhNWM0YzZkYTlmODIxNTI3ODE2NjRkMS90ZXh0cmVnaW9uOmE1MGE4MWM2YmE1YzRjNmRhOWY4MjE1Mjc4MTY2NGQxXzgyNDYzMzcyMjQ0MzA_17033ce6-d7e0-40a4-badd-29981ae49c14"
      unitRef="usd">600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <nltx:LicenseAgreementDisclosureTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNjMvZnJhZzoyNjE1OTZjMTQ4MWY0YjAzOGVhNWU3YjNmMmIxM2FjYi90ZXh0cmVnaW9uOjI2MTU5NmMxNDgxZjRiMDM4ZWE1ZTdiM2YyYjEzYWNiXzYxMDE_942ab977-ddae-440c-a2f1-0751d6f0d996">License and patent agreements&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an exclusive license agreement with the University of Washington, or UW, under which UW (on behalf of itself and Stanford University) granted the Company an exclusive worldwide license under certain patent rights, to make, have made, use, offer to sell, sell, offer to lease or lease, import, export or otherwise offer to dispose of licensed products in all fields of use, and a nonexclusive worldwide license to use certain know-how. The foregoing licenses are sublicensable by the Company without UW&#x2019;s consent, subject to certain limited conditions. The Exclusive License Agreement was amended effective as of July 24, 2020 to, among other things, (i) add a jointly owned de novo cytokine antagonist to the agreement, (ii) specify royalties, milestone payments and sublicense consideration payments payable by Neoleukin for certain jointly licensed products, (iii) specify the term for achievement of performance milestones for certainly jointly licensed products, and (iv) terminate UW&#x2019;s right to participate in equity financings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As consideration for the licensed rights, the Company issued 536,813 shares of common stock to UW. These shares were exchanged for 188,974 shares of common stock of the Company and 4,197 shares of non-voting convertible preferred stock on the completion of the Merger. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furthermore, the Company is required to pay; (i)&#160;an annual maintenance fee starting in January 2022 (but excluding any year in which minimum annual royalties are paid); (ii) up to $0.9 million in combined development and regulatory milestone payments with respect to each distinct class of licensed product; (iii)&#160;up to $10.0 million in combined commercial milestone payments based on cumulative net sales of licensed products within each distinct class of licensed products, beginning when cumulative net sales of the class of licensed products equals or exceeds $100.0 million, with the majority payable when cumulative net sales of the class of licensed products equals or exceeds $1.0 billion; (iv)&#160;a low single-digit royalty on net sales of licensed products sold by the Company and its sublicensees, which may be subject to reductions, and subject to minimum annual royalty payments following the first commercial sale of a licensed product; (v)&#160;a certain percentage of any sublicense consideration (other than royalties) the Company receives from sublicensees, based on the stage of development at the time the sublicense is executed; and (vi)&#160;a certain percentage of consideration the Company receives from an acquisition of the Company or its assets based on the stage of development at the relevant time. The Company is obligated to pay royalties on a country-by-country basis until the expiration of the last valid claim within the licensed patent rights in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement will expire upon the expiration of the last valid claim within the licensed patent rights. The Company may terminate the agreement upon prior written notice to UW. UW may terminate the agreement by a specified number of days&#x2019; notice if the Company permanently ceases operations, becomes insolvent or similar, or if the Company challenges the validity of the licensed patent rights. In addition, UW may terminate the agreement for material breach that is not cured within a specified number of days, which cure period is to be at least doubled if the Company is proceeding diligently to cure the default.&lt;/span&gt;&lt;/div&gt;</nltx:LicenseAgreementDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="i40d4ac81f67244daa74169c591a76a81_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNjMvZnJhZzoyNjE1OTZjMTQ4MWY0YjAzOGVhNWU3YjNmMmIxM2FjYi90ZXh0cmVnaW9uOjI2MTU5NmMxNDgxZjRiMDM4ZWE1ZTdiM2YyYjEzYWNiXzY3Nw_734267a5-3b6a-49f8-b1d9-6166ba971529"
      unitRef="shares">536813</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="i0e261bc82ccb41c588ae441128cc8612_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNjMvZnJhZzoyNjE1OTZjMTQ4MWY0YjAzOGVhNWU3YjNmMmIxM2FjYi90ZXh0cmVnaW9uOjI2MTU5NmMxNDgxZjRiMDM4ZWE1ZTdiM2YyYjEzYWNiXzc0Mg_aa2170e8-16c3-4ef1-a080-8764de51a2f0"
      unitRef="shares">188974</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="i6db8900a02d94ac0b3d9b45c02322b98_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNjMvZnJhZzoyNjE1OTZjMTQ4MWY0YjAzOGVhNWU3YjNmMmIxM2FjYi90ZXh0cmVnaW9uOjI2MTU5NmMxNDgxZjRiMDM4ZWE1ZTdiM2YyYjEzYWNiXzc4Nw_6b136ac4-b471-409e-99c5-79d0b3f98f23"
      unitRef="shares">4197</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <nltx:LicenseArrangementsAmountsPayableOnDevelopmentalMilestones
      contextRef="i2d0273c0483c4e869c87c35dd362ea8b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNjMvZnJhZzoyNjE1OTZjMTQ4MWY0YjAzOGVhNWU3YjNmMmIxM2FjYi90ZXh0cmVnaW9uOjI2MTU5NmMxNDgxZjRiMDM4ZWE1ZTdiM2YyYjEzYWNiXzEyMzI_6bf4a9d3-e2fc-4349-8c7a-86814e34b0fb"
      unitRef="usd">900000</nltx:LicenseArrangementsAmountsPayableOnDevelopmentalMilestones>
    <nltx:LicenseArrangementsAmountsPayableBasedOnNetSales
      contextRef="i2d0273c0483c4e869c87c35dd362ea8b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNjMvZnJhZzoyNjE1OTZjMTQ4MWY0YjAzOGVhNWU3YjNmMmIxM2FjYi90ZXh0cmVnaW9uOjI2MTU5NmMxNDgxZjRiMDM4ZWE1ZTdiM2YyYjEzYWNiXzEzNjI_6de808eb-45eb-4025-a016-c07e5517813f"
      unitRef="usd">10000000.0</nltx:LicenseArrangementsAmountsPayableBasedOnNetSales>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b9bb655d75545a397e6154c4fb4f637_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNjMvZnJhZzoyNjE1OTZjMTQ4MWY0YjAzOGVhNWU3YjNmMmIxM2FjYi90ZXh0cmVnaW9uOjI2MTU5NmMxNDgxZjRiMDM4ZWE1ZTdiM2YyYjEzYWNiXzE1OTU_4597734c-1d96-460b-9c3d-40b42b436e6a"
      unitRef="usd">100000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i73035a213d0243978324cca10be3c694_D20200101-20201231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNjMvZnJhZzoyNjE1OTZjMTQ4MWY0YjAzOGVhNWU3YjNmMmIxM2FjYi90ZXh0cmVnaW9uOjI2MTU5NmMxNDgxZjRiMDM4ZWE1ZTdiM2YyYjEzYWNiXzE3MDM_8c2a6b0f-31d1-4ce6-ac8e-46f9e930fc7f"
      unitRef="usd">1000000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNjkvZnJhZzo0ZDNiYjQ5OGVlMTQ0MDI1YmIwMDAyOTljOWFmMGQ2MC90ZXh0cmVnaW9uOjRkM2JiNDk4ZWUxNDQwMjViYjAwMDI5OWM5YWYwZDYwXzYxNA_30402614-a126-4b92-81b1-39430f911612">Commitments and contingencies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company entered into a non-cancelable contract to purchase laboratory equipment for  $0.8 million. The equipment is expected to be delivered in the first half of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, the Company may be subject from time to time to various proceedings, lawsuits, disputes, or claims. Although the Company cannot predict with assurance the outcome of any litigation, it does not believe there are currently any such actions that, if resolved unfavorable, would have a material impact on the Company&#x2019;s financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PurchaseObligation
      contextRef="i2e2fcca578804ccebdb1444503987c24_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNjkvZnJhZzo0ZDNiYjQ5OGVlMTQ0MDI1YmIwMDAyOTljOWFmMGQ2MC90ZXh0cmVnaW9uOjRkM2JiNDk4ZWUxNDQwMjViYjAwMDI5OWM5YWYwZDYwXzEzNQ_b116c23a-bca4-47c1-930c-1c2d278b1c98"
      unitRef="usd">800000</us-gaap:PurchaseObligation>
    <us-gaap:DefinedContributionPlanTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNzk3L2ZyYWc6MzlkYWEwYTQzNDFkNDVjNmJiNzIzY2U4YTNmNTZlMzkvdGV4dHJlZ2lvbjozOWRhYTBhNDM0MWQ0NWM2YmI3MjNjZThhM2Y1NmUzOV8xNjQ5MjY3NDQzNDA5_a640bc8e-b41c-4b98-b222-8a8f8028cfc9">401(k) planIn May 2020, the Company established a 401(k) plan that allows full-time employees to contribute a portion of their salary, subject to statutory limits.  The Company makes matching cash contributions up to a pre-defined annual maximum contribution per employee per year. During the year ended December 31, 2020, the Company&#x2019;s total expense for the matching contributions was immaterial.</us-gaap:DefinedContributionPlanTextBlock>
    <nltx:SubsidiarySaleOfStockTextBlock
      contextRef="i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNzc5L2ZyYWc6ZTRkMThmMmZmZDMxNGU1NTllODVkNzBiNjFhNTM1MWMvdGV4dHJlZ2lvbjplNGQxOGYyZmZkMzE0ZTU1OWU4NWQ3MGI2MWE1MzUxY18xNjQ5MjY3NDQ0MjYy_f140ad40-07e2-41c4-9941-ee96a8d91096">Sale of Aquinox Canada&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 31, 2020, the Company sold all issued and outstanding capital stock of its Canadian subsidiary, Aquinox Canada, to an unrelated third party for cash consideration of $8.2&#160;million. The Company concluded that the sale did not meet the criteria for discontinued operations reporting as it did not represent a strategic shift that had a major effect on the Company&#x2019;s operations and financial results. As of the date of sale, Aquinox Canada&#x2019;s remaining assets included intellectual property and other assets developed through past research and development activities, all of which had no book value. The transaction resulted in a net gain on sale of $7.8&#160;million, after deducting $0.4&#160;million in transaction costs, which is recorded as a reduction of operating loss in the Company&#x2019;s consolidated statement of operations. The sale of Aquinox Canada triggered a significant capital loss carryforward for tax purposes. However, the deferred tax asset related to the capital loss carryforward will be subject to a full valuation allowance as the Company has determined that it is more likely than not that the benefit of the loss will not be realized. Refer to Note 12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further information.&lt;/span&gt;</nltx:SubsidiarySaleOfStockTextBlock>
    <nltx:ProceedsFromSaleOfStockOfSubsidiary
      contextRef="i74a1d2bd4a394b7b96915526dbf4b948_D20200731-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNzc5L2ZyYWc6ZTRkMThmMmZmZDMxNGU1NTllODVkNzBiNjFhNTM1MWMvdGV4dHJlZ2lvbjplNGQxOGYyZmZkMzE0ZTU1OWU4NWQ3MGI2MWE1MzUxY184MjQ2MzM3MjEwMjEy_9552a668-99fe-43e4-961d-0ebdb852119b"
      unitRef="usd">8200000</nltx:ProceedsFromSaleOfStockOfSubsidiary>
    <us-gaap:GainOrLossOnSaleOfStockInSubsidiary
      contextRef="i74a1d2bd4a394b7b96915526dbf4b948_D20200731-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNzc5L2ZyYWc6ZTRkMThmMmZmZDMxNGU1NTllODVkNzBiNjFhNTM1MWMvdGV4dHJlZ2lvbjplNGQxOGYyZmZkMzE0ZTU1OWU4NWQ3MGI2MWE1MzUxY184MjQ2MzM3MjEwODgw_46b70793-3d67-4763-9244-bfcddcb8af95"
      unitRef="usd">7800000</us-gaap:GainOrLossOnSaleOfStockInSubsidiary>
    <nltx:TransactionRelatedCostIncurredForSaleOfSubsidiary
      contextRef="i74a1d2bd4a394b7b96915526dbf4b948_D20200731-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xNzc5L2ZyYWc6ZTRkMThmMmZmZDMxNGU1NTllODVkNzBiNjFhNTM1MWMvdGV4dHJlZ2lvbjplNGQxOGYyZmZkMzE0ZTU1OWU4NWQ3MGI2MWE1MzUxY184MjQ2MzM3MjEwODk0_0aa2818d-27e3-4dc5-8181-51437a12c661"
      unitRef="usd">400000</nltx:TransactionRelatedCostIncurredForSaleOfSubsidiary>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880719729256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 22, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Neoleukin Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0542593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">188 East Blaine Street, Suite 450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Seattle<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">WA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">98102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">245-0312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.000001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NLTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 546.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,326,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part III incorporates information by reference from the registrant&#8217;s definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A, not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, in connection with the registrant&#8217;s 2021 Annual Meeting of Stockholders (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Proxy Statement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001404644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880721760296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 192,556<span></span>
</td>
<td class="nump">$ 143,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,966<span></span>
</td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">194,522<span></span>
</td>
<td class="nump">143,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,570<span></span>
</td>
<td class="nump">2,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">10,154<span></span>
</td>
<td class="nump">770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible asset, net</a></td>
<td class="nump">347<span></span>
</td>
<td class="nump">567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">1,926<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">210,519<span></span>
</td>
<td class="nump">147,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and other liabilities</a></td>
<td class="nump">7,181<span></span>
</td>
<td class="nump">4,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">659<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liability</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,889<span></span>
</td>
<td class="nump">4,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liability</a></td>
<td class="nump">11,306<span></span>
</td>
<td class="nump">447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Non-current finance lease liability</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">19,303<span></span>
</td>
<td class="nump">5,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.000001 par value per share; 100,000,000 shares authorized at December 31, 2020 and 2019; 42,196,296 and 37,996,849 issued and outstanding at December 31, 2020 and 2019, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.000001 par value per share; 5,000,000 authorized at December&#160;31, 2020 and 2019; 0 issued and outstanding at December&#160;31, 2020 and 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">524,022<span></span>
</td>
<td class="nump">441,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(332,806)<span></span>
</td>
<td class="num">(299,529)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">191,216<span></span>
</td>
<td class="nump">141,687<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 210,519<span></span>
</td>
<td class="nump">$ 147,023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880797009016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.000001<span></span>
</td>
<td class="nump">$ 0.000001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">42,196,296<span></span>
</td>
<td class="nump">37,996,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">42,196,296<span></span>
</td>
<td class="nump">37,996,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.000001<span></span>
</td>
<td class="nump">$ 0.000001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880796522072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 24,344<span></span>
</td>
<td class="nump">$ 4,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">17,210<span></span>
</td>
<td class="nump">18,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary', window );">Gain on sale of Aquinox Canada</a></td>
<td class="num">(7,826)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating loss</a></td>
<td class="nump">33,728<span></span>
</td>
<td class="nump">70,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">451<span></span>
</td>
<td class="nump">1,517<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (33,277)<span></span>
</td>
<td class="num">$ (69,442)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common stock - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.64)<span></span>
</td>
<td class="num">$ (2.57)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted average number of common stock outstanding (in shares)</a></td>
<td class="nump">51,825,022<span></span>
</td>
<td class="nump">27,030,355<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOrLossOnSaleOfStockInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880719283192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (33,277)<span></span>
</td>
<td class="num">$ (69,442)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">5,622<span></span>
</td>
<td class="nump">7,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research&#160;&amp; development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">785<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use asset</a></td>
<td class="nump">1,036<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_WriteOffOfRightOfUseAssetUponLeaseTermination', window );">Write-off of right-of-use asset upon lease termination</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign exchange loss and others</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other current assets and non-current assets</a></td>
<td class="num">(2,481)<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">3,018<span></span>
</td>
<td class="num">(2,007)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="num">(169)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">598<span></span>
</td>
<td class="num">(237)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(24,575)<span></span>
</td>
<td class="num">(15,394)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AcquisitionOfAssetsNetCashAcquired', window );">Acquisition of Neoleukin Therapeutics, Inc., net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(2,219)<span></span>
</td>
<td class="num">(879)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(2,219)<span></span>
</td>
<td class="num">(688)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering of common stock and pre-funded warrants, net of commissions of $4,575 and $5,173 in 2020 and 2019, respectively.</a></td>
<td class="nump">71,675<span></span>
</td>
<td class="nump">81,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs</a></td>
<td class="num">(355)<span></span>
</td>
<td class="num">(352)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">5,665<span></span>
</td>
<td class="nump">1,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment on finance lease obligations</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">77,135<span></span>
</td>
<td class="nump">82,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents, and restricted cash during the year</a></td>
<td class="nump">50,341<span></span>
</td>
<td class="nump">66,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of year</a></td>
<td class="nump">143,093<span></span>
</td>
<td class="nump">76,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of year</a></td>
<td class="nump">193,434<span></span>
</td>
<td class="nump">143,093<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_OtherCurrentAssetsAcquiredThroughTheIssuanceOfCommonStock', window );">Other current assets acquired through the issuance of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock', window );">Property, equipment and intangibles acquired through the issuance of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Accounts payable, finance lease and other liabilities assumed through the issuance of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,673)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liabilities arising from obtaining right-of-use asset</a></td>
<td class="nump">10,364<span></span>
</td>
<td class="nump">1,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment unpaid at period end</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AcquisitionOfAssetsNetCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition of assets net cash acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AcquisitionOfAssetsNetCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease right of use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_OtherCurrentAssetsAcquiredThroughTheIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivables prepayments and deposits acquired through the issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_OtherCurrentAssetsAcquiredThroughTheIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property equipment and intangibles acquired through the issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_WriteOffOfRightOfUseAssetUponLeaseTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write-off of ROU asset upon lease termination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_WriteOffOfRightOfUseAssetUponLeaseTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880719790072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Non-Voting Convertible Preferred&#160;Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Non-Voting Convertible Preferred&#160;Stock</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,537,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 72,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 302,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (230,087)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Issuance of common stock and convertible preferred stock for Former Neoleukin common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,000<span></span>
</td>
<td class="nump">4,589,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Issuance of common stock and convertible preferred stock for Former Neoleukin common stock</a></td>
<td class="nump">15,055<span></span>
</td>
<td class="nump">$ 33,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,055<span></span>
</td>
<td class="nump">$ 33,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102,000)<span></span>
</td>
<td class="nump">10,192,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of discounts, commissions and offering expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,263,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of discounts, commissions and offering expenses</a></td>
<td class="nump">80,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock to University of Washington (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock to University of Washington</a></td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants', window );">Conversion of common stock to pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,925,481)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">1,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(69,442)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,442)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,996,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">141,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(299,529)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of discounts, commissions and offering expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,262,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of discounts, commissions and offering expenses</a></td>
<td class="nump">$ 71,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="nump">882,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">882,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">$ 5,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="nump">18,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">$ 199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(33,277)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,277)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,196,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 191,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 524,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (332,806)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock decrease during period conversion of common stock to&#160;pre-funded&#160;warrants shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880718738040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_CommissionsOnPublicOffering', window );">Commissions on public offering</a></td>
<td class="nump">$ 4,575<span></span>
</td>
<td class="nump">$ 5,173<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_CommissionsOnPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission fee on public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_CommissionsOnPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880718685304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Discounts, commissions and offering expenses</a></td>
<td class="nump">$ 4,930<span></span>
</td>
<td class="nump">$ 5,525<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880714348616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of operations</a></td>
<td class="text">Nature of operations<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neoleukin Therapeutics, Inc. (&#8220;Neoleukin&#8221; or &#8220;the Company&#8221;) is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> protein design technology. Neoleukin uses sophisticated computational methods to design&#160;proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.&#160;The Company&#8217;s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880713256856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of presentation and summary of significant accounting policies</a></td>
<td class="text">Basis of presentation and summary of significant accounting policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a) Basis of presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements are presented in United States (&#8220;U.S.&#8221;) dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The financial results are presented on a consolidated basis. All intercompany transactions are eliminated on consolidation. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company sold all of the issued and outstanding capital stock of Aquinox Pharmaceuticals (Canada) (&#8220;Aquinox Canada&#8221;) to an unrelated third party, as further described in Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale of Aquinox Canada</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On December 31, 2020, Neoleukin Corporation, the Company's wholly owned subsidiary, was merged into the Company. As a result, the Company consists of a single operating company without any subsidiaries at December 31, 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b) Use of estimates and assumptions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant areas requiring estimates include valuation and recognition of stock-based compensation, the incremental borrowing rate utilized in the measurement of operating and finance lease liabilities, amortization and depreciation of property, plant and equipment and intangible assets, and pre-clinical, clinical, and other accruals. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c) Reclassification</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reclassified amounts related to prior year amortization of operating lease right-of-use assets, loss on disposal of property and equipment, changes in operating lease liabilities, and payment of offering costs in the consolidated statements of cash flows to conform to current year presentation. This reclassification had no effect on cash used in operating activities or cash provided by financing activities. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d) Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company determines if the contract is or contains a lease. Lease liabilities are recognized on the lease commencement date based on the estimated present value of lease payments over the lease term. To determine the present value of the lease payments, the Company utilizes its estimated incremental borrowing rate based on information available at the lease commencement date as the interest rate implicit in the lease is typically not readily determinable. The related right-of-use assets are recorded net of any lease incentives received. Variable lease cost primarily includes building operating expenses as charged to the Company by its landlords.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We include options to extend the lease in our lease liability and right-of-use asset when it is reasonably certain that we will exercise that option. None of our options to extend the rental term of any existing leases were considered reasonably certain as of December 31, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For leases of office space, the Company has elected to not separate the lease components from the non-lease components.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For leases of office space with a lease term of 12 months or less and which do not include an option to purchase the underlying asset, the Company has elected to recognize the lease payments in the statement of operations on a straight-line basis over the lease term.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(e) Cash, cash equivalents, and restricted cash</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly liquid investments with maturities of three months or less at the date of acquisition are considered to be cash equivalents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash, included in Other non-current assets in the consolidated balance sheets, includes cash deposits the Company maintains with its bank as collateral for the irrevocable letters of credits related to its lease obligations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,556&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,093&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,434&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,093&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(f) Property and equipment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost and are amortized using the straight-line basis over a range of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzE2NDkyNjc0OTYxNDk_956254c7-b20d-4861-9cc1-c72b39fa063a">three</span> to seven years. Expenditures for improvements to the Company&#8217;s office spaces are capitalized and expenditures for maintenance and repairs are expensed as incurred. Leasehold improvements are amortized over the lesser of useful life and term of the lease.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the carrying value of property and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition, and other economic factors. Based on management&#8217;s assessment there were no indicators of impairment of property and equipment as at December&#160;31, 2020 and 2019.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(g) Earnings (loss) per share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Common stock equivalents are included in the calculation of diluted earnings per share only in periods of net income. Such common stock equivalents are excluded in the calculation of diluted net loss per share in periods of net loss as inclusion of such amounts would be anti-dilutive. Outstanding pre-funded warrants as of December&#160;31, 2020 of 12,663,010 are considered outstanding as of their issuance date and are included in the basic and diluted net loss per share calculation because they are fully vested and exercisable at any time for a nominal cash consideration.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(h) Asset acquisitions/Intangible assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of acquisition, the Company determines if a transaction should be accounted for as a business combination or acquisition of assets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For an acquisition of assets, the cost of acquiring the asset group, including transaction costs, is allocated to the acquired assets and assumed liabilities based on their relative fair values without giving rise to goodwill. Acquired in-process research and development assets are expensed if management determines that the assets do not have an alternative future use. Other long-lived intangible assets are recorded at the acquired cost and amortized using the straight-line method over their estimated useful life. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset is tested for impairment when events or changes in circumstances indicate that the carrying value of the asset may not be recoverable.&#160;The Company recognizes an impairment loss when carrying amount is not recoverable and the estimated fair value of the intangible asset is less than its carrying value.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(i) Income taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the differences between events that have been recognized in the Company&#8217;s consolidated financial statements and the tax bases of assets and liabilities recognized at enacted tax rates. In estimating future tax consequences, Accounting Standards Codification ("ASC") 740 generally considers all expected future events other than enactments of and changes in the tax law or rates. The measurement of deferred tax assets is reduced, if necessary, by the extent of the valuation allowance. We will establish a valuation allowance for deferred tax assets if it is more likely than not that these items will expire before we are able to realize their benefits or that future deductibility is uncertain. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment tax credits relating to scientific research and experimental development are accounted for as a reduction in operating expenses. They are recorded in the period when there is reasonable assurance the credits will be realized. If investment tax credit amounts subsequently received are less or more than originally recorded, the difference is treated as a change in estimate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(j) Research and development costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred and include items such as: employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations that conduct clinical trials and preclinical studies, the cost of acquiring, developing and manufacturing clinical trial materials, facilities, and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, and other supplies and costs associated with clinical trials, preclinical activities, and regulatory operations. Restructuring costs associated with the termination of research and development programs and related employees are included in research and development costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development costs are expensed in the period incurred unless management believes a development project meets generally accepted accounting criteria for deferral and amortization. No product development expenditures have been deferred to date. The Company records costs for certain development activities based on management&#8217;s evaluation of the progress to completion of specific tasks or information provided to the Company by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(k) Accounting for stock-based compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued stock options and restricted stock units (&#8220;RSUs&#8221;). The Company measures the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The cost of such award is recognized on a straight-line basis over the requisite service period, which is generally the vesting period. The Company accounts for forfeitures as they occur. We utilize newly issued shares to satisfy option exercises.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of options using the Black-Scholes option pricing model on the grant date. This approximation uses assumptions regarding a number of inputs that requires management to make significant estimates and judgments. The expected term represents the period that the Company&#8217;s stock-based awards are expected to be outstanding. As the Company does not have sufficient historical experience for determining the expected term of the stock option awards granted, the Company has based its expected term for awards issued to employees on the simplified method, which represents the average period from vesting to the expiration of the stock option. In addition, the Company does not have sufficient trading history for the Company&#8217;s common stock, and therefore, the expected stock price volatility for the Company&#8217;s common stock was estimated by taking the average historical price volatility for industry peers. The Company has never declared or paid any cash dividends to common stockholders and does not presently plan to pay cash dividends in the foreseeable future. Consequently, the Company used an expected dividend yield of zero. The risk-free interest rate was based on the yields of treasury securities with maturities similar to the expected term of the options for each option group.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each RSU is measured using the closing price of the Company&#8217;s common stock on the date of grant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(l) Restructuring costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for restructuring costs in accordance with ASC 420,&#160;Exit or Disposal Cost Obligations. ASC 420 specifies that a liability for a cost associated with an exit or disposal activity be recognized when the liability is incurred, except for a liability where employees are required to render service until they are terminated in order to receive termination benefits and will be retained to render service beyond the minimum retention period. A liability for such one-time termination benefits shall be measured initially at the communication date based on the fair value of the liability as of the termination date and recognized ratably over the future service period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The charges that the Company expects to incur in connection with the restructuring are subject to a number of assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the restructuring plan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(m) Segment reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in one segment, the research and development of&#160;de novo&#160;protein therapeutics using sophisticated computational algorithms and methods to address unmet medical needs. Our primary areas of focus are in oncology, inflammation, and autoimmunity. The Company&#8217;s operations and its assets are held in the United States.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(n) Fair value of financial instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of certain of the Company&#8217;s financial instruments, including cash, cash equivalents, receivables, accounts payable and other liabilities, approximate their fair values because of their nature and/or short maturities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, and December&#160;31, 2019, the Company had $108.3 million and $40.0 million in money market funds, respectively. Money market funds are level one financial instruments as their pricing can be obtained from an actively traded exchange.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(o) Concentration of credit risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents. Cash and cash equivalents are invested in accordance with the Company&#8217;s investment policy. The primary objective for the Company&#8217;s investment portfolio is the preservation of capital and maintenance of liquidity and includes guidelines on the quality of financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(p) Recently issued and recently adopted accounting standards</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12 &#8220;Simplifying the Accounting for Income Taxes.&#8221; The objective of the standard is to improve areas of GAAP by removing certain exceptions permitted by ASC Topic 740-- Income Taxes and clarifying existing guidance to facilitate consistent application. ASU 2019-12 is effective for fiscal years and interim periods beginning after December&#160;15, 2020. The Company has incurred net losses since its inception and maintains a full valuation allowance on the net deferred tax assets. As such, the Company does not expect the adoption of this standard to have a material impact on the financial condition, results of operations and cash flows, or financial statement disclosures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued &#8220;ASU 2018-15, Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.&#8221; The objective of the standard is to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The Company adopted this standard on January 1, 2020 on a prospective basis. The adoption of this ASU did not have a material impact on the Company&#8217;s financial condition, results of operations, cash flows, and financial statement disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880714310392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc.<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AcquisitionOfAssetsAbstract', window );"><strong>Acquisition of Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AcquisitionOfAssetsDisclosureTextBlock', window );">Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc.</a></td>
<td class="text">Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc.<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;8, 2019, Neoleukin Therapeutics, Inc., or Former Neoleukin, and Aquinox Pharmaceuticals, Inc., or Aquinox, completed a transaction pursuant to the Agreement and Plan of Merger dated August&#160;5, 2019. Former Neoleukin became a wholly owned subsidiary of Aquinox and Aquinox subsequently changed its name to Neoleukin Therapeutics, Inc. All of the outstanding shares of common stock of the Former Neoleukin were exchanged for 4,589,771 shares of common stock of the Company and 101,927 shares of non-voting convertible preferred stock of the Company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total consideration paid was $51.6 million and consisted of (in thousands, except share amounts):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of 4,589,771 Aquinox common stock</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of 101,927 Aquinox convertible preferred stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash consideration for fractional shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,578&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Aquinox securities issued to stockholders of Former Neoleukin was based on the closing stock price on August&#160;7, 2019, the last day of trading prior to the completion of the transaction.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction was accounted for as an asset acquisition as Former Neoleukin did not meet the definition of a business as substantially all of the value was in the In-Process Research&#160;&amp; Development (&#8220;IPR&amp;D&#8221;) asset. The estimated fair value of the IPR&amp;D asset of $47.7 million was expensed as the Company determined that the asset has no alternative future use.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the assets acquired and liabilities assumed (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, prepayments and deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,673&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,578&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AcquisitionOfAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition of assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AcquisitionOfAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AcquisitionOfAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition of assets disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AcquisitionOfAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880713256856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and equipment, net</a></td>
<td class="text">Property and equipment, net<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:46.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.911%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Book Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture, fixtures, and IT equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,155&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">585&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,570&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:46.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.911%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Book Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture, fixtures, and IT equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,748&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense on property and equipment totaled $0.6 million and $0.2 million for the years ended December&#160;31, 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880714338664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible asset, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible asset, net</a></td>
<td class="text">Intangible asset, net<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes intangible asset (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(312)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net intangible asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">347&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">567&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Merger as discussed in Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an assembled workforce was acquired. In an asset acquisition, an assembled workforce meets the asset recognition criteria and is separately recognized as an intangible asset and amortized over its expected life. The amortization period has been established as 3 years based on management's judgement. The Company will recognize $0.2 million and $0.1 million of amortization expense in fiscal years 2021 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880714365480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts payable and other liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accounts payable and other liabilities</a></td>
<td class="text">Accounts payable and other liabilities<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and preclinical expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and vacation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,181&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,125&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880803807960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into lease arrangements for its facilities as well as certain equipment, classified either as operating or finance leases.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a lease agreement for approximately 33,300 square feet of office space in Seattle, Washington for the Company&#8217;s principal executive offices, a laboratory for research and development and related uses (the "Blaine lease"). In January 2020, the Company issued an irrevocable letter of credit in the amount of $0.5 million for the security deposit in accordance with the terms of the lease. The lease commenced on January 15, 2020 and rent obligations were scheduled to commence on December 1, 2020. The Company will also be responsible for the payment of additional rent to cover the Company&#8217;s share of the annual operating and tax expenses and utilities costs for the building. The lease was originally scheduled to expire on December 1, 2028, with the option to extend the lease for two five-year terms.  The lease provides for a tenant improvement allowance of $8.0 million, which is included in the base rent, and an optional additional tenant improvement allowance with a maximum amount of $1.5 million, which will result, if elected, in additional rent expense recognized over the term of the lease. In September 2020, the Company elected to utilize this additional tenant improvement allowance. This resulted in a remeasurement of the lease liability due to an increase in lease payments over the term of the lease. The Company recorded an increase to the lease liability and related right-of-use asset of $1.0 million.  In November 2020, the Company executed an amendment to this lease that extends the scheduled rent commencement date to February 1, 2021 and the base term expiration to February 1, 2029. This amendment was accounted for as a modification to the lease and resulted in an immaterial reduction of the lease liability and related right-of-use asset.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31,2020, there was a tenant improvement allowance receivable of $0.9 million recorded in other current assets on the consolidated balance sheets related to reimbursable build-out costs incurred by the Company.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a lease agreement&#160;for approximately 6,272 square feet of office space in Seattle, Washington, for the Company&#8217;s former principal executive offices, a laboratory for research and development and related uses. In June 2020, the Company executed an amendment to this lease pursuant to which the Company has the option to terminate the lease, without penalty, at any point subsequent to November 1, 2020 with 45 days advance written notice. At December 31, 2020, the Company determined that it is reasonably certain to not exercise this termination option. On March 24, 2021, the Company executed a second amendment to this lease, pursuant to which the term of the lease is extended through September 30, 2026. This will result in an increase in fixed rental payments over the updated term. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2020, the Company terminated its lease agreement for 10,946 square feet of office space in Vancouver, Canada. The lease termination resulted in an extinguishment of the lease liability and the write-off of the related right-of-use asset. After incurring additional expenses included in the termination fee of $0.5 million, the Company recognized a loss of $0.3 million on the termination of the lease, which was recorded in general and administrative expenses in June 2020. In addition, the Company wrote-off leasehold improvements and other property and equipment associated with the lease and incurred a loss on disposal of $0.2 million in June 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, and December&#160;31, 2019, the Company&#8217;s operating lease right-of-use assets were $10.2 million and $0.8 million, respectively. As of December&#160;31, 2020, and December&#160;31, 2019, the Company's</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">finance lease right-of use-assets, included within property and equipment on the consolidated balance sheet, were $0.3 million and $0.3&#160;million, respectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,097&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term&#8212;finance leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.33 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term&#8212;operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.97 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.83 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate&#8212;finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.11%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.11%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate&#8212;operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.88%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.37%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of the present value of the operating lease payments for the Blaine lease did not include the option to extend the lease for two five year terms.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the future payments under the Company&#8217;s operating and finance lease liabilities were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Lease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,572)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(659)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current lease liabilities&#8212;December&#160;31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,306&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into lease arrangements for its facilities as well as certain equipment, classified either as operating or finance leases.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a lease agreement for approximately 33,300 square feet of office space in Seattle, Washington for the Company&#8217;s principal executive offices, a laboratory for research and development and related uses (the "Blaine lease"). In January 2020, the Company issued an irrevocable letter of credit in the amount of $0.5 million for the security deposit in accordance with the terms of the lease. The lease commenced on January 15, 2020 and rent obligations were scheduled to commence on December 1, 2020. The Company will also be responsible for the payment of additional rent to cover the Company&#8217;s share of the annual operating and tax expenses and utilities costs for the building. The lease was originally scheduled to expire on December 1, 2028, with the option to extend the lease for two five-year terms.  The lease provides for a tenant improvement allowance of $8.0 million, which is included in the base rent, and an optional additional tenant improvement allowance with a maximum amount of $1.5 million, which will result, if elected, in additional rent expense recognized over the term of the lease. In September 2020, the Company elected to utilize this additional tenant improvement allowance. This resulted in a remeasurement of the lease liability due to an increase in lease payments over the term of the lease. The Company recorded an increase to the lease liability and related right-of-use asset of $1.0 million.  In November 2020, the Company executed an amendment to this lease that extends the scheduled rent commencement date to February 1, 2021 and the base term expiration to February 1, 2029. This amendment was accounted for as a modification to the lease and resulted in an immaterial reduction of the lease liability and related right-of-use asset.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31,2020, there was a tenant improvement allowance receivable of $0.9 million recorded in other current assets on the consolidated balance sheets related to reimbursable build-out costs incurred by the Company.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a lease agreement&#160;for approximately 6,272 square feet of office space in Seattle, Washington, for the Company&#8217;s former principal executive offices, a laboratory for research and development and related uses. In June 2020, the Company executed an amendment to this lease pursuant to which the Company has the option to terminate the lease, without penalty, at any point subsequent to November 1, 2020 with 45 days advance written notice. At December 31, 2020, the Company determined that it is reasonably certain to not exercise this termination option. On March 24, 2021, the Company executed a second amendment to this lease, pursuant to which the term of the lease is extended through September 30, 2026. This will result in an increase in fixed rental payments over the updated term. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2020, the Company terminated its lease agreement for 10,946 square feet of office space in Vancouver, Canada. The lease termination resulted in an extinguishment of the lease liability and the write-off of the related right-of-use asset. After incurring additional expenses included in the termination fee of $0.5 million, the Company recognized a loss of $0.3 million on the termination of the lease, which was recorded in general and administrative expenses in June 2020. In addition, the Company wrote-off leasehold improvements and other property and equipment associated with the lease and incurred a loss on disposal of $0.2 million in June 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, and December&#160;31, 2019, the Company&#8217;s operating lease right-of-use assets were $10.2 million and $0.8 million, respectively. As of December&#160;31, 2020, and December&#160;31, 2019, the Company's</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">finance lease right-of use-assets, included within property and equipment on the consolidated balance sheet, were $0.3 million and $0.3&#160;million, respectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,097&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term&#8212;finance leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.33 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term&#8212;operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.97 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.83 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate&#8212;finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.11%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.11%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate&#8212;operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.88%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.37%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of the present value of the operating lease payments for the Blaine lease did not include the option to extend the lease for two five year terms.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the future payments under the Company&#8217;s operating and finance lease liabilities were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Lease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,572)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(659)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current lease liabilities&#8212;December&#160;31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,306&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880714106248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' equity</a></td>
<td class="text">Stockholders&#8217; equity<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a) Common stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue 100,000,000 shares of common stock with a par value of $0.000001 per share as of December&#160;31, 2020. As of December&#160;31, 2020, and 2019, the total number of shares of common stock issued and outstanding was 42,196,296, and 37,996,849, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, the Company completed an underwritten public offering of 3,262,471 shares of its common stock at a price of $15.25 per share and pre-funded warrants to purchase 1,737,529 shares of its common stock at a price of $15.249999 per prefunded warrant.  The pre-funded warrants can be exercised at any time after issuance for an exercise price of $0.000001 per share. The aggregate net proceeds received by the Company from the offering were $71.3&#160;million, net of underwriting discounts, commissions, and offering costs of approximately $4.9&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2019, the Company completed an underwritten public offering of 10,263,750 shares of its common stock at a price to the public of $8.40 per share. The aggregate net proceeds received by the Company from the offering, net of underwriting discounts, commissions, and offering costs of approximately $5.5&#160;million, were $80.7&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b) Preferred stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue 5,000,000 shares of preferred stock with a par value of $0.000001 per share. As of December&#160;31, 2020 and December&#160;31, 2019, 0 shares of preferred stock were issued or outstanding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c) Merger with Former Neoleukin</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;8, 2019, the Company issued 4,589,771 shares of common stock and 101,927 shares of non-voting convertible preferred stock as consideration in the Merger among Aquinox, Former Neoleukin and Apollo Merger Inc. (see Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Each share of non-voting convertible preferred stock was convertible into 100 shares of common stock and was entitled to receive dividends, on an as-is converted to common stock basis, when dividends are paid to common stockholders. The holders of preferred stock were only entitled to vote when it impacts the rights of the preferred stockholder.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;12, 2019, the Company&#8217;s stockholders approved the conversion of 101,927 shares of non-voting convertible preferred stock into 10,192,700 shares of the Company&#8217;s common stock. As of December&#160;31, 2020, the Company did not have any outstanding non-voting convertible preferred stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d) December 2019 pre-funded common stock warrants</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;17, 2019, Neoleukin entered into an exchange agreement (the &#8220;Exchange Agreement&#8221;) with certain stockholders, pursuant to which the Company exchanged an aggregate of 10,925,481 shares of common stock held by the stockholders&#160;for&#160;pre-funded&#160;warrants&#160;(the &#8220;Exchange Warrants&#8221;) to purchase an aggregate of 10,925,481 shares of common stock (subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting common stock), with an exercise price of $0.000001 per share. The Exchange Warrants may be exercised at any time after the date of issuance, except that the Exchange Warrants cannot be exercised by the stockholders if, after giving effect thereto, the stockholders would beneficially own more than 9.99% of the outstanding common stock, subject to certain exceptions. The holders of the Exchange Warrants will not have the right to vote on any matter except to the extent required by Delaware law.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Exchange Warrants meet the conditions for equity classification, the proceeds previously received for the shares of common stock will remain in additional paid-in capital. Upon the exercise of the warrants the proceeds received along with the exercise price will be recorded in common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(e) Stock option plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2014, the Company&#8217;s stockholders approved the 2014 Equity Incentive Plan (&#8220;2014 Plan&#8221;) which became effective in March 2014. The 2014 Plan is the successor to and continuation of the Joint Canadian Stock Option Plan (the &#8220;2006 Plan&#8221;). No further grants will be made under the 2006 Plan. The 2014 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards, and other forms of equity awards to employees, directors, and consultants.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the maximum number of shares of common stock that may be issued under the 2014 Plan was 9,786,363. The number of shares of common stock reserved for issuance under the 2014 Plan will be increased by the number of shares subject to stock options granted under the 2006 Plan that would have otherwise returned to the 2006 Plan, such as upon the expiration or termination of a stock award prior to vesting. As of December&#160;31, 2020, there were  23,958  shares subject to stock options granted under the 2006 Plan. Additionally, the number of shares of common stock reserved for issuance under the 2014 Plan will automatically increase on January&#160;1 of each year for a period of up to 10 years, beginning on January&#160;1, 2015 and ending on and including January&#160;1, 2024, by 4.00% of the total number of shares of capital stock </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outstanding on December&#160;31 of the preceding calendar year, or a lesser number of shares determined by the board of directors. On November&#160;12, 2019, the Company&#8217;s stockholders approved the increase in the number of shares reserved from issuance under the 2014 Plan by 4,500,000 shares. All awards granted pursuant to the 2014 Plan have a contractual term of ten years. All awards granted to date are equity classified and subject to service based vesting, typically over a period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMzMvZnJhZzo3ZWJjZjEwY2I1ZTQ0MjY1YTFlZjdlMDYyMTAwY2NlYi90ZXh0cmVnaW9uOjdlYmNmMTBjYjVlNDQyNjVhMWVmN2UwNjIxMDBjY2ViXzE2NDkyNjc0OTM5ODM_38a5a479-ddde-4ba0-9188-8ce886f75bc3">one</span> to four years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares available to be granted under the 2014 Plan was 6,037,532 and 6,556,534 as of December&#160;31, 2020 and 2019 respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stock options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company's stock option activity and related information for the year ended December&#160;31, 2020 is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:34.039%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life<br/>(In Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value   <br/>(In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,840,538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,037&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,404,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(882,624)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.42</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(515,925)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.69</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,846,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878,082&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.02&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,547&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, 882,624 shares of common stock were issued upon exercise of options with an aggregate intrinsic value of $6.0 million. During the year ended December&#160;31, 2019, 326,094 shares of common stock were issued upon exercise of options with an aggregate intrinsic value of $1.3 million. The weighted-average grant date fair value of options granted during the years ended December&#160;31, 2020 and December&#160;31, 2019 was $8.70 and $2.17 per share, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted is estimated using the Black-Scholes option pricing model with the following weighted average assumptions:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:65.311%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.311%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected terms (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.02</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.07</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Restricted stock units</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company's restricted stock unit activity and related information for the year ended December&#160;31, 2020 is as follows: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:57.320%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.168%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.843%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.169%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.26</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.47</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.47</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(f) Stock-based compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is classified in the consolidated statements of operations as follows (in thousands):</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:56.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.758%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.761%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,622&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,683&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized compensation for all stock-based compensation was $24.9 million as of December&#160;31, 2020, which is expected to be recognized over a weighted-average period of 3.15 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(g) Employee stock purchase plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2020 Employee Stock Purchase Plan (&#8220;2020 ESPP&#8221;) was adopted by the Company&#8217;s Board of Directors in March 2020 and approved by the Company&#8217;s stockholders in May 2020. A total of 759,936 shares of common stock have been reserved for issuance under the 2020 ESPP.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to share and dollar limits as described in the plan, the 2020 ESPP allows eligible employees to contribute, through payroll deductions, up to 15% of their earnings for the purchase of the Company&#8217;s shares of common stock at the lower of 85% of the closing price of the Company&#8217;s common stock on the first trading day of the offering period or 85% of the closing price of the Company&#8217;s common stock on the last trading day of the offering period. There are two six-month offering periods during each fiscal year, ending on May 15 and November 15. </span></div>During the year ended December&#160;31, 2020, the Company issued 18,352 shares of common stock at a price per share of $10.84 under the 2020 ESPP. Cash received from the purchases under the 2020 ESPP for the year ended December&#160;31, 2020 was $0.2 million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880802771800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">Restructuring<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the Company&#8217;s Board of Directors approved a restructuring plan to reduce operating costs and better align the Company&#8217;s workforce with the needs of its business following the June&#160;27, 2018 announcement that its Phase 3 Leadership 301 clinical trial evaluating once-daily, oral rosiptor for the treatment of IC/BPS failed to meet its primary endpoint. The Company has halted all further development activities with rosiptor. In 2018 and 2019, the Company incurred and paid aggregate restructuring charges of $7.4 million related to clinical trial closing costs, contract cancellations, closing of its office in San Bruno, California, severance payments and other employee-related costs. During the second quarter of 2019, the Company revised its original estimate of aggregate restructuring charges lower by $2.0&#160;million based upon updated information from its vendors related to a completed project. There were no amounts accrued as of December&#160;31, 2020 or December&#160;31, 2019.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;6, 2018, the Company&#8217;s Board of Directors approved an additional restructuring plan to further reduce operating costs.  The Company incurred and paid aggregate restructuring charges of $1.6&#160;million related to severance payments and other employee-related costs.  There were no amounts accrued as of December&#160;31, 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, the Company incurred and paid an immaterial amount of restructuring charges. For the year ended December&#160;31, 2019, restructuring recoveries of $1.9&#160;million were recorded in research and development expenses and restructuring costs of $0.7&#160;million were recorded in general and administrative expenses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880714419096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other income, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock', window );">Other income, net</a></td>
<td class="text">Other income, net<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income is presented for all periods (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:71.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange gains (losses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880800683672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per common stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net loss per common stock</a></td>
<td class="text">Net loss per common stock<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company excluded the following potentially dilutive shares from diluted net loss per share as the effect would have been anti-dilutive for all periods presented:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEARS ENDED </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,848,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,840,538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable under 2020 ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,057,310&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,912,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880719176152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text">Income taxes<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax recovery varies from the amounts that would be computed by applying the expected U.S. federal income tax rate (21%) as shown in the following table:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statutory federal income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposal of Aquinox Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expiration of NOLs (section 382)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax Credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax recovery</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net loss before taxes (in thousands):</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(522)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,129)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,313)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,277)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,442)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income tax assets and liabilities result from the temporary differences between the amount of assets and liabilities recognized for financial statement and income tax purposes. The significant components of the deferred income tax assets are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. net operating losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development deductions and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease Liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets:</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU Assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,893&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,815&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,893)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2020, the Company sold all issued and outstanding capital stock of its Canadian subsidiary, Aquinox Canada, to an unrelated third party for cash consideration. As of the date of sale, Aquinox Canada&#8217;s remaining assets included intellectual property and other assets developed through past research and development activities, all of which had no book value. The transaction resulted in a net gain on sale of $7.8&#160;million. The sale of Aquinox Canada triggered a significant capital loss carryforward for tax purposes. However, most of the capital loss carryforward is limited by the prior ownership change under Section 382.  The remaining unlimited portion of the capital loss carryforward will be subject to a full valuation allowance as the Company has determined that it is more likely than not that the benefit of the loss will not be realized. After the sale, Aquinox Canada's tax attributes of $51.7&#160;million including the net operating losses, scientific research and experimental development expenditures and investment tax credits are no longer reflected in the deferred tax assets and valuation allowance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020 and December&#160;31, 2019, the Company had U.S. federal net operating losses ("NOL") carryforwards for tax purposes of approximately $58.1 million and $25.5 million, respectively, which were available to reduce taxable income. Of the $58.1 million of federal NOL carryforwards, $1.7 million will expire between the years 2028 and 2037 and the remaining $56.4 million are indefinite. The Company also has U.S. federal research &amp; development tax credits of $1.0 million and $0.2 million as of December&#160;31, 2020 and December&#160;31, 2019, respectively, that begin to expire in 2039. The Company completed a formal study under IRC Section 382 through 2019  to determine the U.S. tax attributes available for use.  The U.S. attributes disclosed reflect the conclusion of that study. However, subsequent ownership changes may further affect the limitation in future years. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company maintains a full valuation allowance on its net U.S. deferred tax assets. The assessment regarding whether a valuation allowance is required considers both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. In making this assessment, significant weight is given to evidence that can be objectively verified. In its evaluation, the Company considered its cumulative losses and its forecasted losses in the near-term as significant negative evidence. Therefore, the Company determined that the negative evidence outweighed the positive evidence and a full valuation allowance on its assets will be maintained. The Company will continue to assess the realizability of its assets going forward and will adjust the valuation allowance as needed. The valuation allowance decreased by $42.9&#160;million for the year ended December&#160;31, 2020. The decrease is primarily due to the sale of Aquinox Canada and the write-off of the related tax attributes, and partially offset by an increase in US net operating losses and research and development tax credits. The valuation allowance increased by $0.6&#160;million for the year ended December&#160;31, 2019. The increase is primarily related to an increase in deferred tax assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies judgment in the determination of the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. As of December&#160;31, 2020, the Company had no uncertain tax positions.</span></div>The Company currently files income tax returns in the United States, the jurisdictions in which the Company believes that it is subject to tax. Further, while the statute of limitations in each jurisdiction where an income tax return has been filed generally limits the examination period, as a result of loss carryforwards, the limitation period for examination generally does not expire until several years after the loss carryforwards are utilized. Other than routine audits by tax authorities for tax credits and tax refunds that the Company has claimed, the Company is not aware of any other material income tax examination currently in progress by any taxing jurisdiction.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880714266776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and patent agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_LicenseAgreementAbstract', window );"><strong>License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_LicenseAgreementDisclosureTextBlock', window );">License and patent agreements</a></td>
<td class="text">License and patent agreements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an exclusive license agreement with the University of Washington, or UW, under which UW (on behalf of itself and Stanford University) granted the Company an exclusive worldwide license under certain patent rights, to make, have made, use, offer to sell, sell, offer to lease or lease, import, export or otherwise offer to dispose of licensed products in all fields of use, and a nonexclusive worldwide license to use certain know-how. The foregoing licenses are sublicensable by the Company without UW&#8217;s consent, subject to certain limited conditions. The Exclusive License Agreement was amended effective as of July 24, 2020 to, among other things, (i) add a jointly owned de novo cytokine antagonist to the agreement, (ii) specify royalties, milestone payments and sublicense consideration payments payable by Neoleukin for certain jointly licensed products, (iii) specify the term for achievement of performance milestones for certainly jointly licensed products, and (iv) terminate UW&#8217;s right to participate in equity financings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the licensed rights, the Company issued 536,813 shares of common stock to UW. These shares were exchanged for 188,974 shares of common stock of the Company and 4,197 shares of non-voting convertible preferred stock on the completion of the Merger. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the Company is required to pay; (i)&#160;an annual maintenance fee starting in January 2022 (but excluding any year in which minimum annual royalties are paid); (ii) up to $0.9 million in combined development and regulatory milestone payments with respect to each distinct class of licensed product; (iii)&#160;up to $10.0 million in combined commercial milestone payments based on cumulative net sales of licensed products within each distinct class of licensed products, beginning when cumulative net sales of the class of licensed products equals or exceeds $100.0 million, with the majority payable when cumulative net sales of the class of licensed products equals or exceeds $1.0 billion; (iv)&#160;a low single-digit royalty on net sales of licensed products sold by the Company and its sublicensees, which may be subject to reductions, and subject to minimum annual royalty payments following the first commercial sale of a licensed product; (v)&#160;a certain percentage of any sublicense consideration (other than royalties) the Company receives from sublicensees, based on the stage of development at the time the sublicense is executed; and (vi)&#160;a certain percentage of consideration the Company receives from an acquisition of the Company or its assets based on the stage of development at the relevant time. The Company is obligated to pay royalties on a country-by-country basis until the expiration of the last valid claim within the licensed patent rights in such country.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the expiration of the last valid claim within the licensed patent rights. The Company may terminate the agreement upon prior written notice to UW. UW may terminate the agreement by a specified number of days&#8217; notice if the Company permanently ceases operations, becomes insolvent or similar, or if the Company challenges the validity of the licensed patent rights. In addition, UW may terminate the agreement for material breach that is not cured within a specified number of days, which cure period is to be at least doubled if the Company is proceeding diligently to cure the default.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_LicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_LicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_LicenseAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_LicenseAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880719213416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and contingencies</a></td>
<td class="text">Commitments and contingencies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company entered into a non-cancelable contract to purchase laboratory equipment for  $0.8 million. The equipment is expected to be delivered in the first half of 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may be subject from time to time to various proceedings, lawsuits, disputes, or claims. Although the Company cannot predict with assurance the outcome of any litigation, it does not believe there are currently any such actions that, if resolved unfavorable, would have a material impact on the Company&#8217;s financial condition, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880714329736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">401(k) plan</a></td>
<td class="text">401(k) planIn May 2020, the Company established a 401(k) plan that allows full-time employees to contribute a portion of their salary, subject to statutory limits.  The Company makes matching cash contributions up to a pre-defined annual maximum contribution per employee per year. During the year ended December 31, 2020, the Company&#8217;s total expense for the matching contributions was immaterial.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235116<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880718608088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Aquinox Canada<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_SubsidiarySaleOfStockAbstract', window );"><strong>Subsidiary Sale Of Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_SubsidiarySaleOfStockTextBlock', window );">Sale of Aquinox Canada</a></td>
<td class="text">Sale of Aquinox Canada<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2020, the Company sold all issued and outstanding capital stock of its Canadian subsidiary, Aquinox Canada, to an unrelated third party for cash consideration of $8.2&#160;million. The Company concluded that the sale did not meet the criteria for discontinued operations reporting as it did not represent a strategic shift that had a major effect on the Company&#8217;s operations and financial results. As of the date of sale, Aquinox Canada&#8217;s remaining assets included intellectual property and other assets developed through past research and development activities, all of which had no book value. The transaction resulted in a net gain on sale of $7.8&#160;million, after deducting $0.4&#160;million in transaction costs, which is recorded as a reduction of operating loss in the Company&#8217;s consolidated statement of operations. The sale of Aquinox Canada triggered a significant capital loss carryforward for tax purposes. However, the deferred tax asset related to the capital loss carryforward will be subject to a full valuation allowance as the Company has determined that it is more likely than not that the benefit of the loss will not be realized. Refer to Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further information.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_SubsidiarySaleOfStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Sale Of Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_SubsidiarySaleOfStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_SubsidiarySaleOfStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Sale of Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_SubsidiarySaleOfStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880798964504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text">Basis of presentationThe accompanying consolidated financial statements are presented in United States (&#8220;U.S.&#8221;) dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The financial results are presented on a consolidated basis. All intercompany transactions are eliminated on consolidation. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company sold all of the issued and outstanding capital stock of Aquinox Pharmaceuticals (Canada) (&#8220;Aquinox Canada&#8221;) to an unrelated third party, as further described in Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale of Aquinox Canada</span>. On December 31, 2020, Neoleukin Corporation, the Company's wholly owned subsidiary, was merged into the Company. As a result, the Company consists of a single operating company without any subsidiaries at December 31, 2020.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates and assumptions</a></td>
<td class="text">Use of estimates and assumptionsThe preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant areas requiring estimates include valuation and recognition of stock-based compensation, the incremental borrowing rate utilized in the measurement of operating and finance lease liabilities, amortization and depreciation of property, plant and equipment and intangible assets, and pre-clinical, clinical, and other accruals. Actual results could differ from those estimates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text">ReclassificationThe Company reclassified amounts related to prior year amortization of operating lease right-of-use assets, loss on disposal of property and equipment, changes in operating lease liabilities, and payment of offering costs in the consolidated statements of cash flows to conform to current year presentation. This reclassification had no effect on cash used in operating activities or cash provided by financing activities.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company determines if the contract is or contains a lease. Lease liabilities are recognized on the lease commencement date based on the estimated present value of lease payments over the lease term. To determine the present value of the lease payments, the Company utilizes its estimated incremental borrowing rate based on information available at the lease commencement date as the interest rate implicit in the lease is typically not readily determinable. The related right-of-use assets are recorded net of any lease incentives received. Variable lease cost primarily includes building operating expenses as charged to the Company by its landlords.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We include options to extend the lease in our lease liability and right-of-use asset when it is reasonably certain that we will exercise that option. None of our options to extend the rental term of any existing leases were considered reasonably certain as of December 31, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For leases of office space, the Company has elected to not separate the lease components from the non-lease components.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For leases of office space with a lease term of 12 months or less and which do not include an option to purchase the underlying asset, the Company has elected to recognize the lease payments in the statement of operations on a straight-line basis over the lease term.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, cash equivalents, and restricted cash</a></td>
<td class="text">Cash, cash equivalents, and restricted cash<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly liquid investments with maturities of three months or less at the date of acquisition are considered to be cash equivalents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash, included in Other non-current assets in the consolidated balance sheets, includes cash deposits the Company maintains with its bank as collateral for the irrevocable letters of credits related to its lease obligations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text">Property and equipment<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost and are amortized using the straight-line basis over a range of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmI1MzAxNGM0ZjEzODQ0MDM5ZWJjNWE2ODY0M2YzMWEyL3NlYzpiNTMwMTRjNGYxMzg0NDAzOWViYzVhNjg2NDNmMzFhMl8xMDkvZnJhZzo4MWY5ZTBiODBmNDQ0MDc0YmVhNmI2ZjRhZjgxMWY1MS90ZXh0cmVnaW9uOjgxZjllMGI4MGY0NDQwNzRiZWE2YjZmNGFmODExZjUxXzE2NDkyNjc0OTYxNDk_956254c7-b20d-4861-9cc1-c72b39fa063a">three</span> to seven years. Expenditures for improvements to the Company&#8217;s office spaces are capitalized and expenditures for maintenance and repairs are expensed as incurred. Leasehold improvements are amortized over the lesser of useful life and term of the lease.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the carrying value of property and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition. In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of assets. The factors considered by management in performing this assessment include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition, and other economic factors. Based on management&#8217;s assessment there were no indicators of impairment of property and equipment as at December&#160;31, 2020 and 2019.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (loss) per share</a></td>
<td class="text">Earnings (loss) per shareBasic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Common stock equivalents are included in the calculation of diluted earnings per share only in periods of net income. Such common stock equivalents are excluded in the calculation of diluted net loss per share in periods of net loss as inclusion of such amounts would be anti-dilutive. Outstanding pre-funded warrants as of December&#160;31, 2020 of 12,663,010 are considered outstanding as of their issuance date and are included in the basic and diluted net loss per share calculation because they are fully vested and exercisable at any time for a nominal cash consideration.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AssetAcquisitionsintangibleAssetsPolicyTextBlock', window );">Asset acquisitions/Intangible assets</a></td>
<td class="text">Asset acquisitions/Intangible assets<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of acquisition, the Company determines if a transaction should be accounted for as a business combination or acquisition of assets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For an acquisition of assets, the cost of acquiring the asset group, including transaction costs, is allocated to the acquired assets and assumed liabilities based on their relative fair values without giving rise to goodwill. Acquired in-process research and development assets are expensed if management determines that the assets do not have an alternative future use. Other long-lived intangible assets are recorded at the acquired cost and amortized using the straight-line method over their estimated useful life. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset is tested for impairment when events or changes in circumstances indicate that the carrying value of the asset may not be recoverable.&#160;The Company recognizes an impairment loss when carrying amount is not recoverable and the estimated fair value of the intangible asset is less than its carrying value.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text">Income taxes<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the differences between events that have been recognized in the Company&#8217;s consolidated financial statements and the tax bases of assets and liabilities recognized at enacted tax rates. In estimating future tax consequences, Accounting Standards Codification ("ASC") 740 generally considers all expected future events other than enactments of and changes in the tax law or rates. The measurement of deferred tax assets is reduced, if necessary, by the extent of the valuation allowance. We will establish a valuation allowance for deferred tax assets if it is more likely than not that these items will expire before we are able to realize their benefits or that future deductibility is uncertain. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment tax credits relating to scientific research and experimental development are accounted for as a reduction in operating expenses. They are recorded in the period when there is reasonable assurance the credits will be realized. If investment tax credit amounts subsequently received are less or more than originally recorded, the difference is treated as a change in estimate.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
<td class="text">Research and development costs<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are charged to expense as incurred and include items such as: employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations that conduct clinical trials and preclinical studies, the cost of acquiring, developing and manufacturing clinical trial materials, facilities, and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, and other supplies and costs associated with clinical trials, preclinical activities, and regulatory operations. Restructuring costs associated with the termination of research and development programs and related employees are included in research and development costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development costs are expensed in the period incurred unless management believes a development project meets generally accepted accounting criteria for deferral and amortization. No product development expenditures have been deferred to date. The Company records costs for certain development activities based on management&#8217;s evaluation of the progress to completion of specific tasks or information provided to the Company by vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued expense.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Accounting for stock-based compensation</a></td>
<td class="text">Accounting for stock-based compensation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued stock options and restricted stock units (&#8220;RSUs&#8221;). The Company measures the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The cost of such award is recognized on a straight-line basis over the requisite service period, which is generally the vesting period. The Company accounts for forfeitures as they occur. We utilize newly issued shares to satisfy option exercises.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of options using the Black-Scholes option pricing model on the grant date. This approximation uses assumptions regarding a number of inputs that requires management to make significant estimates and judgments. The expected term represents the period that the Company&#8217;s stock-based awards are expected to be outstanding. As the Company does not have sufficient historical experience for determining the expected term of the stock option awards granted, the Company has based its expected term for awards issued to employees on the simplified method, which represents the average period from vesting to the expiration of the stock option. In addition, the Company does not have sufficient trading history for the Company&#8217;s common stock, and therefore, the expected stock price volatility for the Company&#8217;s common stock was estimated by taking the average historical price volatility for industry peers. The Company has never declared or paid any cash dividends to common stockholders and does not presently plan to pay cash dividends in the foreseeable future. Consequently, the Company used an expected dividend yield of zero. The risk-free interest rate was based on the yields of treasury securities with maturities similar to the expected term of the options for each option group.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each RSU is measured using the closing price of the Company&#8217;s common stock on the date of grant.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy', window );">Restructuring costs</a></td>
<td class="text">Restructuring costs<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for restructuring costs in accordance with ASC 420,&#160;Exit or Disposal Cost Obligations. ASC 420 specifies that a liability for a cost associated with an exit or disposal activity be recognized when the liability is incurred, except for a liability where employees are required to render service until they are terminated in order to receive termination benefits and will be retained to render service beyond the minimum retention period. A liability for such one-time termination benefits shall be measured initially at the communication date based on the fair value of the liability as of the termination date and recognized ratably over the future service period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The charges that the Company expects to incur in connection with the restructuring are subject to a number of assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the restructuring plan.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment reporting</a></td>
<td class="text">Segment reportingThe Company operates in one segment, the research and development of&#160;de novo&#160;protein therapeutics using sophisticated computational algorithms and methods to address unmet medical needs. Our primary areas of focus are in oncology, inflammation, and autoimmunity. The Company&#8217;s operations and its assets are held in the United States.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments</a></td>
<td class="text">Fair value of financial instrumentsThe carrying amounts of certain of the Company&#8217;s financial instruments, including cash, cash equivalents, receivables, accounts payable and other liabilities, approximate their fair values because of their nature and/or short maturities.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risk</a></td>
<td class="text">Concentration of credit riskFinancial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents. Cash and cash equivalents are invested in accordance with the Company&#8217;s investment policy. The primary objective for the Company&#8217;s investment portfolio is the preservation of capital and maintenance of liquidity and includes guidelines on the quality of financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued and recently adopted accounting standards</a></td>
<td class="text">Recently issued and recently adopted accounting standards<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12 &#8220;Simplifying the Accounting for Income Taxes.&#8221; The objective of the standard is to improve areas of GAAP by removing certain exceptions permitted by ASC Topic 740-- Income Taxes and clarifying existing guidance to facilitate consistent application. ASU 2019-12 is effective for fiscal years and interim periods beginning after December&#160;15, 2020. The Company has incurred net losses since its inception and maintains a full valuation allowance on the net deferred tax assets. As such, the Company does not expect the adoption of this standard to have a material impact on the financial condition, results of operations and cash flows, or financial statement disclosures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued &#8220;ASU 2018-15, Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.&#8221; The objective of the standard is to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The Company adopted this standard on January 1, 2020 on a prospective basis. The adoption of this ASU did not have a material impact on the Company&#8217;s financial condition, results of operations, cash flows, and financial statement disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AssetAcquisitionsintangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset acquisitions/Intangible assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AssetAcquisitionsintangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880718481096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and summary of significant accounting policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,556&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,093&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,434&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,093&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Restrictions on Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:56.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,556&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,093&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,434&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,093&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880714383256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AcquisitionOfAssetsAbstract', window );"><strong>Acquisition of Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock', window );">Schedule of Total Consideration Paid</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total consideration paid was $51.6 million and consisted of (in thousands, except share amounts):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of 4,589,771 Aquinox common stock</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of 101,927 Aquinox convertible preferred stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash consideration for fractional shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,578&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Summary of the Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the assets acquired and liabilities assumed (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, prepayments and deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,673&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,578&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AcquisitionOfAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition of assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AcquisitionOfAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition of assets consideration of transaction fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880714431976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:46.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.911%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Book Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture, fixtures, and IT equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,155&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">585&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,570&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:46.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.911%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Book Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture, fixtures, and IT equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,748&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880714336056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible asset, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Asset</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes intangible asset (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(312)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net intangible asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">347&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">567&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880714431976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts payable and other liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Other Liabilities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and preclinical expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and vacation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,181&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,125&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880715954872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of right-of-use asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,097&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock', window );">Supplemental Balance Sheet Information Related to Leases</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term&#8212;finance leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.33 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term&#8212;operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.97 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.83 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate&#8212;finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.11%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.11%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate&#8212;operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.88%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.37%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Supplemental Cash flow Information Related to Leases</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Company's Operating Lease Liability</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the future payments under the Company&#8217;s operating and finance lease liabilities were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Lease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,572)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(659)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current lease liabilities&#8212;December&#160;31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,306&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Company's Finance Lease Liability</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the future payments under the Company&#8217;s operating and finance lease liabilities were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance Lease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,572)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(659)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current lease liabilities&#8212;December&#160;31, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,306&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental balance sheet information related to leases for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880796737080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company's stock option activity and related information for the year ended December&#160;31, 2020 is as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:34.039%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Life<br/>(In Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value   <br/>(In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,840,538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,037&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,404,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(882,624)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.42</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(515,925)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.69</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,846,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878,082&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.02&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,547&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted Average Assumptions</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted is estimated using the Black-Scholes option pricing model with the following weighted average assumptions:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:65.311%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.311%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected terms (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.02</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.07</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of RSU Activity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company's restricted stock unit activity and related information for the year ended December&#160;31, 2020 is as follows: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:57.320%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.168%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.843%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.169%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.26</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.47</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.47</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is classified in the consolidated statements of operations as follows (in thousands):</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:56.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.758%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.761%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,622&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,683&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880714423224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other income, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Other Income, Net</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income is presented for all periods (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:71.880%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange gains (losses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880718761176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per common stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Securities Excluded From Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company excluded the following potentially dilutive shares from diluted net loss per share as the effect would have been anti-dilutive for all periods presented:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEARS ENDED </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,848,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,840,538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable under 2020 ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,057,310&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,912,538&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880718929160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Income Tax Recovery</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax recovery varies from the amounts that would be computed by applying the expected U.S. federal income tax rate (21%) as shown in the following table:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statutory federal income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disposal of Aquinox Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expiration of NOLs (section 382)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax Credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax recovery</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Net (Loss) Income Before Taxes</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net loss before taxes (in thousands):</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(522)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,129)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,313)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,277)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,442)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Deferred Income Tax Assets</a></td>
<td class="text">The significant components of the deferred income tax assets are as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. net operating losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development deductions and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease Liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets:</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU Assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,893&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,815&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,893)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880796557064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and summary of significant accounting policies - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding pre-funded warrants (in shares) | shares</a></td>
<td class="nump">12,663,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds | $</a></td>
<td class="nump">$ 108.3<span></span>
</td>
<td class="nump">$ 40.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember', window );">Office | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extended line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880715893368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of presentation and summary of significant accounting policies - Cash and cash equivalents and restricted cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 192,556<span></span>
</td>
<td class="nump">$ 143,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">878<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash</a></td>
<td class="nump">$ 193,434<span></span>
</td>
<td class="nump">$ 143,093<span></span>
</td>
<td class="nump">$ 76,928<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880796776792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 08, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition Of Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 47,716<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition Of Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">$ 47,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition Of Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock issued for acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,589,771<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nltx_NonVotingConvertiblePreferredStockMember', window );">Non-voting convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition Of Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock issued for acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AcquisitionOfAssetsAxis=nltx_AquinoxMember', window );">Aquinox | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition Of Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock issued for acquisition (in shares)</a></td>
<td class="nump">4,589,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AcquisitionOfAssetsAxis=nltx_AquinoxMember', window );">Aquinox | Non-voting convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition Of Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock issued for acquisition (in shares)</a></td>
<td class="nump">101,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nltx_NonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nltx_NonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AcquisitionOfAssetsAxis=nltx_AquinoxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AcquisitionOfAssetsAxis=nltx_AquinoxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880796872520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. - Schedule of Total Consideration Paid (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 08, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition Of Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AcquisitionsOfAssetsCashConsiderationForFractionalShares', window );">Cash consideration for fractional shares</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AcquisitionsOfAssetsTransactionCosts', window );">Transaction costs</a></td>
<td class="nump">3,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AcquisitionsOfAssetsConsiderationTransferred', window );">Total consideration</a></td>
<td class="nump">51,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock | Aquinox</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition Of Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AcquisitionsOfAssetsFairValueOfSharesIssued', window );">Fair value</a></td>
<td class="nump">$ 33,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nltx_NonVotingConvertiblePreferredStockMember', window );">Non-Voting Convertible Preferred&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition Of Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock issued for acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nltx_NonVotingConvertiblePreferredStockMember', window );">Non-Voting Convertible Preferred&#160;Stock | Aquinox</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition Of Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock issued for acquisition (in shares)</a></td>
<td class="nump">101,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition Of Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock issued for acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,589,771<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock | Aquinox</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition Of Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AcquisitionsOfAssetsFairValueOfSharesIssued', window );">Fair value</a></td>
<td class="nump">$ 15,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock issued for acquisition (in shares)</a></td>
<td class="nump">4,589,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AcquisitionsOfAssetsCashConsiderationForFractionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisitions of assets cash consideration for fractional shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AcquisitionsOfAssetsCashConsiderationForFractionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AcquisitionsOfAssetsConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisitions of assets consideration transferred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AcquisitionsOfAssetsConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AcquisitionsOfAssetsFairValueOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisitions of assets fair value of shares issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AcquisitionsOfAssetsFairValueOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AcquisitionsOfAssetsTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisitions of assets transaction costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AcquisitionsOfAssetsTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AcquisitionOfAssetsAxis=nltx_AquinoxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AcquisitionOfAssetsAxis=nltx_AquinoxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nltx_NonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nltx_NonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880797010008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. - Summary of the Assets Acquired and Liabilities Assumed (Details) - Aquinox<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Aug. 08, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract', window );"><strong>Assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits', window );">Receivables, prepayments and deposits</a></td>
<td class="nump">560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment', window );">Property and equipment</a></td>
<td class="nump">1,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets', window );">In-process research and development</a></td>
<td class="nump">47,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset', window );">Intangible asset</a></td>
<td class="nump">659<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet', window );">Total assets acquired</a></td>
<td class="nump">53,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities', window );">Accounts payable and other liabilities</a></td>
<td class="nump">1,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability', window );">Financing lease liability</a></td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed', window );">Total liabilities assumed</a></td>
<td class="nump">1,673<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total consideration</a></td>
<td class="nump">$ 51,578<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition of assets recognized identifiable assets acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition of assets recognized identifiable assets acquired and liabilities assumed net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition of assets recognized identifiable assets acquired assets net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition of assets recognized identifiable assets acquired, cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition of assets recognized identifiable assets acquired, in process research and development asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition of assets recognized identifiable assets acquired, receivables, property and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition of assets recognized identifiable assets acquired, receivables, prepayments and deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition of assets recognized identifiable assets acquired, Intangible asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition of assets recognized identifiable liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition of assets recognized identifiable liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition of assets recognized identifiable liabilities assumed, accounts payable and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisition of assets recognized identifiable liabilities assumed, financing lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AcquisitionOfAssetsAxis=nltx_AquinoxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AcquisitionOfAssetsAxis=nltx_AquinoxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880719616712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and equipment, net - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 4,155<span></span>
</td>
<td class="nump">$ 2,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Amortization</a></td>
<td class="nump">585<span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">3,570<span></span>
</td>
<td class="nump">2,060<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nltx_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">3,402<span></span>
</td>
<td class="nump">1,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Amortization</a></td>
<td class="nump">426<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">2,976<span></span>
</td>
<td class="nump">1,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nltx_FurnitureFixturesAndITEquipmentMember', window );">Furniture, fixtures, and IT equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">753<span></span>
</td>
<td class="nump">743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Amortization</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">$ 594<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nltx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nltx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nltx_FurnitureFixturesAndITEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nltx_FurnitureFixturesAndITEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880719219608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880796522056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible asset, net - Summary of Intangible Asset (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 659<span></span>
</td>
<td class="nump">$ 659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(312)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net intangible asset</a></td>
<td class="nump">$ 347<span></span>
</td>
<td class="nump">$ 567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected amortization expense 2021</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected amortization expense 2022</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880712999560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts payable and other liabilities - Schedule of Accounts Payable and Other Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade accounts payable</a></td>
<td class="nump">$ 1,323<span></span>
</td>
<td class="nump">$ 1,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AccruedClinicalExpensesCurrent', window );">Accrued clinical and preclinical expenses</a></td>
<td class="nump">1,687<span></span>
</td>
<td class="nump">944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and vacation</a></td>
<td class="nump">3,244<span></span>
</td>
<td class="nump">1,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">927<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and other liabilities</a></td>
<td class="nump">$ 7,181<span></span>
</td>
<td class="nump">$ 4,125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AccruedClinicalExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical studies, which covers fees paid to CROs, investigative sites in connection with clinical studies and contract manufacturers in connection with the production of clinical study materials; and fees paid to vendors in connection with the preclinical development activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AccruedClinicalExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880719514056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>option</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_TenantImprovementAllowance', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AdditionalTenantImprovements', window );">Additional tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_TenantImprovementAllowanceReceivable', window );">Tenant improvement allowance receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_TerminationFeesForLeaseTermination', window );">Termination fees for lease termination</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Loss on termination of lease</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,154<span></span>
</td>
<td class="nump">770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_WA', window );">Washington</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_NumberOfOptionToExtendLease', window );">Number of options to extend lease | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_LeaseAgreementExtendedPeriod', window );">Lease agreement extended period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_WA', window );">Washington | Office space, principal executive offices and laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Lease agreement, square feet of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_NumberOfOptionToExtendLease', window );">Number of options to extend lease | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_LeaseAgreementExtendedPeriod', window );">Lease agreement extended period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_OperatingLeaseRightOfUseAssetIncreaseDueToRemeasurement', window );">Operating lease, right of use asset, increase due to remeasurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_OperatingLeaseLiabilityIncreaseDueToRemeasurement', window );">Operating lease, liability, increase due to remeasurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_WA', window );">Washington | Office space, former principal executive offices and laboratory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Lease agreement, square feet of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_NumberOfDaysAdvanceNoticeMustBeGivenToTerminateTheLease', window );">Number of days advance notice must be given to terminate the lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Lease agreement, square feet of office space | ft&#178;</a></td>
<td class="nump">10,946<span></span>
</td>
<td class="nump">10,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AdditionalTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Tenant Improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AdditionalTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_LeaseAgreementExtendedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease agreement extended period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_LeaseAgreementExtendedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_NumberOfDaysAdvanceNoticeMustBeGivenToTerminateTheLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Days Advance Notice Must Be Given To Terminate The Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_NumberOfDaysAdvanceNoticeMustBeGivenToTerminateTheLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_NumberOfOptionToExtendLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of option to extend lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_NumberOfOptionToExtendLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_OperatingLeaseLiabilityIncreaseDueToRemeasurement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Liability, Increase Due to Remeasurement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_OperatingLeaseLiabilityIncreaseDueToRemeasurement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_OperatingLeaseRightOfUseAssetIncreaseDueToRemeasurement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right of Use Asset, Increase Due to Remeasurement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_OperatingLeaseRightOfUseAssetIncreaseDueToRemeasurement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_TenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tenant improvement allowance pursuant to lease arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_TenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_TenantImprovementAllowanceReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Element represents the carrying amount as of balance sheet date of amounts receivable related to tenant improvement allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_TenantImprovementAllowanceReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_TerminationFeesForLeaseTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of termination fees related to lease termination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_TerminationFeesForLeaseTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121604053&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=nltx_OfficeSpaceFormerPrincipalExecutiveOfficesAndLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=nltx_OfficeSpaceFormerPrincipalExecutiveOfficesAndLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880797136216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Finance lease cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use asset</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">2,368<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short term lease cost</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">321<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total net lease cost</a></td>
<td class="nump">$ 3,097<span></span>
</td>
<td class="nump">$ 502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term&#8212;finance leases</a></td>
<td class="text">2 years 5 months 12 days<span></span>
</td>
<td class="text">3 years 3 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term&#8212;operating leases</a></td>
<td class="text">7 years 11 months 19 days<span></span>
</td>
<td class="text">1 year 9 months 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate&#8212;finance leases</a></td>
<td class="nump">7.11%<span></span>
</td>
<td class="nump">7.11%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate&#8212;operating leases</a></td>
<td class="nump">12.88%<span></span>
</td>
<td class="nump">5.37%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880719770184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash flow Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 460<span></span>
</td>
<td class="nump">$ 236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_FinanceLeasePrincipalAndInterestPayments', window );">Cash paid for amounts included in the measurement of finance lease liabilities</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_FinanceLeasePrincipalAndInterestPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Principal and Interest Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_FinanceLeasePrincipalAndInterestPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880799108520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Company's Operating and Finance Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance lease liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">December 31, 2021</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">December 31, 2022</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">December&#160;31, 2023</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">December&#160;31, 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">December 31, 2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">$ (62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Non-current lease liabilities&#8212;December&#160;31, 2020</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating lease liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">December&#160;31, 2021</a></td>
<td class="nump">2,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">December&#160;31, 2022</a></td>
<td class="nump">2,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">December 31, 2023</a></td>
<td class="nump">2,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">December&#160;31, 2024</a></td>
<td class="nump">2,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">December 31, 2025</a></td>
<td class="nump">2,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">7,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">19,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(7,572)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">11,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(659)<span></span>
</td>
<td class="num">(556)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current lease liabilities&#8212;December&#160;31, 2020</a></td>
<td class="nump">$ 11,306<span></span>
</td>
<td class="nump">$ 447<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880706697432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 07, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 20, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 17, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 12, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 08, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>offering </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.000001<span></span>
</td>
<td class="nump">$ 0.000001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,196,296<span></span>
</td>
<td class="nump">37,996,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,196,296<span></span>
</td>
<td class="nump">37,996,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock | $</a></td>
<td class="nump">$ 71,300<span></span>
</td>
<td class="nump">$ 80,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,675<span></span>
</td>
<td class="nump">$ 81,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Public offering costs | $</a></td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 355<span></span>
</td>
<td class="nump">$ 352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.000001<span></span>
</td>
<td class="nump">$ 0.000001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_StockConversionRatio', window );">Stock conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants', window );">Conversion of common stock to pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,925,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_PercentageOfOutstandingStockPerStockholderMaximum', window );">Maximum percentage of outstanding stock per stockholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,846,289<span></span>
</td>
<td class="nump">5,840,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">882,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Common stock issued upon exercise of options aggregate intrinsic value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options granted (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.70<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation cost (in dollars per share) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation cost, weighted-average period recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nltx_StockIncentivePlanTwoThousandFourteenMember', window );">2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of shares of common stock that may be issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,786,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_PeriodSharesReservedForIssuanceWillIncrease', window );">Years of increase in shares of common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_StockBasedCompensationIncreaseInCommonStockIssuancePercentage', window );">Shares of common stock reserved for issuance percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available to be granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,037,532<span></span>
</td>
<td class="nump">6,556,534<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nltx_EquityIncentivePlanTwoThousandSixMember', window );">Equity Incentive Plan 2006</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nltx_NonVotingConvertiblePreferredStockMember', window );">Non-voting convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock issued for acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_ConvertiblePreferredStockToBeConverted', window );">Shares to be converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nltx_PreFundedCommonStockWarrantsMember', window );">Pre funded common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock in prefunded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,925,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.000001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of shares under public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,262,471<span></span>
</td>
<td class="nump">10,263,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock issued for acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,589,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock, Shares issued upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,192,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants', window );">Conversion of common stock to pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,925,481)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">882,624<span></span>
</td>
<td class="nump">326,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AcquisitionOfAssetsAxis=nltx_AquinoxMember', window );">Aquinox | Non-voting convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock issued for acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_AcquisitionOfAssetsAxis=nltx_AquinoxMember', window );">Aquinox | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock issued for acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,589,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=nltx_PreFundedWarrantsMember', window );">Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock in prefunded warrants (in shares)</a></td>
<td class="nump">1,737,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_PreFundedWarrantIssuedPricePerShare', window );">Pre funded warrant issued (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.249999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.000001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Shares issuable under 2020 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of shares under public offering (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Shares issuable under 2020 ESPP | 2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">ESPP common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">759,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">ESPP max contribution rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">ESPP purchase price of common stock, percent of market price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear', window );">ESPP number of offerings per year | offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod', window );">ESPP offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nltx_PublicStockOfferingMember', window );">Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of shares under public offering (in shares)</a></td>
<td class="nump">3,262,471<span></span>
</td>
<td class="nump">10,263,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Sale of shares under public offering (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.25<span></span>
</td>
<td class="nump">$ 8.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_ConvertiblePreferredStockToBeConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_ConvertiblePreferredStockToBeConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>employee stock purchase plan number of offering per year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_PercentageOfOutstandingStockPerStockholderMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Outstanding Stock Per Stockholder, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_PercentageOfOutstandingStockPerStockholderMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_PeriodSharesReservedForIssuanceWillIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The time period over which the number of shares reserved for issuance under the stock based compensation plan will increase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_PeriodSharesReservedForIssuanceWillIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_PreFundedWarrantIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price per pre-funded warrant sold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_PreFundedWarrantIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_StockBasedCompensationIncreaseInCommonStockIssuancePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage increase in the number of authorized common shares for grant under the stock based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_StockBasedCompensationIncreaseInCommonStockIssuancePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_StockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock conversion ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_StockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock decrease during period conversion of common stock to&#160;pre-funded&#160;warrants shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nltx_StockIncentivePlanTwoThousandFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nltx_StockIncentivePlanTwoThousandFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nltx_EquityIncentivePlanTwoThousandSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nltx_EquityIncentivePlanTwoThousandSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nltx_NonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nltx_NonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nltx_PreFundedCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nltx_PreFundedCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_AcquisitionOfAssetsAxis=nltx_AquinoxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_AcquisitionOfAssetsAxis=nltx_AquinoxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=nltx_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=nltx_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nltx_A2020EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nltx_A2020EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nltx_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nltx_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880796778216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Schedule of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Option Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at beginning of period (in shares)</a></td>
<td class="nump">5,840,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">2,404,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(882,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options cancelled/forfeited (in shares)</a></td>
<td class="num">(515,925)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at end of period (in shares)</a></td>
<td class="nump">6,846,289<span></span>
</td>
<td class="nump">5,840,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Stock Options Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 5.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">11.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share)</a></td>
<td class="nump">6.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options cancelled/forfeited (in dollars per share)</a></td>
<td class="nump">15.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at end of period (in dollars per share)</a></td>
<td class="nump">$ 6.42<span></span>
</td>
<td class="nump">$ 5.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Option Activity, Additional Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted average remaining contractual life (in years)</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding at beginning of period, Aggregate intrinsic value (in dollars)</a></td>
<td class="nump">$ 45,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding at end of period, Aggregate intrinsic value (in dollars)</a></td>
<td class="nump">$ 53,127<span></span>
</td>
<td class="nump">$ 45,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, Number of options (in shares)</a></td>
<td class="nump">1,878,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 5.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted average remaining contractual life (in years)</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, Aggregate intrinsic value (in dollars)</a></td>
<td class="nump">$ 17,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880715759128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Schedule of Weighted Average Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">93.00%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected terms (years)</a></td>
<td class="text">6 years 7 days<span></span>
</td>
<td class="text">6 years 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="nump">0.42%<span></span>
</td>
<td class="nump">1.43%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880721752456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Schedule of RSU Activity (Details) - Restricted stock units<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>RSU Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested beginning balance (in shares) | shares</a></td>
<td class="nump">72,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted (in shares) | shares</a></td>
<td class="nump">152,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock units vested (in shares) | shares</a></td>
<td class="num">(36,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock units forfeited (in shares) | shares</a></td>
<td class="num">(1,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested ending balance (in shares) | shares</a></td>
<td class="nump">186,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>RSU Activity Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units granted (in dollars per share) | $ / shares</a></td>
<td class="nump">9.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Restricted stock units vested (in dollars per share) | $ / shares</a></td>
<td class="nump">3.47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Restricted stock units forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">3.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880719880488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' equity - Summary of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 5,622<span></span>
</td>
<td class="nump">$ 7,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,999<span></span>
</td>
<td class="nump">486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,623<span></span>
</td>
<td class="nump">$ 7,197<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880796584808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 06, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=nltx_RestructuringPlan1July2018Member', window );">Restructuring Plan, July 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring and related cost, cost incurred to date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Revised estimates during the year</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=nltx_RestructuringPlan1November62018Member', window );">Restructuring Plan, November 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring and related cost, cost incurred to date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAccrualAdjustment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAccrualAdjustment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=nltx_RestructuringPlan1July2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=nltx_RestructuringPlan1July2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=nltx_RestructuringPlan1November62018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=nltx_RestructuringPlan1November62018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880715961928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other income, net - Schedule of Other Income Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="nump">$ 490<span></span>
</td>
<td class="nump">$ 1,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses)</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expenses</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">$ 451<span></span>
</td>
<td class="nump">$ 1,517<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880796865864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net loss per common stock - Schedule of Securities Excluded From Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">7,057,310<span></span>
</td>
<td class="nump">5,912,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">6,848,289<span></span>
</td>
<td class="nump">5,840,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">186,500<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Shares issuable under 2020 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">22,521<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880799092952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income tax Recovery (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal income tax rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">14.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness', window );">Disposal of Aquinox Canada</a></td>
<td class="num">(5.20%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">26.50%<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent', window );">Expiration of NOLs (section 382)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax Credits</a></td>
<td class="num">(2.50%)<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax recovery</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Expiration Of Net Operating Losses, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880715954872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Net (Loss) Income Before Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Canada</a></td>
<td class="num">$ (522)<span></span>
</td>
<td class="num">$ (2,129)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.</a></td>
<td class="num">(32,755)<span></span>
</td>
<td class="num">(67,313)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Total</a></td>
<td class="num">$ (33,277)<span></span>
</td>
<td class="num">$ (69,442)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880719934248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Income Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Canadian net operating losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 39,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">U.S. net operating losses</a></td>
<td class="nump">12,328<span></span>
</td>
<td class="nump">5,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development deductions and credits</a></td>
<td class="nump">1,040<span></span>
</td>
<td class="nump">11,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">422<span></span>
</td>
<td class="nump">1,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_DeferredTaxAssetsLeaseLiability', window );">Lease Liability</a></td>
<td class="nump">2,513<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock Compensation</a></td>
<td class="nump">717<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets:</a></td>
<td class="nump">17,182<span></span>
</td>
<td class="nump">58,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred income tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">ROU Assets</a></td>
<td class="nump">2,132<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="nump">157<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">2,289<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_DeferredTaxAssetsBeforeValuationAllowance', window );">Net deferred income tax assets</a></td>
<td class="nump">14,893<span></span>
</td>
<td class="nump">57,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(14,893)<span></span>
</td>
<td class="num">(57,815)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_DeferredTaxAssetsBeforeValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Before Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_DeferredTaxAssetsBeforeValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880796806248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary', window );">Gain on sale of Aquinox Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,826<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses carried forward for tax purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,100<span></span>
</td>
<td class="nump">25,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_OperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carryforwards subject to expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_OperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss carryforwards not subject to expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,900)<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nltx_AcqinoxCanadaMember', window );">Acqinox Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary', window );">Gain on sale of Aquinox Canada</a></td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_DeferredTaxAssetsTaxCreditCarryforwardsReducedDueToSaleOfForeignEntity', window );">Tax attributes no longer reflected in deferred tax assets and valuation allowance</a></td>
<td class="nump">$ 51,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_DeferredTaxAssetsTaxCreditCarryforwardsReducedDueToSaleOfForeignEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Credit Carryforwards Reduced Due To Sale Of Foreign Entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_DeferredTaxAssetsTaxCreditCarryforwardsReducedDueToSaleOfForeignEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_IncomeTaxesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Taxes Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_IncomeTaxesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_OperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards not subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_OperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_OperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_OperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOrLossOnSaleOfStockInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nltx_AcqinoxCanadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nltx_AcqinoxCanadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880797036120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and patent agreements - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesByIndustryAxis=nltx_UniversityOfWashingtonMember', window );">University Of Washington</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_LicenseAndPatentAgreementsLineItems', window );"><strong>License and patent agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_LicenseArrangementsAmountsPayableOnDevelopmentalMilestones', window );">License arrangements, amounts of development milestones payment</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_LicenseArrangementsAmountsPayableBasedOnNetSales', window );">License arrangements, amounts payable based on net sales</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_LicenseAndPatentAgreementsLineItems', window );"><strong>License and patent agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for service (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock issued for acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,589,771<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndMaintenanceMember', window );">License and maintenance | University Of Washington</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_LicenseAndPatentAgreementsLineItems', window );"><strong>License and patent agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued for service (in shares)</a></td>
<td class="nump">536,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndMaintenanceMember', window );">License and maintenance | Common stock | University Of Washington</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_LicenseAndPatentAgreementsLineItems', window );"><strong>License and patent agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock issued for acquisition (in shares)</a></td>
<td class="nump">188,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndMaintenanceMember', window );">License and maintenance | Minimum | University Of Washington</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_LicenseAndPatentAgreementsLineItems', window );"><strong>License and patent agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer, excluding assessed tax</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndMaintenanceMember', window );">License and maintenance | Maximum | University Of Washington</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_LicenseAndPatentAgreementsLineItems', window );"><strong>License and patent agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer, excluding assessed tax</a></td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nltx_NonVotingConvertiblePreferredStockMember', window );">Non-voting convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_LicenseAndPatentAgreementsLineItems', window );"><strong>License and patent agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock issued for acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=nltx_NonVotingConvertiblePreferredStockMember', window );">Non-voting convertible preferred stock | License and maintenance | University Of Washington</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_LicenseAndPatentAgreementsLineItems', window );"><strong>License and patent agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock issued for acquisition (in shares)</a></td>
<td class="nump">4,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_LicenseAndPatentAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License and patent agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_LicenseAndPatentAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_LicenseArrangementsAmountsPayableBasedOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Arrangements, Amounts Payable Based On Net Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_LicenseArrangementsAmountsPayableBasedOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_LicenseArrangementsAmountsPayableOnDevelopmentalMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Arrangements, Amounts Payable On Developmental Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_LicenseArrangementsAmountsPayableOnDevelopmentalMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesByIndustryAxis=nltx_UniversityOfWashingtonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesByIndustryAxis=nltx_UniversityOfWashingtonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndMaintenanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndMaintenanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=nltx_NonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=nltx_NonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880718639592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139880796901160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Aquinox Canada (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary', window );">Gain on sale of Aquinox Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,826<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=nltx_AcqinoxCanadaMember', window );">Acqinox Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_ProceedsFromSaleOfStockOfSubsidiary', window );">Consideration from sale of assets</a></td>
<td class="nump">$ 8,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary', window );">Gain on sale of Aquinox Canada</a></td>
<td class="nump">7,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nltx_TransactionRelatedCostIncurredForSaleOfSubsidiary', window );">Transaction cost on sale of asset</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_ProceedsFromSaleOfStockOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of stock of subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_ProceedsFromSaleOfStockOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nltx_TransactionRelatedCostIncurredForSaleOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction related cost incurred for sale of subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nltx_TransactionRelatedCostIncurredForSaleOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nltx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOrLossOnSaleOfStockInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=nltx_AcqinoxCanadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=nltx_AcqinoxCanadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>82
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" #\@GE2Z]4A!+0&  !B&@  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;*59;6_;-A#^W/T*PBN&%HACB9(=ITT".':R>6U2+T[;=<,^T!(=$Y%(CZ3R
M\N]WE&3+">23@.5#K+=[^.B.?(YW.GE4^MZL.+?D*4VD.>VLK%U_Z/5,M.(I
M,X=JS27<62J=,@NG^JYGUIJS.#=*DQ[UO$$O94)VSD[R:S-]=J(RFPC)9YJ8
M+$V9?C[GB7H\[?B=S84;<;>R[D+O[&3-[OB<VZ_KF8:SWA8E%BF71BA)-%^>
M=D;^ATEPY SR)[X)_FAVCHE[E852]^YD&I]V/,>()SRR#H+!SP,?\R1Q2,#C
MWQ*TLQW3&>X>;] O\Y>'EUDPP\<J^2YBNSKM##LDYDN6)?9&/?[&RQ?J.[Q(
M)2;_3QZ+9\.P0Z+,6)66QL @%;+X94^E(W8,AMX> UH:T%<&_KX1@M(@:&L0
ME@9A[IGB57(_3)AE9R=:/1+MG@8T=Y [,[>&UQ?2Q7UN-=P58&?/QNJ!:S*#
M$),N^3J?D'=OWY.W1$AR)9($(F-.>A;&<4_WHA+SO,"D>S!]2JZ4M"M#+F3,
MXY< /2"X94DW+,\IBCCAT2$)_ -"/>K5$!KCYE=,'Q)*<W._QGR"F_^>21C=
MJQO]Q=L$6Y\'.5Z ^OSOT<)8#?/^'P0RW$*&.62XST$JRF U6G+[O.9U$</-
M?:_["6'1W[+HMV,QDC)C";GA:Z5M'1T<Q^J,(W0&6SJ#=G1F7 L5N]E(8)'4
M^J<!J9Q_/[UYTS 'CK;<CE#$<::UHW8I3 2>^L&91OGA:-VN3[N!C_ :;GD-
M6TXDS4#<<VW>'T8<:\D2@\7Q>,OI&,6YD%;89W!5PLEUEBZXKN."8WB>WPT&
M 3U"^/A>)9I>&T8W_$ZX-0SNNF9I;=P:@*ZY2GAV#W)[N^*:K7EF160.R%1&
MAQC3'7GWVS %/*4ABLP%](#,+4PSHC09JTQ:_0R_<3U]''UR@9&D%4G:AN0M
M>R+3&":?6(HH9XJ$NP'R>-CU^B'M'P<8PTJQ_: -PU$<:VX@/N4!^0S/D2^R
MWG<XI#\<D@MF+#E/F$.!>Y#$(3:9@-B$?4QE_"HO^+BROR8^=F<0^%OU*&M)
MXW!SSJQ-L$7M5\G"QU7^-;7MI)QI]2!D5.]4'//["*-6)0X?U_O7U&;*6%#I
MO\1Z_TK!$8^'OD<Q;E7B\!LR1\X,]OC[J>  P\$ (U)E"A^7]\_*9:[92DE,
MEAM :-CO>H&/NJ;*$SXN\K<"YB912^+3=XOW9,ZC3(.W:FGA2&.5IB _<ZNB
M^P.RAN3\P)*,D[?>H>?^L%1+JS1"<?6''!L+>4?FS^E")74T&P"N/]_^B3&I
MT@3%A7SC*G+Q%*V8A&I@7T)K +H>S2>C/S!.55:@K;+"=Z@)N_<2] H"R@S,
MMIA,C<GJIUL#YK7"J%7I@+9*!]]4 ND3RN5\;Z)K2Z4&))Q0)?.TE<QO=I7%
MCBV?6B"J63TQ'/$'-QBS2N5I*Y6?2LMU4>2[/2[;4*UEAB,V,*M$GK82^3QT
M9 RYYT[I6JUHP+E6LLNBB ,,@,0%(,:PDGJ**W7)<)ZR)"'GF8';ICZ6.$Y#
M/44KR:>X6I>$+E*N[]SL^A40[ H24;IFLMYW_Z]$H)7V4URQI^/+&S+*8F%A
M!S&RED/&SK>0EPF[JV6&XS4Q"RJ5#UH5"_,5"!GFJ@:81D*5V >M:H)9MDA$
M!/Y1K&X93DJ4?H[B^H</9_T0M@X/=8-7JAZT4O67"7:^8K#1(E\R"U&3+B?6
M-7E*Y,$.H9 &=. %P1Y6.QT97(8W9:_9J91@*2]<C;?D(%3UN]$&U!G3EDRG
M4R(J4 ,G1;O634X80&\&($NM4F)7'"YMZLI??AY2_^BC<:U,(44NGVNMGIZ)
MF]X\K]2M(@LP!M6)R:. Y>@@RH0N8#QP:)76G=^%R;NVZTR;C!4 4,EF24')
M#T<'1"I+X!R$T8(=[*<\$K-GP%H6USCA@ H[+7>X+'H8SZZ'$;G>5N$YNQ+F
M92>(N.4([TY<O^G -1DC)679 =Y2KWE[U[?;0%U!E>2T!P;/9\]*)3'D7O+.
MV3H+ZGTL#&:YH^9;1^4W_8_OL<HZJ%)N@"?($6#&.>X^A6D :%S058X-6O;=
M=KM)EW"Q-EDT@#4U.:O\&K1LOY6LRB[<?EXXW.4/C%654X-6.74,Q#20FLJ8
M/Y%/O%Z1<2A7!X1>. C#.F:]G::\RY?YQPT#,QZVC$5_?GMU^P%EE'\VZ%6/
M%U]?KIA+MX8D? FFWN$11% 7'S2*$ZO6>8M_H:Q5:7ZXX@R6A7L [B^5LIL3
M-\#VL]+9?U!+ P04    " #\@GE2YU09S@4%  "?$P  &    'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;)58;6_;-A#^*X0;%!M@QR3UWC@&F@3%^F%;T+3;
M9UJB;2*2Z(I4W.S7CZ05R18IV0G@6)3OCL\=C_<<N=CSZEEL*97@5Y&7XG:R
ME7+W:3X7Z9861%SS'2W5+VM>%42J8;69BUU%26:4BGR.(0SG!6'E9+DP[QZK
MY8+7,F<E?:R J(N"5*]W-.?[VPF:O+WXQC9;J5_,EXL=V= G*G_L'BLUFK=6
M,E;04C!>@HJN;R>?T:=['&@%(_$/HWMQ] RT*RO.G_7@:W8[@1H1S6DJM0FB
MOE[H/<US;4GA^-D8G;1S:L7CYS?K7XSSRID5$?2>Y_^R3&YO)_$$9'1-ZEQ^
MX_L_:..0 9CR7)C_8-_(P@E(:R%YT2@K! 4K#]_D5Q.((P7D#RC@1@%?JN U
M"IYQ](#,N/5 )%DN*KX'E996UO2#B8W15MZP4B_CDZS4KTSIR>4]+P7/648D
MS< =R4F94O"DS0DP S^>'L!O5[^#*\!*\'W+:T'*3"SF4LVL]>=I,\O=818\
M,,L#3:^!AZ8 0PP=ZO<7JZ/D5'VN_&V=QJW3V-CSAIRNJXJ6$A AE)\C!KW6
MH&<,^D,&B=@"%1J0Z@?ZLV8O)%<S.$-U,!484WJ7O2Q1@H,@7,Q?CD/B$/,]
MF'BMV E2OT7JCR+]6VYII1)K.  'D <KX0G(L _1%@K@ +Z@Q1>,XOO.)<DO
MP!<X\/D!QCV$#C'?"Y+0#3)L08:C(!\K548K^6J67*_V3A4V.04EE2ZLH07"
M"R+80VH+81A"-\ZHQ1F-+[9"220K-R"GJM2!2M>T&5_/:C4PL77!C>R8013X
M/;RV5!0-P(U;N/$HW*^E).6&K?(&W&! 8SN@?M3#9\L$8>3&E[3XD@OV3LG+
MV?G\3!SYB?O[QQ;R!D*(8%?/X04;:!A8HWZ2: @&NJZ>8'/((3^">&!_HR/"
M01<5WYR1%<N99'2L J.NIB,\ZOCG-.6U*KE@1UZ)R2&U.;E9LL&IFI!@.Y=1
MC/H!L:5\A(.!<'3,@<:IH[]'W["^.I%Z%H8PL%;.%CIFEU.<'6^@<>+XPDK3
M&UR"TN8%WP)IRX1X &/''>@]Y'%NU6UNB.+8PFE+^9$_M DZ D'C#/+741'A
M[\H FR<0\F"_LCC$?'^@_*&.3M XGQRC7K\C'UR,$O<1.X3\H:SM& 6-4\HA
M(\YE@LT5*/&..ID&H8-2/&\(8D<J*!FMAT^2I\];GF>T$A\_Q!A%-Z:GZ,?R
MM-/M^ "/\\$]+PIU7!)ZEBFX@M=0_R%5)2N@FM2: I5^0&Q)16\ @G *#Y_#
M*P%(+;>\8O^IXP&10'7BM%@IA;=FWE19W9;? !]/58\XQ4EH7GK1-%'#V$\
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M< *5 +Q?<RX?;]2/_-4?4_-_ %!+ P04    " #\@GE2Y&RA*$P"   P!0
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M;$:+BR0U53,Y;6-3[LCSJ>8Z6M\(ZCV"JX#[[$5T*BQS8N1XGLL1Y6) *7^
MLBCAVEEJ OQF%:I_ ^1,:>)5/O*Z*)]$?(-R#D>+&91%63R!=S3I/$IX1S_
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M93J7S<>1PIOD>I\E9])&H@+X'218B>]P+!%_C(N2T=5)<.S1''#D^:@QT/(
M<QWV);(A7S=PP%\>[#(\D78:"R"Z.MC'&0,USP2'3+]MI5)CYW[0MM'LI=VS
MW.L0@P^HQG&RI=UL"?!UR0KE82B@VVW)KY%+6X>U* 5M,RB-SA,PE%QOPIFR
M=CR936O8^(GS> BH:ZE<8SLU^ $Q^!_(F\Q,X@*$PJ6!6NGX&'N#6O2V84@S
MF&R.\> 3CLF9?ISGR7))UHAW=0.B8++_-#F>NY3OX!Y/G8G9))$*'.7W7%O"
MP2'?P"  JI;-F+*((VD!2B"":)8R]/1(D!5XS3P!#%HR*OI42)@#(;5L073F
M-%E>[(.4D81JG@!4<@ "$H*6!;_4A@#S!"F:H\L$0$$MG+:1>&619<(6"'%L
MPFOLP+6WR)HL)0AB,6-3W((C<J48] V6MF?[WSYW;D3XA0O2"I28&RDQ^<$@
M*.!Q;:LUZ@>F)ZE7MU&4G"1Z#Q,)0F2/ZM0W7,FP_IYE,0>;"?=./I2#=Y%T
M2(5<%U!QR29#59L4!M,!YH4Y!2(.ZYF$7TH[""T21@1Q8"O+=/$"*B[6V!GZ
M;2P64R2!;W5"&HL/$0/X1Z(ZQ2=OS('\QM!+5]@I"*S18WN",!;F@+8YLO>(
MKEG2 &>87Q@@D/)3ZHJA8BH)+G3#\(8;'V$V>#\?"D#C KESJ2WJ4$G28(;I
MZX5N[SDF4#W942FH$#PE%(*$!U?%>-/A2TFW8,^.406'#5:.6S1V)0J-U2#V
ME1C=\48Q3TI% 7XJQ(H!P?\)A68@2ZQ\63X20H#;4]3K7*=S11CT!O_T\(N$
MF<(:1=*? Q\O>+7K \@-I]\>1@[\<_D-6RUSM,^G^DI=?G,U>_7J-?UT_7)V
M\<W+?7M1;[Y^HZC O+SZ#DF66/@S0J,37LZN7UX7)[Q8GJJ/DQ#NV,>CQ*4[
M24-<&.&+""OQ31]2,7'4JV$$A!$'?QMCV0=J0(H&M/<<@S)^F$:=;+S(VMIZ
M_I62C:&3\$\J@RKKJWY#97_%Z+0F^!=SS/19NHVY:Z,EX2]$ -B8C3K'[0&G
M+/N."KK"/"@##W&2(+\\1\[#V9'X("JI)A!\;7-GHY*DM::LA8B,BI',%)OE
M70\/)&UPU )G[01G9"*EK!C;"RQ.B!%RI3S*?0SQ#$()DD$F1&6>*F-JT=@2
MVQ82Y#@60P) K/.AC):+75EUPX^@6B[3V8!LX.=#B-]*RDHA<L XL9!"AL(7
M=8CUF LDH8@N<4H+:\ ) Q/9DBPKHI[E8ED* <FV"T0 $RH"C3-$5VR$A5R\
M=E;@^U#B46!S&ULE5N?4*Q1L.K#)7OSU=R/>.E8P8Q/4(=$TG<3=0E/'S5]/
M-U5X%44?),[5J?I1^Q8"0\@BG9^2M!'PR%ZHIUDQ&&5K&+ZPE%>:JI>8#WW5
M*&SJY.#Y 7Q!OS_R)("B [D('+SMF1ZJ_6D["9W X)!(;+<5C;B4@*3S,,O]
MHV0PDB^67 056XSR[.V1;]@KRIPK9BR<Q30$+-^S;R4Q#6)P+>/L2!JS0;QC
M0[<!Y+^C%'*,*&EA/OVAHZ<T<' J+]"QYQ)2;Z7,8H_<4EA0<.GL&6^.0F*N
M?BFD31V+):$\I%*XLV9*IZ&O@,K9Z]?(')<7^Y"G5*&.&,H@"%"[E3.QU%DQ
M3^SK8,&6Q[V8XS(HI;4PE>X%I.YXQV5/]1B!NMC<C>5#JOZXI6PWABU'*_+0
M-N;/L6G!2=:GZH8C?@'QPOF'_9X/5?(,)FC;,2!\KIS796N;H$;24I7".I-(
M(&E!692".*QJ0;UO5K,?0<\BOE*)0+%ZZMM9Q#*ARZ3F=I^DMY5W_38A2?ZJ
M()/;,3,*!*A[796P'S_->YFZ[%ARD]2,.Y=EAP&&P0@2]ECDBI"=?87X0C&=
MRS^G5L[55!-2URP>9MLS1,&*A$/-!>VK=>SE/9C&I7B82^U8 =>D@"+9%)K)
M"" ^%6LD'J^04!NL;"/%DFU[ZKL(:F]<NP*^>3 3K<$#Q#02V@"?O@B=-@;"
MJ7-%!*D-B .TP ,@[V7L/>R3P7T+\8X)E)00$D75H7'WY['28$W38&F^WZ\4
MK!&FP C3E8^(  1<2,]EP%\Y7P_P:X0^NB/2&- 1@; Q+P@"]A30BP([:I<G
M$T:$1U<-(LIRE>@N0\:R>X_'MC!9S<!#=\/(09H6HQYY;9;&<R6IGXY- E*B
ME)ZQ81TM3/=H!G7R.<. L,!V,>Y&AC(:^>.C!")LD;H11R@LS@,=IM6"@/&D
MEXXVL&W4&F=^<2OZGNB >)BIF2IFT7>48[1'&KQU]="[?7%R<W=[<JJ^OKXH
MAIHIKG/0.@#+R>39@=D.F,)<W'&U,#A#8KK1C^0FD8-/AW.(*=TQL*[[BO"E
MI?Q-@8MG;Q$S<?^J2^9:S$^H@";_XWZ<],4"%=.6ZLBIA6P7DS0L8^,-@88Z
M=?>FV0G?Y%')J:FC!UV'U(/;PD1A/4O'T%2*/'(CKF-T$[L]\+<%Q+ZT$D-X
MLRCFFOCN;'0!0MEM[+&1_E,71K1>-A<X!CH5*DN=4&AZ'.=)F][&7O HZ/O)
M5.J%#&X03W1&69.[<:B.2A?<)>%(('K9O.2 TGN6/,?$R .+CX,?"ZD&L\NB
MZU3P.W0=^H48?=?L<MMW*.3 "6N.5>:\71& D95,[VPO&G#$Q_$,B$@$8LS$
M5@J5"'._TTSI2/Z4&<P7OF9D-O24HT C,NW9"&5B)H6;&)?@U/"M,IMMXW9F
MZ)4GA91 ).@FCHS;.MO9;.AJYX.X7:GTRAM3M/;R["0;D/,KW<;I5XR26$0&
MDH=V$)VE<7\<Z^6/0P>:S#$X-4L"2F-(8(V>ZD"9K8XWIYZCX5-F5"N.1F*Q
ME,S"D((U";&&4U81-F0XEL5!-N_3I)*[?D9FH:!T^IS0;[=-$G!4:PB.1J*Q
MQ[8OE]E(*,.D*W6>5@34'5VGR3W>V/[LLS FS^$P*W.4E R/XCMDTY77FQ#/
MC 84+>JPV#NZ#U,R1\4S9=L#<AR%@\+FV#L+4+DPD.4#=SGWJ/V=M+;ACN3$
MU9OBCD[E+9M&$<Q)S -,U&D:0MNRX99',<T(+3W!BR'_#UG!<3EVB,8HL0KK
M7&#'6<@HO [3S\4S;0TS9*:8TUA9#+D<=TX:DR\$("]S@.]TN.<X5\[P\FSU
M<&"%!%YS?R35%%IFZFEV+!J:JX]I"!$A$X6G@0U2\FCZ2>87!N3(O0[:ENMC
MX3-[),'<\=">9A[4+H^W4DI*9KG^]689YR933>9IX!7DRHNMI0*L?#\X/0+Y
M_6F)DXC38Q<M1EJG&4Z\$A5[,7&HMM=!EB_[EG);NOGTZ]UO87S]*\\:!!*%
M490,QC_8JAAI<BIZBFEI&8O71Z [OI>"D$J H:68(2(8:6E%S8HS[BH<XGW>
M14C*IW/*X=W';<XOCYX8J:.@-HF%H3DE8;ET9\9O)HQNSQRM'?#?TD0_E1DT
M(F8%:V&X%Z?@@(N/U'B*6I(6&D$C:#,L=VEVE^:E87S><#OGL#&;=#U4G.\;
M#9NYJ];4[TP[;V$#M&#C:M.,Y)_#"#4&J+IYLM%M>QDW#W>ED!,@>\Z+14/0
MMML^%2K/W<$JKV2.[V/]WM>KC;3]/JU-T6BG.:@W\>I!*&-W+F#WRY_28]A4
MAA20FO> =$6KBZ_'C5H]SH2A;Q!Z&M,2@%60$/(A9TN!KF; ZI+OD@K&'*09
M5>&;B3360,)]I3\+ WQU8K07NY@\&XV) %O.EU&Q@>\]\!TBZ3@D,]\39NKN
M1J%R^$N&'V,UEP^C+%#RP?6?KNNICMDQ,<)-V89$G+M<!!\6LD,;-K?T/9<Q
ML[&4A2(R<?BMH\*#"Y4_LC%?G!S:#E3*Z?O<5(OB*10_>0@23(_HLX,<C=_S
M75*F3+!JNJW$?5:O. ?P#4R>]5)ZXHF')-9,'5Q8:E]".TF>48,()W2UC>?]
M^F"CF)-(6,$8&7)Q,4>=]3;7*'M7=MAIVD&P:3^ULZ;AD/[9>!=OQMAP?[:D
MF=_XRLVCWHOR_*PD8\\Y98<87*5)_?[D'J9K(:;"_ X]*<4\DKVA9DQT*FY_
MIAE5&21Y$5(=E\Z2U\H>'=W>C->JJYQ_GK6:R%JZ1\!NC 3>G$X"Y*.YPT\L
MGKCY?7-WJZ[ICO"/3Z@U\=P/Z?;>+67&7\J9?5R;$%GJBNJBAR7M<^E:[D%W
M5KZ<D6\(1IRU2WW F'-3,5UL;$N<1+/$;1</&];("'2,\&/6B)-5+@!3EB8L
MU PC@E16Q M]GI;*M15"(Z.J(S<S^,Y,+N4)#4^>M# [%QMC%,DW/:4>ZNAP
M^HPHX&9/C(Q(7&O.>( P>3R2O9R=#<]2DU#JAMB$A6GU;6J$'=[E.P1'14,R
MP]SR]#RI*10&[^3K41D3Q>[.&!!%Q,7=@**CGJ$(^R,'*E9UO)+=QA>4<OTW
MMFQ27>@77#O1,+I #P6^B-AZ?*FV0.>IUFYV>T@52U#/)HI2.LI5! 7-.&R6
MCF)'YL=&5/?<!BM[K;0;X[?4=.))OUO.<E>,VU-CQYE-,$W1&3%A<ZKN#,.;
MXDYV2;Z4U_&>;4OZ6,G]V[CE=,'+74JP]L#E8V<DX'N]Y;<<$AX,;DO)RTI[
M@2J(7F[0DE\W*R2U;AV+;P$*K%E(D,N\OMW0&,#4G/I:NAI HT<?KRSNXC5R
MZDFXJD_5.IBH7.-6.^K_+!N]V>AAOJ[[SEFV]FZLQ1QGBQMEW'22!D,:PJPI
M#TV]X ))MZ?JIY&G#$5868)\*L<>Q2WZ5"H?B?^3FY4MKF/W>"0X40HF"T_A
M'SD[CSZD@S.^4YV1>&K.EC.V-#K-(]I6LRMCLW.*2FN869%4YS3FG'CEA,[>
M^_CRFWTL6JNO+B_>S%\B*C9-NF[_U?7%_")_ J$A-1KR1']OJ&T,"$*,\\T-
M!&;RV)\/5L2^Z ,7).:(MJ2DLCY7,*@?&,$O8B1GT*K3NY$-OW54<UDM52D,
MPYT2Z*'KN,7+)M*X)12C?II6K4#FK>,DP/$ZQ[!"0E3%%95-51X4]DZ:I3=N
MBDN_Z0[:U(VR^3.7S<39XK1\ C1,V7#1O.8WX:(+)G=VS!V/1X] Y]$&OEMB
M$\=-ZG6\(>X?BLN \CK61 M3;G"F.\;YXN,*'YJ&1[DQ\]'U)5IVU)DE+"[Y
M&9F?D%.55T,/4ECN[7&:Y]%E1)KR#H^\@W#46F!/6WZ)0]))\2Z:3Y_IVNUW
M T,>>GTHWOX:_.VGF[OW::\; %7ZYNSR2L4VS9T4=+N$6/?:1''*^8GFE^D5
M0];LH-%<O D=K#1' UOO'LP0R/E-J@5U$C>.Y_<I*@J<8YO>$M#H8KE$>/.3
MV]J*!G=G9R-2Q'"I\2^4YSO<I&@9M[C4SJ9 %YV#>Y34S:YBB[04".B66UW)
M3)<V4':B=T1">K&'QDKYLLW"K&S+I;E>XIM!^I>OTH7P@VY:Z@RG*RQ<F/!
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MPK\'LBR ^Z4Q?O/"#K;_1T[_!5!+ P04    " #\@GE2;"1UM/("  #9!@
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ML)05"#M.+0J.=5B.V??@YSLKR5#AB]$:PZT)A70Q#@N[-3$&"B<].BDB.TE
MR(5S\]3^X/84&DD!^[N6A9B^Q^QDOW(3)&?"QX9UC"U*5CB.)__L)!I.:$NH
M&76#:  I7 ?)PA SY;!'X2@*&*,:EA##FLOJZG\A^-R6W;P#OK:Z$68/\;D,
MC.%D,LY8@I2*:LHTV3 =#'Q2SP@%PH8PG&G%!RQ4SX"OV31&\R0;,3R%PEB9
MU7[\?^\M/=(V'2Y%4'""PK;&=S(W6(>?Q+K3QF_NW1_F5KBM- 0**PZ=C,_G
M";A.M;N%MTU4RHWUK+MQ6O./#EUPX/W*\NWL%R'!\.M<_0M02P,$%     @
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MM0N@\THI>S1<@6%:+W\#4$L#!!0    ( /R">5) J@,=JPD  )HQ   9
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M24.H-,K&;9A.BW+. H Y7_! I0IQRARZ6H$[: O3VK94A(,DQQ:J#.5&O0I
MXPDA]8K]<]V56):;9J%%5EIGY_9AXG:0KA7:+;-7"ML3A&)L3>%/4OE:I9;T
M])GDOY5H5*KMYV<.C)D>>'T5WE5ZK66J$5&9SZ?!:#IR)O@L:3_8<0'=--5'
MJ7N;ZRPNE.Q@\\$='93LF==9_1'SWF.<C ZG&1C9 #L*:&!Z562NHNR=(3Q&
M>$#JJL607/O&@3Q-%5N=-;$@NPY ..'"YA[^PPW24\8"P'*-&XV"Q63^1R3%
M/0T:IOO@N K_H)G0LAHD$&I6 -JUQ2BUU. 6LE=3][)7LG!3%(H(;1+NP'/!
M%2^OPK&7:JVSC,<''1I<+T[8ZY5+E\:U8+@QK?B#WMX(> JG&:/8:)+M$V,W
MER%JS7:2LLFZ5NJT$;%R25NFX =B$?>!8-E2P"2V'UR4*.<EK3\O#;D'=C2!
M_>?T(HT9?*5WP$IK9)J,/&EETF(PZ8T@X%=D>8=0M?]U2^L^!==I<+Z@L7,%
M19,B6)EHV-CN1TF"$A=W5',\JA[\7+0;%1"(TO&2 <-'&A2WS[UO0CM]SS.9
M.HY<\EZBRJ7&!W27ZFB(=9%P&@QI8CF*F*=I,)G@9S0^-2=NIL&/1K4?>W%]
M4S\D>M3[?5WV , ]T^&, :H%2C3+)8A[5D4;ZD3(T:>X"3EDB89/E#/3U.S*
M%^)]HY*/3B4_\Z,='+V!%B65>\T'34OR0R=N@+ '\R0Q">;C(30S%^=B,@A#
M,1O,\'(\(?WY,J&U?A2,A^-@!*\+P\&T66X+]HOY/ JFT?A23 ?CJ-D0DRNG
MJ4JN(?E*::)U,0DGU"Q=BG RF"X^PRKT0;/T:1#-%^"/J<^9U<DH"-'5WSH>
MV$5.&3D,YK-Y,)Q'+.PP\L*B]9V,9^)=Q</$S]DE$%[&D]5O9PK'J:E;VM:N
M5'=C;?>(*@WWESKNS NG@V$[K'P6?P1,HPC>O_A_\-<9@KN*8^==\$IZGW2E
M'D/&2NK.+/1QKDSZTI4GP^+H7)1C_AP.X=;/HT$X:[O9QP]@B-,^-\?S-R*0
M,&O+\5N5-7]O4AE_NOH8 ^=)O;Y_0!%*&[8F46G;F+CP=<\-?'36J@%J5EMW
MXXLC<K)8MP_$-H&G 8KHE$!E,1)?B<40OYK5=I1''_>6"-9+<<$ZI:B$U^/7
M3'S0Y2>D&H4*BXPSI(#Z2H2#,5'_<*RH?A+_3I3A?RT0-H#WGF9DX, -) Z]
M8Q9QJCP7HP$"_81TM=7#B=N]&$334WO]91>C*6V]?))N!_)"RMI^]Y,\$UBA
MDI\PT_,!1+A8^8;URF53>N2CLM*I\>0"*F*\IG#OIFE?@E"O8E*=2,<Q_FQY
MA,31Z2?P7=6+"SYHJA+F+"]/.BWTH+AU):LG"C%G<AYR>6Y*PMR G@PBT<RG
MXI\JPVTI;Y<)JC%-#\.Y"^Z<& %S1_@["\+%3/QHFN+P*;F!\S@6\;'I?.2/
M51D-!M89/]7IG>-*.'V",.-,U'D\=RK9!+ZQ)PQI8M'40PE_MZ]_#E"S+8A&
M Y38OAR[6%^*6]]Y>@]K!I$\OOCQ2$7*9FE.N7KFKC[U:#1!.S_>W;6C"<@F
M$P#<P>.[AOR;NEQ^5Y?+W<F%A^NF$#Y!I#_?H^/[^NF][Q!PP6RR"!:CZ<EA
M+U6T2Z6R9W1+7DZ4=YU:M7D8GL#;@4:IWE+T2FH2RKC0RS9P<FX_>[3(:RA$
M5*K7/)]O1@3NH0HESV5E%1TK3+7>B%SN"]P$ZDD5^P&(;[PF=7^$% 734^?5
M#D\:DY]X_G#J,9(; ())AYWSYA(@@^'<U@R$/_=80_A^>Z6+$F0+R45;(IN\
MT#R9K1VY^%/N X(]YSI.\(7K4>P.IM4/5UOZ'M#CC65==7 KO-(ENA+?-;8=
M+3FC;W/;)G R$,>^J7/=^<;3EAXTTO>Z2)8JL^[+3\VGS5?';MPWIMKM[GMG
M""$TW24ZUQ6.#@>SR9D;AM5OK,GY^U-+8]'N\\N-DG!RVH#UE3&V?D,7-%^H
M>_T_4$L#!!0    ( /R">5(R17<\:P0  .,*   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;)U6VW(;-PS]%8R:Z9.BU2V^I+)F++N9.I.T'KN7ATX?
MJ%U(RX9+;DBN9?U]#[B2+#N*D_I!*RX)' "' !:3E?.?0LD<Z;XR-IQURACK
MMUD6\I(K%7JN9HN3A?.5BGCURRS4GE61E"J3#?O]HZQ2VG:FD[1W[:<3UT2C
M+5]["DU5*;^>L7&KL\Z@L]VXT<LRRD8VG=1JR;<<_ZBO/=ZR'4JA*[9!.TN>
M%V>=\\';V5CDD\"?FE=A;TT2R=RY3_)R59QU^N(0&\ZC("C\W?$%&R- <./S
M!K.S,RF*^^LM^KL4.V*9J\ 7SOREBUB>=4XZ5/!"-2;>N-4OO(GGC>#ESH3T
MI%4K.X9PWH3HJHTR/*BT;?_5_8:'/863_E<4AAN%8?*[-92\O%1132?>K<B+
M--!DD4)-VG!.6[F4V^AQJJ$7IS<<HF_RV'AMEY,L E(.LGRC/FO5AU]1'PSI
MH[.Q#/2S+;AX#)#!EYU#PZU#L^&SB)><]V@TZ-*P/^P_@S?:!3A*>*/O"9"4
M+>B&C8I<T+DDA(Z: _U]/H<4,N2?9RR.=Q;'R>+XI93^#W6ZLO2^,6NP,3CI
M4BR9+EQ5*[O^\8>3X>#XIT SIWQ!;D&7VB/5G0^DZMJ[.X2H4#?[:+51EJ+#
M;M'D3"AMKZ(<Y"[$D-B9<XSL21F]M ?M296A&4!]I6.91"QS$<0%#9!Y$Q!1
M"+1P!B4OZ"+SOK%,P^-NB@26K&MLSBCOB&,5D^IUB?JB$7U =V$?2EW3J#^@
M'!3I7!F*7N/)=\HTK=L.$*\+I<VZ2\[CS+N@:W  XSZ9C>A4,5F!>U<7V>SZ
MEA90 #G@H9*V)Y9KKZ4G$=NB=MK&'OW^$#K!+?R,)(TRAA:-![1'\=^AJ=4)
M73TD4Z)EZTA/;G 3<B&+TT>W2-KFC?<"C.-::2R62\]+9.B3N\M+Y9><:'YU
MW!NC&1C3=L8VG1'.$Z)R R>VE]O%GTTY3KD";09:4)?]C=CF_MQBH7&YVM(M
MDF7F&^NZ=(%\ *56JRX%A.T% OZN)?@V<5SBA*O:N#7SZZU;R7B/+ML@)/3
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M+<OTG1 !G"^<B]L7,;";:Z?_ 5!+ P04    " #\@GE2 QN?Z6 "   J!0
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M> /Z7FFJ[F'C PQ#??$;4$L#!!0    ( /R">5(9;:1FE0D  (P8   9
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MQ\EPPG:>GX@;!,UV^XZ&Z4% M>.O>D__A"^:)-X-\N^H"T@:!XRA K1A.&:
MF-K!>>[D30\*C0>.X(,$&N,WB>($NC'\CM,DFDY(W[-IE,;IB?AJ/%R(:6D:
M)=,IKS@[C\9C+/Z@$,X0MLX*Z9R"U12T7,NYSK6G[$ T0</;)/&JJ(Q%E>E
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M<FMR$_&N=%RB.5KN8;S8,4 >VXJTUJ=-_:+IC2FE%KSB8##%A*X(X0:F'H!
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M(74^>WE94)B,=9J('[*9U5Y@C7G8XUO$(05@O?->#I-$</RZK;\"4$L#!!0
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M>:@[I8Z)W0*H6V4WB![(0LE_Q\FB(V1L:UTT@JV#@&1G"L4^/&)#%C_9) '
M8M21=1M04O-AC0 ^[Q6CQ0,3LQ?*1IH5E,(W3QK,[:%K PV+.3QF<W##7+8Q
MG5#AUDK=Z0, M.B&DF.P0>%&<-6Y(! .(FP AOL%?#M0%YRTNR$'1_7ZU5D^
M/GT?&B>6PT<>7!Z!!U?,>JKZH."U\"!Y(!$Z*=3H;U<BW;.71K>*0\0S3V>H
M=]JP.\RIB]Z>3^G]D+L1;B5956'-T&QT>I* ZP=''Y!MHUD+2VS]N&QXUJ(+
M"?R]MI9V01 8IO?B#U!+ P04    " #\@GE2_+01'3D$   P"0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970R-"YX;6RE5MMNW#80_97!UNB3L1?9B8UTO8#M
MM$@*I#'L7AZ*/G"ED<28(A62LNQ^?<^0N\HVL//0ONR2U,R9F3,7<CTZ?Q]:
MYDB/G;'A8M;&V+]9+$+9<J?"W/5L\:5VOE,16]\L0N]954FI,XMBN7R]Z)2V
ML\TZG=WXS=H-T6C+-Y["T'7*/UVQ<>/%;#7;']SJIHURL-BL>]7P'<??^AN/
MW6)"J73'-FAGR7-],;M<O;DZ%?DD\+OF,1RL22+9.G<OF_?5Q6PI#K'A,@J"
MPM\#7[,Q @0W/N\P9Y-)43Q<[]%_2K$CEJT*?.W,'[J*[<7L?$85UVHP\=:-
M[W@7SRO!*YT)Z9?&+'OR>D;E$*+K=LKPH-,V_ZO''0\'"N?+%Q2*G4*1_,Z&
MDI=O552;M7<C>9$&FBQ2J$D;SFDK2;F+'E\U].+F3ADF5]/EYT%;]TC7RJI*
MK1<1V"*Q*'<X5QFG> %G5= '9V,;Z$=;<?5O@ 6<FCPK]IY=%=]$?,OEG$Y6
MQU0LB^4W\$ZF2$\2WLE+D0[;H"N-RJ,4],>:[J(K[^G/RVV('N7QUS>LG$Y6
M3I.5T__-YW_!H8^6?A[,T\3+,<66Z=IUO;)/%)RI2!E#.H2!L;05H1%#Q$+;
MADK5ZZ@,A10WT'4,&5DKB[[<$W3\E5E8<0"CP7HV*@(YMMI7U"L?GPB3 <BA
MI=*A5ROV*O4;X(_.YP6*UACLY_3K@:<0+<U0)2054Q!!(JYT1=9%ZF0>R6GI
M=62O5;)2Z0#%J*T$A[F4+04,A][Y*!&J@)@F%)Q[#FPC*9(41VYT2:'5=<QV
M6P62T$Z? ,YUC4E!\/R TN^_.R]69S^$0VO":JVMLJ4&ES"  1#F=!DD9-&M
M8$C6$M'75$Z GF5D9I\#(P]ZSXBV$4,*O@R [[U8!LLIET#W>_F*'S!2^T2A
M=T/3(AU!8@ZL?-DFA9U,ERB0^:>CYG"<:@0.CJV&H)!@'<GDI =E!LZI E\V
MJ#P[<Y#)-_!ED9L&S@M785>G1V?S\WVJ@5\C:;!>#65*R]%R?KK_*AB'V*4+
M$2YE7[004SHO/""7"KN$D>MIEP0 &A=" GHF55*&SN@J%2IJ/W**_XL^ON<0
MP_--%KUN&O;B @7=6%WK4@%AWS[)>*F\?T)1C@J-(,49U2/U@^]=8,"_<R.X
M][D_<4NP%SR12>FCJ9%<+O,7H4>P1EN6[OPD]2F=2/6 0\E5;C6DTXVH1Q;.
M#@="JZ1.D O<'/M>0W^ Y<YY)J/O&<,$QS;UR]2+6[9<Z[@OZ.15<D2DX RN
M?Z/_YFI.MQ*:./6+0]&OBF-Z;TO7L83*(1%3#S[5K;;Y#2'#X+E)NSBXQ3KV
M3;JK)9V#C?E"FTZGY\!EO@6_B.>WQ ?E&XU6-5Q#=3D_>S4CG^_GO(FN3W?B
MUD7<L&G9XDG#7@3PO78(9[<1 ],C:?,/4$L#!!0    ( /R">5)<HAFWCQ8
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M5LK<48*A/!TCK^LQFD[&3GVZ4):)*';\[D=RCCP^S<!RHIY>O!XL@Q$WPVJ
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M$F"< 9UG6F.[< &Z3Y/Y'U!+ P04    " #\@GE2^T0HS\8#  !X"   &0
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MOZUIY*-V#O1^JY0]&B[ \!-9_ )02P,$%     @ _()Y4O![G7YP @  ,@4
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M%6ME26-^6=&GAMHYT'FAE-T:CF#X)M,_4$L#!!0    ( /R">5(K7 @4G0(
M *<%   9    >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;'U4VV[;, S]%<+8
M0PL$]2U9+D@,).V&#5BQH.VVAV$/BDW'0F7)D^2F_?M1<N*F0Y,72Y1(GL,C
MD_.=TH^F0K3P7 MI%D%E;3,+0Y-76#-SI1J4=%,J73-+IMZ&IM'("A]4BS")
MHH]AS;@,LKD_6^MLKEHKN,2U!M/6-=,O*Q1JMPCBX'!PQ[>5=0=A-F_8%N_1
M_FC6FJRPSU+P&J7A2H+&<A$LX]EJZ/R]PT^..W.T!U?)1JE'9WPM%D'D"*'
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M@^W(#4O\PX"R ;A?2&GV$]N3NG]6]@]02P,$%     @ _()Y4B2"P0L_ P
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M>M?HLG?]4/6#%X;$6L YVR1;J3^^8T. 4PA=Z9HO"0:_>3//XX>9'81\5EL
M35[RK%!S9ZOU[KWKJG@+.5,W8@<%/DF%S)G&H=RX:B>!)1:49Z[O>6,W9[QP
M%C-[;R47,U'JC!>PDD25><[DWW>0B</<H<[QQF>^V6ISPUW,=FP#:]!?=BN)
M([>)DO <"L5%022D<^>6OE_Z%F!G?.5P4)UK8DIY$N+9#!Z2N>.9C""#6)L0
M#/_VL(0L,Y$PCV]U4*?A-,#N]3'Z!UL\%O/$%"Q%]@=/]';N3!R20,K*3'\6
MAU^A+B@T\6*1*?M+#O5<SR%QJ;3(:S!FD/.B^F<OM1 = !V= ?@UP'\M(*@!
M@2VTRLR6=<\T6\RD.!!I9F,T<V&UL6BLAA=F&==:XE...+WX"'(#DHB4? *1
M0?G,"_*X!<EV4&H>J[?DH8AO""L2<ONMY(5X(:LM0_UB^YQEQQGOR!I;+"DS
M,,$>A68960I<[@2#V15;,9Z0JWO0C&?J&@%?UO?DZLTU>4,LJ2@5TJB9J[$N
MDYT;US7<537X9VJX+3<WQ)N\);Y'ISWPY3#\'C#]@/;!752SD=1O)/5MO.!<
M.C$*I;BM^?>4W"H%6I$_?\-IY$%#KOX:( D:DL"2C,Z0+)G:DO@[?7%/DU0R
MNSU0?(7+!+UJ5I%#&]EL\_TBG+G[GF1&33*CP60>)2M418PY*=W+6H48=U@#
M;S+N)PX;XG"8V+;9=S+T48<GU"$-HTD_][CA'@^O@"CV(#5_PHY'!TU!2D@(
M;MCXF?QSW"P#*QTU/-'EVFG2D$P&B_G N"1[EI70I]_DI&&"8!3X_?I-&\KI
M(.4G4;S[*C0O-J0KY>HHY<\_T;'WR]KH.5 @]5JC\RZG(^WX*1TLRR9,N%(E
M=H/9DJS#>X5&5^W+ZUZ?HB>-2CU\(7O]2M/6D:C_?VG]JMZEK4W1X(*JMP9$
MAQWH!U2_HZ?.1/%-X$=G5&_-B0Z[TU+D.=*K_VKAUG'H^()BMH9#H\NU<'0B
MYBB<3*.(GE&S=2@Z;%%=-5_7I*T3T>GE=/5;!_*]'S#9&MQU61IZX9E7L]\:
MDG\Q0[KS3PVI?S7=S@G4'/\_,KGAA2(9I(CT;B(L2U8GZFJ@Q<X>2I^$QB.N
MO=SB5PA(,P&?IT+HX\"<<YOOFL6_4$L#!!0    ( /R">5)[OY6700,  #8)
M   9    >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;(U6VV[;, S]%<'8PP9L
M]26QG19)@+3%L +;$+2[/"LV$PN5)4^2D_;O1\F.D\V.MY=$-YYS2$JDYP>I
MGG4!8,A+R85>>(4QU8WOZZR DNHK68' G:U4)34X53M?5PIH[HQ*[D=!D/@E
M9<);SMW:6BWGLC:<"5@KHNNRI.KU%K@\++S0.RX\LEUA[(*_G%=T!T]@OE=K
MA3._0\E9"4(S*8B"[<);A3>WX<0:N!,_&!STV9A85S92/MO)0[[P JL(.&3&
M0E#\V\,=<&Z14,>O%M3K.*WA^?B(_M$YC\YLJ(8[R7^RW!0+;^:1'+:TYN91
M'CY!ZU!L\3+)M?LEA_9LX)&LUD:6K3$J*)EH_NE+&X@S@RB\8!"U!I'3W1 Y
ME??4T.5<R0-1]C2BV8%SU5FC."9L5IZ,PEV&=F;Y!=0.%)%;\A4DA_J9"?*M
M $4KJ W+]'OR(+(K0D5.5K]J)N0+61<4PY&Y?<J/)SZ0IR:Q%LL40%9:@]%D
ME:&9@MQ!?&9TPS@S#+3=KTM<?WL/AC*NWR'$D>(-<3)DK=%*SWV#GEJ]?M9Z
M==MX%5WP:E7OKD@P>T^B(+S^_G1/WKYY]R>*CW'J@A5UP8H<[.02;.,2;5VZ
M&8&<=) 3!SF] 'E'=>%"D]D!(/"><A!FT.D&*G90]KGMEY-H%LW]_8" :2=@
M.BK@$3) S@T'S"0^[(J^EI;?B<JADIH-BVE@DS,Q<1(,:XD[+?&HEK7":J/,
MJ^.VL:BLE"'RN$<>!I/I,'O2L2>C[ _B0Z5D!EICN=% 55:T0=AC\;HH)>E)
MF:9IF QK23LMZ3^T&"IV#+-"J+UT0\1ICSB)KX=I9QWM;)3VFS24-XRG:S[$
M/>LG?Q+%X3#[=<=^/?J\SJL#;:K#V!,+@U.-"T;=6F69K.V=QLM-74PQK1*+
ME"+\Q#E89H+^19NF%YY<>%9TPU%!'YF@(F-B1SA@2^E4O YJ"'L:L*Q=D' J
M96'T'ZGF_9 /2HCZ84C2R04-I]H7CA>_1D,FL<?GV')LFQYD[]>].(S3V5_T
M_ED7M%\47ZC:,:$QQ%NT"ZY2!%!-DVXF1E:N,6ZDP3;KA@5^V("R!W!_*Z4Y
M3FRO[3Z5EK\!4$L#!!0    ( /R">5(6-JHY:P,  $<-   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0Q+GAM;+U776^;,!3]*Q;J0RME!1L(H4HB->FJ5>JF
MJ%][F/;@!J>Q:G!JFZ3=KY]-")  6=5V?0DVG'/O\?7EQ/177#S*.2$*/,<L
MD0-KKM3BQ+;E=$YB+(_Y@B3ZR8R+&"L]%0^V7 B"HXP4,QLY3M>.,4VL83^[
M-Q'#/D\5HPF9""#3.,;B94087PTL:&UN7-&'N3(W[&%_@1_(-5&WBXG0,[N(
M$M&8))+R! @R&UBG\&2,'$/($'>4K&1E#,Q2[CE_-).+:& Y1A%A9*I,"*PO
M2S(FC)E(6L=3'M0J<AIB=;R)?IXM7B_F'DLRYNPGC=1\8/4L$)$93IFZXJMO
M)%^0;^)-.9/9+UCE6,<"TU0J'N=DK2"FR?J*G_-"5 C0:R&@G(!>2W!S@ILM
M=*TL6]895GC8%WP%A$'K:&:0U29CZ]70Q&SCM1+Z*=4\-9P(W1%"O0"<1( \
MI72A]TAU0*([Z NXUET3I8P /@-;R*\;)#@\(PI3)H\T_/;Z#!P>'($#0!-P
M,^>IU%C9MY46:M+9TUS4:"T*M8@Z(]-CX,(.0 YR&NCC5]-AN$VW=7F*&J&B
M1BB+Y_ZC1ATP85@O>;L ORXU'%PH$LO?>Y*Y13(W2^:U)!MSJ9HJMF;Y&<N\
MF\NA!WV_;R^K=:F#4.#U"M"6(*\0Y.T5=#J=IG'*L"(1.(VY4/0/-F]@D\AU
MI&XEO]_;U5C'='LM$OU"HK]7X@_=K"/M%. .LY0T"?-K25T_<':4U4'(Z3K-
MTKJ%M.Y>:9=$>\R<LPC0>"'XDIB>D7OZ)"@"!_^_*7M%LMY;FG+<JU7,"UL*
M%A:IPH]JMW%8WU77;4X/G=(0G?<UTS@/4,T+_: E;\6(X?Y.P?=<8,7%2^G#
M>[8.ENX%/\&^8.E?\&T&EM.V=LMST,X[V(""/O1;BEMZ&/PX$X-UA_)0=U=G
M@XVA%I6EC<'W^AAL\*@PJ(FKHZ#GM[T9I97!_5YVGHJ$JE20#IC19S.0G:R;
M+FY>U[*EM\%/,#=8NAM\D[V-8-W?@DH9\V(W@+RV6I<N"#_,!D>P[H/0#W=E
MUD$H;)&)2K-$[S3+41Z@>B;Q0V]'7 /(\W?_2.S**==\8GS'XH$F$C RTRSG
M.-!TL3ZUKR>*+[*#[SU7^AB=#>?Z2X<( ]#/9YRKS<2<I8MOI^%?4$L#!!0
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MC=(:F.^9$'HWL0'JOC_Y U!+ P04    " #\@GE2-&+TQ:H"  !K!P  &0
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MN7/MN[4[NW9[_LK4!A6J]^WF(5QMLZ[_TD6K3=2UN^A?6;P$:;I>'#84T8+
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M)^9C:5%9-=WA5N\&6#59;G6 N7O8W-=H)\WAW%RGD4^PD>OM2LZ?TV/D\X#
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MNA7F2>Z_0*UG8/D2*;3[DGUU=M3W2++51N8U&#W(>5']Z6L=AQ- .+P B&I
M="T@K@&Q$UIYYF3=44.G8R7W1-G3R&8'+C8.C6IX8;.X- IW.>+,=&EDLLFD
M8*#T6P(O6VX.Y"-9XFUA6P%$IN39A0(8F>U 86;)3&/.2YL%3=[=@:%<Z/=C
MWZ [EM1/:M/SRG1TP708D0=9F$R3^X(!.R?P44<C)CJ*F4>=C'>0]$@<?B!1
M$ 4M#BVNAH<W'>[$36QCQQ=?X+NOHOECMM)&X7W]V<'9;SC[CK-_B?.UQ >
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M+2U)%/VSF"B^M"UHQI5N:':8ZG\.%"9 /Y]SKG83LT'U%]/_#U!+ P04
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MWN4 CW)9M6/50(O"=C0+H;$_LJ]K;&%!F@#\OA1";P>F0-,43_X#4$L#!!0
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MJMJK1CLPLFJZ]4=IL/=O'G.\GH&R'^#[3$KS,K &^@O?]G]02P,$%     @
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MM !SOA9"[P.;H/N(9+\!4$L#!!0    ( /R">5)YNMP!O ,  $\-   9
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M$ 4-\%DW? Y))WQ^,CR\? KWL81U':.ZCI'SUSNECG.F$RYUH8!\>X>&Y,9
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MN.RSRQAX!-H-P/<+I>S+C7-0?DF9_@=02P,$%     @ _()Y4G*-4T;^ 0
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MEOII V$"]'[!N=I-3#-TCV7Z%U!+ P04    " #\@GE2JA(_3RD#   2$P
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M.&[VP;W]*%SO4^'F7[#1;U!+ P04    " #\@GE2EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( /R">5+6$2QG]P0
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M\E+6Y36,=_ S?.20%W&O<M75]2F479D+*ZO-QXB;#RF/?P!02P,$%     @
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ _()Y4IE<G",0!@  G"<  !,
M             ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" #\@GE2Z]4A!+0&  !B&@  &               @($."   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ _()Y4N=4&<X%!0  GQ,  !@
M             ("!^ X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    ( /R">5)WN9K:T@(  +L)   8              " @3,4  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #\@GE2O>'8[Y0#  "O
M"@  &               @($[%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @ _()Y4C=\^+US!P  'QX  !@              ("!!1L
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( /R">5)6Z1>G
M]P4  *0:   8              " @:XB  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    " #\@GE2Y&RA*$P"   P!0  &
M@(';*   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ _()Y
M4EZ]C9I: @  4@4  !@              ("!72L  'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    ( /R">5)]< (+, ,  ,D&   8
M      " @>TM  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /R">5)-I_A@A0(  +D%   9              "
M@;!4  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ _()Y
M4D"J QVK"0  FC$  !D              ("!;%<  'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    " #\@GE2E.,V##P-  !<)P  &0
M        @(%.80  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   ( /R">5(R17<\:P0  .,*   9              " @<%N  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ _()Y4@,;G^E@ @  *@4
M !D              ("!8W,  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    " #\@GE20_K*S<X"  #@!0  &0              @('Z=0
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( /R">5(9;:1F
ME0D  (P8   9              " @?]X  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @ _()Y4H5IA(D"!P  XQ$  !D
M ("!RX(  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #\
M@GE2-,>$BD #  #I!@  &0              @($$B@  >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( /R">5(/4]).K (  ,D%   9
M          " @7N-  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#
M%     @ _()Y4ORT$1TY!   , D  !D              ("!7I   'AL+W=O
M<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #\@GE27*(9MX\6  !<
M1P  &0              @('.E   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM
M;%!+ 0(4 Q0    ( /R">5*DW.BL_P(  *8(   9              " @92K
M  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ _()Y4OM$
M*,_& P  > @  !D              ("!RJX  'AL+W=O<FMS:&5E=',O<VAE
M970R-RYX;6Q02P$"% ,4    " #\@GE28;SIX-@"  !0!@  &0
M    @(''L@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (
M /R">5+P>YU^< (  #(%   9              " @=:U  !X;"]W;W)K<VAE
M971S+W-H965T,CDN>&UL4$L! A0#%     @ _()Y4BM<"!2= @  IP4  !D
M             ("!?;@  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"
M% ,4    " #\@GE2_IF<39L$  !^#P  &0              @(%1NP  >&PO
M=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( /R">5)<5Z"2IP0
M /T+   9              " @2/   !X;"]W;W)K<VAE971S+W-H965T,S(N
M>&UL4$L! A0#%     @ _()Y4C/%G+!S @  +04  !D              ("!
M <4  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " #\@GE2
MO!DC*O0"  #\!0  &0              @(&KQP  >&PO=V]R:W-H965T<R]S
M:&5E=#,T+GAM;%!+ 0(4 Q0    ( /R">5)3&-,DTP0  %H+   9
M      " @=;*  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%
M  @ _()Y4A:+=9!? P  5@L  !D              ("!X,\  'AL+W=O<FMS
M:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #\@GE22)QFRH0"  "_!@
M&0              @(%VTP  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+
M 0(4 Q0    ( /R">5(D@L$+/P,  !4,   9              " @3'6  !X
M;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ _()Y4O&=H7*&
M P  XPP  !D              ("!I]D  'AL+W=O<FMS:&5E=',O<VAE970S
M.2YX;6Q02P$"% ,4    " #\@GE2>[^5ET$#   V"0  &0
M@(%DW0  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( /R"
M>5(6-JHY:P,  $<-   9              " @=S@  !X;"]W;W)K<VAE971S
M+W-H965T-#$N>&UL4$L! A0#%     @ _()Y4@&TJ5]+ @  ,@4  !D
M         ("!?N0  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
M    " #\@GE2<OY:>= "   #"   &0              @($ YP  >&PO=V]R
M:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( /R">5(T8O3%J@(  &L'
M   9              " @0?J  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL
M4$L! A0#%     @ _()Y4F9=XO$H!0  V!4  !D              ("!Z.P
M 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " #\@GE2)1=]
MEY4#  !(#   &0              @(%'\@  >&PO=V]R:W-H965T<R]S:&5E
M=#0V+GAM;%!+ 0(4 Q0    ( /R">5)JD^H1@P(  #<&   9
M  " @1/V  !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @
M_()Y4H[(>MS8 P   A   !D              ("!S?@  'AL+W=O<FMS:&5E
M=',O<VAE970T."YX;6Q02P$"% ,4    " #\@GE2V6_RK_L)  !R.   &0
M            @('<_   >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4
M Q0    ( /R">5*!RU7_7@0  %@1   9              " @0X' 0!X;"]W
M;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ _()Y4M'H3@:5 @
MD0<  !D              ("!HPL! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX
M;6Q02P$"% ,4    " #\@GE2EVGQ#!,#  #9"@  &0              @(%O
M#@$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( /R">5+%
MMAQAXP(  -$(   9              " @;D1 0!X;"]W;W)K<VAE971S+W-H
M965T-3,N>&UL4$L! A0#%     @ _()Y4BL-ZNYP P  5@T  !D
M     ("!TQ0! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /R">5)YNMP!O ,  $\-   9              "
M@4,E 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ _()Y
M4J+33RQX P  +@L  !D              ("!-BD! 'AL+W=O<FMS:&5E=',O
M<VAE970V,"YX;6Q02P$"% ,4    " #\@GE2!3<QFR,$  !5$0  &0
M        @('E+ $ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0
M   ( /R">5)RC5-&_@$   ($   9              " @3\Q 0!X;"]W;W)K
M<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ _()Y4ATY.1I\ @  . <
M !D              ("!=#,! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q0
M2P$"% ,4    " #\@GE2JA(_3RD#   2$P  #0              @ $G-@$
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( /R">5*7BKL<P    !,"   +
M          "  7LY 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( /R">5+6$2QG
M]P0  ,PI   /              "  60Z 0!X;"]W;W)K8F]O:RYX;6Q02P$"
M% ,4    " #\@GE2)V75I0P"  "$)0  &@              @ &(/P$ >&PO
M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #\@GE2[M7M&.8!
M  #U)   $P              @ ',00$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+
4!08     1P!' &@3  #C0P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>97</ContextCount>
  <ElementCount>407</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>38</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006006 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1405401 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1407402 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/Natureofoperations</Role>
      <ShortName>Nature of operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Basis of presentation and summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies</Role>
      <ShortName>Basis of presentation and summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsInc</Role>
      <ShortName>Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Property and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/Propertyandequipmentnet</Role>
      <ShortName>Property and equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - Intangible asset, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/Intangibleassetnet</Role>
      <ShortName>Intangible asset, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Accounts payable and other liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/Accountspayableandotherliabilities</Role>
      <ShortName>Accounts payable and other liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2128108 - Disclosure - Stockholders' equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/Stockholdersequity</Role>
      <ShortName>Stockholders' equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2135109 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2137110 - Disclosure - Other income, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/Otherincomenet</Role>
      <ShortName>Other income, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2140111 - Disclosure - Net loss per common stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/Netlosspercommonstock</Role>
      <ShortName>Net loss per common stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2143112 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/Incometaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2149113 - Disclosure - License and patent agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/Licenseandpatentagreements</Role>
      <ShortName>License and patent agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2151114 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/Commitmentsandcontingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2153115 - Disclosure - 401(k) plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/A401kplan</Role>
      <ShortName>401(k) plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2154116 - Disclosure - Sale of Aquinox Canada</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/SaleofAquinoxCanada</Role>
      <ShortName>Sale of Aquinox Canada</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Basis of presentation and summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies</Role>
      <ShortName>Basis of presentation and summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Basis of presentation and summary of significant accounting policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesTables</Role>
      <ShortName>Basis of presentation and summary of significant accounting policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aqxpharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncTables</Role>
      <ShortName>Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsInc</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Property and equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/PropertyandequipmentnetTables</Role>
      <ShortName>Property and equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aqxpharma.com/role/Propertyandequipmentnet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2317304 - Disclosure - Intangible asset, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/IntangibleassetnetTables</Role>
      <ShortName>Intangible asset, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aqxpharma.com/role/Intangibleassetnet</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2320305 - Disclosure - Accounts payable and other liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesTables</Role>
      <ShortName>Accounts payable and other liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aqxpharma.com/role/Accountspayableandotherliabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2323306 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aqxpharma.com/role/Leases</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2329307 - Disclosure - Stockholders' equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/StockholdersequityTables</Role>
      <ShortName>Stockholders' equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aqxpharma.com/role/Stockholdersequity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2338308 - Disclosure - Other income, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/OtherincomenetTables</Role>
      <ShortName>Other income, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aqxpharma.com/role/Otherincomenet</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2341309 - Disclosure - Net loss per common stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/NetlosspercommonstockTables</Role>
      <ShortName>Net loss per common stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aqxpharma.com/role/Netlosspercommonstock</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2344310 - Disclosure - Income taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/IncometaxesTables</Role>
      <ShortName>Income taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.aqxpharma.com/role/Incometaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Basis of presentation and summary of significant accounting policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails</Role>
      <ShortName>Basis of presentation and summary of significant accounting policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2406404 - Disclosure - Basis of presentation and summary of significant accounting policies - Cash and cash equivalents and restricted cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesCashandcashequivalentsandrestrictedcashDetails</Role>
      <ShortName>Basis of presentation and summary of significant accounting policies - Cash and cash equivalents and restricted cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails</Role>
      <ShortName>Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. - Schedule of Total Consideration Paid (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails</Role>
      <ShortName>Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. - Schedule of Total Consideration Paid (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. - Summary of the Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. - Summary of the Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Property and equipment, net - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>Property and equipment, net - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Property and equipment, net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/PropertyandequipmentnetAdditionalInformationDetails</Role>
      <ShortName>Property and equipment, net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Intangible asset, net - Summary of Intangible Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/IntangibleassetnetSummaryofIntangibleAssetDetails</Role>
      <ShortName>Intangible asset, net - Summary of Intangible Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Accounts payable and other liabilities - Schedule of Accounts Payable and Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails</Role>
      <ShortName>Accounts payable and other liabilities - Schedule of Accounts Payable and Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Schedule of Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2426414 - Disclosure - Leases - Supplemental Cash flow Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/LeasesSupplementalCashflowInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Supplemental Cash flow Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2427415 - Disclosure - Leases - Schedule of Company's Operating and Finance Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Schedule of Company's Operating and Finance Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - Stockholders' equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2431417 - Disclosure - Stockholders' equity - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/StockholdersequityScheduleofStockOptionActivityDetails</Role>
      <ShortName>Stockholders' equity - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2432418 - Disclosure - Stockholders' equity - Schedule of Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/StockholdersequityScheduleofWeightedAverageAssumptionsDetails</Role>
      <ShortName>Stockholders' equity - Schedule of Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2433419 - Disclosure - Stockholders' equity - Schedule of RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/StockholdersequityScheduleofRSUActivityDetails</Role>
      <ShortName>Stockholders' equity - Schedule of RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2434420 - Disclosure - Stockholders' equity - Summary of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/StockholdersequitySummaryofStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' equity - Summary of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2436421 - Disclosure - Restructuring - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/RestructuringAdditionalInformationDetails</Role>
      <ShortName>Restructuring - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2439422 - Disclosure - Other income, net - Schedule of Other Income Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/OtherincomenetScheduleofOtherIncomeNetDetails</Role>
      <ShortName>Other income, net - Schedule of Other Income Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - Net loss per common stock - Schedule of Securities Excluded From Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/NetlosspercommonstockScheduleofSecuritiesExcludedFromComputationofEarningsPerShareDetails</Role>
      <ShortName>Net loss per common stock - Schedule of Securities Excluded From Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2445424 - Disclosure - Income Taxes - Schedule of Income tax Recovery (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails</Role>
      <ShortName>Income Taxes - Schedule of Income tax Recovery (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2446425 - Disclosure - Income Taxes - Schedule of Net (Loss) Income Before Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/IncomeTaxesScheduleofNetLossIncomeBeforeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Net (Loss) Income Before Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2447426 - Disclosure - Income Taxes - Components of Deferred Income Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Components of Deferred Income Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2448427 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2450428 - Disclosure - License and patent agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails</Role>
      <ShortName>License and patent agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2452429 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="nltx-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2455430 - Disclosure - Sale of Aquinox Canada (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.aqxpharma.com/role/SaleofAquinoxCanadaDetails</Role>
      <ShortName>Sale of Aquinox Canada (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.aqxpharma.com/role/SaleofAquinoxCanada</ParentRole>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="nltx-20201231.htm">nltx-20201231.htm</File>
    <File>ex1021-uwagreementamendment.htm</File>
    <File>ex1022-hollyvanceemploymen.htm</File>
    <File>ex1023rigakupoupdated1.htm</File>
    <File>ex1024neoleukinleaseamendm.htm</File>
    <File>ex211-listofsubsidiaries.htm</File>
    <File>ex231-consentofindependent.htm</File>
    <File>ex232-consentofindependent.htm</File>
    <File>nltx-20201231.xsd</File>
    <File>nltx-20201231_cal.xml</File>
    <File>nltx-20201231_def.xml</File>
    <File>nltx-20201231_lab.xml</File>
    <File>nltx-20201231_pre.xml</File>
    <File>nltx-20201231xex311.htm</File>
    <File>nltx-20201231xex312.htm</File>
    <File>nltx-20201231xex321.htm</File>
    <File>nltx-20201231xex322.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>88
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nltx-20201231.htm": {
   "axisCustom": 1,
   "axisStandard": 18,
   "contextCount": 97,
   "dts": {
    "calculationLink": {
     "local": [
      "nltx-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nltx-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "nltx-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nltx-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nltx-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "nltx-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 487,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 3,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 7
   },
   "keyCustom": 57,
   "keyStandard": 350,
   "memberCustom": 16,
   "memberStandard": 20,
   "nsprefix": "nltx",
   "nsuri": "http://www.aqxpharma.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.aqxpharma.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Basis of presentation and summary of significant accounting policies",
     "role": "http://www.aqxpharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies",
     "shortName": "Basis of presentation and summary of significant accounting policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nltx:AcquisitionOfAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc.",
     "role": "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsInc",
     "shortName": "Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nltx:AcquisitionOfAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Property and equipment, net",
     "role": "http://www.aqxpharma.com/role/Propertyandequipmentnet",
     "shortName": "Property and equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - Intangible asset, net",
     "role": "http://www.aqxpharma.com/role/Intangibleassetnet",
     "shortName": "Intangible asset, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Accounts payable and other liabilities",
     "role": "http://www.aqxpharma.com/role/Accountspayableandotherliabilities",
     "shortName": "Accounts payable and other liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - Leases",
     "role": "http://www.aqxpharma.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128108 - Disclosure - Stockholders' equity",
     "role": "http://www.aqxpharma.com/role/Stockholdersequity",
     "shortName": "Stockholders' equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135109 - Disclosure - Restructuring",
     "role": "http://www.aqxpharma.com/role/Restructuring",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137110 - Disclosure - Other income, net",
     "role": "http://www.aqxpharma.com/role/Otherincomenet",
     "shortName": "Other income, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140111 - Disclosure - Net loss per common stock",
     "role": "http://www.aqxpharma.com/role/Netlosspercommonstock",
     "shortName": "Net loss per common stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i2e2fcca578804ccebdb1444503987c24_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i2e2fcca578804ccebdb1444503987c24_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143112 - Disclosure - Income taxes",
     "role": "http://www.aqxpharma.com/role/Incometaxes",
     "shortName": "Income taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nltx:LicenseAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149113 - Disclosure - License and patent agreements",
     "role": "http://www.aqxpharma.com/role/Licenseandpatentagreements",
     "shortName": "License and patent agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nltx:LicenseAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2151114 - Disclosure - Commitments and contingencies",
     "role": "http://www.aqxpharma.com/role/Commitmentsandcontingencies",
     "shortName": "Commitments and contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153115 - Disclosure - 401(k) plan",
     "role": "http://www.aqxpharma.com/role/A401kplan",
     "shortName": "401(k) plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nltx:SubsidiarySaleOfStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2154116 - Disclosure - Sale of Aquinox Canada",
     "role": "http://www.aqxpharma.com/role/SaleofAquinoxCanada",
     "shortName": "Sale of Aquinox Canada",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nltx:SubsidiarySaleOfStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Basis of presentation and summary of significant accounting policies (Policies)",
     "role": "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies",
     "shortName": "Basis of presentation and summary of significant accounting policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Basis of presentation and summary of significant accounting policies (Tables)",
     "role": "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesTables",
     "shortName": "Basis of presentation and summary of significant accounting policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nltx:AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. (Tables)",
     "role": "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncTables",
     "shortName": "Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nltx:AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Property and equipment, net (Tables)",
     "role": "http://www.aqxpharma.com/role/PropertyandequipmentnetTables",
     "shortName": "Property and equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317304 - Disclosure - Intangible asset, net (Tables)",
     "role": "http://www.aqxpharma.com/role/IntangibleassetnetTables",
     "shortName": "Intangible asset, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i2e2fcca578804ccebdb1444503987c24_I20201231",
      "decimals": "6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.aqxpharma.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320305 - Disclosure - Accounts payable and other liabilities (Tables)",
     "role": "http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesTables",
     "shortName": "Accounts payable and other liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323306 - Disclosure - Leases (Tables)",
     "role": "http://www.aqxpharma.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329307 - Disclosure - Stockholders' equity (Tables)",
     "role": "http://www.aqxpharma.com/role/StockholdersequityTables",
     "shortName": "Stockholders' equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338308 - Disclosure - Other income, net (Tables)",
     "role": "http://www.aqxpharma.com/role/OtherincomenetTables",
     "shortName": "Other income, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341309 - Disclosure - Net loss per common stock (Tables)",
     "role": "http://www.aqxpharma.com/role/NetlosspercommonstockTables",
     "shortName": "Net loss per common stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344310 - Disclosure - Income taxes (Tables)",
     "role": "http://www.aqxpharma.com/role/IncometaxesTables",
     "shortName": "Income taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i2e2fcca578804ccebdb1444503987c24_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405403 - Disclosure - Basis of presentation and summary of significant accounting policies - Additional Information (Details)",
     "role": "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails",
     "shortName": "Basis of presentation and summary of significant accounting policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i2e2fcca578804ccebdb1444503987c24_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i2e2fcca578804ccebdb1444503987c24_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406404 - Disclosure - Basis of presentation and summary of significant accounting policies - Cash and cash equivalents and restricted cash (Details)",
     "role": "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesCashandcashequivalentsandrestrictedcashDetails",
     "shortName": "Basis of presentation and summary of significant accounting policies - Cash and cash equivalents and restricted cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i2e2fcca578804ccebdb1444503987c24_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. - Additional Information (Details)",
     "role": "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails",
     "shortName": "Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "icc0c497a9b7e42ff89e71ed4e700c005_D20190808-20190808",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nltx:AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i562c09437d76488daa016091ce08fa2a_D20190808-20190808",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nltx:AcquisitionsOfAssetsCashConsiderationForFractionalShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. - Schedule of Total Consideration Paid (Details)",
     "role": "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails",
     "shortName": "Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. - Schedule of Total Consideration Paid (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nltx:AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i562c09437d76488daa016091ce08fa2a_D20190808-20190808",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nltx:AcquisitionsOfAssetsCashConsiderationForFractionalShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Operations",
     "role": "http://www.aqxpharma.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i99076ffdc9d3414f812225c38a835667_I20190808",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nltx:AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411407 - Disclosure - Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. - Summary of the Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. - Summary of the Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i99076ffdc9d3414f812225c38a835667_I20190808",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nltx:AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i2e2fcca578804ccebdb1444503987c24_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Property and equipment, net - Schedule of Property and Equipment (Details)",
     "role": "http://www.aqxpharma.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails",
     "shortName": "Property and equipment, net - Schedule of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i2e2fcca578804ccebdb1444503987c24_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Property and equipment, net - Additional Information (Details)",
     "role": "http://www.aqxpharma.com/role/PropertyandequipmentnetAdditionalInformationDetails",
     "shortName": "Property and equipment, net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i2e2fcca578804ccebdb1444503987c24_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - Intangible asset, net - Summary of Intangible Asset (Details)",
     "role": "http://www.aqxpharma.com/role/IntangibleassetnetSummaryofIntangibleAssetDetails",
     "shortName": "Intangible asset, net - Summary of Intangible Asset (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i2e2fcca578804ccebdb1444503987c24_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i2e2fcca578804ccebdb1444503987c24_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Accounts payable and other liabilities - Schedule of Accounts Payable and Other Liabilities (Details)",
     "role": "http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails",
     "shortName": "Accounts payable and other liabilities - Schedule of Accounts Payable and Other Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i2e2fcca578804ccebdb1444503987c24_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nltx:TenantImprovementAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Leases - Additional Information (Details)",
     "role": "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nltx:TenantImprovementAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Leases - Schedule of Components of Lease Expense (Details)",
     "role": "http://www.aqxpharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails",
     "shortName": "Leases - Schedule of Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426414 - Disclosure - Leases - Supplemental Cash flow Information Related to Leases (Details)",
     "role": "http://www.aqxpharma.com/role/LeasesSupplementalCashflowInformationRelatedtoLeasesDetails",
     "shortName": "Leases - Supplemental Cash flow Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i2e2fcca578804ccebdb1444503987c24_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427415 - Disclosure - Leases - Schedule of Company's Operating and Finance Lease Liabilities (Details)",
     "role": "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails",
     "shortName": "Leases - Schedule of Company's Operating and Finance Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i2e2fcca578804ccebdb1444503987c24_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i2e2fcca578804ccebdb1444503987c24_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - Stockholders' equity - Additional Information (Details)",
     "role": "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails",
     "shortName": "Stockholders' equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "ibcd7f5cd1b2a4a29a2a3ab167bb32bce_D20200707-20200707",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i9532edde7a4d48b5887af8007e83465c_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431417 - Disclosure - Stockholders' equity - Schedule of Stock Option Activity (Details)",
     "role": "http://www.aqxpharma.com/role/StockholdersequityScheduleofStockOptionActivityDetails",
     "shortName": "Stockholders' equity - Schedule of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432418 - Disclosure - Stockholders' equity - Schedule of Weighted Average Assumptions (Details)",
     "role": "http://www.aqxpharma.com/role/StockholdersequityScheduleofWeightedAverageAssumptionsDetails",
     "shortName": "Stockholders' equity - Schedule of Weighted Average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "icd60841f3d0c4c839e994b21197a5e5a_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433419 - Disclosure - Stockholders' equity - Schedule of RSU Activity (Details)",
     "role": "http://www.aqxpharma.com/role/StockholdersequityScheduleofRSUActivityDetails",
     "shortName": "Stockholders' equity - Schedule of RSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "icd60841f3d0c4c839e994b21197a5e5a_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434420 - Disclosure - Stockholders' equity - Summary of Stock-based Compensation Expense (Details)",
     "role": "http://www.aqxpharma.com/role/StockholdersequitySummaryofStockbasedCompensationExpenseDetails",
     "shortName": "Stockholders' equity - Summary of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i4ded9a42fb4c43d59acd21cbb286e7ab_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436421 - Disclosure - Restructuring - Additional Information (Details)",
     "role": "http://www.aqxpharma.com/role/RestructuringAdditionalInformationDetails",
     "shortName": "Restructuring - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i4ded9a42fb4c43d59acd21cbb286e7ab_D20190101-20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439422 - Disclosure - Other income, net - Schedule of Other Income Net (Details)",
     "role": "http://www.aqxpharma.com/role/OtherincomenetScheduleofOtherIncomeNetDetails",
     "shortName": "Other income, net - Schedule of Other Income Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - Net loss per common stock - Schedule of Securities Excluded From Computation of Earnings Per Share (Details)",
     "role": "http://www.aqxpharma.com/role/NetlosspercommonstockScheduleofSecuritiesExcludedFromComputationofEarningsPerShareDetails",
     "shortName": "Net loss per common stock - Schedule of Securities Excluded From Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445424 - Disclosure - Income Taxes - Schedule of Income tax Recovery (Details)",
     "role": "http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails",
     "shortName": "Income Taxes - Schedule of Income tax Recovery (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446425 - Disclosure - Income Taxes - Schedule of Net (Loss) Income Before Taxes (Details)",
     "role": "http://www.aqxpharma.com/role/IncomeTaxesScheduleofNetLossIncomeBeforeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Net (Loss) Income Before Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i2e2fcca578804ccebdb1444503987c24_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447426 - Disclosure - Income Taxes - Components of Deferred Income Tax Assets (Details)",
     "role": "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails",
     "shortName": "Income Taxes - Components of Deferred Income Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i2e2fcca578804ccebdb1444503987c24_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i732d643094fe48eabda3a3bdcda606d7_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006006 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i732d643094fe48eabda3a3bdcda606d7_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainOrLossOnSaleOfStockInSubsidiary",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448427 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.aqxpharma.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i2e2fcca578804ccebdb1444503987c24_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i2d0273c0483c4e869c87c35dd362ea8b_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nltx:LicenseArrangementsAmountsPayableOnDevelopmentalMilestones",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450428 - Disclosure - License and patent agreements - Additional Information (Details)",
     "role": "http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails",
     "shortName": "License and patent agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i2d0273c0483c4e869c87c35dd362ea8b_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "nltx:LicenseArrangementsAmountsPayableOnDevelopmentalMilestones",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i2e2fcca578804ccebdb1444503987c24_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452429 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.aqxpharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i2e2fcca578804ccebdb1444503987c24_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainOrLossOnSaleOfStockInSubsidiary",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455430 - Disclosure - Sale of Aquinox Canada (Details)",
     "role": "http://www.aqxpharma.com/role/SaleofAquinoxCanadaDetails",
     "shortName": "Sale of Aquinox Canada (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i74a1d2bd4a394b7b96915526dbf4b948_D20200731-20200731",
      "decimals": "-5",
      "lang": "en-US",
      "name": "nltx:ProceedsFromSaleOfStockOfSubsidiary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nltx:CommissionsOnPublicOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1405401 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "role": "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlowsParenthetical",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "nltx:CommissionsOnPublicOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1407402 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of operations",
     "role": "http://www.aqxpharma.com/role/Natureofoperations",
     "shortName": "Nature of operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nltx-20201231.htm",
      "contextRef": "i7f51bd22a12640bc81f1256ebb4bf2c3_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 38,
   "tag": {
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Canada"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r351",
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r351",
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nltx_A2020EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Employee Stock Purchase Plan",
        "label": "2020 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2020 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "A2020EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nltx_AccruedClinicalExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical studies, which covers fees paid to CROs, investigative sites in connection with clinical studies and contract manufacturers in connection with the production of clinical study materials; and fees paid to vendors in connection with the preclinical development activities.",
        "label": "Accrued Clinical Expenses Current",
        "terseLabel": "Accrued clinical and preclinical expenses"
       }
      }
     },
     "localname": "AccruedClinicalExpensesCurrent",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_AcqinoxCanadaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acqinox Canada",
        "label": "Acqinox Canada [Member]",
        "terseLabel": "Acqinox Canada"
       }
      }
     },
     "localname": "AcqinoxCanadaMember",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/SaleofAquinoxCanadaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nltx_AcquisitionOfAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition of assets [Abstract]",
        "label": "Acquisition of Assets [Abstract]",
        "terseLabel": "Acquisition of Assets [Abstract]"
       }
      }
     },
     "localname": "AcquisitionOfAssetsAbstract",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "xbrltype": "stringItemType"
    },
    "nltx_AcquisitionOfAssetsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition of assets.",
        "label": "Acquisition of Assets [Axis]",
        "terseLabel": "Acquisition of Assets [Axis]",
        "verboseLabel": "Acquisition of Assets [Axis]"
       }
      }
     },
     "localname": "AcquisitionOfAssetsAxis",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails",
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nltx_AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition of assets consideration of transaction fair value.",
        "label": "Acquisition Of Assets Consideration Of Transaction Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Total Consideration Paid"
       }
      }
     },
     "localname": "AcquisitionOfAssetsConsiderationOfTransactionFairValueTableTextBlock",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nltx_AcquisitionOfAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition of assets disclosure.",
        "label": "Acquisition Of Assets Disclosure [Text Block]",
        "terseLabel": "Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "AcquisitionOfAssetsDisclosureTextBlock",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsInc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nltx_AcquisitionOfAssetsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition of assets.",
        "label": "Acquisition of Assets [Domain]",
        "terseLabel": "Acquisition of Assets [Domain]"
       }
      }
     },
     "localname": "AcquisitionOfAssetsDomain",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails",
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nltx_AcquisitionOfAssetsNetCashAcquired": {
     "auth_ref": [],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition of assets net cash acquired.",
        "label": "Acquisition Of Assets Net Cash Acquired",
        "terseLabel": "Acquisition of Neoleukin Therapeutics, Inc., net of cash acquired"
       }
      }
     },
     "localname": "AcquisitionOfAssetsNetCashAcquired",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition of assets recognized identifiable assets acquired.",
        "label": "Acquisition of Assets Recognized Identifiable Assets Acquired [Abstract]",
        "terseLabel": "Assets acquired:"
       }
      }
     },
     "localname": "AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAbstract",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition of assets recognized identifiable assets acquired and liabilities assumed net.",
        "label": "Acquisition of Assets Recognized Identifiable Assets Acquired And Liabilities Assumed Net",
        "totalLabel": "Total consideration"
       }
      }
     },
     "localname": "AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition of assets recognized identifiable assets acquired assets net.",
        "label": "Acquisition of Assets Recognized Identifiable Assets Acquired Assets Net",
        "totalLabel": "Total assets acquired"
       }
      }
     },
     "localname": "AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents": {
     "auth_ref": [],
     "calculation": {
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition of assets recognized identifiable assets acquired, cash and cash equivalents.",
        "label": "Acquisition of Assets Recognized Identifiable Assets Acquired Cash And Cash Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredCashAndCashEquivalents",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition of assets recognized identifiable assets acquired, in process research and development asset.",
        "label": "Acquisition of Assets Recognized Identifiable Assets Acquired In Process Research And Development Assets",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredInProcessResearchAndDevelopmentAssets",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition of assets recognized identifiable assets acquired, receivables, property and equipment.",
        "label": "Acquisition of Assets Recognized Identifiable Assets Acquired Property And Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredPropertyAndEquipment",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition of assets recognized identifiable assets acquired, receivables, prepayments and deposits.",
        "label": "Acquisition of Assets Recognized Identifiable Assets Acquired Receivables Prepayments And Deposits",
        "terseLabel": "Receivables, prepayments and deposits"
       }
      }
     },
     "localname": "AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredReceivablesPrepaymentsAndDeposits",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition of assets recognized identifiable assets acquired, Intangible asset.",
        "label": "Acquisition Of Assets Recognized Identifiable Assets Intangible Asset",
        "terseLabel": "Intangible asset"
       }
      }
     },
     "localname": "AcquisitionOfAssetsRecognizedIdentifiableAssetsIntangibleAsset",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed": {
     "auth_ref": [],
     "calculation": {
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "nltx_AcquisitionOfAssetsRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition of assets recognized identifiable liabilities assumed.",
        "label": "Acquisition of Assets Recognized Identifiable Liabilities Assumed",
        "totalLabel": "Total liabilities assumed"
       }
      }
     },
     "localname": "AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition of assets recognized identifiable liabilities assumed.",
        "label": "Acquisition of Assets Recognized Identifiable Liabilities Assumed [Abstract]",
        "terseLabel": "Liabilities assumed:"
       }
      }
     },
     "localname": "AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAbstract",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition of assets recognized identifiable liabilities assumed, accounts payable and other liabilities.",
        "label": "Acquisition of Assets Recognized Identifiable Liabilities Assumed Accounts Payable And Other Liabilities",
        "terseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedAccountsPayableAndOtherLiabilities",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "nltx_AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumed",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisition of assets recognized identifiable liabilities assumed, financing lease liability.",
        "label": "Acquisition of Assets Recognized Identifiable Liabilities Assumed Financing Lease Liability",
        "terseLabel": "Financing lease liability"
       }
      }
     },
     "localname": "AcquisitionOfAssetsRecognizedIdentifiableLiabilitiesAssumedFinancingLeaseLiability",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_AcquisitionOfAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition of Assets [Table]",
        "terseLabel": "Acquisition of Assets [Table]"
       }
      }
     },
     "localname": "AcquisitionOfAssetsTable",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails",
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nltx_AcquisitionsOfAssetsCashConsiderationForFractionalShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails": {
       "order": 1.0,
       "parentTag": "nltx_AcquisitionsOfAssetsConsiderationTransferred",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisitions of assets cash consideration for fractional shares.",
        "label": "Acquisitions Of Assets Cash Consideration For Fractional Shares",
        "terseLabel": "Cash consideration for fractional shares"
       }
      }
     },
     "localname": "AcquisitionsOfAssetsCashConsiderationForFractionalShares",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_AcquisitionsOfAssetsConsiderationTransferred": {
     "auth_ref": [],
     "calculation": {
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisitions of assets consideration transferred.",
        "label": "Acquisitions of Assets Consideration Transferred",
        "totalLabel": "Total consideration"
       }
      }
     },
     "localname": "AcquisitionsOfAssetsConsiderationTransferred",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_AcquisitionsOfAssetsFairValueOfSharesIssued": {
     "auth_ref": [],
     "calculation": {
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails": {
       "order": 2.0,
       "parentTag": "nltx_AcquisitionsOfAssetsConsiderationTransferred",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisitions of assets fair value of shares issued.",
        "label": "Acquisitions Of Assets Fair Value Of Shares Issued",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "AcquisitionsOfAssetsFairValueOfSharesIssued",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_AcquisitionsOfAssetsTransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails": {
       "order": 3.0,
       "parentTag": "nltx_AcquisitionsOfAssetsConsiderationTransferred",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisitions of assets transaction costs.",
        "label": "Acquisitions Of Assets Transaction Costs",
        "negatedTerseLabel": "Transaction costs"
       }
      }
     },
     "localname": "AcquisitionsOfAssetsTransactionCosts",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_AdditionalTenantImprovements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Tenant Improvements.",
        "label": "Additional Tenant Improvements",
        "terseLabel": "Additional tenant improvements"
       }
      }
     },
     "localname": "AdditionalTenantImprovements",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_AquinoxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aquinox .",
        "label": "Aquinox [Member]",
        "terseLabel": "Aquinox"
       }
      }
     },
     "localname": "AquinoxMember",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails",
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nltx_AssetAcquisitionsintangibleAssetsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisitions/Intangible assets",
        "label": "Asset acquisitionsIntangible assets [Policy Text Block]",
        "verboseLabel": "Asset acquisitions/Intangible assets"
       }
      }
     },
     "localname": "AssetAcquisitionsintangibleAssetsPolicyTextBlock",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nltx_CommissionsOnPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission fee on public offering.",
        "label": "Commissions On Public Offering",
        "terseLabel": "Commissions on public offering"
       }
      }
     },
     "localname": "CommissionsOnPublicOffering",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_ConvertiblePreferredStockToBeConverted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock to be converted.",
        "label": "Convertible Preferred Stock To Be Converted",
        "verboseLabel": "Shares to be converted"
       }
      }
     },
     "localname": "ConvertiblePreferredStockToBeConverted",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nltx_DeferredTaxAssetsBeforeValuationAllowance": {
     "auth_ref": [],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Before Valuation Allowance",
        "label": "Deferred Tax Assets, Before Valuation Allowance",
        "totalLabel": "Net deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsBeforeValuationAllowance",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Lease Liability",
        "label": "Deferred Tax Assets, Lease Liability",
        "terseLabel": "Lease Liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_DeferredTaxAssetsTaxCreditCarryforwardsReducedDueToSaleOfForeignEntity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Tax Credit Carryforwards Reduced Due To Sale Of Foreign Entity",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards Reduced Due To Sale Of Foreign Entity",
        "terseLabel": "Tax attributes no longer reflected in deferred tax assets and valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsReducedDueToSaleOfForeignEntity",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation Expiration Of Net Operating Losses, Percent",
        "label": "Effective Income Tax Rate Reconciliation Expiration Of Net Operating Losses, Percent",
        "negatedLabel": "Expiration of NOLs (section 382)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossesPercent",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nltx_EmployeeStockPurchasePlanNumberOfOfferingPerYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "employee stock purchase plan number of offering per year",
        "label": "Employee Stock Purchase Plan Number Of Offering Per Year",
        "terseLabel": "ESPP number of offerings per year"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanNumberOfOfferingPerYear",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nltx_EquityIncentivePlanTwoThousandSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plan Two Thousand Six [Member]",
        "terseLabel": "Equity Incentive Plan 2006"
       }
      }
     },
     "localname": "EquityIncentivePlanTwoThousandSixMember",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nltx_FinanceLeasePrincipalAndInterestPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Principal and Interest Payments",
        "label": "Finance Lease, Principal and Interest Payments",
        "verboseLabel": "Cash paid for amounts included in the measurement of finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeasePrincipalAndInterestPayments",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesSupplementalCashflowInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_FurnitureFixturesAndITEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture, Fixtures, And IT Equipment",
        "label": "Furniture, Fixtures, And IT Equipment [Member]",
        "terseLabel": "Furniture, fixtures, and IT equipment"
       }
      }
     },
     "localname": "FurnitureFixturesAndITEquipmentMember",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nltx_IncomeTaxesDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes Disclosure",
        "label": "Income Taxes Disclosure [Line Items]",
        "terseLabel": "Income Taxes Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesDisclosureLineItems",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nltx_IncomeTaxesDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes Disclosure",
        "label": "Income Taxes Disclosure [Table]",
        "terseLabel": "Income Taxes Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxesDisclosureTable",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nltx_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liabilities.",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease right of use assets.",
        "label": "Increase Decrease In Operating Lease Right Of Use Assets",
        "negatedTerseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nltx_LeaseAgreementExtendedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease agreement extended period.",
        "label": "Lease Agreement Extended Period",
        "terseLabel": "Lease agreement extended period"
       }
      }
     },
     "localname": "LeaseAgreementExtendedPeriod",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nltx_LicenseAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Abstract]",
        "terseLabel": "License Agreement [Abstract]"
       }
      }
     },
     "localname": "LicenseAgreementAbstract",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "xbrltype": "stringItemType"
    },
    "nltx_LicenseAgreementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement Disclosure.",
        "label": "License Agreement Disclosure [Text Block]",
        "terseLabel": "License and patent agreements"
       }
      }
     },
     "localname": "LicenseAgreementDisclosureTextBlock",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/Licenseandpatentagreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nltx_LicenseAndPatentAgreementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and patent agreements",
        "label": "License and patent agreements [Line Items]",
        "terseLabel": "License and patent agreements [Line Items]"
       }
      }
     },
     "localname": "LicenseAndPatentAgreementsLineItems",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nltx_LicenseAndPatentAgreementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License And Patent Agreements",
        "label": "License And Patent Agreements [Table]",
        "terseLabel": "License And Patent Agreements [Table]"
       }
      }
     },
     "localname": "LicenseAndPatentAgreementsTable",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nltx_LicenseArrangementsAmountsPayableBasedOnNetSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Arrangements, Amounts Payable Based On Net Sales",
        "label": "License Arrangements, Amounts Payable Based On Net Sales",
        "terseLabel": "License arrangements, amounts payable based on net sales"
       }
      }
     },
     "localname": "LicenseArrangementsAmountsPayableBasedOnNetSales",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_LicenseArrangementsAmountsPayableOnDevelopmentalMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Arrangements, Amounts Payable On Developmental Milestones",
        "label": "License Arrangements, Amounts Payable On Developmental Milestones",
        "terseLabel": "License arrangements, amounts of development milestones payment"
       }
      }
     },
     "localname": "LicenseArrangementsAmountsPayableOnDevelopmentalMilestones",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_NonVotingConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-voting convertible preferred stock.",
        "label": "Non-voting convertible preferred stock [Member]",
        "terseLabel": "Non-Voting Convertible Preferred\u00a0Stock",
        "verboseLabel": "Non-voting convertible preferred stock"
       }
      }
     },
     "localname": "NonVotingConvertiblePreferredStockMember",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nltx_NumberOfDaysAdvanceNoticeMustBeGivenToTerminateTheLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Days Advance Notice Must Be Given To Terminate The Lease",
        "label": "Number Of Days Advance Notice Must Be Given To Terminate The Lease",
        "terseLabel": "Number of days advance notice must be given to terminate the lease"
       }
      }
     },
     "localname": "NumberOfDaysAdvanceNoticeMustBeGivenToTerminateTheLease",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nltx_NumberOfOptionToExtendLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of option to extend lease.",
        "label": "Number Of Option To Extend Lease",
        "terseLabel": "Number of options to extend lease"
       }
      }
     },
     "localname": "NumberOfOptionToExtendLease",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nltx_OfficeSpaceFormerPrincipalExecutiveOfficesAndLaboratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office Space, Former Principal Executive Offices and Laboratory",
        "label": "Office Space, Former Principal Executive Offices and Laboratory [Member]",
        "terseLabel": "Office space, former principal executive offices and laboratory"
       }
      }
     },
     "localname": "OfficeSpaceFormerPrincipalExecutiveOfficesAndLaboratoryMember",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nltx_OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office Space, Principal Executive Offices and Laboratory",
        "label": "Office Space, Principal Executive Offices and Laboratory [Member]",
        "terseLabel": "Office space, principal executive offices and laboratory"
       }
      }
     },
     "localname": "OfficeSpacePrincipalExecutiveOfficesAndLaboratoryMember",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nltx_OperatingLeaseLiabilityIncreaseDueToRemeasurement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Liability, Increase Due to Remeasurement",
        "label": "Operating Lease, Liability, Increase Due to Remeasurement",
        "terseLabel": "Operating lease, liability, increase due to remeasurement"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityIncreaseDueToRemeasurement",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_OperatingLeaseRightOfUseAssetIncreaseDueToRemeasurement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Right of Use Asset, Increase Due to Remeasurement",
        "label": "Operating Lease, Right of Use Asset, Increase Due to Remeasurement",
        "terseLabel": "Operating lease, right of use asset, increase due to remeasurement"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetIncreaseDueToRemeasurement",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_OperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards not subject to expiration.",
        "label": "Operating Loss Carryforwards Not Subject To Expiration",
        "terseLabel": "Operating loss carryforwards not subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_OperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards subject to expiration.",
        "label": "Operating Loss Carryforwards Subject To Expiration",
        "terseLabel": "Operating loss carryforwards subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_OtherCurrentAssetsAcquiredThroughTheIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables prepayments and deposits acquired through the issuance of common stock.",
        "label": "Other Current Assets Acquired Through The Issuance Of Common Stock",
        "terseLabel": "Other current assets acquired through the issuance of common stock"
       }
      }
     },
     "localname": "OtherCurrentAssetsAcquiredThroughTheIssuanceOfCommonStock",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_PercentageOfOutstandingStockPerStockholderMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Outstanding Stock Per Stockholder, Maximum",
        "label": "Percentage Of Outstanding Stock Per Stockholder, Maximum",
        "terseLabel": "Maximum percentage of outstanding stock per stockholder"
       }
      }
     },
     "localname": "PercentageOfOutstandingStockPerStockholderMaximum",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nltx_PeriodSharesReservedForIssuanceWillIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The time period over which the number of shares reserved for issuance under the stock based compensation plan will increase.",
        "label": "Period Shares Reserved For Issuance Will Increase",
        "terseLabel": "Years of increase in shares of common stock reserved for issuance"
       }
      }
     },
     "localname": "PeriodSharesReservedForIssuanceWillIncrease",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nltx_PreFundedCommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Funded Common Stock Warrants [Member]",
        "terseLabel": "Pre funded common stock warrants"
       }
      }
     },
     "localname": "PreFundedCommonStockWarrantsMember",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nltx_PreFundedWarrantIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price per pre-funded warrant sold",
        "label": "Pre Funded Warrant Issued Price Per Share",
        "terseLabel": "Pre funded warrant issued (in dollars per share)"
       }
      }
     },
     "localname": "PreFundedWarrantIssuedPricePerShare",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "nltx_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre funded warrants",
        "label": "Pre Funded Warrants [Member]",
        "terseLabel": "Pre-funded warrants"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nltx_ProceedsFromSaleOfStockOfSubsidiary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of stock of subsidiary.",
        "label": "Proceeds From Sale Of Stock Of Subsidiary",
        "terseLabel": "Consideration from sale of assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfStockOfSubsidiary",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/SaleofAquinoxCanadaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property equipment and intangibles acquired through the issuance of common stock.",
        "label": "Property Equipment And Intangibles Acquired Through The Issuance Of Common Stock",
        "terseLabel": "Property, equipment and intangibles acquired through the issuance of common stock"
       }
      }
     },
     "localname": "PropertyEquipmentAndIntangiblesAcquiredThroughTheIssuanceOfCommonStock",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_PublicStockOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Stock Offering",
        "label": "Public Stock Offering [Member]",
        "terseLabel": "Public Stock Offering"
       }
      }
     },
     "localname": "PublicStockOfferingMember",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nltx_RestructuringPlan1July2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Plan 1 July 2018 [Member]",
        "label": "Restructuring Plan1 July2018 [Member]",
        "terseLabel": "Restructuring Plan, July 2018"
       }
      }
     },
     "localname": "RestructuringPlan1July2018Member",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/RestructuringAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nltx_RestructuringPlan1November62018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Plan, November 6, 2018 [Member]",
        "label": "Restructuring Plan1 November62018 [Member]",
        "terseLabel": "Restructuring Plan, November 2018"
       }
      }
     },
     "localname": "RestructuringPlan1November62018Member",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/RestructuringAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nltx_ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental balance sheet information related to leases for the periods presented.",
        "label": "Schedule Of Supplemental Balance Sheet Information Related To Leases [Table Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nltx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period",
        "terseLabel": "ESPP offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nltx_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extended line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nltx_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Table]",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nltx_StockBasedCompensationIncreaseInCommonStockIssuancePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage increase in the number of authorized common shares for grant under the stock based compensation plan.",
        "label": "Stock Based Compensation Increase In Common Stock Issuance Percentage",
        "terseLabel": "Shares of common stock reserved for issuance percentage"
       }
      }
     },
     "localname": "StockBasedCompensationIncreaseInCommonStockIssuancePercentage",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nltx_StockConversionRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock conversion ratio",
        "label": "Stock Conversion Ratio",
        "terseLabel": "Stock conversion ratio"
       }
      }
     },
     "localname": "StockConversionRatio",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nltx_StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock decrease during period conversion of common stock to\u00a0pre-funded\u00a0warrants shares.",
        "label": "Stock Decrease Increase During Period Shares Conversion Of Common Stock To PreFunded Warrants",
        "terseLabel": "Conversion of common stock to pre-funded warrants (in shares)"
       }
      }
     },
     "localname": "StockDecreaseIncreaseDuringPeriodSharesConversionOfCommonStockToPrefundedWarrants",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "nltx_StockIncentivePlanTwoThousandFourteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Incentive Plan Two Thousand Fourteen [Member]",
        "verboseLabel": "2014 Plan"
       }
      }
     },
     "localname": "StockIncentivePlanTwoThousandFourteenMember",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nltx_SubsidiarySaleOfStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Sale Of Stock",
        "label": "Subsidiary Sale Of Stock [Abstract]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAbstract",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "xbrltype": "stringItemType"
    },
    "nltx_SubsidiarySaleOfStockTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Sale of Stock",
        "label": "Subsidiary Sale of Stock [Text Block]",
        "terseLabel": "Sale of Aquinox Canada"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockTextBlock",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/SaleofAquinoxCanada"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nltx_TenantImprovementAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tenant improvement allowance pursuant to lease arrangements.",
        "label": "Tenant Improvement Allowance",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "TenantImprovementAllowance",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_TenantImprovementAllowanceReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Element represents the carrying amount as of balance sheet date of amounts receivable related to tenant improvement allowance.",
        "label": "Tenant Improvement Allowance Receivable",
        "terseLabel": "Tenant improvement allowance receivable"
       }
      }
     },
     "localname": "TenantImprovementAllowanceReceivable",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_TerminationFeesForLeaseTermination": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of termination fees related to lease termination.",
        "label": "Termination Fees For Lease Termination",
        "terseLabel": "Termination fees for lease termination"
       }
      }
     },
     "localname": "TerminationFeesForLeaseTermination",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_TransactionRelatedCostIncurredForSaleOfSubsidiary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction related cost incurred for sale of subsidiary.",
        "label": "Transaction Related Cost Incurred For Sale Of Subsidiary",
        "terseLabel": "Transaction cost on sale of asset"
       }
      }
     },
     "localname": "TransactionRelatedCostIncurredForSaleOfSubsidiary",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/SaleofAquinoxCanadaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nltx_UniversityOfWashingtonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "University Of Washington [Member]",
        "terseLabel": "University Of Washington"
       }
      }
     },
     "localname": "UniversityOfWashingtonMember",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nltx_WriteOffOfRightOfUseAssetUponLeaseTermination": {
     "auth_ref": [],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write-off of ROU asset upon lease termination.",
        "label": "Write Off Of Right Of Use Asset Upon Lease Termination",
        "terseLabel": "Write-off of right-of-use asset upon lease termination"
       }
      }
     },
     "localname": "WriteOffOfRightOfUseAssetUponLeaseTermination",
     "nsuri": "http://www.aqxpharma.com/20201231",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r185",
      "r186",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r324",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r185",
      "r186",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r324",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OfficeBuildingMember": {
     "auth_ref": [
      "r334",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Building [Member]",
        "terseLabel": "Office"
       }
      }
     },
     "localname": "OfficeBuildingMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r128",
      "r178",
      "r179",
      "r305",
      "r323",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r128",
      "r178",
      "r179",
      "r305",
      "r323",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r181",
      "r185",
      "r186",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r324",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r181",
      "r185",
      "r186",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r324",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r129",
      "r130",
      "r178",
      "r180",
      "r326",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r129",
      "r130",
      "r178",
      "r180",
      "r326",
      "r334",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_WA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WASHINGTON",
        "terseLabel": "Washington"
       }
      }
     },
     "localname": "WA",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/Accountspayableandotherliabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and other liabilities",
        "totalLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails",
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r6",
      "r26"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r24",
      "r146"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r16",
      "r225"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r70",
      "r71",
      "r72",
      "r222",
      "r223",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r187",
      "r189",
      "r228",
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r172",
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Discounts, commissions and offering expenses"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r189",
      "r218",
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequitySummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/NetlosspercommonstockScheduleofSecuritiesExcludedFromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/NetlosspercommonstockScheduleofSecuritiesExcludedFromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/NetlosspercommonstockScheduleofSecuritiesExcludedFromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/NetlosspercommonstockScheduleofSecuritiesExcludedFromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Lease agreement, square feet of office space"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r67",
      "r111",
      "r120",
      "r126",
      "r133",
      "r259",
      "r261",
      "r265",
      "r309",
      "r316"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r35",
      "r67",
      "r133",
      "r259",
      "r261",
      "r265"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r190",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of presentation and summary of significant accounting policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/Basisofpresentationandsummaryofsignificantaccountingpolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Acquisition Of Assets [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails",
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncSummaryoftheAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r60",
      "r61",
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchase of property and equipment unpaid at period end"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r21",
      "r58"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesCashandcashequivalentsandrestrictedcashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesCashandcashequivalentsandrestrictedcashDetails",
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r8",
      "r59",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r53",
      "r58",
      "r63"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesCashandcashequivalentsandrestrictedcashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of year",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of year",
        "totalLabel": "Total cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesCashandcashequivalentsandrestrictedcashDetails",
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r53",
      "r270"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents, and restricted cash during the year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r65",
      "r67",
      "r82",
      "r83",
      "r84",
      "r86",
      "r88",
      "r94",
      "r95",
      "r96",
      "r133",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of common stock in prefunded warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Outstanding pre-funded warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/Commitmentsandcontingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "ESPP common stock reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r70",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.000001 par value per share; 100,000,000 shares authorized at December 31, 2020 and 2019; 42,196,296 and 37,996,849 issued and outstanding at December 31, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred income tax liabilities"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r100",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of credit risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "verboseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r13",
      "r14",
      "r173",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Convertible preferred stock, Shares issued upon conversion (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy": {
     "auth_ref": [
      "r64",
      "r156",
      "r157",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation.",
        "label": "Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]",
        "terseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r11",
      "r12",
      "r237",
      "r310",
      "r315"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "nltx_DeferredTaxAssetsBeforeValuationAllowance",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangibles"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "nltx_DeferredTaxAssetsBeforeValuationAllowance",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r240"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r245",
      "r246"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "U.S. net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "auth_ref": [
      "r245",
      "r246"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "terseLabel": "Canadian net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r245",
      "r246"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r243",
      "r245",
      "r246"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development deductions and credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r245",
      "r246"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock Compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r245",
      "r246"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "terseLabel": "ROU Assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r245",
      "r246"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesComponentsofDeferredIncomeTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "auth_ref": [
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for defined contribution plan.",
        "label": "Defined Contribution Plan [Text Block]",
        "terseLabel": "401(k) plan"
       }
      }
     },
     "localname": "DefinedContributionPlanTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/A401kplan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r56",
      "r144"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/PropertyandequipmentnetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r56",
      "r110"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per common stock - basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r64",
      "r89",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings (loss) per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Net loss per common stock"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/Netlosspercommonstock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r270"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r233"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "negatedTotalLabel": "Income tax recovery"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r233",
      "r252"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "negatedLabel": "Statutory federal income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r233",
      "r252"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "negatedLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r233",
      "r252"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "negatedLabel": "Change in tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness": {
     "auth_ref": [
      "r233",
      "r252"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation.",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Percent",
        "negatedLabel": "Disposal of Aquinox Canada"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r233",
      "r252"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "negatedLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r233",
      "r252"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "negatedLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r233",
      "r252"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "negatedLabel": "Stock compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r233",
      "r252"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r233",
      "r252"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "negatedLabel": "State income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r233",
      "r252"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "terseLabel": "Tax Credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofIncometaxRecoveryDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and vacation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation cost (in dollars per share)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized stock-based compensation cost, weighted-average period recognized (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Shares issuable under 2020 ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/NetlosspercommonstockScheduleofSecuritiesExcludedFromComputationofEarningsPerShareDetails",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Outstanding stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/NetlosspercommonstockScheduleofSecuritiesExcludedFromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r70",
      "r71",
      "r72",
      "r74",
      "r79",
      "r81",
      "r93",
      "r134",
      "r172",
      "r175",
      "r222",
      "r223",
      "r224",
      "r248",
      "r249",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r328",
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesByIndustryAxis": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by industry sector, examples include but are not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.",
        "label": "Industry Sector [Axis]",
        "terseLabel": "Industry Sector [Axis]"
       }
      }
     },
     "localname": "EquitySecuritiesByIndustryAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquitySecuritiesIndustryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Industry sector consisting of government, private and corporate entities engaged in business activities, including but not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.",
        "label": "Industry Sector [Domain]",
        "terseLabel": "Industry Sector [Domain]"
       }
      }
     },
     "localname": "EquitySecuritiesIndustryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r64",
      "r263",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair value of financial instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r280",
      "r286",
      "r296"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "verboseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "verboseLabel": "Finance lease liability"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r279",
      "r295"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "negatedLabel": "Less: current portion",
        "terseLabel": "Finance lease liability"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of Company's Finance Lease Liability"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Non-current lease liabilities\u2014December\u00a031, 2020",
        "verboseLabel": "Non-current finance lease liability"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "verboseLabel": "December 31, 2021"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "December 31, 2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "December\u00a031, 2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "December\u00a031, 2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "December 31, 2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r281",
      "r290"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Payment on finance lease obligations"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease right-of-use asset"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r280",
      "r286",
      "r296"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "verboseLabel": "Amortization of right-of-use asset"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r293",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate\u2014finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r292",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term\u2014finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Intangible asset useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IntangibleassetnetSummaryofIntangibleAssetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IntangibleassetnetSummaryofIntangibleAssetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IntangibleassetnetSummaryofIntangibleAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Expected amortization expense 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IntangibleassetnetSummaryofIntangibleAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Expected amortization expense 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IntangibleassetnetSummaryofIntangibleAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r136",
      "r138",
      "r140",
      "r142",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r140",
      "r307"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IntangibleassetnetSummaryofIntangibleAssetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IntangibleassetnetSummaryofIntangibleAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r136",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r140",
      "r306"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.aqxpharma.com/role/IntangibleassetnetSummaryofIntangibleAssetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net intangible asset",
        "verboseLabel": "Intangible asset, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.aqxpharma.com/role/IntangibleassetnetSummaryofIntangibleAssetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r269"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/OtherincomenetScheduleofOtherIncomeNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign exchange gains (losses)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/OtherincomenetScheduleofOtherIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r57",
      "r268",
      "r269"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedTerseLabel": "Unrealized foreign exchange loss and others"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.",
        "label": "Gain (Loss) on Termination of Lease",
        "negatedTerseLabel": "Loss on termination of lease"
       }
      }
     },
     "localname": "GainLossOnTerminationOfLease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainOrLossOnSaleOfStockInSubsidiary": {
     "auth_ref": [
      "r43",
      "r44",
      "r56",
      "r312",
      "r322"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries.",
        "label": "Gain (Loss) on Disposition of Stock in Subsidiary",
        "negatedTerseLabel": "Gain on sale of Aquinox Canada",
        "terseLabel": "Gain on sale of Aquinox Canada"
       }
      }
     },
     "localname": "GainOrLossOnSaleOfStockInSubsidiary",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.aqxpharma.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/SaleofAquinoxCanadaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative expenses",
        "verboseLabel": "General and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/RestructuringAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/StockholdersequitySummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "verboseLabel": "In process research and development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r68",
      "r251"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofNetLossIncomeBeforeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofNetLossIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r68",
      "r251"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofNetLossIncomeBeforeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Canada"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofNetLossIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r68",
      "r111",
      "r119",
      "r122",
      "r125",
      "r127"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofNetLossIncomeBeforeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesScheduleofNetLossIncomeBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/RestructuringAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/StockholdersequitySummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/RestructuringAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/StockholdersequitySummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r234",
      "r235",
      "r242",
      "r250",
      "r253",
      "r254",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/Incometaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r38",
      "r64",
      "r231",
      "r232",
      "r235",
      "r236",
      "r241",
      "r247",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.",
        "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other current assets and non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible asset, net"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/Intangibleassetnet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r46",
      "r48"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/OtherincomenetScheduleofOtherIncomeNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/OtherincomenetScheduleofOtherIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r294",
      "r296"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total net lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Components of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]",
        "verboseLabel": "Finance lease cost"
       }
      }
     },
     "localname": "LesseeDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Company's Operating Lease Liability"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "December\u00a031, 2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "December 31, 2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "December\u00a031, 2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "December 31, 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "December\u00a031, 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r27",
      "r67",
      "r121",
      "r133",
      "r260",
      "r261",
      "r262",
      "r265"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r67",
      "r133",
      "r265",
      "r311",
      "r319"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAssumed1": {
     "auth_ref": [
      "r60",
      "r61",
      "r62"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.",
        "label": "Liabilities Assumed",
        "negatedLabel": "Accounts payable, finance lease and other liabilities assumed through the issuance of common stock"
       }
      }
     },
     "localname": "LiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r29",
      "r67",
      "r133",
      "r260",
      "r261",
      "r262",
      "r265"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndMaintenanceMember": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset and process of preserving asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and Maintenance [Member]",
        "terseLabel": "License and maintenance"
       }
      }
     },
     "localname": "LicenseAndMaintenanceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r97",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/Natureofoperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r53",
      "r54",
      "r57"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r36",
      "r37",
      "r39",
      "r57",
      "r67",
      "r73",
      "r75",
      "r76",
      "r77",
      "r78",
      "r80",
      "r81",
      "r85",
      "r111",
      "r119",
      "r122",
      "r125",
      "r127",
      "r133",
      "r265",
      "r313",
      "r321"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently issued and recently adopted accounting standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.aqxpharma.com/role/OtherincomenetScheduleofOtherIncomeNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income, net",
        "totalLabel": "Other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.aqxpharma.com/role/OtherincomenetScheduleofOtherIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r111",
      "r119",
      "r122",
      "r125",
      "r127"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "negatedTotalLabel": "Total operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r287",
      "r296"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "verboseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: current portion",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current operating lease liability",
        "verboseLabel": "Non-current lease liabilities\u2014December\u00a031, 2020"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.aqxpharma.com/role/LeasesScheduleofCompanysOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r282",
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "verboseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesSupplementalCashflowInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r278"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r293",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate\u2014operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r292",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term\u2014operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating losses carried forward for tax purposes"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r28"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesScheduleofAccountsPayableandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": {
     "auth_ref": [
      "r41",
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Other Nonoperating Income and Expense [Text Block]",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeAndExpenseTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/Otherincomenet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/OtherincomenetScheduleofOtherIncomeNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expenses"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/OtherincomenetScheduleofOtherIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of offering costs",
        "terseLabel": "Public offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r190",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.000001 par value per share; 5,000,000 authorized at December\u00a031, 2020 and 2019; 0 issued and outstanding at December\u00a031, 2020 and 2019"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassification"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from public offering of common stock and pre-funded warrants, net of commissions of $4,575 and $5,173 in 2020 and 2019, respectively.",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r51",
      "r221"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r51",
      "r221"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r24",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r149",
      "r336",
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/Propertyandequipmentnet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r23",
      "r145"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r9",
      "r10",
      "r147",
      "r320"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.aqxpharma.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Net Book Value"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.aqxpharma.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r22",
      "r64",
      "r147",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r9",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/PropertyandequipmentnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r9",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "verboseLabel": "Purchase obligation"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
        "terseLabel": "Acquired in-process research and development",
        "verboseLabel": "Acquired in-process research\u00a0&amp; development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/RestructuringAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/StockholdersequitySummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r64",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r8",
      "r58",
      "r63",
      "r308",
      "r317"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesCashandcashequivalentsandrestrictedcashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesCashandcashequivalentsandrestrictedcashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/NetlosspercommonstockScheduleofSecuritiesExcludedFromComputationofEarningsPerShareDetails",
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/Restructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "auth_ref": [
      "r151",
      "r153",
      "r161",
      "r163"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs incurred to date for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "terseLabel": "Restructuring and related cost, cost incurred to date"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/RestructuringAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r56",
      "r150",
      "r157",
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/RestructuringAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/RestructuringAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/RestructuringAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/RestructuringAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r152",
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "terseLabel": "Restructuring reserve"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/RestructuringAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveAccrualAdjustment1": {
     "auth_ref": [
      "r150",
      "r158"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.",
        "label": "Restructuring Reserve, Accrual Adjustment",
        "negatedTerseLabel": "Revised estimates during the year"
       }
      }
     },
     "localname": "RestructuringReserveAccrualAdjustment1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/RestructuringAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r175",
      "r225",
      "r318",
      "r331",
      "r332"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r70",
      "r71",
      "r72",
      "r74",
      "r79",
      "r81",
      "r134",
      "r222",
      "r223",
      "r224",
      "r248",
      "r249",
      "r328",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r108",
      "r109",
      "r118",
      "r123",
      "r124",
      "r128",
      "r129",
      "r131",
      "r177",
      "r178",
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue from contract with customer, excluding assessed tax"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r291",
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease liabilities arising from obtaining right-of-use asset"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/SaleofAquinoxCanadaDetails",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Other Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/AccountspayableandotherliabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/NetlosspercommonstockScheduleofSecuritiesExcludedFromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Securities Excluded From Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/NetlosspercommonstockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Supplemental Cash flow Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of Deferred Income Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncometaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Income Tax Recovery"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncometaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r189",
      "r217",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r136",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Asset"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IntangibleassetnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Net (Loss) Income Before Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncometaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of Other Income, Net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/OtherincomenetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r24",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/PropertyandequipmentnetScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Summary of the Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r8",
      "r63",
      "r308",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r154",
      "r155",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/RestructuringAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r190",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofRSUActivityDetails",
      "http://www.aqxpharma.com/role/StockholdersequitySummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r196",
      "r206",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Weighted Average Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r64",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Restricted stock units forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Restricted stock units forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock units granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Restricted stock units granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Non-vested ending balance (in shares)",
        "periodStartLabel": "Non-vested beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Non-vested ending balance (in dollars per share)",
        "periodStartLabel": "Non-vested beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "RSU Activity Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Restricted stock units vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Restricted stock units vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividends"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofRSUActivityDetails",
      "http://www.aqxpharma.com/role/StockholdersequitySummaryofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "ESPP max contribution rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "terseLabel": "RSU Activity"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Maximum number of shares of common stock that may be issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available to be granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Stock Option Activity, Additional Disclosure"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable, Number of options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable, Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Common stock issued upon exercise of options aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options cancelled/forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Options outstanding at end of period, Aggregate intrinsic value (in dollars)",
        "periodStartLabel": "Options outstanding at beginning of period, Aggregate intrinsic value (in dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r198",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding at end of period (in shares)",
        "periodStartLabel": "Options outstanding at beginning of period (in shares)",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Option Activity"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Options outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Stock Options Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r188",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options cancelled/forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r64",
      "r190",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Accounting for stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "verboseLabel": "Award expiration period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r212",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected terms (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable, Aggregate intrinsic value (in dollars)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, Weighted average remaining contractual life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding, Weighted average remaining contractual life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "ESPP purchase price of common stock, percent of market price"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Sale of shares under public offering (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r288",
      "r296"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StandbyLettersOfCreditMember": {
     "auth_ref": [
      "r170",
      "r171",
      "r258",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.",
        "label": "Standby Letters of Credit [Member]",
        "terseLabel": "Standby Letters of Credit"
       }
      }
     },
     "localname": "StandbyLettersOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r65",
      "r67",
      "r82",
      "r83",
      "r84",
      "r86",
      "r88",
      "r94",
      "r95",
      "r96",
      "r133",
      "r172",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r32",
      "r70",
      "r71",
      "r72",
      "r74",
      "r79",
      "r81",
      "r93",
      "r134",
      "r172",
      "r175",
      "r222",
      "r223",
      "r224",
      "r248",
      "r249",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r328",
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r70",
      "r71",
      "r72",
      "r93",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r31",
      "r172",
      "r173",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock into common shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r14",
      "r15",
      "r172",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of common stock to University of Washington (in shares)",
        "verboseLabel": "Shares issued for service (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r172",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of discounts, commissions and offering expenses (in shares)",
        "verboseLabel": "Sale of shares under public offering (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period, Shares, Purchase of Assets",
        "terseLabel": "Issuance of common stock and convertible preferred stock for Former Neoleukin common stock (in shares)",
        "verboseLabel": "Stock issued for acquisition (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.aqxpharma.com/role/LicenseandpatentagreementsAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/MergerofNeoleukinTherapeuticsIncandAquinoxPharmaceuticalsIncScheduleofTotalConsiderationPaidDetails",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r14",
      "r15",
      "r172",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock units vested (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r172",
      "r175",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)",
        "terseLabel": "Options exercised (in shares)",
        "verboseLabel": "Options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/StockholdersequityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r14",
      "r15",
      "r172",
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of common stock to University of Washington"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r172",
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of discounts, commissions and offering expenses"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period, Value, Purchase of Assets",
        "verboseLabel": "Issuance of common stock and convertible preferred stock for Former Neoleukin common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r32",
      "r172",
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r18",
      "r19",
      "r67",
      "r132",
      "r133",
      "r265"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r66",
      "r175",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/Stockholdersequity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/SaleofAquinoxCanadaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.aqxpharma.com/role/SaleofAquinoxCanadaDetails",
      "http://www.aqxpharma.com/role/StockholdersequityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/SaleofAquinoxCanadaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credits for research and development"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r98",
      "r99",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates and assumptions"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/BasisofpresentationandsummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase (decrease) in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r289",
      "r296"
     ],
     "calculation": {
      "http://www.aqxpharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/LeasesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Basic and diluted weighted average number of common stock outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.aqxpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921835-210448"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3,4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121596127&loc=d3e12803-110250"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/subtopic&trid=2235116"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121604053&loc=SL77918607-209975"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(g))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r348": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r349": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r351": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r352": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r353": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r354": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r355": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r356": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(9))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>89
<FILENAME>0001628280-21-005630-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-005630-xbrl.zip
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M2%0%,HF19D+?2"])\HK#)&>BC(=6F$S%&- *1E:)MV8BRO3U(\LEW6PBN0'
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M]>/CQJ.B'OOUDZ/]I4<]#IZFV^9A_>B@^1S!E*>TWY80;%D;\W(5;#/U$WT
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MB%?H< 17"++E55TL$3'J'+EWG&#YET7"9#P=ED3X]=V;-_\(_O[B[<7E70B
MLYYV;]?C]&N*YN_?,4IP^R6U4^+QN\?O[NJ[=HSF[1-DTW'#\'CTI;_1E_YH
M<J;L2!=I\.N8)8C70L"9E\-UJ(?APSV9I=$6_K,L5O%/_P-02P,$%     @
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M5WUBUFL"AWCKEZP_-47HJ6E.C1\BS2E+HH.9<I0G*R51^F]A.C8ZZ=+,0TY
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M=YBC5T$3["V#Y)NJOOF!O3,US(Y\=M!\GMH:Q?JRBW]?DSJ/0G.UX'I)09:
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MYD9W#I ?"AD@0>D=4)P6K]<0A8&#O$4H H$#?03UC^+[EVQY<Z\5/G'/D5^
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M"OQ\)]S;N%4#>?7G@9RP/"GT P)A2ET4J2G%3(U!#F$O] "T[_K(QHI0K#K
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M+CRP=7["/G<'Y_!$]OFBQUKLLM4;=-M7IZT>N[SJ75[T.P6ZJGUQW@=]]VH
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MA2AN6<"K)J:0"Y$KEQA%*LRM,W\Q99AJVFZY&S[ Y0BW+V+XY*DA..&IQ/1
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M.GE!4ZOO+O%<=M=2:.J9X*CY^\WB*%@2M@E\G>.@4KPJ5$PY0""#>@BJ\9C
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M;8</@.M.N7_'QWKK_U6UT3-0I8<OJG2N3+)@K2?B6] L-TH%E5BH'4KV":V
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MJR>P3&Y@&I?2=O+3I5,M;,U\5C.7V'<*X4/@SLQSB$?!<"R*2VREG#&,QN:
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MG?8^)[#QQP<[Y]==@-_N!3SWXA3@_=,-;&#K2TQ"VZ*QI7N>;^D.M5T=UIT
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M?8FV9O"UK?F8(WSQ2,H76O'=&\J'E49*+<>LZ>NDY%J2,6 7]+;#-SS)M+S
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MBLXT586=NB.I(E5)=8C)Q/)#XN,R-BW@5,>+^6.7M6!U70]VKQ^H6'@L@LP
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M P.@_0]&@_K!S>85HQF2A+W^0V[OT1#']-^![ZX#X2>YHIS=J=QM^:[F((#
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MQ=< L]&ZTM)%I*X[+ZI?P6QST.&L]WG4/]JHAU7=,HCN,-!D"8^'I 7#=US
M/ EV*IFK)VH^#+>8[JZRE7]RH1 Z]>W(IUI^]>U;Z^XD*9I&A=,9]">WS*R!
M7& [G#[AA"%;);#1G]?/1UH_M$(D%D9JW.4-:*8H!7':4=Y/ZL&':'5I2L)X
M=DNPO&TH">,:Q?"N;ZJJ%F5D2A]!F_#99YQY>?OR#0IMB_SZFH8'&'/1<;9,
MF!^L$$QJ9H4Q<R%VIV[(3<&2/Q/9)1). 1TDD=51L.KOY5*">ML(CFX7VV)#
M^3Q+%JZM8'?%J;3!C!;^ ?5A$A0;<CEUL-_TN-J.;6D[_WKMF3K&+\"_G+%@
MI_$LORLLV/1:')D=)3R@*H-L8&A6UTSS)NPB(N*]M&SNY>*_+0/O;*$G1Z"D
MJC<+KL9-P*Z9TC:KJCS7IFSL!0%DD8?@N^]'#Q59 3GYGO\&3J>W+F6%/)6E
MJUT"*^VCMX&\(?GUKCED/H^E/A6+CR<L@9( DSB-IIA;**0Q7_J(6T@/ ,.@
MDN[' BU;$#_>Q,*Z_6WX<LC)^,K!7&CHJPG^%)I-O?$#<)-*.TP&"GQ$"TJB
M!>Z21WF+S'A,(J'Y;\//R#4REJK.-2FN#^1^'<YG4F6<F)]!XX/S9%5(DHK%
M*,8/^K^H&;,.B_%R\4UXG@M0MXV&U9$X8)119M></I!H(D7/Y#C-LJSJ35'Q
M[T!"00M#2BY&,,M[CT8(@NEM'#FJ!'WZ[&(5/GV7<P.<D&C$[Z31'J)MN8PE
MVPT19W#)L)G501O-77A.).T8#*D31R+BE?1K\B4Z-FA5N#1$K$M0/^AK6"=Q
M>!!Y!7[T+&U L=%/(!)T!<L17BY>CE(?MR:*/281GDU+,"LK2V+'PF;;[ZDX
MJ",8>PKC->K&2Y9QDB0B*.46A!%8Y0TU8PJGBG(@P8@R?RKZ4KDDZ06ZC7R'
MZC[\^7H[Z(N6/L5]V+GH\',O3L\'J$Q=26OE<,04Y22&HU@YW;^)1/R$M6"=
MOMEOG.2@9,FH?.YMM%?[TPHR#(!@=I@L7MAG2'H%[-,,-;7>&KXP6K1=WYOO
MB$.W(,E"R5>5-2AL[=>T5?6NLJ2YCY3W85B.RK(:Q\,!8>RKID<?I_D^VRM[
M[,3/;$5[@!*ET?U*O?WA5**6QB;*@P&KQA;514N#=9(S/2>!>%@>;,=JQ+!J
MOJ6()#JU.[*-Z9+!Y<0<BL:7]4+S!IO*SW*,'P_@&B(<K<QNL$G2%8Y6JK)]
M;S9[8"UE1?!1G)Y?$O326<E*Q" E]8<GD+2ZILJ)V@RM(<!7A@M)R@@>UA!.
M*/ZE=;EZ(-5X^&%PJ>K V^$F;/IB940 .K7E-IW<+;M><Z@(K.9W7T2-VL2G
M 5KDD,ZU:TN;F^NX[5)PS&B2T"D<F:&R<9LX@7&(<YOD1K@:0VDP0BP@'P_0
M?7+R@+D%?+%HP8B>>V+N>$R*GW/*-?*Q&MSV7)U(9YTBN.+5#]]^P<O& Q,:
M$[:3G>/;0@F0"$(B!9N X9:[/X>66(>SC'W$*L @EI0!GT*&FXPQ[Q_"^;:V
MW)+!EB,"8W[ZALL&)G%%Q/&==$]*CVA JZWJS7<AH"YXS#WY&X84O\0 ]FV/
MKT83)$=%R6C1CDCA84O#8MSF>YH!N 0L:"O6Q-UJZF%Q)_>811M.N&OB?5 7
MJ3VC,#Z.[M54UO@M]N'S!6S?BR=,:?_;WQ;Z+!)8M^*(EX()[ASVZ<@FH/6N
M\8=><1H^D)ZU9DOL2."BXPP$4ONN#PMB\ H^:Q$929S=]HHU">.C.GS!,0S1
MZ+9L=YEB32'6%H-[^242O8M\:<W0LV&*!6"9')<KQ550RWQ;+SDQC?<,8]V$
MMX/R9]T:E'5M&614<TETC%E%PDL0!_$2C$A)P\;EXA6;=PPZ>\:CD:< F#S;
M<NA4<$1^I%IEA_/]@T2>E;RN3#3CQ45$F$X5OI4(/(:Q=,_\8OC,#STKSN;H
MD<R1SL/IV*07T28= 51$<S+<[,E&F=N['O20._X=AWGX0_O)M*F:M%$<EQ)<
M[I!Q("P>%6UUX@;J:N)_4A[*>M\A[<A_M)*O48Y;30DM5.W0L%!PR8XC.5AC
M2X/'#.;I\NAF@]'L#GL1_!I@6,@W#E9J:\XI_4II(F+49*1!RL2TK_<2,\UO
MYA/=O5#*.K7=&Q[JGMW[Z1/O7I:4X]W[Z>0B>]!&1LZ58@J2B9M:3Q23&LN3
MB-25+7&&C5/$H B#CW 0#99&PFS.QH90?@ML=N..V;;?;"2A\T%6A/*MT*?4
MLT\2V(VRTK*94F%H,U>Z^^W9T[O&;3X!\ZK!Y+A5EO,+I""X8AQ\EIMR/ZA%
MF(U1$E$J32F$C>6.D&P8L+X@8-[5$$9M19Q44B.(VULH#!W%PLTM#%A)D_Y+
M,W'R[&S#KI187:^4(!\3)V?1\*"W'5,JQY+$'YY_(L2^\-/(4(-@4WC4H/'*
M%7&Y?'PVE2A  SYE:<JV(W%2J5)05Q *1%B1:!>A-=GGZ%D6F<,TQ45&M<BI
M>8&X"GG6R<G;41OA%B6JLJ&.H89/@?#[ZW(%FO/&M1*E;4/<=!(+5-"99N;.
MX.\!\2OF.W;96]50B0-SZA,B670>A#ME.1#H(:Y*B8Q.=R!2-?R4X?=_>/$)
M\^4CZVQ-$KYD9/>OW=8[\1S!R[I21";CM(:>=F3^BX$]4&6)R.\$V#XF\(Q2
M+WY^VFFW$IIXXX>6>_4'Q<IT^UL?)$CZ<NN#XOXL7XCS7RHKSQ41MCBUV4@_
MP#!?2MBU))O'.8H!IY7<UDH<)$K!D +;6%"!Q ,8;618^-=Y!Z;5P6LYN9=J
M-=U%GX+WPA]P<QUN1=(!"R3&'[8>KACMQ##41;6A'GUYEHPHU;1RB.T6+=:Z
M= ?#L 78M[_N\^7[?(,N**T#0!1>9-G.8"&W_?YZ!@N=QK.<P4)_(QNA#EX;
MM4K$I(]*MV,O1]/K(P-F8B 8[\V@>H& LJRU<GY+M2R")]T4VW6(P=:G?H1>
MM6T/"55'TCQ 7D-G26 0#N P/&CH<PF-H6$^TUH2D$X)1,,76#NN?A&AD;(\
M)^S0Z2DH7 I)4X0<<'033+MOJ760&WI<!TZ)WKZGI#$L3B7\5?MR&PL\5"AB
M^\Y",^[A1JDZEOV<@]E8! ^<#4BBQGQ8*>,CEZEL"&/5VKO=>DK3U<5-.-S7
MFG)_?)7TI\A[&W0_Z66_4JA5VPG,:9\;K$@>GIEXXYI0G@@ML7EH#B(>M(!3
MC. .<5]=S!.VB;X%9T#QN7"#:'A"?K</2%RS@'Z%;G*7EZ?$;'6\R ^Z%:D6
M; \*G!;H.]-OB_N+Z96NM5*9U-ODHR(PL]"+4S3]YV><VEB1F [$*ICQ85F4
M>P:D::],3+2%N$/\OK3EW]C#<&_A)! ]H$3;ZHHHGPZVHZBZUJ*M7>_AV628
M4,8V@??X8^+;U@?(JVB0@DMH:#!Z [?L:*6-'S%&W,!7M5R,"<?SGLJK<DT_
M=&#C@ZE;%@U(K'WCVJ9VQ!HR;\)VP'K"W.4MRGEYLU OF/@.OGV=+91+9[DE
M#6>81,A6&7A(+FII!]\C3'<''T@]7#,*00-MO1='6VEN@-Z/Q,5L\7P^B:ZM
MZ#%GG](4J]*GY('CQUN#XE4'IBU_U@<R\:OY1Z)<!;V-\ *YNW-N);TY F6]
MCJUCOIAV&R1/R-T&BC\E@TB-$(C9)<YOX I<T-(E]2,%N5C[!N R"C'.8GB?
MSPDJXO!CLTUA?V*UF8E=ZO^W>3BQKEG.7!0K;5DND==C_N>X[#06!%R""MD4
MBM9-$C'+T -#4E$.O+%534S+%_%<\K%RG0!3DQS<DK#<ZT,:6F])[.&@F3$#
M-L:]^1LQR^9!<N@CFA8%;.?0"#@:'6\$,%==_CZAJB)I@!!7%TV<4OY6-.3>
M$D^'X=X\&X34M<?1*DM= VP:\.?I!(8#DSV8P<7T&@Q+<<'^)+*+,A7Q39CD
M=%TT*0D)%-@@/#K9A80S7/!@8/VB^E%GX%H6<_/[AO.:C)3)5[=E*ZV'6+Y4
M^;4Z#-6CJF(K-LQJ8? :R[SR;*B"/<J<T<H\,)[=2>+O(Q#P2GZ)_31W6H83
M3VV"=B+05;B^=2=T38+'BH.HL#H2:%7\4WI;!:A,O3NQEI6=;7'1R1U^?YD3
ME0PJ560X=SDXZ$*<6J8:]*>Y1[\0$A4,JKFB\707EZK=*]YVKL/4+7>_T.-<
MX$JP M+$YK_55]#5*+OTP)&@=#)9I[0@[GE82GVJ>W7,*N^[4EU;:TSW)40[
M:79/O *+"I72SG0KD_3:]4.&..XS/]B"TN.M5<6C*&%?:)/''T.JO6]']],Z
M3[22BCB>ZR7.V*^$V*GJ+54Q,&5R(S S16^3B/L(.2I_)1=D[F\."U;WW=:<
M#4)MDQ>[+",MJW-,F=C1PNLDZG%GM=&1@G=O= 8+*GC4<VD'^\ 244<#W$[:
M[32)A A-GA2$PJB[19K$&.&;TYE$C"AQ4'3NHSV9GN%F9$W6T?BG[K::L55T
M:B7+<9/<AP?VK@:[570J&5HJ$'( H0Y[T1GT@X=#0!M>C11,'*B2.ELI0WT0
M.F@]C>BG8 AH@<(]CS(Q_NV5IPR)K9GR0QP:JI.%WP$7P"=GS^3;:FW"@"'&
M7L\D:0QD3X:!S!3/#SG)M&9B%XO!?-TC12T4RDJ8D -^BF#J"'Y4RW&Y>(4O
M*#8)OOQ4I=IY3Z24)=K>NF_57T U,)S^'=]963\[R#?EE6Q/&EC[9"O9BQUG
M5$[\M+H:6QUIF_Z%!;-2S50I<&K)5FC@E7^4W"0"G@X[P\@4V(>2O)K?OKY?
M/!]RC@V<5(&B$,N[7E>KH]@9J+>WRM/L;HEGH84,R"VMJ;OP/;J#7%/YDY@]
M3U5&N!X71X,,?C$XQ,+;<-T_2Y90A-Z32R4Q#2OQN.<RDCO&QE,>,6?!3";]
M8;N@-MM:/H7#>: GCQ@W89;$F332=_&/EW-OP\"G#$.B$&,A^^<,P;O7W_X
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M8HV,<"2^R459I0LH,FNXKS%9,4!$IMJ2/O73F[H/C<\(3F%ZO^_B8?#D+_(
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M[%'2*AK5L>"$I_CY5T8E?J7Y0G7O-^6M)$?72O"7JD>YE$F\N^">*+V=400
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MEJI+EHYKM.^LXE.)\VL6@JHPRC_K3B_:9>,Q:K.Q?Z1\D#M(U3AF)"V\\')
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M VA[^4'+I)E0 ',*AP:B*R^&B7NNSN>LHSG0C J^[+YNV-",CB1Y &W1((?
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MVX07D!/FKWM"P(7'_98H$*D6M[C:A,DX8#I??WL5!;@\O>(,G#3\.F\,3"A
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MW"GT!'!E!?"<XL%'W:$?.E?8NBQ9#3C;(-9H2R&#3$U]^)?V'/24(1#DJ <
M)+GA]7'LYWG!?)P]+P,^E0BF0Q8F7.&;,55'WJ\ -5T7LF-T3CHB8-T5-L[7
MIB;)2"# 8A",O$/)H))><R:K/<_]1TGE" ] M>&T[<Q4!L^L#O;AP'#N35^N
M@(X<=8TC$UA:1M8#1>VZA$5JZ>$6>5/W"0Q9S((0G'-@/80"8Z%J4R' R"#@
M68;+-\0W>EXFC[I,B(N-@6HABMJ3$I$D_J4!(>_R?^%4F<=H_2ZAL9^>H;&G
M\2QG:"SA$P7;I[V#(HHY6>Y_E/ZNXTU=VBKIO5!N'&B+2&7(@+,1!6CL89NE
M 9UHI9QMNTP)0D\;:/HEBU5D--K+0D$UI70.MO6NZ'"[R ;T"]HHPH T;7=!
M%R354QH4^:%65Y%_S(4;! 0QP2)5*O;4HA$FWH]9VG"N5Y(Y%:#Q2AZ.'(K+
MXM)='B A*)1=+GZB+@QYB[(-2Z1#DZITQA45<9QF[K'EUL%KZ=N>]9QO0FAK
MOVW[9H-6T29?E4)BI7\K=[N^BA\-!]:N]E=$/3JL[&M7@<92A.I-'%5/I@KU
M"N3T^1TX+TRIJ\6V7'-;#Q5U<GSR<O$##[H,L(U(.H%)HQ UGF@Y#CTK^Z8T
M'!4A?+D'3Q&>:-,229HI@!;-D+1>:<\+W#%W#X&$6L.5WYUR<\K PHL,;]1?
MM]2 0]0^F90X'$0DJF936L]SJD9RX>U!,A)+X )8&C2+!/;R.I +*=XGO>J*
MC8?K*A-&XW*YN)INAK\S>Y8Q7+5<.R$S!T5/T$XF!$SO-W=/;)M,AXBYV<-5
M;GS3X5TJ3,,P\4F Y$AYB2L2.4PD[4C@_[=%M>EN#ED49>+-:U6+:'Z1[ '5
M+B+$IS=Q_T2OM/7_AF5_4^2W)3K>B $7AQ.G(F3F= 5^5]3;HG]/447P,\%5
MA59__NN.&)/,9(T63&8]<Z^U33/IO7^0:E8\TXZ(6"9+CB>QG.ZZ=B?O[%5_
MAZW5#UH?@\:&(UW+2%RM6!TPL06S8F+W-3=SP@4=K'Y"J!G(-<FHT-&(XDC*
ME))O&\A!R;V#[0GA'.$M#^%..X[8]3@._ES?:;-NOMU0P':C+%A%L-JKUDK4
M$8*S#F\KW_G(@>RL/9B>[Q6UP]_63Q==_]O?M,$WDM73L;EF>&5PMZ;-C_1"
MA\<5[RF,^I+U$-\7P:$Y=$2^3JR;Y'$LYRX>+WR>E^&\C,:0>=:I7V'>QF?,
M@7\>UWO7>S /#5Q#:S$9KW(G[B?^IA'L()$T0WMRC(XB:83D&76VW+1M';I8
M;Z)RMVXK28NC^)8X]&IJHX<)!)?^(=R/M=7X-3S?OAXNJ<M!E=)A!R9Z[?HY
M_<!Z=E7*DGVHQP">C#'2^D@'9Y1=#F]PX,$_=KELKHRDS^,55\M&ZU-S%8#H
MZ8I'PLQ4$(= !(#@\VIU6[9T0Z+Z(>:)(J8B)QX'W%: !Z\H+JHNXG$.+:WP
M)DM)=E9N((;:??0HSGV*<.BF^$<A%V IB7Y?)U+&&TJ%5SO77DD3C6TB/N.V
MV)2M_![CD*A]YDMCS9A.X<<WY?2]EM)3B9!),?71?&J4+S,E<MJ7BW?S\RR!
MT"0@ [X#-S.#P P:<M0*Y)#E$F:&A]_+X+A>9VBYAY%MZAS9BCM'82&PX(:B
M-'T(1*1*&>-O!&20\4=DKB,MI6=)5P09%M+Y4(:4;1C_/EB:3**X5JI<@U>Z
MKG\FK?"\(6C\/:-'?!OZ)! L>1W67Y];3??;4OE4%C^((IPDTMZ]_O:'3#OW
MA'.759?70-]L:4&TW85QR(TE[9T6>.+0'F')8:Y6$ S-)OG00"]JXAH[F,^=
M:34GXZT"8PEG>>W8B]I818[4<PD*;S/GIENPZZP^D[.BE]W?8^W6'PGH%ETD
M?*'EQVL7(5Y<C-Y3SY7!'L(Q2>^Z'3Y)Q)V(K*/3A5&&X9V<'G-,0)QXA!4"
M&>+QMT3,U'R,0M09<!!4;636_[O"#OZALRXCZEPIMIP*U":5);'JT,J O:Z;
M%7O"CO^*Y)3G[B>WLOZ%<$_9<SCK^43Y1["E[4H, L\OD2_)!FF)=YCF..ZQ
MN%&4F5L+Z%4?QJ#N^0]:<9LIQ5XNKL8,5,%!*22W5[70R'6?F3F)":Z/%[&Q
M(HLQ>"LDSMVU*+TW>< 092C!OL93]'$>39I'C8&+6(KLRD9Y1(.)/,NN!O!0
MK\84B96*5$U0=PS.^:&W)#DXAK30H/"U#PD_!3!2W!?SX!?E-X%JE^? 5BBR
MOB$K&X.V+Y'W5F:KO)OZ.FB<S)'Y\6::U5..]B-3&@OT7/ZG$64Z.7@(+/C5
MMG78UO0MUABWAK#T*9)A+D69RLW[W$,H94M\3:5LT0U]7:2IV!11*M0L SJ$
MT9?($+,]R#N=9&1I)HC*D59=#:RZX_&8/SN]X+2LGMJYPL%]+-GGB#XWHV+$
M+TOQ."KE'IU*-6G!QTIVT8F?(3\^)$$;(_)[8\:'B: Q%4LMG#UGBI)'5C".
M2UAB0(EN8^O+5*8</#>B.NSUGB::AL](L8\V8]SUIWEDU_D7X\-D4K-S=\6O
M0,Y@)ZL5FZ46P&PK*KH"$EFM_,TH;YE0N.N409U>#JKYN?M= K;^> 9LG<:S
MG!)@ZVRW'F:W.-U<1@W;U428]$NDLAN5,GUPVD[0*]_+*'@^B1YW1A.=BI%>
M4M-0CEJ4GH3!>)I1Z#PO'\U#&$R*2%S!>6N"^T! OZ;HN'87VX>H.B(?+7YF
MZCA*^JSK9BZ%)NX@BP1(H_-Y6A]YNSFU,E5I0_?LK#8;)[L%=D2J9N<I>=PI
M8<54D-A1 4H#5F.QDYG0DL7TYHD(:ZEGN2+2><(>=\(8H,5MZ2G/V%%U#,9[
M 6(; :'A1VY[V0H*%G(4CI'7'7LJ&WZ>S\?>@&A,EF+GA\V?HZQD JL=\58)
M&H,$FPX.BLUNRSX_U&=_Y=$/-@6H$V3?I 0YMXT=9A#X-&UK$K)4DXT:LJGB
M$93KSA/VR 0?7A?5LP,(/$)Y XX00-PTU+\QJK0!VJK)^$EHTFG7,!*.?!%4
MYR[W(WU,$T"HV F-6O/2FAWF8=LL&31/R_JPQBR!5>!^ YAW@@5_^GGX)WH$
M5$-IBO1:&E.<3GU*8<H8M-L"] <.^*%]9K>(=&G:VX+ -)4,\70;@$>TT>0/
M-H[6'[?D#=Z4U^4,)7]C&(?D(#PNJ?7D,W??#CHROI%#S;/.H//E.MSPEDOT
M[OW'O3)<S 4PB&KJU$O.X,"F+[N$XE#ZST>7L ^@+A]\?*I;&ZU">I]!T7A/
MW/@9;]G,4Y@#XA1YXJ;5WH:T'%.1^+:K-P6W $X_ MX<7S>,&\FKY23 1/JB
MA*T:X1PY&2=<_N$T++D-8FI1_@O]X8N?BNR?_7(F!O#-NR]8_@#LL9,--U,(
M13*VQ(Y,4 R*U0A*0AB=ILA;8&.<)AQK5:UYE[;]]3^4^LB38P+*I:=:4XC0
M5QA2D*>&>>@K=W#>!+M"S < 4W"G)):]7^:7BQ_J\'3[FC(S- $NU&QUN43:
ME>NR3I@35GU+D!4\=.S-))4(P"F2J'57ME%F4K1@Y%U8C \L:]=DZ-9@=2!,
M F0?DGTIC7W8NX5FB-;<H9IJRSB\<7H).4IA1_O5",&A^%* S2WO!;L8?90Q
M*"M;4#%!0_;DAK1VU.9.&M?NQH%&#$W+W<HEK,8VC*4<PC2+U+^1^K& E' ?
M3;B&8. )L%;NPOC#%+CY$!GF@][<.AC TL#XB(L7+*?W#?V#87+Q;\__I'^D
M?]U!<0W86(4_=/7/Y9+N@#DT:M\]>DIDL5V7DFY:+X0=D6[&^4+[^?F?L!**
M[;;5,^PB+'E2@>-QV^YOB-CYFN*K;/&^JN\JPDZ^?/7B3ZXK8"#/Y)M2/5O5
MD7,B:@9D$IHK[ B_XN-^"%JR%Y*14FSO;=Z"<(3@^.\7[:$*-G\7+-7- 7NQ
M93#3;I_#Q+XO5U7!L2/K[6F;5";M5&%=DC.0=WVK2&[ LZQOFE!JR%'(1,NF
MPW;C(9O>;OJ\5=$WM<TITG^Z9)IB"^RUOL2).P/6S2X=+M95Q<W0Z#A?;O/6
M]=J*.<3J$V'4CH>.#!'9=&*AYVX[I\?U:G@#@8>E>#L&X=&)#(M#,#B>D/A<
M%?#IN7AWNI;[RB;NCIX,8IU=;&CF>&#TEECR;&,*:5*'+ 8=2TN#>NFQ<[EX
M,_D1=B33-\'^9Y" AM]58>,8V[CY//Z_[+WKDN/&E2W\*HP3,U]X(M!]U)(]
MED81$]%J63/RL:P.M3S^#9)@%=PD4 :(*O$\_9=[[4ON3"1857*WJW3$/S-6
M%W'+R\Y]67NM[33$OO?X)\#L:'<#-\TN+(ZP9[ZL4O&U]AZ'63MEQN)!HIA<
M'F1%\+/Z4;WM;ZC!GQ#ZC&D:F11 L(M"MF>CKL\.[B3>'^<)!M1#!@6%60G.
M5<\6:C$@_2_0K_-L_1=1-]'=]I&<7UR,]('D\23M#YY: $M:LV)R9P5[B]^R
MJ>&-TH*C/P=+_'(E>Y<\S4IZ"]2;&\6!:"FOTNY.RZ=Q/)#F4S024<4M05.C
M3T0>C3L53 AI$_8!J @(G*E3)1OT(D_VL2K^B]TNZIP+X]=VJ.]<;3]KA+CD
M6_]I\U(0M]3N)>UG1*!XF:*/.T7ER)V=1<S"7:T$(F;#J4/9L\. B^D^[I#+
MQ'WPB>/3!:ZCB'E?-Z1%WJJN#B=3Y61S!^WY4L6O$G'YNPOB\GF\RP5Q^<NS
M1=Q^J\0NXG=1_/K<H[/N%$MD+DNHCONYLE21V.^Y$?@]LG)5K"E*'/0W;H3U
MM8*KGGQH[9H.K[8;Z@/3F]5=UT\L *W4:=6#4+2CNB.H ?"Q5J5Y#OKU>.PW
M[R'KT(B,.KD;SS[)A"9*2OP3N7U[X/9M[>76893<)[*8KEVBWJ %IAVOM4]&
M*P<C".PH$HT-I2E1!@5 2?/:;!H=*4DD&?1,/V$XPHN&B)M3B,2\;?_BDP5Q
MEL/T\YL.64=6?-^SA&7:^0/YP'&4B]UG[=H]LQV4QY5>ZF9:AZ5/Y'FZ(+5;
M!:LYCC9]=+0%_F-?6P=J^LW("Q+81^@&F(LCO&3LNA['Z7###9'<2,RPR62.
MTYM2+I :M5<A4(7Z=2T%]9M:6VZ)GDM6#(I%_.J;\/11VE%11Q)V2Y'([(Y#
MOP<90=S@RIR>?=8X'[1MY5$"/VL;A^L[2J&H6?G%;>P'F](O?BL8 *09:JK-
ML9+%MATW/0@3&58[XT[SI9C(;DGA5EQ;X0;[/'NK1&FN"&=HI:E#_:@S+ #-
M?,0#<)X17I3.W-,/]9(-??6[<N^N$>YQ"^Y(RR>\*U$C@>\CX]O3>:@B">><
M1R]$N^U-PTRQ!>DUE91>HIWZ2T?DFL"^1[%Q3-8+GLMY">'0;RE!*26N2.JV
M0!_)<\Y4N);%ER[]9G7%%/C3C1 XZ573".[8Q[#Q0;@%Z\NQ\,WJ![;@KD\W
MS? "#1O!#..C6O[?R.X.KAQ)UNR&C.'_;917AZN)A_"U7 ?#?VIU ;X$E1,Z
M.BU])M?_C/A\J>YXUW#UG,A-KREEH=L1!EN:?B?Y/JR#,GR,IH;0""!%F+KV
M[U-:--74.AM&=[9)=WW*J'C^:><6%=D![< O;^;;UF_D7PX0Q^8+5;3K>KN*
M>C,YK$G!3.2<L%(\Y37"CZ9A% D1;=L71IV$S(TIG0$S&!<XJNB?E6]UE=AQ
M.=*F+J4H._2HH4KM&%NP!,8*:[0O=L=69I&XU]9;C!EJCF9>G@042I%?V!,*
M1;BJ/))Q"O@2@F1TAM19DMDR$)-0BAB?]^B,%RU&--JW1X!<2GE D>'H14^M
M"+"@ J8[E'K:<L)3?.R-26Y>'H-O4_MX3G%<Q*?G$4K4V\++1A%12Q@H-"AK
M[[*P:J.-.04OSDCASQ+"RUE#%_I:$A?9V1QM4#B/O/#/?/O^V*^V2D5E=7"I
M>Y\O=PJ ;D82)C0H89O#S44YG'<(K[8SC,H+.X*-AE0F0UA#FU0!/_TXTKQL
MF@$T*JZ5QE+BNS[USI)*]EF.1+"MK3UY\M <0.1TE),+^P#@@-6ZWT:!UDBD
ME[+V6,?J,%WQ_>!C7BMW6/@YB1HJ3QM3!X61O2(A0U3V@<>[H3KEJ" M1B$=
M.49),$!S"%0OL\!+MH0?\W 'F4NNPCED 'D3P;NHC\>&8B2F%#@P]9SCE-:I
ML!,/000,,,,JE$ Z8_PIL7VI$[VP?#C<B*"?",$@>G\L4*1WR$[6&\8^Q"8X
MH5V*D$ZB_\/XAW46_F  WY.>"+QN_O%UK(Z ?W>X(C7%A0]_=9XQ&VGUJ1BQ
M) NTM6N9W!D73M0OV! 8F>)1VQM8@7JH4)[\N=NQ>WBK:.-Q_%68&$5$A;5E
MB!Y 7R,S!O(9=/")J"A6R$Z1"E6XXDA0!8;O@#O]R%?N=<F4&5J_:G@G*C[D
MFH!9O4@ .&0MYG$.;QJ36(3=)DL[*8*DM1S/@,,I,K+\%&P%@1S%? H,C"4!
MC+GKGE$]0UHN3DZF%5,$/ L=B7,]X#TDXKQ9BJG @ 9=$,7:XKXIHZ5Z,8DB
M'2@ &09:9KG]-C&F?A^?82\6A<4Q.*U< &<.E1NG7Y%LM^"8UKLFT\:A(+B[
ME1 L?<Y;_QP+=YU3$R+FX[Z)V#'B"6WN<7[^WU;$>61"_:V+ Y(4IW<WC2Q0
MA30L:<YV0W9*9&RWS4: JPT HK)2= 0C275,K\J2=U1P(4K9"B@?'/O88JR[
M*?>RXSML_"GA2Q:9ZZ% 48SN5,[W"LK?.7+K3$<"9,U5D8)C,<<H(<V"Y(0W
M%[^T2%ARS4O<!P/\Q05"\GSX& .?":Y DR(\,%@DX#@@K,C89XZC:4%P_RJ!
MF>_#*R*5<I;>^T>SL'P0!*-)FJZ+1+]9%J[H!452U-3EX48_.S876Z),KT9.
ML"K;<+-30F..A3DAJ\NW4%OL'> W>?Q+W@'\@$CPGFX&H.J/H^YNS%-WW4@8
M;[O_Y>H;F52Z(_/&^^821\J=J>K>*,DVNSQF-I8&C+,FA?Z6A4%9M#''-'D+
M;*8T?=C=+[@4CTOY]PLNY7F\RW/"I3S18M3TS(^)-D^=6Q>R1J2A-QS@3@IY
M16M>KQP;XW1#JD.IV)%9$[1G[^L[IS6T^,!H;F NPPUK^ =3\/SW)?O7$D9A
MO[="B"?>C=Z)L4[%RYMN>].WG3:<W:]NSDXR8<);H@K7&U'W=5,3VM5TMHK#
M2*>VVG0VDV1$^1SARS3GI@H$SAVSPF"!B-^B_.2+98SY-&PV$R5R\]="LS?/
M7"D+^[4D350E"M?(?4. >T?M,;[7K_1>Q6/!W-=P<+;'V%#+!,G!!;CI]YKY
M*'C"A<B/.P-FR<?O0M3.Y<'HK9,:<12]&Z>1VO34:UJ2,N8T3KT_C9JX%P[J
M0]B[;>,[AZ10I4Y;X4B5Z#;\9 RW'[F?OV42BOS;) G;T<;;(\8.RR@A[)[/
MG)S.\>&$?" HPYHH G;NK6/3IZ23D#B $J(T?N+Y# !K4MKJL3FNZ\U[SOQ:
M%3)[?>EPW(<?8@9IHNL-^H'1S!J+0VDO>QCD8 4H2*(<(UH(N<&4PW5>$DZN
MT2N0&)HV#&QC/7WZNMPT!T?L>+J1#5S#D5[!]W0.=KE:#(^K$3J1(B$%+;RQ
M&--(>R,C:N8;AF0B&%FAK:+U&!,-$@F(D[BF=0%<RE S&$:,B_AR"[0%L-=I
M$.=*8. /9XM0C&^SJ$U"M/2)O[A([4V"<#H[>J3;&M-)E/P(L8TUQ'H#R5&\
MLE?:UK2J/F7W$*9A,7$^H%1>T_5;O /:W35)1&(2 A9OZ V6VN71-0W?DI5;
MUM331]_\[9^_SFX5X5I.AR"3?_CYKR+;=-N.]=70-%;J9)L#T]B:'<US=+:)
M2J*TW)C&=V5*H&F0DC-/C^^,2[OO3'0J*=[.8RE:^H=&0%F4@>W#<L4_(PZG
M6C6Q)#1#3(Q9-\PF6W"Y^7CR[?+(U)AX7.&32/P@U9MPF:3S:$(N<L'3-#$K
M[OCB5NE%:@Y,I._.HV=I=GLKV2TZ;<8JLE%P)VN&)C+1'1':\1E0.B4D!SKY
MG.QSRF@^0*R=O9:<HJ:8^%,"?;9#,0U8VFW930PV&<M)6L/G3 :#$"-@$#SP
MGD6GE+:Q@UT[E!SAC4VL$$?D4[N,-IC+SZ>8C,53[=($^D_H9(L!353$,IUO
M;Y@KYJ, 9+**###/2W(3P*XGEMSLG^6@'(>G'16$A67]G91DW+L>>4!]Z8O\
M*&; YT$(#B,2EC5SLM;<IM\18PY\O05GLT\S&)>Y^DC]X>P#=R& .4[B/XL>
MZ+JOARU3;GW[PU?A?S3':T(=;E2*-?S3S^+PTJ2A;E7X\H)%8)%T0B+UP_G=
MF_0^YW^CV-I</7(D^)^I_G5921][UT>?5'<]%A$RJHJ:"^XCA7L<5R3THA13
MB&DH3^"8(!.$^.,(O)0A-OKAJN[T$,#3W_SPO42__( 0GT@H8AQ FB>(9<RN
MN>I5E4K3MN@1<IDUBC3 T1)!:_2L6/CGE[XLNP^[[+(-SPN#<82WK='%6=$5
M\3X2#8[*L;[X 1]_:D8E*UVH5JM9($2\II7[P7+/BB=M(L\/#JRPYUFUPFH.
MEDZ6YK5VVPA[E1UU:?ZHXO-E1I^QD#\JQ-')PSRNO=3<H"BRRW+[L,N-;'JL
MEAA59X+:?MR27!,#SF! T02667G%/)/@G-?*.%6_[^\6[H)TF;QJ3C%;OF=R
MA!ZG@1&LP$A:RZ+P:K^8;M@%HCI)> %!Z>1O<5F)'YZ,P4L)J%^BID>GSRN[
M+FA"(TLG7<+M8'>B'N9^O1>1>,F3%JC%DZYA2?BE!V,1FE0\):U64LK"6[_3
M=BM$C85CN<_\^LNZ^S@N^)X=V.S4JR1\HT,UC^"*<UD*Q2I/YZ9I?[>$G.>M
M]NH>AN4N'.!@5:@-(7]F+]14O9,BKHI"D]P*&3(A8X[$W(_D8KXLQP]_(%,9
MIU KNY>X7D_.*SK1BD?G1:\T02G^_H)2?![O\IQ0BA=+]7!+10":/4+.OP?O
M2MHO%XR393FUZ69T&N<NF'P<7AO-1*Y,!G?)A)^)<9Y+NXTK[%(^](JZ8"\U
MC7]Z:5.*3G"K3>+4USG#Q'5'*6,LSCRY1Q,K,%SX.C]RK>.&204H\)F#MG:Y
M<@,[Q37)8\SS4;3'-\U (-,U J2R#/%%D>QC;44-HB-&O)8>TIL!1C*363(J
MB:R7WGK2?4>73_VAQKQ#GB:2('LU&86RC_S3$*S0M&I?*9\33*<3L;O<&0XU
M VY9GM_X^0.3&,,#?H4((M.J3Z%+ #!,1(]-&C^"]'V2N@Q%J9IO< 5)#!TG
M'LIR.W+H"E5:65GHC)S0P@L/#5<>MY)!C-BV'/@F0BI?TQIXQVOONSZ<V#UZ
MP+ZB*JJ]V=?OOONJBHL*3R.T]_+=U4$X<!PK".W:93Q%8,['UHJ(=BY)J1<#
M=;=^V#XH D_0?(:@I*=R'4Z$(^:/B3W%EAQ 7B@7D:KNFR[7NBV[":/2ZK/=
M-%[W^VWEX6QB% 20L""^5/F!\PV.M5)-\=YFKJAH5/!9)ICA[A%M5&_T>^5.
M%!D7ZW*I5#6&/O6*FB(Z$961L='Q5#KP@6LC2MA%F$E!\9LG2;0?PO9!^<2V
MFYK"?+FV22U^>#85QRKHMG&*#5S5AW5[-?5<UK>Z#;HTVD/L</XNL@:93&+D
M-\%ZV#?U%BFM6C"#]P)32UD'^P"'I)<[2X?3.;&S996]E6G7/&XA(QT[0SQG
M^\8ATU7^._:XT$OQ 94Z-8*RE92O(Y-/MC/.1/V\)@+,09H"/#=C0(3;G ?[
MR,>EZPC;Y6;AN0"BSQY@GC+(U^<8>7S'E&5"ML&2)N5&^P+Z/ZJ3S8&K(@C&
MS$?$-!+%I1>5#)7A]*J%@A8)LG20I:9_[AK.:ZY%Y&]"'")Z&TR,JL$B)F[<
M7#?;:=^XVL#+U3O7(C1;?_A4[!M1%PH+^-@P<Q1S)"E .%+8&F49L[U:C98F
M8-YEOM3:+5B+FHI9BN FS6!%!:T'Z3'B5AN0@$#&;=V0R6>JU2JA^6+M+B7Y
M^T<$5)GOOQX.>K.$8*S(IA'.^.[D%D\RUZ4BL8SC0YBO9Q04[L!-<"I/OR]_
M%BGV?/>A7T2:$%U?G"O,4BN8TVF<V\>E\1<.KMCNDAYYL.IW;23?LCZ#9OOT
MPWO6[+WE\7"C1(>J;Q'D(]BQBDMX/!L]HO24CR8G#KV54>8XBG>3=_5_&Y4/
MG$P56><F[,\;\67X!!6G%IVH_::>'>=<3KS3J:Z4V><G:@\Y);/N&1]Q&?^X
MV;=7K>Q];K:%A:(P,)S-E-,SEC>I>:8=T'-_J9* Q5D4)3:"%1-N(OUD1K\J
M9RDX0N#R\!<1SY0O:[$<HA9CQ;CY)IRHI3Z;I<AZTX9E0T']J]]_R=@Y&23]
MM["_T%7;"RD5.T51@Q3]HD;<6::FXUA,R;* _>.9Q8#P.7<;/&-.HI7$WFD5
M40F9V/5$K]E1O0K]F2.]7#N)3ITSJA%NQ/;Q&\4JID:;F6K9G9*2,[""4L%B
MGWW?324 PCE;NBQ*K_RF]'F, >2ZO,9A9QL6JVS[W,SV;*0D*K6@M]UN/W&;
M'3,VHJN8^Y<IR O'4***%U7'"V$\0AH<L]>GD1>1^]W4A1.'R).V7%5&U(S@
M*E?<Y)=/1)?;;E&F^QQCY;YM)B%+&<-V77.!MV7WR]%VQ^YN"\#0O8T04-AB
M.)FG_<O/W'9_#__?61@>4[+?,>L<,P(VS@L.NG CQ/:[LM+\ 3Y;IG:HQ*U.
MH7K6%VWRU"]7?X@K=\'[<2%:J1]P[J$OT]95 %P%SX]9_*[K_4)^=L;8-./&
MHW_\6],'8[Q51]"[C$WSG@.S2+!4:%5+=+T4QZXO,]9[<27S/L:4YBTR#((#
MSB(%L (PJSH3]8L:;:%14L^C"'$4-Y+LXPZ!Q'-P7Q[K'4HZ@='@PDX^"%G!
M#48D1LBE)6?8)16HH 3PQ/F:7:YKX>-ITN2 -+N89SQ&*5#LD%/2=8<LKX-I
MYP5'E-,[$]JD11<"J<@XD&Y/H_AS.2'D3-I.\M1//WD_0WW%5$+">&MN2&>.
M<_$VIV<GDOAG^>K%C(C--6;12JCI[*0.F;=PN>,G]&!LM9Q445P?A9-;<VX2
MWMZ[@%ZNWIY9U0C+E=#XT2LLM;;I6A+'R7U6IHC,#L[RJ]WASRK#+#-,5#^O
M$\WDA>V+6XS7&GQ)&HH)%VH6KHWL0NZM(0H3Q^Z"$O(HH<\O**'G\2[/"27T
M9,+<7'G9.KXJY:=2HY"9_YGQ(XJRN/4E.YGT9%GNS*GCT666JWM&1!"/='R^
MB06F0O^S.I^MC&:G(C,)$8PXETJ_<)8Y@:V^G@KDY5(R;#JB=$96^"\=HL]W
MQU\ >]"W%!IL65M-<L:T+$:JY"<J6G(N_F&B4#Z\9_A(64)%7AWE1949&1LB
MU3F6P@+5H8@] %&VC,YMX31;*,6*G%D2K]#!#J@U^1;H1424/IB\6]U%JN,8
M!$CA@N^8*AT4V+FY9@4I'L<7$SY!?(+Z6+J<>),<)>T]C.2+BTIB).3Q6>R.
MPDRE3A.]^SSQ$*LQZ5LD:@5PK\&RHB.V^!(5L=^UKK,H0M%ES^0IJ:%I#^LI
M&#LX@)*^R_)GLXLH,.35QZ% >*W3R]7W]C$EEJ;YTG*P^L(%234P#S?FV8 J
MS;?S0S06G[RPRHS8A;-R1_[>DEH=I>>%4]OFP%@AJ5:6+40Q1TNT 8LKJ'=-
M,M"'8G)UJ8.]UJ4800FK;=^,> -)[-7N-PN/-]8MMYQFIB)).*Q/B#0*]SN=
M^9B/\VI@X+?O)UR*4>L-L?P>M]7"L4/?(^LVE@/KB .(Y/3W*13H.Z<+@C:,
M0#$-X;5D9J-4%Q,*1;CN&>[K?'V2?> 'J(XCZ_ME@-"$3O4!/'OG)ZMP^(#B
M:'[ZY+J0T;5A^U@7N VM0S%QFK8MP"374O=/:IOQIKK3?VGRD.P _-!LF,V[
MZ>K-4;Y4YFC?7+6C%J1B*MZ7D3T))FEENGV@6XAGB#N,-K12AH95Y(2AZU9)
M,!)-#[.P)[.O:E[O80^=BRAJY:RZ9P'"$O%NY%.IW7!]#;)[>.33S^]#E6.X
M(9)6.^.E*O&%%-U+@K55R5!0%2U<$*+?RJ:42^K^](8&C92GHG4 &P1GG,3B
MP9K(H?UM5[#=<#<ITZ/G\IRA<6B4G);0%BZS;PM41&V<^=#<H)!C,%Q0_S'\
MCC+94E9R2Y.UA'S:T1C9U.27&6O/+JR*$2DM8^/D)1ON5;:;N%*[6X?GP!EP
MTA?ZMFEZ#(2RN%N>^6HNKA?$=V2S6+"@HFS U4 FF>2&E."ZH<4@/A:N^8[8
M_]GZY,N8*ZR*',2UX2B*93YVU-\@8\4C:S>CF>+_:,,+-L,M60PF6/GN'1]$
M81]U&]7!M6= ZRC>1W N%><QKUD*R;D^J,7>$M B??W!MA#UQ5 >5W*KO(%M
MW6$4[%M?AC$;CW& O"EFXQD3ZW8KNSL\?68.=@>$6]F #^BAR!9].K:)'2[:
M$^90-.=?C8K6?\@)H#9_@5MG=AK%V[HSSX9+X/WHY(1%CM6MA&@H:^YZZEC=
M$49-Y533&>=_#>MB0+T^//L6>[D^@3P*M-S,.A"OL3&\Z<.A?!+0P0G?C0I5
M;<O4*K1BG-I@Y^ZZ[ [-6!C @2&8X(?>H91/H^GG.+M 8E3&2<%F[YHM195G
MIC5-E-?&[YL\1CYM5 52/T+/W^)\A[[M3S]Y]4E%%0>R)F&POE_7!X8'L30P
ML8+?8?6])HW.+1R@-S39KS<\-IVH=S)<MW#TKH>^WC9,]C3"JY$N;.I^ RMV
MQ>,JC6Y 7XLG?#7T=ZQJY@\O:BD O53372/>I9"6M5.N:NHA"#-23^SBU6M@
MBI6H(-RZ&Z%6L,G"85K][B$ ^V7OJ83KC&!A F'<M/Y)ENJNX9 S(VI'2()=
M M@92ZU;#]G U\H-7:9&GB^[B=U)L=*%V2B//K=K_!36&+4T)$]5'-#0K&GA
M[EMW $NZA3<DU>-Q=FQ;]"MPJH= -[?M=@*RX+I'<&1P)CN)6CPT;&G*1R&D
M3"BZ8L4?Q?1@H _30=^(NAYV@*9UX10_VA&&_?;J=R]?_2MB+C$9_MO85N*
M>OW=6S#^?/J9_#[\@Z3';F[DN<>>(?9X:AC%24[,_,'!D%"Y0^ZR.!/LZTWK
M,:POV#YG9YS[AO_D>AX=>5O!G.UP2G'*A-X51#;U?H-+S$>EWC;Z+QMEV'+^
MA)&Q3$?#VS%P!E O=63)NF:0J,5=CH4Y9K#!NNLF@L%U/:TLLHK@$F\:-%>E
MD@N^8;)G[FWBKI?\SWK@Q5EZ33W2WCFN:CHW6Z8[Y].1VX%B]JO!2JRY.2B2
MESA7TX6WY(\B_('H9C0 _!=ZEV;0[$TR  YXXUYH8#7>4W,4-4YBKJ+C=M
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M)O[FS=O7G)%#(E"=F7D..UW-!4Q"8<UP71,KBE$F3%++?R,39X!R)@P)7TQ
MF,0SOD, 3(V6'&=U[*CSCYK1-SL]\R5*@TS#34-PW:Y;N/4GGE!7VNT=XH/!
M>O6)]0FIL0W_2U4IF;#FI 23^@.Z+8)ZFC<P<E2"1F 2>7H8_Q? 1FBLU+4&
MJA:JS9*C)D<_0B( >_2(U6S7S30 !X;UP;P^2I-4;P2?S1ZG<6C*@RB0.W*O
MCK8ZUN$,';4;JS@<26</XB[]#_T)+V6,,O::"!')\F24SQT0J&.SF33ZH[8*
M0@!ORZ%.)H=DD)(-#EAA^5,L#"]&^L=I3- !Z[Y_K[:$$FCB9H2[3 /3?2)L
MJ-N!00#(C%.I"\D8(TW5&E08^&'6!9)N4LK\MEM%Q0H@><N0Y83XBP(196 5
MM'W<\7O_H1:U[33A43C@I/\S7/%B/;3KAC-^&5B(YPC@)VQ[1 -AG[:$.A*Z
MXN__R+=Z]X<W*R36;YG-23B;<)URZ=$%\R$N/W?94/P:L0"??7+! CR/=[E@
M ?[S3=88;*8B['_BP&/16]KBYCMD#H-OTHU>V88]("E*U3 05UUX,>3)PT@>
MLJ;K8SRM&[ A)I%5K,C+B9&%RP*^IJ"S$:;H61=WM0H'T0U%&WP$B;=H<+08
M3+/QWO9,7^FJ.W(])?#V_:F1L\P!_O)S?73X35>/BB^"T>LZ84OG\R[G3K/G
MW_7#>U>;V))8LO+]!@^2"0;]<USZU=Z(TTB@".2+,>K>NLO9]\S=N_^1_!UY
M\U7:QP(2SQPHRF!J*6/1?$^C+NS@V!NY_IE6?W'"".,(?F/OG'1]]P*>I9[/
M]'MX:<2SR.U )/'0[EKIZ8]N WM&)_7N4B1N%H%*:KK97#M%"CXM.4F>]_L0
M3R"':>PXT>8BOWZQCURJT6GL"@K-)BV%2N(T=]>.5D>M-(WNZZH/#\19$+4<
MB%O%;2DJ+P6>+B,4.?&DB\0QF[I*-'XQHQM\YAN#/+A$[2'.#69A*6-2B#'3
M0OCH<?9-N.28T;6FDA7;9AULM%&$.5NDTJ5@&OF?MM];U&NG +>QE>@G-B%2
MX5G:#" #<B]#9PHE"-B,[2EQAM,^O:_2_/O75=(0H23?]G$X[%S$_G:?$3G'
M%'43MG@KH;92H0(P=]M&!,WJ]@$?'%[]Z@6)*9!U8IRS\K9!5Z$PF/T@K"U.
M*03/*_R6@SE72L[$&E#5BTMH##\<=R?/8. 59WF('[NV[CP@(@I"2)VVRY-*
MM1"LEPB<7!*5:"+HK0L?/<;@!H<!+6ZG8!H6*]/5&DIDJ'E5Q\@U/ ^+H/E)
M"\A0--4)38*>"&PJQ:U/;T,>F7S]@V29LV3YG"7C3#78Y<_'&0V'8?<9Q"?A
M<=8@RQGYO'"<8VPRBORG'^M[F7S="DY'U+6VCVGG._. -[1\*^XX'2C%*+SW
M/QT%$J4C\X#!9?]FS,K@5I.,9,J*M(C$IKF%3Q25M/O5MTRB;TK^ 7F1IA-<
MAVL!7, )O%R]539C[2U4^N=&>RECMS<:5$P,G3<HRV>S+^.)I)3KNX!-0(%&
MAJO4H\/D1SG?%#]KUKP&&/4#E[L;U:0#3:$\FG\N]N-76O<M30 '+X.D'<,'
M$B)"]ZT((X,AW(:;.6X$O0RA\7OVO (78P?]J&"\;0&D0*&B$[ED,%_:68?>
M1B<L):+"2VH\KR7-=:(UT,6$(UGQ!'+!\2/'#ONQX32XY--QA(1%2N^8U4W/
M %P,[94O)3[S&-JB3-!<NN5%%.)1^*>< '3+A-Y<.E"A2Y3O7A<QNUU 3E'$
MU%1+P)N82.5R+-708Q)7)HU>X<!+FR#N#3L;#8(HG')R=E)Z5\%WM9 >:Q!O
M$'S^<_CGX4IBHAS" X1O_K*FW,24VS$DL<"YH5=%[_BZ.?4R<!(IS>CHYH71
MR@E])3(*QH; I'Q$O<V8ZPVMSH*$Q1CU&6X;$YHQ\^KX&62'E<!T0L1RO[DH
MF.5^2,A1E/(X/V.V +/-]Z+>J%(@'?#?(1R:KS]Y>&;8,B1AG13@PR@C!4^L
M%UK@$!!'5>9T>2BE"U%R;9;?0QMQXT#1.'FR8&[+K2,$"%\]&D=UQCEV1B_H
M'_J.Y^VX_ @;.6<-\[3^5CXZ,QT"QML[WA,<DDIB93W\>!!@$(;,(BUX5QGS
MI#]88F3%VC'>V''YB41</>A6F5$H1H/^<O5=^#N]257Z)N/>:Q%K<Z&)U)WH
M\;HM;PC#Q74<.!";>N0.(_HQJ$O<5A\%"3,>DPB;TC?$S5'YK(3/FX2M&B':
MW$2Z1C]G9$1/!Y\7=D)E)=!6*Y!7T>2:73*)"3NF[7V-9 ][:$T1*?7TUX2,
M^:' W$,_!6>6 =VU(N^:P#"2>@9&%9_FJ-J/PH\#NQ6NVRX_2V4+N6-9/&?R
M^ASD.+$6!SG8T#=^U_!G1DT:69?K$ ;OM9T"2](H8(P 3M&H+\,63,#I?#.Y
MD[9.L([2EA=C/& 1NS.5@QUGX:?G_43&JR4\/32::P[JQ7\C5_\GRQP@H!>J
M0*3DX2!+ I5I&A#P.MZ-6 A@_^E(XH%J('IB+#K*$,JW8_^6BL!GSY$9!AW9
M$V6B3>@+M:(/NFC^'YD'QU[DXK/4QW&D^2-0$$QSQ/RA+Z@$,!T4/208#/TQ
M0UQ0<!>NF$<?Z6QS6' ,&Y,@IU1V&(^8F**CQ&^(F&:ZZ;N?Q<6D.^PXIV&:
MCY6"33GKG*C34+?(#? 0:^%U=7>Y(<F=(\QPB=J+N:;##G)K_ 6UUT@,D:UK
M=7IF)%KF_B@6ZS$].9**8AM,..5JAM^#//BFYA(1*ZC, _HDML:-T6"R+^&<
M+W7SI&[^ZE(W?Q[O\NNHFS\R0?I7:1OKJ&,L]IDE:'3/%:RQ SHRV]U)>OT$
MX5Z(&92YQ D6STG""7.=,A%'P>FZ<T0N["6BZ"L.FT8?;;<;:A./I1,'NYX=
M&TD+L6)?/'&BSYD@Y!TR?A@H80Z'R**HM7]/@UTS91^PV<\\ (KBO<8%)*=)
MEX^B9B(Q4 GE;.:G@S,J!3>DKHXYP9+Y2M@2/<R,*W*;Z\+;T. W/VV:)M[J
MA2T-U&G(K^MQAUZIANZ6O[9(O^I%5I-HA:L(8.(J;H*X8I?XB4E\<B/)*.V3
M7GA62=OAE+D$-!QN5WGV?1<OLF?WP( QXIS74[OGDSZ?^TJZAP8M.W.00%""
M6. /_@3[&,+.?B":';^;--'L0;KD<+'$HV3T8^!1(BMW)L)@B;-WG2U4_V:5
M]6U2:P/5)*15=RB\WE(6Q2R 3KM8 0LH^?>0Q(HN(U)F7MV:]Q4>*P"@A&^.
M12"I/F+0)L):J$-9M&0.:OG7<%]B'JE-2V7O&U9\_<( (],-..U0C8TC<?+3
M5'IL>",O)9(;3/[6)DT^*<DE3SMR)5[PTL;BZ2WKXX]7MV3B-Z]$/%(9ZUQ5
MXL]-OV^F]Q3AAPW*NZ'W/0LW[4W#TG*[)5.CH0+/BE"\2W+ZR8?P7AB(#),6
M2*P*SUMTM.0'PL,LG$'" 0DO&8,YI[R+9CB9(G>9#[QO U4>-[/Y6;=Q:2K
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M7-_P"3MN3(4_G. 0>,JYY:B]J95V%^UBO+"Y*VQ)H,U(KOJ5>0/!,36G=A"
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M?*-OAF+B1M ]*&DS.4H&#ANT"<??5F0WDI\IPTORM<_<OA7Z-@!% 5XYQU>
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M5<D:LX/N0KOU,8V&02;6'EIA3!<>;9&">FMN!$.&PNG@U3<$< $JC/-XNVE
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M?+TP58'(5>6P=<F=]VWY@;/1&Q'<$#-%Y;9K%I;9X"0U N<&T^HU J44V;=
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MO3[>&5$MG@;V>>JTY9P5<?2T/YR0I&'<U;8D"2 "9^"W_9XRQ,'5^\%76$5
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M,]$?FZVAXG1(8F"?#UIQ53LW7L8;V1C955X;P*0)>';(:R"G9-K+#[/7/]0
MC]?R<YRB!X&=H3+,0M< JI,@@;)Z(J.R:3 I+IY0JD>:S]/R-U\VZ8?=I/_]
M[=O7K\^>BKR5QKB73.$9*VGI=&Q^:C:3+6Z1_)'US7]K0"F_N6Y8667;J ]\
M\J9;.9#5A+/:$;O8%?4>'9J:>6=*RY:$VH1_,P2FO*<T?.7S^="*M(K6.F4%
M\E]%[?RN0Y\3KN%CAJ/1X.9N%7&*0$P/N.4/J(23>B_P.$;Y!:=X]9OFY=5+
MS7SB\4A\<D9E:9CIH]O=">,L^TI\#[@"]+^G&QHFIH ,[H7PNU*]P:7.=H"!
M#K:KNY/]39[BMCCW%E.V;R/T\=*M8.07%(M'*T/K9#XB(Y_[HSOXI2HAR\1=
M<J %-%QZJS[.[B<T>6SF^^]O?_S#F_\64G1&FS+.HH4&WBQEAIR_60E!YR:)
MHGA,A:_8"@K,)8]02:AFW/!CO0M/2V32),<G>.Z30$/#J @G%.O7Z?%+G15;
MSKXCZA..0 ],TCS>D86FPXX/DTVI:V;C%Q0@"97I*9[QHP9W(P)QY0$ #59^
M_6Z"8TR;,3QKU!;;Q#VE*M>Y]?UK!"[\]I,+<.%YO,MS BY<;/OC<R%OKT\C
MT1AWJ[>J//INHHQ?UU \]6!3+UC4:.8SIO =:!]9XY8S=NL6>(,-VSSM9C2Z
MKWF<3](>IJG#OE8Y48VFENMVOQV:SACO_YL-\+<&8WLK;N-O&#X@K]W\1%5L
M^K)_8^IQPL*&-^SXT C_].:[=U5R4#BX!"8\&%0GXBHN,YU$.QD)$J!I\--7
M7R)M@0A')V)<_0;J/"H[SL(SVW[#Z52<6B"D[V\HE1H\-_S73;\-QQ/^@V/:
MZY:.+&Z(E-H;M1S2_!G_@_1EQ>QG.FO9']% K"F=.;':XG"YIJK8K"I 8)$$
M#F?>'BZ&'X9Z7.E(@*U<*X@$X&@/M&+H/.9M8P!#KAWDXR\3LSP-*A1CSY>7
M?L C+_W/']Y$U2&<[*](.&/?;PBMSJEX5 "%+;1<JXULP7:)JP[S#?(4D^-Z
MJ$$4.Q.QCW4&NS_G\?,<OD)1*A8V;=<3%X"YXY&Q'5;[R>LM\DIA?_1[Y(F=
M(UB*A]K#>AI&=LUS<@W);!&K1?*/I?*=%SIF1 W OEC:?%^,DA#(<\_!HF+;
M470#3C'VRWZK,#HSS>%SIPZ9.ES)+ 174[L5GE>M\3I3E/T0_X-"]FG/ #&1
MV"IDB>Y94,E'@JDX-8GDVP^TDJ[:W=%7JY+</9^:F#&Q,^K);[/P-:FB<9^!
MQRKM6DB!D55-(V M:Z5+*FNL^-],D$N"6THAD<T%KTN? +EMV* ]9)QX6'T
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M0D_:+.A9 5X(1\^]EV$*Z"GB,B\M$*?PGGT#FHR'VT90C:09,%(/#/H7>]_
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M/W7?DS&"V+SA%L;M/9%JQMO:%#^4RL#)NY1W#ZK58HHZECLE$9%)!EK(!,0
MM$2/TV^VCYUQ3J="2B*I,385K;X-TU6 L>]2TP:I4)=[(G3<*"MU>I0+\N6)
MTBJ\E&!-2][<)M[1Z3[U_[0F><X])?K5?%:5N&QO#%!D=K*4O[,YRCU YHXP
M5OSQ$B74^!_RRI.@2^R)K%AXV$ZM.UM44('H/SK(6L%KM/5AFE5-/3Y*>;EM
M:V7#,U?18#JUHZ 6+((G+;\]5 B+1M]KQ  ^79I .@>;">OK=>]C&8QG5P;I
M4/._PZ"'\>Z<V@WYM ?EIFS+##;+# 9MF4$SQO(XR@P.#5_HGE8;J9'_O:Z)
MV,AJ1[3Q\4XC!<V5ZP1:5^D_5TWL=5WGUO6<;VL_+P%0)(CMQP[#KF9XD^;=
M'+V58,;[GMQ7@3'U!37KQ<1.L7"KT^"@J3V8AM_A;ZEC,@EY0\5" \ CA#0F
M.V"Y"65P(TY =J6$E::8;:+MT*V!&0U#@)%-3-RPGX<7+8%ZL3L54R-T-=7S
MH?3@.P(]N#7<@=7^NAWVP+;9-00"6TW!@NH&8-#2$T(X@Y!^BA'RM8SY3BD4
MH_ MURJ1%'#"%X>&':**! %!E1CE,424_Y)8VMDQ@O=6;9MW"<9@S?U;PC&<
ME4^BN#*U]=4>W-O!2"CWE)GJ5<3'8,9W;'(NYG)2U  )F5)!:/!("=E:Y&&6
M3 474/"38$=0I5C;3&>/0:?TT[D(!7P'BI(PP7RDG#HJ+9UI^<T57>/-]0P;
MY6)V6?2V1$BI2FQK?5%GJW\C.U0:"G%\>%62#*K9J3&.<&X@>]'/:>4T>#U9
M\QR%XF(Q!3.,$=C:.J2'7Z*=5\L;J\7,(A,RV7B"X1>+A"+#BC*MPWDAQ-U$
M!3_31$01)K\*!4PL^]D"F?2M8(2DV2X$N.H8[!@S'G]]/$HH=.]3?2>A4U4W
MH3D%RG1/9,W<Q!<9H:H#/,/3+W'2"DFWH6P,77"AL)KIO1ML\Q+,@)=.CG%.
MM^?I#-OZ+H@(9I6MN4*37J-;P_245&F[*EFWQVJ7K\/<$%K%O4ROK<X)UAU)
MAG@PG\E0*G(;O'_S=,C@JPI0EE>7O-I"MD,9LD.DT>!:FF!6'53M82F5@=A@
M=?68[M8CB7)'AXK4T#2U'WY.Z-7+J)Y'YP2NB3^"OV[*0>VTJ5R#,G5$+B0^
MCBSLQ8C#0AD71@9,G4F-J$VIB=-.UUBQ++D7IK2.N@UB-,Y+<!P\N@VX!UN5
MX:,80)CP/E+^D[+*"@T 3;MZW;9EJ[!'C07F0JPX' U;ORQ6LD&U7/@LX^G"
M:D;>A?6N#,WZB@\-/X[E5B?.>2EEK1->*QN:6445A11\#6I=V:B"U0NRJH#E
M',S9[E72QUD/]!HB E#FFYON9:JKB:7 :$GDU24]H/:&4PZ4[)JG"Y9D^2)]
M! F%D6B?N+YBUU+9;&:88RMRL@WD(R4\R\Y':#\*CT+$ E[J;]4EH[4EO8H;
MH Q53=.W>V1KD4[*]X$JQI.#-D^T,[2J!DMZJ/*!L[5=4\IU>!9L^@N+N(1
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MI>X9]?L2!Z/^J!2,.+B2->.EBMNX+"$[A,$6_-+KP1.GXJ^9]%?2S21T)?)
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MXF0[@8I:P?AN!&-_ J,-XJ)V<^_M)F@>9U&[V7>[V8RF6P;2O0D;2U>]S$3
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MGDDP#MPX' T'W;X0H1A3Z:3_'7:4M ?W'DLGV]-YV]-IS()(]./>1'AN;RK
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M"9X]/_OX"N;ZV_79QW_,__CTC\NS#QO._1J<^^&@WQN&X<0=PJ&&"[D[=H,
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M=0+>WL4+6!:B_\H;C^7*6\#H).:T^>-[50Y[ES23I2AZ.,Z8\^[=C'"*&5K
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MF\>OOZ8B+"!VRZA7ZATBE>4>>V -AH!":H'A,AUDHEQH3Q'R8F65M"&Z<[)
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MN'/H2U'D.UO^'W/'8TUT=9@B 4A)4:HD!H'"U &2CJU 9(,38AE/ZC^2GU,
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MGZ,X1KKWY[^[6S^V#O?^7*>;7_]]N/DCOOO17M@>GZOX#$_W.;2"<^$ -U@
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MLH:S94>D2*E(J4BI2*E(J4BI2.F^*@%<]H6@XYY:HZ0EG"(+#=)28$RE=XA
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MQ",:/0>)*7>&7.TU+'[*Z[#?C=-:K?_?J#,\+^&,!;V&F912[2RUA'@@):&
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M]GLK.#,\7Z?4"['WJ7[5:&Z2G>;?QXTCC^LGNV+W^S>XU@>QT_S]I+%UP/=
M7W;^NJX7[6-8 :EO?1.-[U]HX^K+Y=Y1^W"OV6X# 1'U3[MX9^OP&/1%_.>J
M_G,?'BGC@6IDF(B(<RN0<X0C!BX;%S1:S]3UB>$NBU6P\)K47&*LF144*^ZL
M(M)3?GTL]/C1UVQ^]LO."K_SND\]*_PO?QC#>3ONI(\M /CX)ZAUN"Y8S4QL
MWK!,7>[SQ+S/O<KAOS3+E$$.>"/2(7EIDC)1RY4?'=Z<F@D^:*ET?@)K@R_I
MU5K79/H%30W7@BW3K4G*#<W$X_<4XAM"RB=I@$2?9K'WZUCUT+X]YA7,X?[5
MC8Q>6/>8F2GER][NFWIFB_7'>OGIO_-Z7545V55%]A-U?[Z%V:Y8HL&2U'80
MY[W:^_ZU5;_:OJQ??8&UP!I/OEWL?/KC>&=K^V?]^[>+W:._#_>.-J_J?UV/
M\S;:>Y^VK^I'VU>-K5U>O_IZLM?<Y+LG7SBLZ>=>\_=6X_O'$[C7G_^Y^C"9
M:"# SS#:@+.%74*<JH"<=A)9+8TEN40JZK5W\N'C?*H&$Q6<O6PX>ZRL@ K.
M'AO.QJ?]V!$6O!,H&0)PIAE#+MB$"&>86)?RY.<7!6>OOLG$9/=/>Y_NGZ^S
MH/4?J\6K)G9E,D.I@J:%H&FJ@Z' EAL:*)(!YY1.K9"FG* H66!.2&(P7WO'
MR.QQSS^K.O37H+:_@#]4:OM(:CMF%-8GA:E(2.:AIYP3CZR,!E%K;/*,>I_P
MVCNS(EK[ZD-/N;WU]8..1QV0<6NRT=MR[A[C :TV?*\6Z5JIE,47@=13-?N2
M)&UT](A2SU$>3ESFTX@@K,72FR0!J1E_Y :#CZ E+R/65>%EA9<KQ78KO%P"
M+\?,EE-+$]? ;+DP@)=)(.L)0UQAS FS4E"S]D[(UX.7]TOSOCVQ<942@C9[
MM3/;[=<ZJ<@"K<?N0>P")ZZ%5L^?@XX$X,JU1J<?:VR]-KR7)UII\8V_M?KP
MX/T]UCY8+"R]$3OM>'X,*VT>QJX]B^>P@[WUVO:IWRC25C?_Y[QUVOE9^WQH
MNR?6%Z\#6I3O>.*[NO4><L^KP@4Y<3FW_J+3/4Z=KH^U"]@#ZV'9W1@V8)G#
M]_7+O_9:68UN_/1)!' K=K3\3#?ZSL%I\9F:[P(:=ENV>#"M7JT700+ WV]?
M#M]VE0.IO?S=,PEA^3.#&"N\J0.Z4FO!E7+U@,_QUW8KQ8V\"U.1V-H97+ 3
M:H?PK2[&TUKL915J]0[+*SUZAN-$+CGLC/\MG'=S@O/]+<.W7DSG[3_A;EZH
M55@^U_$#7/_X,G]_8VO[HM'<W9<N-SA1!JG(2"Z !%JL8T241^&B%]@1"[3X
M.A(.<LJ=S2@"0@#*8@^*@4K_IU<[.@_ESZ6TO.^<@/9=UBY:[?98#!<J05C2
MO5JD\N"VN-F$N'\H:VD:L+3F16S_B'58YV%O=6H5?KE,;?_<:1Y?U(_JER!/
M;&=K<]\XC(.B%@E#12Y="$A+0Y'FQE*BB<'>WU&ZL&B-RLH)R"[H1_.B4\G%
M2"X.]JEUVD>CD<ZSF3A6'!G ?/@U)"M8X,SK+!?D9KD 0C!E?(:E;4 /4BL_
MZ@$PP6Z305$+I<L7M0SL.:<;*B<KGW5*V_Q;-[9M_K9!CO*@]'7B@P,:B\<?
ML0X8ZWG_YH_,I#$^$VU4Y-H#FOCWL#O.?CV(R'6C/48VP6)_L^T+>]E;^]<T
M#P82?.T97K_]&V\RI2>[R=(Q #W/ PSRYH [$KOY7; FNS)KJ1UV,[C]U]V5
M4FKM75'%D?7C?<;%8K"AG750;O9>[N?#/+2@BZ]L09=\\H*N3>_![^WW/MO+
MO%?P:_<\AC];UK7:@!&QMWD:=H#7=R?^-"[Z>G_>[<*VKDZ=SI>A/<%@!VC]
M)$<9&NV]YB:N'QWCG4_?+O? ONR>P&<^[5[43_9:]9F:R"^LL;5[N0LVHD[_
M;M>WOESN-+_PO>8?[<;WKZU=NGNQ=[1YN7>R??F?JR]\GUF,C5(4N9B)!7$&
M&:(Y@BT0$K;&*SQ3^Y6L9-BRS ^ &1!BM?;:\> $CU'%<+VN9[A+X#L7VU18
MD4[>%G" 1ONR1#'8G0OY=<5@UR7Q-,P*XXI5A?UR:1/[GA@?/-'(!J$09T!C
MG<$*40N\-IIHC%K]JK#!QD[*;A:L7JLW"@R-B\9>2$D8D(<-7!*(96K"]-.4
M6?'EQM??51-V\T4?M-C[U<4]7DW8,JF(JU7-@W]5L=@=+5!><D447J2*;/GG
M4#WE-U9W5MQQLVL#T+5K_.WM5J(MV*/L]91N+-J(;/GDG7L'#Z\Q[D)4!Q[=
M"AU2+T>RRT/JL_;>T8&H7^W2QLD'7L^?.:GCG2T@VB<?+AJ?OO#&=WAMZ^/)
MWO4^9"=_G^QL'5\UCH""-W,/LR^7NU?Y_=\N=^%[]K8.R-X1W-OWO>-K]6DL
M&&\85P@KF^>^!XMT'@"DG0H>"QR#* 8 ,5J-0*Y@[HW#W"_HMUC!W"/"W#@7
MQUGG"!@B9 7-XPF]04;8@ )L8""8!L)=ACF)^4N!N==<N88G R\>7LH+*N*(
MN;G=\/?!T57O[92RK1 O.VWW?_XVV*+W@QT9G-SV*L!:!K"FJMD2X)*B*2#B
MG$)<18NL9;F#H?..8"E);EX(@*4?G#Y8%;6MK@(_-,NWTM(GT-(QK0C6):X\
M0SHQF;TGH!5>&?B)ZH UEL*:M7>&/YA45"5L2_"&SDD6]/( ,7.'']8O7_K^
M(@>XK1!?&#HX'T[.VIW+&+_&HHQVXKRTPJ-E\&BJ1(M9V#;) 86X 3PRU"/M
MB$)>6!\H)<ZJM/:.K=.'(U(UAW%UU?@7Q"DJ-7YT-1[3"A.D4TIX!'O($0^2
M(X,#10GGC!6.I5<BDW_*'CQ59X4F-:X\L2A2R_+QV/5\D"H \=15W<6CGTVQ
MJK!F&:R9FH3HG &&8 .2(2C &F&1(]X@XHQWQ$0I7-%_HPHSO&(U?:QBXDI-
M'U=-)]KD &Y:;35R@D;$K67(!J:1(-C8Q+FFB@&S9P]NO+="D8:JC\+3'-F^
MZCX**QCRF$T6KW#R$7'RVU0$)!+)HC,H8 8X2;E%EG,'B,F]MM$XFT?<JW6B
M9VOD7FK;A0I>*WA=57C]]2DS%;P^.KQ.Y-$PH:*3!BD6<K=&1Y%16B#X@0CA
M/&;.K+WCZX2*5P.O]^AJ\^OG^JF5+0-53UX&^F?L]6+\V#JUIS[^&6TO]E:G
MS,X/5?IJM_G'R6ZS_G/WZ-O/!OV&]SZ!4IWL"G@/WZ5?0-4W?^YL-=J-]]?+
M[!J'H.J'\)UP[0]LK_GU>.^DT=H[.KYL7!T>[6W5+^M;H/+PG?^YJI/&UO9^
MGH87'(](.DX1EP3T4D>)0IZ\9HAW*O#K=9U$2L6B"(2SR)UC3CAC>50Q&4L-
M]C.5>;]B5W?.8J[B/CVH]C7OJ^,ALA0U8DEBQ,$[028YC2P65(@4HA7F^KY*
M+#@C41-*%5<*VZA]P)@'C8-0Q%S?U_))S\6TQ>IS[Q:H:P)H&=,@"QY6RP,(
M"\Z>5]0!Q!=K3M9NN,[=-WC]@9B(O9!8ZL QT!!#'=9"1.D$\=*N8-'I9->?
MHC*J&#_8J;7S7M5LMVM/RP9!O6)&;>XRE:P?EJ?:7NTBMMOYOQXLFVV=CB=5
MK]=\V_9ZK=2*H19;Y9%&K]89ZET-OBZ5T%I>K;=QGRK6U7A4N866'3ZD@VXL
M'E'QA.S96;?S$^ACT<KK1@+;^Y_4O\9@N<+""L\!R3P',75.NUR_+&DR(*[F
MA@ !783!=J/=25^C;7_H]6&%GP<SQD=,%;\Y^)OHLW5T\+-Q]6'?63!D6#G$
ME+6(!\J0I@(C[P 5->'@V],< 5UG&,^VO^G]S[GMQEJ*L:C:[J34 @$'>?5%
MZYN_HNWWVW&]]MWV#D$+^A/#GP?"];__2U.B_MVKG75;I[YU5B0@1W^>N]@,
MOJ^WGJ7/NMR(I-.]++ZA&WO1=OUAD8$4XH_8[I03X_/OW?+TO'8.:E;[1[[8
MVN]M4->!ZJW]LVAN]X<%^(.ORW*V/KFD6JO7RT>1N1<=N#8_.KZH(F_'?K]L
M_>>[,;1R0^^RV]U)]I/RWQ<:7BZC\E8:C2/FX+-I:A,!$/6)@6\G!@$R3&8;
M0UUKG@#/JMOJ7V[%HJ//"O5U^N6F_7*G>0#W]$74MPXHK&]?4(89)QIE(P6R
MK3S27&ADO,"9QW&F0^[K-.M4S8PJ[PT>,^Q%\9SSYN>*SFXH(/T"$+]X'TC(
M26_8P*"0MK+77 F>OG,"0NK+UG1#^2-B8M9Y]J1K'0?^4F&9L\4!_>H-.F2$
M&ABKX9?D[QB5?0_FI<]I; =RTZFY6+2:ROT5LB@/[^K,7A9*D[M7@4>7KVC;
MY1J*"^56B_-TM7>8M7YPE_84[J,]8>KR??3MSU$A0?$'4.A1EX?>P+[F3[OS
M5CO[DI./*?>A[( +"?:R#69EZN[A2UO=>?>NU\>[T#DKU*]X>S_FY8R^.U_W
M1C4M/W==4Q/!@DCM-;@"UGH+Y#]9(8/DP(RDFDO"QRJ[W?@XVQL2[-8%R$XO
MGDZE% ,KA!O:23O%.IJ=#\7J"R99&:V1T3K8!_*K)(DQS[3(<[$91SK /V#)
MP,D/-GD/1JM_T9E5[-O<K:5V>D[;SWE;6VSBYI \E1L;P^>B1^F;WM'CB_K5
MMWV?E(_4)20L^-? .F SD^0(3*24C/I =5I[EX 4H-Q(;Z;M9X&[&[4)$ %B
M^J,58HDT%MX Y!M@^R3_O22P-K>7*>![0=N]E%L^SX@7DM$L5K8]7MCF<%V5
M,1\8\\;6M_T4-*>,@G (S.$?CY'6/"$74L1"@K[FZ)W>F,-2!\8<#,1A"RAC
M*WM]OGT>RD;3A17*$M,M_+BBV_#IP(3D\KBQ8;Q5A@KC8VLG%MRA\Y,E6>'R
M[4(G"U-&*YX1K57J!_NK16K<]W-GZP-<?W-?!ZM=[@>;@'(CKK5$EHB,/#3'
M4!05>4@2N84?#D5JT$*X=]X&"6JE6FP7K:G7"YIXC5D-6X-.-+X>$:T,8]?8
MXW9VH\[Z)=69]54&5\I<IZ!85_ EAR#A]Q3;3+O@W>722WVP\-L)7/N\&X?D
M<$R?ANF90(3/8[YHT; ;'");-CL=8&_)*WNWWM@D4\W/HAL&/M?PZ^#;YUUX
MTL,KSAE0)Z'SWK!;^((:)V)@/I<$!D$YMTX;Q151R3BE+,-DX(<9AF_1N.GP
MZM>\J)WTK5=VX=T>W,_6>6QVODX^VC>LC-?P_>C#/CQ_RI*7R+/<U<X+@W2R
M!!%X_,HQ;X04"YV1/L'.#D\]+ZL]O=>>IABHI[D;I@X!]E0+9%R /=4^"4YS
M,#N7V\ZQV3<B+G"\[3P<XL>-@%A$CTHH@7T\#2<#=[: Q1),^H>V/W -RXD%
M8Q>S@.BABUU\- #2Y,]_C*Y;.NSKXS;.(_)0 %SAG-JA[WGM V: M>-%E?,6
MBF-VN'+!4W.@]:036JGE1]\S!L$2^B:@&M#R) =?NZW"NH3S4BMN@.S;D?,7
MS:28?[SYU&,^[AI( D]LLH7>2*RZ@ZD8MW,_,%^Q]6/8Z'@578FOHQ6^88"Z
MS@"_[2N3 )H$18' /SQ9CXSG' 5N'$E4X4B+B0"S^;^C".&(NH ^ENUX?9D0
M4VI5+X>JLC+FYJ8YB:+0/F?;A>#T#HNA*4.E!&7OQM:).^_V"F$J@F.H<]X?
M!,V &N7OAL]?3F(>8.(+/TPJDU@>=J+DO6'.&NFMC9S OPDG+FGP,9A@DICO
M.^'J0.E!D9R?]8-](&N@*<0CC'-.*/A-2%L'!C\E&I+#VN9Z?;E.U9S)&HL?
M(:W?>(:4=Q(4\(F.DLI3H_/3N"3K. .U/K?EGTNWL7]-+Z9CUYE2M$X+]C$T
MYF6,.P,"^)"VW;^$^\D+O:R==5KPS;USUXO_<SZX]H@E#4X'RAC%;1%0 =;(
M.9R8H3G:PL T.8^559(GJ?C0',F!.<*2X;D1T& OYP:VM^QE;S/\R-C7Z/1A
M0^KGO?[O\1/LT&FSTQS>,.#%(.C]UM3I6F#T>%^JX WV'&G'-.(T::2)5B@F
M#VI'E)(>*#07,Q%1V((<!?A1!J>ZK3XPF-II\= W:IO]*;HS1Z!#+,4O6Z7,
MEO.15S94MM<Y!=MT.4J! #F#;\T*T/6MWB#Z,!3=@HP6 KU1VSFMU0L]H[PD
MT#=I4#YLZQ0SO^;JT?H-BC038L@+CH- ._RUVSD_.)R(I3!<+$,.:/E$"&=(
MK2?B&JGU<^ < *K,AC?.STJ[GM>PL>+&>&< 8H/[O[;O(] )1?K+O*2/18PR
M8TDYESRF3G 7G<YU!)89SEADWH:!$RZGG?#**#\(17:O&A?[W&J-160YI)D0
MCUXBK21!6L!C]T[(8'-O/KQNN%S8*O\-J-(Y!^E?K[VWIS;8R>/;2>6_YJV"
M7( -/V_U#F\++0X=ZXQ:$7S4-'SC+<YK;3-/^QDPY.(4>AP '1U$7P_[3ZX4
M;G7A:#T+(1?$D.3A(1IAG<(\9\2E1)@C=F@M&4;SI'S&>1LMYF.,O8^=;F$#
M)_[\AEVWZ=C2SM;Q?I(>1PSF$/PU!?)-,'+26:1X=)): P14WI[<,0U\DW,H
M:^U.K_<,TM!K'9S"3]<A[A/8V3]A13NG$\*PDZ;S MZZ3#2*4V0/6R\#$L1'
MQ .VR$0%[GS06O)@%%.%3,PV71X/<IM%ADF4&AWXV-Z4YW\03V-WT$S3!OAH
MJ]?O%J/8)M%G[#V4XU4'$#4MB!?=S@#UBBL>=MIA,NS4FQC\<S:P=<6?1KFH
M&1$[OE4@Y2@E9AQ ' 41AF)^F@?OGG5Z.8EG]43^+YLG PVM^N<V\+X/PSNM
MA'\$B-O[A#'O0J1(,X_!4Q *&0VZ8(-T-'A,P*>[8[KEE(2N-HN=CMF6\:.Q
M)Y/E?-YKQ*S/#1R,D]=*/9DE&(-,O!6;_7GKP>,;UHX/>*?Y;9^K%*3R AD2
M\PQA:\ <!(&LU(: 7R*4I9D"/^; UR4K,V?R>JN=O0?NL7IS=Y]2KXU/!+D8
M=>[.)P'W1$!!!B^3L<19EG%OMJG7F A.S6&M/0JV_)_>\QUIS<SN+.>:E2&0
M9SYLFZJ"&0%M#K"B$FC7QVY:9B]@DVZ@.7<>K*RO)&9/5EA6>CU";-+8JN]+
M8;C@6"(1(G 81ADR2AGD@TX8 )PPY>\@\+\.L*L=?\2T[IWF\7YP$8/WCA&3
MVB-."$?6!(.2,Q93Z[U.?/[NESA\ YS?-5>[FK1]O=:<5I.V5V,MSS!I>WX-
M\M(UQ7?6"#]U^3M@[OM.K[]B8X.?H^Z]OD],X,1R@5+.K.2&2P3TQJ$4I77:
M <\1;.4G!S<+SG=RUCDMS^ FSQ"&N=4%[[.]P0CAWEL8("PVJ.*//Y-7;'"Z
MW*C?VU\#&'N:Q=YOB/+C#1!^6=-7?\6<X%<SJ/9^XX ?9>KOJWEF;VBX;X&+
M'Z?"&3E-<ZD1THN,MUMJBO1]ISP\R2(?J8=]V=_0K&Z#P_)DXJ0#B[D:G1W.
MGB4\I&OP:VOR..\67TV;QH=F]\]T K\EDC0I=BO4BW$Y1V?0B_%H]R@<[WSZ
M(G:^?V$[S0.\>_3U<.?['\=[S5V^>_(E=VELU;<.2/WR>B_&1JM!O_"]K6.Q
MM^7%SM;75N/3![%[\K7=.#IL[6WE+HW;%SM;WZZNC0ATDF+/@T.>DX2XMAXY
M&C0R(BA,I(^<\;5W<W*F7GSC_@J&7BD,!1(]%DDES2+7U)@08L V*B>C\(ED
M&")F $/W&4A0P= 3P="@)6P#KK'S99\YYZ71"=D038Z':^22,TA3^!>#/>%8
MKKTCKVDXP:),[_F(_W9VOF*O.(:<3F!==G31FQBB]J24:+@G@UFL%?XLA#]3
M,P\UI44W4*2$RI-1<C895@J!\ LJ Y:4Y=R9:N#A*];51^ -DV?D5[';";9W
M6&GP$VKP-(,P3.0]#$A@"@PBY3%DD1.$ Q="46Q)SHTJTB#IOU=(E5_ST,.R
M".M:PNFM@<,W/TCM$4C#DBFU^>BX J&%0&AJ#F+2FE B#:(IB@Q N:M/9"AX
MZ3UFA!BFUM[1=28?/'-U]0(JE0(_602BTM*':^DT5:!*R1 81<P;#YH:&#(Z
M241C("021XWT.=BP2A-+7_WIXE^'G6Z_K&Q_($]X$P[+HP<7BN>?BRXKF%D.
M9J:F""H6B:5*(FT90(S0!CD!SHD2!EO&4N3)K;UC?)7&KU=!A56G I6./EQ'
MKU$![:D%*$52!2#M01/DB(@H44%IHBHF(7+=W&,-HZLB!O>@ G_;;FLPAZ0*
M&/QR(C!\^A7&+(<QNY,\@! .SYIIY'UP@"^>(*M20%I90RQ.F$8+/( ^>)9P
M%1)8715]=!Y0J>B#572:!F AF,68(]@<DKNI@(8*4%A"8Z26&J_SQ(5'&/E=
M1006J'[IY YTI[%_"P^H1HY7(\=7D5+=^PRF@O#E(-Q/LJQL2?,D342L3X@K
MG)"U''8G!&J##&!DP8MCZ_CA(=V5&2K^2-&:"D K %U]PENAY-(H.4UT%6/1
M!>X1E;@8!ZZ1LY8@KY.D5G&A"%E[)_!LFZB7BI,%3?Y74:<\V1=C<C#YT]3E
M%YU._QI,6]E)?YV?G;6+MH:V_7O9NN>OW+EG^[3D"O",OY8]7YN=P>CZJH[_
MRWZ0G.2IB'D,7D#<1($,EP0QPHAAP5)GZ#WK^ E]MD+^R<V?;MQ4:XWW?W(X
M1CDY/??U'M?V5\7\53%_5<R_5#'_LU)/?2^,F&]@7W4%?=5UH.HZ<)=:?"]^
MR3V<84GV('?&/[&MTW$^<4X9&J1U3S5<O+DRZ;$*_U=-9&[UV^;2VT5Z0,Z9
M?9/G4]]6XC#<N\URZ[X.=V[4[9^\4%8[\.).&A0\MB./=Z^R!_8![WW_\!/^
MR^JT<;3W:5?LPF?V/FWSW;^N>W&[##RVD\;5UZ-ZL]W:;7YM[S8_PG]]]OS@
M.]O@_7T\WCTZ//S/U8?)6)>A!DNE* HIQ[I\B,BI6$R@4HGJ8*,'#XYNS)F3
MD[?K05KQRUIJO'S-6J379J59SZA9X_@(K1_L1Z6\(=*CJ*5&7*> ;'068?A7
MYI-[V-2U=VR#L7MHUZM/U%G$-E_K.[\<#MW]@%X83#R! 9ZN%ZB XE& 8JIO
MBI=&:14%BIPYQ 'FD<4^(@/[%@((@8EL[9W:&)\V/8()OF^VS9M2GR>PLI7Z
M/(WZ3-M9$U0 G2'(&Y,GN'"%K#,:,4^)U0PG'W/-_89^$CO[XGW@T.H5L]1K
M(*KQT9W?A?'AI!5".Z[:N>1I,8GU4:8>\ 6X^-9@;[[F"8VQZR>'-R%:P<4]
MX&*J/8>4AC+I,?)<YBYE+B =(T;26QHQCK"A+EM;,IN<][^>V]E]S9JTW#2)
M2I-^M29-&UZJA#"$2^2Q%@@TBB)+ T<R*O!V!<<QD7MIT]MS;N<9W3?OU?Y:
MLWLK.:_@XL%P,=700B@?:-"V; K*+='(!NH1208V36%I'%@J0C?T;!7K<I;W
MK?NXO];R5LKTY,HT;7MYDII@3E!*Q"">Z:PS.(+3&W"4(G&7U-H[L<%FLY3G
MV-[GR&D;%2*/TMK>V][AQW;G8C+#*<M.N],[[U8Y;*2Q]6T_:NU!/2T2GG'$
M"77(4$>1EB(ZP"D2*']A.6P>MKV68-_OR%_+PZ.KX315/EN5SU8-IZG2Q*HT
ML2>S3IF'U,XL;!>8HYH]R=RU-QZOVRH'Z)Z 50):4L[433.ST&]I:_UH:2VO
MNPSJ+54Y/7KGC6F'[+.]S'+:>S4E3_5,G;_7+W>_[W)X'8-7Q':/#G[N-8_A
M>W;9W@EX99_J;.?]=:\+*#4%#^T*KGUT /3Z"]G9"JV=K8_M'?"^&D?A!+RR
MX]TKSZ\ERQ5M-WD C\N&A+@Q!CD>%=+P@L>::\EPGG""'[?<Z;54?59H]G;0
M[(G[EE9HMBR:C6-(K'ZPKY(UU%N*;+01<2\\,K!#B--(#>>"@P #_V,/'MKT
MJQ#MU9\C+<5,IY(Y'CQNY4UT67HT.E84[DX>2W_NPFZUSFQ[\S0,IS94>+84
MGDWE4<K@M3/:(Q8P19Q[AISF#'E%$R<N)9STVKN'D[.J-]KJ:NVCT8Y*:Y]4
M:Z=9B'.>!.$PRI,-<OJF1$8HB[ QD<2D>!2@N2LWK>WV([/YYP_RV0Y<FD +
MX';\>7LT8#<SA3,0Y,P2?MCV>1S^\7HDZVP@Z 7GR&_XO6WA H-7 Y"1TTY_
M2$(&WU!<I-^IP7.-IZ'X8_GV_!TWJG3YN>OI'BZY;(1Y DZJ@]/$Y\H9*Q2S
MBK%TARW>;GR<S=<^/3^Y #(*]SZE\HWBA'PG[13K:'8^%*LO$&"DY?B%:OGR
M!X\?X/KP]R./&UF[F]O[ALMD)4\H!J41QR8BZ_-X$N5I8#$%C<W:N_Y%9T9I
M:[<6L"RSTW-2\>=M;;&)FP?=6-#B<F-C^ R+Z(0WO:/'%["^?<R [N8'&Z,0
MB M'D)'.( Q/GPH:C&+@"J;6CUCDS,\DTN?BK-[&]!GLTZ8-3)KG/P<^S67=
M]L^[\-\J56!K<]\G&EED%(EH%>()6^08CTCJG.:,/;=LMMW-TV[:G['7BW$Z
MFE-MWNSF[>Z;!!CK(T9< R'BVB:DA6%YKF0BUBD:N+UGGL?SL8[-?FUX.%VR
M-4;6:UDVU@M&D,YAPR?X!;"U6#*,]YT36.YED1BK_MV;H"06V,2- 8W:!3#S
M%Y@C8LR&%FRI%!&YH9EX_*P+OB&D?((4$<'NE\NQ\&+5+TD1N5<SH!4\PQ\8
MRUH!N/=(@'BU#V(\0'+V4;SZO(;)1*$,PZ1*3*B.\NZ(J2U7;''[O/$1XQN&
MT+;.8P.NV+R([1^Q#I<_?"U1M<Y%X^B+V-GR=._[WG$F>-GCVCW:%/4M3W:/
MCAFLX;)^M2T:U_/#CS:SE\8;5WOMO9,O5WO-+W2G^7NKOG5\T;CZN[73]'"_
MVW#-8W(M4\$&@YDD 87B7,]1X(Y$2N1,C!I+KPA/CQ$+KQ(5*G1[J^BV0%/^
M6US>"@ ?$0 OQ^.3;:*..)P;_8+S+ 5'UDB/'#>1:.JY]B*/3R;RP4-8JM2&
M)R*GM,I.>&Y.MAMMMWG1J9!H(22:3DL0,L4\!-*F(@9+\S01YU!RE&)F 8=P
MJ-(2*G7]122CTN@E-7K,+8+B+F G4;1:(ZY8KFG'''',#76>>9[3%>@ZU2N7
MLO"68ENL&O>^$O3AL!MC!3<+P<U4QZI '7!AQI$7O&ANEZD$I\@*[WPRW)!
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M&KJDAHYI@A+6TN H$M0$Q)F*R.;<C!@#2[!+)$FV]DZ*%5'17Q22>"X%*TA
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MNKK=>LQ#H$E4OZMCR*03&UJ+>B>16\FX-5(#&3;@P@HAG228)^&QC>)^Q\@
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MWF5TOB!^4W5VYO[P?T:]!5N]!G#"#EC]_4F7P FWFFT_>$$,%H.\'92K <P
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MM=Y:92.)7#D:1:HISHN&NHM,EZT-3[8![H#'1.<= IO?(R"U'%DE/<J='G6
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ML(ANY1U?4%6I=FN\&L5]#AY1Z_0#ZO0LB; :3 "E(_+ )7+X;4Z6<1H)(:4
MLX%:[K)U0/3END"U/^/1%/*?T?9C8QPK?J\^,Z\;CA[17U$:DE_"HK(RDX6I
MX>=6\./G*07#4G.I&9*>!\2E$<@(S)$3W$@7L+6DE"43"^ITU,Z)5Z/%=R<5
MM:H^GJK.,@429/):$803 U7-M02=!^*@A#-.<F(-":"J;)D4]=7[&OX>=/VW
MQI_=XY/8Z9<\HMKE\.0NA]Q]9?2W]S_R0L3I!0&CY8_8B:DUZ/]]:'OQ#P"E
M,'W!G]W^H :G6X'3P3R/B%H$[;E#-!B&.)<<:0(_C,0X8JNU3F#&*+),A[*U
M:V+)6$2MX,NDX'/LPVHCHQ)(Q.Q[%#PB0RQ%.!HNG<0V&;/RCN':2_&$NED:
M1]>^B2<G'&7>:T2Y%:)\NW2:X9R+)'+$(A6 *-@CC25!))+ <="N4 :R5&>G
MM>/AI5"&6D7OI**SF[[@Q%OL+(H^.,05)T#HO4$R))]8LE)ZE@LM+E/@TJMW
M.90BO!<%4VZ2$7X#R^1M-(I>CGC+C[UNOSXXO1TVO3^]:&KO<?/\R[Z0'.P1
M0E$BEB!.HT$NZ8BBHBE&I81A"OB#6B7ZH0(B'JWE\W/Y(]ZJUC]+$$6M]7?2
M^N9$Z[<VWN\[KZ@D02#F@T6<<8T,)PHI \9#)")A25?>";V*^;W33Y]$ZU^]
MDV)1G<*I2H(/WGA^6>[QZHGHY^TOC0K:ZC.OY:"74[4M\]D[3.MZKV<[!_$U
M5;)^^C(MN8%5LCF/1Z)H*48\48*<$!%A)C"1&JL05&G?Q^K@VU>LSH_@KJIU
M]E&JE8#.>D(M5LRCR!5'W!N";.(..8D5]DY)E;*!*.LCJ_K(:ED YA&.K*8
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MS)?*\RQZBYC5.9 )C=+H.L7,:-H+EZKQR\K6]C]7?IT!M_XE<,[X8$^ N/P
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MJ VL"+YGD^P>;YXV-];/MG?:1]M?/QPW/WZBS3_G&='G;TWZ5VMKXQNPH"_
MBCZ=-H_@^X[6X;.;8OMK4^Q^W3W=V]@]S8$56^O[#(/1*0E'>9X1&$X4:>((
M8H8#&S*$2$+GXRIP((S$:"*1E!NFK.>6:J!._W][5]J<MI:T_XHJ4_66/6.P
MCC9$4C-5WI+K>[W%.#>3?$D)21C%0F(DB(-__=M]%DFL!@Q&X'.K<A-C$&?K
MIY?3_733 ZD  VHDKZ*P#U3MNL6=6"*OXMGO+Y_: 9 3*<(3,H-I7BTC)(S9
MS7_%Q; F*Q5TN7%/]3P/N(-*:F)F)D:7,%3:S>"Q++7X0@BS*P)FKI2JX/[5
M1>[LZ>KSCR8(E:OI3J7I.D;%J+FD IX'.,.NYFDUNTG<NHUQQW'F/^'[,NLB
MWW=JV XEJWM^B.DS.0<7,_%%P@WL*BFYH7;.QAUCZ25&\L&\3%@:3;,/'A=X
MM,,R-.(>4:N<.0%Q]O<O!U1]OZB_X2&A\YCV PQ=8:H.JQS"C HT], \.0HQ
M+>9^.+<6I!/-C2YF=;H\#0JL^W[BL'))6D9(DS&Y/X2-2>]Y8630RU-2>9(N
M?@0S:>%/GJW)_"BL/>)IOFCI'* YDOC4(O- M%O.KY@6>H)-$_?!HZ0I34XA
M*11&#$,<]EZRI(^\6B++XSG@Z;?4;<WM046PL;; <5RH6F$=ADVM7BNO96.N
MW;(Y1:(-GYHTM-H-EOPF=*+2V#)/#_J%]GWP[:MK73Z%#]^^GCU^N_O\='7Z
M\>'J]&^LT@JNGLZ?OFE?C&]W5YVKN^_AY=/#+^_3WX;WQY_A=RW\U?P9P_-O
MV]_NCMM7IY?JY=?/ZA6MTCK7+W]>_?Q^UV[#3^2J\^7I^F\$\\_FY<]O.@ P
M?,^1^<-AB^M7,*D"+1N[TM0T,&\<NV6KFNVVW/JH96-:NF.XJJW65=OP+1^T
MHFVJENNTZH[KD_JH96.H9.]A7^G"VL^V8\J&KI,-JV>GCZA\Z0PFF3 I,EX'
M:9NR)Q36A?EGM"8RI573%8K&?J<;Q@/?IUZ7*\XQ(M<PV6N08#"*<D<7PENL
M2 &-'U9.P&D4<EWP0.D.>FZ;T5,S$NE,5E)^D>L@@E<\)DSYM?)O&CHK?@"=
MQ&S(] >\0*XJ+"-B6N7>9#;M#'M[,?)M4H[-U,^RU/)1#PT84R>#CD#U15+T
MWV2Q6%T6BY5C+"4L%GNIZ5$;"JILR,:PUEN(DI.V%[C<RV->N*8P+[[?@?]U
MU^Y<=KYWOI]>PG=^(5=W87A]^O?#U=-Q</7S8QN>32Z_7HZ8%]T0B[JO/WT;
MP"<?+I_.U.]W7\CUUR_&U=?/^N6G<PW&AUQ&O[^1(?-"A;\'/UK$4!W/4"MJ
MS=<J8&(8E7K=(!7?KUN.[=6).EZ0HIE$:SJ^7?-;\-9FR[&:+JI<B[A>TZH;
MH^9%8R(1PO*6QD2E_^R@9$>*V1TIRMB5@0KQ#7-S4[PA+H@Q_%7"E@RO+]/&
MY<_/VN73);@39X_P9_"C#MO@6)8-DMSR*X;N@TQ;Q*NH&!BS38T0[%9C3R M
MF]"3H<!]Q/N-9,6>]'K5"SP: NCX/J?W0EX3L.[H,4,&,($=12\\\:E]3+N9
MT$@"?PJ\CEPE>'D(AQ[>[=^#3DC;08MS12'[@,-2)7CMS;280.';4*SR$ &/
M"\@.+.62]:WLP+)A<;\^O7_\85C-FEJKZQ7=LY!2V=(K=<TP*LV6ZWENTP:W
MUYRC!<L!KQ[W6#K&@G2XKZ8-[O)#?LMTVTF<]LXC&G"DI4/LS,C#,GY8'M0?
MJN-H-K&]BE;S]8KAN68%?B05DQAZ#<QLU[((1NW'ZT!&&W4,P8T+>Y#=1]/$
M=Q<;E'F""(%G^!1BL9R@2@3V1]$;31/L:4:-EYP"9RB6^WI-@R:W_R@R%?6V
MN:'/K<^K?*]BT(-$.\A*+M9D,M,GOL?%"MRY+E$$(P1>M*YU9#/'08^(H!X-
M(@98C&J"^R[/]\E[BW$L6YT>QUHD9*&]D]&O-QW](O;&KL/.00,Q%5BO*B><
MBCA@1&RG09HS;+!KU".7)A(Z^ * ._^1U6UYRL?,&<DS>.:]R&;[A"SU4>^]
M9M##O"&YOHJC2<.>5YS-9^X^R[';1U5ZDI,X9(XD#4=XV$NLG#NVH&X]RRT0
M3"O,CB.[N!&3[HY/>A,'CFW)^/^O^PG(9."WE#.:&8W5$M<ML/A 3^_%\,MN
M LYZT*475>(-,7O#/H^ZB2?DLCGE"4XNR]DC:+H"IXWVV=.>7TIECUIV[-H.
MH.2VCUGV1'<JQ-SSV;B(Z?&?&!4,6G(-F $GYCKC!?L ,-30(W7=8.QCC)]D
MG^?D<@NU%81LV)Q$FZ?5TV!,53G.,[K!A!PAP1ZP.0Z'@0XXZPG--\959/_D
MN:B4O5MTT!S]NH-Y%PF)"0X8^R?:\6RWA ]P4"1@Z5%7PTGCB*J@/),EQ*#*
M7-)*M)*+ZR5X-ZPD,7.5;GW&VQ,IYVCC1;#$'+"4:]B PH&^%5&WT@IQ)YL>
M\R+3+H:H1:>!['9>Z%'!1TY_]K#FB9*]\%7@)TK!8S@4_^.K0$\O34VB5#7!
MF# *66PM*7U5961.F)W4I_EMR/LTA+Q4A,19QKPPZNOVD_FG,UR1H:E$5UH)
MC.0Q3AYP1F7SZ8;/*F^>CB_?)Q1$/XK!;]3EXS<S>853!ZL;J(';P,,9T]2)
MZ^3>B8(GD6/&MO,.P,@#9X1]*DUI3#T#V>%& X4#MAN;=K#178O'Y*YX>;&8
M6&'.RBC-UQ1B^)U0,07G9NY%*H%"8?TRF)7"(EQ^I/""'C&?Q3;>R].B0+,D
M&!R?U19 7%!1+CZ6X(3IK_3D( TJ,J'1KB;<0AEDH;MX_ ,'BXUU-T[>>81;
M"/):X,45U6RCJG%T::K3S(I-GLR[22.G%_^#%#S,2?.88:WDS;$QB?Q@A DY
M&%^\M/@95A.(E;$L_[Q(0\],:_8ER,*#K].?LF ]*\T5^HH_;HK)?I#UN(!9
M\+XOR V" Z/5<!UZ*XR64-:L*AQ4:9"$MBC"?E<K6Z6(2A<*;SM^!&\B#/ET
M1;X%G2(**+8&BI%\$*:";7(*SL0!8RWF =?<M1@M_(-/_O3=S J@*:5#9M[P
M:8!5X8VJF,N4\5MF]-98/QND#[QWD5AO5B5 @^*P!,+PA5></MO< N;ES)84
M@K+K <_'D!6G]>J& ?64,C*";@PB2XMPDZ(SAE],[R("C!+Z5>4KL[<C3R3
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M7#;$"T*PE9*C<?!H>WZFRET*#PDR@&<W-% ,$SW@-7SLC^IZ$YW>>P-&;1Q
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MOUQA6;SW_F3A_])\^)7>;*K<E5KJI.3UI>RL['\MQA3,+[Y2>/RE'FIQ>KP
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ME\+NA" -:Z?7QOL+_6<V'Z:!C86C=!I<I%1594M):_&D)\6<X,@URUTJ?K;
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MY__SZR^?V:-XHC!;%"5=,#U!D?VYJ'[XRY+1LL+\+%W@Y!/Z7W#]&-0_@GX
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ML#6=%NJ/(=P&:J9[" <6,"V"P8;BIAO;_1*\$>!F.$ MM$CWP(ZD.[8!?MX
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M4/J2A=C3'@6R3LF\-]<9.R<UV@"[:9;W8UQ8-M:B4G)D4S^B]APNTWGV4.U
MRPN$;NC-E,3+D7R5DAL;4M=&N(-F.E:0#%52XW#"5ZN?<9+WKF(9IU_JH?S=
M"S5P>?OTG"^_UK'?\_GRFY[KDV B^ZKMWEGLI\KDI![D!!.E_/D84L9]&'NQ
M9)X4)$W-*Z6;S#@UY:^F&61;H@%=4ZU[KS9D6Z@M1K@;J("NT1Q8QC1 MN@%
M&X+!I\& M-#_7 ,ZDO[W;EZCF8MG'12MNZ*5CP(P'55:1=)4(:6 %MH]O@[7
M*QZ%* '72>ZZE7#336W[/:N_U@TZRR4H.[: J[+J-MAW*I=& XVG7-KPM:-<
M6KW8\UZYR?U9\%]IMJA6F8G&;(H$8D$8!%"*4!G]4<QARBB#B(024\0D0Z&-
M'[)CKJE)_$V3S04'3UMB+:^?.[ UO)!V@]C05]0ML%ITGC?G[>^MS^/A]":[
M8[IQ[[;/\WUPVVWP2C^1<<W_>U64E>IYO[SFO.I6KM71C-\N;NAS5M)YY95,
M]Z]=/HFZN_DZ!?EC%:;>)!+K!^J03)P2CR.:PC!(.$0\4G(G\E*8\$3XDHB0
M,:NB$4,3/#7A]?E$N0@[Z37X,IN)P"DMWL!R]/KC[<W5\?OO=IF(3=<;G0)7
ME8AH\>1.UHX%O$N!/3C-HTK]L59@_^@8;=Y+:MK=R7??V:/>%;IPTIVBJWC4
M__].4?"5SC7QGT11YAE3%HS^A3H)=W_0>G*&L9 D\ 1,/#^%2K7%,(WC ":A
MX%10AG!DI>H.0./43IF:16TYBH9)D&M3LOY[H;VP3'%P5?T7B"TC5Y6BF&_X
MK![H4_O.[2=@=AR]\L(.? )MUW3-7UT#3ZWE3;66^K_@77LMMVS5O]1KN_^S
MU@NNJ^ -LA+N2^&Y)?,5ZN$-@O/QHGC#3-7OK/DDOHK%2KQ7J-PL%U55E-^S
M\O%&G8_+)Y$K0N<KG:JF&TZK_^/W]/LL"% 2B<2#'$6!,E]TY6BLSA*/"I&$
MZB3!U"A6X@(:IG96-"P _77I=KL5$^";X@*PAHTK?8S4C%0]Z34G.N?'[F#H
MLUYF@G_@51A8L.\LP,W. MQL%F## U@SH1.+W$GL"R!T*9'[D#&JQ+T IWV)
M>LE0?1W*FZZ>:M#5D^#^+$ TBE./PA@%6$E$I"2B+AN-N,\DBE(N66A7-OK(
M+#V"$@:6>M>,U5<JS_2E#E7?#4NHTIW+1Y&W>]1JX:?Y >5COEP]/%;W.#H_
MNGI1:6:L%1IKZX\^7!I3/W0_N,?R/V_1:\ASZ7(^R;I;5_/A-".[F$_R>>A:
M/OVHG= H\G+V63QH5\-?Q?(AI\^/&:/SMTM]YS)3FA+S&(N@[M(+$9$(IHGN
MU2YBI4H%4B!BI$AUSC(U5:E-(?A2TV@8$-F-9O=.=X;1P'O=#A[CW6[$?L=^
M5^^W]KKZU_X^[YY@E)UNQ.-ZKYL]?$$"Y8'O\# G)]W/R7GW_3G+JX=KQ^(L
M06$DXXA"'C($44H()'X0PH!@(2D.4EW2RJI)CS/:;/;,.-U[*C*5E;6FL]V4
M\D70O%>2I)-E-%-"7F5I!A9G#I(BM]R!FCW'F9 N$7>> >F$N/$S'UUB>C3C
MT>D$?9**6'T1I :[D]JXU#Z[=;WP6ZZFS&2F;:+Z=^LN.?6_/HAR%K,P2'T?
M0]\7$J(X81!C(:"("?93Z:4RY295+IQ08Z4CCE89@U;D =I0:Y,T<^GJ= OL
MT3$?^EY^RXHVP&L26_T80)N=]:\WC9^:?RN6QEPAFY2G$5=JI'#8O15K=DJK
MHTK67K&]C;3^]T*4KB);74'<G5)UZ20CIELYPF,W%<O5H#VM&IV6J[_M7[*%
MN%5_+68H\</03P.()$H@\D4 TRA@,.*$Q8PA(3"VJNMR,,74O!<;"L$732.H
MB#1T7W0 :6@@7 3/T)J^'3+VNOI)YITJW8>SC*L]G^3R0 T^_63/_<T>!5_-
MA9(M2I+P;+[2[=L^"[;**U=H?9<B>'W7\O2\J@^Y._F.YKKP=+%.UM^6(0P)
M(IR0$&).8B4DI _3E*10$I_*A,<B(9&5?'!.XN3D2\.A/M6W?($U8^!]?;^Y
M8:T*96F8,RAO,=;"&\JS5UW.H>5A:R7;[!U=5FFTK.#+?:7/#5+Y<KC%<"J?
MW5,YKGP?#.6#\V&XF?J=+W^EV>*795'<+>Y%_I0MFNFJG-]9P+TX202#))2>
MOC=7)X67Z/LPP0/"?1GSJ$>6?]></>[3QTCRU^3J>,1R2["6!M6-NIU<[P3<
M3$)?C-](EV:*3/"C)O0G#=W]+G2_=$)G+2A-,'$I\CKG&U5XF7"^+X:,WNE9
M:FY.U;BRR@9:WZA3CW$18!A+BB&*N>[DSHAN($62(/9B+.PJRQU,,36%L:*P
MTA:KFCAV%^H=2)K)A\OP&5@JV$)C7_OM)/=.2[T=SC)N9;>37!X4<CO]I&78
M3/F<SWZ_GB4)D8'O)[H5B=(*!$LA34,?QC21+):$$6QD/S;C36WO_DZ+1Z5I
ME::9BVM8NO=F#V8'WHB_7W_^W[<?_GI_]\%!(,LN=QVM%?63BD<?5W^#^F_M
M>)5FG'$B4W:)WL2@[/W8;I-PD<W>*=6^?/G;<KY:E#1_>9_-U6<[8RDB(4D#
M*#TOABCQE%J=AC'T/)80(64:14:GX,D9IK:1:B+!ADI0DVFVJT[CV+W/G* S
M\,ZS!<9X&YYEOF-CJG?KTT_]9?_0.SWN*!OU+%OKK7O^P1Y!!9O6&J)XFQ5L
MOBQ6N=A>$O@B#K ?ZD"!6&UKH?-N:$AAQ(7D?B(CGR7&9:JZYYK:!M^V@1$%
MV-+;XQ+&!.CN?>\8OH$EP+C(6=S*NT-PI#OW$T@ZND$W@Z/S?OS,$./=?IOQ
MLG.W;?B*RV[3W[-BE@3<CT42065G"(A\C& J!(.<I2GF 8H#:>4O.#G3U 3J
MB5[)X(LFUM)[<!I>,R>"$] &%J,]\7+46KJ%Q?"-I?5D$V@KW>+9K*ET^X4+
M(URJ:[99ZDDOXAZ",I:^TK>0A*GD@5*__(3Z2/TOBWM%M]Q/L09H*WZCHJ]O
M4,N]06G/RQ$9>+N;@]$_CN7^L-RCXQB6^_'J0'9S=S)VY?Z""H\Z@^>3COFN
MCAHIDP!A(B&56$)$? HI"@E,8J;^%\=^@(AI+MUFU"GNT:PHJ]RP7P75.E+]
MD5J<VKNPG7$E]@5CA.W9 P>K;+D#OB_-CML..%HVW $/[>RWPU_VO(:KCN+W
ME.F4V9?JJ_)XY/L)B6'@A[J%IX\@#=7?/,3"B'(B:$JMKN$.IIC:SFQTPS6)
MO?3H(T":':.7P3/P7K5$QOX2[B3S3B_A#F<9]Q+N))<'EW"GG^RWO^^>A<Z:
M6CQ4=_:?LH?'\D[^5M11YM=/R[S,_EFY7MY]U]E88L9\EN*82LAXF*BCF"0P
M5:<RC+COJ2,ZD&DJ;':_+0%3DPUM$O5U=*XY@$L)5T63FV$G)ZP7Q$R*# GS
MP#)F0_JZN<>G-<2*_CI!Z0KL+$/#@SLQU!<]ET+*FH9115A?A/8%7.]Q>MS(
MO!52Y'E5-JA.HSGJ>B@^";YB@K]=B?OE9ZIC+M\O<Y$]+.HKHIDODB# 2@'R
M$0HAHE$":40)]'%(DS!B$2%&^I!#FJ8F)+6#C99EGJ6K4A1@L03SI=)/<Z#V
MQUQ4I19U:\R&=UTX;9/6MN!5\\QZ8V^:-EA<:CA:98-KH_'7;F#)NV9(7XLT
MF:!7X(2S5*>45GP!Q1BX7P+-&KB3H&$.U-R-OW 6MU;C+^!(MUMC+J3=S9A;
MR#MOT!Q--=Y-FUML=F[D' _=X_#]F"_545^^Z&JGSU45AP6_51MA\9"E<[')
M;[VOZ\C=/XK;IHK<G6RUE)UQ+TW",)00HT29(])+(/&B (HTQCQ(TL@S<^,[
MI&EJA^^:JZNJC/5SW?UHH4_<#6?;['%W=?M<KK+!X3O^V@U\^*X9 AN.@&()
MM'C:5FEHN%)_"K#F2XOL=M/L\5?-XN0=?_5&.GDWJ^AH[[FJZ> 6\,YSU]%4
MXYV[;K'9.7<=#]W/Y_<Q;T[_:K J#;#0\P@^"U$<!!Q1Z M.=:E*#"G&#&*"
M0H\*%DN*;+Q[IZ>:WBFYUI&K?78%BHK8:B.*NLQ<_1/+.G,=8)MY[MQ ./AA
MM4;O<XU>32>H"77GB#L/ADN76\=LHSK7SG.][T8S>..2]C795[&)Z=-M#G2E
MFH6^DZA.TYNJ_<&M,A*H=NTTS\QT]\6$Q!*FA$80A0F!&*N_!=(G01"F*.7(
MKHYV?V*,MLZHY;9K.K4;3'N_="^:/DUE>BV,F1P:&.PQ6\3H0@W;@-^Z2<PN
M(U=@NQX-,YM'KW3-!J;.;M?=8"[!UGW3EU[4O$)OETM0.]["Y:(1>XI5I?>5
M+]OZ#6]>;A=\591Y'2D@*,,)41I9Y,5*=,H@@&DH X@\[I$@35'B6Y7BZIYN
M:JK9FC9=7$7MHU[A%V< -A2!SF ;6,Q9(F8OKXR <"J3NF<<5^X8<7\@6\S>
MNJA:PN]4%\HM[_+JXO3==W5.987XF&?:@&Q^632_+?R91&%,1>Q!R@-E[1%/
M*+&B3#X/1X2E2"826\5R]*)B:M)F32]XU@17AA]?SN<T+W3)\=H(M+0!^ZV.
MF4P:'/.!1=6FCD-#I/KLZP /71N\68F*C=8SQ>8AAQWY+@)R@)(0EH2\1M6(
M?EB=*"S1<["^G?&4X%VQ4LGBQ4/5@6^N;;QKK?S5K6'2HNHW-1-(H-3W$&0D
MT$T:)((T\2@,)<(D)3B0J95'S'CFJ<G%'<*;1ID5Z6!+NU(T&NHMU3/S]3"3
MBH.@/+ D= 5PC\YVEF"Y[6=G.OG(7>PL,3GL76<[0$_+<:^@WQM:9$S-]U;7
M!!1\1@4-F PX3 A6\HM*#M/ QQ G-,81(C%"5OT\S\PW-:GU091@KHON:=VM
M?9$&($@UZ=5&XS7Q3I2]<PMB:&JZ@WEHE]I!)=,K\&:#;$.O0]/3#!BGMN>9
M*<<U/LWX/[ ^#5_K6Z7H\Q.=S]^LBFPABF(F$I_B@,>0(RP@0B*"%/, AD0R
MAC'#!*5V-8IVQI^:D&D*\50T@C61MO6)=A'LEA(.<!E:*EA!TJ,RT5'&+ZY+
MM#OJR%6)CK)T6)/H^&,]0O!^4:;5HA!*"GQ4JLFBO'[(195J6=1IWI&,O#"6
M C)&D?8U,X@C3F 8!-QG$4X#9E2@SV2RJ6WIAMPJY*HF&&PIMDNB-\*Z>[^[
M1G#@S3\V>!:!9@Y!'"F"K!-,1]%@AJATAGF=&V.\^"U#;G8"LTS?N:R;7+%N
M[7.?TT6AC#]]G[@LRF(6XC@( Y1 STL91'X40QJB%,HXIH$@@1]$U*)$NO'$
M/0(AQJB3WB)366U%QX?>$V\#>>L,OM'[O!4Z]K?IW-9&\F8()/OU:G."Z/C]
MV(I60[9R_QL=H-_:69A,>ZJ='NA5^J:=Y>M4;[3S+[K(@V_UB&]ZC!9O5V+C
M@Y9"Z\5)!(6@5&=\1C#%80P)HSA&7D)1&-HU;K:9WF:'C-.;>9NA736R /.&
M?L-LOUYK8.9&&PK7H15H9=D)<04.4M_7'+Q<K1LI7U5I>D-<"_3!;KB$]S/S
MOV*RNQDRW8GNAF/TDVVW"Y;K2=Z*^L_;.HO@<3E78Q1U7,JGY7S^OL[ZFQ%=
M92L6(0Q#Y$,4QPBF7*;: R"Y)RA./-_FRL!R_JFY M;D@Q_7#/RDPT+;//Q/
M4',!OF@^0,.(Y1VH[3*92< !P1]8" Z N[4,[(F>2S%H2\*HDK G/OO"L.\P
MKLJPUVXD1(@,(Q%!3+"RP:-4*HTND1!SF7B8)GZ*^64EV"?IZCQ91-S:3]>!
MK8&][0:QX872\&!=6FA]JJ[,5RBR;NZ_['C]E8NKG_9:&CQ^F<.RNQ5Y2VM5
MCZDOB+_/%G3!]K7:EQGA49RB1$ I>:@422^"U$<IC$1,J*!AX FC!(:!Z)N:
M2-Z0V<^@'FH5[9RFK[ VX[E8J\:_M1]PRQ]H,PA:'(*&1;!=V(K)K3W_N@O;
MSX?["@L\OL>WY?#-MPN=M1=ZWEIH6K-Z!>2I+3R E]CQ0ICZE%U-^RH>:,>8
MG?)7NYZF9^\#'?*5J@&Y;@8M%D6U?ZYU3/U#=<OYYF7[2.. NM:6UMUSY71O
MHO$UR;\+'8 O^/57D=,'\4GH3I"*WIOEHO)5K>A<]X+U9Z'',59V$_02RB%"
M$8<TYACZF#/*11S'B57WE5?@86IJ0<,)$%M6KL":&4!K;I28:M@!;,N/DC^R
M3F9Z$32W+6+Q&M^/F7MKXE_%P I)Q1JL> -M_D$+ )"^@/9S#0B@0D%?,50X
M;+*M]CZJ!@RP00.TX*AZ<3MLGO%Z:^FT0\<KL#%N&Y#76Z>#7B.O2$K?XDM+
M)@0OWBM8CY=-BZ- BH1Z,-8)N2A*$23"HQ G//2(%X8\L<K*/3OCU(ZY-<%
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M/87X4.[5D_/U+."G-..\"9-HG6_K^*8PD%&2I 0&?J*.#D0D3 -U=- HB9+
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MH'.8*-5KE'['4]TDODKF_+"L2\0LRED8I8Q[<0"%]%-U% 42IBA!T!->A.(
M42^Q2I8Z.LO4#INZ+>%BN8 -@4W6M9W .@ZHF5RZ&*:!Q4^-4$U@%2/3D.A.
MOG0BX%*,')]H5&G1R>N^4.A^N&?:I%K<#VJYJU#Z4,9$V=0!E)0H;88P"G%*
M$AC$@1\&* VP7:92>_"I[71-&]#$]4MW;,-FMK'[@C'P?C;&P3YA\0C#3C,3
MV^./FX)XA+.#7,-CSS@U'_]&YROQ07RK?E/,6"1\%E$"J2]TQQ;BJ\T;8!C3
M%,<)9T*$5H4BC6:=VJX^92Q>@86HR@'PK*@;SEY5OU=F2K9<%%4:]%)*46G3
MHO;-6Q[Z9JMTD7'2'_M7M$DJHI6F(+[5#PQOB1R':00#9&_B*=@=Q[$P-#=.
MO#Q<7H+Z85UCMYCY"8E"7?=6(D]G39,0$HP$1(%D'HU1BM/$*FO::OJIR34=
MI-Z0YCZ)H(6ZF7@:#LN!Y91Y\/\6\%<*Z#_$;^Q@_18%DPO$/T2G3Y#]D5'Z
M5O,N=&TL_8>N*?&5SO4-PGN:Y94(W39\G6'L41H$ 0Q$H$PLD3)(B%H?E"0>
M9Z&D ;42:\8S3TVB_;I<B!?P1/._*\5,KA;<4K"90VXFTP8!<F!Q5@5V:=6U
M^DN+["N@":]5KU:;:9?ENBW1<ENOVW3RD0MV6V)R6+';=H !KB.K[M49*P6O
M'KO^1G/^091W\OTREZ*N(SZ+&941XEQ)L539FE1(2(2GK<[09R%#*0]29S>4
M)A1-3;IM:6XN*U<+=<J K^K'ZD?#W(09K9R#RS'7ZS&!^[+6<M6/5TQIH[5R
M&K08&^D:S0;CT6[6C(B:@M%KCZ'5_9O5P/U$=%,Z.0AQB-5G#1,B(V7Z)CXD
M*=<Q!@'%C,>2<#(KER6=F\G9'E7,-X,/:-SJ.7I=M!G5%N_/_,"2Z4R9;FN)
M<JR0LANQ,&:%Y./<[&]0-[6'CR94MY+YW[QL'VGBPJK=KM6S\N5VH>1 52>\
MJ*[F[A_IXNY9#Z'OY^JS_L.JJE='J)]&R)-05EV<1"P@X91!3A#U<1@C/Q&S
MNFO1YY+FI:':-!;]-IMFGXOA]H\B$C8:52H>LL5"'^TIG5<7 /UUK-$^BDA7
M<^(X@7Z E>XL$PQ)&&(8^#)F"1$)BF7S4;Q;&!96F? GL>9AE ]"5*5T_DA?
M@Z%F/L7U'5J#;U5<:7/=+KNBT]J.5F:I%?F:>]!B']2!+*4" #0(5.$L-0;J
MKQ4*#M7]L1?.J5DP&O'CF@]CK\F!F3$Z ?:%"C\+IBR@\L4/TONLG(L9(GX4
M8XR@B&4($0\0)$DHH1=)'V&:T"3$IF4)]P>?FA^G(DJ[ /S@Q_0GL";7O.C@
M 7K=8OY23 :6Q+9P6!40/,7W!>4"#X8<K3C@*6;:I0!//M//FJES>\5.-DLF
MBE8^RR;Q70A*6<)BF.IZHHB@ !))/2@C%),H3".>$+NT!?/);3[G<5(6&MK!
MO,K,G:\3@>P410OTS32]81 =6$"LH3Q,H&OHO@**\$$J#-CCY5)#LIA]5!7'
M'I5]':7'"+WE5U:*JI?&[:)LFFDTX<ZBG$5<:1>IAZ&7^ *B1&*8)E+") EP
M@KTX2%-[F=4QX?3DU);(VEE:!35:2ZE.C'WD)0G#D#&=Q.8I>%,A(RB4;B?"
M* X"YMGXF]TA/(8?6M_V9'L8.X776/ [ FUX8:\(;;K?M#[.37)(!WQ]Q+L!
M*HY%>M>,8XMQ ^Z/B&Z3MT9VGC<6ZE_5@V5QNZAOUGX7V<.C,E>OE2BE#Z+Z
MY5M:BDWTPRR-<1H&?@IU?('N!9C %)% &:!^&$F6AHC8Q1R,2__4+-LUP9#6
M%(,'33+@.AA2ZN"AKU7PD++UEC6_]0--] )?SN<T+\"SR&N_ZEANU9X?S\#.
MU>$_B>F[6#=.U!H%W9UV'6:Q1@(T4-2/  U&*U!M K[6R]9Q$A[7GBS\,?RN
MEZV/,^_KA638G;=]&OCNG?8S#V$6<YE"+(@'42PP) P3F C?%]BCH6%%$0>T
M3.T<W#>JANN:OK\HW6?2R% /'>K2ZG1^9]KS?M^D&&]IAFM9?\$2_3&:TN_O
MIU?J/7\"9Y?=Y?>GF&S_^!-87-(A_M20/8ZVSZNTR'A&\Y?/="[N9!53N:UM
MB5/*$X]'T.<^A2CQ8W6(*;,%>X1&.(U]ZAG5)#"8:VI'DZ91;\%KM32+Y7=P
M0Q>44PLI> 9:@P/('6!#&S ;0L$:MJ:MJDD%46OH+ X(=Q".= "<@M*1(#?#
MHU-0GQEB/$%LQLN.H#5\I6?8N!+3/)NO=-YC<[N<B>+==S9?<<'?*^*UI;.J
MOZ [^8[F.F:R4 9,;>B\'!^@JG(B$,<AE3%,69HH&R(F$"?*<(W]) HCD@84
M13;^MP%IG9H@;U,*MJ3VJCPSY!*;><DFLG!#6RS]ULP^:']X-)UF @Q([KCI
M!</C?I"S,,*4/13P*IUIQ<HZSTEM O_#\FM58SI6!R^NNZ3/$L^CB4<2W8<8
M0X11"E-/_<<3$LL@P-*71EW@S*><FA3?(1IHJG7 <$TVT&1;J)=FF!LHZ,Z1
M'%BL'H+H@QV*P9>:9AMEW0Q-"YW=.:HCJ>Z=GVA\!<P MM/GK;#J5.O-1AI/
MN[?B;$?)MWNS9\T1S<&BS*M/ZE-6_+TN9:+_-A-,)G&J3N_$CW1MD8! 2J,
M$O7?&#'D^[%G567D]%Q3D]([I%9EX"I20:YHM:PPT@&PF:;L"+:!1?(N8IJX
MJZ;T4?./C\MYQE[ E^;/05JR&$#EM(1(QW3C%@TYS_=!F1"#5]Q%D+_\2LLJ
M2GVOYU#,O$AP[D-"4@I1$$M(.2:0D0AYQ$\9XE8M["SFGIK(V>_U1!<O_[,
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M[JK89=/;T82OTD:A87D=EV:CGXL"8!R8B;KP/NR29$Q0<!4#?!\$Q&$I,1[
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M V28VLK[V]\^_RU:RH.&ME5B@9O5/V0V[+8!@3$.O "TTE<Y/VU3C<.LGNA
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MQU_HZ4-'^2@OZM)^AY<O&+8$'^X-?IE3-E^89;[V=<]B!E62,PXP36( "46
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M)Q$.D&)4'AR.TC$-WO"DH06C-)-^72WT'64=E_?K:B//M4U7,2DR 140C*0
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MLL[W<]FHXL_JN0U*GR;10$E&M9=N0^O8F+KQ:9YB+W^5FQD162+S6(!,)@)
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M4^8EI#SZ\JSAZ(WHZ7W >%$\-GH<1.Y8W>"E M+SFHJVFL:,9%@(#CG@J1
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M7M0*?A<9#<VVN2YQ:.(]S]W67A_]7JGJ6#K'ZRM@1WAO-;&!6?)-YM0]W#8
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ME!98Y"E3.>5.J28]8TV-(MIJ 4W$<4?<Z/=*8,>3K#Z8+3=P?L +O9$;CMO
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M[+:4CJB<:5+I^H1!7<FUH;WY]/*Z7GVK @'W$?:(JYRF!02I@B:8& O $HE
M)K,<BX*BI+!J"W-EG*F152UI--^+ZIK&< U8"S/6#UR!::=!JB.E18J"$U).
MG<5](#:2H7G?:2%^^6TS!FBY-;_>]1.GG8A=?PW%KR%WI9'XQ=O';"!^38>C
MQN%7+Q_ I94)>M*QH>7Q3TO]TY?5LKKJ4VDFEDMME'+SNGV1LZ(0$J9%!D0!
M33II'@-*J+8>$89$V[ 0*JMHZ=M%F1HC5Q4Y2_.U\$KL9GNF?R;7)EU;K=;1
MO-'"[,D:-1PHZ+:9L^#ST>8C,.77KHF?3[OD[$S03\NH5J9Q8[3J1(_C3XS#
M\C':!(U5'64GG-X)-%.CMP2;K[+CR*#;S=?5>OX_=9?>ZLNJ/S7S17U9FY5G
MN]3D5]U6?W1UXZ.#GK[&.^)K+?(R#;W+U6TCC+>B>4'B8-'S\\2AP6BF,N]N
M+TZ*0M)$+VX\,:6.TU0!*O5.(R8)RT6:,D:56_Q9]_%36[]JZ6PVWS;8V?DQ
MAB,2> 6Q!V- V-@YG?U&BAV,,')PV#GM3N/!SEXUP)J]Y_]WOEQ]?T>75-"V
MS72<$Y(J"+ 4J;9120H8B@5(BSB%J4(Q1U;?[:4!IO;E-B)&M8P.=LLY\"S,
MQ!LA"?SI'J)QO5&T'2P.1MJ-\(RUN;=[:=P,HQ[5>\V=<_>-9\3T2'U@FO1=
M-[#!3G6Z\*Z)84ECR7D.%< L40 B*0$I8@JD$!DG1$$A$I?HU8.G.Y'6"-&K
MSV:,J T=<JG2>1X\.X-C,"2A2:LIH_+.=V3/686]MG0Y&&#<UBSG=#MIL7+V
M(O=<MN8)'^<EIPMS1/MA*=Z;WL1ICI"*A0*YA!Q 83*+H<"@2"1E19K@),EL
MT]@N#3(UBZ.1,ZH%K7M5:E&C]]8MHWLA[?^6?0$5^),>A)%3OMHU$&Y(5;OX
MZ-&RU*XIUTU0NWKML-5Y=Y+9=-/;[VY30J 4K !QGA4 YB0'C-("R 0A1C-%
MH5VPW=61IO;A[P_KW1,I+L-IMW9[ 2GP1[_'IQ4RB _A*A0^5_C+@XVZVE_5
M^7CEOW[#C;1@,CK>T?7ZAUJM34OS<L;S@B2*94#E2 *8R 2P-(D!Q3PG/%6$
MQ^D@7C@9:FK$8#*+5@?DH%]]KB6>UT=?1NC*8;^AW\V)\>O*N0=:#^Z.!'(3
MFJ,Q2-5\Y4#,  1R$8H@#'(ZVMM0R$6M+W+(Y3L&%FL^;N78KH4J88CBE("\
MH#F N!" 9CP!>0I)G&'%B'*BD$L#38U 3ONB#CZ*N(BM'4WX0"PP20P#R[V
M\Q4DO-9POC36N&6<KVA\4LGYVO7#V.%)ZL=L^69K0L+?Z0=_D>5,8H)9#',0
M4PP!1 P!(F,&<@9%EL8J*5*G2.US@TR-%0YDC'@MI!L;G,72C@EN12@P"QR"
M\^X*.,Y??Y_V/K_\L^.,^M7W:7K\Q?=>.[#_*/\JQ=8TISFITGR_%)U"B57!
MC&?Y??.SEO[?LP1G*85Y#(B@>K=!(-.[#<% 5F0$9DG!%7$R%0;*,37.V-75
MKX+Q=G6"F[H'^Z+ECLU-!TZ2'=., 'U@,FHU.,!\#W:507-09K72)#*J1)4N
M'NV6&]'TVG=UH"CC-F>]#:^3#JXW/F[@6>IR,Q?SQ78S_R8_2Z[YV0SQX3M?
M;(44I@&8(89M?:[^H(XMMU_F2_EI(U_*F4@1R;.8@CPW!:$I3 !C$ ')8E+D
M.!8XL6JFZ%NPJ?%L5Z]HKUC4:E:WO.OH9JCAW,[%:!A5*CIN]+Q-N>7A\1M,
M9.ASYS'GT/WPVC/@7L^]?<DV[I&Y9T1/3MM]/]]CH:19+F(D64*TO4R((7:]
M@:8Y!'%!8E%P3G,B7.)KSHXRS3B;D](\'JKOW%)S9T(4>*G23N#J.B$XZ?Q
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MF*>89(E3/:'STTR-O$_T2*N%O3*CO0'6(?HF"%Q#W[D/C]1U&?W^B+UEGOZ
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M9[^=Q>4T3\/B^\2Z((PG'H2I?2MY]8XD<<ASY#$6G5)I<L^P VWC7C<T0MC
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MAP()C3?1&A]*DZ$]+09]K-W;ZJ-.E\M:!?9N]OXLGDS3NT(XIZTY2;P@2UY
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M&?V>K4?@YPA)=X"3]XOI?'%9SU6[JJX/@[5.+B][?L9E6DS7KRPF.F1N?"[
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M4 <!Q/7I06G^:3;];\RO<VV?5::8SR5;Y4*DD0_Z9AKB]&3=I8B^=W:*^?;
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M2+I=W=5,6=TV K_'"JP+Y0YZ\/+P!S8U7=N(?CH#%HP+L@A(P5DZ1:, IV0
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M0GBT-:]9+QC);PVWF[,VQ-0Y42-W&1L36X>HI5^+]78^2^<,62&D%-I"LJZ
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M'RO<N\REW0L 39+4*I.22&)!E.$6/F4.*1-NC#1:JSH]3H?FI!_L7^LUS[C
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M4_[$';.$N0!.T8@;N$'W5=@,V6<F&",<_=>ZEWZ'$]VN:3H$7?MO^2JKL8$
MX)[7-8OK<H-[R>*_EJMIN)K%3:G"#KLF>(;!509! K+K5 *K4RH.J.1>*Q)=
MG<ENI]'=0@>[FL"MK\RFL/OCA@!D\FJY3*LELOC+U'E<HR62V6'342IRI!ET
M2++T::9@E?3 K)7H6_#(2)7>BD?2.^Y98GVLUE->XZ[AI^)]W2=OW;ED97_!
M./?["7ELA[U@2)?R**;.X&X&&[UWQ(%@MOR0"FV;CR"E3(DSH9.NDE-5T=WL
MXYU<K7Y.L30U+?U2;_!YWQ]\>1*ICP&7!J"%+R?W.@)N  QD(#Q;7,A"5ND?
M,0#M[3J?AV#MT?7*F95Z:F.\86[S>C#]YH\R.?3M[*>9*W>8M[Q:1K)07D&P
M&1T7(07XTLA<R&"XISRK7">5]&B2V_4]:^-V !5>#%R[_M3%D\&G76]MC1-J
M<[0TE1&1MC3=3P2,#QZ(%RIEAXN5UKFE/H'H=EW0VI =1(T7 ]I-6/C@&S].
M\2\6-4W=]<1IXZT) J0.Z'VK@%P+PX%YIYD2C-LP&GA?(G[<2NPQ03RH6B\&
MS._F):2XP:]A +FI37]ZHL1$A8@;C9+0]9\2(7-PFAI@+NE$@LQ"CN9$]&>C
M%\#E:P1X)55?--2?'GQ?NN%.C(A*F: @2VN*.CQ8HBDP%(XA3NG@FH+[?E9Z
M05[]52 _D,HO!O8H]C_GR^DZ*^6'F^5TEI;+2<3UK++%=1U4:8$J&#CG,EA*
MG%:>EG$%8Z'[28I[@5B_1A"?KL"+P>IM[/OHM/OO[OIFK>SKZ_F_W2RD"=$V
ML[).(]?E,H8E\ 9C"RU$M#8K0]UH"#Z CUZX-J\1U[64/2K:NZ&E?;C'W6BZ
MV.0*ODNK][==HDH[NU2R!D-QQ+(56AM<VT2:@#HP"9PP%OEFC MMHPP[(-\S
M.W8PDGKAU5X*7D=4U\489?SE&Z1MNEI.")>:V.2A3 T$$4D$#(DE(%_4&F<2
MJ7,_=!B9_>X\R*5@] RZ:B!/H0]W7:.^^^%&RXD0(68G!%!2QM)XE*G1.D!(
M1%(5M'2J3E^U(XCMA\I7>15WDM[:&4KU-*MOYC/<"&YP+]AL"O/9<J*E,E:*
M!-*60@,C*%CG-/Z(DD?B@C]G>/44B?W@^$INV$[6T<D@K-R(\\FT$O13BGNR
MG>;6?6/HE)F7WE,Q<^8@%L]1"L*%C12C$ZXH*TD%$FQ@&DRTGF;-HZK5>;YR
M*4B1\KK&Z?%*VLF@3,O-5<K$9.6ESV5))5(&QN%"+JV3M:$I:V=UC%4NPHXG
MN=UTF4.0]7092745-N!%'L'I;<+OQ*?H8M<P7J&;+!)UX+TH];'$$!U8#*)*
MQNL)-+>;)7-FN!ZEQ,O$ZZ_3V7PQ77U_.T,R4C>V\>%3?OK7#7[\:UK],8_W
M4SJ6$V9-#@F=J2P\+F4M&0:$S$(RF7.?4HJY2O>P,_+8;@K.F=?#64#2;%OZ
M+4&4.[[YK+ VO\NAO_MX?=P\C#M\P(L&]X>/9?(,#K$F7&MM/9@40IE!34HE
M H&$\1U/2CN6JK1JJ^@0WTO[J;*,N[(/D057%J-66B;G.N7!85@)VNJ$.Y&R
M(E6I^>I%7;MN[B%XV;63PRNF 0_A$2,/KA[>N,7B.]K^?[M%O//9G5-)A\"
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M$.E+6Y/,P69:./,RXS_6ZRI5<,_0-#I\3M7XO([X1S8Z'\LQ=+>@F,:%Y+.
MQ".:W2 "[JFJ+"@;','_R5YMLWH9F;NWCIAR46L;.DZB+<!@@]Y$@F)6!O2K
M2AJN8^CD,RI %I\K!26)[#/LKS\0QC801VIL5^='B&]DK?\ZG4V_W'S9$)Y]
MX-&KB(1S"D))!E;9;K(R8\J@ $*?3:.7WA^\>63-'Z.W^1!"'%O[[ML6X1'-
MFM4*HS1?$G8L,V 384"<])&Y:*+M4S/<3_O;;QXG$AE,^T<+L0$7\NZ@9STV
M[;Z?56<,I98D2.$@.Y$!HW@4B4!GR5!NBK]-LZK2\.M9JD9,L3O+L>K)FF@
M5CL\;)SMI$/*(1GP)C)<8:7A+"( @E.$F9!2U%7F-#Y)32,'K*=K>W=.^,FB
M;P _2/Z7^6S[O"\E'J(P#K1$DRJ\H^!*MI87,GK#O/&YRJ201Y2,BYL!M/NX
M9^\)HA[U:/6A4'Y+X6;1M43\X?O;6;Q9KA;?UU<609LL<TF>P'U9^%C*[5/I
M0Z62B=HY&ZOT0GF>K!%3>FMN8P/JH@$[M,O-+2^;E<)X2(+Q!(F5T4P"@T5G
M;40@6"$S\237:5GP/%DM6*AA / "MD[0QMAWB;_/IF@!E\C.^_P/M_QC.ON\
MFL_N&)$Z<)DABVY2(BF30M"ZIXPK,V<O'>]7.OS<6]I"R2FJG->0Z]@ V6^C
M?[G+3V;2!Z-3-P&DS +)&AP)',HP>,^$ML3U*W'J\;(1ZP-J;%=59-S AK4N
M95XN;TH!Z0+1_R$MIO/8S29:KG__\_SV%FTY$4%RAW("8U,YL"J-/UPF8+G.
MV627G:W2WN(P,IM,I#H2(H^B_FKZ:L(U?Y:_#S>+\(=;IO=Y,UW0AVBXBP$\
MFO^27,3 !HT>@B<N"A(4954&I1U$99-Y$V= XTG:&A6,#V2W-?MC77FS_."^
MEWWD_>S']#5=S_\LG[GK7Z?7:8F^ ZXZ%A(7C&00$:4I.$>660I@7- NF<SM
M[C'H"_OLX30T>4MZ&NC.J956O+F];'9S ]_/WJ55:?F AEX(&33Z-(D6GX83
M#=8YM/N">,Z-=%*+82"W\^8F3]?/ ;13--" X_<15\GL)OV,(GTSGW4U _^8
MKOYX@U'5_$M:_/0M7-_$,OL(;3?^OU0A3CCQWH4R2] ["8)H#5Z$!)0'AD&Y
M%_VN>X]H;G8PK4V>E@VSZ=;67+-%8>7D>;KJ).EF,2#OR&6:A3+5YP'M_2J_
MGGO<,.5=O0D>J,O]UOL0?6^VW_=$/W0G<B99.;"BS &R$?\4C(,@<3,4C!-A
M^B3M''5#TIO*(2Z&7GS9??%DM@0#H^S*34@ 47I:FN0I$)M+-96WVE>Q<(>1
M.?I$ODHH>^JJJ9+R+L3(/>!YZ-+78U]5PS@>R>@HAM/X;)DT&61)_UU#.C.&
M@82(,9E2[53E?O"LAO,N>O?7T\_KACI<<*%$<)"I0*=%N S>1X]+F40:G%>$
M5#&.CTFY) -X"%IV#>")2ACP$&5H,W<E"/WGG]=N=HSANO_+PYBB/<0,9US^
MQ(!@#<]9_)A6T\5.]X;[&37,9Q,$Q_C1HG9+<."RHD S=5JYQ'RJ<J!Y (T#
M#$C#,*A;-HNIOREO_("BWVY@P:34+($FI<5@TK9TQ\"X6G@?,OZ)I"I97R\1
M-KK1J8*B)P:I#:>>9KVL<F0SSU?_NKD?CW&,(7KJ,<.8I!<)'*+MQ]/3:&Y1
MQ%ED,5H&I)3CBI!UF9ZG@! C!#=2I-UYF'N.%)]]S4G'I$\^^1ZJ1! AD]20
M2"A0%;I4%9>V;2D(28U0Y 0.6F@Q-)P&'QQ^#BC72S(!)\12SSRMFD&HU@[H
M>53%J*7T:/:+QPFB7"=[DA,XFI/,#H-PW:__6!6[<'<U>??P]XMU\M"O:?7'
M/+Z=?4W+54I;K_SA^^,OWWYMG3$BC4/6O"F3"6QIIB/ &NU!99=$"#&PW49"
M ]TS#\A$LU;J$#SMGZEW9BTW<(.S?Y:<YMZID"@HE\M4% P4;4P<*/$R:9:=
MMU5RWQL;YC@^2'I/@#Q$8RU [^69=2SRI()@R$R9O<R< <M+28HUE-JD=)!5
MHKC+G0!Y$ 8.GP!YB$+&3G]X:FZAC\ID%SFD9"1N$[CF' L*_R0%BT1G*OLE
MU5SB!,B#E/?2!,A#)-F"L7EJQ?QR=Y7N/+$9 QI(7I<#4>/0("</5&?FK- Z
M<W&VS>Z7@]*?!T_ZNXP=[SC=C6V3/BSFI3!N6?(NMIC!?]V/@8J).:=D!D9+
M,PA.#7JQ@8'5,2IOF3&Z7R%&CY<UN(T=J=AY12DW8+_ZS _+6F2>HP?F)!KY
MX!R:=AK+K KT"IB*@5?I13K44+<S6++!<%9++V,;J"VOX6.Z=JMRB+]<O9V%
MFT))J0I8,WG/G=/)!J+0E'M?RH"3 \=5 NZYUSK)Z&@_<W7PJ\=)3ZYMO.IJ
MH/Y)ZN:#\L.[9?K?_^W_ U!+ P04    " #\@GE2*%)..NP'  !E)0  %P
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M=; V ?26G<2/!O!L=_6:VH&MH.NG@98HBP@E:A05Q_OK=Z2DQ'FU68 V[8+
MD'2\X]WOGN3@U7@^"CZ?35 B4X;.SG\[G8Y0R[3M3_[(ML?!&+T//IZBMN6X
M*! X*ZBD/,/,MB>S%FHE4N8]V]YL-M;&M[A8V\'"5J+:-N.\(%8DH];)0'V!
M7X*CDU\&KTP3C7E8IB23*!0$2Q*ALJ#9&GV*2'&!3+->->+Y5M!U(I'G>"[Z
MQ,4%O<0575+)R$DC9V!7[P-;;S)8\6A[,HCH):+1VQ;UR>K87WG'7MQUVX==
M![?CV#GV2.Q$ON.3^"\7E+1A><53R"TC;ULIS<R$J/U[;<\ZZN2ROZ&13'JN
MX_S:TDM/!C'/).PG@+]ZK,3<$R;)E30QH^NLITUJ5:P-.>2,B]Z>H__ZBF+&
M.*5LVWL3T)04:$8V:,%3G+TQ"G"#61!!XVIA0?\AH!.HIU\WE<I'((?1C#0F
MN)Y2>G*5T!65R/<L][;&NX9CL0;;)<^!"\3NZ!X"V$2\D/*SR?QT<OYA.D/!
M^\EB>#8Y#Z:CI8&FLY'UTQDSFBR"Z;OI:!A,YS/(O,7R?#@+4#!_U)(?17/W
M&)U;2VMDH>5DI+5W_8YC_/!Z#Y=H.)Z?!9/Q3P5W W+7.43S=RKTT7*X^&TX
MFRS-^9^GD\]H. H4Q7,<[[^E <TBL*SG'>7?OAZU'S1NFJ&09QD)55M!&RH3
M)!."AEE68H86).="(A[#=IR1\H)F*$B(P#DI)0T+2/TLM-"^8GF]=^QY3G_$
MTQQG6_WF]@\02'W'1?IZSSUT^JYC?JB>8B[T1EN"!2( 0X3&)"3IBHAJ@>\:
MJNLX!L(%BBF#!=?:+4E8"FB$  /.(C2Y"A.<K0GTJS2E1:$L@7^U,H+FAD!A
M B;L:ED9UB@)9ACH#VBK$N2@WRTT%CA, %L#C1)*8M@!=I3TDJ!Y'-.0" 6)
M$E=;:R#X)FD,#WDIBA*#(R5'BY*1VG ?FVY[?W50O99@L+AKRK49PU!#[G;]
MMK8>IQ5 NP;L+KXQ0Z&Q4QTJKS8:="HL<<1SU?%W%;VU4L5Y;=X2BQ7.2&'.
MKQC9-HJI.#> CJ6AF-7"%2DT*=VBBXQOP%MKL+QSW']*/AQ"I.8XBF ",1F)
M9:_3OI,@Y@MFR+Y[T!CQ_;>_C8O;L?RV @)RL,G-N&1L"SF<YDP%T76."/)W
M2051PUFA/',G&/8QI*9 ;F<_.FB\?3NF.MV^BJ?_@0.]'].!-(,BF&)=>*$&
M2PRL$7S5OFB\BZD ]^:"%,J1AB)CQA"P@390H8&0@V<+0W/%-,-9J+Z#P$@?
M%71-@%4EJ^* YU"^%:&X4\.>-,%UM!<E7C'24%=<0#$S 4Z&\X+TFH=^1(N<
MX6V/9AH4S=2O9:VXE#Q5XOJ7JG*&F-6M7D=-1:ZG_6[7.N[X:N"7,.7+J-FX
M/@M8^BQ@R^@^S0?.;N=1LF.YC]*^)+9S9'6=IXFUM<J5V@!, 4"_;?FMAJ$.
MCIZ77R'W]FRLXN4N-A4L+Y1&K_?:1_U"_U9%Y/[O0RWT.JIJJ+Z @J,P>")R
M==3I<2H'+#BC$6I >"ZLUP?*[XWM%X%KTO&;J:8E]J@$-,(G*/O(2'3G_/T<
M=]NZ1GRUU[Q0 GS$(DRJ0/<Z1G4E\L3N^$(:!PDMZLD4PKWJ!F&HR[V:%53Q
M?V@VAYEND] P051"YV#0:E3C*5#&)8H(C!31,P9R];V6 ?)7JOV%7$"3T]=/
MJRWL%,.<GH6* BN@(ZE=U*W4UXX?#T[3-T.TOSM$&X@_8_#>) 1X!+3=2,VZ
MT+>)DH-C66^LSQEU/[T-Z8%1/5-1MVJ5,K!2V;<F&1C#=J!02#'0I<2@SJVA
MH"C!(14@CW?J.[=E.:^N"WO:B[#QO?NSFW*J^[%SPX)74%-+>9_E*U=N]6]U
M :BO(D_^!5!+ P04    " #\@GE2(E[>K+,%  #.%   %P   &YL='@M,C R
M,#$R,S%X97@S,C(N:'1MW5AM;]LV$/Z^7\$Z6)L UJNM)'YI ,]Q4*.I'=@*
MNGX::(FRB%*D1E%QO%^_(R4E3M*T68 V[8+ D'3D\;GGCG='#E^=SL?AIXL)
M2E7&T,7E'^?3,6I9CO.Q,W:<T_ 4O0L_G*.N[7HHE)@75%'!,7.<R:R%6JE2
M>=]Q-IN-O>G80JZ=<.%H55V'"5$0.U9QZV2HO\ OP?');\-7EH5.151FA"L4
M28(5B5%94+Y&'V-2?$:658\:BWPKZ3I5R'=]#WT4\C.]PI5<4<7(2:-GZ%3O
M0\<L,ER)>'LRC.D5HO';%G5[J^#82Z+HD/C=(#Y>!9@DGGN8X$/<Q4GG+P]
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M9W)E96UE;G1A;65N9&UE;G0N:'1M4$L! A0#%     @ _()Y4DF$!US=*@
M9 0! !X              ( !M!L  &5X,3 R,BUH;VQL>79A;F-E96UP;&]Y
M;65N+FAT;5!+ 0(4 Q0    ( /R">5)P@S27(S<  '6H 0 :
M  "  <U&  !E>#$P,C-R:6=A:W5P;W5P9&%T960Q+FAT;5!+ 0(4 Q0    (
M /R">5(O5>0,218   &@   >              "  2A^  !E>#$P,C1N96]L
M975K:6YL96%S96%M96YD;2YH=&U02P$"% ,4    " #\@GE24!O90KX"   _
M"0  '               @ &ME   97@R,3$M;&ES=&]F<W5B<VED:6%R:65S
M+FAT;5!+ 0(4 Q0    ( /R">5(XA38@ 0,  +T(   >              "
M :67  !E>#(S,2UC;VYS96YT;V9I;F1E<&5N9&5N="YH=&U02P$"% ,4
M" #\@GE2:W*BDQ(#  !5"0  '@              @ 'BF@  97@R,S(M8V]N
M<V5N=&]F:6YD97!E;F1E;G0N:'1M4$L! A0#%     @ _()Y4J\ >AWCX (
M9M@7 !$              ( !,)X  &YL='@M,C R,#$R,S$N:'1M4$L! A0#
M%     @ _()Y4NTC!NZV$P  X]@  !$              ( !0G\# &YL='@M
M,C R,#$R,S$N>'-D4$L! A0#%     @ _()Y4H,M8+@B)@  _YD! !4
M         ( !)Y,# &YL='@M,C R,#$R,S%?8V%L+GAM;%!+ 0(4 Q0    (
M /R">5+DZT><<DT  'A! P 5              "  7RY P!N;'1X+3(P,C Q
M,C,Q7V1E9BYX;6Q02P$"% ,4    " #\@GE2M2M/6%?L   :U D %0
M        @ $A!P0 ;FQT>"TR,#(P,3(S,5]L86(N>&UL4$L! A0#%     @
M_()Y4A;-( ^PB   83L& !4              ( !J_,$ &YL='@M,C R,#$R
M,S%?<')E+GAM;%!+ 0(4 Q0    ( /R">5(H4DXZ[ <  &4E   7
M      "  8Y\!0!N;'1X+3(P,C Q,C,Q>&5X,S$Q+FAT;5!+ 0(4 Q0    (
M /R">5*:^.GJX <  $0E   7              "  :^$!0!N;'1X+3(P,C Q
M,C,Q>&5X,S$R+FAT;5!+ 0(4 Q0    ( /R">5(:J*\8L@4  .44   7
M          "  <2,!0!N;'1X+3(P,C Q,C,Q>&5X,S(Q+FAT;5!+ 0(4 Q0
M   ( /R">5(B7MZLLP4  ,X4   7              "  :N2!0!N;'1X+3(P
F,C Q,C,Q>&5X,S(R+FAT;5!+!08     $0 1 *T$  "3F 4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
